Scientific Program

Hig
h S Publish
ati ed P
sfa .U.M
cti .P.
on data
.* L co
ow nfirm
Irr s 2

ita
tio
Start with n.

SI
MP
satisfaction in mind
LIFY DOSIN
G1

ENT OVERU
EV SE
PR
†3

L TRETI
TRO NO
ON IN
C
4

RETIN-A MICRO® (tretinoin gel) microsphere, 0.04% and 0.1% are indicated for topical application in the treatment of acne vulgaris.
Important Safety Information:
RETIN-A MICRO (tretinoin gel) microsphere, 0.04% and 0.1% is contraindicated in individuals with a history of sensitivity reactions to any
of its components. The skin of certain individuals may become excessively dry, red, swollen or blistered. If warranted, these individuals
should temporarily reduce the amount or frequency of application, or discontinue use temporarily or altogether. Patients should be
encouraged to minimize exposure to sunlight, including sunlamps, and to use a sunscreen with a SPF of 15 or higher and protective clothing.
The most common adverse reactions to RETIN-A MICRO 0.04% and 0.1% were limited to mild or moderate irritation of the skin. 1.3% of
patients using RETIN-A MICRO 0.04% and 6% of patients using RETIN-A MICRO 0.1% discontinued due to irritation. RETIN-A MICRO
0.04% and 0.1% showed a visible reduction in total mean lesion count in as little as 2 weeks with full benefits seen after 7 weeks.
Please see brief summary of prescribing information on the next page.
*Reported at the end of the 12-week P.U.M.P. Study.
†
Data based on a consumer preference study designed to evaluate preference of Pump versus tube delivery. 104 male and female acne sufferers between the ages of 13 and 36
completed the study.3
References: 1. RETIN-A MICRO 0.04%/0.1% [prescribing information]. Los Angeles, Calif: Ortho Dermatologics; May 2006. 2. Eichenfield LF, Nighland M, Rossi AB, et al; PUMP Study
Group. Phase 4 study to assess tretinoin pump for the treatment of facial acne. J Drugs Dermatol. 2008;7(12):1129-1136. 3. Data on file, Ortho Dermatologics. 4. Embil K, Nacht S.
The Microsponge ® Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul.
1996;13(5):575-588.

RETIN-A MICRO ® is a brand of Ortho Dermatologics division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

© Ortho Dermatologics division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2009 09DD0217 10/09 Printed in the USA

FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE.
Brief Summary
Retin-A Micro® (tretinoin gel) microsphere, 0.1% and 0.04% is a formulation containing 0.1%
or 0.04%, by weight, tretinoin for topical treatment of acne vulgaris. This formulation uses
patented methyl methacrylate/glycol dimethacrylate crosspolymer porous microspheres
(MICROSPONGE® System) to enable inclusion of the active ingredient, tretinoin, in an aqueous
gel.
IMPORTANT NOTE: This information is a BRIEF SUMMARY of the complete prescribing
information provided with the product and therefore should not be used as the basis
for prescribing the product. This summary has been prepared by deleting information
from the complete prescribing information such as certain text, tables, and references.
The physician should be thoroughly familiar with the complete prescribing information
before prescribing the product.
INDICATIONS AND USAGE: Retin-A Micro (tretinoin gel) microsphere, 0.1% and 0.04%, is
indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the
use of this product in the treatment of other disorders have not been established.
CONTRAINDICATIONS: This drug is contraindicated in individuals with a history of sensitivity
reactions to any of its components. It should be discontinued if hypersensitivity to any of its
ingredients is noted.
PRECAUTIONS:
General:
• The skin of certain individuals may become excessively dry, red, swollen, or blistered. If the
degree of irritation warrants, patients should be directed to temporarily reduce the amount
or frequency of application of the medication, discontinue use temporarily, or discontinue
use all together. Efficacy at reduced frequencies of application has not been established.
If a reaction suggesting sensitivity occurs, use of the medication should be discontinued.
Excessive skin dryness may also be experienced; if so, use of an appropriate emollient
during the day may be helpful.
• Unprotected exposure to sunlight, including sunlamps, should be minimized during the use of
Retin-A Micro (tretinoin gel) microsphere, 0.1% and 0.04%, and patients with sunburn should
be advised not to use the product until fully recovered because of heightened susceptibility to
sunlight as a result of the use of tretinoin. Patients who may be required to have considerable
sun exposure due to occupation and those with inherent sensitivity to the sun should exercise
particular caution. Use of sunscreen products (SPF 15) and protective clothing over treated
areas are recommended when exposure cannot be avoided.
• Weather extremes, such as wind or cold, also may be irritating to patients under treatment
with tretinoin.
• Retin-A Micro (tretinoin gel) microsphere, 0.1% and 0.04%, should be kept away from the
eyes, the mouth, paranasal creases of the nose, and mucous membranes.
• Tretinoin has been reported to cause severe irritation on eczematous skin and should be used
with utmost caution in patients with this condition.
Information for Patients: A Patient Information Leaflet has been prepared and is included with
each package of Retin-A Micro (tretinoin gel) microsphere, 0.1% and 0.04%.
Drug Interactions: Concomitant topical medication, medicated or abrasive soaps and cleansers,
products that have a strong drying effect, products with high concentrations of alcohol, astringents,
or spices should be used with caution because of possible interaction with tretinoin. Avoid contact
with the peel of limes. Particular caution should be exercised with the concomitant use of topical
over-the-counter acne preparations containing benzoyl peroxide, sulfur, resorcinol, or salicylic acid
with Retin-A Micro (tretinoin gel) microsphere, 0.1% and 0.04%. It also is advisable to allow the
effects of such preparations to subside before use of Retin-A Micro (tretinoin gel) microsphere,
0.1% and 0.04%, is begun.
Carcinogenesis, Mutagenesis, Impairment of Fertility: In a 91-week dermal study in
which CD-1 mice were administered 0.017% and 0.035% formulations of tretinoin, cuta-
neous squamous cell carcinomas and papillomas in the treatment area were observed in
some female mice. These concentrations are near the tretinoin concentration of these clinical
formulations (0.04% and 0.1%). A dose-related incidence of liver tumors in male mice was
observed at those same doses. The maximum systemic doses associated with the administered
0.017% and 0.035% formulations are 0.5 and 1.0 mg/kg/day, respectively. These doses are
two and four times the maximum human systemic dose applied topically, when normalized
for total body surface area. The biological significance of these findings is not clear because
they occurred at doses that exceeded the dermal maximally tolerated dose (MTD) of tretinoin
and because they were within the background natural occurrence rate for these tumors in
this strain of mice. There was no evidence of carcinogenic potential when 0.025 mg/kg/day
of tretinoin was administered topically to mice (0.1 times the maximum human systemic dose,
normalized for total body surface area). For purposes of comparisons of the animal exposure
to systemic human exposure, the maximum human systemic dose applied topically is defined
as 1 gram of Retin-A Micro (tretinoin gel) microsphere, 0.1% applied daily to a 50 kg person
(0.02 mg tretinoin/kg body weight).
Dermal carcinogenicity testing has not been performed with Retin-A Micro (tretinoin gel)
microsphere, 0.04% or 0.1%.
Studies in hairless albino mice suggest that concurrent exposure to tretinoin may enhance the
tumorigenic potential of carcinogenic doses of UVB and UVA light from a solar simulator. This
effect has been confirmed in a later study in pigmented mice, and dark pigmentation did not
overcome the enhancement of photocarcinogenesis by 0.05% tretinoin. Although the significance
of these studies to humans is not clear, patients should minimize exposure to sunlight or artificial
ultraviolet irradiation sources.
The mutagenic potential of tretinoin was evaluated in the Ames assay and in the in vivo mouse
micronucleus assay, both of which were negative.
The components of the microspheres have shown potential for genetic toxicity and teratogenesis.
EGDMA, a component of the excipient acrylates copolymer, was positive for induction of structural
chromosomal aberrations in the in vitro chromosomal aberration assay in mammalian cells in
the absence of metabolic activation, and negative for genetic toxicity in the Ames assay, the
HGPRT forward mutation assay, and the mouse micronucleus assay.
In dermal Segment I fertility studies of another tretinoin formulation in rats, slight (not statisti-
cally significant) decreases in sperm count and motility were seen at 0.5 mg/kg/day (4 times
the maximum human systemic dose applied topically, and normalized for total body surface
area), and slight (not statistically significant) increases in the number and percent of nonviable
embryos in females treated with 0.25 mg/kg/day (2 times the maximum human systemic dose
applied topically and normalized for total body surface area) and above were observed. In oral
Segment I and Segment III studies in rats with tretinoin, decreased survival of neonates and
growth retardation were observed at doses in excess of 2 mg/kg/day (17 times the human
topical dose normalized for total body surface area).
Dermal fertility and perinatal development studies with Retin-A Micro (tretinoin gel) microsphere,
0.1% or 0.04%, have not been performed in any species.
Pregnancy: Teratogenic Effects: Pregnancy Category C.
In a study of pregnant rats treated with topical application of Retin-A Micro (tretinoin gel)
microsphere, 0.1%, at doses of 0.5 to 1 mg/kg/day on gestation days 6-15 (4 to 8
times the maximum human systemic dose of tretinoin normalized for total body sur-
face area after topical administration of Retin-A Micro (tretinoin gel) microsphere, 0.1%)
some alterations were seen in vertebrae and ribs of offspring. In another study, pregnant
New Zealand white rabbits were treated with Retin-A Micro (tretinoin gel) microsphere, 0.1%, at
doses of 0.2, 0.5, and 1.0 mg/kg/day, administered topically for 24 hours a day while wearing
Elizabethan collars to prevent ingestion of the drug. There appeared to be increased incidences
of certain alterations, including domed head and hydrocephaly, typical of retinoid-induced
fetal malformations in this species, at 0.5 and 1.0 mg/kg/day. Similar malformations were
not observed at 0.2 mg/kg/day, 3 times the maximum human systemic dose of tretinoin after
topical administration of Retin-A Micro (tretinoin gel) microsphere, 0.1%, normalized for total
body surface area. In a repeat study of the highest topical dose (1.0 mg/kg/day) in pregnant
rabbits, these effects were not seen, but a few alterations that may be associated with tretinoin
exposure were seen. Other pregnant rabbits exposed topically for six hours to 0.5 or 0.1 mg/
kg/day tretinoin while restrained in stocks to prevent ingestion, did not show any teratogenic
effects at doses up to 17 times (1.0 mg/kg/day) the maximum human systemic dose after topical
administration of Retin-A Micro (tretinoin gel) microsphere, 0.1%, adjusted for total body surface
area, but fetal resorptions were increased at 0.5 mg/kg. In addition, topical tretinoin in non
Retin-A Micro (tretinoin gel) microsphere formulations was not teratogenic in rats and rabbits
when given in doses of 42 and 27 times the maximum human systemic dose after topical ad-
ministration of Retin-A Micro (tretinoin gel) microsphere, 0.1%, normalized for total body surface
area, respectively, (assuming a 50 kg adult applied a daily dose of 1.0 g of 0.1% gel topically).
At these topical doses, however, delayed ossification of several bones occurred in rabbits. In
rats, a dose-dependent increase of supernumerary ribs was observed.
Oral tretinoin has been shown to be teratogenic in rats, mice, rabbits, hamsters, and subhu-
man primates. Tretinoin was teratogenic in Wistar rats when given orally or topically in doses
greater than 1 mg/kg/day (8 times the maximum human systemic dose normalized for total
body surface area). However, variations in teratogenic doses among various strains of rats have
been reported. In the cynomolgus monkey, which metabolically is more similar to humans than
other species in its handling of tretinoin, fetal malformations were reported for doses of 10
mg/kg/day or greater, but none were observed at 5 mg/kg/day (83 times the maximum human
systemic dose normalized for total body surface area), although increased skeletal variations
were observed at all doses. Dose-related increases in embryolethality and abortion also were
reported. Similar results have also been reported in pigtail macaques.
Topical tretinoin in animal teratogenicity tests has generated equivocal results. There is evidence
for teratogenicity (shortened or kinked tail) of topical tretinoin in Wistar rats at doses greater
than 1 mg/kg/day (8 times the maximum human systemic dose normalized for total body surface
area). Anomalies (humerus: short 13%, bent 6%, os parietal incompletely ossified 14%) have
also been reported when 10 mg/kg/day was topically applied. Supernumerary ribs have been a
consistent finding in rats when dams were treated topically or orally with retinoids.
There are no adequate and well-controlled studies in pregnant women. Retin-A Micro should be
used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
With widespread use of any drug, a small number of birth defect reports associated temporally
with the administration of the drug would be expected by chance alone. Thirty human cases
of temporally associated congenital malformations have been reported during two decades of
clinical use of Retin-A. Although no definite pattern of teratogenicity and no causal association
has been established from these cases, five of the reports describe the rare birth defect category
holoprosencephaly (defects associated with incomplete midline development of the forebrain). The
significance of these spontaneous reports in terms of risk to the fetus is not known.
Non-Teratogenic Effects: Topical tretinoin has been shown to be fetotoxic in rabbits when
administered 0.5 mg/kg/day (8 times the maximum human systemic dose applied topically and
normalized for total body surface area), resulting in fetal resorptions and variations in ossifica-
tion. Oral tretinoin has been shown to be fetotoxic, resulting in skeletal variations and increased
intrauterine death in rats when administered 2.5 mg/kg/day (21 times the maximum human
systemic dose applied topically and normalized for total body surface area).
There are, however no adequate and well-controlled studies in pregnant women.
Animal Toxicity Studies: In male mice treated topically with Retin-A Micro (tretinoin gel) mi-
crosphere 0.1%, at 0.5, 2.0, or 5.0 mg/kg/day tretinoin (2, 8, or 21 times the maximum human
systemic dose after topical administration of Retin-A Micro (tretinoin gel) microsphere, 0.1%,
normalized for total body surface area) for 90 days, a reduction in testicular weight, but with
no pathological changes were observed at the two highest doses. Similarly, in female mice
there was a reduction in ovarian weights, but without any underlying pathological changes, at
5.0 mg/kg/day (21 times the maximum human dose). In this study there was a dose-related
increase in the plasma concentration of tretinoin 4 hours after the first dose. A separate toxi-
cokinetic study in mice indicates that systemic exposure is greater after topical application to
unrestrained animals than to restrained animals, suggesting that the systemic toxicity observed
is probably related to ingestion. Male and female dogs treated with Retin-A Micro (tretinoin gel)
microsphere, 0.1%, at 0.2, 0.5, or 1.0 mg/kg/day tretinoin (5, 12, or 25 times the maximum
human systemic dose after topical administration of Retin-A Micro (tretinoin gel) microsphere,
0.1%, normalized for total body surface area, respectively) for 90 days showed no evidence of
reduced testicular or ovarian weights or pathological changes.
Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many
drugs are excreted in human milk, caution should be exercised when Retin-A Micro (tretinoin
gel) microsphere, 0.1% or 0.04%, is administered to a nursing woman.
Pediatric Use: Safety and effectiveness in children below the age of 12 have not been established.
Geriatric Use: Safety and effectiveness in a geriatric population have not been established.
Clinical studies of Retin-A Micro did not include sufficient numbers of subjects aged 65 and
over to determine whether they respond differently from younger subjects.
ADVERSE REACTIONS:
The skin of certain sensitive individuals may become excessively red, edematous, blistered, or
crusted. If these effects occur, the medication should either be discontinued until the integrity
of the skin is restored, or the medication should be adjusted to a level the patient can tolerate.
However, efficacy has not been established for lower dosing frequencies.
True contact allergy to topical tretinoin is rarely encountered. Temporary hyper- or hypopig-
mentation has been reported with repeated application of tretinoin. Some individuals have been
reported to have heightened susceptibility to sunlight while under treatment with tretinoin.
OVERDOSAGE: Retin-A Micro (tretinoin gel) microsphere, 0.1% and 0.04%, is intended for topical
use only. If medication is applied excessively, no more rapid or better results will be obtained and
marked redness, peeling, or discomfort may occur. Oral ingestion of large amounts of the drug
may lead to the same side effects as those associated with excessive oral intake of Vitamin A.
Rx only.
Patent Nos.: 4,690,825; 5,145,675 & 5,955,109
Distributed by: OrthoNeutrogena
DIVISION OF ORTHO-MCNEIL PHARMACEUTICAL, INC.
Los Angeles, CA 90045
© OMP 2006 06DD0123 7/06
RETIN-A MICRO® is a registered trademark of Ortho-McNeil Pharmaceutical, Inc.
®
MICROSPONGE is a registered trademark of Cardinal Health, Inc., Dublin, OH.
 THANK YOU
to our 2010 Sustaining Members!
The generous philanthropic support of our
Sustaining Members and friends of the Academy
helps us continue to promote excellence through our
many programs. Thank you so much for your help in
Furthering Excellence in Dermatology…
Today and Tomorrow!

Visit the Pillars in Giving Recognition

Module in the Ernest N. Morial Convention Center.

SCIENTIFIC ASSEMBLY
COMMITTEE
Lawrence F. Eichenfield, M.D., FAAD,
chair
Janet A. Fairley, M.D., FAAD
Henry W. Lim, M.D., FAAD
Joan Guitart, M.D., FAAD
William D. James, M.D., FAAD,
president
Ronald L. Moy, M.D., FAAD,
president-elect
Robert D. Greenberg, M.D., FAAD,
secretary-treasurer
Suzanne Olbricht, M.D., FAAD,
assistant secretary-treasurer
Erik J. Stratman, M.D., FAAD,
chair, Council on Education
Robert S. Kirsner, M.D., Ph.D., FAAD,
deputy chair, Council on Education
Robert T. Brodell, M.D., FAAD,
chair, Annual Meeting Evaluation
Task Force
Michael E. Ming, M.D., FAAD,
chair, Needs Assessment Task Force
TARGET AUDIENCE
The primary target audience of the American Academy of Dermatology’s Annual Meeting is
its members. Secondary audiences for the Academy’s Annual Meeting include dermatology
residents and others.
OVERALL LEARNING OBJECTIVES
Upon completion of the activity, participants should be able to:
• Recognize the results of current and evolving research.
• Update their knowledge about recent advances in the diagnosis, management, and
treatment of diseases of the skin, hair, nails, and mucous membranes.
• Review and interpret basic knowledge and skills in medical dermatology, dermatologic
surgery, pediatric dermatology, and dermatopathology.
• Improve practice management skills.
• Integrate new principles to improve their everyday practice of dermatology.
CONTINUING MEDICAL EDUCATION CREDITS
The American Academy of Dermatology is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education for physicians.
The American Academy of Dermatology designates this educational activity for a maximum
of 54.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate
with the extent of their participation in the activity.
The American Academy of Dermatology’s 69th Annual Meeting is recognized by the
American Academy of Dermatology for 54.5 AAD Recognized Category 1 CME Credits
and may be used toward the American Academy of Dermatology’s Continuing Medical
Education Award.
All Annual Meeting activities, unless otherwise specified, are approved for direct-sponsored
AAD Category 1 CME Credit.
Credit is calculated on a 1/4-hour basis and will be reflected on member transcripts within four
to six weeks after the meeting. For AAD meeting policies on CME, please see pages 46-47.
Register for the meeting and make hotel reservations online at www.aad.org
American Academy of Dermatology, 930 E. Woodfield Road, Schaumburg, IL 60173
Phone: (847) 330-0230 • Fax: (847) 330-1090 • website: www.aad.org
© 2010 American Academy of Dermatology, Schaumburg, IL
No part of this publication may be reproduced without the prior written permission of the
American Academy of Dermatology.
For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 3
 President’s Message
There is something about the city of New Orleans that is both uniquely American and, with all its cultural
diversity, an international urban melting pot. Visitors come to New Orleans throughout the year for Mardi Gras
celebrations, warm weather, world-famous cuisine, lively music, and an atmosphere of southern hospitality at its
finest. New Orleans boasts the Café Du Monde (in business since the Civil War), the French Quarter, the Garden
District, and the contrasting business district, all thriving historic communities.
If you have not been to the city since the Academy’s last visit there, in 2005, I think you’ll be surprised how much
the city has both maintained its charm and revitalized its metropolis. Recent years have been hard on a city that
is almost paradoxically known as “the Big Easy.” But the people of New Orleans have repeatedly proved to be of
hearty, resilient stock in the face of adversity.
Like the great city of New Orleans, which perseveres thanks to the unbending spirit of its citizens, dermatology
thrives thanks to the dedication of the practitioners who have committed themselves to promoting and advancing
quality patient care. It’s that sort of spirit of dedication and determination that I believe makes our profession as
strong as it is.
New Orleans also has an impressive history of diverse dermatology presentations and lecturers. In 1999, the late,
great Walter Shelley, M.D., presented his “Self-portrait of a Dermatologist” at Chateau Sonesta Hotel in New
Orleans, as part of a dermatology society meeting in the city. In 2005, Elizabeth McBurney, M.D., gave a talk
on “Spitfire and Scandal: Huey P. Long’s Lasting Influence on Louisiana Medicine,” at the Restaurant August
in New Orleans, and at the Academy’s 2005 Annual Meeting, Peyton E. Weary, M.D., presented “Impact of
Global Climate Change, Biodiversity and Population on Human Health.” As you look at the 2010 Annual
Meeting scientific program and speakers, you’ll see that one thing remains consistent from year to year, and that’s a
presentation of important voices and new perspectives in dermatology. I hope you are eagerly anticipating this rich,
diverse, and medically important program as much as I am.
I hope you greet New Orleans and the 2010 Annual Meeting with that same sense of stalwart, can-do feeling, and
also with the same sense of excitement that comes from taking a solid foundation and building something great
into something even greater. That’s what New Orleans and dermatology are all about.

Sincerely,

William D. James, M.D., FAAD

President, American Academy of Dermatology
First home. First wrinkle. First visit.

e s c ribe
Pr New®
the OVA
REN mp
Pu

First choice.
Prescribe RENOVA first—and provide the true value of control in a pump patients prefer.
1

Controlled-dose delivery helps ensure proper use—which may lead to optimal results and long-lasting value for your patients.
RENOVA® (tretinoin cream) 0.02% is indicated as an adjunctive agent for use in the mitigation (palliation) of fine facial wrinkles in patients who use
comprehensive skin care and sunlight avoidance programs. RENOVA DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE
PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN.
Important Safety Information:
RENOVA® (tretinoin cream) 0.02% is contraindicated in individuals with a history of sensitivity reactions to any of its components and should be discontinued
if a reaction occurs. The safety and efficacy of using RENOVA 0.02% daily for greater than 12 months has not been established. RENOVA 0.02% is proven
effective on lightly pigmented skin, Fitzpatrick skin types I, II, and III. Do not use RENOVA 0.02% if the patient is taking drugs known to be photosensitizers,
pregnant, or nursing. RENOVA 0.02% is a dermal irritant. Almost all patients experience skin reactions, including dryness, peeling, burning/stinging, erythema,
and itching. In some patients, this may be severe. If the degree of local irritation warrants, patients should be directed to use less medication, decrease
frequency of use, discontinue use temporarily, or discontinue use altogether. Exposure to sunlight should be avoided
or minimized while using RENOVA 0.02% and use of a sunscreen with a SPF 15 or higher is recommended.
Please see a sales representative for Full Prescribing Information.

1. Data on file, Ortho Dermatologics. ONLY FROM

RENOVA is a trademark of Ortho Dermatologics. © 2010 Ortho Dermatologics 10DD0053 04/10 Printed in USA
© 2010 Ortho Dermatologics 10DD0053 04/10 Printed in USA
FOR TOPICAL USE ON THE FACE. NOT FOR
OPHTHALMIC,
ORAL, OR INTRAVAGINAL USE.
Brief Summary
RENOVA (tretinoin cream) 0.02% contains the
active ingredient tretinoin in a cream base.
IMPORTANT NOTE — This information is a
BRIEF SUMMARY of the complete prescrib-
ing information provided with the product
and therefore should not be used as the
basis for prescribing the product. This sum-
mary was prepared by deleting from the
complete prescribing information certain
text, tables, and references. The physician
should be thoroughly familiar with the com-
plete prescribing information before pre-
scribing the product.
INDICATIONS AND USAGE:
(To understand fully the indication for this prod-
uct, please read the entire INDICATIONS AND
USAGE section of the labeling.)
RENOVA (tretinoin cream) 0.02% is indicated
as an adjunctive agent (see second bullet point
below) for use in the mitigation (palliation) of
fine facial wrinkles in patients who use compre-
hensive skin care and sunlight avoidance pro-
grams. RENOVA DOES NOT ELIMINATE
WRINKLES, REPAIR SUN-DAMAGED SKIN,
REVERSE PHOTOAGING, or RESTORE
MORE YOUTHFUL or YOUNGER SKIN. In
double-blinded, vehicle-controlled clinical
studies, many patients in the vehicle group
achieved desired palliative effects on fine wrin-
kling of facial skin with the use of comprehen-
sive skin care and sunlight avoidance programs
including sunscreens, protective clothing, and
non-prescription emollient creams.
• RENOVA 0.02% has NOT DEMONSTRATED A
MITIGATING EFFECT on significant signs of
chronic sunlight exposure such as coarse or
deep wrinkling, tactile roughness, mottled
hyperpigmentation, lentigines, telangiectasia,
skin laxity, keratinocytic atypia, melanocytic
atypia, or dermal elastosis.
• RENOVA should be used under medical super-
vision as an adjunct to a comprehensive skin
care and sunlight avoidance program that
includes the use of effective sunscreens (mini-
mum SPF of 15) and protective clothing.
• Patients with visible actinic keratoses and
patients with a history of skin cancer were
excluded from clinical trials of RENOVA 0.02%.
Thus the effectiveness and safety of RENOVA
0.02% in these populations are not known at
this time.
• Neither the safety nor the effectiveness of
RENOVA for the prevention or treatment of
actinic keratoses or skin neoplasms has
been established.
• Neither the safety nor the efficacy of using
RENOVA 0.02% daily for greater than 52 weeks
has been established, and daily use beyond
52 weeks has not been systematically and
histologically investigated in adequate and well-
controlled trials. (See WARNINGS section.)
CONTRAINDICATIONS:
This drug is contraindicated in individuals with a
history of sensitivity reactions to any of its compo-
nents. It should be discontinued if hypersensitivity
to any of its ingredients is noted.
WARNINGS:
• RENOVA 0.02% is a dermal irritant, and the
results of continued irritation of the skin for
greater than 52 weeks in chronic use with
RENOVA are not known. There is evidence of
atypical changes in melanocytes and ker-
atinocytes and of increased dermal elastosis in
some patients treated with RENOVA 0.05% for
longer than 48 weeks. The significance of these
findings and their relevance for RENOVA
0.02% are unknown.
• RENOVA should not be administered if
the patient is also taking drugs known to be
photosensitizers (e.g., thiazides, tetracy-
clines, fluoroquinolones, phenothiazines, sul-
fonamides) because of the possibility of aug-
mented phototoxicity.
Exposure to sunlight (including sunlamps) should
be avoided or minimized during use of RENOVA
because of heightened sunburn susceptibility.
Patients should be warned to use sunscreens
(minimum SPF of 15) and protective clothing
when using RENOVA. Patients with sunburn
should be advised not to use RENOVA until fully
recovered. Patients who may have considerable
sun exposure, e.g., due to their occupation, and
those patients with inherent sensitivity to sunlight
should exercise caution when using RENOVA and
follow the precautions outlined in the Patient
Package Insert.
RENOVA should be kept out of the eyes,
mouth, angles of the nose, and mucous mem-
branes. Topical use may cause severe local
erythema, pruritus, burning, stinging, and peel-
ing at the site of application. If the degree of
local irritation warrants, patients should be
directed to use less medication, decrease the
frequency of application, discontinue use tem-
porarily, or discontinue use altogether and con-
sider additional appropriate therapy.
Tretinoin has been reported to cause severe irrita-
tion on eczematous skin and should be used only
with caution in patients with this condition.
Application of larger amounts of medication than
recommended has not been shown to lead to
more rapid or better results, and marked redness,
peeling, or discomfort may occur.
PRECAUTIONS:
General: RENOVA should be used only as an
adjunct to a comprehensive skin care and sunlight
avoidance program. (See INDICATIONS AND
USAGE section.)
If a drug sensitivity, chemical irritation, or a sys-
temic adverse reaction develops, use of RENOVA
should be discontinued.
Weather extremes, such as wind or cold, may
be more irritating to patients using tretinoin-
containing products.
Information for Patients: See Patient
Package Insert
Drug Interactions: Concomitant topical med-
ications, medicated or abrasive soaps, shampoos,
cleansers, cosmetics with a strong drying
effect, products with high concentrations of
alcohol, astringents, spices or lime, permanent
wave solutions, electrolysis, hair depilatories or
waxes, and products that may irritate the skin
should be used with caution in patients being
treated with RENOVA because they may
increase irritation with RENOVA.
RENOVA should not be administered if the patient
is also taking drugs known to be photosensitizers
(e.g., thiazides, tetracyclines, fluoroquinolones,
phenothiazines, sulfonamides) because of the pos-
sibility of augmented phototoxicity.
Carcinogenesis, Mutagenesis, Impairment of
Fertility: In a 91-week dermal study in which CD-1
mice were administered 0.017% and 0.035% for-
mulations of tretinoin, cutaneous squamous cell
carcinomas and papillomas in the treatment area
were observed in some female mice. These con-
centrations are near the tretinoin concentration of
this clinical formulation (0.02%). A dose-related
incidence of liver tumors in male mice was
observed at those same doses. The maximum
systemic doses associated with the 0.017% and
0.035% formulations are 0.5 and 1.0 mg/kg/day.
These doses are 10 and 20 times the maximum
human systemic dose, when adjusted for total
body surface area. The biological significance of
these findings is not clear because they occurred
at doses that exceeded the dermal maximally tol-
erated dose (MTD) of tretinoin and because they
were within the background natural occurrence
rate for these tumors in this strain of mice. There
was no evidence of carcinogenic potential when
0.025 mg/kg/day of tretinoin was administered
topically to mice (0.5 times the maximum human
systemic dose, adjusted for total body surface
area). For purposes of comparisons of the animal
exposure to systemic human exposure, the maxi-
mum human systemic dose is defined as 1 gram of
0.02% RENOVA applied daily to a 50 kg person
(0.004 mg tretinoin/kg body weight).
Studies in hairless albino mice suggest that con-
current exposure to tretinoin may enhance the
tumorigenic potential of carcinogenic doses of
UVB and UVA light from a solar simulator. This
effect has been confirmed in a later study in pig-
mented mice, and dark pigmentation did not
overcome the enhancement of photocarcino-
genesis by 0.05% tretinoin. Although the signifi-
cance of these studies to humans is not clear,
patients should minimize exposure to sunlight or
artificial ultraviolet irradiation sources.
The mutagenic potential of tretinoin was evaluated
in the Ames assay and in the in vivo mouse
micronucleus assay, both of which were negative.
In dermal Segment I fertility studies in rats, slight
(not statistically significant) decreases in sperm
count and motility were seen at 0.5 mg/kg/day (20
times the maximum human systemic dose adjust-
ed for total body surface area), and slight (not sta-
tistically significant) increases in the number and
percent of nonviable embryos in females treated
with 0.25 mg/kg/day (10 times the maximum
human systemic dose adjusted for total body sur-
face area) and above were observed. A dermal
Segment III study with RENOVA has not been per-
formed in any species. In oral Segment I and
Segment III studies in rats with tretinoin, decreased
survival of neonates and growth retardation were
observed at doses in excess of 2 mg/kg/day (83
times the human topical dose adjusted for total
body surface area).
Pregnancy:
Teratogenic effects: Pregnancy Category C.
ORAL tretinoin has been shown to be teratogenic in
rats, mice, rabbits, hamsters, and subhuman pri-
mates. It was teratogenic and fetotoxic in Wistar
rats when given orally or topically in doses greater
than 1 mg/kg/day (42 times the maximum human
systemic dose normalized for total body surface
area). However, variations in teratogenic doses
among various strains of rats have been reported.
In the cynomolgus monkey, which, metabolically, is
closer to humans for tretinoin than the other species
examined, fetal malformations were reported at
doses of 10 mg/kg/day or greater, but none were
observed at 5 mg/kg/day (417 times the maximum
human systemic dose adjusted for total body sur-
face area), although increased skeletal variations
were observed at all doses. A dose-related increase
in embryolethality and abortion was reported.
Similar results have also been reported in pigtail
macaques.
TOPICAL tretinoin in animal teratogenicity tests has
generated equivocal results. There is evidence for
teratogenicity (shortened or kinked tail) of topical
tretinoin in Wistar rats at doses greater than
1 mg/kg/day (42 times the maximum human
systemic dose adjusted for total body surface
area). Anomalies (humerus: short 13%, bent 6%,
os parietal incompletely ossified 14%) have
also been reported when 10 mg/kg/day was der-
mally applied.
There are other reports in New Zealand White rab-
bits administered doses of greater than 0.2
mg/kg/day (17 times the maximum human sys-
temic dose adjusted for total body surface area) of
an increased incidence of domed head and hydro-
cephaly, typical of retinoid-induced fetal malforma-
tions in this species.
In contrast, several well-controlled animal studies
have shown that dermally applied tretinoin may be
fetotoxic, but not overtly teratogenic, in rats
and rabbits at doses of 1.0 and 0.5 mg/kg/day,
respectively (42 times the maximum human sys-
temic dose adjusted for total body surface area in
both species).
With widespread use of any drug, a small num-
ber of birth defect reports associated tempo-
rally with the administration of the drug would
be expected by chance alone. Thirty human
cases of temporally-associated congenital
malformations have been reported during two
decades of clinical use of another formulation
of topical tretinoin (Retin-A). Although no defi-
nite pattern of teratogenicity and no causal
association has been established from these
cases, 5 of the reports describe the rare birth
defect category holoprosencephaly (defects
associated with incomplete midline develop-
ment of the forebrain). The significance of
these spontaneous reports in terms of risk to
the fetus is not known.
Non-teratogenic effects:
Dermal tretinoin has been shown to be fetotoxic in
rabbits when administered 0.5 mg/kg/day (42
times the maximum human systemic dose normal-
ized for total body surface area). Oral tretinoin has
been shown to be fetotoxic, resulting in skeletal
variations and increased intrauterine death, in rats
when administered 2.5 mg/kg/day (104 times the
maximum human systemic dose adjusted for total
body surface area).
There are, however, no adequate and well-
controlled studies in pregnant women. RENOVA
should not be used during pregnancy.
Nursing Mothers: It is not known whether this drug
is excreted in human milk. Since many drugs are
excreted in human milk, mitigation of fine facial
wrinkles with RENOVA 0.02% may be postponed
in nursing mothers until after completion of the
nursing period.
Pediatric Use: Safety and effectiveness in
patients less than 18 years of age have not
been established.
Geriatric Use: In clinical studies with RENOVA
0.02%, patients aged 65 to 71 did not demon-
strate a significant difference for improvement
in fine wrinkling when compared to patients
under the age of 65. Patients aged 65 and over
may demonstrate slightly more irritation,
although the differences were not statistically
significant in the clinical studies for RENOVA
0.02%. Safety and effectiveness of RENOVA
0.02% in individuals older than 71 years of age
have not been established.
ADVERSE REACTIONS:
(See WARNINGS and PRECAUTIONS sections.)
In double-blind, vehicle-controlled studies involv-
ing 339 patients who applied RENOVA 0.02% to
their faces, adverse reactions associated with the
use of RENOVA were limited primarily to the skin.
Almost all patients reported one or more local reac-
tions such as peeling, dry skin, burning, stinging,
erythema, and pruritus. In 32% of all study
patients, skin irritation was reported that was
severe, led to temporary discontinuation of
RENOVA 0.02%, or led to use of a mild topical
corticosteroid. About 7% of patients using
RENOVA 0.02%, compared to less than 1% of the
control patients, had sufficiently severe local
irritation to warrant short-term use of mild topical
corticosteroids to alleviate local irritation. About
4% of patients had to discontinue use of RENOVA
because of adverse reactions.
Approximately 2% of spontaneous post-marketing
adverse event reporting for RENOVA 0.05% were
for skin hypo- or hyperpigmentation. Other sponta-
neously reported adverse events for RENOVA
0.05% predominantly appear to be local reactions
similar to those seen in clinical trials.
OVERDOSAGE:
Application of larger amounts of medication than
recommended has not been shown to lead to
more rapid or better results, and marked redness,
peeling, or discomfort may occur. Oral ingestion of
the drug may lead to the same side effects as
those associated with excessive oral intake of
Vitamin A.
Rx only.
Marketed by: Ortho Dermatologics
DIVISION OF ORTHO-MCNEIL-JANSSEN
PHARMACEUTICALS, INC.
Los Angeles, CA 90045
© OMJPI 2008 Made in Canada
U.S. Patents 4,603,146 and 4,877,805
732954 201530
AMERICAN ACADEMY
of DERMATOLOGY
extends a very sincere thank you
to all of our corporate partners
who have provided support for various
2010 Academy programs and activities.

Please visit our Corporate Partner

Scientific Program
Recognition Module in the Ernest N. Morial
Convention Center and view Corporate Partner
Recognition in the Program-at-a-Glance
 Chair’s Message
New Orleans welcomes the American Academy of Dermatology back for the 69th Annual Meeting. The Academy
has planned a truly remarkable educational roster for our first visit back to this exciting city since 2005. We are
offering an outstanding set of courses, symposia, workshops, discussion groups, and focus sessions touching on every
aspect of our diverse specialty.
The highlight of the meeting will be the plenary session, taking place on Sunday, February 6. The session leads
off with the Clarence S. Livingood, M.D., Award and Lectureship, presented by Neil Prose, M.D. Dr. Prose will
present “Cultivating Curiosity,” in which he will discuss the role of curiosity in understanding our patients and
providing empathetic care. Also featured will be Thomas Kupper, M.D., presenting the Marion B. Sulzberger,
M.D., Award and Lectureship. His lecture, “Skin in the Game: New Perspective on T Cells, Immunity, and
Cancer,” will explore how our growing understanding of T cells is changing the way we think about immunity,
vaccination, cancer, and inflammatory skin disease and how these insights are in turn impacting patient care.
Also featured will be W. Marston Linehan, M.D., recipient of the Lila Gruber Memorial Cancer Research Award
and Lectureship. He will explore how research into the genetic basis and clinical manifestations of kidney cancer is
leading to better treatments for these diseases in a lecture on “Familial Kidney Cancer Syndromes with Cutaneous
Manifestations.” This year Anton Stuetz, Ph.D., will present the Phillip Frost Leadership Lecture. His lecture,
“Lessons Learned During Research and Development of New Medicines for Treatment of Skin Diseases,” will
explore research leading to recent breakthroughs in the treatment of fungal infections, atopic dermatitis, and more.
The plenary session will also feature guest speakers James Carville and Mary Matalin. Representing opposite sides
of the political scene, this couple will give an insider’s look at life in Washington, D.C. Academy members will also
have a chance to hear a report on the latest AAD activities from President William D. James, M.D., and a look at
what the future holds from President-elect Ronald A. Moy, M.D.
The Annual Meeting has always featured cutting edge information in the diagnosis and treatment of skin disease,
but the latest news in research takes center stage in a new session, “Late-Breaking Research” on Saturday, February
5. The most significant dermatologic research abstracts are being solicited, and the best of these will be selected for
presentation at this new session, directed by Richard L. Gallo, M.D.
“Late-Breaking Research” is just one of the many new, exciting, and innovative sessions being offered at the 69th
Annual Meeting. I invite you to review this program book and select from the myriad topics and formats being
offered.
Sincerely,

Lawrence M. Eichenfield, M.D., FAAD

Chair, 2011 Annual Meeting
 When dry skin calls for a serious solution…
Recommend AmLactin ®

recommended by dermatologists
for rough, dry skin1

AmLactin® Rejuvenating Moisturizers

Nourishing formulas— combine emollients, humectants, and alpha-hydroxy acid to
exfoliate and hydrate dry skin and dry skin associated with Keratosis Pilaris (KP) Visit us online at
● AmLactin Moisturizing Body Lotion & Cream
®
www.amlactin.com
Everyday hydration— 12% lactic acid provides powerful therapy leaving skin
noticeably soft and smooth
for samples, coupons
& more information!
● AmLactin XL® Moisturizing Lotion
Targets severely dry skin— features ULTRAPLEX,® an extra-strength blend of three
alpha-hydroxy compounds, clinically proven to improve smoothness and hydration

Serious care for softer skin TM

For complete directions and cautions, please refer to individual product labels. 1-800-654-2299 www.upsher-smith.com
©2010 Upsher-Smith Laboratories, Inc., Maple Grove, MN 55369
Reference: 1. Most recommended moisturizing product for rough, dry skin. Omnibus Study. Dermatology Times. May 2009. 103985.02
 TABLE OF CONTENTS
AAD Art Exhibit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 292-293
AAD Meeting Policies
Independence in CME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Disclosure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Content Validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Outcomes Measurement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Disclaimer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Age Limits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Camera/Video Recording . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Cell Phones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Smoking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Alcoholic Beverages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Official Language . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Scientific Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
AAD Staff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Academy Election Information. . . . . . . . . . . . . . . . . . . . . . . . . . 32
Ancillary Groups and Reunions . . . . . . . . . . . . . . . . . . . . 347-351
Badge Information
Identification. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
On-site Pick Up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Mailing of . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Car Rental Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Certificate of Attendance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Chair’s Message . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Charitable Contributions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Child Care Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Committee Meetings . . . . . . . . . . . . . . . . . . . . . . . . . . . . 344-346
Continuing Medical Education Credits . . . . . . . . . . . . . . . . . . . . 3
Evaluation and CME Verification . . . . . . . . . . . . . . . . . . . . . . . 44
TABLE OF CONTENTS
Exhibits
AAD Resource Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Electronic Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . 44, 265-294
Technical. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44, 297-334
Alphabetical Directory . . . . . . . . . . . . . . . . . . . . . . . . . . . . 328
Product Category Directory . . . . . . . . . . . . . . . . . . . . 330-334
General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33-48
Honors and Awards . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 340-343
Hotel and Travel Information. . . . . . . . . . . . . . . . Brochure, 41-42
Important Dates and Times . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
In Memory. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 337-338
Indices
Subject . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 353-374
Faculty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375-383
Advertising . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 384
Information Desks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Letters of Invitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Meeting Location . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Meeting Room Locations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
New This Year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52-53
On-Site Services and Exhibits . . . . . . . . . . . . . . . . . . . . . . . 43-46
Academy Offices/Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43-44
Attendance Verification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
SEPARATE ENCLOSURE
REGISTRATION AND HOUSING BROCHURE
Registration and Housing Form / Office Staff / Registered Nurses Registration Form / Hotel Reservation Information
10 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Business Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Cyber Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
WiFi Lounges . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Press Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Information Desks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Restaurant Reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
First Aid/Nursing Mothers’ Room . . . . . . . . . . . . . . . . . . . . . . . 46
Optional Activities . . . . . . . . . . . . . . . . . . . . . . . . Brochure, 38, 46
Overall Learning Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Payment Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Personal Program Schedule . . . . . . . . . . . . . . . . . . . . . . . . . 27-28
Plenary Session
Business and Bagels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
Welcome Address . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
Clarence S. Livingood, M.D., Award and Lectureship . . . . . . . 159
President’s Address . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
Marion B. Sulzberger, M.D., Memorial Award
and Lectureship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
President-Elect’s Address . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
Lila Gruber Memorial Cancer Research Award
and Lectureship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
Eugene J. Van Scott Award for Innovative Therapy of the
Skin and Phillip Frost Leadership Lecture . . . . . . . . . . . . . . . . 162
Guest Speakers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
Presidents Message . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Program Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15-24
Registration Information . . . . . . . . . . . . . . . . . . . . . . . . . . . 34-38
Member Instructions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34-37
Non-Member Instructions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Spouse/Guest Instructions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Confirmations and Changes . . . . . . . . . . . . . . . . . . . . . . . . 35, 38
Categories, Access, and Fees . . . . . . . . . . . . . . . . . . . . . . . . 36-37
Cancellations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Optional Activities . . . . . . . . . . . . . . . . . . . . . . . Brochure, 38, 46
Corrections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Group Registration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
On-site Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Restaurant Reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Scientific Assembly Committee . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Scientific Sessions
Thursday, February 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57-58
Friday, February 4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59-104
Friday/Saturday, February 4/5 . . . . . . . . . . . . . . . . . . . . 105-106
Saturday, February 5 . . . . . . . . . . . . . . . . . . . . . . . . . . . 107-151
Sunday, February 6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152-183
Monday, February 7 . . . . . . . . . . . . . . . . . . . . . . . . . . . 185-233
Monday/Tuesday, February 7/8. . . . . . . . . . . . . . . . . . . . 234-235
Tuesday, February 8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236-264
Scooter/Wheelchair Rental . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Shuttle Bus Service . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Target Audience . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Travel Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
ACZONE® (dapsone) Gel 5% Pediatric Use
Safety and efficacy was evaluated in 1169 children aged 12-17 years old treated with
ACZONE® Gel, 5%, in the clinical studies. The adverse event rate for ACZONE® Gel, 5%, was
similar to the vehicle control group. Safety and efficacy was not studied in pediatric patients
INDICATIONS AND USAGE less than 12 years of age, therefore ACZONE® Gel, 5%, is not recommended for use in this
ACZONE® Gel, 5%, is indicated for the topical treatment of acne vulgaris. age group.

CONTRAINDICATIONS Geriatric Use

None. Clinical studies of ACZONE® Gel, 5%, did not include sufficient number of patients aged 65
and over to determine whether they respond differently from younger patients.
WARNINGS AND PRECAUTIONS
G6PD Deficiency
Hematological Effects ACZONE® Gel, 5% and vehicle were evaluated in a randomized, double-blind, cross-over
Oral dapsone treatment has produced dose-related hemolysis and hemolytic anemia. design clinical study of 64 patients with G6PD deficiency and acne vulgaris. Subjects were
Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are more prone to Black (88%), Asian (6%), Hispanic (2%) or of other racial origin (5%). Blood samples were
hemolysis with the use of certain drugs. G6PD deficiency is most prevalent in populations of taken at Baseline, Week 2, and Week 12 during both vehicle and ACZONE® Gel, 5% treatment
African, South Asian, Middle Eastern and Mediterranean ancestry. periods. There were 56 out of 64 subjects who had a Week 2 blood draw and applied at
There was no evidence of clinically relevant hemolysis or anemia in patients treated with least 50% of treatment applications. ACZONE® Gel was associated with a 0.32 g/dL drop in
ACZONE® Gel, 5%, including patients who were G6PD deficient. Some subjects with G6PD hemoglobin after two weeks of treatment, but hemoglobin levels generally returned to baseline
deficiency using ACZONE® Gel developed laboratory changes suggestive of mild hemolysis. levels at Week 12.
If signs and symptoms suggestive of hemolytic anemia occur, ACZONE® Gel, 5% should be There were no changes from baseline in haptoglobin or lactate dehydrogenase during
discontinued. ACZONE® Gel, 5% should not be used in patients who are taking oral dapsone ACZONE® or vehicle treatment at either the 2-week or 12-week time point.
or antimalarial medications because of the potential for hemolytic reactions. Combination The proportion of subjects who experienced decreases in hemoglobin ≥1 g/dL was similar
of ACZONE® Gel, 5%, with trimethoprim/sulfamethoxazole (TMP/SMX) may increase the between ACZONE® Gel, 5% and vehicle treatment (8 of 58 subjects had such decreases
likelihood of hemolysis in patients with G6PD deficiency. during ACZONE® treatment compared to 7 of 56 subjects during vehicle treatment among
Peripheral Neuropathy subjects with at least one on-treatment hemoglobin assessment). Subgroups based on
gender, race, or G6PD enzyme activity did not display any differences in laboratory results
Peripheral neuropathy (motor loss and muscle weakness) has been reported with oral
from the overall study group. There was no evidence of clinically significant hemolytic anemia
dapsone treatment. No events of peripheral neuropathy were observed in clinical trials with
in this study. Some of these subjects developed laboratory changes suggestive of mild
topical ACZONE® Gel, 5% treatment.
hemolysis.
Skin
OVERDOSAGE
Skin reactions (toxic epidermal necrolysis, erythema multiforme, morbilliform and scarla-
ACZONE® Gel, 5%, is not for oral use. If oral ingestion occurs, medical advice should be
tiniform reactions, bullous and exfoliative dermatitis, erythema nodosum, and urticaria) have
sought.
been reported with oral dapsone treatment. These types of skin reactions were not observed
in clinical trials with topical ACZONE® Gel, 5% treatment.
ADVERSE REACTIONS
Clinical Studies Experience
Because clinical trials are conducted under prescribed conditions, adverse reaction rates Rx ONLY
observed in the clinical trials of a drug cannot be directly compared to rates in the clinical
trials of another drug and may not reflect the rates observed in practice. © 2008 Allergan, Inc.
Serious adverse reactions reported in patients treated with ACZONE® Gel, 5%, during clinical Irvine, CA 92612, U.S.A.
trials included but were not limited to the following: ®
marks owned by Allergan, Inc.
• Nervous system/Psychiatric – Suicide attempt, tonic clonic movements. U.S. Patents 5,863,560; 6,060,085; and 6,620,435
• Gastrointestinal – Abdominal pain, severe vomiting, pancreatitis.
• Other – Severe pharyngitis
In the clinical trials, a total of 12 out of 4032 patients were reported to have depression (3
of 1660 treated with vehicle and 9 of 2372 treated with ACZONE® Gel, 5%). Psychosis was
reported in 2 of 2372 patients treated with ACZONE® Gel, 5%, and in 0 of 1660 patients
treated with vehicle.
Combined contact sensitization/irritation studies with ACZONE® Gel, 5%, in 253 healthy
subjects resulted in at least 3 subjects with moderate erythema. ACZONE® Gel, 5%, did not
induce phototoxicity or photoallergy in human dermal safety studies.
ACZONE® Gel, 5%, was evaluated for 12 weeks in four controlled studies for local cutaneous
events in 1819 patients. The most common events reported from these studies include
oiliness/peeling, dryness, and erythema.
One patient treated with ACZONE® Gel in the clinical trials had facial swelling which led to
discontinuation of medication.
In addition, 486 patients were evaluated in a 12 month safety study. The adverse event profile
in this study was consistent with that observed in the vehicle-controlled studies.
Experience with Oral Use of Dapsone
Although not observed in the clinical trials with ACZONE® Gel (topical dapsone) serious
adverse reactions have been reported with oral use of dapsone, including agranulocytosis,
hemolytic anemia, peripheral neuropathy (motor loss and muscle weakness), and skin
reactions (toxic epidermal necrolysis, erythema multiforme, morbilliform and scarlatiniform
reactions, bullous and exfoliative dermatitis, erythema nodosum, and urticaria).
DRUG INTERACTIONS
Trimethoprim-Sulfomethoxazole
A drug-drug interaction study evaluated the effect of the use of ACZONE® Gel, 5%,
in combination with double strength (160 mg/800 mg) trimethoprim-sulfamethoxazole
(TMP/SMX). During co-administration, systemic levels of TMP and SMX were essentially
unchanged. However, levels of dapsone and its metabolites increased in the presence of
TMP/SMX. Systemic exposure (AUC0-12) of dapsone and N-acetyl-dapsone (NAD) were
increased by about 40% and 20% respectively in presence of TMP/SMX. Notably, systemic
exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence
of TMP/SMX. Exposure from the proposed topical dose is about 1% of that from the 100 mg
oral dose, even when co-administered with TMP/SMX.
Topical Benzoyl Peroxide
Topical application of ACZONE® Gel followed by benzoyl peroxide in subjects with acne
vulgaris resulted in a temporary local yellow or orange discoloration of the skin and facial hair
(reported by 7 out of 95 subjects in a clinical study) with resolution in 4 to 57 days.
Drug Interactions with Oral Dapsone
Certain concomitant medications (such as rifampin, anticonvulsants, St. John’s wort) may
increase the formation of dapsone hydroxylamine, a metabolite of dapsone associated with
hemolysis. With oral dapsone treatment, folic acid antagonists such as pyrimethamine have
been noted to possibly increase the likelihood of hematologic reactions.
USE IN SPECIFIC POPULATIONS
Pregnancy
Teratogenic Effects: Pregnancy Category C
There are no adequate and well controlled studies in pregnant women. Dapsone has been
shown to have an embryocidal effect in rats and rabbits when administered orally in doses of
75 mg/kg/day and 150 mg/kg/day (approximately 800 and 500 times the systemic exposure
observed in human females as a result of use of the maximum recommended topical dose,
based on AUC comparisons), respectively. These effects were probably secondary to
maternal toxicity. ACZONE® Gel, 5%, should be used during pregnancy only if the potential
benefit justifies the potential risk to the fetus.
Nursing Mothers
Although systemic absorption of dapsone following topical application of ACZONE® Gel,
5%, is minimal relative to oral dapsone administration, it is known that dapsone is excreted
in human milk. Because of the potential for oral dapsone to cause adverse reactions in
nursing infants, a decision should be made whether to discontinue nursing or to discontinue
ACZONE® Gel, 5%, taking into account the importance of the drug to the mother.
 all three animal species. Embryotoxicity was observed in rats, rabbits, and monkeys at oral doses

Finacea
of azelaic acid that generated some maternal toxicity. Embryotoxicity was observed in rats given
2500 mg/kg/day (162 times the maximum recommended human dose based on body surface
® area), rabbits given 150 or 500 mg/kg/day (19 or 65 times the maximum recommended human
(azelaic acid) Gel,15% dose based on body surface area) and cynomolgus monkeys given 500 mg/kg/day (65 times the
maximum recommended human dose based on body surface area) azelaic acid. No teratogenic
effects were observed in the oral embryofetal developmental studies conducted in rats, rabbits
and cynomolgus monkeys.
For Dermatologic Use Only–Not for Ophthalmic, Oral, or Intravaginal Use
An oral peri- and post-natal developmental study was conducted in rats. Azelaic acid was administered
Rx only from gestational day 15 through day 21 postpartum up to a dose level of 2500 mg/kg/day.
BRIEF SUMMARY Embryotoxicity was observed in rats at an oral dose that generated some maternal toxicity (2500
CONSULT PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION mg/kg/day; 162 times the maximum recommended human dose based on body surface area). In
addition, slight disturbances in the post-natal development of fetuses was noted in rats at oral
INDICATIONS AND USAGE doses that generated some maternal toxicity (500 and 2500 mg/kg/day; 32 and 162 times
FINACEA Gel, 15%, is indicated for topical treatment of inflammatory papules and pustules of mild the maximum recommended human dose based on body surface area). No effects on sexual
to moderate rosacea. Although some reduction of erythema which was present in patients with maturation of the fetuses were noted in this study.
papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in
Because animal reproduction studies are not always predictive of human response, this drug should
rosacea in the absence of papules and pustules has not been evaluated. Patients should be
be used only if clearly needed during pregnancy.
instructed to avoid spicy foods, thermally hot foods and drinks, alcoholic beverages and to use
only very mild soaps or soapless cleansing lotion for facial cleansing. Nursing Mothers: Equilibrium dialysis was used to assess human milk partitioning in vitro. At an
azelaic acid concentration of 25 µg/mL, the milk/plasma distribution coefficient was 0.7 and the
CONTRAINDICATIONS milk/buffer distribution was 1.0, indicating that passage of drug into maternal milk may occur.
FINACEA Gel, 15%, is contraindicated in individuals with a history of hypersensitivity to propylene Since less than 4% of a topically applied dose of azelaic acid cream, 20%, is systemically absorbed,
glycol or any other component of the formulation. the uptake of azelaic acid into maternal milk is not expected to cause a significant change from
baseline azelaic acid levels in the milk. However, caution should be exercised when FINACEA Gel,
WARNINGS
15%, is administered to a nursing mother.
FINACEA Gel, 15%, is for dermatologic use only, and not for ophthalmic, oral or intravaginal use.
There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid Pediatric Use: Safety and effectiveness of FINACEA Gel, 15%, in pediatric patients have not been
has not been well studied in patients with dark complexion, these patients should be monitored established.
for early signs of hypopigmentation.
Geriatric: Clinical studies of FINACEA Gel, 15%, did not include sufficient numbers of subjects
PRECAUTIONS aged 65 and over to determine whether they respond differently from younger subjects.
General: Contact with the eyes should be avoided. If sensitivity or severe irritation develops with
ADVERSE REACTIONS
the use of FINACEA Gel, 15%, treatment should be discontinued and appropriate therapy instituted.
Overall, treatment related adverse events, including burning, stinging/ tingling, dryness/tightness/
In a transgenic mouse study, chronic use of FINACEA Gel led to an increased number of animals
scaling, itching, and erythema/irritation/ redness, were 19.4% (24/124) for FINACEA Gel, 15%,
with papillomas at the treatment site (see PRECAUTIONS: Carcinogenesis, Mutagenesis, and
and 7.1% (9/127) for the active comparator gel at 15 weeks.
Impairment of Fertility). The clinical relevance of the findings in animal studies to humans is not clear.
In two vehicle controlled, and one active controlled U.S. clinical studies, treatment safety was
Information for Patients: Patients using FINACEA Gel, 15%, should receive the following monitored in 788 patients who used twice daily FINACEA Gel, 15%, for 12 weeks (N=333) or for
information and instructions: 15 weeks (N=124), or the gel vehicle (N=331) for 12 weeks.
• FINACEA Gel, 15%, is to be used only as directed by the physician.
Table 3. Cutaneous Adverse Events Occurring in ≥1% of Subjects in the Rosacea Trials by
• FINACEA Gel, 15%, is for external use only. It is not to be used orally, intravaginally, or for the eyes.
Treatment Group and Maximum Intensity*
• Cleanse affected area(s) with a very mild soap or a soapless cleansing lotion and pat dry with a
soft towel before applying FINACEA Gel, 15%. Avoid alcoholic cleansers, tinctures and astringents, FINACEA Gel, 15% Vehicle
abrasives and peeling agents. N=457 (100%) N=331 (100%)
• Avoid contact of FINACEA Gel, 15%, with the mouth, eyes and other mucous membranes. If it Mild Moderate Severe Mild Moderate Severe
does come in contact with the eyes, wash the eyes with large amounts of water and consult a n=99 n=61 n=27 n=46 n=30 n=5
physician if eye irritation persists. (22%) (13%) (6%) (14%) (9%) (2%)
• The hands should be washed following application of FINACEA Gel, 15%. Burning/
• Cosmetics may be applied after FINACEA Gel, 15%, has dried. stinging/
tingling 71 (16%) 42 (9%) 17 (4%) 8 (2%) 6 (2%) 2 (1%)
• Skin irritation (e.g., pruritus, burning, or stinging) may occur during use of FINACEA Gel,
15%, usually during the first few weeks of treatment. If irritation is excessive or persists, use Pruritus 29 (6%) 18 (4%) 5 (1%) 9 (3%) 6 (2%) 0 (0%)
of FINACEA Gel, 15%, should be discontinued, and patients should consult their physician Scaling/dry
(See ADVERSE REACTIONS). skin/xerosis 21 (5%) 10 (2%) 5 (1%) 31 (9%) 14 (4%) 1 (<1%)
• Avoid any foods and beverages that might provoke erythema, flushing, and blushing (including Erythema/
spicy food, alcoholic beverages, and thermally hot drinks, including hot coffee and tea). irritation 6 (1%) 7 (2%) 2 (<1%) 8 (2%) 4 (1%) 2 (1%)
• Patients should report abnormal changes in skin color to their physician.
Contact
• Avoid the use of occlusive dressings or wrappings. dermatitis 2 (<1%) 3 (1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%)
Drug Interactions: There have been no formal studies of the interaction of FINACEA Gel, 15%, Edema 3 (1%) 2 (<1%) 0 (0%) 3 (1%) 0 (0%) 0 (0%)
with other drugs.
Acne 3 (1%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%)
Carcinogenesis, Mutagenesis, Impairment of Fertility:
*Subjects may have >1 cutaneous adverse event; thus, the sum of the frequencies of preferred
Systemic long-term animal studies have not been performed to evaluate the carcinogenic potential
terms may exceed the number of subjects with at least 1 cutaneous adverse event.
of azelaic acid. In a 26-week dermal carcinogenicity study using transgenic (Tg.AC) mice, FINACEA
FINACEA Gel, 15%, and its vehicle caused irritant reactions at the application site in human dermal
Gel, 15%, and the gel vehicle, when applied once or twice daily, did not increase the number of
female Tg.AC animals with papillomas at the treatment site. No statistically significant increase in safety studies. FINACEA Gel, 15%, caused significantly more irritation than its vehicle in a cumulative
the number of animals with papillomas at the treatment site was observed in male Tg.AC animals irritation study. Some improvement in irritation was demonstrated over the course of the clinical
after once daily application. After twice daily application, FINACEA Gel, 15%, and the gel vehicle studies, but this improvement might be attributed to subject dropouts. No phototoxicity or
induced a statistically significant increase in the number of male animals with papillomas at the photoallergenicity were reported in human dermal safety studies.
treatment site when compared to untreated males. This suggests that the positive effect may be In patients using azelaic acid formulations, the following additional adverse experiences have been
associated with the vehicle application. The clinical relevance of the findings in animals to humans reported rarely: worsening of asthma, vitiligo depigmentation, small depigmented spots, hypertrichosis,
is not clear. reddening (signs of keratosis pilaris), and exacerbation of recurrent herpes labialis.
Azelaic acid was not mutagenic or clastogenic in a battery of in vitro (Ames assay, HGPRT in V79 Post-marketing safety-Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure
cells {Chinese hamster lung cells}, and chromosomal aberration assay in human lymphocytes) with FINACEA Gel, 15%, to the eye (see PRECAUTIONS).
and in vivo (dominant lethal assay in mice and mouse micronucleus assay) genotoxicity tests. Distributed under license; U.S. Patent No 6,534,070
Oral administration of azelaic acid at dose levels up to 2500 mg/kg/day (162 times the maximum www.myfinacea.com
recommended human dose based on body surface area) did not affect fertility or reproductive
©2010, Intendis, Inc. All rights reserved, July 2010
performance in male or female rats.
Pregnancy: Teratogenic Effects: Pregnancy Category B Manufactured by Intendis Manufacturing S.p.A., Segrate, Milan, Italy
There are no adequate and well-controlled studies of topically administered azelaic acid in pregnant Distributed by:
women. The experience with FINACEA Gel, 15%, when used by pregnant women is too limited to
Morristown, NJ 07962
permit assessment of the safety of its use during pregnancy.
Dermal embryofetal developmental toxicology studies have not been performed with azelaic acid, Intendis is part of the Bayer Group
15%, gel. Oral embryofetal developmental studies were conducted with azelaic acid in rats, rabbits,
and cynomolgus monkeys. Azelaic acid was administered during the period of organogenesis in 6706803BS
 1

A zzAA

a 2,3
on no offA m
s
ms o of a
f acctitoi the
nisism r y
ec
echhaan a n de
l
eemm le s ions
pl n
nt i
m e intenance data 4
pi

a
ltlti

e
ov km
Muu

e
M

we
pr

- aattiieennttbbeennee
inuous im

6 ll pp f
nnaa
3

ttio
io

fitist
ddii

s*
Ad
Cont

®
*myfinaceaskinsavvy.com – a website for patient support and education
Finacea is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some
reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy
for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.
Finacea is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. Finacea is contraindicated in individuals with
a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/
stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing
safety—Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports
of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexion,
these patients should be monitored for early signs of hypopigmentation.
Please see brief summary of full Prescribing Information on following page.
References: 1. Draelos ZD, Kayne AL. Implications of azelaic acid’s multiple mechanisms of action: therapeutic versatility. Poster presented at: 66th Annual Meeting of the American Academy of
Dermatology; February 1-5, 2008, San Antonio, TX. 2. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results
from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48(6):836-845. FINACEA was only studied in clinical trials for 12 weeks. 3. Elewski BE, Fleischer AB,
Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:
1444-1450. 4. Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich P. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel
as maintenance monotherapy. J Drugs Dermatol. 2009;8(7):639-648.
©2009 Intendis, Inc. All rights reserved. 09-JA-004 October 2009
 PROGRAM OVERVIEW

Represents restricted session in program overviews Represents activities that meet MOC-D
Restricted Session open to dermatologists and corporate M
O
This activity has been approved by the ABD to satisfy
individual members only! A ticket is required for admittance C component 2 of MOC-D

Represents Practice Management Session in program overviews Represents Leadership Institute in program overviews
Practice Management Session open to eligible Leadership Institute — addresses leadership
office staff/registered nurses competencies specific to dermatologists

Represents Patient Safety Session in program overviews Represents Health Information Technology (HIT) in
program overviews
Patient Safety Session
Health Information Technology Sessions

Represents Audience Response System Session

Audience Response System Session

THURSDAY, FEBRUARY 3 U011 Medical and Aesthetic Dermatology in

Skin of Color . . . . . . . . . . . . . . . . . . . . . . . . . . . .68
Course — 8:00 a.m. to 1:00 p.m.
C001 Volunteers Abroad Course: Beginner . . . . . . . . . .57 U012 Leading with Your Strengths . . . . . . . . . . . . . . . . .68
U013 Vitamin D and Dermatology . . . . . . . . . . . . . . . .68
Course — 1:00 p.m. to 5:00 p.m.
C002 Volunteers Abroad Course: Advanced . . . . . . . . . .58 Forums — 9:00 a.m. to 11:00 a.m.
F001 Advanced Medical Dermatology . . . . . . . . . . . . . .69
F002 Erosive Vulvar Diseases: Approach to Diagnosis,
FRIDAY, FEBRUARY 4

PROGRAM OVERVIEW
Differential Diagnosis, and Treatment. . . . . . . . . .69
Course — 7:00 a.m. to 9:00 a.m. F003 Case-Based Challenges in Pediatric Dermatology 70
C06A Basic Self-Assessment of Dermatopathology . . . . .64 F004 Geriatric Dermatology: Advanced Cases . . . . . . . .70
F005 Board Blitz . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .71
Discussion Groups — 7:15 a.m. to 8:45 a.m.
F006 Vitiligo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .71
D001 Pregnancy Dermatoses: Moving Towards a
Better Understanding . . . . . . . . . . . . . . . . . . . . . .64 F007 Management of Difficult Wounds. . . . . . . . . . . . .72

D002 Appropriate Uses of Lasers . . . . . . . . . . . . . . . . . .64 F008 Decreasing Iatrogenic Problems

in Your Practice. . . . . . . . . . . . . . . . . . . . . . . . . . .72

Focus Sessions — 7:15 a.m. to 8:45 a.m.

Workshop — 9:00 a.m. to 11:00 a.m.
U001 Tricks of the Blade . . . . . . . . . . . . . . . . . . . . . . . .65
W001 MOC Self-Assessment A. . . . . . . . . . . . . . . . . . . .72
U002 Management of Post-Acne Scarring . . . . . . . . . . .65
U003 Management of High-Risk Squamous Courses — 9:00 a.m. to 12:00 p.m.
Cell Carcinoma (SCC) . . . . . . . . . . . . . . . . . . . . .65
C003 Pediatric Dermatology . . . . . . . . . . . . . . . . . . . . .73
U004 Advances in Web-Based Medical Education:
How Best to Teach Dermatology . . . . . . . . . . . . .66 C004 Diagnosis and Therapeutics:
The Fundamentals. . . . . . . . . . . . . . . . . . . . . . . . .74
U005 High-Yield “Power Hour” for Residents . . . . . . . .66
C005 Basic Contact Dermatitis . . . . . . . . . . . . . . . . . . .74
U006 International Teledermatology Overview. . . . . . . .66
U007 Ectodermal Dysplasias . . . . . . . . . . . . . . . . . . . . .66 Symposia — 9:00 a.m. to 12:00 p.m.
U008 Recognition and Management of S001 Disorders of Pigmentation . . . . . . . . . . . . . . . . . .75
High-Risk Skin Cancer . . . . . . . . . . . . . . . . . . . .67
S002 Alopecia: Workup and Treatment . . . . . . . . . . . . .75
U009 Phototherapy and Photochemotherapy:
Nuances and Peals for the Practicing Clinician . . .67 S003 Hot Topics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .76
U010 The Tzanck Smear Test: Reintroducing Our Good S004 When Bad Things Happen to Good Doctors . . . .76
Old Friend! . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .67 S005 Leading from Your Vision to Exceptional Service 77
S006 Approach to Pigmented Lesions . . . . . . . . . . . . . .78

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 15

 PROGRAM OVERVIEW

Represents restricted session in program overviews Represents activities that meet MOC-D
Restricted Session open to dermatologists and corporate M
O
This activity has been approved by the ABD to satisfy
individual members only! A ticket is required for admittance C component 2 of MOC-D

Represents Practice Management Session in program overviews Represents Leadership Institute in program overviews
Practice Management Session open to eligible Leadership Institute — addresses leadership
office staff/registered nurses competencies specific to dermatologists

Represents Patient Safety Session in program overviews Represents Health Information Technology (HIT) in
program overviews
Patient Safety Session
Health Information Technology Sessions

Represents Audience Response System Session

Audience Response System Session

Courses — 9:00 a.m. to 5:00 p.m. U020 Challenging Diagnostic Cases for Advanced
C007 Immunology . . . . . . . . . . . . . . . . . . . . . . . . . . . . .79 Practitioners: PA/NP II. . . . . . . . . . . . . . . . . . . . .87

C008 Derm Exam Prep Course: Refresher . . . . . . . . . . .79 U021 Acne in the Adult Female Patient . . . . . . . . . . . . .87
U022 Vulvar Dermatoses . . . . . . . . . . . . . . . . . . . . . . . .87
Course — 9:30 a.m. to 11:30 a.m. U023 Highlights from JAAD . . . . . . . . . . . . . . . . . . . . .88
C06B Basic Self-Assessment of Dermatopathology . . . . .80 U024 Leading Confidently through Powerful
Communication . . . . . . . . . . . . . . . . . . . . . . . . . .88
Forums — 12:00 p.m. to 2:00 p.m. U025 A Personalized Planner for Rejuvenation. . . . . . . .88
F009 Photobiology for Dermatologists . . . . . . . . . . . . .80 U026 Teledermatology 101: Integrating Teledermatology
into Your Practice . . . . . . . . . . . . . . . . . . . . . . . . .89
PROGRAM OVERVIEW

F010 Hidradenitis Suppurativa: An Update . . . . . . . . . .81

F011 Dermatopathology Made Simple . . . . . . . . . . . . .81 Course — 12:30 p.m. to 2:30 p.m.
F012 Update on Genetic Skin Disease . . . . . . . . . . . . . .82 C06C Basic Self-Assessment of Dermatopathology . . . . .89
F013 EHR Implementation, Maintenance, and
Lessons Learned . . . . . . . . . . . . . . . . . . . . . . . . . .82
Courses — 2:00 p.m. to 5:00 p.m.
F014 Challenging Diagnostic Cases for Advanced
C009 Dermatologic Syndromes and Genetic Disorders 90
Practitioners: PA/NP I . . . . . . . . . . . . . . . . . . . . .83
C010 Advanced Contact Dermatitis. . . . . . . . . . . . . . . .90
F015 Ethical Economics in Dermatology and
Dermatologic Surgery . . . . . . . . . . . . . . . . . . . . . .83 C011 Live Patient Demonstration: The State of the
Art of Aesthetic Dermatology . . . . . . . . . . . . . . . .91
F016 Advances in Dermatologic Surgery . . . . . . . . . . . .84

Symposia — 2:00 p.m. to 5:00 p.m.

Discussion Groups — 12:15 p.m. to 1:45 p.m.
S008 Consultative Dermatology for the
D003 Selected Topics in Medical Dermatology. . . . . . . .84
Hospitalized Patient . . . . . . . . . . . . . . . . . . . . . . .91
D004 Dealing with Disappointing Outcomes and
Medical Mistakes . . . . . . . . . . . . . . . . . . . . . . . . .84 S009 Advanced Medical Dermatology . . . . . . . . . . . . . .92
S010 Surviving Healthcare Reform . . . . . . . . . . . . . . . .92
Focus Sessions — 12:15 p.m. to 1:45 p.m. S011 Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . .93
U014 When Acne Really Isn’t Acne . . . . . . . . . . . . . . . .85 S012 Aging Gracefully . . . . . . . . . . . . . . . . . . . . . . . . . .93
U015 Merkel Cell Carcinoma. . . . . . . . . . . . . . . . . . . . .85 S013 Leading Others for Peak Performance . . . . . . . . . .94
U016 Sports Dermatology —
Skin Infections in Athletes . . . . . . . . . . . . . . . . . .85
U017 Clincial Trials for the Private Practitioner . . . . . . .86
U018 Outcomes Research in Dermatology. . . . . . . . . . .86
U019 Sun, Drugs, and Invervention: How to Prevent
Non-Melanoma Skin Cancer . . . . . . . . . . . . . . . .87

16 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 PROGRAM OVERVIEW

Discussion Groups — 2:30 p.m. to 4:00 p.m. SATURDAY, FEBRUARY 5

D005 Dermatoethics: Contemporary Issues Poster Discussion Sessions — 7:15 a.m. to 8:45 a.m.
in Ethics and Professionalism . . . . . . . . . . . . . . . .94
PD01 Surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .112
D006 Serologic Testing for Connective Tissue Diseases 94
PD02 Clinical Dermatology . . . . . . . . . . . . . . . . . . . . .112
Focus Sessions — 2:30 p.m. to 4:00 p.m.
Discussion Groups — 7:15 a.m. to 8:45 a.m.
U027 Practical Approaches to Medical and Cosmetic
Dermatology in Skin of Color . . . . . . . . . . . . . . .95 D007 Leading from Conflict to Resolution . . . . . . . . .113
U028 Oral Ulcers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .95 D008 PUVA and Phototherapy Beyond Psoriasis . . . . .113
U029 Skin Cancer in Patients with Non-Melanoma
Hodgkin’s Lymphoma. . . . . . . . . . . . . . . . . . . . . .96 Focus Sessions — 7:15 a.m. to 8:45 a.m.
U030 Treatment of Pediatric Psoriasis. . . . . . . . . . . . . . .96 U038 Nanotechnology . . . . . . . . . . . . . . . . . . . . . . . . .114
U031 Dermatomyositis. . . . . . . . . . . . . . . . . . . . . . . . . .97 U039 Good Closures Gone Bad: A Story of Blood,
Pus, and Tears . . . . . . . . . . . . . . . . . . . . . . . . . . .114
U032 Chronic Inflammatory Hand and
Foot Dermatoses . . . . . . . . . . . . . . . . . . . . . . . . . .97 U040 Military Unique Dermatology . . . . . . . . . . . . . .114
U033 Electrolysis: When Laser Isn’t the Answer . . . . . . .98 U041 Uncommon Cutaneous Infections:
Clinical and Histologic Features . . . . . . . . . . . . .114
U034 Pediatric Hyperhidrosis and Ectodermal Dysplasia:
To Sweat or Not to Sweat? . . . . . . . . . . . . . . . . . .98 U042 The Vices of Devices in Dermatology . . . . . . . . .115
U035 Paraneoplastic Dermatoses . . . . . . . . . . . . . . . . . .98 U043 Dermatopathology Challenges Encountered
by the Mohs Surgeon . . . . . . . . . . . . . . . . . . . . .115
U036 Subcutaneous Fat in Dermatology . . . . . . . . . . . .98
U044 Tumescent Liposuction, Lasers, and New Devices:
U037 Paraneoplastic Autoimmune Multiorgan A State-of-the-Art Liposuction Practice. . . . . . . .115
Syndrome (PAMS) . . . . . . . . . . . . . . . . . . . . . . . .99
U045 Non-cultured Epidermal Suspension in Vitiligo:
From Lab to Clinic . . . . . . . . . . . . . . . . . . . . . . .116
Course — 3:00 p.m. to 5:00 p.m.
U046 Social Media and Dermatology: How Twitter and

PROGRAM OVERVIEW
C06D Basic Self-Assessment of Dermatopathology . . . . .99 Facebook Will Help You and Your Practice. . . . .116
U047 Mini - MBA for the Dermatologist. . . . . . . . . . .116
Forums — 3:00 p.m. to 5:00 p.m.
U048 Challenging Cases in Pediatric Dermatology. . . .117
F017 Resident Jeopardy . . . . . . . . . . . . . . . . . . . . . . . .100
F018 Atopic Dermatitis . . . . . . . . . . . . . . . . . . . . . . . .100 Forums — 9:00 a.m. to 11:00 a.m.
F019 Journal Watching . . . . . . . . . . . . . . . . . . . . . . . .101 F024 Evaluation and Management of Hemangiomas. .117
F020 Volunteerism and Humanitarianism . . . . . . . . . .101 F025 Dramatic Oral Disease . . . . . . . . . . . . . . . . . . . .118
F021 FDA Presents: Information for Dermatologists. . .102 F026 Chronic Urticaria and Angioedema:
F022 Coding and Office Management. . . . . . . . . . . . .102 What’s New in Pathogenesis and Treatment . . . .118
F023 Psoriasis Guidelines: Implementing Them in F027 Practical Approaches to Patient Problems . . . . . .119
Your Practice. . . . . . . . . . . . . . . . . . . . . . . . . . . .103 F028 What You Need to Know About Coding
But Were Afraid to Ask. . . . . . . . . . . . . . . . . . . .119
Workshops — 3:00 p.m. to 5:00 p.m. F029 Acne and Rosacea Update . . . . . . . . . . . . . . . . . .120
W002 Dermatology Speaker Development . . . . . . . . . .104 F030 Managing Online Reputation . . . . . . . . . . . . . . .120
W003 MOC Self-Assessment: Dermatopathology . . . . .104 F031 Food Allergy and Dermatology . . . . . . . . . . . . . .121

Workshop — 9:00 a.m. to 11:00 a.m.

FRIDAY/SATURDAY, FEBRUARY 4/5 W004 MOC Self-Assessment: Procedural
Course — 9:00 a.m. to 5:00 p.m. Dermatology. . . . . . . . . . . . . . . . . . . . . . . . . . . .121
C012 Structure and Function of the Skin . . . . . . . . . . 105

Symposium — 9:00 a.m. to 5:00 p.m.

S007 Gross and Microscopic Dermatology . . . . . . . . .106

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 17

 PROGRAM OVERVIEW

Represents restricted session in program overviews Represents activities that meet MOC-D
Restricted Session open to dermatologists and corporate M
O
This activity has been approved by the ABD to satisfy
individual members only! A ticket is required for admittance C component 2 of MOC-D

Represents Practice Management Session in program overviews Represents Leadership Institute in program overviews
Practice Management Session open to eligible Leadership Institute — addresses leadership
office staff/registered nurses competencies specific to dermatologists

Represents Patient Safety Session in program overviews Represents Health Information Technology (HIT) in
program overviews
Patient Safety Session
Health Information Technology Sessions

Represents Audience Response System Session

Audience Response System Session

Courses — 9:00 a.m. to 12:00 p.m. Discussion Groups — 12:15 p.m. to 1:45 p.m.
C06E Basic Self-Assessment of Dermatopathology D009 Educate Your Patients and Improve Outcomes . .133
Discussion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .122 D010 Recent Advances in Skin Biology and
C013 Advanced Botulinum Toxin: Skin Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . .133
Live Patient Demonstration . . . . . . . . . . . . . . . .122
C014 Coding, Documentation, and Practice Focus Sessions — 12:15 p.m. to 1:45 p.m.
Management . . . . . . . . . . . . . . . . . . . . . . . . . . . .123
U049 Avoiding Complications and Maximizing Results
in Cutaneous Laser Surgery. . . . . . . . . . . . . . . . .134
Symposia — 9:00 a.m. to 12:00 p.m.
U050 Viral Exanthem Update . . . . . . . . . . . . . . . . . . .134
S014 Patient Safety and Quality . . . . . . . . . . . . . . . . .124
U051 Therapy for Lipodermatosclerosis,
PROGRAM OVERVIEW

S015 Advanced Pediatric Dermatology . . . . . . . . . . . .125 Venous Ulceration, and Atrophie Blanche. . . . . .134
S016 Drug Actions . . . . . . . . . . . . . . . . . . . . . . . . . . .125 U052 Diseases of Male Genitalia . . . . . . . . . . . . . . . . .134
S017 Therapeutic Decision Making in U053 Through the Looking Glass: The Use of
Cutaneous Oncology . . . . . . . . . . . . . . . . . . . . .126 Dermoscopy in the Management of the
S018 Late-Breaking Research . . . . . . . . . . . . . . . . . . . .126 Pigmented Lesion Patient . . . . . . . . . . . . . . . . . .135
U054 Building Beauty: Understanding Facial
Courses — 9:00 a.m. to 5:00 p.m. Proportions, Phi, and the Use of Volumizing
C015 Internal Medicine . . . . . . . . . . . . . . . . . . . . . . . .127 Soft Tissue Fillers . . . . . . . . . . . . . . . . . . . . . . . .135
C016 Advanced Self-Assessment of Dermatopathology 127 U055 Practical Approaches to Cosmeceuticals . . . . . . .135
C017 Advanced Dermoscopy . . . . . . . . . . . . . . . . . . . .128 U056 Recommended Screening Practices in
Medical Dermatology . . . . . . . . . . . . . . . . . . . . .136
Forums — 12:00 p.m. to 2:00 p.m. U057 Procedural Safety in Dermatology. . . . . . . . . . . .136
F032 Multidisciplinary Preventive Networking in U058 From Stem To Skin: Precursor Cells That Have
Occupational Contact Dermatitis . . . . . . . . . . . .129 a Lot of Potential . . . . . . . . . . . . . . . . . . . . . . . .136
F033 Introduction to Oral Dermatology . . . . . . . . . . .130 U059 Potpourri of CPC . . . . . . . . . . . . . . . . . . . . . . . .136
F034 From the Dermatology Rheumatology Clinics: U060 Stress, the Nervous System, and Cutaneous
Practical Tips and Advances in Management . . .130 Immunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .137
F035 Practical Aspects of Biologic Therapy . . . . . . . . .131
F036 Careers in Academic Dermatology . . . . . . . . . . .131 Courses — 2:00 p.m. to 5:00 p.m.
F037 Pediatric Dermatology: Systemic Evaluation of C018 Dermatologic Drug Safety and Efficacy . . . . . . .137
Cutaneous Findings in Infants and Children: C019 Hair and Nails . . . . . . . . . . . . . . . . . . . . . . . . . .138
What’s New and What’s True?. . . . . . . . . . . . . . .132
C020 Live Patient Demonstrations: Application of
F038 Itch . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .132 Our Aesthetic Toolbox for the Treatment of
Medical and Dermatologic Disorders . . . . . . . . .139
Workshop — 12:00 p.m. to 2:00 p.m.
W005 MOC Self-Assessment:
Pediatric Dermatology . . . . . . . . . . . . . . . . . . . .133

18 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 PROGRAM OVERVIEW

Symposia — 2:00 p.m. to 5:00 p.m. SUNDAY, FEBRUARY 6

S019 Rheumatologic Dermatology . . . . . . . . . . . . . . .139 Discussion Groups — 7:00 a.m. to 8:00 a.m.
S020 Birthmarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . .140 D013 Challenging Pediatric Dermatology Cases. . . . . .154
S021 Skin of Color . . . . . . . . . . . . . . . . . . . . . . . . . . .141 D014 Advances in Pemphigus and Pemphigoid . . . . . .154
S022 Acne and Rosacea . . . . . . . . . . . . . . . . . . . . . . . .142
Focus Sessions — 7:00 a.m. to 8:00 a.m.
S023 Teledermatology . . . . . . . . . . . . . . . . . . . . . . . . .143
U073 Amyloidosis: Changing Our
View in Dermatology . . . . . . . . . . . . . . . . . . . . .154
Discussion Groups — 2:30 p.m. to 4:00 p.m.
U074 Eczema Centers: World Experiences . . . . . . . . . .154
D011 Women With Hair Loss . . . . . . . . . . . . . . . . . . .144
U075 Drug Safety: Do No Harm . . . . . . . . . . . . . . . .155
D012 Aging Skin: Mechanism-Based Rejuvenation . . .144 U076 Immunofluorescence in Dermatopathology . . . .155
U077 Hair Disease and the African American Patient .155
Focus Sessions — 2:30 p.m. to 4:00 p.m.
U078 Case-Based Approach to Lentigo Maligna. . . . . .156
U061 Calciphylaxis. . . . . . . . . . . . . . . . . . . . . . . . . . . .144
U079 Dermatologic Disease in Asians . . . . . . . . . . . . .156
U062 Herpes Simplex and Varicella Zoster Virus . . . . .144 U080 Uncommon Neonatal Dermatosis . . . . . . . . . . .156
U063 Dermatoscopy. . . . . . . . . . . . . . . . . . . . . . . . . . .145 U081 Medical and Surgical Practice . . . . . . . . . . . . . . .156
U064 Helping You Meet Component 4 of MOC. . . . .145 U082 Practical and Realistic Office Mycology for the
U065 Dermoscopy: It’s Time for A Quiz . . . . . . . . . . .145 Epidemiology, Diagnosis, and Treatment of
Human Mycoses . . . . . . . . . . . . . . . . . . . . . . . . .157
U066 Compliance in Pharmaceutical Development:
What You Need to Know . . . . . . . . . . . . . . . . . .145 U083 Hair Highlights: Common and Challenging
Hair Loss Disorders . . . . . . . . . . . . . . . . . . . . . .157
U067 Twists and Splits: How to Approach Hair Shaft
Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .146 U084 Climate Change, Allergy, and the Skin . . . . . . . .157
U068 Electrosurgery Update. . . . . . . . . . . . . . . . . . . . .146 U085 Emerging Laser and Aesthetic Technology . . . . .158
U069 Half-Truths, Lies, and Statistics: Understanding

PROGRAM OVERVIEW
Medical Statistics for the Practitioner . . . . . . . . .146 P151 Plenary Session — 8:00 a.m. to 12:00 p.m.
U070 Getting Started with Interpolation Flaps. . . . . . .146 8:00 a.m. Business and Bagels . . . . . . . . . . . . . . . . . . . . . .159
U071 Warts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .147 8:45 a.m. Welcome
Lawrence M. Eichenfield, M.D. . . . . . . . . . . . . . .159
U072 Pediatric Dermatologic Surgery in the 8:50 a.m. Clarence S. Livingood, M.D.,
Outpatient Setting: Tricks of the Trade . . . . . . . .147 Award and Lectureship
Neil S. Prose, M.D. . . . . . . . . . . . . . . . . . . . . . . .159
Forums — 3:00 p.m. to 5:00 p.m. 9:15 a.m. Introduction of President/President’s Address
F039 Treating Severe Skin Disease in Children . . . . . .147 William D. James, M.D. . . . . . . . . . . . . . . . . . . .160
F040 Resident Transitions . . . . . . . . . . . . . . . . . . . . . .148 9:45 a.m. Marion B. Sulzberger, M.D., Memorial Award
and Lectureship
F041 Finessing Facial Reconstruction. . . . . . . . . . . . . .148 Thomas S. Kupper, M.D. . . . . . . . . . . . . . . . . . . .160
F042 Hair and Nail Clinicopathologic Correlations. . .149 10:15 a.m. President-Elect’s Address
F043 Role of Dermatologist in Management of Skin Ronald L. Moy, M.D. . . . . . . . . . . . . . . . . . . . . .161
Disease in Solid Organ Transplant Recipients . . .149 10:30 a.m. Lila Gruber Memorial Cancer Research
F044 Dermatology Teaching and Education Group. . .150 Award and Lectureship
W. Marston Linehan, M.D. . . . . . . . . . . . . . . . . .161
F045 Rosacea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .150
11:00 a.m. Eugene J. Van Scott Award for
F046 Leading Your Team by Coaching Innovative Therapy of the Skin and
and Mentoring . . . . . . . . . . . . . . . . . . . . . . . . . .150 Phillip Frost Leadership Lecture
Anton Stuetz, Ph.D. . . . . . . . . . . . . . . . . . . . . . .162
Workshops — 3:00 p.m. to 5:00 p.m. 11:30 a.m. Guest Speakers
Mary Matalin and James Carville. . . . . . . . . . . . .162
W006 MOC Self-Assessment: Contact Dermatology . .151
Symposium — 11:00 a.m. to 2:00 p.m.
S024 Residents and Fellows Symposium . . . . . . . . . . .163

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 19

 PROGRAM OVERVIEW

Represents restricted session in program overviews Represents activities that meet MOC-D
Restricted Session open to dermatologists and corporate M
O
This activity has been approved by the ABD to satisfy
individual members only! A ticket is required for admittance C component 2 of MOC-D

Represents Practice Management Session in program overviews Represents Leadership Institute in program overviews
Practice Management Session open to eligible Leadership Institute — addresses leadership
office staff/registered nurses competencies specific to dermatologists

Represents Patient Safety Session in program overviews Represents Health Information Technology (HIT) in
program overviews
Patient Safety Session
Health Information Technology Sessions

Represents Audience Response System Session

Audience Response System Session

Discussion Groups — 12:15 p.m. to 1:45 p.m. Discussion Groups — 2:30 p.m. to 4:00 p.m.
D015 Urticaria and Angioedema . . . . . . . . . . . . . . . . .159 D017 Churning Out the Learning . . . . . . . . . . . . . . . .173
D016 Photodermatology . . . . . . . . . . . . . . . . . . . . . . .159 D018 Practice Tips and Surgical Gems . . . . . . . . . . . . .173

Poster Discussion Sessions — 12:15 p.m. to 1:45 p.m. Focus Sessions — 2:30 p.m. to 4:00 p.m.
PD03 Acne . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .164 U098 HIT EMRs and Documenting Clinical Care:
PD04 Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .164 Pitfalls and Promises . . . . . . . . . . . . . . . . . . . . .174
U099 Lumps and Bumps in Children. . . . . . . . . . . . . .174
Focus Sessions — 12:15 p.m. to 1:45 p.m. U100 Current Management of Skin Cancer in
U086 Melasma: Pathogenesis and Treatment . . . . . . . .165 Transplant Patients . . . . . . . . . . . . . . . . . . . . . . .175
PROGRAM OVERVIEW

U087 Fulfilling Great Expectations: Caring for U101 Pediatric Drug Eruptions . . . . . . . . . . . . . . . . . .175
New Mothers and Mothers-to-Be . . . . . . . . . . . .165 U102 From Pigment to PUPP (or PEP): What to Expect
U088 Hereditary Diseases of the Epidermis . . . . . . . . .165 When Your Patient is Expecting . . . . . . . . . . . . .175
U089 Lasers 101. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .166 U103 Drug Reaction Update 2011. . . . . . . . . . . . . . . .176
U090 Angiogenesis and Clinical Dermatology . . . . . . .166 U104 Cosmeceuticals: Topical Therapies for Treating
the Aging Face . . . . . . . . . . . . . . . . . . . . . . . . . .176
U091 Challenging Cases in Dermatopathology . . . . . .166
U105 Advances in Fat Transfer and Liposuction for
U092 Opening Your Own Practice: Correction of Lipodystrophy: The USC
Blunders and Breakthroughs . . . . . . . . . . . . . . . .166 Experience . . . . . . . . . . . . . . . . . . . . . . . . . . . . .176
U093 Notes of a Therapeutic Iconoclast . . . . . . . . . . . .167 U106 What’s That? Syndrome Update . . . . . . . . . . . . .176
U094 Dermatologic Manifestations of HIV and AIDS 167 U107 Dermatology in Cinema . . . . . . . . . . . . . . . . . . .177
U095 Biologic Drugs for Psoriasis: U108 Safety of Biologic Therapies: What’s the
Do We Use Them Enough?. . . . . . . . . . . . . . . . .167 Real Story? . . . . . . . . . . . . . . . . . . . . . . . . . . . . .177
U096 Medical Therapies and How They Work . . . . . . .167
U097 Immunostimulatory Treatment of Skin Cancer. .168 Forums — 3:00 p.m. to 5:00 p.m.
F047 Managing an Efficient Practice . . . . . . . . . . . . . .177
Symposia — 2:00 p.m. to 5:00 p.m. F048 Psoriasis as a Systemic Disease. . . . . . . . . . . . . . .178
S025 New Emerging Therapies . . . . . . . . . . . . . . . . . .168 F049 Laser Pearls . . . . . . . . . . . . . . . . . . . . . . . . . . . . .178
S026 Cutaneous Oncology . . . . . . . . . . . . . . . . . . . . .169 F050 What’s New in Immunomodulation . . . . . . . . . .179
S027 Contact and Occupational Dermatitis . . . . . . . .170 F051 Controversies in Vitamin D . . . . . . . . . . . . . . . .179
S028 Nails . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .171 F052 Advanced Dermatopathology . . . . . . . . . . . . . . .180
S029 Lessons from Great Leaders . . . . . . . . . . . . . . . .172 F053 Autoimmune Disease Update . . . . . . . . . . . . . . .180
S030 Electronic Health Record (EHR) Physician F054 Dermatologic Health of Women. . . . . . . . . . . . .181
Demonstration Symposium . . . . . . . . . . . . . . . .172
S031 Tropical Dermatology . . . . . . . . . . . . . . . . . . . . .173

20 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 PROGRAM OVERVIEW

Workshops — 3:00 p.m. to 5:00 p.m. Courses — 9:00 a.m. to 12:00 p.m.
W007 Effective Communication . . . . . . . . . . . . . . . . . .181 C021 Intermediate Cosmetic Surgery . . . . . . . . . . . . . .198
W008 Basic Dermoscopy. . . . . . . . . . . . . . . . . . . . . . . .182 C022 Advanced Practice Management: Mini MBA . . .199
W009 MOC Self-Assessment B. . . . . . . . . . . . . . . . . . .183 C023 Advanced Pediatric Dermatology . . . . . . . . . . . .200

Symposia — 9:00 a.m. to 12:00 p.m.

MONDAY, FEBRUARY 7 S032 Cutaneous Tumors Benign and Malignant . . . . .201
Poster Discussion Sessions — 7:15 a.m. to 8:45 a.m.
S033 Photodermatology. . . . . . . . . . . . . . . . . . . . . . . .202
PD05 Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .187
S034 Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .203
PD06 Internal Medicine . . . . . . . . . . . . . . . . . . . . . . . .187
S035 Controversies in Dermatologic Drug Therapy. . .204
Discussion Groups — 7:15 a.m. to 8:45 a.m. S036 Blistering Disease . . . . . . . . . . . . . . . . . . . . . . . .205
D019 Enhancing Observational Skills. . . . . . . . . . . . . .188 S037 Key Surgical Principles We All Should Know . . .206
D020 When Does Chronic Dermatitis Become Cutaneous
T Cell Lymphoma? . . . . . . . . . . . . . . . . . . . . . .188 Courses — 9:00 a.m. to 5:00 p.m.
C024 Infectious Diseases . . . . . . . . . . . . . . . . . . . . . . .207
Focus Sessions — 7:15 a.m. to 8:45 a.m. C025 Fundamentals of Dermoscopy . . . . . . . . . . . . . .208
U109 Pediatric Connective Tissue . . . . . . . . . . . . . . . .189
U110 Review of Dermatological Adverse Reactions . . .189 Forums — 12:00 p.m. to 2:00 p.m.
U111 Reconstruction in Dermatologic Surgery: F063 Young Physician Pearls and Pitfalls:
An Introductory and Review Session . . . . . . . . .189 A Survival Guide for the First 10 Years . . . . . . . .209
U112 Histopathology of Scarring Alopecia. . . . . . . . . .190 F064 The Approach to the Patient with Cutaneous
T-Cell Lymphoma. . . . . . . . . . . . . . . . . . . . . . . .209
U113 Immunology for Dermatologists . . . . . . . . . . . . .190
F065 What’s New and Emerging: Therapeutics . . . . . .210
U114 Stem Cells in Melanoma and Nevi . . . . . . . . . . .190

PROGRAM OVERVIEW
F066 Merkel Cell Carcinoma: Diagnosis,
U115 Medication Use: Improving Adherence Management, and Controversies . . . . . . . . . . . . .210
and Compliance . . . . . . . . . . . . . . . . . . . . . . . . .191
F067 Managing Hair Loss Made Easy . . . . . . . . . . . . .211
U116 Utilize websites that Enhance Your Career . . . . .191
F068 Use of Physician Extenders . . . . . . . . . . . . . . . . .211
U117 Diagnosis and Management of Unusual
Skin Tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . .192 F069 Cutaneous Oncology: Multidisciplinary
Management of Common and
U118 Holy Moly: Religion and the Skin . . . . . . . . . . .192 Uncommon Skin Cancers . . . . . . . . . . . . . . . . . .212
U119 New Botulinum Toxins Practice Integration . . . .192 F070 Fungal Infections . . . . . . . . . . . . . . . . . . . . . . . .212

Forums — 9:00 a.m. to 11:00 a.m. Workshop — 12:00 p.m. to 2:00 p.m.
F055 Vitiligo: Problems and Solutions. . . . . . . . . . . . .193 W012 Dealing with Difficult People and Looking
F056 Therapeutic Safety. . . . . . . . . . . . . . . . . . . . . . . .193 Forward to It. . . . . . . . . . . . . . . . . . . . . . . . . . . .213
F057 Adolescent Dermatology . . . . . . . . . . . . . . . . . . .194
F058 Hair Loss in Women. . . . . . . . . . . . . . . . . . . . . .194 Discussion Groups — 12:15 p.m. to 1:45 p.m.

F059 Case-Based Discussion in Cutaneous D021 Dermatology, Diagnosis, and the Visual Arts . . .213
Lymphomas . . . . . . . . . . . . . . . . . . . . . . . . . . . .195 D022 Common Dermatologic Diseases with Myriad
F060 Immunohistochemistry in Dermatology . . . . . . .195 Treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . .213

F061 Medical Dermatology Challenge: Complex Cases

from the Collection of Dr. Samuel Moschella. . .196 Focus Sessions — 12:15 p.m. to 1:45 p.m.
F062 Ethical Dilemmas in Dermatology . . . . . . . . . . .196 U120 Sexually Transmitted Infections:
The Current Standard of Diagnosis and Care . . .214
Workshops — 9:00 a.m. to 11:00 a.m. U121 Update on Graft-Versus-Host Disease . . . . . . . .214
W010 MOC Self-Assessment: Cosmetic Dermatology .197 U122 High-Risk Squamous Cell Carcinomas:
A Clinical and Pathologic Case Review. . . . . . . .214
W011 Leading by Advocating for Dermatology. . . . . . .197
U123 Forensics in Dermatology . . . . . . . . . . . . . . . . . .215

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 21

 PROGRAM OVERVIEW

Represents restricted session in program overviews Represents activities that meet MOC-D
Restricted Session open to dermatologists and corporate M
O
This activity has been approved by the ABD to satisfy
individual members only! A ticket is required for admittance C component 2 of MOC-D

Represents Practice Management Session in program overviews Represents Leadership Institute in program overviews
Practice Management Session open to eligible Leadership Institute — addresses leadership
office staff/registered nurses competencies specific to dermatologists

Represents Patient Safety Session in program overviews Represents Health Information Technology (HIT) in
program overviews
Patient Safety Session
Health Information Technology Sessions

Represents Audience Response System Session

Audience Response System Session

U124 Graft-Versus-Host Disease. . . . . . . . . . . . . . . . . .215 U134 Issues in Office Design . . . . . . . . . . . . . . . . . . . .227

U125 Penile Growths . . . . . . . . . . . . . . . . . . . . . . . . . .216 U135 What’s New in Dermatopathology and Why
U126 Healing the Pyoderma Gangrenosum Ulcer: It’s Important to You. . . . . . . . . . . . . . . . . . . . . .227
Lessons for the PG Clinic . . . . . . . . . . . . . . . . . .216 U136 Management of Challenging Pigmented Lesions. . . 227
U127 Interactive Clinical Pathologic Challenge . . . . . .217 U137 Developing a Unified Approach to Investigating
U128 Leg Ulcer Quiz for the Astute Dermatologist! . .217 Autoimmune Disease . . . . . . . . . . . . . . . . . . . . .227
U129 Informed Shared Decision Making in U138 Digital Imaging and Medical Informatics: Decision
Psoriasis Management . . . . . . . . . . . . . . . . . . . . .217 Support for Clinicians and Teachers . . . . . . . . . .228
U130 Sarcoidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . .217 U139 Inherited Cancer Syndromes:
The Role of the Dermatologist . . . . . . . . . . . . . .228
PROGRAM OVERVIEW

U131 Neurofibromatosis. . . . . . . . . . . . . . . . . . . . . . . .218

U140 Past, Present, and Pearls of Treatment of
U132 The Year in Review in Pediatric Dermatology: Autoimmune Bullous Disease . . . . . . . . . . . . . . .229
How Does It Change My Practice? . . . . . . . . . .218
U141 Skin Signs of Systemic Disease . . . . . . . . . . . . . .229
U142 Cryosurgical Update . . . . . . . . . . . . . . . . . . . . . .229
Courses — 2:00 p.m. to 5:00 p.m.
C026 Basic Botulinum Toxin . . . . . . . . . . . . . . . . . . . .219
Forums — 3:00 p.m. to 5:00 p.m.
C027 Sclerotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . .220
F071 Advanced Treatment for Chronic Wounds . . . . .230
C028 Soft Tissue Augumentation . . . . . . . . . . . . . . . . .220
F072 Medium and Deep Chemical Peeling . . . . . . . . .230
F073 Techniques for Flap Success . . . . . . . . . . . . . . . .230
Symposia — 2:00 p.m. to 5:00 p.m.
F074 The Use of the Confocal Microscope in a
S038 Surgical Pearls . . . . . . . . . . . . . . . . . . . . . . . . . . .221
Private Clinical Practice . . . . . . . . . . . . . . . . . . .231
S039 Therapeutic and Diagnostic Pearls . . . . . . . . . . .221
F075 Alopecia CPC . . . . . . . . . . . . . . . . . . . . . . . . . . .231
S040 Fundamentals of Cutaneous Surgery. . . . . . . . . .222
F076 Pediatric Dermatology . . . . . . . . . . . . . . . . . . . .232
S041 Clinical Issues in Medical Dermatology . . . . . . .223
F077 Aesthetic Dermatologic Complications . . . . . . . .232
S042 International Dermatology . . . . . . . . . . . . . . . . .224
F078 Epidermolysis Bullosa: Cases and Discussion . . .233
S043 Melanoma Update . . . . . . . . . . . . . . . . . . . . . . .225
Workshop — 3:00 p.m. to 5:00 p.m.
Discussion Groups — 2:30 p.m. to 4:00 p.m.
W013 MOC Self-Assessment Office-based Safety . . . . .233
D023 Cutaneous T-Cell Lymphoma . . . . . . . . . . . . . . .226
D024 PAPA Syndrome, SAPHO, and Acne:
Skin and Bones and Inflammation . . . . . . . . . . .226 MONDAY/TUESDAY, FEBRUARY 7/8
Courses — 9:00 a.m. to 5:00 p.m.
Focus Sessions — 2:30 p.m. to 4:00 p.m. C029 Dermatology Review. . . . . . . . . . . . . . . . . . . . . .234
U133 Psychodermatology: Not Just a Delusion; ‘Bugs,’ C030 Basic Dermatopathology . . . . . . . . . . . . . . . . . . .235
Trichotillomania, and the Morgellons Debate. . .226

22 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 PROGRAM OVERVIEW

TUESDAY, FEBRUARY 8 Symposia — 9:00 a.m. to 12:00 p.m.

Discussion Groups — 7:15 a.m. to 8:45 a.m. S044 Therapeutic Hotline . . . . . . . . . . . . . . . . . . . . . .247
D025 Integration of Photodynamic Therapy into S045 Disorders of Mucous Membranes . . . . . . . . . . . .247
Your Practice. . . . . . . . . . . . . . . . . . . . . . . . . . . .238
S046 Pediatric Dermatology . . . . . . . . . . . . . . . . . . . .248
D026 A Practical Approach to Photosensitivity. . . . . . .238
S047 Managing Melanoma in the Modern
Millennium. . . . . . . . . . . . . . . . . . . . . . . . . . . . .249
Focus Sessions — 7:15 a.m. to 8:45 a.m. S048 Cutaneous Lymphomas. . . . . . . . . . . . . . . . . . . .249
U143 Pediatric Surgery . . . . . . . . . . . . . . . . . . . . . . . . .238 S049 Cosmetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .250
U144 Serial Screening for Melanoma: Measures S050 Organizational Approaches to AIDS/STDs
That Have Consistently Achieved Early From a Global Perspective. . . . . . . . . . . . . . . . . .250
Detection and Cure . . . . . . . . . . . . . . . . . . . . . .238
U145 Advances in Psoriasis. . . . . . . . . . . . . . . . . . . . . .239
Forums — 12:00 p.m. to 2:00 p.m.
U146 Management of Cutaneous Toxicity in the Era
F086 BCC Update and Options of Treatment . . . . . . .251
of Targeted Chemotherapy . . . . . . . . . . . . . . . . .239
F087 Nail Disorders in Children . . . . . . . . . . . . . . . . .251
U147 Dermatological Signs of Child Abuse . . . . . . . . .239
F088 Clinical Trials . . . . . . . . . . . . . . . . . . . . . . . . . . .252
U148 Lessons Learned from Challenging Pediatric Cases:
Targeted Novel Molecular Therapies . . . . . . . . .239 F089 Advances in Photomedicine . . . . . . . . . . . . . . . .252
U149 Overgrowth Syndromes . . . . . . . . . . . . . . . . . . .240 F090 Autoimmune Mucocutaneous Blistering
Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .253
U150 Skin Cancer Viruses: Bench to Bedside. . . . . . . .240
F091 Supportive Onco-dermatology:
U151 Approach to Non-scarring Hair Loss in Women. . . 240
Dermatologic Reactions in Oncology . . . . . . . . .253
U152 Cutaneous Mucinosis . . . . . . . . . . . . . . . . . . . . .241
F092 Diagnosing and Monitoring Hair
U153 Facing Facial Dermatoses . . . . . . . . . . . . . . . . . .241 and Scalp Disease . . . . . . . . . . . . . . . . . . . . . . . .254

Forums — 9:00 a.m. to 11:00 a.m. Discussion Group — 12:15 p.m. to 1:45 p.m.

PROGRAM OVERVIEW
F079 Update on Alopecia Areata . . . . . . . . . . . . . . . . .241 D027 Differential Diagnosis of Leprosy in
a Non-Endemic Country . . . . . . . . . . . . . . . . . .254
F080 Fractional Laser and Light-Based Technologies . . .242
F081 Geriatric Dermatology . . . . . . . . . . . . . . . . . . . .242
Focus Sessions — 12:15 p.m. to 1:45 p.m.
F082 Managing Office Politics: Private Practice,
Academics, and Everything in Between. . . . . . . .243 U154 Caring for the Hospitalized Patient: Interesting
Cases from the Inpatient Consultative Service . .255
F083 Psoriasis Therapy in the Age of Biologics . . . . . .243
U155 What’s New in Skin Cancer Prevention . . . . . . .255
F084 Medical Applications of Topical
Photodynamic Therapy . . . . . . . . . . . . . . . . . . . .243 U156 Finding the Needle in the Haystack:
A Guide to More Effective Patch Testing . . . . . .255
F085 Autoimmune Blistering Disorders. . . . . . . . . . . .244
U157 Rosacea Update. . . . . . . . . . . . . . . . . . . . . . . . . .255
U158 Acne: Etiopathogenesis and Treatment 2011. . . .256
Workshop — 9:00 a.m. to 11:00 a.m.
U159 An Approach to Cultural
W014 Dermoscopy Cases . . . . . . . . . . . . . . . . . . . . . . .244 Diversity in Dermatology . . . . . . . . . . . . . . . . . .256
U160 Pigmented Lesions in Pediatric Dermatology . . .257
Courses — 9:00 a.m. to 12:00 p.m.
U161 Actinic Keratoses Update . . . . . . . . . . . . . . . . . .257
C031 Advanced Cosmetic Surgery and Aesthetics . . . .245
U162 Full Facial Approach with Botulinum Toxin
C032 Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .246 and Hyaluronic Acid: Cases From a
European Practice . . . . . . . . . . . . . . . . . . . . . . . .257

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 23

 PROGRAM OVERVIEW

Represents restricted session in program overviews Represents activities that meet MOC-D
Restricted Session open to dermatologists and corporate M
O
This activity has been approved by the ABD to satisfy
individual members only! A ticket is required for admittance C component 2 of MOC-D

Represents Practice Management Session in program overviews Represents Leadership Institute in program overviews
Practice Management Session open to eligible Leadership Institute — addresses leadership
office staff/registered nurses competencies specific to dermatologists

Represents Patient Safety Session in program overviews Represents Health Information Technology (HIT) in
program overviews
Patient Safety Session
Health Information Technology Sessions

Represents Audience Response System Session

Audience Response System Session

U163 Garden Variety Derm: Identifying and Managing
Exposures to Hazardous Plants and Arthropods in
the Garden . . . . . . . . . . . . . . . . . . . . . . . . . . . . .258
U164 Hypercoagulability, Purpura, and the Skin . . . . .258
U165 The Management of TEN/SJS:
The US Army Burn Unit Experience . . . . . . . . .258
U170 Pitfalls in Dermatopathology: When Things Are
Not What They Seem to Be . . . . . . . . . . . . . . . .262
U171 Frontiers of Dermatopathology: Utility,
Methodology, and Interpretation of Current
(and Future) Molecular Testing. . . . . . . . . . . . . .262
U172 Transplant Research in Dermatology . . . . . . . . .262

Courses— 2:00 p.m. to 5:00 p.m. Forums — 3:00 p.m. to 5:00 p.m.
C033 Advanced Surgery . . . . . . . . . . . . . . . . . . . . . . . .259 F093 Psychocutaneous Medicine . . . . . . . . . . . . . . . . .263
C034 Skin Resurfacing and Rejuvenation. . . . . . . . . . .259 F094 Melasma: Advances in the Treatment of a
PROGRAM OVERVIEW

Therapeutically Challenging Disease . . . . . . . . . .263

Symposia — 2:00 p.m. to 5:00 p.m. F095 Challenges in the Diagnosis and Management of
Lentigo Maligna Melanoma . . . . . . . . . . . . . . . .264
S051 Evidence-Based Medicine . . . . . . . . . . . . . . . . . .260
F096 Phototherapy . . . . . . . . . . . . . . . . . . . . . . . . . . .264
S052 Surgical Complications . . . . . . . . . . . . . . . . . . . .261

Focus Sessions — 2:30 p.m. to 4:00 p.m.

U166 Great Cases in Teledermatology . . . . . . . . . . . . .261
U167 Establishing a Mohs Practice:
Pearls for New Surgeons . . . . . . . . . . . . . . . . . . .261
U168 Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .261
U169 Cryosurgery Present and Future . . . . . . . . . . . . .261

24 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

When comedonal acne is your primary concern…
PRESCRIBE DIFFERIN® GEL, 0.3%

Primarily comedonal acne:

EXAMPLE A

EXAMPLE B

POWERFUL EFFICACY HIGH PATIENT SATISFACTION

From baseline to week 12, lesion reduction 86% of patients on adapalene gel, 0.3%
(total, noninflammatory, and inflammatory) were satisfied or very satisfied vs 69%
was similar to tazarotene gel, 0.1%1* on tazarotene gel, 0.1%1*
Local tolerability scores comparable
to tretinoin gel microsphere, 0.04%2†

*A phase 3b, 12-week, noninferiority, multicenter, investigator-blinded, controlled clinical study of patients 12 to 35 years of age with acne vulgaris (N=172). At the end of 12 weeks,
neither product was found to be inferior. 160 patients participated in the satisfaction survey.
†A single-center, randomized, investigator/evaluator-blinded, bilateral (split-face) comparison of healthy subjects ≥18 years of age (N=30). Subjects received Differin® Gel, 0.3%
on one half of the face and tretinoin gel microsphere, 0.04% on the other half for 22 days.

Important Safety Information

Of the patients who experienced cutaneous irritation (erythema, scaling, dryness, and/or
stinging/burning) during the clinical trial, the majority of cases were mild to moderate in
severity, occurred early in treatment, and decreased thereafter. Adverse events that occurred
in greater than 1% of the subjects included dry skin (14.0%), skin discomfort (5.8%), pruritus
(1.9%), desquamation (1.6%), and sunburn (1.2%). Pregnancy Category C.
Concomitant use of potentially irritating products or overexposure to sunlight or sunlamps,
extreme wind or cold, may increase the potential for irritation. Use of sunscreen and
protective clothing over treated areas are recommended when exposure cannot be avoided.
Please see brief summary of Prescribing Information on adjacent page. www.differin.com
DIFFERIN® (adapalene) Gel, 0.3% Rx only ADVERSE REACTIONS: In the multi-center, controlled clinical trial, signs and symptoms of local cutaneous irritation
were monitored in 258 acne patients who used DIFFERIN® Gel, 0.3% once daily for 12 weeks. Of the patients who
BRIEF SUMMARY experienced cutaneous irritation (erythema, scaling, dryness, and/or burning/stinging), the majority of cases were
For topical use only. Not for ophthalmic, oral or intravaginal use. mild to moderate in severity, occurred early in treatment and decreased thereafter. The incidence of local cutaneous
INDICATIONS AND USAGE: DIFFERIN® Gel, 0.3% is indicated for the topical treatment of acne vulgaris in patients irritation with DIFFERIN® Gel, 0.3% from the controlled clinical study is provided in the following table:
12 years of age and older. Table 2: Physician assessed local cutaneous irritation with DIFFERIN® Gel
CONTRAINDICATIONS: DIFFERIN® Gel, 0.3% should not be administered to individuals who are hypersensitive to Incidence of Local Cutaneous Irritation with DIFFERIN® Gel, 0.3% from Controlled Clinical Study
adapalene or any of the components in the gel vehicle. (N=253*)
PRECAUTIONS: Maximum Severity Scores Higher Than Baseline
General: Certain cutaneous signs and symptoms of treatment such as erythema, scaling, dryness, and
stinging/burning may be experienced with use of DIFFERIN® Gel, 0.3%. These are most likely to occur during the Mild Moderate Severe
first four weeks of treatment, are mostly mild to moderate in intensity, and usually lessen with continued use of the Erythema 66 (26.1%) 33 (13.0%) 1 (0.4%)
medication. Depending upon the severity of these side effects, patients should be instructed to either use a mois- Scaling 110 (43.5%) 47 (18.6%) 3 (1.2%)
turizer, reduce the frequency of application of DIFFERIN® Gel, 0.3% or discontinue use.
Dryness 113 (44.7%) 43 (17.0%) 2 (0.8%)
If a reaction suggesting sensitivity or chemical irritation occurs, use of the medication should be discontinued.
Exposure to sunlight, including sunlamps, should be minimized during use of adapalene. Patients who normally Burning/Stinging 72 (28.5%) 36 (14.2%) 9 (3.6%)
experience high levels of sun exposure, and those with inherent sensitivity to sun, should be warned to exercise cau- * Total number of subjects with local cutaneous data for at least one post-Baseline evaluation.
tion. Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot
Table 3: Patient reported local cutaneous adverse events with DIFFERIN® Gel
be avoided. Weather extremes, such as wind or cold, also may be irritating to patients under treatment with
adapalene. DIFFERIN® (adapalene) Gel, 0.3% Vehicle Gel
Avoid contact with the eyes, lips, angles of the nose, and mucous membranes. The product should not be applied
N=258 N=134
to cuts, abrasions, eczematous or sunburned skin. As with other retinoids, use of “waxing” as a depilatory method
should be avoided on skin treated with adapalene. Related* Adverse Events 57 (22.1%) 6 (4.5%)
Information for Patients: Patients using DIFFERIN® Gel, 0.3%, should receive the following information and instruc- Dry Skin 36 (14%) 2 (1.5%)
tions: Skin Discomfort 15 (5.8%) 0 (0.0%)
1. This medication is to be used only as directed by the physician. Desquamation 4 (1.6%) 0 (0.0%)
2. It is for external use only.
3. Avoid contact with the eyes, lips, angles of the nose, and mucous membranes. * Selected adverse events defined by investigator as Possibly, Probably or Definitely Related
4. Cleanse affected area with a mild or soapless cleanser before applying this medication. Related adverse events from the controlled clinical trial that occurred in greater than 1% of patients who used
5. Moisturizers may be used if necessary; however, products containing alpha hydroxy or glycolic acids should DIFFERIN® Gel, 0.3% once daily included: dry skin (14.0%), skin discomfort (5.8%), pruritus (1.9%), desquamation
be avoided. (1.6%), and sunburn (1.2%). The following selected adverse events occurred in less than 1% of patients: acne flare,
6. Exposure of the eye to this medication may result in reactions such as swelling, conjunctivitis, and eye contact dermatitis, eyelid edema, conjunctivitis, erythema, pruritus, skin discoloration, rash, and eczema.
irritation. In a one-year, open-label safety study of 551 patients with acne who received DIFFERIN® Gel, 0.3%, the pattern of
7. This medication should not be applied to cuts, abrasions, eczematous, or sunburned skin. adverse events was similar to the 12-week controlled study.
8. Wax epilation should not be performed on treated skin due to the potential for skin erosions. OVERDOSAGE: DIFFERIN® Gel, 0.3% is intended for topical use only. If the medication is applied excessively, no
9. During the early weeks of therapy, an apparent exacerbation of acne may occur. This may be due to the more rapid or better results will be obtained and marked redness, scaling, or skin discomfort may occur. Chronic
action of the medication on previously unseen lesions and should not be considered a reason to discontinue ingestion of the drug may lead to the same side effects as those associated with excessive oral intake of vitamin A.
therapy.
Drug Interactions: As DIFFERIN® Gel, 0.3% has the potential to induce local irritation in some patients, concomi- Marketed by:
GALDERMA LABORATORIES, L.P.
tant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cos- Fort Worth, Texas 76177 USA
metics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices, or Manufactured by:
lime) should be approached with caution. Particular caution should be exercised in using preparations containing DPT Laboratories, Ltd.
sulfur, resorcinol, or salicylic acid in combination with DIFFERIN® Gel, 0.3%. If these preparations have been used, San Antonio, Texas 78215 USA
it is advisable not to start therapy with DIFFERIN® Gel, 0.3%, until the effects of such preparations have subsided. GALDERMA is a registered trademark.
Revised: June 2007 325089-0607
Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenicity studies with adapalene have been con-
ducted in mice at topical doses of 0.4, 1.3, and 4.0 mg/kg/day, and in rats at oral doses of 0.15, 0.5, and 1.5
mg/kg/day. These doses are up to 3 times (mice) and 2 times (rats) in terms of mg/m²/day the potential exposure
at the maximum recommended human dose (MRHD), assumed to be 2.5 grams DIFFERIN® Gel, 0.3%. In the oral
study, increased incidence of benign and malignant pheochromocytomas in the adrenal medullas of male rats was
observed.
No photocarcinogenicity studies were conducted. Animal studies have shown an increased risk of skin neoplasms
with the use of pharmacologically similar drugs (e.g., retinoids) when exposed to UV irradiation in the laboratory or
to sunlight. Although the significance of these studies to human use is not clear, patients should be advised to avoid
or minimize exposure to either sunlight or artificial UV irradiation sources.
Adapalene did not exhibit mutagenic or genotoxic effects in vitro (Ames test, Chinese hamster ovary cell assay,
mouse lymphoma TK assay) and in vivo (mouse micronucleus test).
Reproductive function and fertility studies were conducted in rats administered oral doses of adapalene in amounts
up to 20 mg/kg/day (up to 26 times the MRHD based on mg/m² comparisons). No effects of adapalene were found
on the reproductive performance or fertility of the F0 males or females. There were also no detectable effects on the
growth, development and subsequent reproductive function of the F1 offspring.
Pregnancy: Teratogenic effects. Pregnancy Category C. Retinoids may cause fetal harm, when administered to
pregnant women. Adapalene has been shown to be teratogenic in rats and rabbits when administered orally (see Animal
Data below). There are no adequate and well-controlled studies in pregnant women. DIFFERIN® Gel, 0.3% should be
used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The safety and efficacy of
DIFFERIN® Gel, 0.3% in pregnancy has not been established.
1. Human Data
In clinical trials involving DIFFERIN® Gel, 0.3% in the treatment of acne vulgaris, women of child-bearing potential
initiated treatment only after having had a negative pregnancy test and used effective birth control measures during
therapy. However, 6 women treated with DIFFERIN® Gel, 0.3% became pregnant. One patient elected to terminate
the pregnancy, two patients delivered healthy babies by normal delivery, two patients delivered prematurely and the
babies remained in intensive care until reaching a healthy state and one patient was lost to follow-up.
2. Animal Data
• No teratogenic effects were seen in rats at oral doses of 0.15 to 5.0 mg/kg/day adapalene representing up Reference: 1. Thiboutot D, Pariser DM, Egan N, et al; Adapalene Study Group. Adapalene gel 0.3% for the
to 6 times the maximum recommended human dose (MRHD) based on mg/m² comparisons. Adapalene has treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad
been shown to be teratogenic in rats and rabbits when administered orally at doses 25 mg/kg representing Dermatol. 2006;54:242-250.
32 and 65 times, respectively, the MRHD based on mg/m² comparisons. Findings included cleft palate,
microphthalmia, encephalocele and skeletal abnormalities in the rat and umbilical hernia, exophthalmos and Marketed by:
GALDERMA LABORATORIES, L.P.
kidney and skeletal abnormalities in the rabbit. References:
Fort 1. Thiboutot
Worth, Texas 76177 USAD, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel
• Cutaneous teratology studies in rats and rabbits at doses of 0.6, 2.0, and 6.0 mg/kg/day exhibited no feto- compared to tazarotene
Manufactured by: 0.1% gel in the treatment of acne vulgaris. J Drugs Dermatol. 2008;7
toxicity and only minimal increases in supernumerary ribs in both species and delayed ossification in rabbits. (6)(suppl):S3-S10.
DPT 2. Data on file. Galderma Laboratories, L.P. A 3-week, single-center, randomized,
Laboratories, Ltd.
Systemic exposure (AUC0-24h) to adapalene 0.3% gel at topical doses of 6.0 mg/kg/day in rats and rabbits investigator/evaluator-blinded,
San Antonio, Texas 78215 USA bilateral (split-face) comparison, clinical study of adults 18 years of age
represented 5.7 and 28.7 times, respectively, the exposure in acne patients treated with adapalene 0.3% gel GALDERMA is ahealthy
and older with registered
skintrademark.
(N=30).
Revised: June 2007 325089-0607
applied to the face, chest and back (2 grams applied to 1000 cm2 of acne involved skin).
Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted Differin andisGalderma aretrademark.
registered trademarks.
Galderma a registered
in human milk, caution should be exercised when DIFFERIN® Gel, 0.3% is administered to a nursing woman. ©2007 Galderma Laboratories, L.P.
©2010 Galderma
Galderma Laboratories,
Laboratories, L.P. L.P.
Pediatric Use: Safety and effectiveness in pediatric patients below the age of 12 have not been established. Galderma Laboratories, L.P.
Geriatric Use: Clinical studies of DIFFERIN® Gel, 0.3% did not include subjects 65 years of age and older to deter- 14501 N. Freeway
14501
Fort N. Freeway
Worth, TX 76177
mine whether they respond differently than younger subjects. Safety and effectiveness in geriatric patients age 65 Fort Worth, TX 76177
and above have not been established. DIFF-088 Printed03/10
DIF-888 in USA 11/07 www.differin.com
 PERSONAL PROGRAM SCHEDULE

You may use this personal program schedule to plan your daily/weekly schedule while on site at the meeting.
Fill in appropriate time slots as necessary with your schedule.

THURSDAY, FEBRUARY 3
8:00 a.m. to 12:00 p.m.

12:00 p.m. to 5:00 p.m.

FRIDAY, FEBRUARY 4
7:00 a.m. to 9:00 a.m.

7:15 a.m. to 8:45 a.m.

9:00 a.m. to 11:00 a.m.

9:00 a.m. to 12:00 p.m.

9:00 a.m. to 5:00 p.m.

9:30 a.m. to 11:30 a.m.

12:00 p.m. to 2:00 p.m.

12:15 p.m. to 1:45 p.m.

12:30 p.m. to 2:30 p.m.

PERSONAL PROGRAM SCHEDULE

2:00 p.m. to 5:00 p.m.

2:30 p.m. to 4:00 p.m.

3:00 p.m. to 5:00 p.m.

FRIDAY/SATURDAY, FEBRUARY 4/5

9:00 a.m. to 5:00 p.m.

SATURDAY, FEBRUARY 5
7:15 a.m. to 8:45 a.m.

9:00 a.m. to 11:00 a.m.

9:00 a.m. to 12:00 p.m.

9:00 a.m. to 5:00 p.m.

12:00 p.m. to 2:00 p.m.

12:15 p.m. to 1:45 p.m.

2:00 p.m. to 5:00 p.m.

2:30 p.m. to 4:00 p.m.

3:00 p.m. to 5:00 p.m.

continued

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 27

 PERSONAL PROGRAM SCHEDULE

You may use this personal program schedule to plan your daily/weekly schedule while on site at the meeting.
Fill in appropriate time slots as necessary with your schedule.

SUNDAY, FEBRUARY 6
7:00 a.m. to 8:00 a.m.

8:00 a.m. to 12:00 p.m.

11:00 a.m. to 2:00 p.m.

12:15 p.m. to 1:45 p.m.

2:00 p.m. to 5:00 p.m.

2:30 p.m. to 4:00 p.m.

3:00 p.m. to 5:00 p.m.

MONDAY, FEBRUARY 7
7:15 a.m. to 8:45 a.m.

9:00 a.m. to 11:00 a.m.

9:00 a.m. to 12:00 p.m.

9:00 a.m. to 5:00 p.m.

12:00 p.m. to 2:00 p.m.

PERSONAL PROGRAM SCHEDULE

12:15 p.m. to 1:45 p.m.

2:00 p.m. to 5:00 p.m.

2:30 p.m. to 4:00 p.m.

3:00 p.m. to 5:00 p.m.

MONDAY/TUESDAY, FEBRUARY 7/8

9:00 a.m. to 5:00 p.m.

TUESDAY, FEBRUARY 8
7:15 a.m. to 8:45 a.m.

9:00 a.m. to 11:00 a.m.

9:00 a.m. to 12:00 p.m.

9:00 a.m. to 5:00 p.m.

12:00 p.m. to 2:00 p.m.

12:15 p.m. to 1:45 p.m.

2:00 p.m. to 5:00 p.m.

2:30 p.m. to 4:00 p.m.

3:00 p.m. to 5:00 p.m.

28 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 Now replenish skin
at the structural level
NEW Cetaphil® RESTORADERM® Skin Restoring Moisturizer
and Body Wash formulated for atopic dermatitis

Patented technology helps restore hydration

in atopic skin1,2:
Ceramides help replenish the skin’s natural lipids
Filaggrin technology helps restore moisture to help rebuild the
damaged skin barrier

Clinically proven to help soothe itch and reduce redness,

dryness and irritation2
Highly tolerable; preservative and fragrance free2

www.cetaphil.com The National Eczema Association (NEA) Seal of Acceptance is

References: 1. Sugarman JL. The epidermal barrier in atopic dermatitis. Semin
Cutan Med Surg. 2008;27:108-114. 2. Data on file. Galderma Laboratories.
Galderma, Cetaphil and RESTORADERM are registered trademarks.
© 2010 Galderma Laboratories, L.P.
Galderma Laboratories, L.P., 14501 N. Freeway, Fort Worth, TX 76177
CETA-186 Printed in USA 08/10
awarded to products that have been created or intended for
use by persons with eczema or severe sensitive skin conditions
and have satisfied the NEA Seal of Acceptance Criteria. NEA
has awarded the Seal of Acceptance to these products with a
4 out of 5 rating. Read the label to determine if these products
contain ingredients that may be unsuitable for your skin. Visit
nationaleczema.org for more information.
AMERICAN ACADEMY
of DERMATOLOGY
extends a very sincere thank you to
our Corporate Partners
for their very generous support of the
2011 Annual Meeting.
Your support is greatly appreciated!

Please visit our Corporate Partner

Scientific
Recognition Program
Module in the Ernest N. Morial
Convention Center and view Corporate Partner
Recognition in the Program-at-a-Glance
Bio-Oil® is a skincare oil that helps improve the appearance of scars, stretch marks
and uneven skin tone. It is a combination of natural oils and vitamins, together
with the breakthrough ingredient PurCellin Oil™. It was developed in 1987 and is
today the number one selling scar and stretch mark product in 12 countries. It is
available at drugstores at the recommended price of $11.99. For comprehensive
product information, and details of clinical trials, please visit bio-oil.com.
Bio-Oil® is a product of Union Swiss, successfully treating skin since 1954.
 Academy Election
Opens February 5
2011 American Academy of Dermatology Election for
Officers, Directors and Nominating Committee Member Representatives, and
Proposed Bylaw Amendments
Watch for your Secure Access Code, which will be sent in mid-January 2011 via e-mail or mail.

Go to www.aad.org/election
View electronic ballot book beginning
January 28, 2011
Listen to candidates and review background materials
Read proposed bylaw amendments
Conveniently VOTE ONLINE
Remember to access the AAD website from your personal computer
whether you are in your hotel room, a designated Wi-Fi Lounge, or the Cyber Center
at the Ernest N. Morial Convention Center.
Ballot books will mail by Friday, February 4, 2011 and will be available on site at the
Ernest N. Morial Convention Center information desks.

Comments from members who voted online . . .

“Easy to vote online, no postage or pen needed.”
“Online voting – I don’t think it could be any easier!"
“The e-mail with direct link and password made the process very easy!”
“I liked being able to click on the name of the candidates on the ballot to refresh my
memory about their qualifications, background, and views.”
“Being able to click on the proposed bylaw changes to read the description
was very helpful.”

YOUR VOTE IS IMPORTANT

 What’s the next number
in this sequence?

1, 4, 9, 25, 49, 121, 169, 289…

(Turn for the answer)

Find out more about 361 at Booth 1440.

© Centocor Ortho Biotech Inc. 2010 8/10 25ST10036

 GENERAL INFORMATION

IMPORTANT DATES AND TIMES TO REMEMBER

(Please refer to the specific section of the General Information pages for additional details regarding these dates and times)

Optional Activities Cancellation Deadline .................................................. Wednesday, January 5, 2011, at 12:00 p.m. (CT)

Early Registration Fees End......................................................................... Wednesday, January 5, 2011, at 12:00 p.m. (CT)

Late Fees Begin ........................................................................................... Wednesday, January 5, 2011, at 12:01 p.m. (CT)

Badge Mailing for Registrations Received by January 5, 2011, at 12:00 p.m. (CT) ............................... January 10 –21, 2011

Housing Cancellation Deadline ....................................................................Thursday, January 13, 2011, at 12:00 p.m. (CT)

Deadline for Program Books and Brochures to Be Mailed .................................................................Friday, January 14, 2011

Deadline to Request a Letter of Invitation ................................................ Wednesday, January 19, 2011, at 12:00 p.m. (CT)

Deadline to Request an Access ID#........................................................... Wednesday, January 19, 2011, at 12:00 p.m. (CT)

Registrants Must Call the Hotels Directly for Changes ............................................ Monday, January 19, 2011 (and beyond)

Registration Cancellation Deadline ........................................................... Wednesday, January 26, 2011, at 12:00 p.m. (CT)

On-Site Registration Begins ..........................................................................Thursday, February 3, 2011, at 12:00 p.m. (CT)

GENERAL INFORMATION
Dermatology in Action Service Initiative................................................ Thursday, February 3, 2011, at 1:00-4:00 p.m. (CT)

Official Start of the Meeting .................................................................................Friday, February 4, 2011 at 7:15 a.m. (CT)
(Specialty Courses on Volunteerism will take place Thursday, February 3 beginning at 8:00 a.m. and 12:00 p.m.)

Technical Exhibits Open ................................................................................Saturday, February 5, 2011, at 10:00 a.m. (CT)

Technical Exhibits Close .................................................................................. Monday, February 7, 2011, at 5:00 p.m. (CT)

Spouse/Guest Access to Exhibit Hall ...................................................................................Monday, February 7, 2011 (Only)

Official Close of the Meeting ...........................................................................Tuesday, February 8, 2011, at 5:00 p.m. (CT)

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 33

 GENERAL INFORMATION
MEETING LOcATION
The 69th Annual Meeting of the American Academy of
Dermatology will take place February 4-8, 2011 in
New Orleans, La. Registration and educational sessions will
be located at:
New Orleans Ernest N. Morial Convention Center
900 Convention Center Blvd.
New Orleans, LA 70130
www.mccno.com
REGISTRATION INFORMATION
Early registration
Early registration and housing for the 69th Annual Meeting
begins at 12:00 p.m. (CT), Wednesday, October 27, 2010,
according to the following schedule:
IMPORTANT NOTE: Registration and housing forms faxed
in prior to the opening of early registration will be held and
processed based on the date and time received and the schedule
listed below.
Physician, life, honorary members,
and applicants for membership ..........................October 27
GENERAL INFORMATION
Graduate members, residents,
research fellows, and medical students .............. November 3
Adjunct and corporate individual members,
physician assistants and nurse practitioners, office
staff, registered nurses, and non-members ...... November 10
Early registration and housing for members and approved
non-members closes at 12:00 p.m. (CT) on January 5,
2011. After this date and time late registration will apply.
January 26 at 12:00 p.m. (CT) through February 3, 2011
at 12:00 p.m. (CT) all registration systems will be closed.
On-site registration will begin at 12:00 p.m. (CT) on
February 3, 2011.
34 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
NON-MEMBER REGISTRATION
Non-members must submit an online request form for
registration approval and access ID number. See the chart
on page 36 for a list of non-member registration categories.
Non-member requests and required documentation will
only be accepted via the online submission site at the
following:
1. Visit www.aad.org
2. Click on Annual Meeting, under the Scientific
Meetings
3. Click on the Attendee tab
4. Click on Non-Member under the Registration section
Once approved, the registration and housing brochure along
with the optional activities brochure will be sent via US mail.
Due to processing and delivery time, these materials can
no longer be sent out after January 14, 2011.
Access ID numbers will be sent to the e-mail supplied
online. The deadline for submission and approval is
January 19, 2011, at 12:00 p.m. (CT).
Allow 10 to 12 days for approval, processing, and receipt
of materials, including access ID number.
Note: In an effort to make the meeting more
environmentally friendly, program books will no longer
be mailed out to non-member registrants. The complete
program book can be viewed online and program books
will be available on site for reference.
Questions:
E-mail: registration@aad.org
Toll-free phone: (866) 503-SKIN (7546)
or (847) 240-1280
SPOUSE / GUEST REGISTRATION
Spouse/guest registration includes spouses, family members
(children 16 years or older), and guests accompanying
registrants. A “guest” is defined as a significant other, friend, or
a child 16 years or older. Spouse/guest registration is available
for one person per physician registrant. A co-worker or an
associate within the industry does not qualify for the guest
registration category. Photo ID and proof of age (driver’s license,
student ID, birth certificate) will be required.
Registrants in this category may attend non-restricted
symposia, the plenary session, electronic poster and
technical exhibits. Spouse/guest registrants will be
admitted into the Technical Exhibit Hall on Monday,
February 7 only. This category will not be issued a
certificate of attendance.
 GENERAL INFORMATION

Early registration instructions

Early registration and housing for the 69th Annual Meeting may be completed online, by fax, or by mail. Registration,
including enrollment in specific sessions, is on a first-come, first-served basis. Registration forms are enclosed with this
mailing. All forms are non-transferable.
REGISTRATION REGISTRATION PAyMENT PROcESSING
TyPE INSTRUcTIONS METhOD TIME
ONLINE REGISTRATION to register and book housing online for the 69th annual meeting, go to: credit card only Instant
www.aad.org/meetings/annual/index.html (Visa, Mastercard,
or American Express)
click on attendee registration and housing. you will need to input the Id number
printed above your name on the back of the registration and housing brochure.

FAX REGISTRATION to register by fax, complete all registration and housing forms and fax to: credit card only three to five
(800) 521-6017 (U.S. and Canada) (Visa, Mastercard, business days
(847) 996-5401 (International) or American Express) from receipt
due to fax volume, confirmation of fax receipt will not be provided.
Registration and housing forms faxed in prior to the opening of early registration
will be held and processed based on the date and time received and the schedule
listed on the previous page.

US MAIL send payment, registration, and housing forms to: credit card Five to seven
(Visa, Mastercard, business days
aad housing and registration
or American Express) from receipt
568 atrium drive
Vernon hills, IL 60061-1731
or
check payable to
registrants should retain a copy of both sides of the form for their records before AAD Housing and
mailing. only materials delivered to the above address will be accepted. Registration

cUSTOMER SERVIcE
For additional assistance in completing your registration call the aad registration office at (847) 996-5876 or (800) 974-3084 or call the aad
meetings and conventions department at (847) 330-0230.

GENERAL INFORMATION
ADA / SPEcIAL ASSISTANcE
academy staff will be available to help individuals with any special needs (i.e., physical). Please complete the appropriate section online or on the
registration form and a staff member will contact you.
TIcKETED SESSIONS
registrants should identify sessions for which they are requesting tickets when they complete general registration (see chart page ?? for
information on session categories, including ticket requirements and tuition fees). enrollment in ticketed sessions is on a first-come, first-
served basis. alternate choices should be identified. enrollment in multiple sessions during the same time slot is not permitted.
TOUR/OPTIONAL AcTIVITy TIcKETS
Physicians who have registered for the meeting and wish to purchase tour/optional activity tickets may do so online or using the spouse/guest
registration form. the physician must enter his or her own name on the form. tickets will automatically be printed along with the physician’s
registration badge. If a spouse or guest is registered, tour tickets will print along with the spouse or guest’s badge.

cONFIRMATIONS AND chANGES

Confirmation letters will be sent to all individuals who register prior to the start of on-site registration. If an e-mail address is
provided, confirmation will be sent via e-mail. If no e-mail address is provided, the confirmation will be sent via fax. If neither
an e-mail address nor fax number is supplied, confirmation will be sent via US mail. Once you have received a confirmation
letter, you may review and print registration information online. To do so, take the following steps:
1. Visit www.aad.org
2. Click on Annual Meeting under Scientific Sessions
3. Click on Attendee Registration and Housing
4. Click on Already Registered. Enter your registration confirmation number and last name, and then click Find Me
Once in your personal record, you may print a copy of your receipt, pay a balance due, or make changes to your registration
and housing. An updated confirmation will be sent after changes are processed.
Ticketed event changes/cancellations for individuals who register by Wednesday, January 5, 2011 at 12:00 p.m. (CT) and who
will be receiving their materials by mail will only be accepted until Wednesday, January 5, 2011 at 12:00 p.m. (CT). After this
date and time ticket cancellations and changes will need to be made at the Tickets Only Counters located in the Full Service
On-Site Registration area located in Hall G of the Convention Center. For housing changes/cancellations refer to the Hotel
and Travel Information section of the program book (page 41).

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 35

 GENERAL INFORMATION

REGISTRATION cATEGORIES, AccESS, AND FEES

The chart below details fees and session access for all categories eligible to register for the 69th Annual Meeting. For further
information on membership eligibility, please refer to http://www.aad.org/members/join/index.html or e-mail mrc@aad.org.

Member categories
REGISTRATION FEES SESSION AccESS
REGISTRATION cATEGORy EARLy, LATE, OPEN TIcKETED RESTRIcTED
Wednesday, Wednesday,
October 27 - January 5 at
Wednesday, 12:01 p.m. (cT) -
January 5 at Tuesday, February 8
12:00 p.m. (cT)

Physician member $445 $510 y y y

Adjunct member** $445 $510 y y n
corporate individual member** $445 $510 y y y
(approved through membership process)
Life member $145 $160 y y y
honorary member no fee no fee y y y
Graduate member, resident, research fellow** $130 $145 y y y – dermatologist,
n – non-dermatologist
Applicant for membership + $130 $145 y y y – dermatologist,
n – non-dermatologist
NOTE: Day Pass — On-site only $510. Medical personnel only. One Day Pass per meeting. Can only be purchased on day of use.

Non-member categories
GENERAL INFORMATION

(see p. 34 for information on submitting a non-member registration materials request)

REGISTRATION FEES SESSION AccESS

REGISTRATION cATEGORy EARLy, LATE, OPEN TIcKETED RESTRIcTED
Wednesday, Wednesday,
October 27 - January 5 at
Wednesday, 12:01 p.m. (cT) -
January 5 at Tuesday, February 8
12:00 p.m. (cT)

Medical student* ** no fee no fee y y n

Non-dermatology resident** $130 $145 y y y
Non-member physician + $1,500 $1,800 y y y – dermatologist,
(treating patients in a office setting) n – non-dermatologist
Physician assistant/nurse practitioner* ** $445 $510 y y n
Resident/Research Fellow** $130 $145 y y y – dermatologist,
(outside US. or canadian program) n – non-dermatologist
Office staff/registered nurse* $225 $250 y Practice n
management
sessions only
Non-member, non-physician (non-member $1,500 $1,800 y y n
corporate individuals, Industry Representatives,
or Scientist/Researcher working in the field of
Dermatology)* **++

NOTE: Day Pass — On-site only $510. Medical personnel only. One Day Pass per meeting. Can only be purchased on day of use.
* this category is not eligible to register a spouse/guest along with their registration.
** this category is not eligible to register office staff/rn along with their registration.
+ only dermatologists in this category may register office staff/rn along with their registration
++ this category of registration will not be issued an expocard with their registration.

36 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 GENERAL INFORMATION

SESSION cATEGORIES AND FEES

The chart below details the sessions being offered at the 69th Annual Meeting, as well as session fees where applicable.
Registrants should sign up for specific sessions requiring tickets when completing general registration.
See p.38 for details on distribution of tickets and other meeting materials.

TUITION FEE
SESSION SESSION TIcKET Members Non-members and Medical students
TyPE DEScRIPTION REQUIRED and PAs/NPs office staff/RNs and residents

courses** Intensive sessions offering in-depth coverage of

a single subject.

half-day courses y $40 $120 $30

One-day courses y $60 $180 $40
Two-day courses y $100 $300 $60
Self-assessment Basic, advanced, and comprehensive sessions; y $90 $300 $50
courses** attendees review slides from skin biopsy
specimens in a format that allows self-assessment.
Derm Exam Prep course: this course is targeted at the Board certified y $300 n/a $150
Refresher** dermatologist preparing for the american
Board of dermatology (aBd) maintenance of
certification in dermatology (moc-d) exam.

residents preparing for their Board exam may

also benefit, but this course is not designed as
a Prep for initial board certification.
Review of Dermatology a course that provides in-depth coverage of y $200 $500 $100
course** multiple areas of medical dermatology; the
course is not inclusive but covers areas of new

GENERAL INFORMATION
information and advancement in the past five
years.
Live Patient Interactive session presenting live y $100 $390 $60
Demonstration** demonstrations of botulinum toxin and soft
tissue filler injection; open to dermatologists
and corporate individual members only.
Restricted symposia* sessions comprised of individual presentations y no fee no fee no fee
focused on a specific subject; open to
dermatologists and corporate individual
members only.
Non-restricted symposia sessions comprised of an individual n no fee no fee no fee
presentation focused on a specific subject.
Workshops** sessions emphasizing media training, clinical y $35 $90 $25
care, and technical skills.
Forums* sessions exploring a single subject. y no fee no fee no fee

Focus Sessions* sessions with an emphasis on discussion and y no fee no fee no fee
participant interaction.

Discussion groups** sessions limited to 50 participants; emphasis y $25 $90 $25

is on active discussion and interaction between
director and audience.
Poster discussion sessions limited to 50 participants with y no fee no fee no fee
sessions* interaction encouraged; emphasis is on
important issues raised in the selected posters.
MOc – Self Assessment a session with interactive question-and-answer y $35 $90 $25
Workshop** format utilizing an audience response system.
Feedback provided to participants to identify
areas of weakness that may require further self-
directed study.
* Tickets for sessions with no fee will hold a seat for 15 minutes after the official start time, after which seats will be available on a first-come, first-served basis for eligible categories.
** Attendees of sessions with a fee must have a ticket for admittance.

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 37

 GENERAL INFORMATION
cancellations
GENERAL REGISTRATION
Registrants who wish to cancel all of their general
registration should send a letter of cancellation via one of
the following methods:
E-mail: aad@experient-inc.com
Fax: (800) 521-6017 or (847) 996-5401
The following policies apply to cancellations:
Deadline: 12:00 p.m. (CT), Wednesday,
January 26, 2011; no refund will be
given for cancellations received after this
date. No exceptions will be made.
Fee: $75 (fee will be deducted from refund
amount); $25 (fee will be deducted for
all spouse/guest cancellations)
Processing: Cancellations received by 12:00 p.m.
(CT), January 26, 2011 will be
processed and refunds issued prior to the
meeting.
No-shows: No-shows are considered to have missed
the Wednesday, January 26, 2011
GENERAL INFORMATION
deadline and are not eligible for
a refund.
On site: No refunds will be issued for on-site
registration.
Name change: Registration is non-transferable. If you
cannot attend the meeting, you must
submit a cancellation; you may not
change the name on your registration.
For hotel reservation cancellation, please see Hotel and
Travel Information section on page 41.
SESSION TIcKETS
Session tickets must be returned prior to the start time of
the session for a refund to be issued. To return session
tickets prior to the meeting, refer to the Confirmations
and Changes section located on page 35. Session tickets
may be returned at the Tickets Only Counters located in
the Full-Service On-Site Registration area located in Hall
G of the Convention Center. Tickets cannot be returned
or exchanged after the start of the session. Refunds will
not be issued for late arrival or for non-attendance.
38 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
OPTIONAL AcTIVITIES
The deadline for cancellation of optional activities is
Wednesday, January 5, 2011 at 12:00 p.m. (CT). Tickets
purchased during late registration are non-refundable.
Cancellations must be submitted in writing via e-mail to
aad@experient-inc.com or fax to: (847) 996-5401 or
(800) 521-6017. Refunds will not be issued for weather
conditions unless the tour operator cancels the activity.
MEETING MATERIALS
Badges, tickets, vouchers
EARLy REGISTRANTS [By JANUARy 5, 2011 AT 12:00 P.M. (cT)]
All individuals, who complete registration by Wednesday,
January 5, 2011 at 12:00 p.m. (CT), will receive their
badges, tickets, and attendance verification/meeting bag
voucher by mail. Registration packets will be sent via
U.S. mail to U.S. registrants and via special courier service
to Canadian and international registrants between
January 10 - January 21, 2011. Materials will be mailed
to the address listed on the recipient’s registration records,
which will also be listed on recipient’s ExpoCard.
REGISTRANTS WhO REGISTER AFTER WEDNESDAy, JANUARy 5,
2011 AT 12:00 P.M. (cT)
All individuals who register after 12:00 p.m. (CT) on
January 5, 2011 will need to pick up badges, tickets, and
vouchers on site. See p. 43 for locations.
cORREcTIONS
Upon receipt, please review materials for accuracy. If a
discrepancy or error is found, send an e-mail to
registration@aad.org by 12:00 p.m. (CT), Wednesday,
January 26, 2011 with the following information:
• Full name
• Registration confirmation number
• Error or discrepancy found
The AAD will make every attempt to make corrections
received by the deadline prior to the start of the meeting.
Corrected tickets must be picked up at the Full Service
On-Site Registration area located in Hall G. (see page 43
for locations and times.) Corrections received after the
deadline must be made on site at the Full Service On-Site
Registration area.
 GENERAL INFORMATION

Changes/Cancellations: Early registrants Badge identification

Ticketed event changes/cancellations for individuals who Registration categories will be indicated by badge color
register by Wednesday, January 5, 2011 at 12:00 p.m. as described below. Specific categories will appear in bold
(CT) (and will be receiving their materials by mail) will at the bottom of each badge.
only be accepted until Wednesday, January 5, 2011 at
BADGE TyPE
12:00 p.m. (CT). After this date and time ticket
cancellations and changes will need to be made at the BLUE Physician members, life members, honorary
Medical members, applicants for membership, graduate
Tickets Only counters located in the Full-Service personnel members, residents, research fellows, physician
On- Site Registration area located in Hall G of the assistants/nurse practitioners, non-dermatology
residents, medical students,
Convention Center. For housing changes/cancellations non-member physicians
refer to the Hotel and Travel Information section of the yELLOW adjunct members, corporate individual members,
program book on page 41. Allied health office staff/registered nurses, and non-member
personnel non-physicians

GREEN spouse/guest (note: no badge will be issued to

Attendance verification, meeting bags, children under 16 years)

handout DVDs, other materials RED exhibitors

Those who registered during early registration and BEIGE Press

received their meeting packet may redeem their ORANGE aad staff
attendance verification/meeting bag voucher and pick up
handout DVDs and other materials on site at the
Letters of invitation
Attendance Verification/Meeting Bag Pick-up Counter.
If you require a letter of invitation, please submit a
This voucher must be redeemed in order to claim CME
written request via e-mail to registration@aad.org once
credit. (See page 44 for counter times and location.)
you have completed your registration. Letters will be sent
after registration verification is complete. Due to security

GENERAL INFORMATION
concerns, letters will only be issued to registrants who
Medical personnel materials pick-up have completed their registration by January 19, 2011 at
Medical personnel who register by Wednesday, January
12:00 p.m. (CT). Allow 3-5 business days for processing.
26, 2011 at 12:00 p.m. (CT) and have not received their
meeting packet in advance and have no changes to make
to their registration, may print their badges, tickets, and
other materials at the Self-Service Materials Pick-up
Stations located in Hall D Lobby. (See p. 43 for hours of
operation.) You will need to scan your registration bar-
code contained in your registration confirmation letter,
or input your registration confirmation number to print
your materials.
A photo ID is required to pick up materials. Each
individual is permitted to pick up ONLY his or her own
registration materials. See p. 43 for locations and times

Note: Session tickets cannot be purchased or

returned at the Self-Service Materials Pick-up
Stations. To make corrections or changes to your
registration you will need to go to the Full Service
On-site Registration area, located in Hall G
(see p. 43 for locations and times).

The self-service Materials Pick Up Stations are

available for medical personnel only.

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 39

 GENERAL INFORMATION

Group registration charitable contribution

Group registration must be completed in advance of the
meeting. On-site group registration will not be available.
Group pick-up is only available for approved groups
who have completed the advance group registration
process with the AAD prior to the meeting. New group
registration and pick-up is not permitted on site.
On-site registration of corporate or medical groups by
group organizers is not permitted. Refer to the Annual
Meeting section of the AAD website, www.aad.org, for
deadline and additional information on group
registration.
Evaluation and cME Verification
CME Credit is awarded based on actual participation in
the learning activities. An overall evaluation form and
CME credit claim form will be provided in the registration
bag distributed on-site at registration. Learners should
complete the session evaluation forms and drop them into
the boxes labeled “CME Evaluations” throughout the
duration of the meeting.
Prior to departure, learners should complete the
GENERAL INFORMATION
You can make a tax-deductible contribution to the
programs below as you register for the Annual Meeting
or in the AAD Resource Center located in the Technical
Exhibit Hall.
AAD Camp Discovery Endowment
Help expand summer camp opportunities for children
with chronic skin conditions! Kids come out of their
shells at AAD Camp Discovery where they meet others
with similar conditions and learn they are not alone. Four
week-long sessions serve nearly 250 children each year.
A fifth week of camp will be added in 2011. Additional
funds are needed to support this new camp as well as
future expansion.
AAD Shade Structure Program
Be part of the Academy’s efforts to reduce the incidence
of and mortality from skin cancer over the next three
decades! The protective shade structures erected through
this program protect hundreds of thousands of people
each day from harmful UV rays.

CME credit claim form and drop it into the “CME

Thank you for
Evaluations” boxes for processing. Credit is calculated
Furthering Excellence in Dermatology…Today and Tomorrow.
on a 1/4-hour basis and will be reflected on member
transcripts within four to six weeks after the meeting.

certificate of Attendance for Nonphysicians

International registrants as well as physicians assistants/
nurse practitioners, office staff/registered nurses, medical
students, corporate individual members, and adjunct
members may print out a Certificate of Attendance on
site. To do so, please take your ExpoCard to the
registration area located in Hall D Lobby of the
Convention Center. Certificate of Attendance Stations
will be available beginning Saturday, February 5th.

40 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng


hOTEL AND TRAVEL INFORMATION
hotel accommodations and reservations
Guest rooms are being held for 69th Annual Meeting
registrants at several major hotels in New Orleans at
AAD discounted meeting rates for those booking
through the AAD Housing Office. These rates are lower
than available hotel rack rates. See the registration and
housing brochure for information on hotel reservations.
Individuals who book reservations directly with the hotel
are not guaranteed the AAD discount.
Reservations may be made online, by fax, or by mail
through the AAD Housing Office in conjunction with
registration for the meeting and according to the
registration schedule on page 34. Hotel reservations for
those not registered for the meeting cannot be
accommodated.
Be prepared to finalize your travel plans immediately as
hotel rooms go quickly. Availability cannot be guaranteed
for reservation requests received after the housing
deadline of January 13, 2011 at 12:00 p.m. (CT).
Payment information
Registration and housing fees may be paid by check
payable to AAD Registration and Housing or credit card
(Visa, Mastercard, or American Express).
For the Latest Program Book InFormatIon PLease reFer to
GENERAL INFORMATION
hotel reservation cancellation
Deadline: January 13, 2011 at 12:00 p.m. (CT)
Send a letter of cancellation to:
• E-mail: aad@experient-inc.com or
• Fax: (800) 521-6017 or (847) 996-5401
A full refund of your deposit will be issued.
After January 13, 2011 at 12:00 p.m. (CT)
Requests for changes or cancellations will NOT be
processed by the AAD Housing Office after 12:00 p.m.
(CT), January 13, 2011. Refund of deposits will NOT
be issued for cancellations received after 12:00 p.m.
(CT), January 13, 2011 regardless of method of
cancellation.
Between January 14, 2011 and January 19, 2011
The Academy will be transferring reservation information
to hotels, and hotels will be processing reservations into
their system.
Refund of deposits will NOT be issued for cancellations
received after 12:00 p.m. (CT), January 13, 2011
GENERAL INFORMATION
regardless of method of cancellation.
Starting January 19, 2011
Contact the hotel directly to cancel or change a
reservation. Phone numbers for the main host hotels will
be posted on the AAD website, www.aad.org, beginning
January 13, 2011.
Refund of deposits will NOT be issued for cancellations
received after 12:00 p.m. (CT), January 13, 2011
regardless of method of cancellation.
No late check-in
Failure to check in on the scheduled date of arrival will
result in the loss of deposit and cancellation of the room.
www.aad.org | 41
 GENERAL INFORMATION

Travel information United and American Airlines

AIR TRAVEL You may also book through your own agency or contact the
The following discounts and services have been negotiated airlines directly. Refer to the ID numbers indicated below to
for registrants traveling to the AAD 69th Annual Meeting receive applicable discounts.
through the Academy’s official travel agency, Association United Airlines: (800) 521-4041
Travel Concepts (ATC), on United Airlines and American ID: 510CK
Airlines:
American Airlines: (800) 433-1790
• Up to 15 percent off applicable classes of service for
ID: 2321BN
United Airlines tickets purchased more than 30 days
prior to the meeting. Restrictions apply.
• 5 percent off applicable classes of service for American cAR RENTAL
Airlines tickets purchased prior to the meeting. Discounts on vehicle rentals with Avis and Hertz are
• Personalized services. available to meeting registrants.
• Low fare options. Avis
• Advanced seat assignment and special meal requests. Contact Avis directly and provide the Avis World Wide
• Frequent flyer program updates. discount number A723900 when making your reservation.
Reservations may be made on the Web or by phone.
The above discounts apply for flights between
February 1 - 11, 2011 to or from Louis Armstrong Website: www.avis.com
New Orleans International Airport. Phone: (800) 831-8000 (U.S.)
Additional services are available through Association Travel (800) 879-2847 (Canada)
(Those outside U.S. and Canada should contact their
Concepts when booking online, including airport parking, local Avis office.)
event tickets, dining reservations, mobile device alerts,
GENERAL INFORMATION

personal profile, 24/7 online access, powerful search options, Hertz

hold trips, and low-fare search options. Contact Hertz directly and provide the discount code
0010533 when making your reservation or submit a coupon
Association Travel Concepts or promotional coupon number. Reservations may be made
Registrants may book online, by phone or e-mail with the on the Web or by phone.
AAD’s official travel agency, Association Travel Concepts
Website: www.hertz.com
Online: www.atcmeetings.com/aad
Phone: (800) 654-2210 (U.S.)
Use the “search for discounted flights” (800) 263-0600 (Canada)
search box to begin your search (Those outside U.S. and Canada should contact their
local Hertz office.)

E-mail: reservations@atcmeetings.com
Phone: (800) 458-9383
Hours: Monday – Friday,
7:30 a.m. to 6:00 p.m. (CT)
Booking fees: online: $10
e-mail: $35
phone: $35
(Fees apply to ticketed reservations)

42 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 GENERAL INFORMATION

ON-SITE SERVIcES AND EXhIBITS

Academy offices/exhibits
All locations are in the New Orleans Ernest N. Morial Convention Center (CC) or Hilton New Orleans Riverside Hotel
(HR) unless otherwise indicated.
AAD Resource Center..................................................................................................................................Booth 3623 (CC)
Board of Directors’ Office ..............................................................................................................................Room 347 (CC)
Business Center ................................................................................................................................................. Lobby F (CC)
Convention Office .......................................................................................................................... Room 353/354/355 (CC)
Development Office ....................................................................................................................................... Room 237(CC)
Cyber Center ............................................................................................................................... Hall E and Lobby G (CC)
Certificate of Attendance Counter ........................................................................................................... Hall G Foyer (CC)
First Aid/Nursing Mothers’ Room............................................................................................... Lobby E and Lobby H (CC)
Information Desks ..................................................................................................................... Lobby D and Lobby G (CC)
Poster Exhibits/Poster Presentations ..................................................................................................................... Hall E (CC)
Registration
Full-Service Registration (Attendee) .................................................................................................................Hall G (CC)
Self-Service Materials Pick-up Stations (Medical Personnel only) .........................................................Hall D Lobby (CC)
Registration (Exhibitor) .................................................................................................................................... Hall E (CC)
Optional Activities ............................................................................................................................................ Lobby F (CC)
Press Office ....................................................................................................................................................Room 286 (CC)
Press Conferenc Room ...................................................................................................................................Room 287 (CC)
Speaker Ready Room ..............................................................................................................................Room 344/345 (CC)
Technical Exhibits ..........................................................................................................................................Halls D-H (CC)

GENERAL INFORMATION
Wi-Fi .......................................................................................................................................................... Public Areas (CC)
Restaurant Reservations.................................................................................................................................... Lobby D (CC)

Registration services
FULL SERVIcE ON-SITE REGISTRATION cOUNTERS: hALL G (cc)
Full-Service On-site Registration will open on Thursday,
February 3 at 12:00 p.m. for those who have not registered
prior to this date and time. Previously purchased tickets can
be returned here, and tickets for available sessions may also
be selected here. A photo ID is required to obtain any
registration materials. Each individual is permitted to pick
up ONLY his or her own registration materials, with the
exception of the spouse/guest badge.
Full-Service On-Site Registration will be open during the
following times:
Thursday, February 3........................12:00 p.m. – 6:00 p.m.
Friday, February 4 ........................... 7:00 a.m. – 5:00 p.m.
Saturday, February 5 .......................... 7:00 a.m. – 5:00 p.m.
Sunday, February 6 ........................... 6:45 a.m. – 5:00 p.m.
Monday, February 7 ........................... 7:00 a.m. – 5:00 p.m.
Tuesday, February 8 ........................... 7:00 a.m. – 5:00 p.m.

Early registrants who simply wish to return, exchange, or

purchase tickets, should proceed directly to a counter marked
Tickets Only within the Full-Service On-Site Registration
area. Medical personnel who registered early and have no
changes should proceed to the Self-Service Materials Pick-up
Stations in Hall D Lobby (CC).

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 43

 GENERAL INFORMATION
SELF-SERVIcE MATERIALS PIcK-UP STATIONS (MEDIcAL
PERSONNEL ONLy): hALL D LOBBy (cc)
Medical personnel who register prior to January 26, 2011 at
12:00 p.m. (CT) and have not received their meeting
packet and have no changes to make may print their
badges, tickets, and other materials at the Self-Service
Materials Pick-up Stations located in Hall D Foyer. At these
self-service stations you will need to scan your bar-code
contained in your registration confirmation letter, or input
your registration confirmation number to print your
materials. A photo ID is required in order to pick up your
materials. Each individual is permitted to pick up ONLY
his or her own registration materials.
Stations will be available during the following hours:
Thursday, February 3......................12:00 p.m. – 6:00 p.m.
Friday, February 4 .........................7:00 a.m. – 5:00 p.m.
Saturday, February 5 ........................7:00 a.m. – 5:00 p.m.
Note: session tickets cannot be purchased or
returned at the Self-Service Materials Pick-up Stations.
To make corrections or changes to your registration
you will need to go to the Full-Service On-Site
Registration area in Hall G of the Convention Center.
(see p. 43 for locations and times).
GENERAL INFORMATION
ATTENDANcE VERIFIcATION/MEETING BAG PIcK-UP cOUNTER:
hALL G LOBBy (cc)
All registrants should redeem their attendance verification/
meeting bag voucher and pick up their handout CD-ROM,
and any updated meeting materials at the Attendance
Verification/Meeting Bag Pick-up Counter beginning at
8:30 a.m. on Thursday, February 3, 2011.
Exhibits
TEchNIcAL EXhIBITS: hALLS D-h (cc)
The Technical Exhibit Hall will be open during the
following hours:
Saturday, February 5 ....................... 10:00 a.m. – 5:00 p.m.
Sunday, February 6 ........................ 10:00 a.m. – 5:00 p.m.
Monday, February 7 ........................ 10:00 a.m. – 5:00 p.m.
Admittance into the Technical Exhibit Hall is limited to
Medical and Allied Health Personnel only on Saturday
and Sunday. Only those attendees with blue or yellow
badges will be given access to the Technical Exhibit Hall
on those days. In addition to Medical and Allied Health
Personnel, Individuals with spouse/guest green badges will
be admitted on Monday, February 7 only.
44 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
Infants and children under age 16 will not be admitted to
the Technical Exhibit Hall. This policy has been created for
the safety of the children of Academy members and guests.
Your compliance is appreciated.
AAD RESOURcE cENTER: BOOTh 3623 (cc)
The AAD Resource Center contains information on
Academy membership, products, or services. Staff will be
available during regular exhibit hours to answer questions.
ELEcTRONIc POSTER EXhIBITS/POSTER PRESENTATIONS:
hALL E (cc)
Electronic Poster Exhibits viewing stations will be open
during the following hours:
Friday, February 4 ...........................7:00 a.m. – 5:00 p.m.
Saturday, February 5 ..........................7:00 a.m. – 5:00 p.m.
Sunday, February 6 ...........................7:00 a.m. – 5:00 p.m.
Monday, February 7 ...........................7:00 a.m. – 5:00 p.m.
Tuesday, February 8 .........................7:00 a.m. – 12:00 p.m.
Poster authors will conduct brief presentations of their
electronic posters at the Poster Presentation Centers in
Hall E during the meeting. A full schedule of
presentations will be available on the Annual Meeting
website at www.aad.org in November and posted on
site at the meeting.
Limited copies of the Poster Abstract Supplement will
be available on a complimentary basis to registered
medical personnel only at the Poster Abstract Counter
located in Hall E at the New Orleans Ernest N. Morial
Convention Center.
Other services
SPEAKER READy ROOM: ROOM 344/345 (cc)
The Speaker Ready Room will be open during the following
hours:
Thursday, February 3....................... 12:00 p.m. – 6:00 p.m.
Friday, February 4 .......................... 6:30 a.m. – 5:30 p.m.
Saturday, February 5 ......................... 6:30 a.m. – 5:30 p.m.
Sunday, February 6 .......................... 6:30 a.m. – 5:30 p.m.
Monday, February 7 .......................... 6:30 a.m. – 5:30 p.m.
Tuesday, February 8 .......................... 6:30 a.m. – 5:00 p.m.

BUSINESS SERVIcE cENTER: LOBBy F (cc)
The Business Service Center is available to all meeting
registrants. Available services include photocopying,
transparencies, fax transmissions and receipts, and FedEx
and US mail drop-off. Payment is required at time of
service; major credit cards are accepted. The Center will be
open during the following hours:
Thursday, February 3..........................2:00 p.m. – 6:00 p.m.
Friday, February 4 ...........................8:00 a.m. – 5:00 p.m.
Saturday, February 5 ..........................8:00 a.m. – 5:00 p.m.
Sunday, February 6 ...........................8:00 a.m. – 5:00 p.m.
Monday, February 7 ...........................8:00 a.m. – 5:00 p.m.
Tuesday, February 8 ...........................8:00 a.m. – 5:00 p.m.
cyBER cENTER: hALL E AND LOBBy G (cc)
Registrants may check e-mails at the Cyber Center, which
will be open during the following hours:
Thursday, February 3..........................8:00 a.m. – 6:00 p.m.
Friday, February 4 ...........................7:00 a.m. – 5:00 p.m.
Saturday, February 5 ..........................7:00 a.m. – 5:00 p.m.
Sunday, February 6 ...........................7:00 a.m. – 5:00 p.m.
Monday, February 7 ...........................7:00 a.m. – 5:00 p.m.
Tuesday, February 8 ...........................7:00 a.m. – 5:00 p.m.
WI-FI (PUBLIc AccESS) (cc):
Wi-Fi will be accessible in public lobbies during meeting
days.
AUDIO REcORDINGS
Pre-Order your Annual Meeting Audio Recordings for a discounted rate of $299!
Each session recording provides a convenient way for you to experience the Annual Meeting and expand your
knowledge of the latest advancements in the specialty of dermatology.
Enjoy the exclusive content that this year’s meeting offers:
• Hundreds of speakers
• Slides synchronized with audio of select talks
• Both MAC and PC Compatible
For the Latest Program Book InFormatIon PLease reFer to
GENERAL INFORMATION
PRESS REGISTRATION/INFORMATION: ROOM 286 (cc)
Journalists who are working for and representing recognized
news organizations are encouraged to register to attend the
meeting as Press. Press may register to attend the Annual
Meeting in advance or at the On-Site Press Registration
Desk. To register, journalists must provide a business card
and samples of their work. All freelancers must present a
letter of assignment.
The Press Office will be staffed by Academy media relations
staff and offer workstations for registered journalists. Press
conferences will be held in Room 287 (CC).
Thursday, February 3..........................2:00 p.m. – 5:00 p.m.
Friday, February 4 .............................. 8:00 a.m. – 5:00 p.m.
Saturday, February 5 .......................... 8:00 a.m. – 5:00 p.m.
Sunday, February 6............................. 8:00 a.m. – 5:00 p.m.
Monday, February 7 ........................... 8:00 a.m. – 5:00 p.m.
ScOOTER/WhEELchAIR RENTAL
Twenty-four hour mobility service is available by contacting
ScootAround, Inc.
Toll-free phone ............................................. (888) 441-7575
E-mail .............................................. info@scootaround.com
GENERAL INFORMATION
Fax ............................................................. (204) 478-1172
Mobility service during Annual Meeting official meeting
hours is available.
Should your needs require mobility service strictly during
official meeting hours, you may reserve a scooter through
the Academy, free of charge. To do so, check the “ADA
Mobile” box under the Personal Information page of your
online registration. You will be required to pick up
and drop off your scooter in the AAD Convention Office
Room 353 each meeting day.
• Audio DVD-ROM with access to online version
• Load talks directly to MP3 player, iTunes playlist and iPod
www.aad.org | 45
 GENERAL INFORMATION
INFORMATION DESKS: LOBBy D AND LOBBy G (cc)
Thursday, February 3........................12:00 p.m. – 6:00 p.m.
Friday, February 4 .............................. 7:00 a.m. – 5:00 p.m.
Saturday, February 5 .......................... 7:00 a.m. – 5:00 p.m.
Sunday, February 6............................. 7:00 a.m. – 5:00 p.m.
Monday, February 7 ........................... 7:00 a.m. – 5:00 p.m.
Tuesday, February 8 ........................... 7:00 a.m. – 5:00 p.m.
OPTIONAL AcTIVITIES
New Orleans is filled with numerous cultural and fun-filled
venues. Come explore New Orleans by signing up for tours
arranged exclusively for registered attendees and their
spouses/guests of the Annual Meeting. Numerous tours in
and around New Orleans are featured in the Optional
Activities Brochure or at www.aad.org. Buses for the tours
will depart from the New Orleans Ernest N. Morial
Convention Center (Hall F lobby).
RESTAURANT RESERVATIONS: LOBBy D (cc)
Thursday, February 3........................12:00 p.m. – 6:00 p.m.
Friday, February 4 .........................10:00 a.m. – 6:00 p.m.
Saturday, February 5 ........................10:00 a.m. – 6:00 p.m.
Sunday, February 6 .........................10:00 a.m. – 6:00 p.m.
Monday, February 7 .........................10:00 a.m. – 5:00 p.m.
GENERAL INFORMATION
To make reservations in advance go to www.opentable.com
or go to www.neworleanscvb.com to see restaurant options.
chILD cARE SERVIcES
Contact the concierge desk at your hotel to arrange for child
care services. Arrangements should be made as early as
possible prior to your anticipated arrival. The Academy has
no control over and assumes no responsibility for the care
provided through the hotels. This information is provided
solely as a service to help registrants identify possible
resources for child care services.
FIRST AID/NURSING MOThERS’ ROOM: LOBBy E AND LOBBy h (cc)
The New Orleans Ernest N. Morial Convention Center is
equipped with first aid rooms with space available for
nursing mothers.
MEETING ROOM LOcATIONS
Please be aware that the room locations in this program book
may change prior to the meeting. Refer to the Program Book
Update under the Annual Meeting section of the AAD website
at www.aad.org. When on site, the Program-at-A-Glance will
have updated room changes. The Program-at-A-Glance will be
distributed to all registrants in their meeting bags.
46 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
ShUTTLE BUS SERVIcE
Shuttle bus service is available for meeting attendees who have
booked reservations through the Academy’s Hotel Reservation
System. Service runs between the convention center and
designated convention hotels. The shuttle bus does not serve
hotels within a three-block radius of the convention center.
Please refer to the Registration/Housing Brochure or the
Registration/Housing website for specific shuttle bus stops.
Those who require special needs transportation should
request rooms at the Hilton New Orleans Riverside. This
route will be equipped with lift vehicles.
AAD meeting policies
INDEPENDENcE IN cME
The mission of the Academy’s continuing medical education
program is to improve patient care and health care outcomes
by maintaining, developing and enhancing medical
knowledge, patient care, interpersonal and communication
skills, and professionalism. As a provider accredited by the
Accreditation Council for Continuing Medical Education
(ACCME) and in support of this mission, the Academy is
dedicated to providing continuing medical education that is
independent, fair, balanced, objective and free of commercial
bias. The Academy employs several strategies to ensure these
standards will be met. The Planning Committee members
submit and consider their own disclosure information and
recuse themselves from planning educational activities should
they have conflicts related to the subject area presented.
When developing an educational program, the Planning
Committee reviews applications and disclosure of conflict
of interest forms, along with physician competence gaps
and evaluative data from past activities in order to develop
programming.
Potential participants are sent detailed guidelines that
provide direction on necessary components to ensure
independence in continuing medical education activities and
to resolve conflict, as itemized below.
Disclosure of Relevant Financial Relationships
The Board of Directors requires that all participants in the
Annual and Summer Meetings comply with all applicable
laws and regulations governing disclosure. Session directors
and speakers are required to provide the Academy with a
comprehensive disclosure of financial relationships with a
commercial interest producing health care goods or services
consumed by or used on patients. Individuals who refuse to
disclose relevant financial relationships are disqualified from
participation in the educational program(s).
Disclosure statements must include all financial relationships
occurring within 12 months of the educational activity.
If no financial relationships exist, the individual is required
to indicate such on the disclosure form. A comprehensive
disclosure of financial relationships is published in the
Program-at-A-Glance and is available online on the
Academy’s website at www.aad.org.

In addition, directors/speakers are expected to make a verbal
disclosure of relevant financial relationships or indicate no
conflicts exist at the beginning of their presentation.
A digital slide with a disclosure template will be provided
to the speaker for inclusion in the presentation prior to the
meeting. Failure to disclose will result in a denial of the
opportunity to participate in the CME activity.
It is the responsibility of the session director to ensure
balance with regards to disclosure of potential conflicts of
interest. In addition, all speakers are required to complete
the speaker attestation form indicating compliance with
these policies.
Content Validation
Academy-sponsored educational activities are designed to
promote improvements or quality in health care and not promote
a specific proprietary business interest or a commercial interest.
Presentations and related materials must be based on scientific
methods generally accepted by the medical community.
Presentations should be evidence-based and discuss the
validity of the evidence upon which they base opinion(s). (See
Sackett et al, BMJ 1996;312:71-2.) This ensures the audience
that the recommendations are supported by the evidence
and contributes to management of any potential conflicts of
interest. Further, if the presentation includes discussion of “off-
label” or investigational use of a commercial product, this also
must be disclosed to the participants.
Continuing Medical Education (CME) must give a balanced
view of therapeutic options. Use of generic names will
contribute to this impartiality. If CME educational material
or content includes trade names, trade names from several
companies should be used where available, as opposed to using
trade names from just a single company. Educational materials
such as slides, abstracts, and handouts cannot contain any
advertising or product-group messages.
Outcomes Measurement
Several methods of evaluation are utilized in assessing the
educational program. Session directors, speakers, attendees, and
formal observers are all given the opportunity to evaluate the
educational content and speaker performance. Included in this
process are measures to rate the success of the Academy’s policies
regarding independence in continuing medical education
activities with particular focus on the absence of commercial bias.
In addition, the Academy may review speaker presentations
stored on the meeting servers to collect aggregate data regarding
disclosure. These data are only used to determine effectiveness
of the Academy’s policies and procedures regarding disclosure.
Should it be determined that a member of the Academy’s
educational program violated the Academy’s “Policy to
Ensure Independence in Continuing Medical Education,”
the individual may not be asked to participate in future
educational programs.
For the Latest Program Book InFormatIon PLease reFer to
GENERAL INFORMATION
DIScLAIMER
The views expressed and the techniques presented by the
speakers at the AAD-sponsored educational meetings are not
necessarily shared or endorsed by the Academy. The Academy
requires speakers to disclose all relevant personal/professional
relationships and any unapproved or “off-label” uses of
medical devices or pharmaceutical agents that they discuss,
describe, or demonstrate during their presentations.
Registrants must use their independent judgment in applying
the information discussed in Academy educational sessions in
the treatment of their patients. Handout materials are
prepared and submitted for distribution by the presenters,
who are solely responsible for their content.
AGE LIMITS
Infants and children under the age of 16 are not allowed
into educational sessions or the Technical Exhibit Hall. This
policy is due to the nature of some presentations and to
ensure the safety of registrants’ children. Your support and
compliance are appreciated.
cAMERA /VIDEO REcORDING
Use of cameras, camera phones, and video cameras is
prohibited in all educational sessions. Violations of this
policy will result in removal from the session and
confiscation of equipment. Directors and room monitors
will be closely monitoring adherence to this policy.
GENERAL INFORMATION
cELL PhONES
Cell phone usage during educational sessions is disruptive
and is therefore prohibited. Attendees are asked to turn off
cell phones or place them on vibrate prior to entering a
session room. Violations of this policy will result in removal
from the session room. Session directors and room monitors
will be closely monitoring adherence to this policy.
g SMOKING
All AAD educational programs in meeting rooms and
seated functions occurring during the meeting are
smoke free. Please also comply with the smoking policy
of each individual facility.
ALcOhOLIc BEVERAGES
The Academy’s official policy regarding the minimum
age for alcohol consumption is the age applicable to
the jurisdiction of the event venue.
OFFIcIAL LANGUAGE
The official language of the Annual Meeting is English.
TIcKETED SESSION ADMITTANcE/WALK-INS
Sessions that have a ticket, but no fee, will hold a seat for
15 minutes after the official start time, after which seats will
be available on a first-come, first-served basis for eligible
categories. Attendees attending sessions with a fee must have
a ticket for admittance.
www.aad.org | 47
 GENERAL INFORMATION
AAD STAFF
Meetings and conventions Department
The Meetings and Conventions Department administers
the Annual Meeting. For further information, please
contact the following staff members by phone or e-mail at
the following: (847) 330-0230, fax (847) 330-1090 or
mrc@aad.org.
Timothy Moses, CMP.........Director, Meetings and Conventions
Debra Barrett ..............................Senior Manager, Meetings
Robin Downey ....................... Senior Manager, Registration
Sara Peterson, CEM ..................... Senior Manager, Exhibits
Amanda Sage, CMP ....................Senior Manager, Meetings
Tamara Pundsack ........................Senior Meetings Specialist
Joni Taylor ................................................Exhibit Specialist
Susan Jackson ................................ Administrative Specialist
Krysten Zarembski ............................Meetings Coordinator
Marisol Sukhu .............................. Registration Coordinator
GENERAL INFORMATION
48 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
Education Department
The Education Department develops and administers the
education program for the Annual Meeting. For further
information, please contact the following staff members by
phone or e-mail at the following: (847) 330-0230 or
mrc@aad.org.
Debbie Gist, MPH, FACME ................Director, Education
Jennifer Thompson, MS ...... Senior Manager, Live Meetings
Chris Presta ................ Senior Manager, Enduring Materials
Jennifer Wahl .................... Program Development Specialist
Joanna King .................................................CME Specialist
creative and Publishing Department
The Creative and Publishing Department edits and produces
the Annual Meeting Program Book.
Lara Lowery ..................... Director, Creative and Publishing
Ed Wantuch ................................................Design Manager
Nicole Torling ................................................Lead Designer
Joe Miller ..................................................Graphic Designer
Katie Domanowski.................... Senior Manager, Publishing
Nate Jenkins ......................................... Production Manager
Carrie DeGuide .................................. Advertising Specialist
Jon Dudek .......................................... Production Specialist
For your patients with tinea pedis, tinea cruris, and tinea corporis

For the fungicidal power you trust, turn to Naftin® (naftifine HCl 1%).
Designed to suit a range of patients and preferences, Naftin® delivers
power against tinea pedis, cruris and corporis. Choose Naftin® Gel,
Naftin® Cream, or the innovative Naftin® Cream Pump and give your
patients the customized care they deserve.

Naftin® (naftifine HCl 1%) Cream and Gel are indicated for the topical treatment of tinea pedis,
tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes,
Epidermophyton floccosum and Trichophyton tonsurans (Gel only).
Naftin® Cream and Gel are contraindicated in individuals who have shown hypersensitivity
to any of their components and are for topical use only.
During clinical trials with Naftin® Cream and Gel, the following side effects were most commonly
reported: burning/stinging, dryness, erythema, itching, local irritation, skin tenderness and rash.

Please see brief summary on the following page.

©2010 Merz Pharmaceuticals All rights reserved. 5/10

Power made personal
BRIEF SUMMARY
Rx ONLY

INDICATIONS AND USAGE: Naftin® Cream, 1% is

indicated for the topical treatment of tinea pedis, tinea
cruris, and tinea corporis caused by the organisms
Trichophyton rubrum, Trichophyton mentagrophytes, and
Epidermophyton floccosum. Naftin® Gel, 1% is indicated
for the topical treatment of tinea pedis, tinea cruris, and
tinea corporis caused by the organisms Trichophyton
rubrum, Trichophyton mentagrophytes, Trichophyton
tonsurans*, Epidermophyton floccosum*. *Efficacy for this
organism in this organ system was studied in fewer than
10 infections.
CONTRAINDICATIONS: Naftin® Cream and Gel, 1%
are contraindicated in individuals who have shown
hypersensitivity to any of their components.

WARNINGS: Naftin® Cream and Gel, 1% are for topical

use only and not for ophthalmic use.

PRECAUTIONS: General: Naftin® Cream and Gel,

1%, are for external use only. If irritation or sensitivity
develops with the use of Naftin® Cream or Gel, 1%,
treatment should be discontinued and appropriate
therapy instituted. Diagnosis of the disease should be
confirmed either by direct microscopic examination of
a mounting of infected tissue in a solution of potassium
hydroxide or by culture on an appropriate medium.

Information for patients: The patient should be told to: Increase patient
Increase patient flow
flow and
and overall
overall
1. Avoid the use of occlusive dressings or wrappings
unless otherwise directed by the physician.
practice efficiency.
practice efficiency.
2. Keep Naftin® Cream and Gel, 1% away from the Increase profits.
Increase profits.
eyes, nose, mouth and other mucous membranes.
Varitronics can
Varitronics can show
show you
you how!
how!
Carcinogenesis, mutagenesis, impairment of fertility:
Long-term studies to evaluate the carcinogenic
potential of Naftin® Cream and Gel, 1% have not been S
S ee
ee more
more patients
patients in
in the
the same
same amount
amount
performed. In vitro and animal studies have not of time without increasing staff.
demonstrated any mutagenic effect or effect on fertility. of time without increasing staff.
Va
Varitronics, Call Systems
Varitronics, the
the leader
leader in
in Non-
Pregnancy: Teratogenic Effects: Pregnancy Call Systems
Category B: Reproduction studies have been performed Va Non- are available
in rats and rabbits (via oral administration) at doses Ve
Verbal
Ve Interoffice Communica-
Verbal Interoffice Communica-
are available
for both new
tio
tions for both new
tions for
for over
over four
four decades,
150 times or more than the topical human dose and have and existing
revealed no evidence of impaired fertility or harm to the tio decades, and existing
fetus due to naftifine. There are, however, no adequate off
offers
offers the most feature-rich
off the most feature-rich construction.
construction.
and well-controlled studies in pregnant women. Because sy
systems
systems on
sy on the
the market
market today.
today.
animal reproduction studies are not always predictive
of human response, this drug should be used during Ou
Our
Our custom
Ou custom designed
designed Call
Call
pregnancy only if clearly needed.
Wall panel Systems
Systems will streamline the
will streamline the
Wall
and panel
pager CS 2000
Nursing mothers: It is not known whether this drug is and pager way
way you
you work
work so
so that
that you
you can
can CS 2000 System
Wireless
excreted in human milk. Because many drugs are excreted Wireless System
in human milk, caution should be exercised when Naftin® decrease your patient’s waiting
decrease your patient’s waiting
Cream or Gel,1% are administered to a nursing woman. time
time while
while increasing
increasing your
your staff‘s
staff‘s
Pediatric use: Safety and effectiveness in pediatric
efficiency.
efficiency.
patients have not been established.
Call,
Call, email,
email, or
or visit
visit our
our web
web site
site today
today to
to
ADVERSE REACTIONS: During clinical trials with see
see how easy it is to benefit from the
how easy it is to benefit from the
Naftin® Cream, 1%, the incidence of adverse reactions efficiency
was as follows: burning/stinging (6%), dryness (3%) efficiency of
of Varitronics’
Varitronics’ Call
Call System.
System.
erythema (2%), itching (2%), local irritation (2%).
During clinical trials with Naftin® Gel, 1%, the incidence
of adverse reactions was as follows: burning/stinging Leading the way in Interoffice Communications
(5.0%), itching (1.0%), erythema (0.5%), rash (0.5%), Leading the way in Interoffice Communications
skin tenderness (0.5%).
800.345.1244 • email:varimed@varitronics.com
800.345.1244 • email:varimed@varitronics.com
Manufactured for Merz Pharmaceuticals, Greensboro, NC 27410 www.varitronics.com
© 2010 Merz Pharmaceuticals Rev 3/10
www.varitronics.com
attract new clients
improve conversions

CANFIELD Scientific, Inc. is the

global leader in photographic imaging systems,
services and products for scientific research
and healthcare applications.

Driven by a quality-focused mission to provide

best-in-class imaging solutions and services,
Canfield has achieved an industry-wide reputation
for excellence and innovation throughout its
product lines, industry services and customer support.

® 3D capture system
3D solutions  & sculptor 3D simulation software
the next dimension of medical imaging accuracy

facial
imaging &  ® COMPLEXION ANALYSIS imager®
analysis transforming skin care practices worldwide

imaging  ® medical imaging software

software the core of advanced medical imaging solutions
to fit your practice today—and in the future

IntelliStudio® OMNIA® TwinFlash® EpiFlash® IntelliFlash®

photography  innovative medical photography systems, accessories,
and custom designed studios

research VECTRA-CR and custom designed

systems &  systems for clinical research
services Clinical researchers around the world rely on Canfield for
the high quality medical imaging their studies demand.

VECTRA, Face Sculptor, Body Sculptor, Breast Sculptor, VISIA, Reveal Imager, Mirror,
DermaGraphix, PhotoFile, MatchPose, IntelliStudio, OMNIA, TwinFlash, EpiFlash,
and IntelliFlash are registered trademarks of Canfield Scientific, Inc.

IMAGING EXCELLENCE FROM

www.canfieldsci.com
| phone +1.973.276.0336
(USA) 1.800.815.4330
 WhAT’S NEW
NEW ThIS yEAR!
REGISTRATION
Meeting Materials Mailing
Meeting materials, including badges, tickets, and
attendance verification/meeting bag voucher, will
now be mailed to ALL registrants including
International registrants who register by January 5,
2011 at 12:00 p.m. (CT).
In order for US, Canadian, and International
registrants to receive their materials by mail,
registration must be completed by Wednesday,
January 5, 2011 at 12:00 p.m. (CT), the close of early
registration. Registration packets containing these
items will be sent via US mail to US registrants and via
special courier service to Canadian and International
registrants between January 10 – January 21, 2011.
Materials will be mailed to the address listed on your
registration records, which will also be listed on your
ExpoCard.
Due to the mailing of meeting materials, pre-meeting
changes/cancellations for ticketed events must be
completed by January 5 at 12:00 p.m. (CT). After this
date and time ticket cancellations and changes must be
made at the Tickets Only Counters located in the Full-
Service On-Site Registration Area located in Hall G of
the Convention Center at the meeting. For housing
changes/cancellations refer to the hotel and travel
WhAT’S NEW
information section of the program book.
REGISTRANTS WhO REGISTER AFTER
WEDNESDAy, JANUARy 5, 2011 AT 12:00 P.M. (cT)
All registrants who register after 12:00 p.m. (CT) on
January 5, 2011 will need to pick up badges, tickets,
and vouchers on site. See p. 43 for locations.
52 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
Medical Personnel Materials Pick-up
MATERIALS PIcK-UP STATIONS (MEDIcAL PERSONNEL ONLy):
hALL D LOBBy, cONVENTION cENTER
Medical personnel who register by Wednesday,
January 26, 2011 at 12:00 p.m. (CT) and who have not
received their meeting packet in advance and have no
changes to make to their registration, may print their
badges, tickets, and other materials at the Self-Service
Materials Pick-up Stations located in Hall D Lobby of the
Convention Center. You will need to scan your
registration bar-code contained in your registration
confirmation letter, or input your registration
confirmation number to print your materials. A photo ID
is required to pick up your materials. Each individual is
permitted to pick up ONLY his or her own registration
materials. Self-Service Stations will be available during the
following hours:
Thursday, February 3...............12:00 p.m. – 6:00 p.m.
Friday, February 4 ..................... 7:00 a.m. – 5:00 p.m.
Saturday, February 5 ................. 7:00 a.m. – 5:00 p.m.
Note: Session tickets cannot be purchased or
returned at the Self-Service Materials Pick-up Stations.
To make corrections or changes to your registration you
will need to go to the Full-Service On-Site Registration
area in Hall G of the Convention Center.
(see p. 43 for locations and times).
The Self-Service Materials Pick-up Stations are
open to Medical Personnel only.
Ticket Only counters
Registrants who wish to only purchase or return tickets
may do so at these specially-designated counters in the
Full-Service On-Site Registration area in Hall G of the
Convention Center. These counters are only for ticket
returns/purchases, not the processing of full on-site
registration. Those who wish to complete registration
on site should proceed to a full service counter in the
on-site registration area.

ScIENTIFIc SESSIONS
SyMPOSIA
S018 Late-Breaking Research Session
A two-hour session dedicated to Late-Breaking Research
will be presented on Saturday, February 5, 2011. All
members of the Academy are invited to submit abstract
presentations for review and selection for this Late-
Breaking Research session. The Late-Breaking Research
session provides an opportunity for a 9-minute oral
presentation. Abstract descriptions are limited to
150 words. The deadline for applications is January 7,
2011, at 5:00 p.m. (CT). Please see page 126 for more
information.
FOcUS SESSIONS
To provide a more diverse program, Focus Sessions
will now be offered three times a day. They will take
place daily 7:15 a.m. to 8:45 a.m.
(Sunday 7:00 a.m. to 8:00 a.m.);
12:15 p.m. to 1:45 p.m.; and
2:30 p.m. to 4:00 p.m.
DIScUSSION GROUPS
To provide a more diverse program Discussion Groups
will now be offered three times a day. They will take
place daily 7:15 a.m. to 8:45 a.m.
(Sunday 7:00 a.m. to 8:00 a.m.);
12:15 p.m. to 1:45 p.m.; and
2:30 p.m. to 4:00 p.m.
Attendance will be limited to 50 registrants.
AAD POLIcy
SESSION LATE ADMITTANcE/WALK-IN POLIcy
As a reminder, due to the high demand of educational
sessions, those sessions that have a ticket, but no fee,
will hold a seat for 15 minutes after the official start
time, after which seats will be available on a first-come,
first-served basis for eligible categories. Those attending
sessions with a fee must have a ticket for admittance.
chARITABLE cONTRIBUTION
You can make a tax-deductible contribution to the AAD
Camp Discovery Endowment and/or the Shade
Structure Program as you register for the Annual
Meeting or in the AAD Resource Center located in the
Technical Exhibit Hall. See page 40 for details.
For the Latest Program Book InFormatIon PLease reFer to
WhAT’S NEW
DERMATOLOGy IN AcTION
SERVIcE INITIATIVE
Members can make a lasting impression as part of their
meeting experience by volunteering to the Academy’s new
Dermatology in Action program, where the AAD gives
back to the community hosting its scientific meetings.
In New Orleans, volunteers will be needed to help paint,
clean up and refurbish a local school. If you are unable
to volunteer time, consider donating some of your
medical supplies. These will be collected at the meeting
and donated to a local clinic. Financial support is also
vital to the program and will be used to support future
and current volunteer activities. To learn more and
sign up to be a part of Dermatology in Action go to
www.aad.org/members/leadership, and watch for more
information in upcoming editions of Annual Meeting
News and Dermatology World.
LEADERShIP INSTITUTE EXPANDS IN 2011
The Academy’s Leadership Institute has proven to be a
popular, effective way to assist in preparing dermatologists
to serve successfully in organized medicine and support
the specialty through effective advocacy and policy
development. In New Orleans in 2011, the AAD has
added exciting Leadership Institute sessions and activities
to the Annual Meeting program, including special
presentations during the plenary session, opportunities to
recognize your favorite mentors, and the ability to
WhAT’S NEW
communicate leadership messages on a new electronic
message board, throughout the meeting.
Look for the Leadership Institute icon in the
program book and check out the latest AAD
leadership buzz at www.aad.org/leadership.
PRODUcT ThEATERS
These unique sessions, being held Saturday through
Monday in Hall F at the Convention Center, will
present new research findings on products, provide
product details, offer demonstrations, and highlight new
products to meeting attendees. Science supporting the
product will be provided by experts in the field, and will
be presented in a relaxed, low-pressure environment.
Product theaters are free to meeting attendees, but be
prepared to arrive early. Seating will be available on a first-
come, first-served basis. These sessions are solely
promotional, and are not eligible for continuing medical
education credit.
www.aad.org | 53
©2010 Abbott Laboratories Abbott Park, IL 60064 64V-415702 August 2010 Printed in U.S.A.
 Orleans for AAD!
See what’s REVEALed at Abbott booth 2721.
 Ortho Dermatologics
commends all

and

members

for their exceptional commitment to the future of dermatology.

Their contributions will help develop the next generation of
teachers and researchers, and enable advancements in patient care.

Please visit the Dermatology Foundation booth #2740 in the technical exhibit area.

Dermatology
Foundation
Shaping the Future of Dermatology

www.dermatologyfoundation.org
THE ONLY VITAMIN D3 OINTMENT AVAILABLE FOR MILD TO MODERATE PLAQUE PSORIASIS

@ss`bgdrsnxntqqdfhldm
0

Customize your regimen with a unique chemical entity different

from other psoriasis treatments
s#ONTAINSANATURALLYOCCURRINGACTIVEFORMOF6ITAMIN$3
s0ROVENSAFEANDEFFECTIVEINA
WEEKSTUDY
The most frequent adverse events (≥3%) reported
in clinical trials were lab test abnormality, urine
abnormality, psoriasis, hypercalciuria, pruritus and skin
discomfort. Vectical® should be used with caution in
patients with known or suspected disturbances in
calcium homeostasis, who are taking calcium or
Vitamin D supplements or who are on diuretics. If
aberrations in parameters of calcium metabolism
Available in 100-g tubes1
occur, discontinue use until these normalize. Caution
patients to avoid excessive exposure to natural or
artificial sunlight after applying the ointment. Avoid
contact with eyes, lips and face. Limit use to
200 grams per week.
Please see next page for brief summary of
Prescribing Information.
VECTICALTM
® (calcitriol) OINTMENT, 3 mcg/g
For topical use only.
Not for oral, ophthalmic, or intravaginal use.
Not to be applied to the eyes, lips, or facial skin.
BRIEF SUMMARY
INDICATIONS AND USAGE:
VECTICAL Ointment is a vitamin D analog indicated for the topical treatment of
mild to moderate plaque psoriasis in adults 18 years and older.
CONTRAINDICATIONS
None
WARNINGS AND PRECAUTIONS
Effects on Calcium Metabolism
In controlled clinical trials with VECTICAL Ointment, among subjects having
laboratory monitoring, hypercalcemia was observed in 24% (18/74) of subjects
exposed to active drug and in 16% (13/79) of subjects exposed to vehicle.
However, the increases in calcium and albumin-adjusted calcium levels were less
than 10% above the upper limit of normal.
If aberrations in parameters of calcium metabolism occur, treatment should be
discontinued until these parameters have normalized. The effects of VECTICAL
Ointment on calcium metabolism following treatment durations greater than 52
weeks have not been evaluated. Increased absorption may occur with occlusive use.
Ultraviolet Light Exposure
Animal data suggest that the vehicle of VECTICAL Ointment may enhance the
ability of ultraviolet radiation (UVR) to induce skin tumors.
Subjects who apply VECTICAL Ointment to exposed skin should avoid excessive
exposure of the treated areas to either natural or artificial sunlight, including
tanning booths and sun lamps. Physicians may wish to limit or avoid use of
phototherapy in patients who use VECTICAL Ointment.
Unevaluated Uses
The safety and effectiveness of VECTICAL Ointment in patients with known or
suspected disorders of calcium metabolism have not been evaluated. The safety
and effectiveness of VECTICAL Ointment in patients with erythrodermic,
exfoliative, or pustular psoriasis have not been evaluated.
ADVERSE REACTIONS
Because clinical studies are conducted under widely varying conditions, adverse
reaction rates observed in the clinical studies of a drug cannot be directly
compared to rates in the clinical studies of another drug and may not reflect the
rates observed in practice.
Clinical Studies Experience
VECTICAL Ointment was studied in two vehicle-controlled studies (419 subjects), and
in one open label study (324 subjects). The table below describes exposure to
VECTICAL Ointment in 743 subjects, including 239 exposed for 6 months and 116
exposed for one year.
Four hundred and nineteen subjects were treated with VECTICAL Ointment twice
daily for 8 weeks. The population included subjects ages 13 to 87, males (284) and
females (135), Caucasians (372) and non-Caucasians (47); with mild (105) to
moderate (313) chronic plaque psoriasis.
Selected Adverse Events Occurring in at least 1% of Subjects in the
Two Pooled Vehicle-Controlled Studies
VECTICAL Ointment Vehicle Ointment
(n=419) (n=420)
Discomfort skin 3% 2%
Pruritus 1% 1%
Among subjects having laboratory monitoring, hypercalcemia was observed in 24%
(18/74) of subjects exposed to active drug and in 16% (13/79) of subjects exposed
to vehicle, however the elevations were less than 10% above the upper limit of normal.
The open label study enrolled 324 subjects with psoriasis who were then treated
for up to 52 weeks. Adverse events reported at a rate of greater than or equal to
3% of subjects treated with VECTICAL Ointment were lab test abnormality (8%),
urine abnormality (4%), psoriasis (4%), hypercalciuria (3%), and pruritus (3%).
Kidney stones were reported in 3 subjects and confirmed in two.
Postmarketing Experience
The following adverse reactions have been identified during worldwide post-
approval use of VECTICAL Ointment: acute blistering dermatitis, erythema,
pruritus, skin burning sensation, and skin discomfort. Because these reactions
are reported voluntarily from a population of uncertain size, it is not always
possible to reliably estimate their frequency or establish a causal relationship to
drug exposure.
DRUG INTERACTIONS
VECTICAL Ointment should be used with caution in patients receiving medications
known to increase the serum calcium level, such as thiazide diuretics. Caution
should also be exercised in patients receiving calcium supplements or high doses
of vitamin D.
References: 1. Vectical® Prescribing Information. Fort Worth, TX: Galderma Laboratories, L.P.; 2009.
2. Data on file. Galderma Laboratories. 3. Lebwohl M, Ortonne JP, Andres P, Briantais P. Calcitriol ointment 3 µg/g is
safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. Cutis. 2009;83:205-212.
USE IN SPECIFIC POPULATIONS
Pregnancy
Teratogenic Effects: Pregnancy Category C.
VECTICAL Ointment contains calcitriol which has been shown to be fetotoxic.
There are no adequate and well-controlled studies for VECTICAL Ointment in
pregnant women. VECTICAL Ointment should be used during pregnancy only if the
potential benefit to the patient justifies the potential risk to the fetus.
Teratogenicity studies with calcitriol were performed in which rats were treated orally
at dosages up to 0.9 mcg/kg/day (5.4 mcg/m2/day) and in which rabbits received
topical application of calcitriol ointment (3 ppm) to 6.4% of the body surface area.
No effects on reproductive or fetal parameters were observed in rats. In rabbits,
topically applied calcitriol induced a significantly elevated mean post-implantation
loss and an increased incidence of minor skeletal abnormalities due to retarded
ossification of the pubic bones. A slightly increased incidence of skeletal variation
(extra 13th rib, reduced ossification of epiphyses) was also observed. These effects
may have been secondary to maternal toxicity. Based on the recommended human
dose and instructions for use, it is not possible to calculate human dose equivalents
for animal exposures in these studies.
Nursing Mothers
It is not known whether calcitriol is excreted in human milk. Because many drugs
are excreted in human milk, caution should be exercised when VECTICAL Ointment
is administered to a nursing woman.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
Geriatric Use
Clinical studies of VECTICAL Ointment did not include sufficient numbers of
subjects aged 65 and over to determine whether they respond differently from
younger subjects. Other reported experience has not identified differences in
responses between the elderly and younger patients.
OVERDOSAGE
Topically applied calcitriol can be absorbed in sufficient amounts to produce
systemic effects.
NONCLINICAL TOXICOLOGY
Carcinogenesis, Mutagenesis, Impairment of Fertility
When calcitriol was applied topically to mice for up to 24 months, no significant
changes in tumor incidence were observed. Concentrations of calcitriol in ointment
base of 0 (vehicle control), 0.3, 0.6 and 1.0 ppm were evaluated.
A two-year carcinogenicity study was conducted in which calcitriol was orally
administered to rats at dosages of approximately 0.005, 0.03, and 0.1 mcg/kg/day
(0.03, 0.18, and 0.6 mcg/m2/day, respectively). The incidence of benign
pheochromocytomas was significantly increased in female rats. No other
significant differences in tumor incidence data were observed.
In a study in which albino hairless mice were exposed to both ultra-violet radiation
(UVR) and topically applied calcitriol ointment, a reduction in the time required for
UVR to induce the formation of skin tumors was observed in all groups that
received the ointment base, including the vehicle-treated control group, relative to
animals that received no ointment but which were exposed to UVR. The time
required for UVR to induce the formation of skin tumors did not differ between
animals that received plain vehicle and those that received vehicle that contained
calcitriol. Concentrations of calcitriol in ointment base of 0 (vehicle control), 0.3,
0.6 and 1.0 ppm were evaluated. These data suggest that the vehicle of VECTICAL
Ointment may enhance the ability of UVR to induce skin tumors.
Calcitriol did not elicit genotoxic effects in the mouse lymphoma TK locus assay.
Studies in which male and female rats received oral doses of calcitriol of up to
0.6 mcg/kg/day (3.6 mcg/m2/day) indicated no impairment of fertility or general
reproductive performance.
Based upon the recommended human dose and instructions for use, it is not possible
to calculate human dose equivalents for animal exposure in these studies.
PATIENT COUNSELING INFORMATION
This information is intended to aid in the safe and effective use of this medication.
It is not a disclosure of all possible adverse or intended effects. Patients using
VECTICAL Ointment should receive the following information:
Instructions for Use
This medication is to be used as directed by the physician. It is for external use
only. This medication is to be applied only to areas of the skin affected by psoriasis,
as directed. It should be gently rubbed into the skin so that no medication remains
visible.
Adverse Reactions
Patients should report any signs of adverse reactions to their physician.
Marketed by:
GALDERMA LABORATORIES, L.P.
Fort Worth, Texas 76177 USA
Manufactured by:
Galderma Production Canada Inc. GALDERMAand
GALDERMA is aVectical
registered trademark.
are registered trademarks.
Baie d’Urfé, QC, H9X 3S4 Canada P51460-0
Made in Canada. Revised: December
January 2009
2009
© 2009 Galderma Laboratories, L.P.
GALDERMA and Vectical are registered trademarks.
Galderma Laboratories, L.P.
14501 N. Freeway, Fort Worth, TX 76177
VEC-337C Printed in USA 12/09
 SCIENTIFIC SESSIONS

For description of session categories and fees see page 37

AAD learner Rights and Responsibilities

As an AAD meeting participant you have the right to expect:
• Content that promotes improvements in quality health care • Content that is valid, reliable and accurate
• Contributions based on the best scientific evidence available • Balanced presentations, free of commercial bias
• Disclosure of relationships with industry • Disclosure of off-label usage

Each speaker has attested to provide the above. Please evaluate each educational activity you attend for its effectiveness in meeting the
identified need and accomplishing the above Learner Rights and Responsibilities.

In addition, each AAD meeting participant is responsible for providing relevant disclosure during Questions and Answers sessions.

OVERVIEw

THURSDAY, FEBRUARY 3
Course — 8:00 a.m. to 1:00 p.m. Course — 12:00 p.m. to 5:00 p.m.
C001 Volunteers Abroad Course: Beginner . . . . . . . . . .57 C002 Volunteers Abroad Course: Advanced . . . . . . . . . .58

COURSE
8:00 a.m. to 1:00 p.m.
Tuition fee and ticket required for admission.

C001 Volunteers Abroad Course: Beginner REFERENCES

THURSDAY, FEBRUARY 3
Room: 395/396 1. Norton SA. The dermatologist’s Baedeker. Preparation
for medical assistance missions. Dermatol Clin. 1999
DIRECTOR Carrie L. Kovarik, M.D. Jan;17(1):187-208, ix-x.
SpEAkERS SCHEDUlE
Mariable Guadalupe Nancy Kelly, M.H.S 8:00 a.m. Welcome and Introduction / Dr. Kovarik
Chavez López, M.D. James J. Nordlund, M.D. 8:05 a.m. Overview of Health care in Developing Countries
Noah A. Craft, M.D., Ph.D. Scott A. Norton, M.D., M.P.H. / Dr. Nordlund
Roberto A. Estrada- Neil Prose, M.D. 8:40 a.m. Volunteering Abroad and Finding the Program for
Castanon, M.D. Wingfield Ellis Rehmus, M.D., M.P.H. You / Dr. Rehmus
Camille Introcaso, M.D. Stephanie Schaefer, M.D. 8:55 a.m. Community Dermatology in Mexico
Jonathan Kantor, M.D. Marta Jane VanBeek, M.D. / Dr. Chavez López / Dr. Estrada-Castanon
9:15 a.m. Working with a Limited Formulary / Dr.VanBeek
lEARNINg OBjECTIVES
9:45 a.m. Working with Local Dermatologists in Resource
Following this course, the attendee will be able to:
Limited Settings / Dr.Craft
1. Recognize the dermatologist’s role in international outreach.
10:00 a.m. Break / Faculty
2. Identify steps necessary to participate in clinical care and
10:15 a.m. Issues of Personal Preparedness / Dr. Norton
education abroad.
/Dr. Schaefer
3. Examine basic concepts in the diagnosis and treatment of
11:00 a.m. International Volunteerism as a Resident / Dr. Introcaso
diseases often seen in developing countries, and learn to work
11:15 a.m. The Dermatologist’s Role in Disaster Relief
with a limited pharmacy.
/ Dr. Kantor
DESCRIpTION 11:30 a.m. Pediatric Dermatology in the International Setting
This course will detail the needs and roles in international outreach / Dr. Prose
and education. The dermatologist’s role in these efforts and 11:45 a.m. Cultural Competence and Language Barriers
opportunities for participation will be reviewed. An overview of / Ms. Kelly
medical humanitarian assistance and tips for planning and preparing 12:00 p.m. Lunch with Table-Top Discussions / Faculty
for participation in a clinical or teaching program abroad will be 6:00 p.m. Informal Networking Dinner (additional fees apply)
provided in this beginner-level course, as well as a review of commonly / Faculty
encountered conditions and diseases in the field. Strategies for working
with a limited pharmacy will also be discussed.
4.75 Category 1 CME Credits

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 57

 SCIENTIFIC SESSIONS

For description of session categories and fees see page 37

COURSE
12:00 p.m. to 5:00 p.m.
Tuition fee and ticket required for admission.

C002 Volunteers Abroad Course: Advanced SCHEDUlE

Room: 395/396 12:00 p.m. Lunch with Table-Top Discussions / Faculty
1:00 p.m. Tropical Dermatology Review / Dr. Kovarik
1:20 p.m. Albino Program in Malawi / Dr. Sethi
DIRECTOR Carrie L. Kovarik, M.D. 1:35 p.m. Dermatology Abroad: Inter-Urban to Remote Villages
SpEAkERS / Dr. Maurer
Daniel Berg, M.D. Scott A. Norton, M.D., M.P.H. 1:50 p.m. Lessons Learned in Tanzania / Dr. Zaenglein
Casey Carlos, M.D. Aisha Sethi, M.D. 2:05 p.m. Population Based Dermatology / Dr. Norton
Toby A. Maurer, M.D. Andrea L. Zaenglein, M.D. 2:50 p.m. Break / Faculty
Karen McKoy, M.D., M.P.H. 3:05 p.m. Dermatologic Surgery Abroad / Dr. Berg
3:20 p.m. HIV and the Global Impact / Dr. Kovarik
lEARNINg OBjECTIVES 3:45 p.m. Teaching Dermatology in Resource Limited Settings
Following this course, the attendee will be able to:
/ Dr. Carlos
1. Recognize the dermatologist’s role in international clinical care
and education. 4:00 p.m. International Teledermatology: Potential and
2. Discuss the diagnosis and treatment of diseases seen more Limitations / Dr. McKoy
commonly in developing countries and disaster areas. 4:20 p.m. Interactive Cases in Teledermatology / Dr. Kovarik
3. Identify steps needed to handle logistical issues in providing 5:00 p.m. Session Wrap-up / Dr. Kovarik
clinical care and education abroad, including creating local 6:00 p.m. Informal Networking Dinner (additional fees apply)
partnerships, capacity building, and designing sustainable / Faculty
THURSDAY, FEBRUARY 3

programs.
DESCRIpTION
The advanced-level course will include some of the topics from
the beginner-level course in more detail, and will also include
new topics for more experienced volunteers. Throughout both
courses, the educational sessions will alternate with travel
vignettes given by dermatologists who have worked in a variety of
countries and assisted in medical care. In addition, the global use
of teledermatology will be discussed, followed by an interactive
session with international teledermatology cases.
3.75 Category 1 CME Credits

Be a part of Dermatology in Action in New Orleans!

Volunteer your time Donate supplies
Help us refurbish a local school on Thursday, From medical to office supplies, a local
February 3rd from 1:00 p.m. – 4:00 p.m. clinic will benefit from your donation.

Provide financial support

$ Your donation provides support for current
and future volunteer activities.
For more information or to
sign up, visit www.aad.org/
members/leadership

58 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng


For description of session categories and fees see page 37
OVERVIEw
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
practice Management Session open to eligible
office staff/registered nurses
Represents Patient Safety Session in program overviews
patient Safety Session
Represents Audience Response System Session
Audience Response System Session
FRIDAY, FEBRUARY 4
Course — 7:00 a.m. to 9:00 a.m.
C06A Basic Self-Assessment of Dermatopathology U011 Medical and Aesthetic Dermatology in
(includes discussion C06E – see page 122) . . . . . .64
Discussion groups — 7:15 a.m. to 8:45 a.m.
D001 Pregnancy Dermatoses: Moving Towards a
Better Understanding . . . . . . . . . . . . . . . . . . . . . .64
D002 Appropriate Uses of Lasers . . . . . . . . . . . . . . . . . .64
Focus Sessions — 7:15 a.m. to 8:45 a.m.
U001 Tricks of the Blade . . . . . . . . . . . . . . . . . . . . . . . .65
U002 Management of Post-Acne Scarring . . . . . . . . . . .65
U003 Management of High-Risk Squamous
Cell Carcinoma (SCC) . . . . . . . . . . . . . . . . . . . . .65
U004 Advances in Web-Based Medical Education: F007 Management of Difficult Wounds. . . . . . . . . . . . .72
How Best to Teach Dermatology . . . . . . . . . . . . .66
U005 High-Yield “Power Hour” for Residents . . . . . . . .66
U006 International Teledermatology Overview. . . . . . . .66
U007 Ectodermal Dysplasias . . . . . . . . . . . . . . . . . . . . .66
U008 Recognition and Management of workshop — 9:00 a.m. to 11:00 a.m.
High-Risk Skin Cancer . . . . . . . . . . . . . . . . . . . .67
U009 Phototherapy and Photochemotherapy:
Nuances and Peals for the Practicing Clinician . . .67
For the Latest Program Book InFormatIon PLease reFer to
SCIENTIFIC SESSIONS
Represents activities that meet MOC-D
M
O
This activity has been approved by the ABD to satisfy
C component 2 of MOC-D
Represents Leadership Institute in program overviews
leadership Institute — addresses leadership
competencies specific to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
U010
The Tzanck Smear Test: Reintroducing Our Good
Old Friend! . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .67
Skin of Color . . . . . . . . . . . . . . . . . . . . . . . . . . . .68
U012 Leading with Your Strengths . . . . . . . . . . . . . . . . .68
U013 Vitamin D and Dermatology . . . . . . . . . . . . . . . .68
Forums — 9:00 a.m. to 11:00 a.m.
F001 Advanced Medical Dermatology . . . . . . . . . . . . . .69
F002 Erosive Vulvar Diseases: Approach to Diagnosis
Differential Diagnosis, and Treatment. . . . . . . . . .69
F003 Case-Based Challenges in Pediatric Dermatology . .70
F004 Geriatric Dermatology: Advanced Cases . . . . . . . .70
F005 Board Blitz . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .71
F006 Vitiligo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .71
FRIDAY, FEBRUARY 4
F008 Decreasing Iatrogenic Problems
in Your Practice. . . . . . . . . . . . . . . . . . . . . . . . . . .72
W001 MOC Self-Assessment A. . . . . . . . . . . . . . . . . . . .72
www.aad.org | 59
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

OVERVIEw
Courses — 9:00 a.m. to 12:00 p.m.
C003 Pediatric Dermatology . . . . . . . . . . . . . . . . . . . . .73
C004 Diagnosis and Therapeutics:
The Fundamentals. . . . . . . . . . . . . . . . . . . . . . . . .74
C005 Basic Contact Dermatitis . . . . . . . . . . . . . . . . . . .74

Advisory Board Symposia — 9:00 a.m. to 12:00 p.m.

S001 Disorders of Pigmentation . . . . . . . . . . . . . . . . . .75
Activities S002 Alopecia: Workup and Treatment . . . . . . . . . . . . .75
S003 Hot Topics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .76
S004 When Bad Things Happen to Good Doctors . . . .76
Advisory Board S005 Leading from Your Vision to Exceptional Service 77
Reference Committee Hearing S006 Approach to Pigmented Lesions . . . . . . . . . . . . . .78
(All AAD Members are Welcome)
Friday, February 4
2:00 p.m. – 4:00 p.m.
Room 350 (CC) Courses — 9:00 a.m. to 5:00 p.m.
C007 Immunology . . . . . . . . . . . . . . . . . . . . . . . . . . . . .79
C008 Derm Exam Prep Course: Refresher . . . . . . . . . . .79

Advisory Board
Reference Committee Executive Session
Course — 9:30 a.m. to 11:30 a.m.
(Reference Committee Members Only) C06B Basic Self-Assessment of Dermatopathology
Friday, February 4 (includes discussion C06E – see page 122) . . . . . .80
4:00 p.m. – 5:00 p.m.
Room 349 (CC)

Forums — 12:00 p.m. to 2:00 p.m.

F009 Photobiology for Dermatologists . . . . . . . . . . . . .80
Advisory Board General Meeting F010 Hidradenitis Suppurativa: An Update . . . . . . . . . .81
(All AAD Members are Welcome) F011 Dermatopathology Made Simple . . . . . . . . . . . . .81
Sunday, February 6
2:30 p.m. – 5:30 p.m. F012 Update on Genetic Skin Disease . . . . . . . . . . . . . .82
Room 383/384/385 (CC) F013 EHR Implementation, Maintenance, and
Lessons Learned . . . . . . . . . . . . . . . . . . . . . . . . . .82
F014 Challenging Diagnostic Cases for Advanced
FRIDAY, FEBRUARY 4

Practitioners: PA/NP I . . . . . . . . . . . . . . . . . . . . .83

Advisory Board Executive Committee F015 Ethical Economics in Dermatology and

Dermatologic Surgery . . . . . . . . . . . . . . . . . . . . . .83
(Executive Committee Members Only)
F016 Advances in Dermatologic Surgery . . . . . . . . . . . .84
Monday, February 7
8:00 a.m. – 9:00 a.m.
Room 349 (CC)

60 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

Represents restricted session in program overviews Represents activities that meet MOC-D
Restricted Session open to dermatologists and corporate M
O
This activity has been approved by the ABD to satisfy
individual members only! A ticket is required for admittance C component 2 of MOC-D

Represents Practice Management Session in program overviews Represents Leadership Institute in program overviews
practice Management Session open to eligible leadership Institute — addresses leadership
office staff/registered nurses competencies specific to dermatologists

Represents Patient Safety Session in program overviews Represents Health Information Technology (HIT) in
program overviews
patient Safety Session
Health Information Technology Sessions

Represents Audience Response System Session

Audience Response System Session

U026 Teledermatology 101: Integrating Teledermatology

Discussion groups — 12:15 p.m. to 1:45 p.m. into Your Practice . . . . . . . . . . . . . . . . . . . . . . . . .89
D003 Selected Topics in Medical Dermatology. . . . . . . .84
D004 Dealing with Disappointing Outcomes and
Medical Mistakes . . . . . . . . . . . . . . . . . . . . . . . . .84
Course — 12:30 p.m. to 2:30 p.m.
C06C Basic Self-Assessment of Dermatopathology . . . . .89
(includes discussion C06E – see page 122)
Focus Sessions — 12:15 p.m. to 1:45 p.m.
U014 When Acne Really Isn’t Acne . . . . . . . . . . . . . . . .85
U015 Merkel Cell Carcinoma. . . . . . . . . . . . . . . . . . . . .85
Courses — 2:00 p.m. to 5:00 p.m.
U016 Sports Dermatology — C009 Dermatologic Syndromes and Genetic Disorders 90
Skin Infections in Athletes . . . . . . . . . . . . . . . . . .85
C010 Advanced Contact Dermatitis. . . . . . . . . . . . . . . .90
U017 Clincial Trials for the Private Practitioner . . . . . . .86
C011 The State of the Art of Aesthetic Dermatology:
U018 Outcomes Research in Dermatology. . . . . . . . . . .86 Live Patient Demonstration . . . . . . . . . . . . . . . . .91
U019 Sun, Drugs and Invervention: How to Prevent
Non-Melanoma Skin Cancer . . . . . . . . . . . . . . . .87
U020 Challenging Diagnostic Cases for Advanced
Symposia — 2:00 p.m. to 5:00 p.m.
FRIDAY, FEBRUARY 4

Practitioners: PA/NP II. . . . . . . . . . . . . . . . . . . . .87

S008 Consultative Dermatology for the
U021 Acne in the Adult Female . . . . . . . . . . . . . . . . . . .87 Hospitalized Patient . . . . . . . . . . . . . . . . . . . . . . .91
U022 Vulvar Dermatoses . . . . . . . . . . . . . . . . . . . . . . . .87 S009 Advanced Medical Dermatology . . . . . . . . . . . . . .92
U023 Highlights from JAAD . . . . . . . . . . . . . . . . . . . . .88 S010 Surviving Healthcare Reform . . . . . . . . . . . . . . . .92
U024 Leading Confidently through Powerful S011 Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . .93
Communication . . . . . . . . . . . . . . . . . . . . . . . . . .88
S012 Aging Gracefully . . . . . . . . . . . . . . . . . . . . . . . . . .93
U025 A Personalized Planner for Rejuvenation. . . . . . . .88
S013 Leading Others for Peak Performance . . . . . . . . . .94

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 61

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

Discussion groups — 2:30 p.m. to 4:00 p.m. Course — 3:00 p.m. to 5:00 p.m.
D005 Dermatoethics: Contemporary Issues C06D Basic Self-Assessment of Dermatopathology . . . . .99
in Ethics and Professionalism . . . . . . . . . . . . . . . .94 (includes discussion C06E – see page 122)
D006 Serologic Testing for Connective Tissue Diseases 94

Forums — 3:00 p.m. to 5:00 p.m.

Focus Sessions — 2:30 p.m. to 4:00 p.m. F017 Resident Jeopardy . . . . . . . . . . . . . . . . . . . . . . . .100
U027 Practical Approaches to Medical and Cosmetic F018 Atopic Dermatitis . . . . . . . . . . . . . . . . . . . . . . . .100
Dermatology in Skin of Color . . . . . . . . . . . . . . .95
F019 Journal Watching . . . . . . . . . . . . . . . . . . . . . . . .101
U028 Oral Ulcers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .95
F020 Volunteerism and Humanitarianism . . . . . . . . . .101
U029 Skin Cancer in Patients with Non-Melanoma
Hodgkin’s Lymphoma. . . . . . . . . . . . . . . . . . . . . .96 F021 FDA Presents: Information for Dermatologists . .102
U030 Treatment of Pediatric Psoriasis. . . . . . . . . . . . . . .96 F022 Coding and Office Management. . . . . . . . . . . . .102
U031 Dermatomyositis. . . . . . . . . . . . . . . . . . . . . . . . . .97 F023 Psoriasis Guidelines: Implementing Them in
Your Practice. . . . . . . . . . . . . . . . . . . . . . . . . . . .103
U032 Chronic Inflammatory Hand and
Foot Dermatoses . . . . . . . . . . . . . . . . . . . . . . . . . .97
U033 Electrolysis: When Laser Isn’t the Answer . . . . . . .98
U034 Pediatric Hyperhidrosis and Ectodermal Dysplasia:
workshops — 3:00 p.m. to 5:00 p.m.
W002 Dermatology Speaker Development . . . . . . . . . .104
To Sweat or Not to Sweat? . . . . . . . . . . . . . . . . . .98
W003 MOC Self-Assessment: Dermatopathology . . . . .104
U035 Paraneoplastic Dermatoses . . . . . . . . . . . . . . . . . .98
U036 Subcutaneous Fat in Dermatology . . . . . . . . . . . .98
U037 Paraneoplastic Autoimmune Multiorgan
Syndrome (PAMS) . . . . . . . . . . . . . . . . . . . . . . . .99

SPECIAL OFFER: THE ART OF AESTHETIC DERMATOLOGY , now available at the new low price of $150!

Learn the latest techniques for facial rejuvenation, injecting collagen, hyaluronic
acid, calcium hydroxyapatite, poly-L-lactic acid, and polymethylmethacrylate.
• Observe live aesthetic demonstrations by expert faculty
FRIDAY, FEBRUARY 4

• Evaluate the aging face

• Understand the value of facial musculature and treatment of the upper and
lower face
The Art of Aesthetic Dermatology was developed for the practicing
dermatologist and has been approved for AMA PRA Category 1 CreditsTM.

Visit the Academy Resource Center Booth 3623 to place your order.

62 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS

Reception Row Events

Friday, February 4, 2011 • Hilton New Orleans Riverside

Residents’ Reception
5:00pm-6:30pm
Napoleon Ballroom

DAN/SkinPAC Reception
5:00pm-7:00pm
Jefferson

Career Fair
5:00pm-7:00pm
Grand Salon ABC

Welcome Reception for Young Physicians and New Members

5:00pm-6:30pm
Versailles Ballroom

International Member Reception

5:00pm-6:30pm
Grand Salon D

Volunteer Fair
5:00pm-7:00pm
Court Assembly
FRIDAY, FEBRUARY 4

Leaders in Giving Recognition Reception

(by invitation only)
5:00pm-7:00pm
Rosedown

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 63

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE DISCUSSION gROUp

7:00 a.m. to 9:00 a.m. 7:15 a.m. to 8:45 a.m.
Tuition fee and ticket required for admission. Tuition fee and ticket required for admission.

C06A Basic Self-Assessment of D001 pregnancy Dermatoses: Moving Towards

Dermatopathology a Better Understanding
Room: 240
Room: 275/276/277
DIRECTOR Samantha A. Vaughan-Jones, M.D.
DIRECTOR Clay J. Cockerell, M.D.
lEARNINg OBjECTIVES
SpEAkERS Antoanella Bardan, M.D. Following this discussion group, the attendee will be able to:
lEARNINg OBjECTIVES 1. Recognize and differentiate the common and specific
Following this course, the attendee will be able to: pregnancy dermatoses.
2. Identify safe and effective treatments for mother and fetus.
1. Interpret and identify dermatologic histological diagnoses more
3. Discuss the effect of pregnancy on other skin diseases.
effectively and accurately.
2. Classify and recognize common histopathologic skin conditions DESCRIpTION
and formulate differential diagnoses. This session will outline the common physiological changes in
pregnancy, including immune changes that predispose pregnant
DESCRIpTION women to skin disease. The terminology of the specific pregnancy
Attendees will view 60 slides from skin biopsy specimens in a format dermatoses historically caused much confusion, and a simplified
that will allow self-assessment. Cases will span the full spectrum of classification and algorithm will be described. Participants will
dermatopathology. Each specimen will be discussed by a faculty learn how to recognize, differentiate, and manage the various
member with emphasis placed on establishing the correct diagnosis pruritic skin disorders. Polymorphic eruption, atopic eruption,
and consideration of the differential diagnosis. These sessions are pemphigoid gestationis, and obstetric cholestasis will all be
directed to dermatology residents and practicing dermatologists. described in detail with previous research findings. The effects
To allow for a larger participation this year, this course will be of pregnancy on common skin diseases will also be highlighted.
offered with duplicate content at 7:00 a.m., 9:30 a.m., 12:30 p.m., Patient education and treatments that are safe and effective in
pregnancy will be summarized.
and 3:00 p.m. Attendees need only select one of these sessions.
1.50 Category 1 CME Credits
This session includes the discussion C06E – see page 122.
2.00 Category 1 CME Credits
D002 Appropriate Uses of lasers
Room: 241
DIRECTOR Ronald G. Wheeland, M.D.
lEARNINg OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Compare the advantages and disadvantages of lasers in treating
patients.
2. Describe the appropriate use of lasers in different clinical
conditions.
3. Determine how lasers interact with tissue to obtain the best
clinical results.
DESCRIpTION
FRIDAY, FEBRUARY 4

This session will consist of a discussion of the most common lasers

available and how they are used appropriately to treat different
skin conditions. The advantages and disadvantages of these devices
in managing a variety of skin conditions will also be detailed. After
this introduction, there will be ample time for the attendees to ask
questions about problems they have encountered in treating their
own patients or to seek advice on how to improve their results.
This highly interactive portion of the session should permit an
exchange of ideas between the attendees and the course director.
1.50 Category 1 CME Credits

64 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U001 Tricks of the Blade U003 Management of High-Risk Squamous Cell

Room: 267/268 Carcinoma (SCC)
DIRECTOR Cyndi Jill Yag-Howard, M.D. Room: 242
lEARNINg OBjECTIVES DIRECTOR Chrysalyne Delling Schmults, M.D.
Following this focus session, the attendee will be able to:
lEARNINg OBjECTIVES
1. Develop surgical tips and tricks that will be satisfying to you
Following this focus session, the attendee will be able to:
and your patients and improve surgical outcome.
1. Identify SCCs that are at increased risk for metastasis, as well
2. Demonstrate creative surgical and perioperative wound care
as medical conditions that elevate patients metastatic risk.
techniques that will enhance surgical cosmesis.
2. Discuss the latest literature regarding prognosis, staging, and
3. Express confidence in your own practice as you venture outside
treatment options for high-risk tumors.
the pages of a surgical textbook.
3. Determine an appropriate staging, treatment, and follow-up
DESCRIpTION strategy for patients with high-risk SCC.
This session is intended for all dermatologic surgeons, whether
DESCRIpTION
new to practice or established, who are interested in picking
Although most SCCs are curable with current therapies, a
up tips to improve surgical outcomes. Included will be the
small subset of tumors fail treatment and metastasize. Thus,
presentation of the SIT and the SIL stitch to improve cosmesis, as
dermatologists must be familiar with the available data regarding
well as the SQ grabbing stitch and the inverted SQ cross mattress
identification and treatment of SCCs with an elevated risk of
stitch for ease of closure. Presenter will review wound care beyond
metastasis. This session will review tumor-specific factors, such
standard petrolatum and bandage and will also address closures,
as degree of perineural invasion and depth of invasion, that
with emphasis on specific closures that work exceptionally well in
increase risk of metastasis. Host factors associated with worse
certain anatomic locations. The audience will be invited to share
outcomes, such as underlying immunosuppression, will also be
experiences as the presenter reviews cases and discusses techniques
addressed. Data on staging options, such as radiologic imaging
that one learns over years of practice.
and sentinel node biopsy, will be discussed. Treatment options,
1.50 Category 1 CME Credits
including Mohs surgery, multidisciplinary surgery, and adjuvant
radiotherapy, will be discussed using case examples. The session
will be geared toward dermatologists and dermatologic surgeons.
U002 Management of post-Acne Scarring 1.50 Category 1 CME Credits
Room: 263
DIRECTOR Gregory J. Goodman, M.D.
lEARNINg OBjECTIVES
Following this focus session, the attendee will be able to:
1. Assess and categorize the patient with post-acne scarring.
2. Adequately prepare and educate the patient about alternative
available treatments.
3. Design and individualize the management of the patient with
post-acne scarring.
DESCRIpTION
Acne scarring may present with different shapes and sizes, and
FRIDAY, FEBRUARY 4

vary greatly in severity. Classification according to the scar type

and severity in both atrophic and hypertrophic scarring is useful in
planning therapy as various scar morphologies and severity require
different approaches. Many new and old therapies are available and
are often best combined. Some -- like punch techniques, subcision,
skin rolling and occasionally botulinum toxin and dermal and
deeper fillers -- are possible in all clinics; others, such as vascular,
pigmented, ablative, nonablative, and fractionated resurfacing
lasers, will require significant clinical interest and expenditure.
1.50 Category 1 CME Credits

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 65

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U004 Advances in web-Based Medical U006 International Teledermatology Overview

Education: How Best to Teach Room: 264
Dermatology DIRECTOR Karen McKoy, M.D., M.P.H.
Room: 274
lEARNINg OBjECTIVES
DIRECTOR Jacqueline C. Dolev, M.D. Following this focus session, the attendee will be able to:
1. Examine the challenges of providing teledermatology
lEARNINg OBjECTIVES
consultation to those in developing countries.
Following this focus session, the attendee will be able to:
2. Prepare for participation in the arena of international
1. Recognize the efficacy of Web-based curricula in dermatology.
teledermatology.
2. Identify key concepts in effective learning of visual cues and
3. Recognize the various types of international teledermatology
pattern recognition.
and reasons for current practices.
3. Summarize current studies evaluating learning retention using
the Web. DESCRIpTION
The International Society of Teledermatology was recently formed
DESCRIpTION with the goal of establishing worldwide access to teledermatology
This session is geared to both educators and practicing services, particularly for reaching underserved or remote patient
dermatologists; whether you are teaching medical students, populations. The third meeting in 2010 had attendees from
residents, or non-specialist providers, or just have an interest in across the world. This session will discuss not only the types of
the theoretical basis of visual learning. The session will emphasize teledermatology activity practiced in various countries (from the
emerging trends in teaching visual diagnostic skills and summarize United States to Australia, government funded or not), but also
current studies utilizing online curricula for knowledge retention. the use of teledermatology as a charitable tool to educate and to
The key elements necessary to teach dermatology as they relate to aid those in underserved and impoverished regions. An invitation
learning theory, pattern recognition, and visual learning will be will be issued and methods discussed to participate in this growing
discussed. international collaboration.
1.50 Category 1 CME Credits 1.50 Category 1 CME Credits

U005 High-Yield “power Hour” for Residents U007 Ectodermal Dysplasias

Room: 270 Room: 269

DIRECTOR Harley A. Haynes, M.D. DIRECTOR Alanna Flath Bree, M.D.

lEARNINg OBjECTIVES lEARNINg OBjECTIVES
Following this focus session, the attendee will be able to: Following this focus session, the attendee will be able to:
1. Examine pearls and measure competency in high-yield topics. 1. Identify the pathogenesis and classification of the major
2. Discuss key topics in dermatology, including drugs used ectodermal dysplasias (EDs).
in dermatology, procedural dermatology, allergic contact 2. Identify and accurately diagnose the major EDs.
dermatitis, and basement membrane disorders. 3. Evaluate and manage patients with the major EDs.
3. Demonstrate comprehension through multiple choice
questions. DESCRIpTION
FRIDAY, FEBRUARY 4

This session will review the pathogenesis, classification, and clinical

DESCRIpTION features of the major ectodermal dysplasias (EDs), including
This forum is designed for dermatology residents who seek to hypohidrotic ectodermal dysplasia, hidrotic ectodermal dysplasia,
achieve a comfort level with four high-yield topics encountered ectodactyly-ectodermal dysplasia-clefting (EEC) syndrome, and
during training. Image-based learning will focus on: 1) ankyloblepharon-ectodermal defects-clefting (AEC) syndrome.
mechanisms of action and side effects of systemic dermatologic Participants will learn how to accurately evaluate and diagnose
therapies, 2) basic concepts of laser and surgical dermatology, 3) these conditions in affected patients. Appropriate management
allergens associated with contact dermatitis, and 4) inherited and strategies will also be discussed.
immunobullous disorders of the epidermal basement membrane. 1.50 Category 1 CME Credits
Multiple choice questions will highlight take-home pearls. These
sessions are popular among residents at our institution.
1.50 Category 1 CME Credits

66 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U008 Recognition and Management of U009 phototherapy and photochemotherapy:

High-Risk Skin Cancer Nuances and peals for the practicing
Room: 284 Clinician
DIRECTOR Clark C. Otley, M.D. Room: 298/299

lEARNINg OBjECTIVES DIRECTOR Charles R. Taylor, M.D.

Following this focus session, the attendee will be able to: lEARNINg OBjECTIVES
1. Discuss features suggesting potentially aggressive behavior of a Following this focus session, the attendee will be able to:
skin cancer. 1. Manage patients on ultraviolet therapy in accordance with their
2. Outline therapeutic considerations when confronted by a high- specific state and distribution of skin disease.
risk skin cancer. 2. Recognize the importance of a given diagnosis to the
3. Identify indications for adjuvant modalities to reduce the risk management of a patient on ultraviolet therapy.
of recurrence of high-risk skin cancers. 3. Choose the best ultraviolet protocol for the treatment of a
given patient.
DESCRIpTION
DESCRIpTION
Dermatologists practicing at the highest level are able to recognize This session is intended for the practitioner of ultraviolet light
features of high-risk skin cancers before recurrence or metastasis, therapy to enhance management skills, taking into consideration a
thus offering optimal treatment to patients. In this session, we patient’s diagnosis, condition, medications, skin type, distribution
will review the latest data on high-risk skin cancers and discuss of disease, and occupation, all the way emphasizing safety. Some
how to prospectively recognize them. More importantly, we individual protocols will be reviewed. Most attention will be spent
will consider various strategies to improve outcomes for patients on narrow band UVB phototherapy, but some mention of other
with high-risk skin cancers, including when to employ adjuvant modalities, such as PUVA and UVA-1 therapy, will occur.
therapies. Learn how to practice cutting-edge cutaneous oncology 1.50 Category 1 CME Credits
through this case based session.
1.50 Category 1 CME Credits
U010 The Tzanck Smear Test: Reintroducing
our good Old Friend!
Room: 283
DIRECTOR Deniz Seckin, M.D.
lEARNINg OBjECTIVES
Following this focus session, the attendee will be able to:
1. Prepare Tzanck smears for diagnosis of skin diseases.
2. Identify the characteristic cytologic features of certain skin
diseases.
3. Choose the Tzanck smear test instead of unnecessary, harmful,
invasive or costly diagnostic procedures.
DESCRIpTION
Cytology is a simple, rapid, and inexpensive diagnostic method
FRIDAY, FEBRUARY 4

which investigates the characteristics of individual cells. Tzanck

smears can aid in the diagnosis of various skin diseases, including
bacterial, viral and fungal infections, leishmaniasis, pemphigus,
spongiotic dermatitis, Darier’s disease, Hailey-Hailey disease,
granulomatous disorders, and tumoral lesions. This session will
teach the preparation of a Tzanck smear and help the attendees
to interpret the characteristic cytologic findings of certain skin
diseases in daily practice. Finally, an algorithmic approach will be
given and participants will be encouraged to discuss the various
case examples that could be diagnosed by a Tzanck smear.
1.50 Category 1 CME Credits

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 67

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U011 Medical and Aesthetic Dermatology in U012 leading with Your Strengths
Skin of Color Room: 293/294
Room: 285 DIRECTOR Elizabeth Shannon Martin, M.D.
DIRECTOR Valerie D. Callender, M.D. SpEAkER
lEARNINg OBjECTIVES Sandra Ellison, Center for Creative Leadership
Following this focus session, the attendee will be able to: lEARNINg OBjECTIVES
1. Recognize the physiological and morphological differences in Following this focus session, the attendee will be able to:
skin of color. 1. Identify his/her own leadership strengths and weaknesses.
2. Assess diagnoses and treatments for common ethnic skin and 2. Demonstrate effective of communication with others.
hair disorders. 3. Implement core leadership competencies into daily practice.
3. Review indications and protocols for cosmetic procedures in
dark-skinned racial ethnicities. DESCRIpTION
No matter the setting, dermatologists are faced with leadership
opportunities every day. Whether they involve staff management,
DESCRIpTION practice promotion/expansion, involvement in organized medicine,
Dark-skinned racial ethnic groups constitute the majority or advancing an academic career, strong leadership skills allow a
of the global populations. This focus session will review physician to meet these challenges with aplomb. This interactive
the pathogenesis and treatment of common skin and hair session will allow participants to perform a personality self-assessment
disorders in darker skin types, including acne, rosacea, post- and focus on how information learned allows the dermatologist to
inflammatory hyperpigmentation, melasma, seborrheic dermatitis, capitalize on his/her strengths and improve on his/her weaknesses.
pseudofolliculitis barbae, keloids, and alopecia. In addition, How to improve communications with others using personality
assessment will also be discussed. This session addresses the
indications and protocols for cosmetic procedures suitable for
Leadership Institute Core Competencies of Increasing Self-Awareness
darker skin types will be discussed, including chemical peels, laser and Communicating Effectively.
hair removal, injectable fillers, and hair transplantation. 1.50 Category 1 CME Credits
1.50 Category 1 CME Credits

U013 Vitamin D and Dermatology

Room: 235/236
DIRECTOR Tissa R. Hata, M.D.
lEARNINg OBjECTIVES
Following this focus session, the attendee will be able to:
1. Outline vitamin D metabolism and relevant sources of vitamin D.
2. Describe how vitamin D relates to the innate immune system in
dermatologic diseases.
3. Assess the validity of the controversies regarding vitamin D and
sunlight.
FRIDAY, FEBRUARY 4

DESCRIpTION
Vitamin D’s role in bone health has been well established. Recently,
however, studies have identified additional roles for vitamin D in the
immune system, cardiovascular system, and in cancer prevention,
causing some to advocate unprotected sun exposure as a means to
increase vitamin D levels. This speaker will review the vitamin D
literature as relevant to the dermatologist, with respect to the safety
and dose of different sources of vitamin D, and the effect of vitamin
D on the innate immune system in atopic dermatitis, psoriasis, and
infections.
1.50 Category 1 CME Credits

68 | amerIcan academy oF dermatoLogy • 68th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F001 Advanced Medical Dermatology F002 Erosive Vulvar Diseases: Approach to

Room: 295/296 Diagnosis, Differential Diagnosis, and
DIRECTOR Lindy Peta Fox, M.D. Treatment
Room: 252/253/254
SpEAkERS
Susan Burgin, M.D. Misha Rosenbach, M.D. DIRECTOR Bethanee Jean Schlosser, M.D., Ph.D.
Amit Garg, M.D. Kanade Shinkai, M.D., Ph.D. SpEAkER
lEARNINg OBjECTIVES Ginat W. Mirowski, D.M.D., M.D.
Following this forum, the attendee will be able to: lEARNINg OBjECTIVES
1. Describe the cutaneous manifestations of autoinflammatory Following this forum, the attendee will be able to:
diseases. 1. Identify primary skin diseases as well as systemic disorders
2. Recognize emerging issues in the evaluation and management which cause vulvovaginal erosions and ulcers.
of rheumatologic disease and drug eruptions as they involve 2. Discuss the differential diagnosis of erosive vulvovaginal lesions
the skin. and the approach to obtaining a diagnosis.
3. Recognize emerging trends in internal medicine and 3. Describe therapeutic options for the management of erosive
consultative dermatology that influence the daily practice of vulvovaginal disorders.
medical dermatology.
DESCRIpTION
DESCRIpTION This session will focus on primary cutaneous diseases and systemic
In this session, attendees will learn to recognize what is at the disorders that commonly present with erosive lesions of the
forefront of medical dermatology, especially where dermatology vulva and/or vagina. Emphasis will be placed on developing
interfaces with internal medicine. This forum is intended for an algorithmic approach to the evaluation and diagnosis
practicing dermatologists and residents, especially those with an of vulvovaginal erosions, including salient clinical features,
interest in medical dermatology and who enjoy caring for patients non-genital cutaneous findings, and the utility of biopsy for
with complex medical dermatologic conditions. The forum will routine histopathology as well as direct immunofluorescence.
emphasize hot topics not yet in textbooks, emerging trends, new Management options for these important disorders will also be
diagnostic tools, and therapeutic updates. discussed. The most up-to-date guidelines for the monitoring of
2.00 Category 1 CME Credits patients with erosive vulvar disease will be provided.
SCHEDUlE 2.00 Category 1 CME Credits
9:00 a.m. Cutaneous Manifestations of Auto-Inflammatory SCHEDUlE
Diseases / Dr. Shinkai 9:00 a.m. Introduction / Dr. Schlosser
9:20 a.m. Questions and Answers / Dr. Shinkai 9:05 a.m. Approach to the Vulvar Examination / Dr. Schlosser
9:25 a.m. Recognizing Psoriatic Arthritis / Dr. Garg 9:25 a.m. Vulvar Erosions: Case-Based Approach to Diagnosis
9:45 a.m. Questions and Answers / Dr. Garg and Treatment / Dr. Mirowski
9:50 a.m. Dermatology in the Internal Medicine Literature 9:50 a.m. Questions and Answers / Faculty
/ Dr. Rosenbach 10:00 a.m. Vulvar Erosions and Ulcers: Case-Based Approach to
10:10 a.m. Questions and Answers / Dr. Rosenbach Diagnosis and Treatment / Dr. Schlosser
10:15 a.m. Hot Topics in Drug Eruptions / Dr. Burgin 10:50 a.m. Questions and Answers / Faculty
FRIDAY, FEBRUARY 4

10:35 a.m. Questions and Answers / Dr. Burgin

10:40 a.m. Inpatient Dermatology: Cases That Have Taught Me
Dermatology / Dr. Fox

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 69

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F003 Case-Based Challenges in pediatric F004 geriatric Dermatology: Advanced Cases

Dermatology Room: 291/292
Room: 281/282 DIRECTOR Joely Anne Kaufman, M.D.
DIRECTOR James R. Treat, M.D. SpEAkERS
lEARNINg OBjECTIVES Robin A. C. Graham-Brown, M.D. Robert A. Norman, D.O.
Following this forum, the attendee will be able to: Malcolm W. Greaves, M.D., Ph.D. Antonella Tosti, M.D.
1. Develop skills in managing common and rare complex Alysa R. Herman, M.D.
pediatric dermatologic patients. lEARNINg OBjECTIVES
2. Recognize and diagnose challenging pediatric dermatologic Following this forum, the attendee will be able to:
patients. 1. Review the physiologic changes in geriatric skin.
3. Select best treatment plans for pediatric patients. 2. Summarize the latest strategies for diagnosis and treatment of
DESCRIpTION pruritus.
In a case-based fashion, we will review diagnostic and treatment 3. Discuss the different therapies for common geriatric conditions
strategies for challenging common and rare pediatric dermatologic represented in case presentations.
patients. Categories reviewed will include neonatal dermatology, DESCRIpTION
vascular lesions and hemangiomas, inflammatory dermatosis, This session will cover the most common geriatric conditions
infectious diseases, drug reactions, procedural challenges, new and encountered in the outpatient setting, including pruritus, drug
emerging pediatric skin conditions and therapeutics. eruptions, cutaneous malignancies, and hair and nail diseases.
2.00 Category 1 CME Credits Focus will be on novel and new therapies for geriatric disorders.
Case presentations will be used for open discussion of interesting
diagnoses or therapies.
2.00 Category 1 CME Credits
SCHEDUlE
9:00 a.m. Introduction / Dr. Kaufman
9:15 a.m. New Therapies for Old Diseases / Dr. Graham-Brown
9:35 a.m. Hair and Nail Disorders in the Elderly / Dr. Tosti
9:50 a.m. Special Considerations for Geriatric Surgical Patients
/ Dr. Herman
10:15 a.m. Pruritus: New Ideas and Novel Therapies / Faculty
10:30 a.m. Case Presentation and Discussion / Dr. Norman
10:50 a.m. Case Presentations and Discussion / Dr. Kaufman
FRIDAY, FEBRUARY 4

70 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F005 Boards Blitz F006 Vitiligo

Room: 255/256/257 Room: 388/389/390
DIRECTOR Jennifer Lucas, M.D. DIRECTOR James J. Nordlund, M.D.
SpEAkERS SpEAkER Rebat M. Halder, M.D.
Adam J. Friedman, M.D.
lEARNINg OBjECTIVES
Michelle B. Tarbox, M.D.
Following this forum, the attendee will be able to:
lEARNINg OBjECTIVES 1. Recognize the types of vitiligo, their clinical course, the latest
Following this forum, the attendee will be able to: information about pathogenesis, and peculiarities about
1. Recognize and/or diagnose commonly tested images related depigmented skin.
to medical dermatology, pediatric dermatology, surgical 2. Identify all forms of treatment of vitiligo, their advantages and
dermatology, and clinical pathologic correlates. disadvantages, indications for use, and outcomes.
2. Identify strengths and weaknesses in one’s knowledge base
DESCRIpTION
for the digital image section of the American Board of
Onset and course and clinical manifesetations of vitiligo will be
Dermatology certification exam, recertification exam, or mock
presented. In-depth review of the known causes intrinsic and
boards and make improvements as necessary.
extrinsic to melanocytes will be presented. Segmental vitiligo will
DESCRIpTION be differentiated from dermatomal aberrations and compared
Studying for the American Board of Dermatology (ABD) with nevus depigmentosus. The alteration in the inflammatory
certification or recertification exam can be overwhelming! system in depigmented skin will be reviewed. The resistance of
This interactive session will provide key points and tips for depigmented skin-to-skin cancer will be discussed. The genetic
identifying and making diagnoses for the digital image portion basis for vitiligo will be presented. In the second hour, all forms
of the certification or recertification exam. Attendees will have of therapy will be reviewed and the importance of the melanocyte
the opportunity to view numerous digital images in rapid-fire reservoir emphasized. The uses of topical medications, ultraviolet
progression preparing them for the digital image portion of the light, surgical transplantation, tattooing, and depigmentation will
exam. High-yield study material will also be covered as the images be discussed in detail.
are reviewed. This session will benefit any dermatologist preparing 2.00 Category 1 CME Credits
for the ABD certification, recertification, or mock board exams.
SCHEDUlE
2.00 Category 1 CME Credits
9:00 a.m. Vitiligo: Manifestation, Causes, and Treatment
SCHEDUlE / Dr. Nordlund
9:00 a.m. Medical/Pediatric Dermatology / Dr. Friedman 10:45 a.m. Questions and Answers / Dr. Nordlund
9:40 a.m. Clinical Pathologic Correlations / Dr. Babb-Tarbox
10:20 a.m. Procedural/Surgical Dermatology / Dr. Lucas

FRIDAY, FEBRUARY 4

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 71

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM wORkSHOp
9:00 a.m. to 11:00 a.m. 9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat Tuition fee and ticket required for admission.
for only 15 minutes after the official start time.

F007 Management of Difficult wounds w001 MOC Self-Assessment A

M
Room: 392 O Room: 288/289/290
C

DIRECTOR Oliver Fred Miller III, M.D. DIRECTOR Steven B. Deliduka, M.D.
lEARNINg OBjECTIVES lEARNINg OBjECTIVES
Following this forum, the attendee will be able to: Following this workshop, the attendee will be able to:
1. Distinguish among the ulcers seen on the feet and legs. 1. Identify the strengths and weaknesses in one’s dermatology
2. Evaluate and treat venous leg ulcers. knowledge and make improvements as needed.
3. Treat ulcerations with various methods of debridement. 2. Demonstrate commitment to lifelong learning and self-
assessment via completion of a forum of 25 questions and
DESCRIpTION
answers.
Discussion will provide an overview of leg and foot ulcer
classification and differential diagnosis followed by a focused DESCRIpTION
discussion of etiology, evaluation, treatment, and aftercare of This session is structured in a question-and-answer format
venous leg ulcers and diabetic neuropathic foot ulcers. A detailed using an automated response system. It will cover topics in
discussion of effective debridement will be included. Practical general dermatology, pediatric dermatology, dermatopathology,
aspects of therapy will be directed to the practicing physician dermatologic surgery, and cosmetic dermatology. The participant
interested in wound care. will have immediate feedback for each session and will be
2.00 Category 1 CME Credits able to identify any areas of weakness that require further self-
directed study. Due to the timed framework of this session, it is
imperative that participants arrive on time for this workshop.
F008 Decreasing Iatrogenic problems 2.00 Category 1 CME Credits
in Your practice * Self-assessment questions utilized in this session are
Room: 265/266 the same as those used for Workshop W005 MOC:
Self-Assessment offered at Annual Meeting 2010.
DIRECTOR Eliot N. Mostow, M.D.
Physicians should not claim CME/MOC credit for
lEARNINg OBjECTIVES attending this session if they attended Workshop W005
Following this forum, the attendee will be able to: at Annual Meeting 2010.
1. Identify examples of iatrogenic problems in a medical
dermatology clinic.
2. Examine the best practice data, where available, to prevent
iatrogenic problems.
3. Develop a system or systems within the practice to reduce
iatrogenic problems and improve patient outcomes.
DESCRIpTION
Iatrogenic problems in dermatologic practice will be discussed
and compared, when possible, to best practice data and systematic
reviews to: identify areas of concern; identify opportunities
FRIDAY, FEBRUARY 4

to prevent these errors and improve patient outcomes in an

efficient and cost-effective manner. Audience participation will be
encouraged.
2.00 Category 1 CME Credits

72 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
9:00 a.m. to 12:00 p.m.
Tuition fee and ticket required for admission.

C003 pediatric Dermatology SCHEDUlE

Room: 238/239 9:00 a.m. Introduction / Dr. Dohil
9:05 a.m. Make A “Rash”-Ional Decision: Exathems In
DIRECTOR Magdalene A. Dohil, M.D. Children / Dr. Mancini
SpEAkERS 9:25 a.m. “Rheum” With A View: Skin Signs of Systemic
Elizabeth Alvarez Connelly, M.D. Ashfaq A. Marghoob, M.D. Disease / Dr. Eichenfield
Andrew Eichenfield, M.D. Robert Sidbury, M.D. 9:35 a.m. Questions and Answers / Faculty
Sheila Fallon Friedlander, M.D. Wynnis L. Tom, M.D. 9:40 a.m. Lumps and Bumps In Kids: When They Need To Go!
Moise L. Levy, M.D. James R. Treat, M.D. / Dr. Connelly
Anthony J. Mancini, M.D. Albert C. Yan, M.D. 9:50 a.m. Pediatric Dermatology Jeopardy: Syndromes You
Should Know! / Dr. Treat
lEARNINg OBjECTIVES 10:05 a.m. Atopic Dermatitis:Tried and Tested Treatment
Following this course, the attendee will be able to: / Dr. Tom
1. Diagnose common and uncommon pediatric dermatologic 10:25 a.m. Questions and Answers / Faculty
conditions more effectively. 10:30 a.m. Vascular Birthmarks: Management Pearls
2. Recognize advances in pediatric dermatology through literature / Dr. Friedlander
updates. 10:45 a.m. Nevi: How They Happen, How to View,
3. Treat a variety of cutaneous conditions in children more What to Do? / Dr. Marghoob
comfortably. 11:00 a.m. Questions and Answers / Faculty
DESCRIpTION 11:05 a.m. Bugs, and the drugs that Treat Them / Dr. Yan
This session will provide practical and clinically useful information 11:20 a.m. Skin Infections and Infestations: Prevention and
on the diagnosis and management of many common skin Treatment / Dr. Levy
conditions in newborns, infants, children, and teens. The focus 11:35 a.m. Pediatric Dermatology: News Flash from the
will be on cutaneous problems that are confusing or difficult for Literature / Dr. Sidbury
those who do not see many children in their practices. It is geared 11:40 a.m. Questions and Answers / Faculty
toward the general dermatologist or dermatology resident.
3.00 Category 1 CME Credits
REFERENCES
1. Eichenfield LF, Frieden IJ, Esterly NB. Textbook of Neonatal
Dermatology 2001.
2. Paller AS, Mancini AJ. Hurwitz Clinical Pediatric Dermatology,
3rd edition. 2006.

FRIDAY, FEBRUARY 4

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 73

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
9:00 a.m. to 12:00 p.m.
Tuition fee and ticket required for admission.

C004 Diagnosis and Therapeutics: C005 Basic Contact Dermatitis

The Fundamentals Room: 386/387
Room: 383/384/385 DIRECTOR Sharon E. Jacob, M.D.
DIRECTOR Peter A. Lio, M.D. SpEAkERS
SpEAkERS Bryan Erik Anderson, M.D. Susan T. Nedorost, M.D.
April W. Armstrong, M.D. David Eric Cohen, M.D. Pamela L. Scheinman, M.D.
Susan Burgin, M.D. Vincent Anthony DeLeo, M.D. James Selwyn Taylor, M.D.
Ruth Ann Vleugels, M.D. Alison Ehrlich, M.D. Erin M. Warshaw, M.D.
Christen M. Mowad, M.D. Matthew Zirwas, M.D.
lEARNINg OBjECTIVES
Following this course, the attendee will be able to: lEARNINg OBjECTIVES
1. Develop an approach to the differential diagnosis of a broad Following this course, the attendee will be able to:
range of inflammatory and neoplastic dermatoses by employing 1. Develop a differential diagnosis of contact dermatitis and
color, reaction patterns, and elements of the Wheel of related entities.
Diagnosis. 2. Identify appropriate allergens for patch testing and allergen
2. Discuss the history of vehicles and therapy in dermatology and sources in implementing allergen avoidance regimens.
formulate an approach to selecting treatment. 3. Evaluate patients for photocontact dermatitis.
3. Recognize clinically important adverse drug interactions to DESCRIpTION
improve therapeutic success and avoid untoward consequences. This session will start with basic information on contact
DESCRIpTION dermatitis, exploring the differential and approach to patch
This course provides a comprehensive approach to differential testing. Common, as well as new and emerging, allergens will be
diagnoses and therapeutics in dermatology. The target is newer discussed. In addition, specific categories of contact dermatitis
practitioners and senior dermatologists who teach residents and will be presented: hand dermatitis, contact dermatitis to metals,
students about these concepts. The course presents a problem- antibiotics and cosmetics, occupational contact dermatitis, and
solving method to assist in the creation of differential diagnoses. photocontact dermatitis. Instructional cases will be presented to
Diagnostic algorithms are introduced, and participants will encourage attendees to ask questions.
practice formulating differential diagnoses using these tools. The 3.00 Category 1 CME Credits
course also presents a framework for thinking about therapy. SCHEDUlE
Starting with an overview of vehicles and drug delivery, this 9:00 a.m. Defining the Differential Diagnosis / Dr. Zirwas
section contains historical insights and practical approaches to 9:20 a.m. Basics of Patch Testing / Dr. Nedorost
implementation. Finally, there will be a review of important 9:35 a.m. Patient Counseling and Education / Dr. Scheinman
therapeutic interactions, some synergistic and others detrimental. 9:50 a.m. Metals Allergy / Dr. Taylor
3.00 Category 1 CME Credits 10:05 a.m. Hand Dermatitis / Dr. Warshaw
SCHEDUlE 10:25 a.m. Preservative-Associated Contact Dermatitis / Dr. Cohen
9:00 a.m. The Wheel of Diagnosis 1 / Dr. Burgin 10:40 a.m. Cosmetic and Plant-Associated Contact Dermatitis
9:45 a.m. The Wheel of Diagnosis 2 / Dr. Vleugels / Dr. Ehrlich
10:30 a.m. Therapeutics: Art and Science / Dr. Lio 10:55 a.m. Photocontact Dermatitis and Photo Patch Testing
FRIDAY, FEBRUARY 4

11:15 a.m. Important Therapeutic Interactions Every / Dr. DeLeo

Dermatologist Should Know / Dr. Armstrong
11:10 a.m. Antibiotic-Associated Contact Dermatitis / Dr. Mowad
11:25 a.m. Sports Gear-Associated Contact Dermatitis
/ Dr. Anderson
11:40 a.m. Case Review: Question and Answer Session
/ Dr. Jacob

74 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMpOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.

S001 Disorders of pigmentation S002 Alopecia: workup and Treatment

Room: Auditorium C Room: 278/279/280
DIRECTOR Harvey Lui, M.D. DIRECTOR Wilma Fowler Bergfeld, M.D.
SpEAkERS SpEAkERS
Jean L. Bolognia, M.D. Rebat M. Halder, M.D. George Cotsarelis, M.D. Melissa Piliang, M.D.
Ilona J. Frieden, M.D. Amit G. Pandya, M.D. Elise Olsen, M.D. Ken Washenik, M.D., Ph.D.
Pearl E. Grimes, M.D.
lEARNINg OBjECTIVES
lEARNINg OBjECTIVES
Following this symposium, the attendee will be able to:
Following this symposium, the attendee will be able to:
1. Diagnosis the common alopecic disorders and have an
1. Classify and recognize important and common pigmentary
disorders in adults and children. evaluation, treatment, and follow-up algorithm.
2. Describe the latest approaches to managing patients with 2. Identify current screening diagnostic laboratory tests and
pigmentary disorders. procedures.
3. Summarize recent scientific advances in the diagosis and
DESCRIpTION treatment of alopecic disorders.
The only organ of the body that manifests disorders of pigmentation
to any significant extent is the skin. Pigment disease is commonly DESCRIpTION
seen in dermatologic practice, and has a major direct impact on Dermatologists are the most knowledgeable physicians to evaluate
normal skin function and overall quality of life. The spectrum and and manage patients with alopecic disorders. This symposium will
various presentations of patients with abnormal skin pigmentation refresh and update the attendees diagnostic and treatment options.
are broad and include hyperpigmentation, hypopigmentation, and 3.00 Category 1 CME Credits
depigmentation. Systematic approaches to classifying and treating
pigmentary conditions based on age, pattern, clinical evidence, and REFERENCES
experience will be the focus of this symposium. Ample time will be 1. Olsen EA. ed. Disorders of Hair Growth: Diagnosis and
scheduled for audience participation. Treatment. New York: McGraw-Hill; 2003.
3.00 Category 1 CME Credits 2. McMichael AJ, Hordinsky M, eds. Hair and Scalp Disease:
Medical, Surgical, and Cosmetic Treatments. Informa Healthcare
REFERENCES 2008.
1. Halder, RM, Nandekar MA, Neal KW. Pigmentary disorders 3. Somani N, Bergfeld WF. Cicatricial Alopecia: Classification
in pigmented skins. In: Halder RM. Dermatology and
and Histopathology. Dermatol Ther. 2008 Jul; 21(4):221-237.
Dermatological Therapy of Pigmented Skins. 1st ed. New York:
4. Blume-Peytavi U, ed. Hair Growth and Disorders. Berlin:
Taylor and Francis; 2006:91-114.
2. Nordlund JJ, Boissey RE, Hearing VJ, King RA, Oetting Springer; 2008.
W, Ortonne J. The Pigmentary System: Physiology and SCHEDUlE
Pathophysiology, 2nd ed. New York: Blackwell Publishing 9:00 a.m. Introduction/Common Alopecic Disorders,
Limited, 2006. Evaluation and Treatment Options / Dr. Bergfeld
SCHEDUlE 9:30 a.m. Update on Scarring Alopecic Disorders / Dr. Piliang
9:00 a.m. An Approach To Pigmentary Disorders / Dr. Bolognia 10:00 a.m. Stem Cells in Alopecia / Dr. Cotsarelis
9:20 a.m. Questions And Answers / Dr. Bolognia 10:30 a.m. Hair Loss in African American Women / Dr. Olsen
FRIDAY, FEBRUARY 4

9:25 a.m. Lines, Segments, and Mosaics: An Update on 11:00 a.m. Emerging Therapies in the Treatment of Hair Loss
Patterned Pediatric Pigmentary Anomalies / Dr. / Dr. Washenik
Frieden 11:30 a.m. Panel Discussion/Questions and Answers / Faculty
9:45 a.m. Question And Answer / Dr. Frieden
9:50 a.m. Melasma: A Critical Update / Dr. Pandya
10:10 a.m. Postinflammatory Hyperpigmentation / Dr. Grimes
10:30 a.m. Lasers for Pigmentary Disorders / Dr. Lui
10:50 a.m. Questions and Answers / Faculty
11:05 a.m. Common Yet Challenging Hypopigmentation
Disorders / Dr. Nordlund
11:25 a.m. Vitiligo: Anything New? / Dr. Halder
11:50 a.m. Questions and Answers / Faculty

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 75

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMpOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.

S003 Hot Topics S004 when Bad Things Happen

Room: Auditorium A To good Doctors
DIRECTOR Kenneth J. Tomecki, M.D. Room: La Nouvelle Orleans Ballroom

lEARNINg OBjECTIVES DIRECTOR Mary E. Maloney, M.D.

Following this symposium, the attendee will be able to: SpEAkERS
1. Recognize a variety of ‘hot topics,’ as identified by registrants at Ilona J. Frieden, M.D. Marta Jane VanBeek, M.D.
the Annual Meeting. Suzanne Olbricht, M.D. Summer R. Youker, M.D.
2. Discuss the ‘hot topics’ of medical and surgical dermatology, Michael D. Tharp, M.D.
including items of social and economic import.
lEARNINg OBjECTIVES
DESCRIpTION Following this symposium, the attendee will be able to:
The ‘hot topics’ symposium will address and highlight a variety 1. Recognize situations that qualify as risk for the physician or
of topics established by registrant consensus at the Annual practice.
Meeting. Those topics, derived from registants’ top three choices, 2. Identify skills that will resolve the situation with the least stress
will reflect the medical/surgical and social/economic concerns and best outcome.
of the membership. The somewhat unstructured session will 3. Delineate risk management strategies (procedures, skills, and/or
be a potpouri of contemporary issues that currently affect and behaviors) to reduce recurrence of these situations.
impact the specialty. Expert speakers will tackle the topics in an
interactive manner, hopefully stimulating debate and minimizing DESCRIpTION
controversy. Presentations will be state of the art, and attendees Many situations arise in medicine that tax our abilities.
will derive a sense of what’s important to dermatologists in 2011. While we are well trained in medicine, we do not have training
3.00 Category 1 CME Credits in the management of angry or threatening patients, charges of
harassment, diversity issues, how to handle missed diagnosis,
and a litany of other challenging problems. This symposium
will address these types of issues. Each presentation will begin
with a case study, and the faculty for that scenario will discuss
the case, with particular attention to the use of leadership skills
in the management of the situation and the employment of risk
management strategies.
3.00 Category 1 CME Credits
SCHEDUlE
9:00 a.m. Introduction / Dr. Maloney
9:05 a.m. Recurrent Cancer Missed: How to Manage
at all Levels / Dr. Maloney
9:25 a.m. Questions And Answers / Faculty
9:35 a.m. The Poor Outcome and How To Manage It
/ Dr. VanBeek
9:55 a.m. Questions and Answers/Discussion / Faculty
FRIDAY, FEBRUARY 4

10:05 a.m. “Was This The Spot?” Wrong Site Surgery

/ Dr. Youker
10:25 a.m. Questions and Answers/Discussion / Faculty
10:35 a.m. Adverse Outcomes in Pediatric Dermatology:
Lessons Learned/ Dr. Frieden
10:55 a.m. Questions And Answers/Discussion / Faculty
11:00 a.m. The New Concepts of Harassment in the Work Place /
Dr. Tharp
11:20 a.m. Questions and Answers/Discussion / Faculty
11:30 a.m. Anger, Frustration and the Unbalanced Life of
A Physician / Dr. Olbricht
11:50 a.m. Questions and Answers

76 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMpOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.

S005 leading from Your Vision The Teaching

to Exceptional Service
Room: 293/294
Tool You’ve Been
DIRECTOR Victor J. Marks, M.D. Waiting For!
SpEAkER Sandra Ellison, Center for Creative Leadership
lEARNINg OBjECTIVES
Educate audiences of
Following this symposium, the attendee will be able to:
1. Design, convey, and teach an inspiring vision for their practice. all ages about the
2. Examine the power of setting behavior standards for the importance of
formation of a desired practice culture. sun-safety and skin
3. Describe the importance of measuring service perception. cancer detection and
DESCRIpTION prevention with the
Developing and teaching an inspiring vision is the central aspect new See SPOT (Skin
of creating the practice you desire. Every practice has a culture,
Cancer Presentation
defined as “the way we do things around here.” Culture comes
from the behaviors of those who make up the workgroup or Outlining The Facts) CD.
practice. We will discuss the importance of vision-setting and
See SPOT CD features:
will help you develop one that fits your ideal future practice. As
importantly, we will show you how to set and reinforce behavior • Four PowerPoint™ presentations
standards for yourself and your employees that will lead to the targeted to: Children, grades K-2;
kind of culture you want in your office.
Children, grades 3-5; Pre-teens and
3.00 Category 1 CME Credits
Teenagers; and Adults

• Corresponding script with each presentation

• Pre- and post-presentation audience

evaluations

• Printable children’s coloring pages

featuring Sammy the Skin Cell

The See SPOT CD is perfect for school

presentations and screening events!
FRIDAY, FEBRUARY 4

Visit the Academy Resource Center

Booth 3623 to place your order!

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 77

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMpOSIUM
9:00 a.m. to 12:00 p.m. Before you take
Open admission, no tuition or ticket.
the MOC-D Exam, take the

S006 Approach to pigmented lesions Derm Exam Prep

Room: 243/244/245
DIRECTOR Ashfaq A. Marghoob, M.D.
Course: Refresher
SpEAkERS
Clara N. Curiel-Lewandrowski, M.D. Allan C. Halpern, M.D. Don’t Pass
James M. Grichnik, M.D., Ph.D. Scott Menzies, MBBS, Ph.D.
Jean-Jacques Grob, M.D. Alon Scope, M.D.
this uP!
lEARNINg OBjECTIVES
Following this symposium, the attendee will be able to: Derm Exam Prep Course: Refresher
1. Recognize the limitations of the ABCDE rule to detect
melanoma. February 4, 2011
2. Describe the added benefit of newer technologies to assist in
melanoma diagnosis. Ernest N. Morial Convention Center,
3. Determine the most appropriate biopsy technique for suspect
pigmented lesions. New Orleans, LA
DESCRIpTION
Management of pigmented lesions depends on their static and
dynamic morphology. However, reliance on static morphology (i.e.,
ABCD) results in sensitivity and specificity for melanoma that is • Benchmark your clinical knowledge
far from perfect. Furthermore, reliance on dynamic morphology against the ABD’s MOC-D recertification
of lesions (i.e., change) is not reliable since nevi change and
melanomas may not reveal changes for many months. Thus, exam study guide
additional techniques to improve our diagnostic accuracy would
be welcomed. These techniques include the ugly duckling sign, • Cover the general dermatology section
cognitive recognition, dermoscopy and confocal. Once a decision to of the MOC-D recertification exam with
biopsy has been rendered the physician will need to decide on the
most appropriate biopsy method (shave, punch, excision). expert faculty
3.00 Category 1 CME Credits
• Earn CME as you prepare for the ABD
REFERENCES
1. Scope et al. The ugly duckling sign: agreement between MOC-D exam
observers. Arch Dermatol. 2008;144:58-64.
2. Argenziano et al. Slow-growing melanoma: a dermoscopy
follow-up study. Br J Dermatol. 2009;162:267-273.
3. Marghoob et al. Dermatologists, general practioners, and the Does not include ABD Exam offered
best method to biopsy suspect melanocytic neoplasms. Arch
Dermatol. 2010;146:325-328. on Wednesday, February 9, 2011
SCHEDUlE
9:00 a.m. Clinical ABCD, Ugly Duckling, and Cognitive
Approach: How Good Are They at Identifying Visit
Melanoma? / Dr. Grob
www.aad.org/meetings/annual
FRIDAY, FEBRUARY 4

9:20 a.m. The Significance of New and Changing Lesions

/ Dr. Grichnik to register!
9:40 a.m. Advances in Imaging to Detect New and Changing
Lesions / Dr. Curiel-Lewandrowski
10:00 a.m. Are All Stable Lesions Benign? / Dr. Marghoob
10:25 a.m. Does Dermoscopy and Confocal Add Utility in
Clinical Diagnosis? / Dr. Menzies
10:50 a.m. Future Technologies to Assist in the in Vivo
Diagnosis of Melanoma / Dr. Halpern
11:10 a.m. Shave, Punch And Excisional Biopsy: The Pros And
Cons / Dr. Scope
11:30 a.m. Questions and Answers / Faculty

78 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
9:00 a.m. to 5:00 p.m.
Tuition fee and ticket required for admission.

C007 Immunology C008 Derm Exam prep Course: Refresher

Room: 391 Room: 260/261/262
DIRECTOR Jeffrey B. Travers, M.D., Ph.D. DIRECTOR M. Yadira Hurley, M.D.
SpEAkERS SpEAkERS
Andrew Blauvelt, M.D. Lloyd S. Miller, M.D., Ph.D. Christie Travelute Ammirati, M.D. Samantha Hill, M.D.
Kevin D. Cooper, M.D. Robert Swerlick, M.D. Milan J. Anadkat, M.D. Summer R. Youker, M.D.
Michael Girardi, M.D. Nicole M. Burkemper, M.D. Claudia Vidal, M.D.
Michael P. Heffernan, M.D.
lEARNINg OBjECTIVES
Following this course, the attendee will be able to: lEARNINg OBjECTIVES
1. Summarize new developments in cutaneous immunology. Following this course, the attendee will be able to:
2. Discuss inflammatory skin diseases such as atopic dermatitis 1. Assess ability to diagnose the 150 conditions identified by
and psoriasis. the American Board of Dermatology (ABD) as required for
3. Explain the role of the immune system in tumor immunology. the General Dermatology module of the Maintenance of
Certification in Dermatology (MOC-D) exam.
DESCRIpTION
2. Identify areas needing additional study in preparation for the
This session is designed to update the audience on new
General Dermatology module of the MOC-D exam.
developments in general immunology with an emphasis on skin
3. Recognize the format used on the MOC-D exam.
immunity, especially those that are of most interest to clinical
practitioners. The session will focus on practical aspects of DESCRIpTION
inflammatory skin diseases such as atopic dermatitis and psoriasis This course is targeted to dermatologists preparing for the
and tumor immunology with emphasis on understanding the American Board of Dermatology (ABD) Maintenance of
pathogenesis and treatment considerations. Certification in Dermatology (MOC-D) exam. Residents
6.00 Category 1 CME Credits preparing for their Board exam may also benefit from this course,
however, this course is not designed for initial Board certification.
SCHEDUlE
The course will review the 150 diagnoses listed as covered in the
9:00 a.m. Cytokines: The Language of Inflammation / Dr. Travers
General Dermatology module of the MOC-D exam in a format
10:00 a.m. Adaptive Immunity / Dr. Cooper
similar to the one used on the exam.
11:00 a.m. Immunology of Cancer / Dr. Girardi
2:00 p.m. Innate Immunity / Dr. Miller Note: This course reviews only diagnoses from the General
2:50 p.m. Immune Tolerance / Dr. Swerlick Dermatology module of the exam and does NOT include questions
3:35 p.m. Immunology of Psoriasis / Dr. Blauvelt from the subspecialty modules.
4:20 p.m. Immunology of Atopic Dermatitis / Dr. Travers 6.00 Category 1 CME Credits
SCHEDUlE
9:00 a.m. General Content Review: Clinical Images / Faculty
12:00 p.m. Break / Faculty
2:00 p.m. General Content Review: Clinical Images / Faculty
FRIDAY, FEBRUARY 4

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 79

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE FORUM
9:30 a.m. to 11:30 a.m. 12:00 p.m. to 2:00 p.m.
Tuition fee and ticket required for admission. Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

C06B Basic Self-Assessment of F009 photobiology for Dermatologists

Dermatopathology Room: 392
Room: 275/276/277 DIRECTOR Gillian M. Murphy, M.D.
DIRECTOR Clay J. Cockerell, M.D. SpEAkERS
SpEAkERS Marjan Garmyn, Prof. Giovanni Leone, M.D.
Antoanella Bardan, M.D. John Lyndon McLeod Hawk, M.D. Henry W. Lim, M.D.

lEARNINg OBjECTIVES lEARNINg OBjECTIVES

Following this course, the attendee will be able to: Following this forum, the attendee will be able to:
1. Interpret and identify dermatologic histological diagnoses more 1. Summarize the principles of photobiology which lead to acute
effectively and accurately. and chronic effects of ultraviolet radiation.
2. Classify and recognize common histopathologic skin conditions 2. Manage photodermatoses and phototherapy more effectively.
and formulate differential diagnoses. 3. Discuss with patients the optimal photoprotection.

DESCRIpTION DESCRIpTION
Attendees will view 60 slides from skin biopsy specimens in aformat Photoprotection is a basic part of the war against skin cancer. It
that will allow self-assessment. Cases will span the full spectrum of comprises avoidance of ultraviolet radiation (UVR) by seeking
dermatopathology. Each specimen will be discussed by a faculty shade, wearing appropriate clothing including hats, and the use of
member with emphasis placed on establishing the correct diagnosis topical sunscreens to protect exposed sites. Systemic photoprotective
and consideration of the differential diagnosis. These sessions are agents offer minor protection by comparison. Patients with
directed to dermatology residents and practicing dermatologists. photodermatoses may achieve photoprotection by desensitization
To allow for a larger participation this year, this course will be techniques. Hazards associated with these strategies will be outlined.
offered with duplicate content at 7:00 a.m., 9:30 a.m., 12:30 p.m., Reduction of exposure to UVR would be expected to reduce skin
and 3:00 p.m. Attendees need only select one of these sessions. cancer rates and reduce photodermatoses. Absolute protection from
This session includes the discussion C06E – see page 122. UVR requires consideration as to whether dietary intake of vitamin
2.00 Category 1 CME Credits D is adequate. This session will review these matters.
2.00 Category 1 CME Credits
SCHEDUlE
12:00 p.m. Introduction to Photobiology for Dermatologists
/ Dr. Murphy
12:05 p.m. Basic Principles Of Photobiology for Dermatologists
/ Dr. Lim
12:25 p.m. What Dermatologists Should Know About
Photodermatoses / Dr. Hawk
12:45 p.m. What Dermatologists Should Know About
Phototherapy / Dr. Leone
1:05 p.m. What Dermatologists Should Know About
Photoageing / Prof. Garmyn
FRIDAY, FEBRUARY 4

1:25 p.m. What Dermatologists Should Know About

Photoprotection / Dr. Murphy
1:45 p.m. Panel Discussion / Dr. Murphy

80 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
12:00 p.m. to 2:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F010 Hidradenitis Suppurativa: An Update F011 Dermatopathology Made Simple

Room: 252/253/254 Room: 388/389/390
DIRECTOR Robert A. Lee, M.D., Ph.D. DIRECTOR Christine Ko, M.D.
SpEAkERS lEARNINg OBjECTIVES
Gregor B. E. Jemec, M.D. Following this forum, the attendee will be able to:
Emily Tierney, M.D. 1. Develop an aptitude for distinguishing low-power slide clues.
2. Formulate a differential from the initial view of a specimen.
lEARNINg OBjECTIVES
3. Predict and recognize evidence at higher power that narrows
Following this forum, the attendee will be able to:
the differential.
1. Diagnose hidradenitis suppurativa, differentiate it from clinical
simulator, and categorize it based on severity. DESCRIpTION
2. Summarize current medical and surgical therapeutic options. This session is aimed at residents in training. A quick overview of
3. Formulate and prescribe a treatment plan based on the current over 150 different entities in dermatopathology is reviewed, using
medical literature. the low-power impression of a slide as the starting point. From
the initial impression, clues at higher power that can lead to the
DESCRIpTION
correct diagnosis are emphasized.
Hidradenitis suppurativa is a chronic, recurrent, scarring
2.00 Category 1 CME Credits
inflammatory dermatosis. It is a common disease that is associated
with considerable morbidity and often poses significant challenges
for the practitioner. Its clinical presentation and corresponding
histopathology will be reviewed. Standard and newer therapeutic
options, including hormone therapy, immunomodulators, surgical
and laser procedures, will be discussed. After this presentation, the
audience will be able to diagnose and accurately stage the disease,
describe its natural history, and summarize current therapies.
They will be able to apply this information to develop a rational
treatment algorithm for this often difficult-to-treat disease.
2.00 Category 1 CME Credits
SCHEDUlE
12:00 p.m. Present Challenges and Future Directions / Dr. Lee
12:35 p.m. Recent Advances in Medical Therapy / Dr. Jemec
1:10 p.m. Recent Advances in Surgical Therapy / Dr. Tierney
1:45 p.m. Questions and Answers / Faculty

FRIDAY, FEBRUARY 4

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 81

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
12:00 p.m. to 2:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F012 Update on genetic Skin Disease F013 EHR Implementation, Maintenance, and
Room: 255/256/257 lessons learned
DIRECTOR Julie V. Schaffer, M.D. Room: 291/292

SpEAkERS DIRECTOR Maithily A. Nandedkar, M.D.

Ilona J. Frieden, M.D. Gabriele Richard, M.D. SpEAkERS
Amy S. Paller, M.D. Eli Sprecher, M.D., Ph.D. Courtney R. Herbert, M.D., M.P.H.
lEARNINg OBjECTIVES Brett D. Krasner, M.D.
Following this forum, the attendee will be able to: Daniel Shay, JD
1. Utilize clinical observations and molecular technology to lEARNINg OBjECTIVES
diagnose inherited skin disorders. Following this forum, the attendee will be able to:
2. Categorize genodermatoses according to their molecular bases 1. Identify and discuss legal issues related to the adoption of
and recognize relationships with complex traits. electronic health records (EHR).
3. Evaluate, counsel, and treat patients and families affected by 2. Analyze two successful dermatology EHR adoption case
genetic skin disease. studies.
DESCRIpTION DESCRIpTION
In recent years, there has been tremendous progress in elucidating Via examination of two dermatology practices as case studies that
the genetic bases of inherited skin disorders. Integration of have successfully adopted different EHRs, this session will provide
clinical and molecular data has simplified categorization and a comprehensive overview of EHRs, help attendees establishing
minimized redundant terminology. This session will review new effective criteria for conducting vendor selection and explain
developments in genodermatoses by grouping diseases according some of the regulatory aspects of EHRs. The case studies should
to their molecular bases, thereby clarifying pathomechanisms also help attendees assess how to successfully plan and prepare
and relationships between conditions. Insights into mosaic skin for EHR adoption. The session will explore legal issues related
diseases and inherited disorders featuring abnormal cornification, to HIPAA compliance with an EHR, its potential impact on
vasculature, and hair will be discussed, highlighting their relevance malpractice, the probable legal pitfalls to avoid when negotiating
to cutaneous physiology and more common multifactorial/ and purchasing software, including contractual terms governing
acquired skin conditions. Progress toward effective management EHR vendor licensing agreements. Bring your questions!
of genodermatoses will also be examined, including therapeutic 2.00 Category 1 CME Credits
advances based on molecular discoveries.
2.00 Category 1 CME Credits SCHEDUlE
12:00 p.m. Introduction and Overview of EHR / Dr. Nandedkar
SCHEDUlE 12:10 p.m. EHR implementation, Lessons Learned from Daily
12:00 p.m. Molecular Insights into Genetic Skin Disease Use / Dr. Krasner
/ Dr. Schaffer 1:10 p.m. Questions ans Answers / Faculty
12:20 p.m. What’s New in Ichthyoses / Dr. Richard 1:25 p.m. Legal pitfalls to avoid with EHR / Dr. Shay
12:40 p.m. The Genetics of Vascular Anomalies: Syndromes and 1:40 p.m. EHR implementation, Lessons Learned from Daily
Beyond / Dr. Frieden Use / Dr. Herbert
1:00 p.m. Questions and Answers / Faculty 1:45 p.m. Questions and Answers / Faculty
FRIDAY, FEBRUARY 4

1:10 p.m. Disentangling the Roots of Inherited Hair Disorders

/ Dr. Sprecher
1:30 p.m. How Gene Discoveries Have Led to Therapeutic
Advances / Dr. Paller
1:50 p.m. Questions and Answers / Faculty

82 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
12:00 p.m. to 2:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F014 Challenging Diagnostic Cases for F015 Ethical Economics in Dermatology and
Advanced practitioners: pA/Np I Dermatologic Surgery

Room: 281/282 Room: 288/289/290

DIRECTOR Arturo P. Saavedra-Lauzon, M.D., Ph.D.
DIRECTOR Alexander Miller, M.D.
SpEAkERS
Jennifer Y. Lin, M.D. Ruth Ann Vleugels, M.D. SpEAkERS
Peter A. Lio, M.D. Fei-Shiuann Clarissa Yang, M.D. Kent Stuart Aftergut, M.D. Clifford Warren Lober, M.D., J.D.
Kenneth E. Bloom, M.D. Steven P. Rosenberg, M.D.
lEARNINg OBjECTIVES
Carl A. Johnson, M.D.
Following this forum, the attendee will be able to:
1. Identify and differentiate inflammatory dermatoses that present lEARNINg OBjECTIVES
to the advanced practitioner in both adults and children. Following this forum, the attendee will be able to:
2. Identify and evaluate new pigmented lesions. 1. Evaluate and contrast various ethical dilemmas faced in
dermatologic practice.
DESCRIpTION
2. Assess how their individual practice patterns relate to accepted
In this session, we will use case presentations to highlight
ethical standards.
important therapeutic and diagnostic criteria that commonly
present to the advanced practitioner. Topics will include: DESCRIpTION
inflammatory dermatoses, pediatric dermatology, collagen vascular This session, directed to all dermatologists, will involve the
disease, common infections, and pigmented lesions. At the end audience in an interactive format utilizing audience response
of the presentation, those attending the session will be able to keypads. Following a discussion of the fundamentals of medical
review answers to common questions regarding presentation and ethics, a panel of dermatologists will present a series of practice
management of a variety of dermatologic complaints that may situations that may generate ethical dilemmas. These will be posed
present to the advanced practitioner. to the audience for polled responses. The panel, together with the
2.00 Category 1 CME Credits audience, will explore the ethical ramifications of the vignettes and
of the tallied audience responses.
SCHEDUlE
2.00 Category 1 CME Credits
12:00 p.m. Common Inflammatory Dermatoses and Masquerades
/ Dr. Yang SCHEDUlE
12:20 p.m. Is This Presentation Consistent with Collagen 12:00 p.m. Fundamentals of Medical Ethics / Dr. Lober
Vascular Disease? / Dr. Vleugels 12:20 p.m. Presentation of Practice Vignettes and Ethical
12:40 p.m. Evaluation of Pigmented Lesions / Dr. Lin Dilemmas / Dr. Aftergut
1:00 p.m. Approaches to the Pediatric Patient / Dr. Lio 12:40 p.m. Presentation of Practice Vignettes and Ethical
1:30 p.m. Understanding Bugs and Skin Infections: Is This Dilemmas / Dr. Bloom
Truly an Infection? / Dr. Saavedra-Lauzon 1:00 p.m. Presentation of Practice Vignettes and Ethical
Dilemmas / Dr. Johnson
1:20 p.m. Presentation of Practice Vignettes and Ethical
Dilemmas / Dr. Rosenberg
1:40 p.m. Presentation of Practice Vignettes and Ethical
FRIDAY, FEBRUARY 4

Dilemmas / Dr. Miller

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 83

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM DISCUSSION gROUp

12:00 p.m. to 2:00 p.m. 12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat Tuition fee and ticket required for admission.
for only 15 minutes after the official start time.

F016 Advances in Dermatologic Surgery D003 Selected Topics in Medical Dermatology

Room: 295/296 Room: 240
DIRECTOR Hubert T. Greenway Jr., M.D. DIRECTOR Joseph L. Jorizzo, M.D.
SpEAkERS lEARNINg OBjECTIVES
David E. Kent, M.D. E. Victor Ross Jr., M.D. Following this discussion group, the attendee will be able to:
Danielle K. Moul, M.D. Seaver Soon, M.D. 1. Evaluate and educate patients on medical dermatology diseases
Diamondis Papadopoulos, M.D. Daniel Ethan Zelac, M.D. effectively.
2. Diagnose and treat dermatologic aspects of rheumatologic
lEARNINg OBjECTIVES
diseases effectively.
Following this forum, the attendee will be able to:
3. Improve use of therapeutic ladders in medical dermatology.
1. Determine appropriate laser technology for both cutaneous
conditions and varicose veins. DESCRIpTION
2. Discuss selected surgical updates in reconstruction. An overview of the approach to the patient with complex
3. Discuss current knowledge/treatment for Merkel cell medical dermatology problems will be presented, followed by a
carcinoma. discussion of specific diseases. Skin and joint problems, systemic
lupus erythematosus, dermatomyositis, aphthosis, pyoderma
DESCRIpTION
gangrenosum, vasculitis, and other medical dermatology referral
This course will focus on selected areas of dermatologic surgery
diagnoses will be reviewed.
with important updates for 2011. Included will be lasers for both
1.50 Category 1 CME Credits
cutaneous medical and cosmetic conditions. Hair transplatation
updates will be presented. Tumor focus will be on update for both
knowledge and treatment of Merkel cell carcinoma. Advanced D004 Dealing with Disappointing Outcomes and
reconstructive focus will include muscle application techniques
as well as the use of delayed forehead flaps. Advances in the Medical Mistakes
treatment of varicose veins with endovenous laser ablation offer Room: 241
exciting new results. DIRECTOR Neil Prose, M.D.
2.00 Category 1 CME Credits
lEARNINg OBjECTIVES
SCHEDUlE Following this discussion group, the attendee will be able to:
12:00 p.m. Introduction / Dr. Greenway 1. Develop an understanding of the medicolegal aspects of
12:05 p.m. Advances in Cutaneous Lasers / Dr. Ross medical mistakes.
12:25 p.m. Advances in Hair Transplantation / Dr. Zelac 2. Perform new skills for speaking with patients who are facing
12:35 p.m. Merkel Cell Carcinoma: Advances in Treatment and disappointment.
Surgery / Dr. Soon
12:50 p.m. Advances In Muscle Plication Adjunct To Facial DESCRIpTION
Reconstruction Defects / Dr. Papadopoulos Disappointing clinical outcomes and medical mistakes are
1:10 p.m. Advances in Delayed Forehead Flaps in Facial inevitable. A number of studies show that patients are less likely to
Reconstruction / Dr. Kent pursue litigation if the physician is truthful and conveys empathy
1:25 p.m. Advances in Varicose Veins: Endovenous Laser and concern. In this experiential workshop, participants will
FRIDAY, FEBRUARY 4

Ablation and Ultrasound Guided Sclerotherapy have the oppportunity to practice skills that will enable them
/ Dr. Moul to communicate with patients when things have not turned out
1:45 p.m. Questions and Answers / Faculty as hoped. The legal and ethical arguments for truthfulness and
transparency will be presented.
1.50 Category 1 CME Credits

84 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U014 when Acne Really Isn’t Acne U016 Sports Dermatology —

Room: 267/268 Skin Infections in Athletes
DIRECTOR Joshua Zeichner, M.D. Room: 285

lEARNINg OBjECTIVES DIRECTOR Brian Burke Adams, M.D., M.P.H.

Following this focus session, the attendee will be able to: lEARNINg OBjECTIVES
1. Identify a differential diagnosis for acne vulgaris. Following this focus session, the attendee will be able to:
2. Determine treatments for patients with acne-like conditions. 1. Recognize cutaneous infections related to sports participation.
DESCRIpTION 2. Manage therapy and disqualification, with an emphasis on
Dermatologists commonly treat acne patients, but sometimes evidence-based medicine, for individuals with sports-related
acne is not really acne. There are many skin conditions that have infections.
a clinical presentation similar to acne vulgaris, but are distinct 3. Discuss prevention strategies for decreasing infectious
diseases. It is important to recognize that alternative diagnoses epidemics in sports teams.
exist, especially if patients are not responding to traditional acne DESCRIpTION
therapies. These patients may have a different disease altogether Infections are inherent to athletic activity, particularly sports
and respond to alternative treatments. with skin-to-skin contact. No differences exist between the
1.50 Category 1 CME Credits causal organisms in athletes and non-athletes; however, the
clinical presentation may vary. By incorporating knowledge of
the sporting activities, the dermatologist can best identify the
U015 Merkel Cell Carcinoma diagnosis, treatment, and prevention strategy. Epidemics of
Room: 265/266 tinea corporis, herpes, and methicillin-resistant Staphylococcus
DIRECTOR Linda Chung-Chin Wang, M.D., J.D. aureus (MRSA) have occurred at the high school, collegiate,
and professional level throughout the world. Sports-related
lEARNINg OBjECTIVES skin infections caused by fungi, bacteria, viruses, and parasitic
Following this focus session, the attendee will be able to: infections will be illustrated and discussed. Specific NCAA
1. Discuss the epidemiology and proposed pathogenesis of Merkel guidelines regarding skin infections and return-to-play issues will
cell carcinoma (MCC). also be discussed.
2. Order appropriate surgical and radiologic evaluations for 1.50 Category 1 CME Credits
accurate staging.
3. Formulate a multidisciplinary treatment plan for this
uncommon skin cancer.
DESCRIpTION
MCC is an aggressive cutaneous neuroendocrine carcinoma.
Despite the rising incidence of MCC, the rarity of the disease
has resulted in the absence of prospective randomized trials on
optimal management. As survival appears to be dependent on
disease stage at diagnosis, prompt accurate diagnosis, staging
FRIDAY, FEBRUARY 4

and initiation of treatment are critical. This session will offer

practical tips on medical and surgical evaluation of MCC.
Treatment recommendations based on DF/BWCC experience
will be outlined. Lastly, this session will describe advances
in management, including evaluation with positron emission
tomography and use of surface mold computer-optimized high-
dose-rate brachytherapy.
1.50 Category 1 CME Credits

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 85

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U017 Clincial Trials for the private practitioner U018 Outcomes Research in Dermatology
Room: 235/236 Room: 263
DIRECTOR Stefan C. Weiss, M.D. DIRECTOR Suephy C. Chen, M.D.
lEARNINg OBjECTIVES lEARNINg OBjECTIVES
Following this focus session, the attendee will be able to: Following this focus session, the attendee will be able to:
1. Identify the impact seasonality has on clinical trial design and 1. Discuss the importance of the different quality of life measures
outcome. for cutaneous diseases.
2. Summarize the critical aspects of clinical trial design. 2. Review the value and importance of cost, cost-effectiveness,
3. Differentiate the key aspects of regulatory strategy utilized to and cost-benefit analyses.
bring a new topical drug to market. 3. Assess the difference between efficacy and effectiveness.
DESCRIpTION DESCRIpTION
The role of seasonality will be discussed, specifically relating There are three main outcome measures of which dermatologists
to clinical trial design, powering of clinical studies, and the should be aware: economic, quality of life, and clinical. This
importance of recognizing the effect of seasonality on management focus session serves as an overview of concepts in each of these
of common dermatologic diseases. This session will highlight the topics. We also will review examples and real-life applications. For
critical steps required to design and implement a successful clinical economic outcomes, we will review the advantages and limitations
trial. The different phases of a clinical trial will be explained with in different cost, cost-effectiveness, and cost-benefit analyses.
a focus on how the private practitioner, as a clinical investigator, For quality-of-life outcomes, we will review generic and disease-
can play a role in that process. The participant will learn about the specific health state measures, as well as utility measures. We will
various nuances of the two primary regulatory pathways (505b1 also discuss the different clinical outcome measures, including the
and 505b2) applied by the industry to bring a new dermatologic differences between efficacy and effectiveness.
drug to market. 1.50 Category 1 CME Credits
1.50 Category 1 CME Credits

Search with Ease!

FRIDAY, FEBRUARY 4

With a database of goods and services that are continually purchased by dermatologists, the AAD Buyer’s
Guide allows members to quickly find what they need without the clutter of general purpose search engines.

Start searching today at www.aaddermatologybuyersguide.com

86 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U019 Sun, Drugs, and Invervention: How to U021 Acne in the Adult Female
prevent Non-Melanoma Skin Cancer Room: 242
Room: 283 DIRECTOR Kanade Shinkai, M.D., Ph.D.
DIRECTOR Gunther F.L. Hofbauer, M.D. lEARNINg OBjECTIVES
lEARNINg OBjECTIVES Following this focus session, the attendee will be able to:
Following this focus session, the attendee will be able to: 1. Select the best treatment(s) for the adult female patient
1. Recognize current options for primary, secondary, and tertiary with acne.
prevention of non-melanoma skin cancers (NMSC). 2. Order appropriate diagnostic evaluation of the adult female
patient with acne in the setting of possible endocrine disease.
2. Compare impact of different preventive modalities.
3. Recognize the clinical manifestations of polycystic ovary
3. Choose appropriate steps to prevent NMSC in patients at risk.
syndrome (PCOS) and its systemic complications.
DESCRIpTION
Non-melanoma skin cancer (NMSC) will be discussed in terms of DESCRIpTION
Acne vulgaris is a common reason why adult women present
primary prevention (reduction of sun damage to the skin by behavior,
to dermatologists and is often challenging to treat. It may also
clothing, sunscreen; systemic photoprotective agents, e.g., alpha-
raise suspicion of underlying endocrine disease. Management of
MSH analogue); secondary prevention (early recognition, education,
acne in an adult female patient may require distinct therapeutic
treatment of field cancerization by 5-FU, imiquimod, photodynamic considerations, including hormonal therapy. In this session, a
therapy, topical and systemic retinoids); and tertiary prevention practical approach to the adult female patient with acne will be
(antiproliferative agents, e.g., 5-FU, retinoids). Treatments will be reviewed to enhance attendees’ ability to treat adult women with
explored for their respective efficacies and applied in practical case acne vulgaris and to correctly identify patients with acne in the
examples for the general population and patients at elevated risk for setting of polycystic ovary syndrome (PCOS). This session is
NMSC. This session targets general medical dermatologists. relevant to any dermatology provider who sees female patients
1.50 Category 1 CME Credits with acne.
1.50 Category 1 CME Credits
U020 Challenging Diagnostic Cases for
Advanced practitioners: pA/Np II U022 Vulvar Dermatoses
Room: 274
Room: 270
DIRECTOR TBD
DIRECTOR Mary Melinda Feldman, M.D.
lEARNINg OBjECTIVES
lEARNINg OBjECTIVES
Following this focus session, the attendee will be able to:
Following this focus session, the attendee will be able to:
1. Recognize and/or diagnosis commonly tested images related
to medical dermatology, pediatric dermatology, surgical 1. Examine the basic histologic patterns of vulvar inflammation.
dermatology, and clinical pathologic correlates. 2. Recognize the clinical features of common vulvar dermatoses.
2. Identify strengths and weaknesses in one’s knowledge base for 3. Discuss treatment options for inflammatory diseases of the
the digital image section of the American Board of Dermatology vulva.
certification exam, recertification exam, or mock boards and DESCRIpTION
make improvements as needed. Vulvar dermatoses can be a diagnostic and therapeutic challenge
FRIDAY, FEBRUARY 4

DESCRIpTION as well as a source of discomfort or distress for patients. Although

Studying for the American Board of Dermatology certification or vulvar disease is not always emphasized during dermatology
recertification exam can be overwhelming! This interactive session training, the dermatologist is uniquely qualified to manage these
will provide key points and tips for identifying and making diagnoses conditions. The goal of this session is to discuss the histologic
for the digital image portion of the certification or recertification patterns of vulvar inflammation and to review the associated
exam. Attendees will have the opportunity to view numerous digital clinical features. An understanding of disease mechanism
images in rapid-fire progression preparing them for the digital image facilitates accurate diagnosis and directs therapeutic decision
portion of the exam. High-yield study material will also be covered as making. Because treatment options are limited and sometimes
the images are reviewed. This session will benefit any dermatologist frustrating, there will be an interactive discussion regarding
preparing for the ABD certification, recertification, or mock management strategies.
1.50 Category 1 CME Credits
board exams.
1.50 Category 1 CME Credits

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 87

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U023 Highlights from JAAD U024 leading Confidently through powerful

Room: 269 Communication
DIRECTOR Bruce Harris Thiers, M.D. Room: 293/294

lEARNINg OBjECTIVES DIRECTOR Marta J. VanBeek, M.D.

Following this focus session, the attendee will be able to:
1. Examine the recent literature in dermatology.
2. Identify new diagnostic approaches to skin disease.
3. Discuss effects and side effects of new therapies.
DESCRIpTION
The speaker, who is Editor of the Journal of the American Academy
of Dermatology, will present an overview of recent key articles 3. Demonstrate strategies for staying focused on key messages in
published in that Journal. Emphasis will be placed on new data challenging situations.
that affect the clinical practice of dermatology.
1.50 Category 1 CME Credits
Staples, that was EASY!
SpEAkER
Marsheila DeVan, Communication Consultant
lEARNINg OBjECTIVES
Following this focus session, the attendee will be able to:
1. Prepare compelling and powerful key messages.
2. Communicate key messages clearly, concisely, and effectively.
DESCRIpTION
The Academy has identified effective communication as a
core competency for leadership in dermatology. Learning how
to successfully craft and convey key messages will help you
communicate effectively in any situation. Attendees will have
the opportunity to practice what they have learned. This session
is designed to challenge participants to focus on creating and
delivering clear and concise messages. The session will be primarily
presented by a communications consultant.
1.50 Category 1 CME Credits

Take the hassle out of

ordering office supplies, U025 A personalized planner for Rejuvenation
Room: 264
furniture, technology,
and print materials DIRECTOR Sandy Sharon Tsao, M.D.
with Staples Advantage®! lEARNINg OBjECTIVES
Following this focus session, the attendee will be able to:
• Over 30,000 products at discounted prices 1. Identify the unique clinical findings for each photoaged
patient.
• Custom printing of business cards, stationery,
2. Recognize the risks and benefits associated with various laser
forms, and more and cosmetic procedures.
3. Develop a treatment plan to meet the patient’s specific
• FREE next day delivery with minimum order of $30 rejuvenation needs.
• Hassle-free returns DESCRIpTION
FRIDAY, FEBRUARY 4

There are numerous existing and emerging modalities available

• Efficient tracking of all practice locations supply for the improvement of photoaging. With so many options, how
orders through one invoice do you develop a tailored treatment approach? We will review
individual features including dyspigmentation, wrinkles and
• “An outstanding Customer Service Experience.”
skin laxity, which can be appropriately targeted and treatments
– certified J.D. Power and Associates combined to achieve a global improvement. The advantages and
disadvantages of procedures, including lasers, peels, botulinum
toxins and fillers, will be discussed. Through a case-based
approach, participants will develop a personalized plan. At the
Visit the Academy Resource Center end of the session, the audience will be equipped to customize a
Booth 3623 to sign up and start saving! treatment plan to meet each patient’s specific needs.
1.50 Category 1 CME Credits

88 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION COURSE

12:15 p.m. to 1:45 p.m. 12:30 p.m. to 2:30 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat Tuition fee and ticket required for admission.
for only 15 minutes after the official start time.

U026 Teledermatology 101: Integrating C06C Basic Self-Assessment of

Teledermatology into Your practice Dermatopathology
Room: 284 Room: 275/276/277
DIRECTOR April W. Armstrong, M.D. DIRECTOR Clay J. Cockerell, M.D.
lEARNINg OBjECTIVES SpEAkERS Antoanella Bardan, M.D.
Following this focus session, the attendee will be able to:
lEARNINg OBjECTIVES
1. Identify sustainable practices of teledermatology, including
Following this course, the attendee will be able to:
store-and-forward and live-interactive teledermatology practice
1. Interpret and identify dermatologic histological diagnoses more
models.
effectively and accurately.
2. Recognize operational needs of incorporating teledermatology
2. Classify and recognize common histopathologic skin conditions
into current practice, including staffing, imaging, and
and formulate differential diagnoses.
communicating with patients and referring providers.
DESCRIpTION
DESCRIpTION
Attendees will view 60 slides from skin biopsy specimens in a format
Teledermatology can be incorporated into academic and private
that will allow self-assessment. Cases will span the full spectrum of
practice settings to improve patient access to dermatologists.
dermatopathology. Each specimen will be discussed by a faculty
A growing number of dermatologists are providing specialty
member with emphasis placed on establishing the correct diagnosis
care through telemedicine. This session will enhance your
and consideration of the differential diagnosis. These sessions are
understanding of sustainable models of teledermatology
directed to dermatology residents and practicing dermatologists. To
practice, and it will help you develop strategies of incorporating
allow for a larger participation this year, this course will be offered
teledermatology into your practice. The practical
with duplicate content at 7:00 a.m., 9:30 a.m., 12:30 p.m., and
details of what is necessary to set up a teledermatology operation
3:00 p.m. Attendees need only select one of these sessions. This
will be discussed.
session includes the discussion C06E – see page 122.
1.50 Category 1 CME Credits
2.00 Category 1 CME Credits

FRIDAY, FEBRUARY 4

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 89

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
2:00 p.m. to 5:00 p.m.
Tuition fee and ticket required for admission.

C009 Dermatologic Syndromes and genetic C010 Advanced Contact Dermatitis

Disorders Room: 238/239
Room: 383/384/385 DIRECTOR Vincent Anthony DeLeo, M.D.
DIRECTOR Susan Joy Bayliss, M.D. SpEAkERS
SpEAkER David Berk, M.D. Anthony A. Gaspari, M.D. Frances J. Storrs, M.D.
Melanie D. Pratt, M.D. James Selwyn Taylor, M.D.
lEARNINg OBjECTIVES Denis Sasseville, M.D. Kathryn A. Zug, M.D.
Following this course, the attendee will be able to:
1. Identify and diagnose common dermatologic syndromes. lEARNINg OBjECTIVES
Following this course, the attendee will be able to:
2. Recognize the major criteria for other rare syndromes.
1. Distinguish clinical relevance of fragrance-positive patch tests.
DESCRIpTION 2. Determine the influence of prosthetic metals on dermatitis.
Physicians who want to become familiar with common and not- 3. Identify new cosmetic allergens.
so-common dermatologic syndromes will get an update on criteria DESCRIpTION
and genetic causes. A question-answer format will be used to help This session will be composed of speakers who practice tertiary
us learn! referral patch testing. The speakers will touch on subjects that deal
3.00 Category 1 CME Credits with the unusual but important cases of allergic contact dermatitis.
Topics to be covered include an update on the basic science aspects
REFERENCES of allergy to topical chemicals in the skin; the true incidence of
1. SB Mallory. An Illustrated Dictionary of Dermatologic clinically relevant fragrance allergy; occupational contact dermatitis;
Syndromes. Taylor and Francis; 2006. new cosmetic allergens; allergy to orthopedic appliances; allergens
2. SB Mallory, A Bree, P Chern. Illustrated Manual of Pediatric in fabrics and furniture; and contact allergy in persons of color.
Dermatology. Taylor and Francis; 2005. 3.00 Category 1 CME Credits
SCHEDUlE
2:00 p.m. Introduction / Dr. DeLeo
2:10 p.m. Basic Science Aspects: New Stuff / Dr. Gaspari
2:30 p.m. Questions and Answers / Faculty
2:35 p.m. Preservatives: Common And Not So / Dr. Zug
2:55 p.m. Questions and Answers / Faculty
3:00 p.m. Implants / Dr. Taylor
3:20 p.m. Questions and Answers / Faculty
3:25 p.m. Occupational Dermatitis-Update / Dr. Sasseville
3:45 p.m. Questions and Answers / Faculty
3:50 p.m. Clothes And Furniture?! / Dr. Pratt
4:10 p.m. Questions and Answers / Faculty
4:15 p.m. Fragrance Allergy: Bah Humbug! / Dr. Storrs
4:35 p.m. Questions and Answers / Faculty
4:40 p.m. Contact Dermatitis In Skin Of Color / Dr. DeLeo
4:55 p.m. Questions and Answers / Faculty
FRIDAY, FEBRUARY 4

90 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE SYMpOSIUM
2:00 p.m. to 5:00 p.m. 2:00 p.m. to 5:00 p.m.
Tuition fee and ticket required for admission. Open admission, no tuition or ticket.

C011 The State of the Art of Aesthetic S008 Consultative Dermatology for the
Dermatology: live patient Demonstration Hospitalized patient
Room: Auditorium B Room: 278/279/280
DIRECTOR Thomas E. Rohrer, M.D. DIRECTOR Daniela Kroshinsky, M.D.
SpEAkERS lEARNINg OBjECTIVES
Kimberly J. Butterwick, M.D. Mary P. Lupo, M.D. Following this symposium, the attendee will be able to:
Alastair Carruthers, M.D. Seth L. Matarasso, M.D. 1. Identify common and complex cutaneous conditions impacting
William P. Coleman III, M.D. Gary D. Monheit, M.D. the hospitalized patient.
Patricia Farris, M.D. Nowell J. Solish, M.D. 2. Recognize emerging cutaneous diseases.
Rebecca L. Fitzgerald, M.D. Susan H. Weinkle, M.D.
3. Manage skin disease in the inpatient setting.
lEARNINg OBjECTIVES
Following this course, the attendee will be able to: DESCRIpTION
1. Assess the aging face and choose the most appropriate injection The dermatologist is an important member of the team caring for
techniques. hospitalized patients. Common problems and their uncommon
2. Identify soft tissue fillers appropriate for a variety of conditions. manifestations will be discussed. Interesting and rare examples of
3. Recognize the importance of facial musculature and how to serious skin conditions will be presented. Valuable diagnostic and
optimize treatment with botulinum toxins. therapeutic interventions will be reviewed. This session is geared
toward dermatologists caring for inpatients as well as physicians
DESCRIpTION
This live interactive session will feature experts from around treating complex patients presenting to the office.
the country demonstrating their soft tissue filler and botulinum 3.00 Category 1 CME Credits
toxin treatment techniques and tips. Attendees will observe in a
live interactive manner how the various faculty members assess,
interact with, and treat a variety of patients. Each area of the face
will be addressed by two faculty members and audience interaction
is encouraged. There will be discussion and demonstration of
optimal techniques using botulinum toxin and a wide variety of
soft tissue fillers.
3.00 Category 1 CME Credits
REFERENCES
1. Kaminer, M, Dover J, Arndt K, eds Atlas of Cosmetic Surgery.
Philadelphia: Elsevier; 2008.
2. Carruthers A, Carruthers J. Botulinum Toxin in Procedures in
Cosmetic Dermatology Series. Philadelphia: Elsevier; 2008.
3. Carruthers A, Carruthers J. Soft TIssue Augmentation In
Cosmetic Dermatology Series. Philadelphia: Elsevier; 2005.
SCHEDUlE
2:00 p.m. Introduction/Tom Rohrer
2:05 p.m. Upper Face Rejuvenation: Forehead and Glabella
FRIDAY, FEBRUARY 4

/ Dr. Ferris / Dr. Lupo

2:30 p.m. Eyes / Tear Trough / Dr. Fitzgerald / Dr. Carruthers
2:55 p.m. Questions and Answers / Faculty
3:00 p.m. Filling the Temple / Dr. Weinkle / Dr. Lupo
3:20 p.m. Volumizing the Mid Face / Dr. Fitzgerald / Dr. Solish
3:50 p.m. Questions and Answers / Faculty
3:55 p.m. Lip Enhancement / Dr. Weinkle / Dr. Matarasso
4:15 p.m. Lower Face Rejuvenation / Dr. Lupo / Dr. Monheit
4:40 p.m. Neck and Hand Rejuvenation
/ Dr. Coleman / Dr. Butterwick
4:55 p.m. Questions and Answers / Faculty

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 91

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMpOSIUM
2:00 p.m. to 5:00 p.m.
Open admission, no tuition or ticket.

S009 Advanced Medical Dermatology S010 Surviving Healthcare Reform

Room: 243/244/245 Room: La Nouvelle New Orleans Ballroom
DIRECTOR Francisco Kerdel, M.D. DIRECTOR Jack S. Resneck Jr., M.D.
SpEAkERS lEARNINg OBjECTIVES
Craig L. Leonardi, M.D. Bruce Elliot Strober, M.D., Ph.D. Following this symposium, the attendee will be able to:
Carlos Ricotti Jr., M.D. Antonella Tosti, M.D. 1. Summarize health system reform impacts on dermatologists
Paolo Romanelli, M.D. Martin N. Zaiac, M.D. and our patients.
2. Prepare for and assess upcoming requirements of health system
lEARNINg OBjECTIVES
reform law and pilot payment reforms.
Following this symposium, the attendee will be able to:
1. Discuss the role of biologics in psoriasis and psoriatic nail DESCRIpTION
disease. How will health system reform affect you and your practice,
2. Identify the essentials of treatment in toxic epidermal and how can you prepare for impending changes? The session
necrolysis. will cover current elements of the health system reform law
3. Detect antibodies against biologic agents and their clinical and those slated for future implementation, focusing on those
significance. provisions most relevant to dermatology. Likely topics include
payment reforms, insurance market reforms, quality measures,
DESCRIpTION
The session will cover several pertinant issues in medical and public reporting. Speakers will also provide information
dermatology. The lectures will include the future of biologics in about the different models of care delivery and payment that are
psoriasis as well as the use of biologics in psoriatic nail disease. being tested and evaluated (e.g., accountable care organizations,
There will also be a lecture on new diseases with important patient-centered medical homes, bundled payments, etc.) and the
dermatological implications. There will also be a lecture on the potential implications for dermatologic care.
medical management of toxic epidermal necrolysis. A lecture will 3.00 Category 1 CME Credits
be dedicated to changes in hair and systemic disease. The final
topic will be that of antibodies against biologics: their prevalence
and clinical significance.
3.00 Category 1 CME Credits
REFERENCES
1. Lecluse LLA et al. Extent and clinical consequences of antibody
formation against adalimumab in patient with plaque psoriasis.
Arch. Dermatol 2010;146:26.
2. de Berker D. Management of Psoriatic Nail Disease. Sem Cut
Med Surg 2009;28:39.
3. Prins C et al. Treatment of toxic epidermal necrolysis with
high dose intravenous immunoglobulins. Arch. Dermatol
2003;139:26.
SCHEDUlE
2:00 p.m. Introduction / Dr. Kerdel
FRIDAY, FEBRUARY 4

2:05 p.m. Role of Biologics in Psoriatic Nail Disease / Dr. Zaiac

2:30 p.m. What’s on the Horizon for the Treatment of Psoriasis
With Biologics / Dr. Leonardi
3:00 p.m. Update on New Diseases with Important
Dermatological Implications / Dr. Romanelli
3:30 p.m. Update on the Medical Management of Toxic
Epidermal Necrolysis / Dr. Ricotti
4:00 p.m. Hair as a Sign of Systemic Disease / Dr. Tosti
4:30 p.m. Anti-Biologic Antibodies: Their Prevalence and
Significance / Dr. Strober

92 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMpOSIUM
2:00 p.m. to 5:00 p.m.
Open admission, no tuition or ticket.

S011 Therapeutics S012 Aging gracefully

Room: Auditorium A Room: Auditorium C
DIRECTOR Mark Lebwohl, M.D. DIRECTOR Zoe Diana Draelos, M.D.
SpEAkERS SpEAkERS
Jeffrey Phillip Callen, M.D. Darrell S. Rigel, M.D. Patricia Farris, M.D. David H. McDaniel, M.D.
Bari B. Cunningham, M.D. Theodore Rosen, M.D. Henry W. Lim, M.D. Dana Lynn Sachs, M.D.
Boni E. Elewski, M.D. Linda F. Stein, M.D.
lEARNINg OBjECTIVES
Suzanne Olbricht, M.D. Bruce Harris Thiers, M.D.
Following this symposium, the attendee will be able to:
lEARNINg OBjECTIVES 1. Summarize areas of intervention in the skin aging process.
Following this symposium, the attendee will be able to: 2. Describe the various technologies to forestall or treat
1. Identify the most up-to-date therapies in topical, systemic, manifestations of skin aging.
surgical, and pediatric dermatology. 3. Discuss with patients the pros and cons of age prevention
2. Prescribe the therapies available for their patients. strategies.
DESCRIpTION DESCRIpTION
This session will emphasize new developments in dermatologic Understanding the aging process and appropriate intervention
therapy. Advances in topical treatments, systemic treatments, methods is key to aging gracefully. This session will examine aging
surgical therapies and procedures, and pediatric treatments will be concepts and the future of antiaging technology while discussing
presented. both topical and oral cosmeceuticals. It will examine the ability
3.00 Category 1 CME Credits of new sunscreens to prevent aging and address skin care issues
in all skin types. A survey of the new consumer-purchased,
REFERENCES
antiaging device market will also be presented. Attendance at this
1. Lebwohl M, Heymann WR, Berth-Jones J, Coulson, I, eds.
symposium is important for those who wish to keep current on
Treatment of Skin Disease. 3rd ed., London: Mosby Elsevier;
antiaging technology and desire a thought-provoking window into
2010.
the future of cosmetic dermatology.
SCHEDUlE 3.00 Category 1 CME Credits
2:00 p.m. What’s New in the Treatment of Connective Tissue
REFERENCES
Diseases? / Dr. Callen
1. Draelos ZD. Cosmeceuticals. Philadelphia: Elsevier; 2008.
2:16 p.m. Therapy of Nail Disorders / Dr. Elewski
2. Draelos ZD. Cosmetic Dermatology: Products and Procedures.
2:32 p.m. Surgical Therapeutics: What’s New? / Dr. Olbricht
Hoboken, NJ: Wiley-Blackwell; 2010.
2:48 p.m. Questions and Answers / Faculty
3:03 p.m. What’s New in Topical Dermatologic Therapy? SCHEDUlE
/ Dr. Stein 2:00 p.m. Introduction: Theories of Aging with Grace
3:19 p.m. Alternative Therapies / Dr. Thiers / Dr. Draelos
3:35 p.m. What’s New in the Treatment of Infectious Diseases? 2:20 p.m. Questions and Answers / Dr. Draelos
/ Dr. Rosen 2:30 p.m. Preventative Aging Gracefully with Novel Sunscreen
3:51 p.m. Questions and Answers / Faculty Technology / Dr. Lim
2:50 p.m. Questions and Answers / Dr. Lim
FRIDAY, FEBRUARY 4

4:01 p.m. Malignant Melanoma and Photoprotection:

New Developments / Dr. Rigel
4:17 p.m. Advances in Pediatric Therapies / Dr. Cunningham
4:33 p.m. What’s New in Medical Dermatology? / Dr. Lebwohl
4:49 p.m. Questions and Answers / Faculty
3:00 p.m. The “Inside Out” Nutraceutical Approach to Aging
Gracefully / Dr. McDaniel
3:20 p.m. Questions and Answers / Dr. McDaniel
3:30 p.m. Structural and Cellular Mediators in Aging Gracefully
/ Dr. Sachs
3:50 p.m. Questions and Answers / Dr. Sachs
4:00 p.m. Topical Cosmeceuticals for Aging Gracefully
/ Dr. Farris
4:20 p.m. Questions and Answers / Dr. Farris
4:30 p.m. Summary: Future Concepts of Aging Gracefully
/ Dr. Draelos
4:50 p.m. Questions and Answers / Dr. Draelos

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 93

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMpOSIUM DISCUSSION gROUp

2:00 p.m. to 5:00 p.m. 2:30 p.m. to 4:00 p.m.
Open admission, no tuition or ticket. Tuition fee and ticket required for admission.

S013 leading Others for peak performance D005 Dermatoethics: Contemporary Issues in
Room: 293/294 Ethics and professionalism
Room: 240
DIRECTOR Bryan Erik Anderson, M.D.
DIRECTOR Lionel Gordon Bercovitch, M.D.
SpEAkERS
Sandra Ellison, Victor J. Marks, M.D. lEARNINg OBjECTIVES
Center for Creative Leadership Jeffrey J. Miller, M.D. Following this discussion group, the attendee will be able to:
Joslyn S. Kirby, M.D. Oliver Fred Miller III, M.D. 1. Apply principles of bioethics and professionalism to issues in
clinical practice.
lEARNINg OBjECTIVES 2. Compare the ethical differences in the practice of a profession
Following this symposium, the attendee will be able to: and a business.
1. Describe the imperative and implement the skill of inspiring 3. Analyze real-life issues relating to conflicts of interest and the
commitment. physician’s fiduciary responsibility.
2. Recognize the importance of selecting well, accepting
idiosyncrasies, and developing employee potential. DESCRIpTION
3. Demonstrate effective methods to provide feedback to Dermatologists and residents face ethical and professional issues
constructively offer others opportunities for improvement throughout their workday yet receive little formal training in
and growth. these disciplines. This session in ethics and professionalism
will present three timely case-based topics of importance to
DESCRIpTION dermatologists. Specific areas that might be covered include
This session is designed for those wishing to enhance their cosmetic dermatology, pediatric dermatology, dermatologist-
leadership competency in leading others to peak performance. industry relationships, regulatory issues, professionalism, and
Inspiring commitment; selecting, developing and accepting physician health. Each topic will include real-life case scenarios
people; coping with change; effective communication and leading and a brief didactic presentation on the relevant bioethical topics,
employees are some of the topics to be discussed. Experts will followed by lively interactive discussion with the audience.
present methods for motivating; “sizing up” and hiring talent; Participants are encouraged to bring their own cases for an “Ask
providing effective feedback; setting goals; bringing out the the Dermatoethicist” interactive session.
best; delegating effectively; offering challenging opportunities 1.50 Category 1 CME Credits
and providing opportunities for growth; broadening employee
opportunities; acting fairly; and achieving excellence.
Development of faculty, residents and employees will be D006 Serologic Testing for Connective Tissue
addressed.
3.00 Category 1 CME Credits
Diseases
Room: 241
SCHEDUlE
2:00 p.m. You Win with People / Dr. Anderson DIRECTOR Diya F. Mutasim, M.D.
2:30 p.m. Motivating People / Dr. Miller lEARNINg OBjECTIVES
3:00 p.m. Developing Staff / Dr. Miller Following this discussion group, the attendee will be able to:
3:30 p.m. Effective Communication / Dr. Marks 1. Order appropriate tests for evaluating patients with
4:00 p.m. Effective Feedback / Ms. Ellison connective tissue diseases.
FRIDAY, FEBRUARY 4

4:30 p.m. Setting Goals / Dr. Kirby
2. Identify the limitations of these tests.
3. Interpret test results in conjunction with clinical data.
DESCRIpTION
The session will focus on the indications and interpretation of
tests that help in the diagnosis of connective tissue diseases.
These will include ANA, antibodies to U1RNP, SM, SSA, SSB,
nDNA, and antiphospholipid antibodies. This session is directed
to practicing dermatologists and residents.
1.50 Category 1 CME Credits

94 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
2:30 p.m. to 4:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U027 practical Approaches to Medical and U028 Oral Ulcers

Cosmetic Dermatology in Skin of Color Room: 274
Room: 283 DIRECTOR Lynne H. Morrison, M.D.
DIRECTOR Andrew F. Alexis, M.D. lEARNINg OBjECTIVES
lEARNINg OBjECTIVES Following this focus session, the attendee will be able to:
Following this focus session, the attendee will be able to: 1. Identify different causes of acute, recurrent, and chronic oral
1. Identify racial/ethnic variations in the epidemiology, clinical ulcers.
presentation, and quality of life impact of dermatologic 2. Differentiate clinical features of diseases presenting with oral
disorders. ulcers.
2. Recognize leading medical and aesthetic dermatologic concerns 3. Evaluate and prescribe appropriate therapy in patients with oral
in non-Caucasian populations. ulcers.
3. Utilize safe and effective treatment approaches for common DESCRIpTION
dermatologic concerns in ethnic skin. This session will present an overview of the diagnosis,
DESCRIpTION evaluation,and managment of patients presenting with oral
Ethnic skin or skin of color refers to the broad range of skin types ulcers. Causes of acute, recurrent, and chronic oral ulcers will
and complexions that characterize individuals of African, Asian, be reviewed, which should help develop a practical approach to
Latino, and Native American descent. Differences in structure, these patients. Conditions that will be covered include recurrent
function, and cultural practices in individuals with ethnic skin aphthousstomatitis, autoimmune bullous diseases such as
contribute to variations in the prevalence and clinical presentation pemphigus vulgaris, paraneoplastic pemphigus, mucous membrane
of numerous skin conditions. This session will serve as a practical pemphigoid, and ulcerative lichen planus. The session is directed
overview of leading medical and aesthetic dermatologic concerns at dermatologists in practice as well as residents. Attendees are
in non-Caucasian populations. Emphasis will be on safe and encouraged to bring questions and cases for discussion.
effective treatment approaches for dyschromias, follicular 1.50 Category 1 CME Credits
disorders, alopecias, and skin aging concerns in patients of color.
1.50 Category 1 CME Credits

FRIDAY, FEBRUARY 4

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 95

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
2:30 p.m. to 4:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U029 Skin Cancer in patients with Non- U030 Treatment of pediatric psoriasis
Melanoma Hodgkin’s lymphoma Room: 269
Room: 267/268 DIRECTOR Kelly M. Cordoro, M.D.
DIRECTOR Jerry D. Brewer, M.D. lEARNINg OBjECTIVES
lEARNINg OBjECTIVES Following this focus session, the attendee will be able to:
Following this focus session, the attendee will be able to: 1. Describe the epidemiology, triggering factors, potential
1. Discuss the relative risk of skin cancer in patients with chronic comorbidities, and unique clinical presentations of pediatric
lymphocytic leukemia and non-Hodgkin’s lymphoma. psoriasis.
2. Recognize the types of skin cancer associated with an increased 2. Choose appropriately among the available systemic, biologic,
risk of recurrence, metastasis, and death in these patients. and light-based treatments for moderate to severe pediatric
3. Formulate an effective treatment plan for skin cancer in psoriasis.
patients with non-Hodgkin’s lymphoma that addresses the 3. Formulate a therapeutic plan for different clinical presentations
higher risks of recurrence, metastasis, and death. of moderate to severe pediatric psoriasis.

DESCRIpTION DESCRIpTION
Non-Hodgkin’s lymphoma is the most common hematologic The management of pediatric psoriasis presents a unique set
malignancy in mankind. Skin cancer is the most common of challenges and requires an updated understanding of the
epithelial malignancy in the world. The combination of inherent epidemiology, triggering factors, potential comorbidities, unique
immunologic disease-related immunosuppression and iatrogenic clinical presentations, and commonly used therapies in this age
treatment-associated immunosuppression in patients with chronic group. This session is designed to arm the clinician with the basic
lymphocytic leukemia (CLL) predisposes them to an increased principles and advanced practices necessary to treat moderate to
incidence of non-melanoma and melanoma skin cancer as well severe psoriasis in children. Systemic, biologic, and light-based
as a higher incidence of adverse outcomes. The pathogenic treatment options alone and in novel combinations are discussed
mechanisms of increased skin cancer in patients with CLL will and the appropriate clinical setting for their use is presented in
be reviewed, as well as the epidemiologic evidence supporting a case-based format. The session is directed towards practicing
an increased incidence. Adverse outcomes associated with skin clinicians and residents.
cancer in patients with CLL, including high rates of recurrence, 1.50 Category 1 CME Credits
metastasis, and mortality will be reviewed. The complexities of
histopathologic interpretation of surgical margins will be discussed
as well as optimal management and prevention strategies.
1.50 Category 1 CME Credits
FRIDAY, FEBRUARY 4

96 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
2:30 p.m. to 4:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U031 Dermatomyositis U032 Chronic Inflammatory Hand and Foot

Room: 284 Dermatoses
DIRECTOR Jason C. Sluzevich, M.D. Room: 264

lEARNINg OBjECTIVES DIRECTOR Robert Bissonnette, M.D.

Following this focus session, the attendee will be able to: lEARNINg OBjECTIVES
1. Recognize morphologic features of classic and atypical Following this focus session, the attendee will be able to:
presentations. 1. Identify and diagnose common inflammatory hand and foot
2. Order appropriate symptom-directed and age-based laboratory inflammatory dermatoses including psoriasis, atopic dermatitis,
studies. contact dermatitis and palmo-plantar pustulosis.
3. Prepare an effective treatment plan cognizant of common 2. Review and discuss evidence-based efficacy of topical therapy,
outcomes. phototherapy, oral systemic, and biologic therapy for hand and
foot inflammatory dermatoses.
DESCRIpTION 3. Select the best treatment option for patients with inflammatory
This session will provide a practical approach to the diagnosis hand and foot dermatoses.
and management of patients with dermatomyositis. A case-based
format will be used to illustrate key diagnostic points with an DESCRIpTION
emphasis on unique clinical presentations. The role and limitations Common inflammatory dermatoses, such as psoriasis, atopic
of histology, immunofluorescence, laboratory testing, and imaging dermatitis and contact dermatitis, often involve hands and
studies will be outlined. A conceptual framework for treatment feet. Unfortunately the morphology of some of these diseases
will be presented, along with a select review of the evidence is sometimes different on palms and soles, making the diagnosis
supporting various treatment modalities. more challenging. Treatment of these inflammatory diseases
1.50 Category 1 CME Credits is also more difficult when palms or soles are involved as the
thickness of the epidermis can limit the efficacy of topical therapy
and phototherapy. This session will review the different clinical
presentations of common hand and feet dermatoses and focus on
their management. Recent data on the efficacy of phototherapy,
oral agents, and biological agents will be discussed.
1.50 Category 1 CME Credits

FRIDAY, FEBRUARY 4

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 97

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
2:30 p.m. to 4:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U033 Electrolysis: when laser Isn’t the Answer U035 paraneoplastic Dermatoses
Room: 285 Room: 270
DIRECTOR Lesly Salgado Davidson, M.D. DIRECTOR Seemal Desai, M.D.
lEARNINg OBjECTIVES lEARNINg OBjECTIVES
Following this focus session, the attendee will be able to: Following this focus session, the attendee will be able to:
1. Identify patients who would benefit from electrolysis. 1. Identify and distinguish early forms and various clinical
2. Distinguish candidates for electrolysis from candidates for laser. presentations of paraneoplastic dermatoses.
3. Compare various methods of hair removal. 2. Utilize recent data from the literature to enable clinicians to
differentiate primary underlying malignancies and their most
DESCRIpTION
common type of skin presentation.
This session is intended for dermatologists and physician
3. Develop treatment and workup plans for patients presenting
extenders. The focus will be on electrolysis: its history, its
with skin conditions suspicious for underlying malignancy.
evolution, and its current indications. We will determine the
profile of patients more likely to benefit from electrolysis than DESCRIpTION
laser. Circumstances where laser therapy is unlikely to achieve Paraneoplastic dermatoses include various papulosquamous,
effective hair removal will be identified. We will assess some other bullous, rheumatologic, pruritic, and hair and nail disorders
non-permanent methods of hair removal. Criteria for choosing a which manifest secondary to underlying malignancy. Numerous
qualified electrologist will be described. clinical and pathologic images encompassing various diagnoses
including paraneoplastic pemphigus, acrokeratosis paraneoplastica,
1.50 Category 1 CME Credits
paraneoplastic dermatomyositis, acquired ichthyosis, scleromyxedema,
Sweet’s syndrome, pyoderma gangrenosum, hypertrichosis lanuginosa
acquisita, and reactive erythemas will be shown and discussed. The
U034 pediatric Hyperhidrosis and Ectodermal use of patient cases and audience participation will facilitate session
Dysplasia: To Sweat or Not to Sweat? attendees’ ability to better formulate workup and treatment plans, as
Room: 235/236 well as develop skills on how to better communicate with other health
care providers. This course is designed for both clinicians in practice
DIRECTOR Jane S. Bellet, M.D. and those in training.
lEARNINg OBjECTIVES 1.50 Category 1 CME Credits
Following this focus session, the attendee will be able to:
1. Assess a pediatric patient with hyperhidrosis and select
appropriate treatment. U036 Subcutaneous Fat in Dermatology
2. Distinguish between the different forms of ectodermal dysplasia Room: 242
and identify clues that can help with the diagnosis. DIRECTOR Mathew M. Avram, M.D.
DESCRIpTION lEARNINg OBjECTIVES
The diagnosis of primary focal hyperhidrosis in children and Following this focus session, the attendee will be able to:
adolescents will be reviewed, as well as an in-depth discussion of 1. Describe the physiology of subcutaneous fat and its effect on
treatment options for axillary, palmar, and plantar hyperhidrosis. systemic health.
The opposite side of the coin will be addressed with a review of 2. Describe the emerging technologies in noninvasive
fat removal.
FRIDAY, FEBRUARY 4

the main forms of ectodermal dysplasia, how to make a diagnosis

and what treatments, if any, may be efficacious. Sweat, whether 3. Critically assess emerging technologies in noninvasive
fat removal.
too much or too little, can be a large problem and this will be
discussed. DESCRIpTION
1.50 Category 1 CME Credits This session will provide an overview of subcutaneous fat in
dermatology with regard to anatomy, physiology, and noninvasive
fat removal. It will begin by examining subcutaneous fat in terms of
its anatomy, physiology, and role in systemic health. It will go on to
critically assess the emerging field of noninvasive fat removal.
1.50 Category 1 CME Credits

98 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION COURSE

2:30 p.m. to 4:00 p.m. 3:00 p.m. to 5:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat Tuition fee and ticket required for admission.
for only 15 minutes after the official start time.

U037 paraneoplastic Autoimmune Multiorgan C06D Basic Self-Assessment of

Syndrome (pAMS) Dermatopathology
Room: 263 Room: 275/276/277
DIRECTOR Sergei A. Grando, M.D., Ph.D. DIRECTOR Clay J. Cockerell, M.D.
lEARNINg OBjECTIVES SpEAkERS Antoanella Bardan, M.D.
Following this focus session, the attendee will be able to:
lEARNINg OBjECTIVES
1. Identify clinical variants of the paraneoplastic autoimmune
Following this course, the attendee will be able to:
multiorgan syndrome (PAMS).
1. Interpret and identify dermatologic histological diagnoses more
2. Recognize the pathophysiology of PAMS.
effectively and accurately.
3. Manage patients with PAMS.
2. Classify and recognize common histopathologic skin conditions
DESCRIpTION and formulate differential diagnoses.
The paraneoplastic disease of epithelial adhesion known
DESCRIpTION
as paraneoplastic pemphigus represents a clinical and
Attendees will view 60 slides from skin biopsy specimens in a format
immunopathological variant of a novel heterogeneous
that will allow self-assessment. Cases will span the full spectrum of
autoimmune syndrome, termed paraneoplastic autoimmune
dermatopathology. Each specimen will be discussed by a faculty
multiorgan syndrome (PAMS), in which patients, in addition to
member with emphasis placed on establishing the correct diagnosis
typical skin lesions, develop small airway occlusion and deposition
and consideration of the differential diagnosis. These sessions are
of autoantibodies in different organs. In some instances anti-
directed to dermatology residents and practicing dermatologists.
desmoglein antibodies are identified, but these do not correlate
To allow for a larger participation this year, this course will be
well with the clinical phenotype. The pathophysiology of
offered with duplicate content at 7:00 a.m., 9:30 a.m., 12:30 p.m.,
PAMS involves cellular autoimmunity responses. The peculiar
and 3:00 p.m. Attendees need only select one of these sessions.
immunopathology of PAMS and its poor prognosis require a
This session includes the discussion C06E – see page 122.
thorough workup to allow differentiation from common forms of
2.00 Category 1 CME Credits
autoimmune pemphigus.
1.50 Category 1 CME Credits

FRIDAY, FEBRUARY 4

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 99

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
3:00 p.m. to 5:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F017 Resident jeopardy F018 Atopic Dermatitis

Room: 386/387 Room: 291/292
DIRECTOR Amit Garg, M.D. DIRECTOR Eric Lawrence Simpson, M.D.
SpEAkERS SpEAkERS
Emmy M. Graber, M.D. James Baker, M.D.
Pranau B. Sheth, M.D. Peter A. Lio, M.D.
lEARNINg OBjECTIVES lEARNINg OBjECTIVES
Following this forum, the attendee will be able to: Following this forum, the attendee will be able to:
1. Assess core competencies across numerous domains in 1. Examine emerging clinical and basic science insights into the
dermatology. pathogenesis of atopic dermatitis.
2. Identify any gaps in medical knowledge. 2. Utilize topical and systemic therapeutics and patient
3. Measure self against colleagues at similar career levels from education more effectively for controlling flares and for relapse
various institutions across the country and internationally. prevention.
3. Demonstrate how to approach the issue of allergy, IgE testing,
DESCRIpTION
and exclusion diets in atopic dermatitis management.
Join your colleagues for self-assessment through a familiar
engaging game show format. Queries and image-based inquiries DESCRIpTION
encompassing the breadth of dermatology are posed to contestants This forum will provide an update on the latest research in atopic
in a friendly competition arrangement. Audience members are dermatitis including disease epidemiology, pathophysiology,
invited to play along. therapy and prevention, and topical and systemic treatments. We
will specifically address alternative medicine, probiotics, biologics,
Will Emory repeat as champions, or will the 2011 AAD Resident and new methods for controlling staphylococcus infections. A
Jeopardy trophy be awarded to another deserving institution? practical approach to effective patient education will be detailed.
Registered participants who wish to represent their training An allergist will provide an evidence-based and practical discussion
program as contestants in teams of two residents should send an of the role of allergy in eczema management.
email indicating their interest to agarg@bu.edu. 2.00 Category 1 CME Credits
2.00 Category 1 CME Credits
SCHEDUlE
3:00 p.m. Introduction and Pathogenesis Update / Dr. Simpson
3:10 p.m. Questions and Answers / Faculty
3:15 p.m. Topical Therapy, Alternative Medicine, and
Education / Dr. Lio
3:45 p.m. Questions and Answers / Faculty
3:55 p.m. Eczema from an Allergist’s Perspective / Dr. Baker
4:25 p.m. Questions and Answers / Faculty
4:35 p.m. Systemic Treatment Ladder and Future Research
Directions / Dr. Simpson
4:50 p.m. Questions and Answers / Faculty
FRIDAY, FEBRUARY 4

100 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
3:00 p.m. to 5:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F019 journal watching F020 Volunteerism and Humanitarianism

Room: 255/256/257 Room: 252/253/254
DIRECTOR Lowell A. Goldsmith, M.D. DIRECTOR Amit G. Pandya, M.D.
SpEAkERS SpEAkERS
Jeffrey Phillip Callen, M.D. George J. Hruza, M.D. Douglas W. Johnson, M.D.
Mary Wu Chang, M.D. M. Angelica Selim, M.D.
lEARNINg OBjECTIVES
Craig A. Elmets, M.D. Hensin Tsao, M.D., Ph.D.
Following this forum, the attendee will be able to:
lEARNINg OBjECTIVES 1. List the various volunteer opportunities available in our
Following this forum, the attendee will be able to: specialty.
1. Evaluate critically the most recent literature in dermatologic 2. Select a volunteer activity that matches the skill set of the
and non-dermatologic journals. attendee.
2. Recognize the difference between fatal and non-fatal flaws in 3. Describe the activities required for volunteering in various roles
peer-reviewed articles. within our specialty.
3. Formulate efficient strategies for tracking the ever-enlarging
DESCRIpTION
literature.
Despite advances in health care, many individuals suffer because of
DESCRIpTION lack of access to dermatologic care. The safety net for individuals
The knowledge and skills needed to thrive in the information worldwide is just not sufficient to hold the many individuals who
explosion will be discussed by members of the Journal Watch fall through. Dermatologists have a unique opportunity to help by
Dermatology editorial board. This group follows over 50 caring for these patients as well as teaching others how to give this
journals annually and reports weekly online and monthly in care. Giving back to dermatology for all is the reason why many
print. The discussions emphasize recently published articles. volunteer in our specialty. This session will highlight dermatology
Members will discuss the articles in their special interest: Dr. volunteer opportunities in inner city clinics, drug-addiction
Callen, autoimmune diseases and pharmacology; Dr. Chang, centers, border cities, international locations, teledermatology,
pediatric dermatology; Dr. Dahl, immunodermatology; Dr. academic institutions, and various organizations.
Elmets, photodermatology; Dr. Goldsmith, genetics; Dr. Selim, 2.00 Category 1 CME Credits
dermatopathology; Dr. Tsao, pigmentation and melanoma.
SCHEDUlE
2.00 Category 1 CME Credits
3:00 p.m. Volunteerism at Home and Abroad / Dr. Pandya
SCHEDUlE 3:45 p.m. Local and International Volunteer Experiences and
3:00 p.m. Gene Watching: My Gene of the Year / Dr. Goldsmith Teledermatology / Dr. Johnson
3:05 p.m. Dermatology Surgery: My Top Cuts / Dr. Hruza 4:30 p.m. Questions and Answers / Faculty
3:25 p.m. Melanoma: Lifting the Dark Cloud / Dr. Tsao
3:45 p.m. Dermatopathology Pearls / Dr. Selim
4:00 p.m. Vitamin D and Photobiology / Dr. Elmets
4:20 p.m. Drugs and Collagen Vascular Diseases / Dr. Callen
4:40 p.m. Pediatric Nuggets from Journal Watching / Dr. Chang
FRIDAY, FEBRUARY 4

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 101
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
3:00 p.m. to 5:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F021 FDA presents: Information F022 Coding and Office Management

for Dermatologists Room: 295/296
Room: 392 DIRECTOR Murad Alam, M.D.
DIRECTOR Susan J. Walker, M.D. SpEAkERS
SpEAkERS Ashish Bhatia, M.D. Clifford Warren Lober, M.D., J.D.
Denise Cook, M.D. Jill A. Lindstrom, M.D. Kenneth E. Bloom, M.D. Alexander Miller, M.D.
Jane E. Liedtke, M.D. Peter D. Rumm, M.D., M.P.H. William Patrick Davey, M.D. Lucile E. White, M.D.
Dirk Michael Elston, M.D. James A. Zalla, M.D.
lEARNINg OBjECTIVES Carl Martin Leichter, M.D.
Following this forum, the attendee will be able to:
1. Identify and provide information, obtained from your clinical lEARNINg OBjECTIVES
practice, that will impact drug safety and advance public Following this forum, the attendee will be able to:
health. 1. Describe recent changes in coding, and pending changes that
2. Optimally utilize the information in drug labeling to make may soon be implemented.
informed clinical decisions. 2. Discuss selected topics in office management, including the
3. Describe the regulatory process for drugs used in dermatology. electronic health record, personnel management, and patient
satisfaction.
DESCRIpTION
This forum, designed for the practicing dermatologist, will discuss DESCRIpTION
the many ways in which dermatologists can participate in the The purpose of this session is to provide an update regarding
ongoing safety dialogue for drugs used in our specialty. FDA current and impending coding changes, including those pertaining
dermatologists will discuss drug safety, with special emphasis on to evaluation and management codes, as well as procedure codes.
risk management programs and the challenges of evaluating risk Additionally, elements of office management will be addressed,
with incomplete information. Recent changes in the format and including adoption of an electronic health record, personnel
content of the physician’s package insert will be presented. At management, and delivery of the ideal patient experience.
the conclusion of this forum, participants will better understand 2.00 Category 1 CME Credits
the process by which drugs become available to the practicing SCHEDUlE
community. 3:00 p.m. Introduction/Growing A Practice In The New Decade
2.00 Category 1 CME Credits /Alam
SCHEDUlE 3:12 p.m. PQRI And Quality Initiatives / Dr. Elston
3:00 p.m. Overview: FDA / Dr. Walker 3:24 p.m. Negotiating With Managed Care Organizations
3:15 p.m. Drug Safety and the FDA Review Process / Dr. Davey
/ Dr. Lindstrom 3:36 p.m. Tips On Personnel Management And Low Cost
3:45 p.m. Medwatch: What, Why, How to Report / Dr. Liedtka Marketing / Dr. White
4:05 p.m. Have You Noticed: Labels Are Changing! / Dr. Cook 3:48 p.m. Informed Consent/Considerations In Pediatric
4:25 p.m. Update on Devices for Dermatology / Dr. Rumm Patients / Dr. Bloom
4:45 p.m. Questions and Answers / Faculty 4:00 p.m. Tips On Coding And Practice Management
/ Dr. Zalla
FRIDAY, FEBRUARY 4

4:12 p.m. Implementing An EMR And Scribing / Dr. Bhatia

4:24 p.m. Winning A Medicare Modifier 25 Audit
/ Dr. Leichter
4:36 p.m. Closure Documentation / Dr. Miller
4:48 p.m. RAC/Medicolegal Issues / Dr. Lober

102 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
3:00 p.m. to 5:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
LOOKING FOR A NEW
F023 psoriasis guidelines: Implementing Them
in Your practice
OPPORTUNITY?
Room: 388/389/390
DIRECTOR Alan Menter, M.D.
SpEAkERS
Steven R. Feldman, M.D., Ph.D.
Craig L. Leonardi, M.D.
Henry W. Lim, M.D.
lEARNINg OBjECTIVES Whether you’re looking for a clinical or academic/
Following this forum, the attendee will be able to:
research position or interested in purchasing an
1. Describe an overall approach to the management of patients
with psoriasis and psoriatic arthritis with an emphasis established practice, the American Academy
on decision-making criteria that enable the clinician to of Dermatology’s Career Development Fair will
individualize therapy based upon disease type, extent, provide you the opportunity to meet potential
response to previous treatments, quality-of-life issues, and employers and network with other professionals
co-morbidities.
just like you!
2. Describe clinical case studies and discuss evidence-based
treatment of cases based on the recently published AAD In addition, experts will be on hand to answer
psoriasis evidence-based guidelines, which include best
questions on starting or expanding an existing
practices.
3. Identify gaps in clinical knowledge patient care. practice, coding and reimbursement, and
practice management.
DESCRIpTION
The session will be helpful in expanding the physician knowledge Free for
base and improving clinical confidence and effectiveness Job Seekers!
in treating psoriasis patients with a wide range of clinical
presentations including psoriatic arthritis. The session will
consist of four presentations with time available after each talk
Hilton New Orleans Riverside
for interaction with the attendees. It will be structured in a
question-and-answer format when case studies are discussed. To Two Poydras Street
prepare participants, all attendees will be sent the full set of AAD New Orleans, Louisiana 70130
guidelines and implementation products in advance so they have
sufficient time to study before the session. A short survey will Friday, February 4, 2011
be conducted before and after the session, and follow-up survey
will follow 6 months later to gauge and evaluate if guidelines and 5:00pm – 7:00pm
presentations were easy to translate into daily clinical practice.
Studies have shown that high-quality guidelines can make
important contributions to improving medical care.
FRIDAY, FEBRUARY 4

2.00 Category 1 CME Credits

Employers can register online at www.aad.org/careerfair
SCHEDUlE
or by contacting the Member Resource Center at
3:00 p.m. Introduction and Overview with Survey / Dr. Menter
3:10 p.m. Topical Therapy for Psoriasis with Case Study 866-503-SKIN (7546).
/ Dr. Feldman
3:35 p.m. Phototherapy for Psoriasis with Case Study / Dr. Lim
4:00 p.m. Systemic Therapy with Case Study / Dr. Menter
4:25 p.m. Biologic Therapy with Case Study / Dr. Leonardi
4:50 p.m. Panel Discussion with Survey / Faculty

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 103
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

wORkSHOp
3:00 p.m. to 5:00 p.m.
Tuition fee and ticket required for admission.

w002 Dermatology Speaker Development w003 MOC Self-Assessment: Dermatopathology

M
Room: 265/266 O Room: 288/289/290
C

DIRECTOR Hilary E. Baldwin, M.D. DIRECTOR Molly A. Hinshaw, M.D.

SpEAkERS SpEAkERS
Steven Kenneth Shama, M.D., M.P.H. Nneka I. Comfere, M.D. Lori D. Prok, M.D.
Whitney A. High, M.D. Brian L. Swick, M.D.
lEARNINg OBjECTIVES
Following this workshop, the attendee will be able to: lEARNINg OBjECTIVES
1. Develop techniques for maximizing the effectiveness of your Following this workshop, the attendee will be able to:
presentations. 1. Determine common and uncommon dermatologic
2. Design effective PowerPoint slides to support your messages histopathologic diagnoses.
and maintain audience interest. 2. Recognize the importance of the clinical-pathologic correlation
3. Choose memorable images and messages. in histopathology.
3. Identify areas for improvement in knowledge of histopathologic
DESCRIpTION
diagnosis using self-assessment.
We are all teachers for our patients, students, and peers. We
all want to leave memorable images and messages with our DESCRIpTION
audience. Yet only 10 percent of what we say is retained by the In this session, attendees will be presented with a wide range
end of the week. What can we do to assure that the 10 percent of histopathologic specimens for diagnosis and self-assessment.
that is remembered is the 10 percent that we want? We will Clinical information may also be provided to aid diagnosis. For
discuss effective strategies and techniques that will make you a each case presented, anonymous answers will be recorded via self-
comfortable, confident, and memorable speaker. response computerized system, followed immediately by discussion
2.00 Category 1 CME Credits of the case.
2.00 Category 1 CME Credits
SCHEDUlE
3:00 p.m. Developing Memorable Messages / Dr. Shama SCHEDUlE
3:30 p.m. Preparing Effective PowerPoint Slides / Dr. Baldwin 3:00 p.m. Cases 1-5 / Dr. High
4:00 p.m. Presentations Are Performance: How to Prepare 3:20 p.m. Cases 6-10 / Dr. Comfere
/ Dr. Baldwin 3:40 p.m. Cases 11-15 / Dr. Prok
4:30 p.m. Handling the Questions and Answers / Dr. Baldwin 4:00 p.m. Cases 16-20 / Dr. Swick
4:45 p.m. Questions and Answers / Faculty 4:20 p.m. Cases 21-25 / Dr. Hinshaw
* Self-assessment questions utilized in this session are the
same as those used for Forum F024 and Workshop
W001 MOC: Self-Assessment offered at Annual
Meeting 2009 and 2010. Physicians should not
claim CME/MOC credit for attending this session if
they attended Forum F024 and Workshop W001 at
Annual Meeting 2009 and 2010.
FRIDAY, FEBRUARY 4

104 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

OVERVIEw

FRIDAY/SATURDAY, FEBRUARY 4, 5
Course — 9:00 a.m. to 5:00 p.m. Symposium — 9:00 a.m. to 5:00 p.m.
C012 Structure and Function of the Skin. . . . . . . . . . .105 S007 Gross and Microscopic Dermatology . . . . . . . . .106

COURSE
9:00 a.m. to 5:00 p.m.
Tuition fee and ticket required for admission.

C012 Structure and Function of the Skin SCHEDUlE

Room: 271/272/273
FRIDAY, FEBRUARY 4, 2011
DIRECTOR Thomas J. Hornyak, M.D., Ph.D. 9:00 a.m. Introduction / Dr. Hornyak
SpEAkERS 9:05 a.m. Skin Embryology and Morphogenesis / Dr. Radhika
Richard August Clark, M.D. Dennis H. Oh, M.D., Ph.D.. 9:30 a.m. Keratinocyte Biology and Pathology / Dr. DiGiovanna
Rachael Clark, M.D., Ph.D. Atit Radhika, Ph.D., M.D. 10:00 a.m. Break / Dr. Hornyak
George Cotsarelis, M.D. John T. Seykora, M.D. 10:15 a.m. Epidermal Cell-Cell and Cell-Matrix Adhesion
Thomas N. Darling, M.D., Ph.D. John Roger Stanley, M.D. / Dr. Kowalczyk
John J. DiGiovanna, M.D. Diane M. Thiboutot, M.D. 11:00 a.m. Pemphigus: Anti-Desmosomal Autoimmune Diseases
Heidi H. Kong, M.D. Hensin Tsao, M.D., Ph.D. / Dr. Stanley
Andrew P. Kowalczyk, Ph.D. Mark C. Udey, M.D., Ph.D. 11:30 a.m. Autoimmune and Inherited Diseases of the Epidermal
Kenneth Howard Kraemer, M.D. Jouni J. Uitto, M.D., Ph.D. Basement Membrane / Dr. Yancey
James G. Krueger, M.D., Ph.D. Kim B. Yancey, M.D. 2:00 p.m. Disease of the Pilosebaceous Unit / Dr. Thiboutot
Lloyd S. Miller, M.D., Ph.D. 2:30 p.m. Cutaneous Photobiology / Dr. Oh
3:00 p.m. DNA Repair Abnormalities and Skin Cancer
lEARNINg OBjECTIVES / Dr. Kraemer
Following this course, the attendee will be able to: 3:30 p.m. Break / Dr. Hornyak
1. Define basic structures in epidermis and dermis, and list their 3:45 p.m. Extracellular Matrix in Acquired and Inherited Skin
functions. Diseases / Dr. Uitto
2. Summarize the pathophysiology of representative dermatologic 4:15 p.m. Wound Healing / Dr. Clark
diseases. 4:45 p.m. Questions and Answers / Dr. Hornyak
3. Describe the rationale of selected therapeutic agents.
SATURDAY, FEBRUARY 5, 2011
DESCRIpTION 9:00 a.m. Introduction / Dr. Hornyak
Lectures will discuss the normal structure and function of cells 9:05 a.m. Adnexal Structures in Skin / Dr. Seykora
and tissues within skin, as well as how these elements are impaired 9:45 a.m. Diseases of Hair / Dr. Cotsarelis
in representative diseases. Specific elements of the skin that will be 10:15 a.m. Break / Dr. Hornyak
discussed include keratinocytes, melanocytes, Langerhans cells, the 10:30 a.m. Melanocytes and Disorders of Pigmentation
epidermal basement membrane, fibroblasts, connective tissue, and / Dr. Hornyak
FRIDAY/SATURDAY, FEBRUARY 4/5
adnexal structures including hair, pilosebaceous units, and sweat 11:00 a.m. Oncogenes and Tumor Suppressor Genes
glands. Abnormal functions of these elements will be related to / Dr. Darling
pathological conditions, including inflammation, autoimmunity, 11:30 a.m. Pathogenesis of BCC, SCC, and Melanoma / Dr. Tsao
blistering, cancer, photosensitivity, dyspigmentation, 2:00 p.m. Innate Immunity / Dr. Miller
infection, and genodermatoses. It will be shown how increased 2:30 p.m. The Cutaneous Microbiome / Dr. Kong
understanding of skin biology is being translated into new 2:50 p.m. Skin as an Immune Organ / Dr. Udey
therapies and improved care for patients. 3:20 p.m. Break / Dr. Hornyak
11.00 Category 1 CME Credits 3:35 p.m. Current Concepts in Psoriasis / Dr. Krueger
4:15 p.m. Regulatory T cells: The Good, the Bad, and the
Ineffective / Dr. Clark
4:45 p.m. Questions and Answers / Dr. Hornyak

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 105
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMpOSIUM
9:00 a.m. to 5:00 p.m.
Open admission, no tuition or ticket. Psoriasis Guidelines:
S007 gross and Microscopic Dermatology Implementing them
Room: 343
DIRECTOR Karen Warschaw, M.D.
in Your Practice
SpEAkERS
Mark A. Cappel, M.D. Tammie C. Ferringer, M.D. Friday, February 4
Michael P. Conroy, M.D. Lawrence E. Gibson, M.D.
3:00 p.m. – 5:00 p.m.
lEARNINg OBjECTIVES
Following this symposium, the attendee will be able to:
1. Review and interpret a wide variety of brief papers with clinical Speakers:
and pathological correlations.
2. Compare and discuss a wide variety of dermatologic entities.
• Alan Menter, M.D. – Forum Director
DESCRIpTION
• Steven R. Feldman, M.D., Ph.D.
Approximately 240 papers of 4 minutes’ duration will be • Henry W. Lim, M.D.
presented during this session. Presentations will be separated into
several broad categories. This session is directed to all academy
• Craig L. Leonardi, M.D.
members and non-members including medical students, residents,
and fellows.
12.00 Category 1 CME Credits
REFERENCES
1. Weedon D. Skin Pathology. 3rd ed.Churchill Livingstone;2010.

This Forum will provide an ideal

opportunity to learn best practices in
the complex management of psoriasis
and psoriatic arthritis. Experts in the
field will review the latest clinical
guidelines with four question-and-
answer presentations.
Attendees receive a full set of recently
FRIDAY/SATURDAY, FEBRUARY 4/ 5

published AAD Guidelines together

with implementation products, which
will assist in using the evidence-based
AAD psoriasis guidelines in your
practice. FREE of charge!

Visit www.aad.org/
meetings/annual to register.

106 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng


For description of session categories and fees see page 37
OVERVIEw
Represents restricted session in program overviews
Restricted Session open to dermatologists and corporate
individual members only! A ticket is required for admittance
Represents Practice Management Session in program overviews
practice Management Session open to eligible
office staff/registered nurses
Represents Patient Safety Session in program overviews
patient Safety Session
Represents Audience Response System Session
Audience Response System Session
SATURDAY, FEBRUARY 5
poster Discussion Sessions — 7:15 a.m. to 8:45 a.m.
PD01 Surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .112
PD02 Clinical Dermatology . . . . . . . . . . . . . . . . . . . . .112
Discussion groups — 7:15 a.m. to 8:45 a.m.
D007 Leading from Conflict to Resolution . . . . . . . . .113
D008 PUVA and Phototherapy Beyond Psoriasis . . . . .113
Focus Sessions — 7:15 a.m. to 8:45 a.m.
U038 Nanotechnology . . . . . . . . . . . . . . . . . . . . . . . . .114
U039 Good Closures Gone Bad: A Story of Blood,
Pus, and Tears . . . . . . . . . . . . . . . . . . . . . . . . . . .114
U040 Military Unique Dermatology . . . . . . . . . . . . . .114
U041 Uncommon Cutaneous Infections:
Clinical and Histologic Features . . . . . . . . . . . . .114
U042 The Vices of Devices in Dermatology . . . . . . . . .115
U043 Dermatopathology Challenges Encountered C06E Basic Self-Assessment of Dermatopathology
by the Mohs Surgeon . . . . . . . . . . . . . . . . . . . . .115
U044 Tumescent Liposuction, Lasers, and New Devices: C013 Advanced Botulinum Toxin:
A State-of-the-Art Liposuction Practice. . . . . . . .115
U045 Non-cultured Epidermal Suspension in Vitiligo: C014 Coding, Documentation, and Practice
From Lab to Clinic . . . . . . . . . . . . . . . . . . . . . . .116
U046 Social Media and Dermatology: How Twitter and
Facebook Will Help You and Your Practice. . . . .116
U047 Mini - MBA for the Dermatologist. . . . . . . . . . .116
U048 Challenging Cases in Pediatric Dermatology. . . .117
For the Latest Program Book InFormatIon PLease reFer to
SCIENTIFIC SESSIONS
Represents activities that meet MOC-D
M
O
This activity has been approved by the ABD to satisfy
C component 2 of MOC-D
Represents Leadership Institute in program overviews
leadership Institute — addresses leadership
competencies specific to dermatologists
Represents Health Information Technology (HIT) in
program overviews
Health Information Technology Sessions
Forums — 9:00 a.m. to 11:00 a.m.
F024 Evaluation and Management of Hemangiomas. .117
F025 Dramatic Oral Disease . . . . . . . . . . . . . . . . . . . .118
F026 Chronic Urticaria and Angioedema:
What’s New in Pathogenesis and Treatment . . . .118
SATURDAY, FEBRUARY 5
F027 Practical Approaches to Patient Problems . . . . . .119
F028 What You Need to Know About Coding
But Were Afraid to Ask. . . . . . . . . . . . . . . . . . . .119
F029 Acne and Rosacea Update . . . . . . . . . . . . . . . . . .120
F030 Managing Online Reputation . . . . . . . . . . . . . . .120
F031 Food Allergy and Dermatology . . . . . . . . . . . . . .121
workshop — 9:00 a.m. to 11:00 a.m.
W004 MOC Self-Assessment: Procedural
Dermatology. . . . . . . . . . . . . . . . . . . . . . . . . . . .121
Courses — 9:00 a.m. to 12:00 p.m.
Discussion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .122
Live Patient Demonstration . . . . . . . . . . . . . . . .122
Management . . . . . . . . . . . . . . . . . . . . . . . . . . . .123
www.aad.org | 107
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

OVERVIEW

Represents restricted session in program overviews Represents activities that meet MOC-D
Restricted Session open to dermatologists and corporate M
O
This activity has been approved by the ABD to satisfy
individual members only! A ticket is required for admittance C component 2 of MOC-D

Represents Practice Management Session in program overviews Represents Leadership Institute in program overviews
Practice Management Session open to eligible Leadership Institute — addresses leadership
office staff/registered nurses competencies specific to dermatologists

Represents Patient Safety Session in program overviews Represents Health Information Technology (HIT) in
program overviews
Patient Safety Session
Health Information Technology Sessions

Represents Audience Response System Session

Audience Response System Session

Symposia — 9:00 a.m. to 12:00 p.m.

S014 Patient Safety and Quality . . . . . . . . . . . . . . . . .124 U051 Therapy for Lipodermatosclerosis,
S015 Advanced Pediatric Dermatology . . . . . . . . . . . .125 Venous Ulceration, and Atrophie Blanche . . . . . .134
S016 Drug Actions . . . . . . . . . . . . . . . . . . . . . . . . . . .125 U052 Diseases of Male Genitalia . . . . . . . . . . . . . . . . .134
S017 Therapeutic Decision Making in U053 Through the Looking Glass: The Use of
Cutaneous Oncology . . . . . . . . . . . . . . . . . . . . .126 Dermoscopy in the Management of the
SATURDAY, FEBRUARY 5

S018 Late-Bre ak in gRe s erca h . . . . . . . . . . . . . . . . . . . .126 Pigmented Lesion Patient . . . . . . . . . . . . . . . . . .135

U054 Building Beauty: Understanding Facial
Courses — 9:00 a.m. to 5:00 p.m. Proportions, Phi, and the Use of Volumizing
C015 In te rn al Me dic in e . . . . . . . . . . . . . . . . . . . . . . . .127 Soft Tissue Fillers . . . . . . . . . . . . . . . . . . . . . . . .135
C016 Advanced Self-Assessment of Dermatopathology 127 U055 Practical Approaches to Cosmeceuticals . . . . . . .135
C017 Advan c e dDe rmo s c oy p . . . . . . . . . . . . . . . . . . . .128 U056 Recommended Screening Practices in
Me dical De rmato ol gy . . . . . . . . . . . . . . . . . . . . .136
U057 Procedural Safety in Dermatology . . . . . . . . . . . .136
Forums — 12:00 p.m. to 2:00 p.m.
U058 From Stem to Skin: Precursor Cells That Have
F032 Multidisciplinary Preventive Networking in
a Lot of Potential . . . . . . . . . . . . . . . . . . . . . . . .136
Occupational Contact Dermatitis . . . . . . . . . . . .129
U059 Po tpourri o fCPC . . . . . . . . . . . . . . . . . . . . . . . .136
F033 Introduction to Oral Dermatology . . . . . . . . . . .130
U060 Stress, the Nervous System, and Cutaneous
F034 From the Dermatology Rheumatology Clinics:
Immunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .137
Practical Tips and Advances in Management . . .130
F035 Practical Aspects of Biologic Therapy . . . . . . . . .131
F036 Careers in Academic Dermatology . . . . . . . . . . .131 Courses — 2:00 p.m. to 5:00 p.m.
C018 Dermatologic Drug Safety and Efficacy . . . . . . .137
F037 Pediatric Dermatology: Systemic Evaluation of
Cutaneous Findings in Infants and Children: C019 Hair and Nails . . . . . . . . . . . . . . . . . . . . . . . . . .138
What’s New an dWh at’s Tru e .? . . . . . . . . . . . . . .132 C020 Live Patient Demonstrations: Application of
F038 Itc h . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .132 Our Aesthetic Toolbox for the Treatment of
Medical and Dermatologic Disorders . . . . . . . . .139
Workshop — 12:00 p.m. to 2:00 p.m.
W005 MOC Self-Assessment: Symposia — 2:00 p.m. to 5:00 p.m.
Pediatric Dermatology . . . . . . . . . . . . . . . . . . . .133 S019 Rheumatologic Dermatology . . . . . . . . . . . . . . .139
S020 Birthmarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . .140
S021 Skin of Color . . . . . . . . . . . . . . . . . . . . . . . . . . .141
Discussion Groups — 12:15 p.m. to 1:45 p.m.
D009 Educate Your Patients and Improve Outcomes . .133 S022 Ac n ean dRo s ca e a . . . . . . . . . . . . . . . . . . . . . . . .142
D010 Recent Advances in Skin Biology and S023 Teledermatology . . . . . . . . . . . . . . . . . . . . . . . . .143
Skin Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . .133
Discussion Groups — 2:30 p.m. to 4:00 p.m.
Focus Sessions — 12:15 p.m. to 1:45 p.m. D011 Women With Hair Loss . . . . . . . . . . . . . . . . . . .144
U049 Avoiding Complications and Maximizing Results D012 Aging Skin: Mechanism-Based Rejuvenation . . .144
in Cutaneous Laser Surgery . . . . . . . . . . . . . . . . .134
U050 Viral Exanthem Update . . . . . . . . . . . . . . . . . . .134

108 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

OVERVIEW

Focus Sessions — 2:30 p.m. to 4:00 p.m.

U061 Calciphylaxis . . . . . . . . . . . . . . . . . . . . . . . . . . . .144
U062 Herpes Simplex and Varicella Zoster Virus . . . . .144

SEARCH.
U063 De rmato s c oy .p . . . . . . . . . . . . . . . . . . . . . . . . . .145
U064 Helping You Meet Component 4 of MOC . . . . .145
U065 Dermoscopy: It’s Time for A Quiz . . . . . . . . . . .145
U066 Compliance in Pharmaceutical Development:

U067
What Yo uNe e dto Kn ow . . . . . . . . . . . . . . . . . .145
Twists and Splits: How to Approach Hair Shaft
Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .146
RECRUIT.
HIRE.
U068 El e cros
t u ge r ry Update . . . . . . . . . . . . . . . . . . . . .146
U069 Half-Truths, Lies, and Statistics: Understanding
Medical Statistics for the Practitioner . . . . . . . . .146
U070 Getting Started with Interpolation Flaps . . . . . . .146
U071 Warts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .147
U072 Pediatric Dermatologic Surgery in the
Outpatient Setting: Tricks of the Trade . . . . . . . .147 Gain access to the most highly qualified
Forums — 3:00 p.m. to 5:00 p.m. candidates in the field of dermatology with
F039 Treating Severe Skin Disease in Children . . . . . .147 AADCareerCompass.org.
F040 Resident Transitions . . . . . . . . . . . . . . . . . . . . . .148
F041 Finessing Facial Reconstruction . . . . . . . . . . . . . .148
EMPLOYERS CAN:

SATURDAY, FEBRUARY 5
F042 Hair and Nail Clinicopathologic Correlations . . .149
F043 Role of Dermatologist in Management of Skin • Post clinical and
Disease in Solid Organ Transplant Recipients . . .149 COMPETITIVE
F044 Dermatology Teaching and Education Group . . .150 academic/research PRICING
F045 Ro s ca e a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .150 positions as well STARTING AT
F046 Leading Your Team by Coaching JUST $350!
and Mentoring . . . . . . . . . . . . . . . . . . . . . . . . . .150 as practices for sale

Workshop — 3:00 p.m. to 5:00 p.m. • Hire for all recruitment

W006 MOC Self-Assessment: Contact Dermatology . .151 needs, including: dermatologists,
nurses, and other healthcare professionals

• Receive e-mail notifications of job seekers

matching open positions

• Obtain discounted membership pricing for

each ad posted

To place job opportunities or

practice for sale online,
visit www.aadcareercompass.org
or contact HealtheCareers Network
toll-free at (888) 884-8242.

Visit the Academy Resource

Center Booth 3623 for
more information.

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 109
 Visit the
Academy Resource Center Booth 3623

MOCmd Vol. 4
The Academy’s premier self-assessment AADDermsOnline.org
program has a new addition! This product can Need a website or have one that needs revamping?
be used for examination preparation, earning AADDermsOnline.org offers premium designs and
CME, and fulfilling Component 2 of Maintenance online search solutions to educate current patients and
of Certification. Purchase the self-assessment attract new ones. Be sure to inquire about discounted
library and save $100. rates for members.

Buyer’s Guide
Search for products and
services a little easier
with this comprehensive
Dermoscopy: A Guide for the Physician supplier listing designed specifically for the field of
Learn more about the Dermoscopy technique dermatology. Updated daily for better search results,
with this extensive two-disc set. View over visit aaddermatologybuyersguide.com to start searching.
to start searching.
8,000 slides and 400 cases for identifying
and diagnosing lesions of the skin.
This activity is available for See SPOT CD
AMA PRA Category 1 Credit TM. Educate patients and the
public on sun-safety and
skin cancer detection and
prevention with the AAD’s
newest teaching tool.
Dialogues in Dermatology Includes four dynamic
New online format offers features PowerPoint™ presentations,
like the ability to download MP3s each targeted to a different
to your iPod, printable transcripts, age group.
and links to additional verified
references for further study.
Subscribe today and save $40!
This activity is available for Practice Management Essential Series
AMA PRA Category 1 Credit TM. Check out the AAD’s latest manuals,
2011 Coding and Documentation
Manual and the new, Dermatology
Employment: A Guide to Personnel
Quality Reporting Policies and Procedures. Show
System special-pricing available at
Use the new QRS system to report your quality the Resource Center!
measures. Available modules include: 2011 PQRI
Melanoma Reporting and E-Prescribing. Don’t leave your
1% CMS bonus behind! Demo the system at the Resource Center.
to see What’s NEW from the Academy!

Clinical Performance Staples Advantage®

Assessment Tool (CPAT) Receive special discounts on office
Designed to help you evaluate supplies, furniture, technology, and
your practice with the goal of print material. Choose from over 30,000
improved patient care, it also products and experience free next day
satisfies Component 4 of MOC and earns CME credit. Available delivery with a minimum order of $30. Sign up at the Resource Center!
modules include: 2011 CPAT Melanoma with PQRI Reporting,
Acne, Atopic Dermatitis, Melanoma, and Office Safety Biopsy.
AADCareerCompass.org
The resources you need to
DermClips find the right employee or
Save time and stay up-to-date with employer. Employers can post practices for sale and clinical or aca-
DermClips, the Academy’s literature review demic positions. Job seekers can search for positions on the new
newsletter, featuring evidence-based online job board and post their résumés/CVs for FREE!
summaries of clinical content. Six issues
per year in print and NEW online format.
This activity is available for AMA PRA Body Mole Map
Category 1 Credit TM.
Teach patients the importance
of monitoring their moles with
the ABCDEs of Melanoma.
AAD Advantage Handout illustrates how to do a
Save, save, save! With AAD self-examination of the skin and
Advantage, the Academy’s includes a chart for tracking suspicious moles.
member buying program through Henry Schein. Receive Discounts on medical
and surgical supplies as well as generic and brand-name pharmaceuticals.
Skin Self-Exam Shower Card
A two-sided, laminated shower card that
AAD Insurance shows the steps of how to conduct a full
The Academy has nine custom- body self-examination of the skin. Also
designed insurance programs explains the ABCDEs of Melanoma.
to help protect your future and the future of your family.

Patient Education Pamphlets

Apparel
Includes a line of white lab coats for men
and women, and scrubs in variety of new
colors with option to personalize. Come
to the Resource Center to purchase and
receive 5% off all AAD Apparel!
A variety of topics including: common
dermatologic conditions, cosmetic
surgery, general dermatology, sun
protection, skin reactions, and viral
diseases. Pick up a FREE sample FREE
Sample
pack at the Resource Center!
Pack!
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

POSTER DISCUSSIONS
7:15 a .m . to 8:45 a .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

PD01 Surgery PD02 Clinical Dermatology

Room: 283 Room: 284
No CME Credits No CME Credits
MODERATOR MODERATOR
Keyvan Nouri, M .D . Jan Izakovic, M .D .
P100 P200
The use of Mohs micrographic surgery for the treatment of Survey of bacterial diversity on infant skin over the first year of life
nonmelanoma skin cancers in the Medicare population
P201
P101 Baby sun protection products: A competitive assessment of eye
Association between Mohs surgery wait times and surgical defect mildness, SPF:PFA ratio, stability, and antimicrobial robustness
size in patients with squamous cell or basal cell carcinoma of the
P202
skin
A large study of 826 patients confirms the safety and effectiveness
P102 of doxycycline monohydrate 40-mg capsules for the treatment of
Safety during dermatologic procedures and surgeries: A survey of papulopustular rosacea
physician injuries and prevention strategies
P203
P103 Lymphoma among patients with atopic dermatitis treated with
SATURDAY, FEBRUARY 5

Skin assessment by high-frequency ultrasound is a useful and topical corticosteroids and/or topical calcineurin inhibitors
reliable method to quantify photoaging in skin
P204
P104 A six-year retrospective review of drug reaction with eosinophilia
Melanocyte-keratinocyte transplantation in the treatment of and systemic symptoms (DRESS)
vitiligo: The experience of an academic medical center in the
P205
United States
A survey of mortality in patients admitted to intensive care with
P105 skin disorders
Association of facial skin aging and vitamin D levels in healthy
P206
middle-aged white women
Cutaneous epithelial to mesenchymal transition is mediated by
P106 TGF-β and TNF-α synergism: implications for scleroderma
Cryosurgery followed by imiquimod 3 .75% to treat actinic
P207
keratosis
Simvastatin inhibits transforming growth factor-β1, induced
P107 collagen type I, CTGF, and α-SMA expression in keloid
A novel high-power bipolar RF technology for noninvasive body fibroblasts
contouring

112 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

DISCUSSION GROUP
7:15 a .m . to 8:45 a .m .
Tuition fee and ticket required for admission.

D007 Leading from Conflict to Resolution

Room: 240
DIRECTOR Christine Poblete-Lopez, M.D.
SEARCH.
SPEAkERS
Mary E . Maloney, M .D .
Paul Seymour, Center for Creative Leadership
APPLY.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 . Identify one’s conflict resolution style and the importance of
WORK.
optimizing this style to effectively manage conflict .
2 . Recognize the role of crucial conversations .
3 . Apply a straightforward and effective method for conflict
resolution .
When you post a résumé/CV on
DESCRIPTION
AADCareerCompass.org, you have access
Conflict occurs when two or more people differ in their views
on a topic or an issue . In the workplace, and life in general, to some of the most desirable positions
there are numerous situations when conflict arises . Handled
in dermatology!

SATURDAY, FEBRUARY 5
inappropriately, conflict can result in strained relationships and
poor cooperation among team members, potentially threatening
the entire mission of the group . This discussion group will give JOB SEEKERS CAN:
participants an opportunity to discuss various areas of conflict
in the workplace and to identify one’s conflict resolution style . • Upload multiple résumés/CVs
The presenters will review principles of conflict management and
effective strategies to resolve conflict including the importance • Search hundreds of clinical and
of crucial conversations . Co-presented with a faculty member academic/research positions,
from the Center for Creative Leadership, participants will learn
straightforward and effective methods for conflict resolution . including practices for sale
The skills developed based on the principles learned will assist
participants in maintaining a highly effective, cohesive, and • Sign up for e-mail
productive team .
1.50 Category 1 CME Credits
alerts when positions FREE
filling your criteria FOR JOB
D008 PUVA and Phototherapy Beyond Psoriasis become available SEEKERS!
Room: 241
DIRECTOR Warwick L. Morison, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 . Discuss the therapeutic spectrum of PUVA and phototherapy .
2 . Select an appropriate form of phototherapy .
3 . Examine the approach to PUVA and phototherapy . To start searching visit
DESCRIPTION www.aadcareercompass.org or
More than 30 dermatoses have now been reported to respond to
PUVA and phototherapy . Atopic eczema, various other eczemas, contact HealtheCareers Network
mycosis fungoides, vitiligo, photodermatoses, chronic graft-versus- toll-free at (888) 884-8242.
host disease, granuloma annulare, and morphea are among these
conditions . The practical details of how to manage these and other
dermatoses will be discussed .
1.50 Category 1 CME Credits

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 113
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
FOCUS SESSION
7:15 a .m . to 8:45 a .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U038 Nanotechnology
Room: 274
DIRECTOR Adnan Nasir, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Discuss the importance of nanotechnology .
2 . Identify the benefits of nanotechnology for consumers and for
dermatology .
3 . Distinguish and identify important pitfalls of nanotechnology .
DESCRIPTION
Nanotechnology is a rapidly growing field with enormous
implications for consumers, patients, and society . Matter made at
the nano scale possesses unique properties allowing for the creation
of substances with advantages over macroscopic precursors . These
advantages include specificity, adaptability, and targeted active
ingredient delivery . A substantial proportion of the patents issued
for nanotechnology-based discoveries are in the realm of cosmetics
and consumer skin care products . The interest in nanotechnology
SATURDAY, FEBRUARY 5
and skin care is expected to burgeon . This session introduces
dermatologists to the benefits and pitfalls of nanotechnology for
consumers, patients, and colleagues .
1.50 Category 1 CME Credits
U039 Good Closures Gone Bad:
A Story of Blood, Pus, and Tears
Room: 267/268
DIRECTOR Emily J. Fisher, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Identify the signs and symptoms of common surgical
complications, including bleeding, infection, dehiscence,
and necrosis .
2 . Develop strategies to minimize common surgical complications .
3 . Select appropriate management plans when surgical
complications arise .
DESCRIPTION
This session will provide the attendee with an understanding of
the four common surgical complications: bleeding, infection,
dehiscence, and necrosis . The signs and symptoms of these
complications will be addressed, as will strategies to minimize
these complications based on current literature . The attendee
also will learn appropriate management plans for surgical
complications that may arise . The discussion will include
appropriate use of anticoagulants and perioperative antibiotics,
identifying sacred cows in dermatologic surgery as well as the
appropriate management of bleeding complications and both
common and rare postoperative infections . This session will be
geared toward beginning practitioners and those interested in
incorporating more dermatologic surgery into their practice .
1.50 Category 1 CME Credits
114 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
U040 Military Unique Dermatology
Room: 285
DIRECTOR Chad Hivnor, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Compare and diagnose unusual tropical dermatologic
conditions encountered while providing military humanitarian
mission support .
2 . Diagnose and treat dermatologic conditions from cases
submitted to the Army Medical Department (AMEDD)
teledermatology site (providing remote consultative services
to military treatment facilities lacking direct dermatology
support) .
3 . Summarize the deployed and stateside military dermatologists’
role in serving our nation in support of the ongoing conflict in
Iraq .
DESCRIPTION
Where are your tax dollars going? This session will review multiple
aspects of dermatology within the military . We will discuss
unique approaches to new problems that we have not experienced
with previous conflicts . Fascinating cases seen on humanitarian
missions will be discussed . We will examine the military
dermatologist’s role serving in the deployed wartime environment .
As deployments leave fewer military dermatologists stateside,
teledermatology has been successfully utilized to fill this void, and
we will review unique cases encountered via our store-and-forward
teledermatology program . Finally, we will explore the unique
training needs of a large military dermatology residency program
training a cadre of 21 Army/ Air Force residents .
1.50 Category 1 CME Credits
U041 Uncommon Cutaneous Infections:
Clinical and Histologic Features
Room: 235/236
DIRECTOR Melissa Piliang, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Assess and diagnose uncommon cutaneous infections .
2 . Identify key histologic features of rare cutaneous infections .
DESCRIPTION
With increasing numbers of immunocompromised patients,
cutaneous infections are on the rise . This will be a case-based
discussion demonstrating the clinical and histologic findings of
rare cutaneous parasitic, fungal, and mycobacterial infections . The
focus will be on new and emerging pathogens, especially those
seen in immunocompromised patients . Supportive diagnostic tests
and treatment options will be discussed .
1.50 Category 1 CME Credits
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
7:15 a .m . to 8:45 a .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U042 The Vices of Devices in Dermatology U044 Tumescent Liposuction, Lasers

Room: 263 and New Devices: A State-of-the-Art
DIRECTOR Stacy R. Smith, M.D. Liposuction Practice
Room: 265/266
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to: DIRECTOR Kimberly J. Butterwick, M.D.
1 . Describe the various classes of medical devices and give
LEARNING OBjECTIVES
examples of their use in dermatology .
Following this focus session, the attendee will be able to:
2 . Distinguish the different methods by which medical devices are
1 . Determine how to initiate or enhance a tumescent liposuction
approved for sale by the FDA .
practice .
3 . Compare the quality and quantity of data provided in support
2 . Distinguish and evaluate new technologies for fat removal .
of a device approval against that provided for drugs or biologic
3 . Apply surgical pearls for optimal results and efficacy in a
agents .
liposuction practice .
DESCRIPTION
DESCRIPTION
Attendees will receive an overview of the classification of medical
Tumescent liposuction is one of the dermatologist’s safest and
devices and an in-depth examination of the methods of approval
most effective means of reshaping the body, yet its popularity is
of medical devices in dermatology . The differences in the quantity
waning . New lasers, devices, and even noninvasive techniques
and rigor of data used to approve devices, as opposed to drugs or
are emerging and will likely facilitate the removal of fat and

SATURDAY, FEBRUARY 5
biologic agents, will be compared and contrasted with extensive
revitalize the public’s interest in these procedures . Several new
use of examples in dermatology . At the conclusion of the session,
laser and light devices for fat melting and skin tightening, utilized
attendees will be better prepared to analyze and draw their own
in conjunction with liposuction, will be compared and contrasted .
conclusions about the evidence supporting the claims of devices
Clinical experience with the water-jet device will be reviewed .
used in dermatology .
Early clinical studies of new ultrasonic devices and injectable
1.50 Category 1 CME Credits
solutions are underway and available data will be presented .
1.50 Category 1 CME Credits
U043 Dermatopathology Challenges
Encountered by the Mohs Surgeon
Room: 242
DIRECTOR Zeina S. Tannous, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Differentiate benign and malignant histology on frozen
sections .
2 . Determine when to seek permanent sections .
3 . Describe rare benign and malignant neoplasms for the Mohs
surgeon .
DESCRIPTION
This session will focus on dermatopathology challenges
encountered by the Mohs surgeon . This will be a clinically relevant
course . It will differentiate benign and malignant findings on
frozen sections . It will identify when the assistance of permanent
sections is indicated . Finally, it will describe rare benign and
malignant tumors that may be encountered by the Mohs surgeon .
1.50 Category 1 CME Credits

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 115
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
FOCUS SESSION
7:15 a .m . to 8:45 a .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U045 Non-cultured Epidermal Suspension in
Vitiligo: From Lab to Clinic
Room: 270
DIRECTOR Davinder Parsad, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Use non-cultured epidermal suspension (NCES) in the surgical
management of vitiligo .
2 . Discuss various modifications of NCES technique to achieve
optimum results .
3 . Apply selection criteria for considering patients for NCES
technique .
DESCRIPTION
The choice of surgical intervention should be individualized
according to the type of vitiligo, stability, localization of lesions,
and cost-effectiveness of the procedure . Recently, non-cultured
epidermal suspension (NCES) is emerging as safe and highly
SATURDAY, FEBRUARY 5
effective surgical modality for the treatment of vitiligo .
Selection criteria and newer concepts in stability of vitiligo will
be discussed . Basic principles of preparation of cell suspension
will be demonstrated . Over the years, several modifications have
been made to this procedure in order to make it faster, simpler,
and more effective . These modifications will be discussed with an
emphasis on how to achieve optimum results .
1.50 Category 1 CME Credits
116 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
U046 Social Media and Dermatology:
How Twitter and Facebook Will
Help You and Your Practice
Room: 264
DIRECTOR Jeffrey A. V. Benabio, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Define social media and distinguish among platforms such as
Twitter, Facebook, and MySpace .
2 . Use social media to inform patients, disseminate information,
collaborate with peers, and promote your practice .
3 . Avoid risks of inappropriate communication with patients,
risks of liability, and potential HIPAA violations .
DESCRIPTION
Social media is the use of electronic tools such as Facebook and
Twitter for connecting, sharing, and discussing information . These
new tools have rapidly and widely been adopted by the public .
I will show how proper use of social media can provide benefits
to health providers and to patients at an unparalleled scope . I’ll
demonstrate how improper use of social media can waste time and
can make health providers liable for misconduct or malpractice .
Connecting with patients appropriately can promote a practice
and connecting with peers can improve physicians’ diagnostic and
treatment skills .
1.50 Category 1 CME Credits
U047 Mini - MBA for the Dermatologist
Room: 298/299
DIRECTOR Jeffrey J. Miller, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Identify critical steps for effective team performance .
2 . Develop key steps in the process of change management .
3 . Apply leadership priniciples to enhance your practice .
DESCRIPTION
As dermatologists, we are called to “lead” and “manage” in the
setting of our work relationships . This session introduces key
skills and concepts that will enhance your leadership brand . In
addition, lessons learned during this session can be applied to your
practice setting, whether it’s university-or community-based . Key
concepts will be illustrated through case discussions .
1.50 Category 1 CME Credits
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION FORUM

7:15 a .m . to 8:45 a .m . 9:00 a .m . to 11:00 a .m .
Ticket required for admission, no tuition fee. Ticket holds seat Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time. for only 15 minutes after the official start time.

U048 Challenging Cases in Pediatric F024 Evaluation and Management of

Dermatology Hemangiomas
Room: 269 Room: 388/389/390
DIRECTOR Leah T. Belazarian, M.D. DIRECTOR Julie Powell, M.D.
LEARNING OBjECTIVES SPEAkERS
Following this focus session, the attendee will be able to: Maria Cecilia Garzon, M .D .
1 . Discuss the clinical features of several challenging pediatric Kimberly A . Horii, M .D .
dermatology diagnoses . Amy J . Nopper, M .D .
2 . Identify an appropriate management strategy and treatment
LEARNING OBjECTIVES
plan for these diagnoses .
Following this forum, the attendee will be able to:
DESCRIPTION 1 . Recognize high-risk infantile hemangiomas, identify indications
This focus session is designed for the general dermatologist and for treatment, and select proper treatment modalities .
dermatology resident who wants to gain more confidence with 2 . Differentiate which infantile hemangiomas require further
difficult pediatric dermatology patients . Several challenging cases investigation and which tests to perform, specifically the role
will be covered with regard to differential diagnosis, laboratory of imaging .
testing, dermatopathology, and management . Examples 3 . Discuss the use of systemic therapies for problematic infantile
of diagnoses to be discussed include morphea and infantile hemangiomas and their potential side effects .

SATURDAY, FEBRUARY 5
hemangiomas .
DESCRIPTION
1.50 Category 1 CME Credits
Infantile hemangiomas (IH) are the most common benign tumors
of infancy . Practicing dermatologists and residents should be
aware of potential complications that may require treatment to
prevent significant morbidity and/or mortality . This forum will
focus on the identification, evaluation, and management of high-
risk IH, including an update on PHACE(S) syndrome . The role
of imaging will be presented as well as hemangioma mimickers .
The use of systemic treatments, including corticosteroids,
vincristine, interferon alfa, and beta-blockers, will be reviewed .
The management of ulcerated hemangiomas will also be discussed .
Recent hemangioma literature and research will be highlighted .
2.00 Category 1 CME Credits
SCHEDULE
9:00 a .m . High-Risk Hemangiomas / Dr. Horii
9:30 a .m . Hemangioma Mimickers and the Role Of Imaging
/ Dr. Powell
10:00 a .m . Topical Treatment of IH and Management of
Ulcerated Hemangiomas / Dr. Garzon
10:30 a .m . Systemic Treatment of Infantile Hemangiomas
/ Dr. Nopper

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 117
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
9:00 a .m . to 11:00 a .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F025 Dramatic Oral Disease F026 Chronic Urticaria and Angioedema:

Room: 255/256/257 What’s New in Pathogenesis and
DIRECTOR Roy Steele Rogers III, M.D. Treatment
Room: 278/279/280
LEARNING OBjECTIVES
Following this forum, the attendee will be able to: DIRECTOR Diane Romayne Baker, M.D.
1 . Recognize dramatic oral diseases .
SPEAkERS
2 . Describe the pathogenesis of these dramatic oral diseases .
James Baker, M .D .
3 . Evaluate and manage these dramatic oral diseases .
Nicholas Arthur Soter, M .D .
DESCRIPTION
LEARNING OBjECTIVES
This forum will present a series of dramatic oral diseases .
Following this forum, the attendee will be able to:
Conditions such as orofacial granulomatosis (Melkersson-
1 . Define, recognize, and differentiate patients with acute
Rosenthal syndrome, Miescher’s cheilitis granulomatosa),
urticaria, chronic idiopathic and chronic autoimmune urticaria .
pyostomatitis vegetans, atypical gingivostomatitis, desquamative
2 . Differentiate patients with urticaria with associated angioedema
gingivitis, mucosal variants of lichen planus, and simple and
from patients with C1 esterase deficiency-related angioedema .
complex aphthosis will be discussed . The learner will recognize,
3 . Select appropriate treatments for acute urticaria patients and
understand, and be able to evaluate and manage these dramatic
for chronic urticaria patients not controlled by antihistamines
oral diseases .
and for patients with hereditary angioedema .
SATURDAY, FEBRUARY 5

2.00 Category 1 CME Credits

DESCRIPTION
Antihistamine-resistant chronic urticaria, with or without
angioedema, is a challenging condition for afflicted patients to
live with and for physicians to treat . In this session we will review
acute and chronic urticaria diagnosis and treatment, discuss the
difference between urticaria and angioedema, discuss autoimmune
urticaria as a subset of chronic idiopathic urticaria and provide
an update on diagnosis of and treatments for hereditary and
idiopathic angioedema . A review of the recent literature on
treatments for severe cases of chronic urticaria as well as speakers’
personal experience will be presented .
2.00 Category 1 CME Credits
SCHEDULE
9:00 a .m . Overview of Urticaria and Angioedema: Diagnosis
and Differences, Pathogenesis and Treatment
/ Dr. Baker
9:35 a .m . Urticaria and Angioedema: Treatments Based on
Pathogenetic Mechanisms / Dr. Baker
10:10 a .m . New and Novel Treatment Options for Severe Cases
of Chronic Urticaria / Dr. Soter

118 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
9:00 a .m . to 11:00 a .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F027 Practical Approaches to Patient F028 What You Need to know About Coding
Problems But Were Afraid to Ask
Room: 281/282 Room: 293/294
DIRECTOR Michael P. Heffernan, M.D. DIRECTOR Joseph S. Eastern, M.D.
SPEAkERS SPEAkERS
Grace D . Bandow, M .D . Gary Goldenberg, M .D . James A . Zalla, M .D .
David Berk, M .D . Jeffrey E . Petersen, M .D .
LEARNING OBjECTIVES
Amit Garg, M .D . Matthew Zirwas, M .D .
Following this forum, the attendee will be able to:
LEARNING OBjECTIVES 1 . Complete the coding of insurance claims accurately and
Following this forum, the attendee will be able to: efficiently .
1 . Describe the best treatment options for difficult medical 2 . Determine with improved accuracy the correct alternative
dermatology problems . when multiple coding options are present .
2 . Outline the best approach to problematic surgical cases .
DESCRIPTION
3 . Discuss treatment options for difficult pediatric dermatology
Coding is a necessary evil in the modern practice of medicine . It
problems .
is a skill all physicians and office administrators must master to
DESCRIPTION maximize speedy, fair, and equitable reimbursement for services

SATURDAY, FEBRUARY 5
A panel of medical, surgical, and pediatric dermatologists rendered . In this forum, two members of the AAD Coding and
will discuss their practical approaches to difficult therapeutic Reimbursement Task Force, each with many years of experience
problems . Through the use of an audience-controlled electronic in the process of coding and in dealing with coding issues affecting
input device, forum participants will be able to compare their private practitioners across the country, will discuss difficult coding
impressions anonymously with those of other attendees in real situations and dilemmas . They also will update the audience on the
time . Additionally, audience participation during the discussion latest coding rules and controversies . A substantial portion of the
will be encouraged . allotted time will be reserved for questions from the audience .
2.00 Category 1 CME Credits 2.00 Category 1 CME Credits
SCHEDULE
9:00 a .m . Medical Dermatology / Dr. Zirwas
9:20 a .m . Medical Dermatology/Dermpath / Dr. Bandow
9:40 a .m . Surgical Dermatology / Dr. Petersen
10:00 a .m . Pediatric Dermatology / Dr. Berk
10:20 a .m . Medical Dermatology/Dermpath / Dr. Goldenberg
10:40 a .m . Medical Dermatology / Dr. Garg

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 119
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
9:00 a .m . to 11:00 a .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F029 Acne and Rosacea Update F030 Managing Online Reputation

Room: 295/296 Room: 391
DIRECTOR Julie Claire Harper, M.D. DIRECTOR Clifford Warren Lober, M.D., J.D.
SPEAkERS SPEAkERS
James Q . Del Rosso, D .O . Brenda Jean Dintiman, M .D .
Diane M . Thiboutot, M .D . Steven R . Feldman, M .D ., Ph .D .
Guy F . Webster, M .D ., Ph .D . Kevin C . Smith, M .D .
LEARNING OBjECTIVES LEARNING OBjECTIVES
Following this forum, the attendee will be able to: Following this forum, the attendee will be able to:
1 . Evaluate the role of diet in the development of acne . 1 . Manage his/her online reputation .
2 . Examine the role of benzoyl peroxide in the treatment of acne 2 . Evaluate internet physician rating sites .
and discuss controversies associated with isotretinoin . 3 . Recognize effective means of responding to defamatory
3 . Identify the pathogenesis and treatment of rosacea . comments on the internet .
DESCRIPTION DESCRIPTION
The session will focus on several important issues associated with It is critical that physicians be aware of comments made about
acne and rosacea . First, the potential role of diet in acne will them on internet sites since disparaging comments can be
SATURDAY, FEBRUARY 5

be reviewed in detail . Additionally, the importance of benzoyl posted by disgruntled patients, former employees, competitors,
peroxide in the treatment of acne will be discussed . Controversies ex-spouses, etc . Comments may appear on physician rating sites
surrounding isotretinoin use will be covered including isotretinoin as well as on more generic sites (yellowpages .com, angieslist .com,
and inflammatory bowel disease . Lastly, an update of rosacea etc .) and persist for years . Presenters will include a dermatologist
pathogenesis and treatment will be presented . who has established and maintains a well-known physician
2.00 Category 1 CME Credits rating site . We will examine the legal elements of libel as well
as the defenses raised by persons posting offensive comments .
SCHEDULE
We will then focus on if, when, and how to respond to negative
9:00 a .m . Diet and Acne / Dr. Thiboutot
comments .
9:20 a .m . Questions and Answers / Dr. Thiboutot
2.00 Category 1 CME Credits
9:25 a .m . Isotretinoin Controversies / Dr. Harper
9:45 a .m . Questions and Answers / Dr. Harper SCHEDULE
9:50 a .m . Benzoyl Peroxide / Dr. Del Rosso 9:00 a .m . Introduction / Dr. Lober
10:10 a .m . Questions and Answers / Dr. Del Rosso 9:05 a .m . Slammed on the Internet! / Dr. Dintiman
10:15 a .m . Rosacea Update / Dr. Webster 9:15 a .m . Survey of Internet Sites / Dr. Smith
10:45 a .m . Questions and Answers / Dr. Webster 9:35 a .m . Is the Comment Legally Libel? / Dr. Lober
10:05 a .m . Managing an Internet Rating Site / Dr. Feldman
10:30 a .m . How to Respond to Libel / Dr. Lober
10:45 a .m . Questions and Answers / Faculty

120 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM WORkSHOP
9:00 a .m . to 11:00 a .m . 9:00 a .m . to 11:00 a .m .
Ticket required for admission, no tuition fee. Ticket holds seat Tuition fee and ticket required for admission.
for only 15 minutes after the official start time.

F031 Food Allergy and Dermatology W004 MOC Self-Assessment: Procedural

Room: 252/253/254 M
O Dermatology
C
DIRECTOR Jon M. Hanifin, M.D. Room: 288/289/290

SPEAkERS DIRECTOR Christie Travelute Ammirati, M.D.

James Bergman SPEAkERS
Lawrence Eichenfield, M .D . Elizabeth M . Billingsley, M .D . Summer R . Youker, M .D .
Matthew Fenton, M .D ., Ph .D . Christine Poblete-Lopez, M .D .
LEARNING OBjECTIVES LEARNING OBjECTIVES
Following this forum, the attendee will be able to: Following this workshop, the attendee will be able to:
1 . Recognize the availability of the new NIAID food allergy 1 . Identify the strengths and weaknesses in one’s knowledge base
guidelines . of dermatologic surgery and make improvements as needed .
2 . Differentiate between true food allergy and misapprehensions . 2 . Demonstrate commitment to lifelong learning and
3 . Discuss the indications and limitations of allergy testing . self-assessment via completion of a forum of 25 questions and
DESCRIPTION answers .
The forum will review the development of the 2010 NIAID food DESCRIPTION
allergy guidelines and how they provide a structure for evidence- This session will present 25 questions that cover several subjects

based evaluation and care of possibly affected patients . Emphasis
will focus especially on management of atopic dermatitis and on
counseling of patients and parents who seek diagnosis and testing
for food allergy .
2.00 Category 1 CME Credits
SCHEDULE
9:00 a .m . NIAID Food Allergy Guidelines: Background and
Highlights / Dr. Fenton
10:00 a .m . Controversies in Definition, Assessment, and
Treatment / Dr. Hanifin
10:30 a .m . Food Allergy Testing: Appropriate and Inappropriate
Use / Dr. Bergman
10:30 a .m . Testing / Dr. Eichenfield
SATURDAY, FEBRUARY 5
in dermatologic surgery . The attendee will be able to assess his/her
level of understanding through the questions and explanations of
the correct answers .
2.00 Category 1 CME Credits
SCHEDULE
9:00 a .m . Questions 1 through 5 / Dr. Youker
9:25 a .m . Questions 6 through 10 / Dr. Billingsley
9:50 a .m . Questions 11 through 15 / Dr. Poblete-Lopez
10:15 a .m . Questions 16 through 25 / Dr. Ammirati
* Self-assessment questions utilized in this session are the
same as those used for Forum F086 and Workshop
W001 MOC: Self-Assessment offered at Annual
Meeting 2009 and 2010. Physicians should not
claim CME/MOC credit for attending this session if
they attended Forum F086 and Workshop W001 at
Annual Meeting 2009 and 2010.

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 121
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
9:00 a .m . to 12:00 p .m .
Tuition fee and ticket required for admission.

C06E Basic Self-Assessment of C013 Advanced Botulinum Toxin: Live Patient

Dermatopathology Discussion Demonstration
Room: 243/244/245 Room: Auditorium B
DIRECTOR Clay J. Cockerell, M.D. DIRECTOR Seth L. Matarasso, M.D.
SPEAkERS SPEAkERS
Antoanella Bardan, M .D . Pedram Gerami, M .D . Fredric S . Brandt, M .D . Ronald L . Moy, M .D .
Brook L . Brouha, M .D . Carrie L . Kovarik, M .D . Joel Lee Cohen, M .D . Thomas E . Rohrer, M .D .
Thomas L . Davis, M .D . Scott D . McClellan, M .D . Kyle Coleman, M .D . Nowell J . Solish, M .D .
Rosalie Elenitsas, M .D . Carlos Ricotti Jr ., M .D . William P . Coleman III, M .D . Patricia S . Wexler, M .D .
Steven R . Feldman, M .D ., Ph .D . Mary S . Stone, M .D . Patricia Farris, M .D . Joshua M . Wieder, M .D .
James E . Fitzpatrick, M .D . Kien T . Tran, M .D ., Ph .D . Mary P . Lupo, M .D .
Kyle J . Garton, M .D . LEARNING OBjECTIVES
Following this course, the attendee will be able to:
LEARNING OBjECTIVES
1 . Recognize the various etiologies of rhytids .
Following this course, the attendee will be able to: 2 . Select and formulate the appropriate aesthetic treatment plan
1 . Interpret and identify dermatologic histological diagnoses more with botulinum toxin and/or soft tissue augmentation for
effectively and accurately . patients who present for improvement in facial appearance .
2 . Classify and recognize common histopathologic skin conditions 3 . Identify and manage complications and adverse events of
SATURDAY, FEBRUARY 5

and formulate differential diagnoses . procedures involving injectable materials .

DESCRIPTION
Attendees will view 60 slides from skin biopsy specimens in a
format that will allow self-assessment . Cases will span the full
spectrum of dermatopathology . Each specimen will be discussed
by a faculty member with emphasis placed on establishing the
correct diagnosis and consideration of the differential diagnosis .
These sessions are directed to dermatology residents and practicing
dermatologists .
2.00 Category 1 CME Credits
SCHEDULE
9:00 a .m . Cases 1-5 / Dr. Fitzpatrick
9:15 a .m . Cases 6-10 / Dr. Stone
9:30 a .m . Cases 11-15 / Dr. Brouha
9:45 a .m . Cases 16-20 / Dr. Kovarik
10:00 a .m . Cases 21-25 / Dr. McClellan
10:15 a .m . Cases 26-30 / Dr. Elenitsas
10:30 a .m . Cases 31-35 / Dr. Gerami
10:45 a .m . Cases 36-40 / Dr. Ricotti
11:00 a .m . Cases 41-45 / Dr. Tran
11:15 a .m . Cases 46-50 / Dr. Davis
11:30 a .m . Cases 51-55 / Dr. Garton
11:45 a .m . Cases 56-60 / Dr. Feldman
12:00 p .m . Questions and Answers / Dr. Bardan
Please note: Must be registered for one of the following sessions / Dr. Rohrer
C06A, B, C, or D to attend this session.
122 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
DESCRIPTION
There are many causes of facial wrinkles and a comparable
number of treatment options . This course is designed to identify
the underlying cause of rhytids and distinguish the differences
between photodamage, muscle hypertrophy, and subcutaneous
tissue loss . The indications and technique for the administration of
botulinum toxin in the upper third of the face will be addressed,
and the rationale and selection criteria for the use of fillers to
improve the lower face will be discussed . This session uses a new
format that will attempt to incorporate audience participation and
interaction . It is hoped that practical clinical questions regarding
toxin and fillers can be adequately addressed by the panel .
3.00 Category 1 CME Credits
SCHEDULE
9:00 a .m . Welcome and Introduction / Dr. Matarasso
9:10 a .m . Treating the Upper Third of the Face with Botox
While Maximizing Brow Elevation / Dr. Wieder
9:25 a .m . Complications with Botox in the Upper Third
of the Face and How to Treat Them / Dr. Moy
9:40 a .m . Monotherapy with Botox in the Lower Third
of the Face / Dr. Solish
9:55 a .m . Complications with Botox in the Lower Third
of the Face and How to Treat Them / Dr. Cohen
10:10 a .m . Dysport for Dummies: Everything You Wanted
to Know About Dysport But Were Afraid to Ask
10:25 a .m . Dysport, The NYC Experience: Who, When and
Where Do I Treat / Dr. Wexler
10:50 a .m . Neurotoxins on the Horizon and Their Status
/ Dr. Brandt
11:05 a .m . Live Patient Demonstration with Neurotoxins
/ Dr. Coleman / Dr. Farris / Dr. Lupo
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE Essential Manuals

9:00 a .m . to 12:00 p .m .
Tuition fee and ticket required for admission. for Every
Dermatology Practice
C014 Coding, Documentation, and Practice
Management
Room: Auditorium A
DIRECTOR Charles N. Ellis, M.D. AAD’s 2011 Coding
SPEAkERS and Documentation
Clay J . Cockerell, M .D . Wayne Sotile, Ph .D . Manual: A Guide for
Scott M . Dinehart, M .D . Allan S . Wirtzer, M .D . Dermatology Practices
Jesse M . Kramer, M .D . Mark J . Zalla, M .D . !
Mary Sotile, Ph .D . James A . Zalla, M .D . NEW
LEARNING OBjECTIVES
Following this course, the attendee will be able to: Assists dermatologists and billing staff in
1 . Utilize CPT codes to describe provided professional services submitting accurate claims to improve the
accurately . reimbursement process.
2 . Implement techniques leading to greater efficiencies and
patient satisfaction .
3 . Use strategies to maximize personal accomplishment .

SATURDAY, FEBRUARY 5
DESCRIPTION
This popular session will continue its successful approach to Dermatology
providing the latest updates on proper coding and documentation Employment Manual:
of various types of professional services . Practice management A Guide to Personnel
topics will touch on patient and physician satisfaction, efficiency Policies and Procedures
methods, and dealing with insurers . Two nationally-recognized
speakers will demonstrate how physicians can maximize personal
resiliency and achievement . We will endeavor to make each topic Provides a framework for quickly hiring, training,
practical and useful immediately upon return to work . and managing office staff.
3.00 Category 1 CME Credits
REFERENCES
1 . Derm Coding Consult . Published quarterly by American
Academy of Dermatology .
SCHEDULE
9:00 a .m . Introduction to Course; Achieving the Pinnacle of Office Policy and
Patient Satisfaction / Dr. Ellis Procedure Manual:
9:20 a .m . Improve Your Office Efficiency / Dr. Kramer A Guide for
9:40 a .m . Negotiating with Insurance Carriers / Dr. Zalla Dermatology Practices
10:00 a .m . Coding and Documentation: A Focused Approach
/ Dr. Wirtzer
10:20 a .m . Achieve More by Letting Go of What’s Holding Teaches techniques that strengthen practice
You Back / Mr. Sotile / Mrs. Sotile operations and improve the patient experience.
10:50 a .m . Surgical Coding / Dr. Zalla
11:10 a .m . Dermatopathology Coding / Dr. Cockerell
11:30 a .m . Updates from AAD Coding and Reimbursement
Task Force / Dr. Dinehart Order these manuals and
11:45 a .m . Questions and Answers / Faculty others from the PME Series
at the Academy Resource
Center Booth 3623 today!

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 123
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
9:00 a .m . to 12:00 p .m .
Open admission, no tuition or ticket.

S014 Patient Safety and Quality REFERENCES

Room: 383/384/385 1 . Elston D, Taylor JS, Coldiron B, et al . Patient safety part 1:
Patient safety and the dermatologist . J Amer Acad Dermatol.
DIRECTOR James Selwyn Taylor, M.D. 2009; 61:171-190 .
SPEAkERS 2 . Elston D, Stratman E, Johnson H, et al . Part 2: Opportunities
Jacques Michael Casparian, M .D . Tri H . Nguyen, M .D . for improvement in patient safety . J Am. Acad Dermatol. 2009;
Brett M . Coldiron, M .D . Mark R . Pittelkow, M .D . 61:193-205 .
C . William Hanke, M .D . Robert Swerlick, M .D . 3 . Cao L, Taylor JS, Vidimos AT . Patient safety in dermtology,
Hillary D . Alice C . Watson, M .D . A reveiw of the literature . Dermatol OnLine J . 2010; 16:3 .
Johnson-Jahangir, M .D ., Ph .D . SCHEDULE
LEARNING OBjECTIVES 9:00 a .m . Introduction / Dr. Taylor
Following this symposium, the attendee will be able to: 9:05 a .m . Health Care Quality: What Is It and How Is It
1 . Define patient safety and quality and describe their major Measured? / Dr. Johnson-Jahangir
tenets; and analyze the importance of patient safety and quality 9:25 a .m . Health Care Quality at the Veterans Administration and
metrics for delivering the best dermatological care . Its Relation to Dermatology Practice / Dr. Casparian
2 . Describe the major patient safety issues in dermatology: 9:45 a .m . Do Electronic Medical Records Improve Patient
medication errors, misdiagnosis or delayed diagnosis, pathology Quality and Safety? / Dr. Pittelkow
specimen processing, communication of laboratory or biopsy 10:05 a .m . Sample Medication Dispensing and Quality Care
SATURDAY, FEBRUARY 5

results, wrong-site procedures, patient identification, and / Dr. Watson

supervision of ancillary staff . 10:20 a .m . Patient Safety Issues in Dermatology and Avoiding
3 . Summarize, evaluate and manage adverse events and errors Laboratory Errors / Dr. Swerlick
related to Mohs and office surgery, hygiene and preventive 10:40 a .m . Real-Life Patient Safety Issues in Mohs and Office
strategies for infections and other patient safety measures Surgery / Dr. Nguyen
focused on practice improvement . 11:00 a .m . Office Accreditation and Patient Safety / Dr. Coldiron
11:20 a .m . The Importance of Hand Hygiene in the Office
DESCRIPTION / Dr. Watson
With the growing focus on patient safety and quality throughout 11:40 a .m . Is the Dermatology Office Safe? / Dr. Hanke
medicine, this year’s symposium will discuss both quality and
patient safety . Speakers include national dermatology patient
safety experts who will review health care quality and its metrics;
the approach to quality at the VA, and quality issues related to
electronic medical records and patient medication sampling .
We will also discuss patient safety issues in dermatology offices
emphasizing laboratory errors, a focus on major safety issues in
Mohs and office surgery, office accreditation and patient safety
and the role of proper hand hygiene in preventing infections and
assessing safety and applying specific patient safety principles
in the office . Our goal is to provide you with a practical
understanding of ideas which are easy to implement in your
practice and which are in the best interests of your patients .
3.00 Category 1 CME Credits

124 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
9:00 a .m . to 12:00 p .m .
Open admission, no tuition or ticket.

S015 Advanced Pediatric Dermatology S016 Drug Actions

Room: Auditorium C Room: 260/261/262
DIRECTOR Sheila Fallon Friedlander, M.D. DIRECTOR Bruce Elliot Strober, M.D., Ph.D.
SPEAkERS SPEAkERS
Anna Lee Bruckner, M .D . Denise W . Metry, M .D . Joel M . Gelfand, M .D ., MSCE James G . Krueger, M .D ., Ph .D .
Adelaide A . Hebert, M .D . Amy S . Paller, M .D . Kenneth B . Gordon, M .D . Craig L . Leonardi, M .D .
LEARNING OBjECTIVES LEARNING OBjECTIVES
Following this symposium, the attendee will be able to: Following this symposium, the attendee will be able to:
1 . Apply recent findings in the diagnosis and treatment of 1 . Critically evaluate evidenced-based studies examining the use of
mechanobullous disorders . novel therapeutics for the treatment of cutaneous disease .
2 . Summarize the latest discoveries and therapies for infantile 2 . Summarize the novel mechanisms of action that are related
vascular lesions . to the pathophysiology of inflammatory skin diseases such as
3 . Review pharmacotherapeutic concepts relevant to pediatric psoriasis and atopic dermatitis .
dermatology . 3 . Apply the knowledge of the mechanisms of action of
inflammatory skin diseases to treatment during clinical
DESCRIPTION
practice .
This advanced pediatric dermatology symposium will focus on
DESCRIPTION

SATURDAY, FEBRUARY 5
“state-of-the-art” issues in our specialty . Recent advances and our
understanding of epigenetics and genetic disorders that impact Based on the peer-reviewed literature and recently presented data
on pediatric practice will be reviewed . Mechanobullous disorders of the past year, this symposium will review the pathophysiologic
and pediatric vascular lesions will be discussed . The latest mechanisms of inflammatory disease, with an emphasis on
pharmacotherapeutic findings impacting on pediatric dermatology psoriasis and atopic dermatitis . Novel therapeutic options both in
will be offered, and we will finish with an overview of the state of early development and near FDA approval will be discussed with
our specialty in 2011 . regard to both safety and efficacy .
3.00 Category 1 CME Credits 3.00 Category 1 CME Credits
REFERENCES SCHEDULE
1 . Textbook of Neonatal Dermatology - 2nd Edition 9:00 a .m . Drug Safety / Dr. Gelfand
2 . Hurwitz Clinical Pediatric Dermatology - 3rd Edition 9:30 a .m . New Therapeutic Targets for Inflammatory Skin
3 . Nelson Textbook of Pediatrics - 18th Edition Disease / Dr. Krueger
10:00 a .m . Update on IL-12/23 Inhibition for Psoriasis
SCHEDULE
/ Dr. Leonardi
9:00 a .m . Welcome / Dr. Friedlander
10:30 a .m . Atopic Dermatitis: Update on Basic Science and
9:05 a .m . Update on Mechanobullous Disorders in Children
Therapeutics / Dr. Gordon
/ Dr. Bruckner
11:00 a .m . Biologic Therapy: Controlling Immunogenicity and
9:35 a .m . Vascular Lesions in Children - What Have We
Loss of Response / Dr. Strober
Learned? / Dr. Metry
10:05 a .m . New Pharmacotherapeutic Concepts Impacting on
Pediatric Dermatology / Dr. Hebert
10:35 a .m . Questions and Answers / Faculty
10:45 a .m . The “Genetic Landscape” in Pediatric Dermatology
/ Dr. Paller
11:15 a .m . Pediatric Dermatology: The State of Our Specialty in
2011 / Dr. Friedlander
11:45 a .m . Questions and Answers / Faculty

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 125
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
9:00 a .m . to 12:00 p .m .
Open admission, no tuition or ticket.

S017 Therapeutic Decision Making in S018 Late-Breaking Research

Cutaneous Oncology Room: 386/387
Room: La Nouvelle Orleans Ballroom DIRECTOR Richard L. Gallo, M.D., Ph.D.
DIRECTOR Desiree Ratner, M.D. LEARNING OBjECTIVES
SPEAkERS Following this symposium, the attendee will be able to:
Monica L . Halem, M .D . Seaver Soon, M .D . 1 . Identify recent topics in skin research .
Hillary D . Johnson- Bret Taback, M .D . 2 . Share information to increase progress in the diagnosis and
Jahangir, M .D ., Ph .D . Timothy S . Wang, M .D . therapy of skin disease .
Elizabeth H . Knobler, M .D . Fiona O’Reilly Zwald, M .D . 3 . Identify next steps for research in dermatology .
Deborah MacFarlane, M .D ., M .P .H . DESCRIPTION
LEARNING OBjECTIVES All members of the Academy are invited to submit abstract
Following this symposium, the attendee will be able to: presentations for review for Late-Breaking Research . The Late-
1 . Discuss current and evolving approaches to the evaluation and Breaking Research Session provides an opportunity for a 9-minute
management of patients with challenging skin cancers . presentation . A maximum of 14 abstracts can be accepted for oral
2 . Examine current controversies in the evaluation and presentation and 5-10 alternates . Abstract descriptions are limited
management of patients with melanoma, squamous cell to 150 words .
carcinoma, and angiosarcoma . 3.00 Category 1 CME Credits
SATURDAY, FEBRUARY 5

DESCRIPTION
Current and evolving approaches to the evaluation and
management of challenging skin cancers will be the focus of this
session . Controversial issues in cutaneous oncology will also be
addressed .
2.75 Category 1 CME Credits
SCHEDULE
9:00 a .m . Introduction / Dr. Ratner
9:05 a .m . How Do I Manage a Patient with Basal nevus
Syndrome Who Presents with Tens, if not Hundreds,
of Tumors? / Dr. Halem
9:20 a .m . What Should I do When the Biopsy Says That My
Patient Has Angiosarcoma? / Dr. Wang
9:40 a .m . How Do I Manage a Patient with Eruptive
Keratoacanthomas? / Dr. Soon
9:55 a .m . Should I Even Consider Treating Lentigo Maligna
with Topical Imiquimod? / Dr. Zwald
10:10 a .m . Questions and Answers / Faculty
10:20 a .m . Break / Faculty
10:30 a .m . When Should a Patient with a Melanoma Less Than
1 mm in Depth Be Considered for a Sentinel Lymph
Node Biopsy? / Dr. Taback
10:45 a .m . What Should I do When the Biopsy Report Shows a
Clonal T-cell Proliferation? / Dr. Knobler
11:05 a .m . What Should I Do with a Patient Without a Personal
or Family History of Melanoma Who Presents with
More Than 50 Large Asymmetric Nevi?
/ Dr. Johnson-Jahangir
11:25 a .m . Should I Perform Surgery When the Biopsy Suggests
Squamous Cell Carcinoma and I don’t Believe That
the Patient Has a Malignancy? / Dr. MacFarlane
11:45 a .m . Questions and Answers / Faculty

126 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
9:00 a .m . to 5:00 p .m .
Tuition fee and ticket required for admission.

C015 Internal Medicine C016 Advanced Self-Assessment of

Room: 238/239 Dermatopathology
DIRECTOR Marta J. Petersen, M.D. Room: 275/276/277

SPEAkERS DIRECTOR Anita C. Gilliam, M.D., Ph.D.

Timothy G . Berger, M .D . Joseph C . English III, M .D . SPEAkERS
Jeffrey D . Bernhard, M .D . Warren R . Heymann, M .D . Lyn M . Duncan, M .D . Rishi R . Patel, M .D .
Jean L . Bolognia, M .D . Whitney A . High, M .D . Tammie C . Ferringer, M .D . Ronald P . Rapini, M .D .
Kristina Patrice Callis-Duffin, M .D . Julie V . Schaffer, M .D . Whitney A . High, M .D . John T . Seykora, M .D .
Mark D . P . Davis, M .D . Robert Swerlick, M .D . Kord S . Honda, M .D . Alun R . Wang, M .D .
Dirk Michael Elston, M .D . John Joseph Zone, M .D . Jennifer Madison McNiff, M .D .
LEARNING OBjECTIVES LEARNING OBjECTIVES
Following this course, the attendee will be able to: Following this course, the attendee will be able to:
1 . Diagnose skin conditions with systemic diseases more 1 . Recognize the pathology of 50 cases of challenging skin lesions .
effectively . 2 . Identify the clinical and pathological features of the 50 cases .
2 . Manage patients with skin disease associated with systemic
disease . DESCRIPTION
3 . Appropriately evaluate patients with skin disease and systemic The self-assessment course in dermatopathology is designed to

SATURDAY, FEBRUARY 5
disease . allow participants to test their skills and knowledge . The faculty
is not able to give an all-inclusive review in this session, but they
DESCRIPTION will include the major areas of skin disease with emphasis on the
This course will provide an update on skin manifestations of diagnosis and clinical correlations of some important skin diseases .
systemic disease as well as systemic diseases associated with skin 6.00 Category 1 CME Credits
disease . Skin findings, evaluation and management of patients
with internal diseases including paraproteinemias, inflammatory
bowel disease, thryoid disease, infections, rheumatoid arthritis,
and hypercoagulable states will be discussed . Skin diseases with
associated systemic disease including bullous disease, psoriasis,
calciphylaxis, and pruritus will also be presented . This course is
directed at practicing dermatologists and dermatology residents .
6.00 Category 1 CME Credits
SCHEDULE
9:00 a .m . Introduction / Dr. Petersen
9:05 a .m . Skin Signs of Systemic Disease / Dr. English
9:30 a .m . Paraproteinemias and the Skin / Dr. Bolognia
10:00 a .m . Calciphylaxis / Dr. Davis
10:30 a .m . The Skin and the Thyroid 2011 / Dr. Heymann
11:00 a .m . Pruritus: When Is It More Than Skin Deep?
/ Dr. Bernhard
11:30 a .m . Cutaneous Vasculitis / Dr. Elston
2:00 p .m . Hypercoagulable States and the Skin / Dr. Swerlick
2:30 p .m . Cutaneous Manifestations of Infections / Dr. High
3:00 p .m . Psoriasis and its Co-Morbidities / Dr. Callis-Duffin
3:30 p .m . Systemic Disease Associated with Bullous Diseases
/ Dr. Zone
4:00 p .m . Inflammatory Bowel Disease and the Skin / Dr. Berger
4:30 p .m . Cutaneous Manifestations of Rheumatoid Arthritis
/ Dr. Schaffer

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 127
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
9:00 a .m . to 5:00 p .m .
Tuition fee and ticket required for admission.

C017 Advanced Dermoscopy SCHEDULE

Room: 291/292 9:00 a .m . Subtypes of Melanoma / Dr. Stolz
9:20 a .m . Dermoscopy in The Gray Zone Between Nevus and
DIRECTOR Ralph P. Braun, M.D. Melanoma / Dr. Grichnik
SPEAkERS 9:40 a .m . Vascular Architecture / Dr. Rabinovitz
Giuseppe Argenziano, M .D . Margaret C . Oliviero, NP 10:00 a .m . Dermoscopy of Melanoma and Chrysalis-Like
Horacio Antonio Cabo, M .D . Giovanni Pellacani, M .D . Structures / Dr. Marghoob
James M . Grichnik, M .D ., Ph .D . Susana Puig, M .D . 10:20 a .m . Unknowns for the Experts / Oliviero, NP
Rainer Hofmann-Wellenhof, M .D . Harold S . Rabinovitz, M .D . 10:40 a .m . The Role of Dermatopathology in the Evaluation
Robert H . Johr, M .D . Alon Scope, M .D . of Equivocal Dermoscopic Lesions / Dr. Soyer
Harald Kittler, M .D . H . Peter Soyer, M .D . 11:00 a .m . Pattern Analysis: A New Concept / Dr. Kittler
Joseph Malvehy, M .D . Wilhelm Stolz, M .D . 11:20 a .m . Digital Monitoring of Pigmented Lesions
Ashfaq A . Marghoob, M .D . Steven Q . Wang, M .D . / Dr. Menzies
Scott Menzies, MBBS, Ph .D . Iris Zalaudek, M .D . 11:40 a .m . Challenging Cases For The Audience / Dr. Johr
Nir Nathanson, M .D ., M .H .S . 2:00 p .m . Lesion Selection For Dermoscopy / Dr. Scope
2:15 p .m . Spitz Nevi / Atypical Spitz Nevi / Dr. Pellacani
LEARNING OBjECTIVES 2:30 p .m . Dermoscopy in General Dermatology / Dr. Puig
Following this course, the attendee will be able to: 2:45 p .m . False-Positive and False-Negative Diagnosis
1 . Discuss new, more advanced dermoscopy topics . / Dr. Argenziano
SATURDAY, FEBRUARY 5

2 . Diagnose and manage difficult situations with more 3:10 p .m . Dermoscopic Clues / Dr. Zalaudek
confidence . 3:30 p .m . Unknowns for the experts / Dr. Argenziano
3 . Utilize dermoscopy in practice with more confidence . 3:50 p .m . Nail Pigmentations / Dr. Braun
DESCRIPTION 4:10 p .m . Difficult Acral Lesions / Dr. Hofmann-Wellenhof
This course will cover selected new aspects of dermoscopy at an 4:25 p .m . Difficult Lesions of the Face / Dr. Malvehy
advanced level such as new dermoscopy criteria and false-positive 4:40 p .m . Unkowns for the Experts with Histopathological
or false-negative diagnosis . Lesions in special locations (e .g ., scalp, Correlation / Dr. Malvehy
mucosa, face, acral, nails) will be covered . We recommend that the
participants should be using dermoscopy already and be familiar
with the nomenclature . This session will not cover all aspects of
dermoscopy nor the basic features .
6.00 Category 1 CME Credits
REFERENCES
1 . Braun RP, Rabinovitz HS, Oliviero M, Kopf AW, and .
Saurat JH . Dermoscopy of pigmented skin lesions . J Am Acad
Dermatol . 2005; 52 (1):109-121,
2 . Marghoob AA, Braun RP, and Kopf AW . An Atlas of
Dermoscopy, New York:Taylor Francis; 2005 .
3 . Malvehy J, Puig S, Braun RP, Marghoob AA, Kopf AW .
Handbook of Dermoscopy. New York: Taylor Francis; 2006 .

128 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
12:00 p .m . to 2:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat YOUR WEBSITE
for only 15 minutes after the official start time.
speaks for
F032 Multidisciplinary Preventive Networking
in Occupational Contact Dermatitis YOUR PRACTICE…
Room: 295/296

What is your
DIRECTOR Swen M John, M.D.
SPEAkERS
Stephan Brandenburg, J .D . Howard Ira Maibach, M .D .
D . Linn Holness, M .D .
LEARNING OBjECTIVES
Rosemary L . Nixon, M .D .
website saying?
Following this forum, the attendee will be able to:
1 . Identify cases and describe systematic strategies for the
prevention of occupational skin disease (OSD) .
2 . Assess the socioeconomic burden of OSD and the active role of
dermatology for society .
3 . Distinguish the various pathogeneses of OSD and predict
outcome in individual cases .
DESCRIPTION

SATURDAY, FEBRUARY 5
Occupational skin diseases (OSD) are at the top of occupational
diseases in most industrialized countries and have a huge
socioeconomic impact due to prolonged sick leave and loss of
productivity . In the past years, various concepts to improve OSD 33% off
prevention have been successfully put to practice; the focus is set-up fees
on appropriate diagnostics and therapy and interdisciplinary for AAD
(dermatological/educational) skin protection training programs for members!
high-risk professions, involving clinics and practices . Dermatologists Your website should
by their specific knowledge and competence - in cooperation with
other disciplines - can save their patient’s health and jobs, and thus
communicate your values,
also save expenses for taxpayers and insurance systems . educate your patients and create
2.00 Category 1 CME Credits
your “brand identity” on the Internet.
SCHEDULE
AADDermsOnline.org, the official web
12:05 p .m . Cases from the Coal Face / Dr. Nixon
12:35 p .m . Specialized Patch Testing in Occupational Allergic service provider of the American Academy
Contact Dermatitis / Dr. Holness
of Dermatology, has the tools to ensure you
1:00 p .m . Anti Irritants-Science and Reality-Hope? / Dr. Maibach
1:14 p .m . Evidence-Based Prevention From an Accident have the best web presence possible!
Insurance’s Point of View / Mr. Brandenburg
1:28 p .m . Preventive Networking in Occupational Dermatology:
Future Options for Our Patients and Our Specialty
/ Dr. John

For more information on

AADDermsOnline.org,
visit the Academy Resource
Center Booth 3623!

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 129
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
12:00 p .m . to 2:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F033 Introduction to Oral Dermatology F034 From the Dermatology Rheumatology

Room: 252/253 Clinics: Practical Tips and Advances in
DIRECTOR Ginat W. Mirowski, DMD, M.D. Management
Room: 278/279/280
SPEAkERS Bethanee Jean Schlosser, M .D ., Ph .D .
DIRECTOR Abrar A. Qureshi, M.D., M.P.H.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to: SPEAkERS
1 . Perform an oral examination and diagnose common oral Elizabeth A . Buzney, M .D . Ruth Ann Vleugels, M .D .
conditions effectively . Arturo P . Saavedra- Laura S . Winterfield, M .D .
Lauzon, M .D ., Ph .D .
2 . Develop a therapeutic approach to challenging oral conditions .
3 . Select the proper oral biopsy technique . LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
DESCRIPTION 1 . Develop a combined clinic with physicians from multiple
This forum will review the oral examination and present common specialties working together .
oral lesions, a therapeutic approach to a number of challenging 2 . Evaluate and work-up patients with cutaneous lupus,
oral conditions, and an introduction to performing oral biopsies . dermatomyositis, fibrotic disorders, pyoderma gangrenosum,
2.00 Category 1 CME Credits and psoriasis/psoriatic arthritis in a multidisciplinary
environment .
SCHEDULE 3 . Treat patients with cutaneous lupus, dermatomyositis, fibrotic
SATURDAY, FEBRUARY 5

12:00 p .m . Introduction to the Oral Examination / Dr. Mirowski disorders, pyoderma gangrenosum, and psoriasis/psoriatic
12:30 p .m . Common and Challenging Oral Lesions / Dr. Schlosser arthritis . Case studies from multidisciplinary clinics will be
1:00 p .m . Challenging Oral Conditions / Dr. Mirowski presented .
1:15 p .m . The Oral Biopsy / Dr. Mirowski
DESCRIPTION
This session will include a brief discussion of multidisciplinary
clinic set-up . Approach to the patient with cutaneous lupus,
dermatomyositis, psoriasis/psoriatic arthritis, fibrosing disorders, and
pyoderma gangrenosum, including taking a history and physical
examination, laboratory investigations and therapy, will be covered .
As examples, case studies from our multidisciplinary clinics will be
presented as dermatologists work with other specialties to manage
and assess the patient together, dwelling on the management and
decision-making process . Therapeutic approaches will focus on
case examples to illustrate choice of systemic therapies including
biologics . We will spend time on off-label treatment options and
therapeutic pearls mainly, emphasizing the treatment of skin disease
in patients who also have multiorgan disease .
2.00 Category 1 CME Credits
SCHEDULE
12:00 p .m . What’s New in Cutaneous Lupus Erythematosus
/ Dr. Buzney
12:20 p .m . Multidisciplinary Approach to Musculoskeletal Pain
in Psoriasis: Do’s and Don’t’s / Dr. Qureshi
12:40 p .m . Novel Diagnostic Tools and Therapeutic Advances in
Fibrotic Disorders of the Skin / Dr. Saavedra-Lauzon
1:00 p .m . Dermatomyositis: Dermatology’s Role in a
For more information visit the Multisystem Disease / Dr. Vleugels
1:20 p .m . Pyoderma Gangrenosum: The Perils of Pathergy
Academy Resource Center Booth 3623 / Dr. Winterfield
1:40 p .m . Discussion / Faculty

130 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
12:00 p .m . to 2:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F035 Practical Aspects of Biologic Therapy F036 Careers in Academic Dermatology

Room: 281/282 Room: 255/256/257
DIRECTOR Richard G. B. Langley, M.D. DIRECTOR Michael D. Tharp, M.D.
LEARNING OBjECTIVES SPEAkERS
Following this forum, the attendee will be able to: Daniel H . Kaplan, M .D .
1 . Develop a practical approach to managing patients on biologic Mario E . Lacouture, M .D .
therapies . Sheetal Mehta, M .D .
2 . Select appropriate patients with psoriasis for biologic therapies .
LEARNING OBjECTIVES
DESCRIPTION Following this forum, the attendee will be able to:
This session is a case-based, interactive, practical session involving 1 . Recognize academic career opportunities .
the use of biologic therapies in the treatment of psoriasis . 2 . Differentiate between academic careers and private practice .
Participants will be provided with a keypad to provide anonymous 3 . Identify individuals in dermatology departments/sections as
responses to cases as part of an interactive audience response potential academic career advisors .
system, to facilitate discussion, and for interest . Cases will involve
DESCRIPTION
the appropriate selection of patients, screening, and choosing the
The goal of this session is to provide dermatology residents and
appropriate biologic agent . Practical aspects of managing patients
fellows with an understanding of the opportunities available in
on biologic therapies will include cases involving vaccinations,

SATURDAY, FEBRUARY 5
academic medicine . Financial compensation and benefits as well
pregnancy, infections, and considerations for those undergoing
as lifestyle issues and job satisfaction will be discussed . Ample time
surgery . Additional cases will be addressed depending on the
will be allotted for questions for a panel of young members of
attendee’s interest or based on specific requests .
academic programs .
2.00 Category 1 CME Credits
2.00 Category 1 CME Credits
SCHEDULE
12:00 p .m . Introduction to Choosing an Academic Career in
Dermatology / Dr. Tharp
12:10 p .m . A Career in Surgical Dermatology / Dr. Mehta
12:40 p .m . A Career in Clinical Dermatology / Dr. Lacouture
1:10 p .m . A Career in Investigative Dermatology / Dr. Kaplan
1:40 p .m . Panel Discussion / Faculty

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 131
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
FORUM
12:00 a .m . to 2:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
F037 Pediatric Dermatology: Systemic
Evaluation of Cutaneous Findings in
Infants and Children: What’s New and
What’s True?
Room: 293/294
DIRECTOR Beth Ann Drolet, M.D.
SPEAkERS
Ilona J . Frieden, M .D .
Maria Cecilia Garzon, M .D .
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 . Recognize the distribution and morphology of infantile
hemangiomas that are markers for developmental anomalies
and/or PHACE syndrome .
2 . Differentiate benign facial capillary malformations from those
that may be at risk for Sturge-Weber syndrome, glaucoma, and
SATURDAY, FEBRUARY 5
or other rare syndromes .
3 . Appropriately evaluate congenital midline anomalies of the skin
in infants and children .
DESCRIPTION
Over the last several years there has been an abundance of new
information relating to the evaluation and management of
birthmarks in children . How should dermatologists incorporate
this new information into their practices when caring for children
with common and uncommon diseases? This session will review
recent literature in pediatric dermatology focusing on appropriate
systemic and radiologic evaluation of cutaneous findings . Specific
topics include: vascular tumors and malformations as markers
of systemic disease, congenital melanocytic nevi and risk for
neurocutaneous melanosis, and midline cutaneous abnormalities
and risk for developmental anomalies of the nervous system .
2.00 Category 1 CME Credits
132 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
F038 Itch
Room: 388/389/390
DIRECTOR Gil Yosipovitch, M.D.
SPEAkERS
Jeffrey D . Bernhard, M .D . Amy S . Paller, M .D .
Peter A . Lio, M .D . Tejesh Surenda Patel, M .D .
Toby A . Maurer, M .D . Jacek C Szepietowski, M .D .
Scott A . Norton, M .D ., M .P .H .
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 . Recognize different types of itch .
2 . Describe the pathogenesis of these types of itch .
3 . Evaluate and manage these types of itch .
DESCRIPTION
This forum is designed to highlight a variety of different types
of chronic itch . Expert clinicians will share their experience in
diagnosis and management of neuropathic itch, pediatric itch, itch
in chronic kidney disease, itch in tropical diseases, HIV itch, and
pruritus in oncology patients as well as complementary therapies
for chronic itch . The learner will recognize, understand, and be
able to evaluate and manage these pruritic entities .
2.00 Category 1 CME Credits
SCHEDULE
12:00 p .m . Challenging cases of Neuropathic Itch / Dr. Bernhard
12:00 p .m . Alternative and Complementary Approaches to
Treatment of Chronic Itch / Dr. Lio
12:00 p .m . Challenging Cases of Itch: Tropical Infections
/ Dr. Norton
12:00 p .m . HIV Itch and its Management / Dr. Maurer
12:00 p .m . Challenging Cases of Pediatric Itch / Dr. Paller
12:00 p .m . Itch in Oncology Patients / Dr. Patel
12:00 p .m . Challenging Cases of Uremic Itch and Their
Management / Dr. Szepietowski
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

WORkSHOP DISCUSSION GROUP

12:00 p .m . to 2:00 p .m . 12:15 p .m . to 1:45 p .m .
Tuition fee and ticket required for admission. Tuition fee and ticket required for admission.

W005 MOC Self-Assessment: D009 Educate Your Patients and Improve

M
O
C
Pediatric Dermatology Outcomes
Room: 288/289/290 Room: 240
DIRECTOR Moise L. Levy, M.D. DIRECTOR Karen E. Edison, M.D.
SPEAkERS LEARNING OBjECTIVES
Bernard Cohen, M .D . Following this discussion group, the attendee will be able to:
Teresa S . Wright, M .D . 1 . Recognize the impact of limited health literacy on patients .
Katherine B . Puttgen, M .D . 2 . Utilize existing resources designed to help improve
communication with patients .
LEARNING OBjECTIVES
3 . Apply techniques discussed when caring for patients .
Following this workshop, the attendee will be able to:
1 . Describe the classification of vascular birthmarks . DESCRIPTION
2 . Manage treatment options for vascular birthmarks . The average American reads at a 7th to 8th grade level; those
3 . Examine the evaluation of selected genodermatoses . over age 65, at a 5th to 6th grade level . This session will
present techniques and resources proven to enhance health
DESCRIPTION
communication with patients . These resources will assist the
This session will be of use to dermatologists interested in pediatric/
attendee and the staff to communicate in a way that helps patients
adolescent dermatology . Clinical cases and questions relative to
process and understand information necessary to make good

SATURDAY, FEBRUARY 5
the cases will be presented . An understanding of key references in
health decisions and follow instructions for treatment .
pediatric/adolescent dermatology will be gained by attendees .
1.50 Category 1 CME Credits
2.00 Category 1 CME Credits

* Self-assessment questions utilized in this session are the D010 Recent Advances in Skin Biology and
same as those used for Workshop W002 and W008 Skin Disease
MOC: Self-Assessment offered at Annual Meeting
Room: 241
2010, Summer Meeting 2010. Physicians should not
claim CME/MOC credit for attending this session if DIRECTOR Stephen I. Katz, M.D., Ph.D.
they attended Workshop W002 and W008 at Annual
Meeting 2010 and Summer Meeting 2010. LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 . List innovative ways to manage patients with new or old
therapies .
2 . Identify methods to diagnose easier with new (or old)
information .
3 . Recognize and use available medications for off-label usage .
DESCRIPTION
Attendees are requested to contribute ideas on diagnosis and/or
treatment, both new and old, but preferably innovative .
1.50 Category 1 CME Credits

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 133
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
12:15 p .m . to 1:45 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U049 Avoiding Complications and Maximizing U051 Therapy for Lipodermatosclerosis,

Results in Cutaneous Laser Surgery
Room: 265/266
DIRECTOR Eric F. Bernstein, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Recognize pitfalls in utilizing lasers and other devices on the
skin .
2 . Manage complications of laser surgery .
3 . Optimize parameters for safe and effective laser treatment .
DESCRIPTION
The complications workshop is a comprehensive review of
complications and how to avoid them in laser surgery . With the
advent of so many new lasers, the ability to understand the key
points behind each technology, as well as pitfalls to avoid in using
these technologies, is becoming more and more difficult . Common
pitfalls to avoid will be presented, as well as clues to optimal
SATURDAY, FEBRUARY 5
Venous Ulceration, and Atrophie Blanche
Room: 269
DIRECTOR Jeffrey E. Petersen, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Evaluate lower extremities for venous disease .
2 . Correctly manage lipodermatosclerosis, atrophie blanche, and
venous ulceration .
3 . Outline the surgical management necessary to improve diseases
of the lower extremities .
DESCRIPTION
At the conclusion of the session, the participant should have an
understanding of venous anatomy of the lower extremity and the
associated disease processes . One will have an understanding of
the surgical and medical therapy necessary for curative treatment
or control of the processes . The role of ultrasound in diagnosis will

treatment settings and tips for maximizing results . The science also be reviewed .
behind these devices will be presented in a rudimentary fashion as 1.50 Category 1 CME Credits
it pertains to safe usage of the devices .
1.50 Category 1 CME Credits
U052 Diseases of Male Genitalia
Room: 284
U050 Viral Exanthem Update
DIRECTOR Ali Moiin, M.D.
Room: 274
LEARNING OBjECTIVES
DIRECTOR Carlo Gelmetti, M.D.
Following this focus session, the attendee will be able to:
LEARNING OBjECTIVES 1 . Distinguish between the skin diseases affecting the penis .
Following this focus session, the attendee will be able to: 2 . Discuss treatment of different conditions affecting the penis .
1 . Recognize viral exanthems more effectively .
DESCRIPTION
2 . Differentiate drug exanthems from microbic exanthems .
There will be over 60 diseases and conditions affecting the penis
DESCRIPTION discussed . There will be a quiz given in this session, so please bring
Exanthem is a word given to a widespread rash that is usually a pen and a piece of paper . The treatments of these conditions will
accompanied by systemic symptoms such as fever or malaise . It be reviewed as well . Please share with us if you have an interesting
is usually caused by an infectious condition such as a virus, and case and bring pictures .
represents either a reaction to a toxin produced by the organism 1.50 Category 1 CME Credits
or an immune response . Exanthems may also be due to a drug,
especially antibiotics . Pathogenesis is quite clear only in a few
cases, as in herpes simplex in which the virus can be found in the
lesion . In many other cases pathogenesis can only be suspected
and an antigen-antibody mechanism is supposed .
1.50 Category 1 CME Credits

134 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting


For description of session categories and fees see page 37
FOCUS SESSION
12:15 p .m . to 1:45 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U053 Through the Looking Glass: The Use of
Dermoscopy in the Management of the
Pigmented Lesion Patient
Room: 264
DIRECTOR Mary C. Martini, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Identify melanocytic and nonmelanocytic patterns on
dermoscopy .
2 . Recognize and identify major dermoscopic findings in
melanoma .
3 . Differentiate between benign melanocytic nevi and melanoma .
DESCRIPTION
This 90-minute session will present a wide array of dermoscopy
images of benign and malignant skin lesions . The clinician will be
instructed on a step-by-step approach to dermoscopy . Emphasis
will be on pattern recognition and how to utilize dermoscopy in a
busy clinical practice . Multiple cases that incorporate dermoscopic
images and the corresponding histopathologic diagnoses will be
presented . The attendee should become familiar with the various
benign melanocytic, nonmelanocytic, and melanoma patterns by
the close of the session and will be able to test his/her knowledge
with the final self-assessment slide presentation .
1.50 Category 1 CME Credits
for the lAtest ProgrAm Book informAtion PleAse refer to
SCIENTIFIC SESSIONS
U054 Building Beauty: Understanding Facial
Proportions, Phi, and the Use of
Volumizing Soft Tissue Fillers
Room: 285
DIRECTOR Timothy C. Flynn, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Analyze the face using principles of mathematical proportions
in order to make faces more attractive .
2 . Identify new methods of re-volumizing faces using soft tissue
fillers to restore a youthful appearance .
3 . Identify specific deep areas of the face amenable to treatment .
DESCRIPTION
Understanding facial proportions is key to working in the aesthetic
field . Key aspects of beauty that must be understood are balance,
symmetry, and harmony . The Greeks used the concept of the golden
proportion . We now understand that proper relationships and curves
SATURDAY, FEBRUARY 5
are essential to producing a more attractive appearance . Youthful faces
have increased volume, making it different than the aging face . This
talk will analyze facial proportions from a classic as well as medical
perspective . Volume restoration techniques will be taught using soft
tissue fillers .
1.50 Category 1 CME Credits
U055 Practical Approaches to Cosmeceuticals
Room: 267/268
DIRECTOR Ellen S. Marmur, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Describe the theoretical routes of penetration for topical
cosmeceuticals through the epidermis .
2 . Assess the available clinical trials that support cosmeceutical
effects .
3 . Formulate an informed approach to patient’s questions about
cosmeceuticals .
DESCRIPTION
In this new age of cosmeceuticals, creative marketing seems
to promise amazing anti-aging effects . Patients are hopeful
yet overwhelmed with choices and look for guidance from
the dermatologist . This session will serve as an update on the
chemistry of cosmeceuticals and on the latest evidence-based
medicine that may support their use .
1.50 Category 1 CME Credits
www.aad.org | 135
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
FOCUS SESSION
12:15 p .m . to 1:45 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U056 Recommended Screening Practices in
Medical Dermatology
Room: 270
DIRECTOR Nicole Fett, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Recognize the subsets of patients with autoimmune connective
tissue disease at risk for interstitial lung disease and implement
screening .
2 . Assess the risk of corticosteroid-induced osteoporosis in medical
dermatology patients and implement a prevention plan .
3 . Recognize the subsets of patients with autoimmune connective
disease who are at increased risk of malignancy .
DESCRIPTION
This session is directed to general and medical dermatologists
and those in training for these positions . This session will review
the literature pertaining to screening for systemic involvement in
SATURDAY, FEBRUARY 5
patients with cutaneous manifestations of autoimmune disease .
Based on the evidence in the literature, and standard practice
when the literature is lacking, recommendations for screening
tests and frequency of screening will be reviewed . The session will
specifically focus on screening in patients with cutaneous lupus
erythematosus, dermatomyositis, morphea, and systemic sclerosis .
1.50 Category 1 CME Credits
U057 Procedural Safety in Dermatology
Room: 283
DIRECTOR Jacob Levitt, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Identify areas of highest risk for injury in dermatological
practice .
2 . Identify ways to minimize risk for injury in dermatological
practice .
3 . Discuss personal experience with injuries and/or best safety
practices amongst the audience .
DESCRIPTION
We will review the results of a survey to dermatology residents
regarding their experience with injury, emphasizing the situations
in which residents appear to be most injury prone . We will
discuss best practices for safe technique, including demonstrations
of safe and unsafe technique . We hope the audience will share
their experience with injury and ways they have discovered to
avoid them .
1.50 Category 1 CME Credit
136 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
U058 From Stem to Skin: Precursor Cells That
Have a Lot of Potential
Room: 235/236
DIRECTOR Jennifer Y. Lin, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Demonstrate understanding of basic definition and biology of
keratinocyte/melanocyte stem cells .
2 . Identify the role of stem cells in cutaneous processes including
wound healing, hair regeneration, and cancer .
3 . Formulate ideas for the role of dermatology in future stem cell
therapeutics .
DESCRIPTION
Stem cells are at the forefront of translational medicine as an
opportunity to regenerate organs and fix genetic diseases . The skin
is a rich source of stem cells and an understanding of their biology
will help clinical dermatologists understand common processes
such as wound healing, hair regeneration, and cancer . This session
is directed towards clinicians and residents who seek to reach a
comfort level with the concept of stem cells and the numerous
clinical implications . We will focus on precursor cells of the
epidermis and their role in skin disorders . Emphasis will also be
placed on therapeutics on the horizon .
1.50 Category 1 CME Credits
U059 Potpourri of CPC
Room: 242
DIRECTOR Jacqueline M. Junkins-Hopkins, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Recognize the limitations of histopathologic diagnosis
without clinical pathologic correlation in diagnosing certain
dermatologic disorders .
2 . Identify dermatologic conditions that may be associated with
systemic disease .
3 . List some conditions that require clinical-pathologic correlation
to make a diagnosis .
DESCRIPTION
The clinical and histopathologic diagnosis of dermatologic
conditions can be challenging, especially since several entities
have overlapping or nonspecific features . Clinical-pathologic
correlation is often critical in this situation . In this session, there
will be several interesting cases presented in which either the
clinical or the histopathologic features contributed to making the
diagnosis . The director is a dermatologist and dermatopathologist,
so the discussion and content will focus on both clinical and
histopathologic aspects of the disorders . Audience participation in
the discussion is encouraged .
1.50 Category 1 CME Credit
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION COURSE

12:15 p .m . to 1:45 p .m . 2:00 p .m . to 5:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat Tuition fee and ticket required for admission.
for only 15 minutes after the official start time.

U060 Stress, the Nervous System, C018 Dermatologic Drug Safety and Efficacy
and Cutaneous Immunity Room: 386/387
Room: 263 DIRECTOR Jeffrey Phillip Callen, M.D.
DIRECTOR Richard D. Granstein, M.D. SPEAkERS
LEARNING OBjECTIVES Boni E . Elewski, M .D . Mark Lebwohl, M .D .
Following this focus session, the attendee will be able to: Dirk Michael Elston, M .D . Cindy Owen, M .D .
1 . Summarize evidence that the nervous system can regulate David Franklin Fiorentino, M .D ., Ph .D . Neil H . Shear, M .D .
cutaneous immunity . Kenneth B . Gordon, M .D . Kenneth Saag,
2 . Evaluate data that stress can affect immunity and inflammation J . Mark Jackson, M .D M .D ., M .S .C .E .
in the skin . LEARNING OBjECTIVES
3 . Discuss the possibility that stress and nervous system influences Following this course, the attendee will be able to:
may impact inflammatory skin disorders . 1 . Identify safety issues for systemic therapies routinely used to
DESCRIPTION treat dermatologic disease .
This session will review recent work demonstrating that 2 . Describe the efficacy of systemic therapies for skin disease .
the nervous system and stress can influence immunity and 3 . Manage patients with dermatologic disease on systemic
inflammation in the skin . The results of studies suggesting that therapies .
products of nerves can influence immunity against chemical DESCRIPTION

haptens as well as malignant tumors will be presented . Evidence
that chronic stress can modulate antitumor immunity will be
discussed . There will be an emphasis on experimental results with
clinical implications . Discussion with participation of all attendees
will be encouraged .
1.50 Category 1 CME Credits
SATURDAY, FEBRUARY 5
Systemic drugs are often used to treat patients with skin disease .
Inherent with their use are potential toxicities . This session will
familiarize the attendee with the indications for use, the selection
of the appropriate patient and the monitoring for toxicity that
should be carried out on treated patients .
3.00 Category 1 CME Credits
REFERENCES
1 . Wolverton SE . Comprehensive Dermatological Drug Therapy .
2nd ed . Philadelphia: Elsevier; 2007 .
2 . Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I .
Treatment of Skin Disease . 3rd ed . Philadelphia: Elsevier; 2010 .
3 . Callen JP, Jorizzo JL, Bolognia JL, Piette WW, Zone JJ .
Dermatological Signs of Internal Disease . 4th ed . Philadelphia:
Elsevier; 2009 .
SCHEDULE
2:00 p .m . Introduction / Dr. Callen
2:05 p .m . Tumor Necrosis Factor-Alpha Antagonists: Long-
Term Safety and Efficacy / Dr. Gordon
2:25 p .m . Methotrexate / Dr. Fiorentino
2:45 p .m . Azathioprine / Dr. Shear
3:05 p .m . Mycophenolate Mofetil / Dr. Jackson
3:20 p .m . Bisphosphonate Therapy: What the Dermatologist
Needs to Know / Dr. Saag
3:40 p .m . Isotretinoin / Dr. Owen
4:00 p .m . Systemic Antifungal Therapies / Dr. Elewski
4:20 p .m . Anti-IL 12/23 / Dr. Lebwohl
4:40 p .m . Antibiotic Therapy / Dr. Elston

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 137
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
2:00 p .m . to 5:00 p .m .
Tuition fee and ticket required for admission.

C019 Hair and Nails SCHEDULE

Room: 243/244/245 2:00 p .m . Introduction / Dr. McMichael
2:05 p .m . Diagnosis and Medical Treatment of Nail Disorders
DIRECTOR Amy J. McMichael, M.D. / Dr. Tosti
SPEAkERS 2:25 p .m . Dermatopathologic Diagnosis of the Nail Unit
Ulrike Blume-Peytavi, M .D . William Millard Parsley, M .D . / Dr. Thompson
Robert S . Haber, M .D . Leonard C . Sperling, M .D . 2:45 p .m . Surgical Management of the Nail Unit / Dr. Miller
Maria K . Hordinsky, M .D . Curtis T . Thompson, M .D . 3:05 p .m . Questions and Answers / Faculty
Christopher James Miller, M .D . Antonella Tosti, M .D . 3:15 p .m . Female Pattern Hair Loss: Diagnostic Office Tools
Nina Otberg, M .D . and Therapeutic Updates / Dr. Blume-Peytavi
3:55 p .m . Alopecia Areata: Updates in Diagnosis and Therapy
LEARNING OBjECTIVES / Dr. Hordinsky
Following this course, the attendee will be able to: 4:15 p .m . Scarring Alopecia: Focus on African American Patients
1 . Diagnose hair, scalp, and nail diseases more effectively / Dr. McMichael
with emphasis on new data for common disorders and 4:30 p .m . Dermatopathologic Diagnosis of Alopecia / Dr. Sperling
dermatopathologic-clinical correlation . 4:35 p .m . Surgical Management of Alopecia / Dr. Parsley
2 . Manage the patient with hair loss and nail disorders using 4:50 p .m . Questions and Answers / Faculty
therapeutic ladders of medical and surgical treatment .
3 . Demonstrate optimal selection and processing of biopsy
SATURDAY, FEBRUARY 5

specimens for the diagnosis of hair and scalp disorders .

DESCRIPTION
Hair and nail unit disorders can be difficult to diagnose, both
clinically and pathologically . This course will review the most
commonly encountered hair and nail disorders in both medical
and surgical dermatology . Recent advances in nonscarring
and scarring alopecia research and treatment will be discussed .
Differences in treatment for patients of color will be presented .
Advances in hair restoration/transplantation will be discussed .
Dermatopathology of both inflammatory and neoplastic disorders
of the nail unit and scalp will be discussed, with emphasis on
updates . This course will be helpful for dermatopathologists and
dermatologists who manage hair and nail unit disorders .
3.00 Category 1 CME Credits
REFERENCES
1 . McMichael AJ, Hordinsky M, eds . Hair and Scalp Diseases:
Medical, Surgical, and Cosmetic Treatments . Informa
Healthcare, 2008 .
2 . Scher RK, Daniel III CR, eds . Nails: Diagnosis, Therapy,
Surgery. 3rd ed . Philadelphia:WB Saunders; 2005 .
3 . Sperling L . An Atlas of Hair Pathology with Clinical
Correlations . Boca Raton, Fl: CRC Press, 2003 .

138 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE SYMPOSIUM
2:00 p .m . to 5:00 p .m . 2:00 p .m . to 5:00 p .m .
Tuition fee and ticket required for admission. Open admission, no tuition or ticket.

C020 Live Patient Demonstrations: Application S019 Rheumatologic Dermatology

of Our Aesthetic Toolbox for the Room: 260/261/262
Treatment of Medical and Dermatologic DIRECTOR Jan P. Dutz, M.D.
Disorders SPEAkERS
Room: Auditorium B Stefan Beissert, M .D . Heidi Tewich Jacobe, M .D .
DIRECTOR Susan H. Weinkle, M.D. M . Kari Connolly, M .D . Julie V . Schaffer, M .D .
David Franklin Fiorentino, M .D ., Ph .D . Victoria P . Werth, M .D .
SPEAkERS Christopher B . Hansen, M .D .
Harold Joseph Brody, M .D . David J . Goldberg, M .D ., J .D .
Jean D .A . Carruthers, M .D . Marina Landau, M .D . LEARNING OBjECTIVES
William P . Coleman III, M .D . Naomi Lawrence, M .D . Following this symposium, the attendee will be able to:
Lisa M . Donofrio, M .D . Mary P . Lupo, M .D . 1 . Recognize common and uncommon cutaneous manifestations
Patricia Farris, M .D . Gary D . Monheit, M .D . of rheumatic disease .
Rebecca L . Fitzgerald, M .D . Rhoda S . Narins, M .D . 2 . Utilize standardized assessment tools to evaluate disease damage
Timothy C . Flynn, M .D . Robert J . Weiss, M .D . and actvitiy .
Dee Anna Glaser, M .D . 3 . Develop treatment plans for these conditions based upon best
available evidence .
LEARNING OBjECTIVES
DESCRIPTION

Following this course, the attendee will be able to:
1 . Evaluate medical and dermatologic disorders and select the
most beneficial treatment .
2 . Develop techniques to maximize patient satisfaction .
3 . Develop methods to avoid surgical complications .
DESCRIPTION
This three-hour live demonstration will include patient evaluation,
treatment options, and a discussion of possible complications .
There will be interactive discussion between the treating physician
and the consulting physician . The experienced team of treating
physicians is multi-disciplinary, including two plastic surgeons .
Audience participation and interaction will be welcomed .
3.00 Category 1 CME Credits
SATURDAY, FEBRUARY 5
Cutaneous abnormalities can be early clues to significant systemic
disease . Rheumatic diseases in particular can present with subtle
and not-so-subtle findings on examination of the skin . Patients do
not present to their physician with a diagnosis of connective tissue
disease, but rather an often localized lesion or complaint related
to the skin . Early diagnosis may prevent significant morbidity . In
this session, the speakers will discuss their approach to patients
with rheumatic skin disease . They will share tips to help clinicians
recognize rheumatic skin disease promptly, and to assess disease
severity . They will also present rationales for current and new
treatments of these challenging conditions .
3.00 Category 1 CME Credits

SCHEDULE
2:00 p .m . Introduction / Dr. Weinkle
2:15 p .m . The Atrophic Face / Dr. Fitzgerald / Dr. Narins
2:25 p .m . Disorders of the Periorbital Region / Dr. Donofrio 2:50 p .m . How I Treat cutaneous Lupus / Dr. Dutz
/ Dr. Carruthers
2:45 p .m . Acne Scarring / Dr. Flynn / Dr. Monheit
3:05 p .m . Angular Chelitis and the Lateral Lip Festoon
/ Dr. Farris / Dr. Goldberg
3:25 p .m . Chemical Peels for Actinic Keratosis
/ Dr. Lawrence / Dr. Brody
3:45 p .m . Effective Utilization of Sclerotherapy
/ Dr. Lupo / Dr. Weiss
4:05 p .m . The Atrophic Actinic Hand / Dr. Flynn / Dr. Landau
4:25 p .m . Innovative Applications for Treatment with
Botulinum Toxin / Dr. Coleman / Dr. Glaser
4:45 p .m . Gummy Smile / Dr. Weinkle
4:50 p .m . Questions and Answers / Faculty
SCHEDULE
2:05 p .m . Morphea – How I Treat it / Dr. Jacobe
2:25 p .m . How I Approach Scleroderma / Dr. Connolly
3:10 p .m . How I Manage Dermatomyositis / Dr. Fiorentino
3:35 p .m . Measuring Disease Severity and Impact in
Rheumatologic Dermatology / Dr. Werth
3:55 p .m . How I Manage Vasculitis / Dr. Beissert
4:20 p .m . Cutaneous Features of Rheumatoid Arthritis
/ Dr. Schaffer
4:40 p .m . Drug-Induced Cutaneous Connective Tissue Disease
/ Dr. Hansen

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 139
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
2:00 p .m . to 5:00 p .m .
Open admission, no tuition or ticket.

S020 Birthmarks DESCRIPTION

Room: 383/384/385 Is that a worrisome birthmark? Do you know the ones that
progress, regress, or become malignant? Is it just a normal variant?
DIRECTOR Tor A. Shwayder, M.D. When should an MRI be performed? Is that child destined to be
developmentally delayed? Should a genetic counselor be called?
SPEAkERS Come with me on a journey of most major and minor birthmarks,
Anita N . Haggstrom, M .D . Crystal Pourciau, M .D . and learn how to answer those questions .
Moise L . Levy, M .D . Dakara A . Rucker Wright, M .D . Topics to be covered:
Ashfaq A . Marghoob, M .D . Sheryll L . Vanderhooft, M .D . aplasia cutis congenital;
Denise W . Metry, M .D . Lisa Xu, M .D . café au lait macules;
congenital nevi;
LEARNING OBjECTIVES
epidermal nevi, nevus sebaceous and the epidermal nevus syndromes;
Following this symposium, the attendee will be able to: hemangiomas and segmental hemangiomas;
1 . Recognize different outcomes for growth-type hemangiomas hypo-and hyperpigmented swirls and blotches and light spots;
and vascular malformations . port-wine stains .
2 . Distinguish benign from worrisome birthmarks and their 3.00 Category 1 CME Credits
underlying systemic associations .
SCHEDULE
3 . Predict the correct percentage of patients with these
2:00 p .m . Hemangiomas / Dr. Haggstrom
associations to better counsel the patient/parents .
2:30 p .m . Segmental Hemangiomas / Dr. Metry
2:55 p .m . Port-Wine Stains / Dr. Rucker Wright
SATURDAY, FEBRUARY 5

3:15 p .m . Aplasia Cutis Congenita / Dr. Pourciau

3:25 p .m . Cafe au Lait Macules / Dr. Xu
3:35 p .m . Hypo-and Hyperpigmented Swirls and Blotches
/ Dr. Vanderhooft
3:45 p .m . Congenital Nevi / Dr. Marghoob
4:30 p .m . Ash-Leaf Spot and Nevus Depigmentosus
/ Dr. Vanderhooft
4:40 p .m . Nevus Sebaceous, Epidermal Nevi, and Epidermal
Nevus Syndromes / Dr. Levy

Don’t Take Chances

When You Travel...
The AAD is pleased to offer you the MedjetAssist program, a leader in both domestic and international emergency
medical evacuations.

A MedjetAssist membership includes:

• Medical transportation to the hospital of your choice
at no cost when traveling more than 150 miles
(Domestic and International) from your primary
residence
• Emergency physician consultation (24 hours a day,
7 days a week)
• Worldwide medical and legal referrals
• Monitoring of medical condition and emergency
message relay
• Translation assistance of foreign medical reports
• Travel intelligence and security information

Stop by the Academy Resource Center Booth 3623 for more information!

140 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
2:00 p .m . to 5:00 p .m .
Open admission, no tuition or ticket.

S021 Skin of Color SCHEDULE

Room: Auditorium A 2:00 p .m . Introduction / Dr. Gathers
2:05 p .m . Management of Common Disorders in Skin of Color
DIRECTOR Raechele Cochran Gathers, M.D. Patients / Dr. Alexis
SPEAkERS 2:25 p .m . Successfully Treating your Patients with
Andrew F . Alexis, M .D . Iltefat H . Hamzavi, M .D . Hyperpigmentation / Dr. Pandya
Eliot Franklin Battle, M .D . Valerie M . Harvey, M .D . 2:40 p .m . Hair Loss and African American Women / Dr. Gathers
Valerie D . Callender, M .D . Roopal Vashi Kundu, M .D . 2:55 p .m . Vitiligo: Perspectives from the Cutting Edge
Mona Amira Gohara, M .D . Amit G . Pandya, M .D . / Dr. Hamzavi
3:10 p .m . Approaching Skin of Color: The Asian and Hispanic
LEARNING OBjECTIVES Perspective / Dr. Kundu
Following this symposium, the attendee will be able to: 3:25 p .m . Questions and Answers / Faculty
1 . Recognize the most common skin and hair conditions 3:40 p .m . Skin Cancer and Skin of Color / Dr. Gohara
encountered among skin of color patients . 3:55 p .m . Vitamin D and Skin of Color / Dr. Harvey
2 . Examine diverse cultural practices in skin of color patients and 4:10 p .m . Peels, Botulinum Toxin and Fillers in Skin Of Color
develop culturally competent therapeutic and management / Dr. Callender
strategies . 4:25 p .m . Lasers in Skin of Color / Dr. Battle
3 . Identify cosmetic protocols and challenges in skin of color 4:45 p .m . Questions and Answers / Faculty
patients .

SATURDAY, FEBRUARY 5
DESCRIPTION
The prevalence of individuals with skin of color is rapidly
increasing in both the United States and around the globe . In
addition to the unique dermatologic conditions encountered in
skin of color, the presentation and response to management of
common disorders may differ in individuals with darker skin hues .
This symposium will discuss diverse cultural practices among skin
of color patients and review common disorders, including keloids,
acne, post-inflammatory hyperpigmentation, pseudofolliculitis
barbae, alopecias, and vitiligo . Skin cancer in skin of color will be
addressed, and common cosmetic protocols and pitfalls for skin of
color will be examined .
3.00 Category 1 CME Credits
REFERENCES
1 . Kelly AP, Taylor SC . Dermatology for Skin of Color . New York,
McGraw-Hill; 2009 .

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 141
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
2:00 p .m . to 5:00 p .m .
Open admission, no tuition or ticket.

S022 Acne and Rosacea SCHEDULE

Room: La Nouvelle Orleans Ballroom 2:00 p .m . Introduction / Dr. Zaenglein
2:05 p .m . The Latest From the Lab: An Update on the
DIRECTOR Andrea L. Zaenglein, M.D. Pathogenesis of Acne / Dr. Kim
SPEAkERS 2:20 p .m . Rosacea: Theories on Pathogenesis and Treatment
James Q . Del Rosso, D .O . Lisa E . Maier, M .D . Implications / Dr. Maier
Emmy M . Graber, M .D . Diane M . Thiboutot, M .D . 2:35 p .m . Difficult Rosacea Cases: What to Do? / Dr. Webster
Jonette Elizabeth Keri, M .D ., Ph .D . Vicente Torres, M .D . 2:50 p .m . Difficult Acne Cases and What I Learned From Them
Jenny J . Kim, M .D ., Ph .D . Guy F . Webster, M .D ., Ph .D . / Dr. Zaenglein
James Joseph Leyden, M .D . 3:05 p .m . Treating Acne and Rosacea: A Latin Perspective
/ Dr. Torres
LEARNING OBjECTIVES 3:20 p .m . Questions and Answers / Faculty
Following this symposium, the attendee will be able to: 3:35 p .m . Facing Up to Acne and Rosacea: A Status Report
1 . Discuss the pathogenesis of acne and rosacea and how it / Dr. Del Rosso
influences management of these conditions . 3:50 p .m . Use of Isotretinoin in Acne and Rosacea / Dr. Thiboutot
2 . Use acne and rosacea therapies, both old and new, safely and 4:05 p .m . The Role of Lasers in Acne and Acne Scarring
effectively in patients . / Dr. Graber
3 . Identify difficult acne and rosacea cases and formulate an 4:20 p .m . When and How to Use Hormonal Treatments in
appropriate treatment plan . Acne / Dr. Keri
SATURDAY, FEBRUARY 5

DESCRIPTION 4:35 p .m . Antibiotic Dosing in Acne and Rosacea: Factors That

This year’s Acne and Rosacea Symposium will update attendees Influence Outcomes / Dr. Leyden
on what is new in the diagnosis and management of these 4:50 p .m . Questions and Answers / Faculty
disorders . Expert panelists will highlight the latest advances in
the understanding of pathogenesis and how this relates to our
treament plan . Problematic cases will be presented to aid the
attendee in troubleshooting difficult patients . Additionally, a Latin
American perspective on acne and rosacea will be given . Therapies
will be discussed in detail, covering the important issues of
antibiotic resistance, safe use of isotretinoin, the role of lasers, and
an update on what’s new in therapy .
3.00 Category 1 CME Credits

142 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
2:00 p .m . to 5:00 p .m .
Open admission, no tuition or ticket.

S023 Teledermatology SCHEDULE

Room: Auditorium C 2:00 p .m . Teledermatology as CME for Primary Care Providers
in Remote Areas / Dr. Colven
DIRECTOR Roy Mitchell Colven, M.D. 2:30 p .m . A Novel Approach to Outreach Using
Teledermatology / Dr. Kovarik
SPEAkERS
3:00 p .m . Evaluating Residents Through Their Teledermatology
Anne E . Burdick, M .D ., M .P .H . William D . James, M .D .
Participation / Dr. Burdick / Dr. Pak
Jonathan A . Dyer, M .D . Carrie L . Kovarik, M .D .
3:40 p .m . Use of Teledermatology as a Soft Power in Iraq and
Jeffrey Scott Henning, D .O . Hon S . Pak, M .D .
Afghanistan / Dr. Henning
LEARNING OBjECTIVES 4:30 p .m . Teledermatology to Manage Ichthyosis (Partnership
Following this symposium, the attendee will be able to: with FIRST) / Dr. Dyer
1 . Examine how online, case-based education in dermatology for 4:00 p .m . Teledermatology: AAD Initiative to Expand
non-dermatologists can improve skin disease care in remote Volunteerism / Dr. James
regions of the United States and abroad .
2 . Use teledermatology to help assess residents’ competence in
patient care, medical knowledge, communication, and systems-
based practice .
3 . Describe how teledermatology can be leveraged to serve
underserved populations in the United States and globally .
DESCRIPTION

SATURDAY, FEBRUARY 5
The ability of dermatologists to reach patients and educate
providers in remote and underserved settings has expanded in
recent years with increasingly affordable technologies . Through
the discussion of cases from all over the world, we will show how
teledermatology has been successfully used as a tool to support
humanitarian missions abroad and to allow dermatologists in
underserved areas to reach more patients . We will also illustrate
that teledermatology is a novel tool for evaluating trainees’
competence in communication skills, patient care, medical
knowledge specific to dermatology, and systems-based practice for
dermatology residents and referring providers .
3.00 Category 1 CME Credits
REFERENCES
1 . Krupinski E, Burdick A, Pak H, Bocachica J, Earles L, Edison
K, et al . American Telemedicine Association’s practice
guidelines for teledermatology . Telemed J E Health . 2008
Apr;14:289-302 .
2 . Burdick AE . Teledermatology: extending specialty care beyond
borders . Arch Dermatol . 2007 Dec;143:1581-1582 .

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 143
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
DISCUSSION GROUP
2:30 p .m . to 4:00 p .m .
Tuition fee and ticket required for admission.
D011 Women With Hair Loss
Room: 240
DIRECTOR Lynn Annette Drake, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 . Determine the cause of the hair loss in some cases, often in a
short time .
2 . Diagnose and categorize hair loss in women more effectively .
3 . Treat hair loss appropriately .
DESCRIPTION
Women with diffuse hair thinning often can have a significant
underlying cause . The physician frequently must be a detective .
This session will identify seven key areas that the physician can
explore to determine the possible underlying causes of hair
thinning, many of which may be serious diseases . Methods to
do this in a timely manner (15-minute office workup) will be
discussed . Finally, methods of treatment related to the underlying
etiology will be identified .
SATURDAY, FEBRUARY 5
1.50 Category 1 CME Credits
D012 Aging Skin: Mechanism-Based
Rejuvenation
Room: 241
DIRECTOR John James Voorhees, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 . Recognize premature aging on face and arms as especially
severe due to the simultaneous presence of both natural aging
and photoaging .
2 . Describe mechanisms whereby collagen deficiency, collapsed
fibroblasts, and excess free radicals are key features of both
aging and photoaging .
3 . Explain how to prevent or rejuvenate aging skin based on
mechanisms identified as key to the process of skin aging .
DESCRIPTION
We now understand that loss of mechanical tension, leading to
collapsed fibroblasts, is at the heart of the aging process . The
collapse causes excess free radicals, which turn on collagen
breakdown and turn off new collagen formation . How to use
this new information to prevent/rejuvenate aging skin will be
highlighted . We have learned that loss of skin collagen during
aging surprisingly is not due to irreversible damage to fibroblasts,
as one might have expected . Rather, when the aged fibroblasts are
removed from dermis, they make normal quantities of collagen .
This raises the hope that one can find ways to cause fibroblasts to
make collagen in skin without removing them . One example to
be presented is injectable fillers, which perform in this fashion,
causing collagen to accumulate .
1.50 Category 1 CME Credits
144 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
FOCUS SESSION
2:30 p .m . to 4:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U061 Calciphylaxis
Room: 242
DIRECTOR John Charles Hall, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Examine and define the syndrome of calciphylaxis and its
consequences .
2 . Distinguish who is a candidate to develop calciphylaxis .
3 . Identify the treatment of calciphylaxis .
DESCRIPTION
This is a relatively new disease of skin and subcutaneous necrosis
that occurs mainly in patients with renal disease . A few exceptions
will be discussed . The pitfalls in making the correct diagnosis
and the differential diagnosis will be reviewed . The many reports
of therapeutic options will be discussed . A safe and effective
therapeutic option finally appears to be available .
1.50 Category 1 CME Credits
U062 Herpes Simplex and Varicella Zoster
Virus
Room: 270
DIRECTOR Arjen F. Nikkels, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Recognize the ever-growing spectrum of herpes simplex and
varicella zoster cutaneous manifestations .
2 . Choose the appropriate diagnostic methods .
3 . Select the most adequate treatment option for these viruses .
DESCRIPTION
Herpes simplex viruses (HSV) are responsible for orolabial
and genital herpes, whereas varicella zoster virus (VZV) leads
to chickenpox and shingles . The recognition, diagnosis, and
treatment of the various HSV and VZV skin infections will be
discussed . The following new treatment options will be explored:
short-course antiviral treatments for orolabial and genital herpes,
providing increased patient compliance, reduced antiviral use, and
similar therapeutic outcomes; combination treatments, usin ganti-
inflammatory and antiviral agents simultaneously for orolabial
herpes; hydrocolloid dressings for orolabial herpes; and shingles
vaccination, reducing the occurrence of shingles and postherpetic
neuralgia .
1.50 Category 1 CME Credits

For description of session categories and fees see page 37
FOCUS SESSION
2:30 p .m . to 4:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U063 Dermatoscopy
Room: 269
DIRECTOR Horacio Antonio Cabo, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Recognize the different dermatoscopy structures and criteria for
melanocytic and non melanocytic lesions .
2 . Utilize the different methods of dermoscopy diagnosis .
3 . Differentiate between melanocytic lesions and melanoma .
DESCRIPTION
Dermoscopy is a two-step procedure: first, differentiating between
melanocytic lesions and non-melanocytic lesions, and second,
differentiating between benign melanocytic lesions and melanoma .
Recognizing which lesions are appropiate for dermatoscopy,
and understanding the dermatoscopy criteria, and knowing the
different methods of dermatocopy diagnosis will improve the
attendees’ clinical diagnostic ability .
1.50 Category 1 CME Credits
U064 Helping You Meet Component 4 of MOC
Room: 274
DIRECTOR Robert S. Kirsner, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Demonstrate an understanding of the MOC process .
2 . Develop a strategy for dealing with the MOC 4 component .
3 . Assess the various options provided by the AAD and other
organizations .
DESCRIPTION
This session will focus on the Maintenance of Certification
(MOC) process, with a specific emphasis on the relatively new
component of how to self-assess your own practice . Discussion
will focus on the options that the AAD is working on to assist
members .
1.50 Category 1 CME Credits
for the lAtest ProgrAm Book informAtion PleAse refer to
SCIENTIFIC SESSIONS
U065 Dermoscopy: It’s Time for A Quiz
Room: 284
DIRECTOR Joel Claveau, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Recognize benign and malignant pigmented and non-
pigmented lesions .
2 . Review and utilize the main dermoscopic criteria and
algorithms .
3 . Assess own knowledge in dermoscopy .
DESCRIPTION
This interactive session is directed to beginners and more advanced
dermoscopists . A variety of instructive cases of pigmented and
non-pigmented lesions will be presented in a quiz format . A brief
description of the main dermoscopic criteria for melanocytic and
non-melanocytic lesions will be presented . Some cases to illustrate
new dermoscopic signs will also be discussed . Participants will
SATURDAY, FEBRUARY 5
be invited to vote during the session and are expected to increase
their interest and knowledge in this essential diagnostic tool .
1.50 Category 1 CME Credits
U066 Compliance in Pharmaceutical
Development: What You Need to know
Room: 264
DIRECTOR Mary C. Spellman, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Identify and define the principles and requirements for
compliance in pharmaceutical development .
2 . Define the basic roles and responsibilities of investigators as
related to the quality of clinical trials .
3 . Explain how good clinical practice impacts clinical research
progress .
DESCRIPTION
Clinical development of pharmaceutical products requires diligent
compliance with current regulatory policies and mandates, or
significant consequences may result . This session will provide
an overview of the principles and scope of applicable regulatory
compliance policies, and review the role of investigators and their
staffs in ensuring quality in clinical studies .
1.50 Category 1 CME Credits
www.aad.org | 145
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
FOCUS SESSION
2:30 p .m . to 4:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U067 Twists and Splits: How to Approach Hair
Shaft Disorders
Room: 265/266
DIRECTOR Paradi Mirmirani, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Identify the basic structures of the hair follicle and hair shaft .
2 . Develop skills for evaluating the hair shaft in the office setting .
3 . Diagnose and differentiate common hair shaft disorders .
DESCRIPTION
This session will provide a basic overview of hair shaft disorders
and is geared toward residents and/or clinicians wanting to
improve their knowledge and skills . The attendee will be
presented with practical tips on evaluating the hair shaft in the
office setting . “Unknowns” will then be presented to highlight
common clinical presentations and review pathogenetic
mechanisms of disease .
SATURDAY, FEBRUARY 5
1.50 Category 1 CME Credits
U068 Electrosurgery Update
Room: 267/268
DIRECTOR Connie M. Chung, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Recognize different modalities of electrosurgery and their
applications .
2 . Identify the risks and complications associated with
electrosurgery .
3 . Evaluate the current practice guidelines and develop
appropriate safety measures for patients with cardiac devices .
DESCRIPTION
Electrosurgery is utilized daily in dermatology . The different
modalities and their applications will be reviewed . With a
significant increase in patients with skin cancers and implantable
cardiac devices, safety measures become a concern . The current
practice guidelines are from the 1990s and were historically
derived from various surgical specialties . Dermatology-specific
complications and an update on cardiac devices will be presented .
The attendees then will have the opportunity to re-evaluate the
current safety guidelines to determine those that are applicable and
essential to dermatology .
1.50 Category 1 CME Credits
146 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
U069 Half-Truths, Lies, and Statistics:
Understanding Medical Statistics
for the Practitioner
Room: 263
DIRECTOR Joslyn S. Kirby, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Discuss evidence-based medicine and critical appraisal of the
literature .
2 . Define common statistical and epidemiologic terms .
3 . Apply these lessons during discussion of articles from the
dermatology literature .
DESCRIPTION
The literature guides the decisions we make for our patients and
practice, thus being a critical reader is essential . An understanding
of statistics and epidemiology is invaluable when critically reading
the medical literature . There are many statistical terms and methods
discussed in the literature and press . This course will focus on
defining and applying common statistical and epidemiologic terms
and methods . Articles from the dermatology literature will be used
as examples . The course is directed toward practicing dermatologists .
1.50 Category 1 CME Credits
U070 Getting Started with Interpolation Flaps
Room: 285
DIRECTOR Jeremy S. Bordeaux, M.D., M.P.H.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Perform an interpolation flap (paramedian forehead
flap, cheek-to-nose interpolation flap, and retroauricular
interpolation flap) .
2 . Develop a thoughtful approach to the indications, limitations,
design, and execution of straightforward interpolation flaps .
DESCRIPTION
Dermatologic surgeons encounter surgical defects best suited for
repair with interpolation flaps (paramedian forehead flap, cheek-to-
nose interpolation flap, and retroauricular interpolation flap) . Due
to lack of knowledge regarding these flaps or lack of experience in
performing these flaps, other surgical repairs that may be functionally
or aesthetically inferior are sometimes used . This session is designed to
help dermatologic surgeons recognize surgical defects that may be best
suited for repair with interpolation flaps . Step-by-step instruction on
proper design and execution of these flaps will be presented . Videos
will be used and audience participation is encouraged .
1.50 Category 1 CME Credits

For description of session categories and fees see page 37
FOCUS SESSION
2:30 p .m . to 4:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U071 Warts
Room: 235/236
DIRECTOR Stephen K. Tyring, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Recognize clinical manifestations of human papillomaviruses .
2 . Recognize the oncogenic potential of certain human
papillomaviruses .
3 . Discuss the available therapies and preventions of human
papillomaviruses .
DESCRIPTION
This session will cover the clinical manifestations of human
papillomaviruses (HPV) as well as laboratory tests that will
confirm the presence and type of HPV . The oncogenic potential of
certain HPV types will be discussed including co-factors that may
contribute to cancer development . The available therapies for HPV
will be covered and will include antiviral and immunomodulatory
treatments . Prevention strategies will be discussed and will include
both quadrivalent and bivalent vaccines .
1.50 Category 1 CME Credits
U072 Pediatric Dermatologic Surgery in the
Outpatient Setting: Tricks of the Trade
Room: 283
DIRECTOR Kenneth E. Bloom, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Formulate an optimal approach to dermatology procedures
in the outpatient relative to: timing, obtaining parental
support, positioning, distraction techniques, topical anesthetic,
analgesia, and office nitrous oxide use .
2 . Perform and/or refer pediatric dermatology procedures for
basic conditions such as warts, molluscum, nevi, and vascular
lesions .
DESCRIPTION
This session will focus on optimizing the pediatric dermatology
surgical experience in the awake office setting . Topics will include
appropriate timing, parental support, patient positioning, and
distractive methods . Additionally, other covered topics will include
the use of topical anesthetics, analgesia, and nitrous oxide use .
Clinical cases will be used to discuss surgical approaches to basic
conditions such as warts, molluscum, nevi, and vascular lesions .
1.50 Category 1 CME Credits
for the lAtest ProgrAm Book informAtion PleAse refer to
SCIENTIFIC SESSIONS
FORUM
3:00 p .m . to 5:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
F039 Treating Severe Skin Disease in Children
Room: 255/256/257
DIRECTOR Wynnis L. Tom, M.D.
SPEAkERS
Anna Lee Bruckner, M .D .
Kelly M . Cordoro, M .D .
Katherine B . Puttgen, M .D .
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 . Recognize situations and conditions that warrant systemic
therapy in pediatric patients .
2 . Identify and choose appropriately among the available therapies
for conditions such as severe atopic dermatitis, psoriasis, and
high-risk hemangiomas .
3 . Develop an approach for the workup and management of
major genetic skin conditions .
DESCRIPTION
SATURDAY, FEBRUARY 5
The dermatologist is at times faced with challenging, severe disease
in children and adolescents . This session discusses the principles
and practice of using systemic therapy in the pediatric population,
particularly for severe atopic dermatitis and psoriasis and high-
risk infantile hemangiomas . The mechanisms of action, benefits,
and toxicities of recognized and novel therapies will be reviewed .
In addition, children may present with findings suspicious for a
genetic disorder, and approaches to their workup and management
will be presented .
2.00 Category 1 CME Credits
SCHEDULE
3:00 p .m . Systemic Therapy for Severe Psoriasis / Dr. Cordoro
3:25 p .m . Questions and Answers / Dr. Cordoro
3:30 p .m . Approaches to the Severe Atopic Child / Dr. Tom
3:55 p .m . Questions and Answers / Dr. Tom
4:00 p .m . Genodermatoses: What to Do / Dr. Bruckner
4:25 p .m . Questions and Answers / Dr. Bruckner
4:30 p .m . The High-Risk Infantile Hemangioma: An Update
/ Dr. Puttgen
4:55 p .m . Questions and Answers / Dr. Puttgen
www.aad.org | 147
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
3:00 p .m . to 5:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F040 Resident Transitions F041 Finessing Facial Reconstruction

Room: 252/253/254 Room: 293/294
DIRECTOR Angela Kyei, M.D. DIRECTOR Tri H. Nguyen, M.D.
SPEAkERS LEARNING OBjECTIVES
Adam J . Friedman, M .D . Elizabeth S . Martin, M .D . Following this forum, the attendee will be able to:
Antoinette E . Hood, M .D . Amit G . Pandya, M .D . 1 . Develop an advanced facial reconstructive strategy based on
Jennifer Lucas, M .D . optimal cosmesis and minimal morbidity .
2 . Identify appropriate measures to maximize patient safety,
LEARNING OBjECTIVES
comfort, and outcome .
Following this forum, the attendee will be able to:
3 . Examine key principles in rhinoplasty surgery as it relates to
1 . Describe the structure, format, and process for the American
nasal reconstruction .
Board of Dermatology examination from the perspective of
ABD administrators as well as dermatologists who recently DESCRIPTION
took the examination . The reconstructive algorithm is vast for challenging facial repairs .
2 . Recognize the challenges of launching a career in dermatology Too often, before and after photos bypass the nuances of flap
and have the tools to get started in private practice and design and closure . This forum will focus on the finer details
academics . of selected closures including appropriate patient preparation,
3 . Identify opportunities to integrate volunteerism into one’s instrumentation, suturing techniques, structural support, and
SATURDAY, FEBRUARY 5

dermatology residency and career . closure . The sequencing of local anesthesia and anxiolysis, for
example, is essential to successful complex reconstruction in
DESCRIPTION
the office . Critical concepts in rhinoplasty surgery will also be
After spending years training to be a dermatologist, residents find
introduced as they apply to facial reconstruction .
themselves with major hurdles to pass before becoming successful
2.00 Category 1 CME Credits
dermatologists, including taking the board examination and
deciding on a career path . This session will provide information
on the structure, format, and process for the American Board
of Dermatology examination from the perspective of ABD
administrators and dermatologists who recently took the
examination . Additionally, successful career dermatologists will
share some of the challenges they faced when launching a career
in academic and private practice, and the AAD Volunteerism
Committee Chair will discuss ways residents can make a difference
in their communities .
2.00 Category 1 CME Credits
SCHEDULE
3:00 p .m . Volunteerism Opportunities for Residents / Dr. Pandya
3:10 p .m . ABD Exam / Dr. Hood
3:25 p .m . Questions and Answers / Faculty
3:40 p .m . Transition from Resident to Fellow to Academic Staff
/ Dr. Lucas
4:00 p .m . Transition to Private Practice / Dr. Martin
4:20 p .m . Questions and Answers / Faculty
4:30 p .m . Panel Discussion: Taking the ABD Exam / Faculty

148 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
3:00 p .m . to 5:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F042 Hair and Nail Clinicopathologic F043 Role of Dermatologist in Management of

Correlations Skin Disease in Solid Organ Transplant
Room: 388/389/390 Recipients
DIRECTOR Adam Rubin, M.D. Room: 278/279/280

SPEAkERS DIRECTOR Marc D. Brown, M.D.

George Cotsarelis, M .D . Beth S . Ruben, M .D . SPEAkERS
Christopher James Miller, M .D . John T . Seykora, M .D . Sarah T . Arron, M .D ., Ph .D . Harold S . Rabinovitz, M .D .
Clay J . Cockerell, M .D . Darrell S . Rigel, M .D .
LEARNING OBjECTIVES Oscar Colegio, M .D ., Ph .D . Thomas Stasko, M .D .
Following this forum, the attendee will be able to: Marcy Neuburg, M .D . Fiona O’Reilly Zwald, M .D .
1 . Diagnose hair and nail disorders more effectively . Edit B . Olasz, M .D ., Ph .D .
2 . Perform clinicopathologic correlations for disorders of the hair
and nails more effectively . LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
3 . Determine optimal selection and submission of biopsy
1 . Develop a skill set for long-term management of skin disease in
specimens for the diagnosis of hair and nail disorders . patients with solid organ transplants .
DESCRIPTION 2 . Recognize the broad spectrum of skin disease affecting patients
Hair and nail unit disorders can be difficult to diagnose both with solid organ transplants, including both medical and
surgical problems .

clinically and histopathologically . The speakers in this forum will
present ways to optimally submit alopecia and nail unit biopsy
specimens . Algorithms to evaluate scarring and non-scarring
alopecias will be discussed . Clinical and histologic evaluation of
both inflammatory and neoplastic disorders of the nail unit will
be reviewed . Emphasis will be placed on correlating the histologic
findings and clinical features in these anatomic areas . This forum
will be helpful for dermatopathologists and dermatologists who
manage hair and nail unit disorders .
2.00 Category 1 CME Credits
SCHEDULE
3:00 p .m . Introduction / Dr. Rubin
3:05 p .m . Surgical Management of the Nail Unit / Dr. Miller
3:25 p .m . Melanonychia / Dr. Ruben
3:45 p .m . Inflammatory Disorders of the Nail Unit / Dr. Rubin
4:05 p .m . Clinical Approach to the Alopecias / Dr. Cotsarelis
4:25 p .m . Histologic Approach to the Alopecias / Dr. Seykora
4:45 p .m . Questions and Answers / Faculty
SATURDAY, FEBRUARY 5
3 . Detect, diagnose and manage common cutaneous sequelae
caused by chronic immunosuppression in solid organ
transplant recipients .
DESCRIPTION
There are over 200,000 people in the United States with solid
organ transplants who have increasing life expectancy . These
patients experience a broad variety of skin disease related to
long-term immunosuppression . This includes high-risk skin
cancer development as well as medical problems including
infections . This session will provide those attending with an
up-to-date comprehensive examination of issues that complicate
the management of these patients . In addition, there will be new
insights into the specific strategies that will improve the overall
care of organ transplant recipients .
REFERENCE
Otley C, Stasko T . Skin Disease in Organ Transplant Patients .
2.00 Category 1 CME Credits
SCHEDULE
3:00 p .m . Medical Problems in the Organ Transplant Recipient
/ Dr. Colegio
3:20 p .m . Infections in the Organ Transplant Recipient
/ Dr. Olasz
3:40 p .m . Skin Cancer in Organ Transplant Recipients,
Epidermiology and Risk Factors / Dr. Stasko
4:00 p .m . Field Disease and Field Therapy in Organ Transplant
Recipients / Dr. Arron
4:20 p .m . Recognition and Treatment of High-Risk Squamous
Cell Carcinomas in Organ Transplant Recipients
/ Dr. Zwald
4:40 p .m . The Role of Specialized Clinics in the Management of
Organ Transplant Recipients / Dr. Neuburg

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 149
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
3:00 p .m . to 5:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F044 Dermatology Teaching and F046 Leading Your Team by Coaching and
Education Group Mentoring
Room: 392 Room: 391
DIRECTOR Ponciano D. Cruz Jr., M.D. DIRECTOR Amy S. Paller, M.D.
LEARNING OBjECTIVES SPEAkER Paul Seymour, Ph .D ., Center for Creative Leadership
Following this forum, the attendee will be able to:
1 . Identify the best teaching outcomes from current and future LEARNING OBjECTIVES
teachers of dermatology . Following this forum, the attendee will be able to:
2 . Catalyze exchange of ideas and collaboration among 1 . Describe the differences between coaching and mentoring and
dermatologic educators . identify situations where each may be most appropriate .
3 . Apply lessons learned during this meeting to improve own 2 . Demonstrate skills that are key to both coaching and
programs . mentoring including active listening, communicating and
providing feedback, and guiding others to self-awareness .
DESCRIPTION 3 . Determine how to initialize, maintain, and conclude a
This forum highlights abstracts focusing on best outcomes in mentoring or coaching relationship .
dermatologic education presented by residency program directors
and current or future teachers of dermatology . The goal is to catalyze DESCRIPTION
exchange of ideas and collaboration among educators, and to challenge To get where you are today, you almost certainly had mentors
SATURDAY, FEBRUARY 5

and inspire teachers to improve their own programs by applying lessons or coaches who set the example and helped to guide you . Are
learned at this meeting . you ready to learn those key skills that make a good mentor or
2.00 Category 1 CME Credits coach so you can develop your team? This session will describe
the difference between coaching and mentoring, explain why
these are both important, and identify when each can be most
F045 Rosacea effective . You’ll learn tools for successful communication, providing
Room: 295/296 effective feedback and guiding others to find the solution . Tips
DIRECTOR Frank C. Powell, M.D. will be offered on how to establish and maintain positive working
relationships . Co-presented with a faculty member from the Center
SPEAkER Jonathan Keith Wilkin, M .D . for Creative Leadership, this interactive session will help you
LEARNING OBjECTIVES develop necessary skills to be an effective coach or mentor, whether
Following this forum, the attendee will be able to: you’re developing residents or faculty in an academic setting or
1 . Describe the spectrum of cutaneous presentations that come building an effective working team of staff in the private office .
under the diagnosis of rosacea . 2.00 Category 1 CME Credits
2 . Recognize the different subsets of rosacea and how to select
therapy according to each subset .
3 . Interpret the differential diagnosis of the rosacea subsets and
the investigations appropriate to alternative diagnoses .
DESCRIPTION
The interactive session will review the differential diagnosis of
erythematous facial skin eruptions leading to the diagnosis of
rosacea . The reasons behind the classification of rosacea into subsets
will then be discussed together with the clinical relevance of these
subsets when choosing therapeutic interventions . The session will
conclude with discussion of possible etiologic factors in rosacea and
the potential future therapies for this chronic disorder .
2.00 Category 1 CME Credits

150 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

WORkSHOP
3:00 p .m . to 5:00 p .m .
Tuition fee and ticket required for admission.

Looking for the Latest

W006 MOC Self-Assessment:
M
O
C
Contact Dermatology Self-Assessment Tool?
Room: 288/289/290
DIRECTOR Christen M. Mowad, M.D.
SPEAkERS
Bruce A . Brod, M .D . Erin M . Warshaw, M .D .
Susan T . Nedorost, M .D . Kathryn A . Zug, M .D . NEW!
LEARNING OBjECTIVES
Following this workshop, the attendee will be able to:
1 . Identify the strengths and weaknesses in one’s dermatology
knowledge as it pertains to contact dermatitis and make
improvements as needed .
2 . Demonstrate commitment to lifelong learning and self-
assessment via completion of a forum of 25 questions and
answers .
3 . List allergens and patch-testing issues .

SATURDAY, FEBRUARY 5
DESCRIPTION
This session will be structured in a question-and-answer format Complete your self-assessment
using an automated response system . It will cover topics in
contact dermatology . The participant will have immediate library with MOCmd™ Vol. 4
feedback for each section and will be able to identify any areas of
weakness that require further self-directed study . MOCmd™ Vol. 4 offers:
2.00 Category 1 CME Credits
• The ability to fulfill Component 2 of
* Self-assessment questions utilized in this session are the Maintenance of Certification
same as those used for Forum F035 and Workshop
W004 MOC: Self-Assessment offered at Annual • Self-assessment questions followed by
Meeting 2009 and 2010. Physicians should not images and sample clinical cases available
claim CME/MOC credit for attending this session if in print, CD-ROM, and online
they attended Forum F035 and Workshop W004 at
Annual Meeting 2009 and 2010. • Links to verified references for further
self-study

• Up to 24 AMA PRA Category 1 Credits ™

Visit the Academy

Resource Center
Booth 3623 to order!

The American Academy of Dermatology designates MOCmd – Vol. 4 for a

maximum of 24 AMA PRA Category 1 Credits™. Physicians should only claim
credit commensurate with the extent of their participation in the activity. This CME
activity is recognized by the American Academy of Dermatology for 24 hours of
AAD Category 1 CME. Credit may be used toward the American Academy of
Dermatology’s Continuing Medical Education Award.

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 151
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

OVERVIEW
Represents restricted session in program overviews Represents activities that meet MOC-D
Restricted Session open to dermatologists and corporate M
O
This activity has been approved by the ABD to satisfy
individual members only! A ticket is required for admittance C component 2 of MOC-D

Represents Practice Management Session in program overviews Represents Leadership Institute in program overviews
Practice Management Session open to eligible Leadership Institute — addresses leadership
office staff/registered nurses competencies specific to dermatologists

Represents Patient Safety Session in program overviews Represents Health Information Technology (HIT) in
program overviews
Patient Safety Session
Health Information Technology Sessions

Represents Audience Response System Session

Audience Response System Session

SUNDAY, FEBRUARY 6 11:00 a .m . Eugene J . Van Scott Award for Innovative Therapy
of the Skin and Phillip Frost Leadership Lecture
Discussion Groups — 7:00 a.m. to 8:00 a.m.
D013 Challenging Pediatric Dermatology Cases . . . . . .154 Anton Stuetz, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .162
D014 Advances in Pemphigus and Pemphigoid . . . . . .154 11:30 a .m . Guest Speakers
Mary Matalin and James Carville . . . . . . . . . . . . .162
Focus Sessions — 7:00 a.m. to 8:00 a.m.
U073 Amyloidosis: Changing Our Symposium — 11:00 a.m. to 2:00 p.m.
View in Dermatology . . . . . . . . . . . . . . . . . . . . .154 S024 Residents and Fellows Symposium . . . . . . . . . . .163
U074 Eczema Centers: World Experiences . . . . . . . . . .154 Discussion Groups — 12:15 p.m. to 1:45 p.m.
U075 Drug Safety: Do No Harm . . . . . . . . . . . . . . . .155 D015 Urticaria and Angioedema . . . . . . . . . . . . . . . . .163
U076 Immunofluorescence in Dermatopathology . . . .155 D016 Photodermatology . . . . . . . . . . . . . . . . . . . . . . .163
U077 Hair Disease and the African American Patient .155
U078 Case-Based Approach to Lentigo Maligna . . . . . .156 Poster Discussion Sessions — 12:15 p.m. to 1:45 p.m.
U079 Dermatologic Disease in Asians . . . . . . . . . . . . .156 PD03 Acne . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .164
U080 Uncommon Neonatal Dermatosis . . . . . . . . . . .156 PD04 Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .164
U081 Medical and Surgical Practice . . . . . . . . . . . . . . .156
U082 Practical and Realistic Office Mycology for the Focus Sessions — 12:15 p.m. to 1:45 p.m.
Epidemiology, Diagnosis, and Treatment of U086 Melasma: Pathogenesis and Treatment . . . . . . . .165
Hu man Myc o s e . s . . . . . . . . . . . . . . . . . . . . . . . .157 U087 Fulfilling Great Expectations: Caring for
U083 Hair Highlights: Common and Challenging New Mothers and Mothers-to-Be . . . . . . . . . . . .165
Hair Loss Disorders . . . . . . . . . . . . . . . . . . . . . .157 U088 Hereditary Diseases of the Epidermis . . . . . . . . .165
U084 Climate Change, Allergy and the Skin . . . . . . . .157 U089 Lasers 1 0 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .166
U085 Emerging Laser and Aesthetic Technology . . . . .158 U090 Angiogenesis and Clinical Dermatology . . . . . . .166
U091 Challenging Cases in Dermatopathology . . . . . .166
P151 Plenary Session — 8:00 a.m. to 12:00 p.m. U092 Opening Your Own Practice:
8:00 a .m . Business and Bagels . . . . . . . . . . . . . . . . . . . . . .159 Blunders and Breakthroughs . . . . . . . . . . . . . . . .166
8:45 a .m . Welcome U093 Notes of a Therapeutic Iconoclast . . . . . . . . . . . .167
Larry Eichenfield, M.D . . . . . . . . . . . . . . . . . . . . .159 U094 Dermatologic Manifestations of HIV and AIDS 167
8:50 a .m . Clarence S . Livingood, M .D ., U095 Biologic Drugs for Psoriasis:
Award and Lectureship Do We Us eThe mEn o uh? . g . . . . . . . . . . . . . . . .167
SUNDAY, FEBRUARY 6

Neil S. Prose, M.D. . . . . . . . . . . . . . . . . . . . . . . .159

U096 Medical Therapies and How They Work . . . . . . .167
9:15 a .m . Introduction of President/President’s Address
William D. James, M.D . . . . . . . . . . . . . . . . . . . .160 U097 Immunostimulatory Treatment of Skin Cancer . .168
9:45 a .m . Marion B . Sulzberger, M .D ., Memorial Symposia — 2:00 p.m. to 5:00 p.m.
Award and Lectureship Lectureship S025 New Emerging Therapies . . . . . . . . . . . . . . . . . .168
Thomas S. Kupper, M.D. . . . . . . . . . . . . . . . . . . .160 S026 Cutaneous Oncology . . . . . . . . . . . . . . . . . . . . .169
10:15 a .m . President-Elect’s Address
Ronald L. Moy, M.D. . . . . . . . . . . . . . . . . . . . . . .161 S027 Contact and Occupational Dermatitis . . . . . . . .170
10:30 a .m . Lila Gruber Memorial Cancer Research S028 Nails . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .171
Award and Lectureship S029 Lessons from Great Leaders . . . . . . . . . . . . . . . .172
W. Marston Linehan, M.D. . . . . . . . . . . . . . . . . .161 S030 Electronic Health Record (EHR) Physician
Demonstration Symposium . . . . . . . . . . . . . . . .172
S031 Tro pical De rmato ol gy . . . . . . . . . . . . . . . . . . . . .173

152 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

OVERVIEW

Discussion Groups — 2:30 p.m. to 4:00 p.m.

Don’t let another
month go by...
D017 Churning Out the Learning . . . . . . . . . . . . . . . .173
D018 Practice Tips and Surgical Gems . . . . . . . . . . . . .173

Focus Sessions — 2:30 p.m. to 4:00 p.m.

U098 HITEMRs and Documenting Clinical Care:
Pitfalls and Promises . . . . . . . . . . . . . . . . . . . . .174
U099 Lumps and Bumps in Children . . . . . . . . . . . . . .174
U100 Current Management of Skin Cancer in
Transplant Patients . . . . . . . . . . . . . . . . . . . . . . .175
U101 Pediatric Drug Eruptions . . . . . . . . . . . . . . . . . .175
U102 From Pigment to PUPP (or PEP): What to Expect
When Your Patient is Expecting . . . . . . . . . . . . .175
U103 Drug Reaction Update 2011 . . . . . . . . . . . . . . . .176
U104 Cosmeceuticals: Topical Therapies for Treating
the Aging Face . . . . . . . . . . . . . . . . . . . . . . . . . .176
U105 Advances in Fat Transfer and Liposuction for
Correction of Lipodystrophy:
The US CExpe rie n c . e . . . . . . . . . . . . . . . . . . . . .176
U106 What’s That? Syndrome Update . . . . . . . . . . . . .176
U107 Dermatology in Cinema . . . . . . . . . . . . . . . . . . .177
U108 Safety of Biologic Therapies: What’s the
Real Story? . . . . . . . . . . . . . . . . . . . . . . . . . . . . .177
Save $
Forums — 3:00 p.m. to 5:00 p.m. online 40 with
versio
F047 Managing an Efficient Practice . . . . . . . . . . . . . .177 n!
F048 Psoriasis as a Systemic Disease . . . . . . . . . . . . . . .178
F049 Laser Pe arl s . . . . . . . . . . . . . . . . . . . . . . . . . . . . .178 Without your
F050 What’s New in Immunomodulation . . . . . . . . . .179
F051
F052
Controversies in Vitamin D . . . . . . . . . . . . . . . .179
Advanced Dermatopathology . . . . . . . . . . . . . . .180
Dialogues subscription!
F053 Autoimmune Disease Update . . . . . . . . . . . . . . .180
F054 Dermatologic Health of Women . . . . . . . . . . . . .181 Members like you are using Dialogues in
Dermatology to stay informed each month on the
Workshops — 3:00 p.m. to 5:00 p.m. latest trends and important topics in dermatology.
W007 Effective C o mmu nci atio n . . . . . . . . . . . . . . . . . .181 With convenient formats, and quick 20-minute
W008 Bas ic De rmo s c oy .p . . . . . . . . . . . . . . . . . . . . . . .182 segments, there isn’t an easier way to stay current! 
W009 MOC Se l fAs - s e s se m n tB . . . . . . . . . . . . . . . . . . .183 NEW online version offers:
• MP3 download capability - great for iPods!
• Streaming audio
• Links to verified references
SUNDAY, FEBRUARY 6

• Printable transcripts
• Editor-in-Chief’s summary on each topic

This program is available for AMA PRA Category 1 CreditsTM

Visit the Resource Center

Booth 3623 to subscribe!

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 153
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
DISCUSSION GROUP
7:00 a .m . to 8:00 a .m .
Tuition fee and ticket required for admission.
D013 Challenging Pediatric Dermatology Cases
Room: 240
DIRECTOR Lawrence A. Schachner, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 . Diagnose difficult and severe pediatric dermatosis .
2 . Demonstrate therapeutic acumen of difficult and severe
pediatric dermatosis .
3 . Summarize the most recent, cutting-edge literature on these
disorders .
DESCRIPTION
The session will focus on severe dermatosis in pediatric
dermatology; severe morphea, unremitting atopic dermatitis and
extensive alopecia areata will be reviewed in detail with emphasis
on best diagnostic techniques and most efficient therapy for these
challenging disorders .
1.00 Category 1 CME Credits
D014 Advances in Pemphigus and Pemphigoid
Room: 241
DIRECTOR Luis A. Diaz, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 . Diagnose pemphigus vulgaris, pemphigus foliaceus, and
bullous pemphigoid .
2 . Apply recognized and newer therapies in treatment of these
diseases .
3 . Differentiate these autoimmune diseases based on the advances
in their pathogenesis .
DESCRIPTION
Structural skin molecules are targeted by “pathogenic”
autoantibodies which are known to induce intra-epidermal and
subepidermal blisters in experimental animals . In pemphigus
vulgaris and pemphigus foliaceus, desmosomal antigens, i .e ., Dsg3
SUNDAY, FEBRUARY 6
and, Dsg1 respectively, are the targets . In bullous pemphigoid
hemidesmosomal antigens, i .e ., BP230 and BP180, are bound
by these autoantibodies . These pathogenic autoantibodies may
trigger blister formation by different mechanisms, e .g ., signal
transduction, apoptosis or inflammation . Therapies aimed at
eliminating pathogenic autoantibodies from these patients will
be discussed .
1.00 Category 1 CME Credits
154 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
FOCUS SESSION
7:00 a .m . to 8:00 a .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U073 Amyloidosis: Changing Our View in
Dermatology
Room: 283
DIRECTOR Omar Lupi, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Recognize clinical, genetic, and epidemiological aspects of the
amyloidosis .
2 . Discuss the new conception of the “conformational disorders .” .
3 . Recognize new routes of transmission related to the
amyloidosis .
DESCRIPTION
Amyloidosis is a group of metabolic diseases that lead to the
deposition of amyloid in different organs, including the skin;
amyloidosis is considered to be of unknown origin with few real
therapeutic opportunities . Until recently, the analysis of the amyloid
structure was the same as described a century ago . However, in
recent years a new body of evidence suggested that amyloidosis
is a group of misfolded protein disorders with a potential of
transmissibility that have been described by different routes . It
is critical to develop a new approach for amyloidosis in order to
understand the new diagnostic and therapeutic possibilities .
1.00 Category 1 CME Credits
U074 Eczema Centers: World Experiences
Room: 235/236
DIRECTOR Jean Francois Stalder, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Discuss the emerging concept of patient-oriented medicine
compared to the evidence-based paradigm .
2 . Identify experiences of eczema centers across the world and
global principles of patient education applied to chronic skin
disease .
3 . Develop a management plan for an education program .
DESCRIPTION
It is an accepted fact today that chronic skin disease impacts a
patient’s quality of life and there is a general problem of weak
adherence to topical treatment . The attempt to tackle these
problems has led to the creation of ‘eczema centers’ or ‘atopic
schools .’ The objective of these centers is to enable the patient
to become an active partner in his/her treatment by increasing
knowledge and coping skills . This session will provide an overview
on therapeutic education experiences worldwide and propose
recommendations and references for setting up education structure .
1.00 Category 1 CME Credits
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
7:00 a .m . to 8:00 a .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U075 Drug Safety: Do No Harm U077 Hair Disease and the African American
Room: 285 Patient
DIRECTOR Bonnie T. Mackool, M.D. Room: 263

LEARNING OBjECTIVES DIRECTOR Diane M. Jackson-Richards, M.D.

Following this focus session, the attendee will be able to:
1 . Summarize the untoward side effects of routinely used topical
agents that have resulted in morbidity and/or even death .
2 . Outline important systemic drug interactions of systemic
agents used in dermatology practice .
3 . Recognize patient risk factors for iatrogenic effects from topical
and systemic agents and ultimately avoid morbidity and
mortality from their use .
DESCRIPTION
This case-oriented approach will review what every dermatologist
should know about two important areas of iatrogenic illness in our
field: first, the potentially serious side effects of the entire range
of topical medications in our specialty, additionally the potential
drug interactions of systemic agents used in our field . The use of
patient cases and audience participation will facilitate attendees’
formulation of individual patient risk in the use of topical or
systemic medication .
1.00 Category 1 CME Credits
U076 Immunofluorescence in
Dermatopathology
Room: 270
DIRECTOR Robert Law, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Develop a comprehensive histopathologic diffrential diagnosis
for the vesiculobullous diseases .
2 . Discuss the pathophysiology of the basement membrane zone
and major intercellular antigens .
3 . Choose the appropriate immunofluorescence modality when
faced with possible immunobullous or connective tissue
diseases .
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Describe the unique structural and physiologic properties of
African textured hair .
2 . Recognize the prevalence of hair and scalp disorders among
African Americans and identify the most common of these
among African Americans .
3 . Develop culturally competent therapeutic protocols for
common hair and scalp disorders among African Americans .
DESCRIPTION
Hair disease, an exceedingly common problem among African
American patients, can be associated with a number of medical,
psychosocial, and cosmetic issues . The unique structure and
physiology of African textured hair undoubtedly plays a role in
the pathogenesis of many disorders common among African
Americans . This session will discuss the current state of the
knowledge regarding the anatomy and physiology of African
textured hair, and review the most common hair and scalp
disorders encountered among African American patients . The
importance of developing culturally competent management
techniques will be emphasized, and specific recommendations
regarding therapeutic protocols and grooming practice instruction
will be made .
1.00 Category 1 CME Credits
SUNDAY, FEBRUARY 6

DESCRIPTION
Dermatologists and dermatopathologists rely heavily on the use of
adjunctive diagnostic tests in daily practice . Immunofluorescence
techniques are vital in establishing many diagnoses, and require
specialized equipment and training to perform with proficiency .
This session reviews the basic pathophysiology of major
immunobullous diseases and discusses the methodology of both
direct and indirect immunofluorescence . Attention is given to
common causes of clinicopathologic discrepancies, with discussion
of selected interesting cases .
1.00 Category 1 CME Credits

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 155
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
7:00 a .m . to 8:00 a .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U078 Case-Based Approach to Lentigo Maligna U080 Uncommon Neonatal Dermatosis

Room: 264
DIRECTOR Dori Goldberg, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Summarize the literature on treatment options for lentigo
maligna .
2 . Compare different surgical approaches to lentigo maligna
including excision and staged excision (slow Mohs) as well as
potential use of imiquimod as a topical agent .
3 . Develop a clinical approach to the management of lentigo
maligna .
DESCRIPTION
The management of lentigo maligna is often complicated by the
poorly defined tumor margins and location of lesions on the head
and neck . Commonly used treatments currently include simple
excision and staged excision (slow Mohs), with Mohs surgery and
topical therapy with imiquimod less frequently employed options .
In this session we will examine how to approach lentigo maligna
and develop a treatment strategy through the review of several
patient cases .
1.00 Category 1 CME Credits
U079 Dermatologic Disease in Asians
Room: 274
DIRECTOR Roopal Vashi Kundu, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Recognize common and uncommon cutaneous disorders in
Asian American skin .
2 . Demonstrate cultural competence when encountering
cutaneous disorders in patients with Asian ancestry .
3 . Manage Asian American patients with skin disorders using safe
and effective treatments .
DESCRIPTION
SUNDAY, FEBRUARY 6
Room: 269
DIRECTOR Margarita M. Larralde, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Identify uncommon neonatal dermatoses .
2 . Discuss the differential diagnoses .
DESCRIPTION
The session will provide practical information about different
and uncommon neonatal dermatoses . There will be interactive
participation with attendees participating in quizzes . The session
will be targeted to general dermatologists, fellows, and residents .
1.00 Category 1 CME Credits
U081 Medical and Surgical Practice
Room: 265/266
DIRECTOR Duane C. Whitaker, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Discuss elements of combining medical and surgical practice .
2 . Outline features of support staff performance .
3 . Explain elements of physician CME that are vital to a changing
and growing practice .
DESCRIPTION
Patient care for cutaneous disease can be comprehensive, and
clinical practice more satisfying when we provide a wider range of
consultation and serivice to our patient population . High-level
medical and surgical practice can be combined . Optimal care in
this setting requires well-trained support staff and a practice ethic
and goal to manage surgical and medical patients in the same day .
Well-selected CME, attentive and patient focused support staff
with excellent communication skill are essential to accomplish ths
goal . Methods to do so and maintain high patient satisfaction are
presented .

1.00 Category 1 CME Credits

The Asian American population is comprised of persons with
ancestry from East Asia, Southeast Asia, and South Asia . The
U .S . Census Bureau predicts the Asian American population will
total 40 million persons by 2050 . Common and uncommon skin
disorders amongst these populations will be discussed emphasizing
acne, melasma, post-inflammatory hyperpigmentation, erythema
dyschromicum perstans, and melanoma . Dermatoses secondary
to Asian cultural practices such as coin rubbing, cupping,
moxibustion and henna tattoos will also be reviewed .
1.00 Category 1 CME Credits

156 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
7:00 a .m . to 8:00 a .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U082 Practical and Realistic Office Mycology
for the Epidemiology, Diagnosis, and
Treatment of Human Mycoses
Room: 242
DIRECTOR Dennis E. Babel, Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Differentiate the cutaneous presentations of superficial through
systemic mycoses more effectively .
2 . Utilize direct microscopy to determine the presence of
cutaneous fungal pathogens more efficiently .
3 . Discuss the epidemiology of fungal diseases to better manage
recurrent mycoses .
DESCRIPTION
This session will detail straightforward procedures that can be
utilized in the dermatology office to efficiently diagnose superficial
through systemic mycoses which demonstrate cutaneous lesions .
The role of efficient direct microscopy will be emphasized . The
most effective means of collecting patient specimen for diagnostic
confirmation will be outlined for each of these entities . The role
of epidemiology in pathogen transmission, disease recurrence,
and common fungal reservoirs will be discussed . Numerous
case presentations will be used to demonstrate the variations in
mycoses presentation .
1.00 Category 1 CME Credits
U083 Hair Highlights: Common and
Challenging Hair Loss Disorders
Room: 267/268
U084 Climate Change, Allergy, and the Skin
Room: 284
DIRECTOR Johannes Ring, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Summarize exact data on facts regarding climate change from
the view of meteorology and atmospheric physics .
2 . Discuss the interaction among climate effects, anthropogenic
pollution, and allergen carriers such as pollen in the outdoor air .
3 . Examine the practical relevance of these climatic changes upon
skin health and allergy .
DESCRIPTION
There is scientific evidence that climate change is a reality and not
a myth . The increase in global earth surface temperature in the last
30 years is man-made and not due to solar irradiation . Implications
of climate change for health will affect allergic and skin diseases
besides infectious diseases and cardiovascular problems due to heat
exposure . Reasons for increases in allergy prevalence may be due to
prolonged allergen exposure (pollen flowering seasons have increased
in the Northern hemisphere by 10 to 14 days) . Due to climate
change, neophytes and new allergens appear in many countries .
Because of anthropogenic effects and atmospheric pollution,
increased allergen exposure can be predicted . An example is the
new epidemic of ragweed (Ambrosia artemisiifolia) sensitization
and allergy in Germany in the last 15 years . The same holds true
for contact dermatitis both allergic and irritant-toxic in origin
(e .g ., Thaumatopoea or oak processionary caterpillar) in increasing
amounts in Northern countries .
1.00 Category 1 CME Credits

DIRECTOR Mary H. Lien, M.D.

LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Select the most appropriate clinical tests to evaluate hair loss .
2 . Diagnose the different types of alopecia more effectively .
3 . Utilize the most appropriate treatments to manage the
common and challenging hair loss patients .
SUNDAY, FEBRUARY 6

DESCRIPTION
We all aim to maximize the efficiency and to reduce the
frustration of the 15-minute alopecia visit . This session will guide
providers in ordering the appropriate clinical tests to evaluate hair
loss patients . Clinical presentations of non-scarring and scarring
alopecias will be reviewed . The correct tissue sampling techniques
for various alopecias and ethnicities, as well as tissue sectioning
preferences, will be discussed . This session will be informative for
dermatologists who are interested in honing their diagnostic and
therapeutic skills in managing hair loss patients .
1.00 Category 1 CME Credits

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 157
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
7:00 a .m . to 8:00 a .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time. Submis
deadlinsion
June 8, e is
2011
U085 Emerging Laser and Aesthetic
Technology
Room: 298/299
DIRECTOR M. Christine Lee, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Compare new technologies with pre-existing older technology .
2 . Examine and evaluate the latest cutting-edge technologies . Everett C. Fox, M.D.,
3 . Recognize the latest research supporting the technology .
DESCRIPTION
Memorial Lectureship
There has been a rapid proliferation of laser and aesthetic
technology over the last several years . Examples include
innovations in lasers, light-based, radiofrequency, ultrasound,
and combination devices . An overview of the evolution of laser
treatments for medical and cosmetic purposes, invasive and The American Academy of Dermatology is pleased to
noninvasive approaches, high-tech and low-tech techniques announce a Call for Nominations for the 2012 Everett C.
will be presented . New and emerging technologies will be
Fox, M.D., Memorial Lectureship. This distinguished
examined and evaluated for their potential roles in the physicians
armamentarium, and they will be compared to pre-existing older award is given to an expert clinical dermatologist
technology . Special emphasis will be placed on devices used in (including dermatopathologists and dermatologic surgeons).
common cosmetic dermatologic challenges . One of the goals
of this session is to help the practitioner approach the decision-
making process of choosing and utilizing laser and aesthetic The selected recipient will receive a cash award of
technology with greater awareness and knowledge . New and
$10,000 and will present a lecture at the Plenary
emerging technologies will include skin tightening (comparing
monopolar with unipolar radiofrequency, infrared light sources, Session of the AAD’s Summer Academy Meeting 2012.
ultrasound, needle delivery devices), all types of fractional
resurfacing, and comparisons of the newest fractional CO2 lasers,
body contouring, and fat-melting devices .
1.00 Category 1 CME Credits For more information or
to nominate someone please visit
www.aad.org/namedlectureships
SUNDAY, FEBRUARY 6

158 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

P151 PLENARY SESSION

8:00 a .m . to 12:00 p .m .
Room: La Nouvelle Orleans Ballroom
Open admission, no tuition or ticket.
Up to 2.00 Category 1 CME Credits

The American Academy of Dermatology’s Annual Business 8:45 a.m. WELCOME

Meeting will be held on February 6, 2011 in the La Nouvelle Larry Eichenfield, M.D.
Orleans Ballroom at 8 a.m. It will follow the agenda below:

8:00 a .m . BUSINESS AND BAGELS

AMERICAN ACADEMY OF DERMATOLOGY
(AAD) BUSINESS MEETING
I. Call Assembly to Order
II. Establish Quorum
III. Introductions and Acknowledgments
IV. President-Elect Candidates’ Statements
V. Recognition of Industry
VI. Awards Acknowledgments * No CME Credit
VII. Secretary-Treasurer’s Report
VIII. Unfinished Business
IX. New Business
X. Announcements
XI. Adjournment

AMERICAN ACADEMY OF DERMATOLOGY 8:50 a.m. CLARENCE S. LIVINGOOD, M.D., AWARD

ASSOCIATION (AADA) BUSINESS MEETING AND LECTURESHIP
I. Call Assembly to Order Neil S. Prose, M.D.
II. Establish Quorum
III. Secretary-Treasurer’s Report
IV. Unfinished Business
V. New Business
VI. Recognition of Retiring Board Officers
VII. Adjournment

INFORMAL DISCUSSION OF ISSUES OF

IMPORTANCE FROM THE FLOOR*

Pursuant to the Administrative Regulations of the
American Academy of Dermatology and American
Academy of Dermatology Association, during any
SUNDAY, FEBRUARY 6

debate at a membership meeting each speaker Cultivating Curiosity

must introduce himself or herself by name and Although curiosity killed the cat, it has
professional position. He or she must also identify immeasurable value in the practice of dermatology.
any potential conflicts of interest. When we approach our patients with curiosity, we
*No CME Credit can begin to understand who they really are. As a
result, we can provide more empathic and more
effective care. How do we cultivate this important
skill and incorporate it into our practice?
.50 Category 1 CME Credits

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 159
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

P151 PLENARY SESSION

8:00 a .m . to 12:00 p .m .
Room: La Nouvelle Orleans Ballroom
Open admission, no tuition or ticket.
Up to 2.00 Category 1 CME Credits

9:15 a.m. PRESIDENT’S ADDRESS 9:45 a.m. MARION B. SULZBERGER, M.D., MEMORIAL
William D. James, M.D. AWARD AND LECTURESHIP
Thomas S. Kupper, M.D.

In his plenary address, Dr. James will reflect on his Skin in the Game: New Perspectives on
year as president, and, more broadly, speak to the T-Cells, Immunity, and Cancer
challenges and the many exciting accomplishments Advances in our understanding of how T cells
that have shaped his year in office. He will talk protect skin is changing the way we think about
about landmark Health System Reform issues that protective immunity, vaccination, cancer, and
has evolved and become legislation since he has inflammatory skin diseases. Increasingly, these
taken office, and its impact on dermatology. insights are being translated into patient care.
New approaches based on T-cell trafficking to
treating patients with cutaneous T-cell lymphoma
Dr. James will also discuss how volunteerism, will be discussed.
partnership and cooperation have coalesced to .50 Category 1 CME Credits
strengthen the profession of dermatology; and
will bring attendees the latest information on the
impact of several key issues, including electronic
health records, the complex requirements for quality
reporting and clinical performance assessment,
Medicare’s Sustainable Growth Rate formula,
health system reform, and the Academy’s aggressive,
multi-front war against skin cancer.
SUNDAY, FEBRUARY 6

His message will demonstrate how the Academy has

made bold strides to improve patient care, educate
the public, and advance our specialty.
* No CME Credit

160 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

P151 PLENARY SESSION

8:00 a .m . to 12:00 p .m .
Room: La Nouvelle Orleans Ballroom
Open admission, no tuition or ticket.
Up to 2.00 Category 1 CME Credit

10:15 a.m. PRESIDENT-ELECT’S ADDRESS 10:30 a.m. LILA GRUBER MEMORIAL CANCER RESEARCH
Ronald L. Moy, M.D. AWARD AND LECTURESHIP
W. Marston Linehan, M.D.

As we look ahead to dermatology in 2011 and Familial Kidney Cancer Syndromes with
beyond, Ronald Moy, M.D., will present his Cutaneous Manifestations
forward-looking vision of the Academy when he My colleagues and I study the genetic basis and
delivers his plenary message as president-elect. clinical manifestations of familial human kidney
cancer syndromes, two of which, Birt-Hogg-Dubé
Among his aspirations for his term, Dr. Moy has and hereditary leiomyomatosis renal cell cancer,
expressed his desire to revitalize the Academy, and have important cutaneous manifestations. Our
he will outline his plan to generate more resources clinical and experimental analyses are leading to
to assist in realizing the Academy’s continuing improved management and targeted therapeutic
vision of excellence. Dr. Moy has advocated approaches for these disorders.
more comprehensive education of the public and .50 Category 1 CME Credits
legislators by dermatologists to help achieve the
Academy’s goals.

He will discuss the value of partnerships and

teamwork, and will outline his plans for a future
that seeks to be prosperous for dermatologists and
beneficial to patients.
* No CME Credits
SUNDAY, FEBRUARY 6

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 161
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

PLN151 PLENARY SESSION

8:00 a .m . to 12:00 p .m .
Room: La Nouvelle Orleans Ballroom
Open admission, no tuition or ticket.
Up to 2.00 Category 1 CME Credits

11:00 a.m. EUGENE j. VAN SCOTT AWARD FOR 11:30 a.m. GUEST SPEAkERS
INNOVATIVE THERAPY OF THE SkIN AND James Carville and Mary Matalin
PHILLIP FROST LEADERSHIP LECTURE
Anton Stuetz, Ph.D.

essons Learned During Research and

L All’s Fair: Love, War, and Politics
Development of New Medicines for Treatment In this highly popular joint presentation,
of Skin Diseases Washington’s best-loved couple, James Carville and
The allylamine antimycotic terbinafine has become Mary Matalin, gives audiences an enlightening
the global standard for the treatment of fungal and entertaining look at today’s most important
infections of the skin and nails. Topical calcineurin political issues as well as a behind-the-scenes look
inhibitors have become the first alternative to at Washington politics. Co-authors of the national
topical corticosteroids in the treatment of atopic bestseller All’s Fair: Love, War, and Running
dermatitis. Recent research indicates potential for President, both Matalin and Carville are
of VEGF inhibitors and topical Smoothened key players on the national political stage, having
inhibitors for treatment of skin diseases. Lessons between them worked for every president over
learned during research and development of these the last 25 years. In this presentation, Carville
projects will be discussed, considered to be relevant and Matalin combine their unique experience as
for today´s efforts to come up with new drugs. perennial political insiders to provide audiences with
.50 Category 1 CME Credits a stimulating, candid, and provocative analysis of
the day’s headlines and today’s hot-button political
issues from both sides of the political aisle for a lively
and engaging exchange of views.
* No CME Credit
SUNDAY, FEBRUARY 6

162 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM DISCUSSION GROUP

11:00 a .m . to 2:00 p .m . 12:15 p .m . to 1:45 p .m .
Open admission, no tuition or ticket. Tuition fee and ticket required for admission.

S024 Residents and Fellows Symposium D015 Urticaria and Angioedema

Room: 343
DIRECTOR Dennis H. Oh, M.D., Ph.D.
SPEAkERS
Michael E . Ming, M .D .
Delphine J . Lee, M .D ., Ph .D .
Jeffrey B . Travers, M .D ., Ph .D .
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 . Identify the latest laboratory-based and/or clinic-based research
findings presented by dermatology residents and fellows .
2 . Recognize developing trends in research in cutaneous biology
and dermatologic disease .
DESCRIPTION
New knowledge about the pathophysiology and treatment of
cutaneous diseases is cruical for the future of our specialty . In
this session, talented young investigators who are actively working
in the laboratory and/or clinic will present their latest research
discoveries . The faculty, who will serve as judges, will select the
residents or fellows who present the most outstanding papers at
the symposium to receive the prestigious Everett C . Fox Memorial
Lectureship .
3.00 Category 1 CME Credits
Room: 240
DIRECTOR Nicholas Arthur Soter, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 . Develop an appropriate evaluation for patients with urticaria
and angioedema .
2 . Select the various classes of pharmacologic agents to treat
urticaria and angioedema .
DESCRIPTION
The evaluation of patients with urticaria and angioedema will
be presented based on pathogenesis . These categories include:
immunologic IgE and IgE receptor-dependent processes,
abnormalities of plasma systems, agents that directly degranulate
the mast cell and alter arachidonic acid metabolism, and
idiopathic disease . Antihistamines of the first, second, and third
generations will be discussed as well as novel and anecdotal
therapeutic agents .
1.50 Category 1 CME Credits
D016 Photodermatology
Room: 241
DIRECTOR John Lyndon McLeod Hawk, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 . Explain the mechanisms of normal and abnormal skin
responses to ultraviolet radiation exposure .
2 . Prevent or treat most of these responses effectively .
3 . Recognize many of the interactions of ultraviolet radiation
with skin .
DESCRIPTION
The nature of ultraviolet radiation damage to the skin and
of the common photodermatoses, particularly polymorphic
light eruption, the effective use of photoprotection and more
specific treatments, and use and efficacy of phototherapy, will be
SUNDAY, FEBRUARY 6

discussed . In addition, matters of major general dermatological

interest such as vitamin D and sun exposure requirements,
sun beds, and sunscreens will be included . This session is
directed at both general dermatologists and those with a specific
photodermatological interest .
1.50 Category 1 CME Credits

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 163
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

POSTER DISCUSSION
12:15 p .m . to 1:45 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

PD03 Acne PD04 Psoriasis

Room: 283 Room: 284
No CME Credits No CME Credits
MODERATOR MODERATOR
Jonette Elizabeth Keri, M .D ., Ph .D . Paolo Romanelli, M .D .
P300 P400
Clindamycin plus tretinoin gel: Treatment of acne patients with all The effect of tumor necrosis factor-alpha inhibitors on the risk of
six Fitzpatrick skin types myocardial infarction in patients with psoriasis
P301 P401
Tretinoin microsphere 0 .1% gel for acne patients Determining the extent to which clinically effective treatment,
ustekinumab or etanercept, reverses the molecular disease profile
P302
of psoriatic skin: Comparisons of lesional, non-lesional, and
Faropenem is effective for inflammatory acne
normal skin
P303
P402
High degree of safety, efficacy, tolerability, lower relapse rates, and
Improvement in nail psoriasis is associated with improved efficacy
improved quality of life associated with high-dose isotretinoin
outcomes in hand and/or foot psoriasis in adalimumab-treated
therapy
patients: Subanalysis of REACH
P304
P403
Managing mild to moderate acne in adolescents: Cutaneous
Ustekinumab demonstrates rapid onset of efficacy in the treatment
tolerability benefits of tretinoin gel (0 .05%) in a study
of moderate to severe psoriasis
subpopulation of 983 subjects aged 10 to <18 years
P404
P305
Cause-specific mortality in patients with severe psoriasis: A
Exacerbation of facial acne vulgaris after consuming pure
population-based cohort study
chocolate
P405
P306
The safety of tumor necrosis factor antagonists in patients with
Meta-analysis of randomized controlled trials using 5% benzoyl
psoriatic disease: A systematic review and meta-analysis of
peroxide and clindamycin versus 2 .5% benzoyl peroxide and
randomized controlled trials
clindamycin topical treatments in acne
P406
A pooled analysis of phase III, randomized, placebo-controlled
clinical trials of the anti-interleukin 12/23 monoclonal antibody,
ABT-874
P407
Gene expression profiling in psoriatic scalp hair follicles:
SUNDAY, FEBRUARY 6

Clobetasol propionate shampoo 0 .05% normalizes psoriasis disease

markers

164 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
12:15 p .m . to 1:45 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U086 Melasma: Pathogenesis and Treatment
Room: 285
DIRECTOR Andreas D. Katsambas, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Recognize and identify melasma in patients .
2 . Develop and implement proper treatment for melasma
patients .
DESCRIPTION
Melasma is a cosmetic problem that can sometimes cause great
emotional suffering . Although no race is spared, melasma appears
to be more common in darker-skinned individuals of Hispanic,
Asian, and Indo-chinese origin . Genetic predisposition, estrogens,
and solar radiation have been incriminated for the pathogenesis
of melasma . Recent advances regarding the management of this
disease will be reviewed, including topical bleaching agents,
combination formulas, chemical peels, and lasers . Finally, a
management plan for different skin types as well as different
categories of melasma (epidermal-mixed-dermal) will be presented .
1.50 Category 1 CME Credits
U087 Fulfilling Great Expectations: Caring for
New Mothers and Mothers-to-Be
Room: 274
DIRECTOR Jenny Eileen Murase, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Discuss with pregnant and lactating patients safety data on
medications frequently used to treat common dermatologic
conditions .
2 . Diagnose and treat nipple dermatitis and thrush during
lactation, and make recommendations on prevention in
lactating mothers .
DESCRIPTION
Dermatologists are often faced with difficult questions from new
U088 Hereditary Diseases of the Epidermis
Room: 238/239
DIRECTOR Takashi Hashimoto, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Diagnose hereditary diseases of the epidermis .
2 . Select the best methods for the diagnosis of hereditary diseases
of the epidermis .
3 . Identify the pathomechanism for the skin lesion in these
hereditary diseases .
DESCRIPTION
This session will present the new findings in various hereditary
diseases of the epidermis, including ichthyosis, palmoplantar
keratoderma and pachyonychia congenita, Darier disease,
Hailey-Hailey disease, and epidermolysis bullosa hereditaria .
The audience will learn to diagnose these diseases clinically
and histopathologically, and will be able to show patients the
genetic background of each disease . Precise information about
the mutation of the responsible gene for each disease also will be
covered . Furthermore, the lecturer will also explain about the
pathomechanism for the skin lesion in these hereditary diseases
of the epidermis . Finally, gene therapy for these diseases will be
described .
1.50 Category 1 CME Credits
SUNDAY, FEBRUARY 6

mothers and mothers-to-be concerned about how the use of

medical therapy during pregnancy and lactation may affect their
children . We will review, through an evidence-based medicine
approach, safety data in pregnancy and lactation . We will discuss
medical malpractice surrounding use of dermatologic therapy in
pregnancy . Finally, we will discuss the appropriate work-up of
nipple dermatitis, when to suspect thrush, medications and other
therapies that are safe to speed recovery, and the appropriate
management of the elusive entity chronic candidal mastitis .
1.50 Category 1 CME Credits

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 165
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
FOCUS SESSION
12:15 p .m . to 1:45 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U089 Lasers 101
Room: 265/266
DIRECTOR Gerald Goldberg, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Identify some of the basic principles and physics of laser-tissue
interaction, which are important in a variety of laser skin
treatments .
2 . Discuss and illustrate specific attributes of multiple laser
modalities in the treatment of vascular entities, pigmented
lesions, wrinkles, scars, epidermal lesions, and unwanted hair .
3 . Develop an understanding of appropriate patient selection,
as well as proper preparation of patient expectation, by
appreciating the potential side effects, complications, and
limitations of skin laser treatments .
DESCRIPTION
This session will offer a brief review of the basic physics and
clinical applications of a wide variety of laser modalities . The use
of lasers for vascular lesions, pigment problems, hair removal,
and epidermal and dermal entities will be discussed . The session
will illustrate some of the primary uses of lasers with clinical cases
from 25 years of laser practice . We will focus the discussion on
treatment of vascular lesions as well as the uses of some of the
new ablative, nonablative, and fractional resurfacing devices . We
will also illustrate creative uses of lasers, alone and in combination
with other modalities . We will discuss patient selection and
complications .
1.50 Category 1 CME Credits
U090 Angiogenesis and Clinical Dermatology
Room: 269
DIRECTOR Jack L. Arbiser, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Determine how to use antiangiogenic therapy in clinical
practice .
2 . Determine which disorders have excessive or deficient
SUNDAY, FEBRUARY 6
angiogenesis .
DESCRIPTION
Malignant, inflammatory, and infectious disease processes induce
angiogenesis in order to initiate and perpetuate themselves .
Dermatologists already use antiangiogenic therapy for the
treatment of common skin conditions . This session will discuss the
use of angiogenesis for skin cancer, inflammatory skin conditions
(psoriasis/atopic dermatitis), and infectious processes such as warts .
1.50 Category 1 CME Credits
166 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
U091 Challenging Cases in Dermatopathology
Room: 264
DIRECTOR Klaus Sellheyer, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Identify difficult dermatopathological cases .
2 . Identify the most relevant differential diagnoses .
3 . Perform the clinicopathological correlation .
DESCRIPTION
We will cover about 30 difficult dermatopathological cases . At
the end of the session the participant should be able to recognize
these cases which include inflammatory, neoplastic, genetic, and
deposition disorders . The differential diagnoses of these cases
will also be discussed . The session is meant to be interactive and
questions between audience and faculty are highly encouraged .
1.50 Category 1 CME Credits
U092 Opening Your Own Practice:
Blunders and Breakthroughs
Room: 267/268
DIRECTOR Robert L. Buka, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Determine whether private practice is the best next step .
2 . Develop a key understanding of foundations behind a
successful private practice .
3 . Demonstrate the leadership required to grow a business from
the ground up .
DESCRIPTION
1 . Decision . The discussion will begin with an overview of
whether this decision is the right one for participants, new
challenges in healthcare reimbursement, the pros/cons of more
autonomy, preparation required before opening a practice .
2 . Location . Identifying the best location for a practice, a space
that will work for you for years to come . Leasing, purchasing,
and lenders will all be reviewed .
3 . Setup . What electronic features are worth it and which still
need further testing? Choosing office staff and associates .
4 . Recruitment . Now the practice is open . Where do you find
patients? A review of advertising and marketing for a new
practice .
1.50 Category 1 CME Credits
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
12:15 p .m . to 1:45 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U093 Notes of a Therapeutic Iconoclast U095 Biologic Drugs for Psoriasis:

Room: 270 Do We Use Them Enough?
DIRECTOR Norman Levine, M.D. Room: 298/299

LEARNING OBjECTIVES DIRECTOR Ronald B. Prussick, M.D.

Following this focus session, the attendee will be able to:
1 . Critically evaluate claims of therapeutic efficacy .
2 . Select optimal treatments for various dermatological
conditions .
3 . Manage patients using aggressive medical regimens .
DESCRIPTION
Alternative views of medical and surgical therapies used in
dermatological practice will be discussed . A review of the recent
literature as well as personal experiences and prejudices will form
the basis for conclusions about which treatments are effective and
which are not worth using . Therapies such as the “pre-biologics,”
psychotropic medications, topical immune modulators, sentinel
node biopsies for melanoma, indications for Mohs micrographic
surgery will be presented . The evolving role of the pharmaceutical
industry in the lives of patients and health care providers will also
be discussed .
1.50 Category 1 CME Credits
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Assess when to consider a biologic drug for a patient with
psoriasis .
2 . Choose which biologic to use .
3 . Evaluate and recognize how to monitor and manage patients
on biologic drugs .
DESCRIPTION
Psoriasis is a systemic autoimmune disease . Instead of a strict
stepwise approach, we will explore decisions based on patient
presentation, disease severity, presence of arthritis, and quality-
of-life measures . We will detemine when it is appropriate to
consider treatment with a biologic drug and look at those available
to us, their advantages and disadvantages . We will also discuss
monitoring guidelines . This session is directed mainly to clinicians
in private practice .
1.50 Category 1 CME Credits

U094 Dermatologic Manifestations of HIV U096 Medical Therapies and How They Work
and AIDS Room: 235/236
Room: 242
DIRECTOR Kevin D. Cooper, M.D.
DIRECTOR Adam D. Lipworth, M.D.
LEARNING OBjECTIVES
LEARNING OBjECTIVES Following this focus session, the attendee will be able to:
Following this focus session, the attendee will be able to: 1 . Choose medical therapies that are best suited for the
1 . Identify cutaneous manifestations of HIV and AIDS . underlying disease mechanism .
2 . Manage cutaneous manifestations of HIV and AIDS . 2 . Explain to patients and family the rationale for drug choice in
relation to disease .
DESCRIPTION
3 . Use drugs to treat inflammatory disease mechanisms and
HIV and AIDS patients develop unique infectious and non-
pathology patterns .
infectious cutaneous diseases, many of which carry significant
morbidity and mortality . The rise of antiretroviral therapy has DESCRIPTION
SUNDAY, FEBRUARY 6

decreased the prevalence of these complications in the United
States, decreasing familiarity with these diseases among US
dermatologists . However, opportunistic infections, HIV-associated
malignancies, hypersensitivity reactions to HIV treatments, and
severe primary inflammatory dermatoses persist in certain HIV-
infected populations in the developed world, and remain very
common in developing nations . This case-based session will use
actual patient encounters from the United States, the United
Kingdom, and Africa to highlight diagnosis and management of
HIV-related skin diseases .
1.50 Category 1 CME Credits
Medical therapies are increasingly targeted to specific disease
mechanisms or are better understood as to which mechanisms
are affected . Inflammatory diseases as well as neoplastic disorders
in dermatology have such drugs available that help patients and
elucidate the underlying disease process . Understanding drug-
targetable disease processes allows one to better treat patients whose
pathologic reaction pattern can be identified but whose specific
subtype might be poorly described in the literature . This session
will discuss examples of medical therapies that target specific basic
mechanisms, with an emphasis on inflammatory disease .
1.50 Category 1 CME Credits

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 167
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
FOCUS SESSION
12:15 p .m . to 1:45 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U097 Immunostimulatory Treatment of Skin
Cancer
Room: 263
DIRECTOR Stephen Brent Tucker, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Explain immunologic mechanisms for eradicating cancer cells .
2 . Select which skin cancers are optimal for immunotherapy based
on histology, location, and patient .
3 . Treat skin cancers by immunostimulation and prevent future
skin cancers by patient education .
DESCRIPTION
The session will include results of immunostimulation for cancer
treatment in general, and applications for skin tumors specifically .
Basic science and histological aspects of immunotherapy in the
skin and the use of immunostimulation for prevention will be
covered . Treatment guidelines to be presented include: selecting
appropriate tumors; discussion of this treatment option with
patients; prevention of side effects; cost of treatment; expected
short- and long-term outcomes, and advantages and disadvantages
of this treatment . Specific protocols using imiquimod, interferon
alfa, and combination treatment will be discussed for those
interested in alternatives to destructive methods .
1.50 Category 1 CME Credits
SUNDAY, FEBRUARY 6
168 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
SYMPOSIUM
2:00 p .m . to 5:00 p .m .
Open admission, no tuition or ticket.
S025 New Emerging Therapies
Room: 243/244/245
DIRECTOR David Eric Cohen, M.D.
SPEAkERS
Macrene Alexiades- Bruce Elliot Strober, M .D ., Ph .D .
Armenakas, M .D ., Ph .D . Antonio Torelo, M .D .
Brian Berman, M .D ., Ph .D . Ken Washenik, M .D ., Ph .D .
Elizabeth K . Hale, M .D . Guy F . Webster, M .D ., Ph .D .
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 . Identify new and emerging treatments for a wide variety of skin
diseases .
2 . Discuss the mechanisms of action of future therapies .
3 . Examine the efficacy and safety of new dermatologic therapies .
DESCRIPTION
This symposium will review new and emerging therapies for
the treatment of a wide variety of dermatologic diseases . This
conference will serve as a repository of information for the most
cutting edge treatments that have become available recently or that
may become part of our therapeutic armamentarium in the future .
3.00 Category 1 CME Credits
SCHEDULE
2:00 p .m . Introduction To New Emerging Therapies And
Discussion Of The Allergen Of The Year / Dr. Cohen
2:20 p .m . Psoriasis / Dr. Strober
2:40 p .m . Fillers And Injectable Cosmetic Devices / Dr. Hale
3:00 p .m . Acne And Rosacea / Dr. Webster
3:20 p .m . Alopecia, Hair And Scalp Disorders / Dr. Washenik
4:00 p .m . Actinic Keratosis And Skin Cancer / Dr. Berman
4:20 p .m . Laser Therapy / Dr. Alexiades-Armenakas
4:40 p .m . Questions and Answers / Dr. Cohen
4:40 p .m . Pediatric Dermatology / Dr. Torello
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
2:00 p .m . to 5:00 p .m .
Open admission, no tuition or ticket.

S026 Cutaneous Oncology SCHEDULE

Room: Auditorium C 2:00 p .m . Introduction and Review of Today’s Session
/ Dr. Rigel
DIRECTOR Darrell S. Rigel, M.D. 2:05 p .m . Magnitude of the Problem: What Is the Real Number
SPEAkERS of Non-melanoma Skin Cancers in the US?
Roger I . Ceilley, M .D . June K . Robinson, M .D . / Dr. Coldiron
Clay J . Cockerell, M .D . Theodore Rosen, M .D . 2:18 p .m . New Concepts in Merkel Cell Carcinoma
Brett M . Coldiron, M .D . James M . Spencer, M .D . / Dr. Nghiem
Robert J . Friedman, M .D . Jennifer A . Stein, M .D . 2:31 p .m . Challenges in Photoprotection / Dr. Rigel
Mark Lebwohl, M .D . Susan M . Swetter, M .D . 2:44 p .m . Topical Therapy for Skin Cancer: Old and New
Paul Nghiem, M .D ., Ph .D . Options / Dr. Rosen
2:57 p .m . Do Psoriasis Therapies Increase Skin Cancer Risk?
LEARNING OBjECTIVES / Dr. Lebwohl
Following this symposium, the attendee will be able to: 3:10 p .m . Managing the Melanoma Patient / Dr. Swetter
1 . Develop better care for patients with skin cancer . 3:23 p .m . Questions and Answers / Dr. Faculty
2 . Assess the risk factors and prognosis for skin cancer . 3:31 p .m . The Dilemma of the Dysplastic Nevus / Dr. Cockerell
3 . Identify the typical questions that skin cancer patients raise 3:44 p .m . Challenges in Skin Cancer Prevention: Can We Make
about their disease and therapies . a Difference? / Dr. Robinson
DESCRIPTION 3:57 p .m . When Our Patients Ask About Tanning and
The most important management issue that we face on a daily Vitamin D . . . / Dr. Spencer
basis in dermatology, from a life-and-death perspective, is skin 4:10 p .m . Diagnosing Melanoma: New Options / Dr. Ceilley
cancer . In the past decade, dermatologists have evolved from 4:23 p .m . Approaches to the Patient with Advanced Melanoma /
merely diagnosing skin cancer to being actively involved in all Dr. Friedman
phases of management . It is therefore incumbent upon us to be 4:36 p .m . Using Dermoscopy for the Face and Feet: Special
up to date on all aspects of cutaneous oncology . The goal of this Considerations / Dr. Stein
symposium is to provide the most up-to-date information on 4:47 p .m . Questions and Answers / Faculty
melanoma to the practicing dermatologist so that patient care can
be optimized
3.00 Category 1 CME Credits
REFERENCES
1 . Rigel et al, eds . Cancer of the Skin, 2nd ed . Philadelphia:
Elsevier; February 2011 .

SUNDAY, FEBRUARY 6

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 169
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
2:00 p .m . to 5:00 p .m .
Open admission, no tuition or ticket.

S027 Contact and Occupational Dermatitis

Room: La Nouvelle Orleans Ballroom
DIRECTOR Susan T. Nedorost, M.D.
SPEAkERS
Bryan Erik Anderson, M .D . Dianne Louise Silvestri, M .D .
Douglas L . Powell, M .D . Erik Joseph Stratman, M .D .
Andrew J . Scheman, M .D .
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 . Identify new occupational and personal care allergens .
2 . Demonstrate testing of patients with atopic dermatitis .
3 . Develop teaching about contact allergy for patients, colleagues,
and self .
DESCRIPTION
Experts in contact dermatitis will provide updates on emerging
allergens and educational resources . Testing in the atopic
dermatitis patient will be discussed in detail . Learn how to teach
yourself, your patients, and colleagues about contact dermatitis .
This session will be of interest to novice and experienced patch
testers .
3.00 Category 1 CME Credits
SCHEDULE
2:00 p .m . Emerging Allergens / Dr. Scheman
2:30 p .m . Patient Education in Contact Dermatitis / Dr. Silvestri
3:00 p .m . Skin Testing for Atopy and Urticaria / Dr. Powell
3:30 p .m . Occupational and Industrial Skin Disease: A Year in
Review / Dr. Anderson
4:00 p .m . Teaching and Learning Contact Dermatitis
/ Dr. Stratman
4:30 p .m . Patch Testing in Atopic Dermatitis / Dr. Nedorost
SUNDAY, FEBRUARY 6

170 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
2:00 p .m . to 5:00 p .m .
Open admission, no tuition or ticket.

S028 Nails SCHEDULE

Room: Auditorium A 2:00 p .m . Enlightening and Educational Nail Cases: CPC From
UCSF / Dr. Ruben
DIRECTOR Nathaniel J. Jellinek, M.D. 2:15 p .m . New Developments in the Diagnosis and
SPEAkERS Management of Onychomycosis / Dr. Scher
C . Ralph Daniel, M .D . Demetrios G . Rigopoulos, M .D . 2:35 p .m . Fungal Melanonychia: A Diagnostic and Therapeutic
Eckart Haneke, M .D . Beth S . Ruben, M .D . Challenge / Dr. Hay
Bianca Maria Piraccini, M .D . Adam Rubin, M .D . 2:55 p .m . Update on the Evaluation and Management of Digital
Phoebe Rich, M .D . Richard K . Scher, M .D . Myxoid Cysts / Dr. Rigopoulos
Bertrand Richert, M .D ., Ph .D . Antonella Tosti, M .D . 3:10 p .m . Questions and Answers with the Experts
/ Dr. Rich / Dr. Daniel
LEARNING OBjECTIVES 3:20 p .m . Dermoscopy and imaging the Nail Unit / Dr. Tosti
Following this symposium, the attendee will be able to: 3:40 p .m . New Developments and Techniques in Nail Surgery
1 . Summarize the most important and relevant advances in / Dr. Richert
medical nail disease . 4:00 p .m . Update on the Management of Melanonychia and
2 . Discuss innovations in nail surgery and recognize significant Nail Melanoma / Dr. Haneke
nail neoplasms . 4:20 p .m . Questions and Answers with the Experts
3 . Choose the best approach to nail diagnosis and treatment . / Dr. Rich / Dr. Daniel
DESCRIPTION 4:30 p .m . Tertiary Care Nail Diseases: The Bologna Experience
This is a symposium directed at clinicians, academicians, and / Dr. Piraccini
residents . It will focus on the most significant and germaine 4:45 p .m . Laboratory and Processing Pearls for Nail Pathology
innovations and advances in the world of nail disease . Updates / Dr. Rubin
will be presented from an international group of physicians who
specialize in nail disease . Topics include onychomycosis, common
inflammatory nail disease, nail surgery, nail tumors (including nail
melanoma), and nail pathology .
3.00 Category 1 CME Credits
REFERENCES
1 . Scher RK, Daniel CR III . Nails: Diagnosis, Therapy, Surgery .
Philadelphia: Elsevier Saunders; 2005 .
2 . Baran R, Dawber RPR, de Berker DAR, Haneke E, Tosti
A . Baran and Dawber’s Diseases of the Nails and Their
Management, 3rd ed . Oxford, UK: Blackwell Science; 2001 .
3 . Zaias N, The Nail in Health and Disease . Norfwalk, CT:
Appleton and Lange; 1990 .
SUNDAY, FEBRUARY 6

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 171
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
2:00 p .m . to 5:00 p .m .
Open admission, no tuition or ticket.

S029 Lessons from Great Leaders S030 Electronic Health Record (EHR)
Room: 278/279/280 Physician Demonstration Symposium
DIRECTOR C. William Hanke, M.D. Room: 260/261/262

SPEAkERS DIRECTOR Mark D. Kaufmann, M.D.

Jean L . Bolognia, M .D . Victor J . Marks, M .D . LEARNING OBjECTIVES
Barbara Ann Gilchrest, M .D . David M . Pariser, M .D . Following this symposium, the attendee will be able to:
Henry W . Lim, M .D . Darrell S . Rigel, M .D . 1 . Assess how other dermatologists in various practice settings
Mary E . Maloney, M .D . Kim B . Yancey, M .D . successfully adopted electronic health record (EHR) systems .
LEARNING OBjECTIVES 2 . Implement an EHR utilizing best practices .
Following this symposium, the attendee will be able to: 3 . Discuss how to enhance patient safety, strengthen care
1 . Recognize how past and present leaders have advanced the coordination, and participate in quality improvements through
specialty . EHR systems .
2 . Identify leadership competencies, accomplishments and styles DESCRIPTION
of past and present leaders in dermatology . Live interactive physician-only (no vendors) demonstration of
3 . Utilize the lessons of these leaders to advance own leadership how EHR implementation was done and pearls on strategies that
goals and the specialty in the future . worked best . This session will provide members with an enhanced
DESCRIPTION understanding of the experiences of EHR dermatology champions .
Each of the eight well-known speakers will each focus on one 3.00 Category 1 CME Credits
past or present leader in dermatology, from across the specialty .
The accomplishments of each leader in a variety of leadership
settings will be highlighted through personal stories and reflections
and used to illustrate one or more of the critical core leadership
competencies . The speakers will discuss how the seven core
leadership competencies for dermatologists have been successfully
utilized by these individuals .
3.00 Category 1 CME Credits
SCHEDULE
2:00 p .m . Overview / Dr. Hanke
2:05 p .m . The AAD Leadership Institute / Dr. Maloney
2:20 p .m . Dr . Marks on Rex A . Amonette / Dr. Marks
2:40 p .m . Dr . Rigel on Alfred W . Kopf / Dr. Rigel
3:00 p .m . Dr . Bolognia on Wilma F . Bergfeld / Dr. Bolognia
3:20 p .m . Dr . Hanke on Walter B . Shelley / Dr. Hanke
3:40 p .m . Dr . Yancey on Stephen I . Katz / Dr. Yancey
4:00 p .m . Dr . Gilchrest on Thomas B . Fitzpatrick / Dr. Gilchrest
4:20 p .m . Dr . Lim on Clarence S . Livingood / Dr. Lim
SUNDAY, FEBRUARY 6

4:40 p .m . Dr . Pariser on Peyton E . Weary / Dr. Pariser

172 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM DISCUSSION GROUP

2:00 p .m . to 5:00 p .m . 2:30 p .m . to 4:00 p .m .
Open admission, no tuition or ticket. Tuition fee and ticket required for admission.

S031 Tropical Dermatology D017 Churning Out the Learning

Room: Auditorium B
DIRECTOR Aisha Sethi, M.D.
SPEAkERS
Noah A . Craft, M .D ., Ph .D . Stephen K . Tyring, M .D ., Ph .D .
Scott A . Norton, M .D ., M .P .H . Justin Wasserman, M .D .
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1 . Recognize how travel, immigration, war, and adoption
geographically affect the practice of dermatology .
2 . Distinguish and diagnose imported dermatoses that
practitioners in developed countries will likely begin to
encounter .
3 . Outline appropriate differential diagnoses and institute
appropriate therapy for these formerly exotic dermatoses .
DESCRIPTION
Once-exotic tropical skin diseases are not so exotic anymore,
due to environmental changes, war, urbanization, refugee
movements, tourism, and the emergence of new diseases . It is
increasingly important that dermatologists and dermatology
residents gain familiarity in this arena, as tropical dermatoses
become more prevalent in developed countries . This session will
cover viral infections, leishmaniasis, and imported dermatoses that
dermatologists in academic and private practice should be on the
lookout for, given the increased ease of travel and globalization .
3.00 Category 1 CME Credits
REFERENCES
1 . Monsel G, Caumes E . Recent developments in dermatological
syndromes in returning travelers . Curr Opin Infect Dis . 2008
Oct;21(5):495-499 .
2 . Patel S, Sethi A . Imported tropical diseases . Dermatol Ther .
2009 Nov-Dec;22(6):538-549 .
3 . Lederman ER, Weld LH, Elyazar IR, von Sonnenburg F,
Loutan L, Schwartz E, Keystone JS; GeoSentinel Surveillance
Network . Dermatologic conditions of the ill returned traveler:
an analysis from the GeoSentinel Surveillance Network . Int J DESCRIPTION
Infect Dis . 2008 . Nov; 12:593-602 .
SCHEDULE
Room: 240
DIRECTOR John A. Zic, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 . Develop strategies to engage audiences in the large group
setting .
2 . Design case presentations to enhance clinical reasoning skills in
the small group setting .
3 . Recognize teachable moments in the clinic setting and how to
give feedback .
DESCRIPTION
This interactive session will enhance your teaching skills in a
number of different educational environments . Dermatologists
who teach on any level will benefit from the shared experiences in
this discussion session . Develop strategies to engage the audience
in the large group setting . The small group setting offers different
challenges to the moderator and the learner . How can you present
a case to enhance clinical reasoning skills? Finally, in the clinic
setting, how do you balance teaching and practicing dermatology?
How do you recognize teachable moments in the clinic? Bring
your tips and challenges as we share educational experiences .
1.50 Category 1 CME Credits
D018 Practice Tips and Surgical Gems
Room: 241
DIRECTOR Roger I. Ceilley, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1 . Develop surgical skills and efficiency .
2 . Develop practice skills, accuracy, and efficiency .
This session will include an overview of practice tips and surgical
gems This will be an interactive session and registrants are
SUNDAY, FEBRUARY 6

2:00 p .m . Viral Infections / Dr. Tyring encouraged to comment, offer surgical tips and practice pearls .
2:30 p .m . Leishmaniasis / Dr. Craft 1.50 Category 1 CME Credits
3:00 p .m . Questions and Answers / Faculty
3:10 p .m . Exotic Skin Disease / Dr. Sethi
3:45 p .m . Tropical Dermatoses of Travelers and Expatriates
/ Dr. Norton
4:20 p .m . Questions and Answers / Faculty
4:25 p .m . Tropical Pathology / Dr. Wasserman
4:55 p .m . Questions and Answers / Faculty

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 173
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
2:30 p .m . to 4:00 p .m .
Switching from paper
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
to electronic
has never been easier!
U098 HIT EMRs and Documenting Clinical Care:
Pitfalls and Promises
Room: 264
DIRECTOR David J. Altman, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Identify important issues in electronic medical record (EMR)
adoption including the impact of recent laws and certifications .
2 . Recognize and assess your practice patterns and how they may Health Information Technology (HIT) has never
be affected by EMR adoption and utilization .
been more important. In order to keep up with its
3 . Assess different types of EMR documentation with regard to these
practice patterns to determine which may be optimal for you . growing demand, the AAD has created the HIT-kit.
DESCRIPTION This free online resource is here to assist members
This session will focus on aspects of EMRs dealing with the clinical as they transition their dermatology practices from
encounter and patient care, rather than practice management . paper to electronic.
We will look at implications of the HITECH Act and evolving
meaningful use criteria, and the evolving CCHIT certification
process, for clinical documentation in EMRs and the benefits and
limitations of these . We will discuss examining practice patterns
and preferences for essential, preferred, unnecessary, wasteful, Within the HIT-kit:
and detrimental processes and habits that affect efficiency and
effectiveness . EMR methods for documenting the clinical encounter • dEHRm – Provides all of the tools and
and care delivered and their pitfalls and promises with regard to these
practice patterns will be discussed .
resources necessary in implementing
1.50 Category 1 CME Credits an EHR

• DermLex – Free online database

U099 Lumps and Bumps in Children of dermatologic terminology
Room: 269
• E-prescribing – Learn how to
DIRECTOR Hanspaul Makkar, M.D.
electronically prescribe and
LEARNING OBjECTIVES
apply for a Medicare Part B bonus
Following this focus session, the attendee will be able to:
1 . Recognize common and less common birthmarks and • HIT Dashboard – Become informed on federal
developmental anomalies in neonates and infants .
2 . Develop a systematic approach to the workup and management regulations within the field of health
of lumps and bumps in infants . information technology
3 . Recognize and distinguish worrisome birthmarks from those
SUNDAY, FEBRUARY 6

that are innocuous .

DESCRIPTION FREE Online Resource!
Birthmarks and nevi in children can be innocuous and most
are benign . Developmental anomalies in neonates and children
occur as a result of errors during embryogenesis . This session is
intended to describe some of these birthmarks and developmental Visit the Academy Resource
defects and to develop an algorithmic approach to workup of these
lesions, including when biopsy and additional workup might be
Center Booth 3623
appropriate . In addition, other lumps and bumps are discussed, to demo today!
including malignancies that present in infancy .
1.50 Category 1 CME Credits

174 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting


For description of session categories and fees see page 37
FOCUS SESSION
2:30 p .m . to 4:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U100 Current Management of Skin Cancer in
Transplant Patients
Room: 283
DIRECTOR Alexandra Y. Zhang, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Recognize increased incidence, associated risk factors,
pathogenesis and the aggressive nature of certain cutaneous
malignancies in transplant patients .
2 . Explain the strategies for prevention and management of skin
cancers by utilizing both existing and novel emerging therapies .
3 . Recognize the importance of vigilant surveillance of skin cancer
in transplant patients .
DESCRIPTION
Skin cancer is the most common malignancy in solid organ
transplant recipients that causes significant morbidity and
mortality . Because of their immunocompromised status,
transplant patients are predisposed to develop certain types
of cutaneous malignancies such as squamous cell carcinoma,
basal cell carcinoma and Kaposi’s sarcoma . Identifying high-
risk patients and individualizing prevention and treatment
strategies are critical in the management of transplant-associated
cutaneous malignancies because of their aggressive nature and
higher rate of metastasis . This focus session reviews the clinical
use of existing and emerging therapies, such as surgical excisions,
topical chemotherapy, immunomodulators, photodynamic
therapy, and systemic chemoprevention with oral retinoids .
Coordination of care by dermatologists and transplant physicians,
in order to optimize immunosuppressant regimens (reduction
of immunosuppression, and the use of proliferation signal
inhibitors), is paramount in the management of transplant-
associated cutaneous malignancies . Interesting cases from the
transplant dermatology clinic will be presented as well .
1.50 Category 1 CME Credits
for the lAtest ProgrAm Book informAtion PleAse refer to
SCIENTIFIC SESSIONS
U101 Pediatric Drug Eruptions
Room: 274
DIRECTOR John C. Browning, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Identify the different types of pediatric drug eruptions .
2 . Discuss the pathophysiology of different drug eruptions .
3 . Assess the course of treatment when a drug eruption is present .
DESCRIPTION
The participant will learn about the wide range of pediatric drug
eruptions, including rare cases . He or she will be able to recognize
these eruptions and know what treatment, if any, is appropriate .
1.50 Category 1 CME Credits
U102 From Pigment to PUPP (or PEP): What to
Expect When Your Patient is Expecting
Room: 270
DIRECTOR Miriam Keltz Pomeranz, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Recognize physiologic changes in a pregnant patient .
2 . Diagnose dermatoses of pregnancy .
3 . Treat the pregnant patient with skin disease .
DESCRIPTION
Pregnancy is a time of many changes in a woman’s body,
including her skin . I will review the physiologic as well as the
pathophysiologic conditions that occur during gestation . The
discussion will include pigmentary alterations, vascular growths,
and other tumors . The specific dermatoses of pregnancy will be
summarized . Recent literature on treatment will be reviewed .
Participants are encourage to bring cases for discussion .
1.50 Category 1 CME Credits SUNDAY, FEBRUARY 6
www.aad.org | 175
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
FOCUS SESSION
2:30 p .m . to 4:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U103 Drug Reaction Update 2011
Room: 242
DIRECTOR Heidi H. Kong, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Identify culprits causing newer drug reactions .
2 . Differentiate the various skin toxicities associated with newer
targeted therapies .
3 . Manage these newer drug reactions .
DESCRIPTION
Cutaneous drug reactions are one of the most common toxicities
associated with medications . As new drugs are continually being
developed, dermatologists will be asked to know and manage
the skin toxicities related to these medications . This session will
review the current literature on drug reactions, including targeted
therapies .
1.50 Category 1 CME Credits
U104 Cosmeceuticals: Topical Therapies for
Treating the Aging Face
Room: 265/266
DIRECTOR Jennifer Lung Linder, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Identify scientifically proven topical ingredients that correct
current and prevent future dermal and epidermal damage .
2 . Develop well-rounded age control regimens tailored to the
individual patient .
3 . Measure product efficacy by evaluating ingredient mechanism
of action .
DESCRIPTION
Developing a deeper understanding of how common
cosmeceutical ingredients interact with the skin will assist in
choosing the best topical products . Topical therapies can help
the physician to correct superficial imperfections and enhance
SUNDAY, FEBRUARY 6
the results of more invasive procedures . Identifying multi-
faceted ingredients that are supported by science will assist the
physician in determining the efficacy of skin care products . The
specific mechanisms of action of anti-aging ingredients, including
retinoids, L-ascorbic acid, melanogenesis inhibitors, peptides
and antioxidants will be discussed . Confidently recommending
products that contain ingredients that provide consistent results
can deepen the physician-patient relationship, and your practice’s
bottom line .
1.50 Category 1 CME Credits
176 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
U105 Advances in Fat Transfer and Liposuction
for Correction of Lipodystrophy:
The USC Experience
Room: 267/268
DIRECTOR Ilya Reyter, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Diagnose lipodystrophy, particularly in the setting of HIV
disease .
2 . Select the best treatment for lipoatrophy and lipohypertrophy .
3 . Recognize the utility of autologous fat transfer for the
treatment of lipoatrophy .
DESCRIPTION
The session will focus on the use of liposuction and autologous
fat transfer for the treatment of lipodystrophy, particularly in
the setting of HIV disease . Participants will learn to recognize
key features of lipodystrophy and to select the most appropriate
treatment for each patient . Advanced techniques in autologous fat
transfer and liposuction will be emphasized, and current research
in fat grafting will be explored . Cases from the USC Department
of Dermatology HIV Lipodystrophy Clinic will be presented and
discussed .
1.50 Category 1 CME Credits
U106 What’s That? Syndrome Update
Room: 235/236
DIRECTOR James G. Dinulos, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Develop a diagnostic approach to patients with epidermolysis
bullosa .
2 . Develop an approach to the management of patients with
common genetic syndromes .
DESCRIPTION
This session will emphasize common syndromes involving
the epidermis such as ichthyosis, epidermolysis bullosa; and
syndromes involving the dermis and subcutis such as aplasia cutis
congenita, vascular malformations; and syndromes presenting
with malformations involving the skin appendages such as
the ectodermal dysplasias . Clinical assessments and diagnostic
evaluations important to the practicing dermatologist will be
emphasized .
1.50 Category 1 CME Credits
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION FORUM

2:30 p .m . to 4:00 p .m . 3:00 p .m . to 5:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time. for only 15 minutes after the official start time.

U107 Dermatology in Cinema F047 Managing an Efficient Practice

Room: 263
DIRECTOR Vail C. Reese, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Demonstrate to patients examples of skin conditions in movies .
2 . Identify categories of skin conditions seen in movies .
3 . Develop empathy for patients .
DESCRIPTION
Spanning over 100 years of cinema, examples of skin conditions
depicted in movies will be presented, in both still images and video .
Updated for 2011, these include adult acne, congenital lesions,
infectious disease, and neoplasms . The psychosocial implications
of the depiction of dermatoses will be explored . Practical examples
that can be used for patient education will be emphasized .
1.50 Category 1 CME Credits
U108 Safety of Biologic Therapies:
What’s the Real Story?
Room: 284
DIRECTOR Mark R. Ling, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1 . Identify the ways in which short- and long-term safety of
biologic drugs can be properly assessed .
2 . Assess the specific data regarding safety of the most widely used
biologics for psoriasis therapy .
3 . Analyze the relative risks and benefits of existing biologic drugs
as an aid to therapeutic decision making .
DESCRIPTION
Biologic therapy for psoriasis has revolutionized our ability to treat
moderate to severe psoriasis . These drugs, when compared to older
systemic agents, demonstrate a superior risk/benefit ratio, based
particularly on their apparently superb safety profiles . However,
Room: 295/296
DIRECTOR Barry Leshin, M.D.
SPEAkERS
Frank Cohen, M .P .A .
Glenn D . Goldstein, M .D .
Victor J . Marks, M .D .
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 . Determine methods to improve office efficiency .
2 . Describe how technology can be used to improve workflow .
3 . Recognize how process improvements can lead to greater
customer service .
DESCRIPTION
This session will provide a comprehensive overview of how to
increase office efficiencies including workflow, staff duties, and
general operations . Best practices will be discussed including
how to optimize patient flow through process improvements
focused on front and back office operations as well as the positive
impact health information technology can have on your practice .
Methods to increase patient satisfaction will also be discussed .
2.00 Category 1 CME Credits
SCHEDULE
3:00 p .m . Introduction / Dr. Leshin
3:10 p .m . Mastering Patient Flow and Process Improvements to
Improve Practice Efficiencies / Mr. Cohen
3:40 p .m . Enhancing Customer Service and Patient Satisfaction
/ Dr. Marks
4:10 p .m . Innovative Techniques in Office Efficiency
/ Dr. Goldstein
4:40 p .m . Enhancing Office Efficiency Through Use of
Electronic Health Records and Health Information
Technology / Dr. Leshin
SUNDAY, FEBRUARY 6

much of what is held as gospel regarding biologic safety is based

on anecdote, misperception, and outright misrepresentation . The
aim of this session is to drill down to the actual available data
on safety . This will allow us to understand these drugs in much
greater depth, allowing practitioners to make better therapeutic
decisions for their psoriasis patients .
1.50 Category 1 CME Credits

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 177
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
3:00 p .m . to 5:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F048 Psoriasis as a Systemic Disease F049 Laser Pearls

Room: 275/276/277 Room: 271/272/273
DIRECTOR James Frederick Libecco, M.D. DIRECTOR Keyvan Nouri, M.D.
SPEAkERS SPEAkERS
Kevin D . Cooper, M .D . Murad Alam, M .D . Jeffrey S . Dover, M .D .
Neil J . Korman, M .D ., Ph .D . Tina S . Alster, M .D . Roy G . Geronemus, M .D .
R . Rox Anderson, M .D . David J . Goldberg, M .D ., J .D .
LEARNING OBjECTIVES
Henry H . L . Chan, M .D .
Following this forum, the attendee will be able to:
1 . Recognize the systemic manifestations of psoriasis . LEARNING OBjECTIVES
2 . Utilize current data and hypotheses to address the health Following this forum, the attendee will be able to:
issues of patients with psoriasis, especially as related to vascular 1 . Assess the laser treatment pearls of vascular lesions, pigmented
disease . lesions, scars, hair removal, acne, psoriasis, hypopigmentation,
3 . Formulate an approach to evaluate new and current body tightening, and facial rejuvenation .
information on the treatment of psoriasis and related systemic 2 . Examine the nature of a vast array of laser/light devices in
disease . various application settings in medical, surgical, and cosmetic
uses .
DESCRIPTION
3 . Recognize pearls for prevention and/or management of
This session will review current data and hypotheses related to
complications in the laser field .
the systemic manifestations of patients with psoriasis . There may
be paradigm shifts in the evaluation and management of these DESCRIPTION
patients that are relevant to clinicians involved in both patient care This forum will be devoted to gaining an insight into refinements
and research . and pearls of the use of lasers/light devices in dermatology . Pearls
2.00 Category 1 CME Credits on treatment of scars, hair removal, facial rejuvenation, acne,
psoriasis and hypopigmentation will be discussed . It should cover
what devices, techniques, and settings are best suited for ethnic
skin . Furthermore, the forum will deliver tips on body tightening
devices and pearls to enhance results . The emphasis will be on
practical tips and ways to avoid and manage complications
using lasers/light devices . Finally, pearls on understanding the
use of lasers/light devices in diagnostics and therapeutics will be
discussed .
2.00 Category 1 CME Credits
SUNDAY, FEBRUARY 6

178 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting


For description of session categories and fees see page 37
FORUM
3:00 p .m . to 5:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
F050 What’s New in Immunomodulation
Room: 291/292
DIRECTOR Anthony A. Gaspari, M.D.
SPEAkERS
Andrew Blauvelt, M .D . Anna Di Nardo, M .D ., Ph .D .
Jeffrey Phillip Callen, M .D . Nanette Blythe Silverberg, M .D .
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 . Discuss the mechanisms and clinical applications of IVIG .
2 . Examine the rationale and outcome of targeted therapies for
inflammatory diseases such as psoriasis .
3 . Define the biologic effects of antimicrobial peptides, topical
sensitizers and TLR agonists and the potential therapeutic
applications .
DESCRIPTION
Dermatologists utilize a number of topical (locally acting) and
systemic medications to target the immune system as therapy
for a variety of skin conditions . Based on recent advances in the
understanding of the pathophysiology of common skin diseases,
there are now targeted therapies such as biologics that can exhibit
dramatic clinical efficacy in psoriasis . Other systemic treatments
to manipulate the immune system such as intravenous gamma
globulin (IVIG) will also be discussed . Locally acting immune-
modulating therapies, such as topical sensitizers, antimicrobial
peptides, and toll like receptor antagonists, will also be discussed .
This forum will address the existing and emerging clinical uses
of these immune-modulating agents, their mechanisms and their
risks and benefits .
2.00 Category 1 CME Credits
SCHEDULE
3:00 p .m . Welcome and Introduction / Dr. Gaspari
3:02 p .m . Immune Modulation with IVIG: Mechanisms and
Uses in Dermatology / Dr. Callen
3:26 p .m . New Developments in Blockade of the IL-23/IL-17
Pathway in Psoriasis / Dr. Blauvelt
3:50 p .m . Antimicrobial Peptides: Properties and Therapeutic
Potential / Dr. Di Nardo
4:14 p .m . Use of Topical Sensitizers in the Treatment of Warts
in Children / Dr. Silverberg
4:38 p .m . What’s New in Toll Like Receptor Agonist Research
/ Dr. Gaspari
5:00 p .m . Closing Comments / Dr. Gaspari
for the lAtest ProgrAm Book informAtion PleAse refer to
SCIENTIFIC SESSIONS
F051 Controversies in Vitamin D
Room: 255/256/257
DIRECTOR Kenneth G. Linden, M.D.
SPEAkERS
Douglas W . Johnson, M .D .
Henry W . Lim, M .D .
James M . Spencer, M .D .
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 . Evaluate the controversies in the relationship of sunlight and
tanning beds to vitamin D synthesis and requirements .
2 . Discuss emerging information on the health effects of vitamin
D, including in cancer prevention .
3 . Manage and advise dermatology patients to optimize vitamin
D therapy to prevent and treat osteoporosis .
DESCRIPTION
The health effects of vitamin D are gaining prominence within
the medical community and with the public . Vitamin D, as it
relates to dermatology, will be discussed in lively but friendly
presentations . Speakers concerned about the levels of vitamin D
in the population and the effect that sun protection has on this, as
well as those who feel that the benefits of sun protection outweigh
any likely risks, will present . Vitamin D and the prevention and
treatment of osteoporosis will be discussed, as will the emerging
science of the possible health effects of vitamin D, such as in
cancer prevention .
2.00 Category 1 CME Credits
SCHEDULE
3:00 p .m . Introduction to Vitamin D / Dr. Linden
3:30 p .m . Skin Types, Photoprotection and Vitamin D
/ Dr. Lim
4:00 p .m . Vitamin D and Skin Cancer Prevention: What
Should Dermatologists Tell Their Patients?
/ Dr. Spencer
4:30 p .m . Diagnosis and Management of Osteoporosis and
Vitamin D in Dermatology / Dr. Johnson
SUNDAY, FEBRUARY 6
www.aad.org | 179
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
3:00 p .m . to 5:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F052 Advanced Dermatopathology F053 Autoimmune Disease Update

Room: 252/253/254
DIRECTOR Jennifer Madison McNiff, M.D.
SPEAkERS
George W . Elgart, M .D . Christine Ko, M .D .
Lynne J . Goldberg, M .D . Beth S . Ruben, M .D .
Jacqueline M . Junkins-Hopkins, M .D .
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 . Recognize the importance of clinicopathologic correlation in
dermatopathology .
2 . Identify findings that are useful in avoiding pitfalls in
diagnosis .
3 . Recognize the value and limitations of special stains and new
techniques in evaluating tissue specimens .
DESCRIPTION
Five experienced dermatopathologists with a background in
clinical dermatology have been asked to present one or more
challenging cases requiring close clinicopathologic correlation for
diagnosis . There will be a detailed discussion of the diagnoses,
with emphasis on potential traps and pitfalls . These presentations
will allow attendees to experience diagnostic challenges as they
presented originally, and to learn how the problems were solved .
There will be an opportunity for questions and discussion
following each presentation .
2.00 Category 1 CME Credits
SUNDAY, FEBRUARY 6
Room: 238/239
DIRECTOR Victoria P. Werth, M.D.
SPEAkERS
Jan P . Dutz, M .D . Heidi Tewich Jacobe, M .D .
David Franklin Dedee F . Murrell, M .D .
Fiorentino, M .D ., Ph .D .
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1 . Discuss autoimmune skin diseases .
2 . Explain the recent developments in autoimmune skin diseases .
3 . Diagnose and treat autoimmune skin diseases .
DESCRIPTION
This session is designed for clinical practitioners with an interest
in more complex autoimmune disease diagnosis, evaluation,
and treatment . There will be an emphasis on the more difficult
diagnostic and management issues that arise in the care of these
patients . Attendees are invited to bring cases/questions related to
these areas .
2.00 Category 1 CME Credits
SCHEDULE
3:00 p .m . Update on Dermatomyositis / Dr. Fiorentino
3:20 p .m . Update on Cutaneous Lupus / Dr. Dutz
3:40 p .m . Update on Morphea / Dr. Jacobe
4:00 p .m . Update on Autoimmune Blistering Diseases
/ Dr. Murrell
4:20 p .m . Update on Quality of Life and Measurement of
Disease Severity in Autoimmune Skin Diseases
/ Dr. Werth
4:40 p .m . Questions and Answers / Faculty

180 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM WORkSHOP
3:00 p .m . to 5:00 p .m . 3:00 p .m . to 5:00 p .m .
Ticket required for admission, no tuition fee. Ticket holds seat Tuition fee and ticket required for admission.
for only 15 minutes after the official start time.

F054 Dermatologic Health of Women W007 Effective Communication

Room: 293/294 Room: 357
DIRECTOR Marianne N. O’Donoghue, M.D. DIRECTOR Patricia Farris, M.D.
SPEAkERS LEARNING OBjECTIVES
Jeffrey Phillip Callen, M .D . June K . Robinson, M .D . Following this workshop, the attendee will be able to:
Iltefat H . Hamzavi, M .D . Diane M . Thiboutot, M .D . 1 . Prepare compelling and relatable key messages .
2 . Explain key messages clearly, concisely, and effectively .
LEARNING OBjECTIVES
3 . Develop strategies for staying focused on key messages in
Following this forum, the attendee will be able to:
challenging situations .
1 . Diagnose and treat the special needs of women with acne and
acne rosacea . DESCRIPTION
2 . Recognize the socioeconomic barriers of health disease in The Academy has identified effective communication as a
women . core competency for leadership in dermatology . Learning
3 . Manage the female patient with lupus erythematosus and with how to successfully craft and deliver key messages will help
hidradenitis suppuriativa . you communicate effectively in any situation . Attendees will
have the opportunity to practice what they’ve learned about
DESCRIPTION
message development in mock media interviews designed to
This session will enable the physician to manage acne in women .
challenge participants to stay focused while delivering their
It will also address the health care and socioeconomic barriers
message . The course director is a previous chair of the Council
for women . It will give a comprehensive view of management of
on Communications . She will be assisted by a communications
lupus erythematosus in women . Finally, it will address the latest
consultant .
medical, surgical, and laser treatment for hidradenitis suppuriativa .
2.00 Category 1 CME Credits
2.00 Category 1 CME Credits
*This session is open to dermatologists and graduate members only .
SCHEDULE
SCHEDULE
3:00 p .m . Dermatology Health in Women / Dr. O’Donoghue
3:00 p .m . Effective Communications: Delivering Key Messages
3:00 p .m . Management of Cutaneous Lupus Erythematosus-
/ Dr. Farris
Special Needs for Women / Faculty

SUNDAY, FEBRUARY 6

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 181
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

WORkSHOP Want more? Order

3:00 p .m . to 5:00 p .m .
Tuition fee and ticket required for admission. DERMOSCOPY
A Guide for the Physician
and continue perfecting the technique.
W008 Basic Dermoscopy
Room: 281/282 • View over 8,000 slides
DIRECTOR Wilhelm Stolz, M.D. and 400 cases

SPEAkERS • Identify and diagnose NEW

Giuseppe Argenziano, M .D . Ashfaq A . Marghoob, M .D . lesions of the skin
Ralph P . Braun, M .D . Harold S . Rabinovitz, M .D .
• Includes two DVDs –
Joseph Malvehy, M .D .
beginner and advanced
LEARNING OBjECTIVES
Following this workshop, the attendee will be able to: Dermoscopy: A Guide for
1 . Analyze the basic criteria of dermatoscopy . the Physician has been
2 . Apply a logical dermatoscopic approach for the efficient approved for AMA PRA
classification of both benign and malignant pigmented skin Category 1 Credits™. CME only available to purchasers.
™. CME only available to purchasers.
lesions .
3 . Demonstrate the benefits from the application of dermatoscopy
in daily practice . Order your copy today
DESCRIPTION
at the AAD Resource Center
The basic criteria of dermatoscopy will be introduced together Booth 3623!
with an efficient stepwise algorithm for the detection of the
various benign and malignant pigmented skin lesions . Experts
in dermatoscopy will present cases where the participants can
learn most . Also, the dermoscopic criteria on the face, as well as
on palms and soles, will be described . At the end of the session,
experts will work through some case diagnoses with the audience .
2.00 Category 1 CME Credits
SCHEDULE
3:00 p .m . Equipment; Differentiation between Melanocytic and
Non-Melanocytic Skin Lesions / Dr. Marghoob
3:20 p .m . Principles of classification in dermatoscopy / Dr. Stolz
3:50 p .m . When Dermoscopy Changed My Mind
/ Dr. Argenziano
4:10 p .m . Dermatoscopy in Special Locations / Dr. Stolz
4:20 p .m . Unknowns for the Experts and the Audience (I)
Experts Dr . Malvehy and Dr . Stolz / Dr. Braun
4:40 p .m . Unknowns for the Experts and the Audience (II)
Experts Dr . Argenziano and Dr . Marghoob
/ Dr. Rabinovitz
SUNDAY, FEBRUARY 6

182 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

WORkSHOP
3:00 p .m . to 5:00 p .m .
Tuition fee and ticket required for admission.

W009 MOC Self-Assessment B DESCRIPTION

M
O Room: 288/289/290
C using an automated response system . It will cover topics in
DIRECTOR Steven B. Deliduka, M.D.
LEARNING OBjECTIVES
Following this workshop, the attendee will be able to:
1 . Identify the strengths and weaknesses in one’s dermatology
knowledge and make improvements as needed .
2 . Demonstrate commitment to lifelong learning and self-
assessment via completion of a forum of 25 questions and
answers .
This session is structured in a question-and-answer format
general dermatology, pediatric dermatology, dermatopathology,
dermatologic surgery, and cosmetic dermatology . The participant
will have immediate feedback for each session and will be
able to identify any areas of weakness that require further self-
directed study . Due to the timed framework of this session, it is
imperative that participants arrive on time for this workshop .
2.00 Category 1 CME Credits
* Self-assessment questions utilized in this session are
the same as those used for Workshop W006 MOC:
Self-Assessment offered at Annual Meeting 2010.
Physicians should not claim CME/MOC credit for
attending this session if they attended Workshop W006
at Annual Meeting 2010.

Report Quality Measures and improve patient care

with the Association you trust introducing...
AAD Measurement Tools!

for dermatology
CLINICAL PERFORMANCE
ASSESSMENT TOOL

AVAILABLE MODULES: Develop a clinical performance improvement plan,

• 2011 PQRI Melanoma Reporting — specifically for your practice, while satisfying
Eligible for 1% CMS bonus Component 4 and earning CME!
• E-Prescribing
SUNDAY, FEBRUARY 6

www.aad.org/QRS AVAILABLE MODULES:

• Acne
• Melanoma
• Melanoma w/PQRI — Eligible for 1% CMS bonus
• Atopic Dermatitis
• Biopsy — coming soon!
www.aad.org/CPAT

Visit the AAD Resource Center Booth 3623 to demo both!

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 183
 SCIENTIFIC SESSIONS

Do More than Value Your Leaders.

BECOME ONE.
Leadership is not only important to the specialty, but it provides dermatologists like you with the means to be

successful in your career and the communities you serve. You’re invited to partake in the AAD’s Leadership Institute

at the Annual Meeting, offering fresh new leadership educational sessions, popular events, and the places to

meet-and-greet with dermatology’s leaders of today and tomorrow.

Don’t Miss these Highlighted Leadership institute Sessions: Leaders Are as Good
friDAY, fEBruArY 4 SAturDAY, fEBruArY 5 as Gold!
u012 Leading with your Strengths D007 Leading from Conflict to resolution
7:15 a.m. – 8:45 a.m. 7:15 a.m. – 8:45 a.m. Show your appreciation to the
Room: 293/294 Room: 240 mentor in your life by picking
S005 Leading from Your Vision to Exceptional f046 Leading Your team by Coaching and up a gold star pin at the
Service Mentoring
9:00 a.m. – Noon 3:00 p.m. – 5:00 p.m.
Leadership Institute kiosk.
Room: 293/294 Room: 391
S013 Leading Others for Peak Performance SuNDAY, fEBruArY 6
Share your thoughts and
2:00 p.m. – 5:00 p.m. participate in an “electronic
Room: 293/294 S029 Lessons from Great Leaders
2:00 p.m. – 5:00 p.m. chat” about leadership
u024 Leading Confidently through Powerful Room: 278/279/280
Communication through the Academy’s
12:15 p.m. – 1:45 p.m. MONDAY, fEBruArY 7 electronic messaging portal.
Room: 293/294 W011 Leading by Advocating for Dermatology Check each day for a new
9:00 a.m. – 11:00 a.m.
Room: 393/394 question and to hear what
your colleagues think about
tuESDAY, fEBruArY 8
f082 Managing Office Politics: Private Practice,
leadership.
Academics, and Everything in Between
9:00 a.m. – 11:00 a.m.
Room: 392
SUNDAY, FEBRUARY 6

Look for other Leadership Institute sessions at the Annual Meeting marked with the through the Program Book.

www.aad.org/leadership
for more information about upcoming Leadership Institute events and ways you can participate.

184 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

OVERVIEW

Represents restricted session in program overviews Represents activities that meet MOC-D
Restricted Session open to dermatologists and corporate M
O
This activity has been approved by the ABD to satisfy
individual members only! A ticket is required for admittance C component 2 of MOC-D

Represents Practice Management Session in program overviews Represents Leadership Institute in program overviews
Practice Management Session open to eligible Leadership Institute — addresses leadership
office staff/registered nurses competencies specific to dermatologists

Represents Patient Safety Session in program overviews Represents Health Information Technology (HIT) in
program overviews
Patient Safety Session
Health Information Technology Sessions

Represents Audience Response System Session

Audience Response System Session

MONDAY, FEBRUARY 7 F061 Medical Dermatology Challenge: Complex Cases

Poster Discussion Sessions — 7:15 a.m. to 8:45 a.m. from the Collection of Dr. Samuel Moschella. . .196
PD05 Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .187 F062 Ethical Dilemmas in Dermatology . . . . . . . . . . .196

MONDAY, FEBRUARY 7
PD06 Internal Medicine . . . . . . . . . . . . . . . . . . . . . . . .187
Workshops — 9:00 a.m. to 11:00 a.m.
Discussion Groups — 7:15 a.m. to 8:45 a.m. W010 MOC Self-Assessment: Cosmetic Dermatology .197
D019 Enhancing Observational Skills. . . . . . . . . . . . . .188 W011 Leading by Advocating for Dermatology. . . . . . .197
D020 When Does Chronic Dermatitis Become Cutaneous
T-Cell Lymphoma? . . . . . . . . . . . . . . . . . . . . . .188 Courses — 9:00 a.m. to 12:00 p.m.
C021 Intermediate Cosmetic Surgery . . . . . . . . . . . . . .198
Focus Sessions — 7:15 a.m. to 8:45 a.m. C022 Advanced Practice Management: Mini MBA . . .199
U109 Pediatric Connective Tissue . . . . . . . . . . . . . . . .189 C023 Advanced Pediatric Dermatology . . . . . . . . . . . .200
U110 Review of Dermatological Adverse Reactions . . .189
U111 Reconstruction in Dermatologic Surgery: Symposia — 9:00 a.m. to 12:00 p.m.
An Introductory and Review Session . . . . . . . . .189 S032 Cutaneous Tumors Benign and Malignant . . . . .201
U112 Histopathology of Scarring Alopecia. . . . . . . . . .190 S033 Photodermatology. . . . . . . . . . . . . . . . . . . . . . . .202
U113 Immunology for Dermatologists . . . . . . . . . . . . .190 S034 Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .203
U114 Stem Cells in Melanoma and Nevi . . . . . . . . . . .190 S035 Controversies in Dermatologic Drug Therapy. . .204
U115 Medication Use: Improving Adherence S036 Blistering Disease . . . . . . . . . . . . . . . . . . . . . . . .205
and Compliance . . . . . . . . . . . . . . . . . . . . . . . . .191 S037 Key Surgical Principles We All Should Know . . .206
U116 Utilize Web sites that Enhance Your Career . . . .191
U117 Diagnosis and Management of Courses — 9:00 a.m. to 5:00 p.m.
Unusual Skin Tumors . . . . . . . . . . . . . . . . . . . . .192 C024 Infectious Diseases . . . . . . . . . . . . . . . . . . . . . . .207
U118 Holy Moly: Religion and the Skin . . . . . . . . . . .192 C025 Fundamentals of Dermoscopy . . . . . . . . . . . . . .208
U119 New Botulinum Toxins Practice Integration . . . .192
Forums — 12:00 p.m. to 2:00 p.m.
Forums — 9:00 a.m. to 11:00 a.m. F063 Young Physician Pearls and Pitfalls:
F055 Vitiligo: Problems and Solutions. . . . . . . . . . . . .193 A Survival Guide for the First 10 Years . . . . . . . .209
F056 Therapeutic Safety. . . . . . . . . . . . . . . . . . . . . . . .193 F064 The Approach to the Patient with Cutaneous
F057 Adolescent Dermatology . . . . . . . . . . . . . . . . . . .194 T-Cell Lymphoma. . . . . . . . . . . . . . . . . . . . . . . .209
F058 Hair Loss in Women. . . . . . . . . . . . . . . . . . . . . .194 F065 What’s New and Emerging:Therapeutics. . . . . . .210
F059 Case-Based Discussion in Cutaneous F066 Merkel Cell Carcinoma: Diagnosis,
Lymphomas . . . . . . . . . . . . . . . . . . . . . . . . . . . .195 Management, and Controversies . . . . . . . . . . . . .210
F060 Immunohistochemistry in Dermatology . . . . . . .195

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 185
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

OVERVIEW

F067 Managing Hair Loss Made Easy . . . . . . . . . . . . .211 Symposia — 2:00 p.m. to 5:00 p.m.
F068 Use of Physician Extenders . . . . . . . . . . . . . . . . .211 S038 Surgical Pearls . . . . . . . . . . . . . . . . . . . . . . . . . . .221
F069 Cutaneous Oncology: Multidisciplinary S039 Therapeutic and Diagnostic Pearls . . . . . . . . . . .221
Management of Common and S040 Fundamentals of Cutaneous Surgery. . . . . . . . . .222
Uncommon Skin Cancers . . . . . . . . . . . . . . . . . .212 S041 Clinical Issues in Medical Dermatology . . . . . . .223
F070 Fungal Infections . . . . . . . . . . . . . . . . . . . . . . . .212 S042 International Dermatology . . . . . . . . . . . . . . . . .224
S043 Melanoma Update . . . . . . . . . . . . . . . . . . . . . . .225
Workshop — 12:00 p.m. to 2:00 p.m.
W012 Dealing with Difficult People and Looking Discussion Groups — 2:30 p.m. to 4:00 p.m.
Forward to It . . . . . . . . . . . . . . . . . . . . . . . . . . . .213 D023 Cutaneous T-Cell Lymphoma . . . . . . . . . . . . . . .226
D024 PAPA-Syndrome, SAPHO, and Acne:
Discussion Groups — 12:15 p.m. to 1:45 p.m. Skin and Bones and Inflammation . . . . . . . . . . .226
D021 Dermatology, Diagnosis, and the Visual Arts . . .213
D022 Common Dermatologic Diseases with Myriad Focus Sessions — 2:30 p.m. to 4:00 p.m.
Treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . .213 U133 Psychodermatology: Not Just a Delusion; ‘Bugs,’
Trichotillomania, and the Morgellons Debate. . .226
Focus Sessions — 12:15 p.m. to 1:45 p.m. U134 Issue in Office Design . . . . . . . . . . . . . . . . . . . . .227
U120 Sexually Transmitted Infections: U135 What’s New in Dermatopathology and Why
The Current Standard of Diagnosis and Care . . .214 It’s Important to You. . . . . . . . . . . . . . . . . . . . . .227
U121 Update on Graft-Versus-Host Disease . . . . . . . .214 U136 Management of Challenging Pigmented Lesions. . . 227
U122 High-Risk Squamous Cell Carcinomas:
MONDAY, FEBRUARY 7

U137 Developing a Unified Approach to Investigating

A Clinical and Pathologic Case Review. . . . . . . .214
U123 Forensics in Dermatology . . . . . . . . . . . . . . . . . .215
U124 Graft-Versus-Host Disease. . . . . . . . . . . . . . . . . .215
U125 Penile Growths . . . . . . . . . . . . . . . . . . . . . . . . . .216
U126 Healing the Pyoderma Gangrenosum Ulcer:
Lessons for the PG Clinic . . . . . . . . . . . . . . . . . .216
U127 Interactive Clinical Pathologic Challenge . . . . . .217
U128 Leg Ulcer Quiz for the Astute Dermatologist! . .217
U129 Informed Shared Decision Making in
Psoriasis Management . . . . . . . . . . . . . . . . . . . . .217
U130 Sarcoidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . .217
U131 Neurofibromatosis. . . . . . . . . . . . . . . . . . . . . . . .218
U132 The Year in Review in Pediatric Dermatology:
How Does It Change My Practice? . . . . . . . . . .218
Courses — 2:00 p.m. to 5:00 p.m.
C026 Basic Botulinum Toxin . . . . . . . . . . . . . . . . . . . .219
C027 Sclerotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . .220
C028 Soft Tissue Augumentation . . . . . . . . . . . . . . . . .220
Autoimmune Disease . . . . . . . . . . . . . . . . . . . . .227
U138 Digital Imaging and Medical Informatics: Decision
Support for Clinicians and Teachers . . . . . . . . . .228
U139 Inherited Cancer Syndromes:
The Role of the Dermatologist . . . . . . . . . . . . . .228
U140 Past, Present, and Pearls of Treatment of
Autoimmune Bullous Disease . . . . . . . . . . . . . . .229
U141 Skin Signs of Systemic Disease . . . . . . . . . . . . . .229
U142 Cryosurgical Update . . . . . . . . . . . . . . . . . . . . . .229
Forums — 3:00 p.m. to 5:00 p.m.
F071 Advanced Treatment for Chronic Wounds . . . . .230
F072 Medium and Deep Chemical Peeling . . . . . . . . .230
F073 Techniques for Flap Success . . . . . . . . . . . . . . . .230
F074 The Use of the Confocal Microscope in a
Private Clinical Practice . . . . . . . . . . . . . . . . . . .230
F075 Alopecia CPC . . . . . . . . . . . . . . . . . . . . . . . . . . .231
F076 Pediatric Dermatology . . . . . . . . . . . . . . . . . . . .232
F077 Aesthetic Dermatologic Complications . . . . . . . .232
F078 Epidermolysis Bullosa: Cases and Discussion . . .233

Workshop — 3:00 p.m. to 5:00 p.m.

W013 MOC Self-Assessment Office Based Safety . . . . .233

186 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

POSTER DISCUSSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

PD05 Cancer PD06 Internal Medicine

Room: 283 Room: 284
No CME Credits No CME Credits
Moderator Moderator
Shasa Hu, M.D. Kenneth J. Tomecki, M.D.
P500 P600
High clinical response rate of Sézary syndrome with immune Tumour necrosis factor-alpha promoter -308G/A (TNFα -308G/
modifying therapies: Prognostic markers of response A) polymorphism in Mexican patients with alopecia areata
P501 P601
Risk factors associated with the developement of a second Vulvo-cervico-vaginal manifestations and evaluation of
melanoma associated with nevus Papanicolaou smears in pemphigus vulgaris and pemphigus
P502 foliaceus
Significantly higher Breslow score of melanomas detected by P602
patients’ self-examination compared to melanomas detected during Analysis of the reactivity of indirect immunofluorescence in
annual dermatology check-up patients with pemphigus foliaceus and pemphigus vulgaris using
P503 rat bladder epithelium as a substrate

Application of a filtration and isolation by size technique for the
detection of circulating tumor cells in cutaneous melanoma
P504
Using standardized patients and moulage to assess students’ ability
to detect melanomas
P505
Characterizing regression in melanomas: a population-based study
P506
Prognosis and risk factors of local recurrence in cutaneous
melanoma
P507
Effectiveness of photodynamic therapy in Bowen disease: An
observational and descriptive study in 50 patients
MONDAY, FEBRUARY 7
P603
A study of 383 patients of tungiasis in Haiti
P604
Antiphospholipid antibody syndrome by levamisole-tainted
cocaine: Case report and review of the literature
P605
Diagnostic guidelines for cellulitis: Recommendations based on
a retrospective analysis of cellulitis admissions to Massachusetts
General Hospital
P606
Expression of pro-inflammatory protein s100a12 (EN-RAGE) in
Behçet’s disease and its association with disease activity

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 187
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
DISCUSSION GROUP
7:15 a.m. to 8:45 a.m.
Tuition fee and ticket required for admission.
D019 Enhancing Observational Skills
Room: 240
DIRECTOR Irwin M. Braverman, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Discuss how visual training can improve observational skills.
2. Develop a better understanding of the obstacles impeding
accurate observation.
3. Examine how narrative paintings can serve as a surrogate for
patients in medical education.
DESCRIPTION
After introduction and review of principles of observational skills,
historical information and research studies will provide evidence
for efficacy of visual training. A hands-on experience using high
quality reproductions of narrative paintings from the Yale Center
for British Art will be provided to all attendees who will examine
these paintings and describe objectively what they see. This session
MONDAY, FEBRUARY 7
will be a replica of the workshop attended by Yale Medical School
students and dermatology residents as part of their curriculum.
This educational session also has been an integral part of the New
England Dermatology Society meetings for the past 10 years when
hosted by Yale Dermatology.
1.50 Category 1 CME Credits
188 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
D020 When Does Chronic Dermatitis Become
Cutaneous T-Cell Lymphoma?
Room: 241
DIRECTOR Sam T. Hwang, M.D., Ph.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Differentiate clinical features of chronic dermatitis vs cutaneous
T-cell lymphoma (CTCL).
2. Order molecular tests that may differentiate chronic dermatitis
from CTCL.
3. Identify unusual clinical stimulants of CTCL (such as allergic
contact dermatitis).
DESCRIPTION
Cutaneous T-cell lymphoma (CTCL) may share certain features
with common skin conditions such as atopic dermatitis, seborrheic
dermatitis, or allergic contact dermatitis. This session will be a case-
based discussion of specific features and laboratory (molecular) tests
that will help clinicians distinguish chronic dermatitis from CTCL.
The use of flow cytometry and PCR-based tests will be emphasized
as these technologies increase our ability to discern inflammatory vs
neoplastic skin processes. A brief overview of the biology of skin-
derived T cells will be provided.
1.50 Category 1 CME Credits

For description of session categories and fees see page 37
FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U109 Pediatric Connective Tissue
Room: 242
DIRECTOR Eulalia Baselga, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize the most frequent clinical presentations and
cutaneous manifestations of connective tissue disease in
children.
2. Select the most adequate treatments for these conditions in
children.
3. Manage and monitor these diseases and the different treatments
proposed.
DESCRIPTION
Connective tissue diseases encompass a wide group of
inflammatory disorders that includes among others lupus
erythematosus, scleroderma, dermatomyositis, and some overlap
syndromes such as mixed connective tissue disease. Many patients
present initially with similar clinical features, particularly during
the first onset of symptoms, which frequently makes the diagnosis
of a specific disease difficult. We will review the most frequent
clinical presentations of these diseases in children. We will also
discuss the workup that will be needed in these children, as well as
the different options of therapy. Finally monitoring treatment for
these patients will also be reviewed.
1.50 Category 1 CME Credits
For the Latest Program Book InFormatIon PLease reFer to
SCIENTIFIC SESSIONS
U110 Review of Dermatological Adverse
Reactions
Room: 298/299
DIRECTOR David R. Adams, M.D., Pharm.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Identify various drugs associated with adverse skin reactions.
2. Identify specific treatment strategies, where appropriate, for
these reactions.
3. Recognize skin findings as possible adverse drug reactions.
DESCRIPTION
Adverse drug reactions (ADRs) are in the differential diagnosis for
most skin diseases. This session will review basic concepts on this
topic along with photo-driven cases and bullets for these ADRs.
Where indicated, specific treatments will be presented.
1.50 Category 1 CME Credits
MONDAY, FEBRUARY 7
U111 Reconstruction in Dermatologic Surgery:
An Introductory and Review Session
Room: 265/266
DIRECTOR Juan-Carlos Martinez, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Describe a surgical defect accurately, including pertinent
characteristics and anatomic considerations.
2. Recognize the basic concepts of tissue movement and tension
vectors as they relate to primary, flap, and graft closures.
DESCRIPTION
This introductory session is ideal for residents and surgical fellows,
as well as those interested in reconstructive surgery. The basics of
dermatologic reconstructive surgery will be covered, including the
concepts of tension vectors, tissue movement, and flap/graft
reconstruction. Multiple post-Mohs defects will be presented. The
closures chosen by the surgeon, including immediate and long-
term photos will be shown along with discussion of why specific
closures were chosen. There will be an emphasis on reconstructive
tips and tricks to optimize functional and aesthetic outcomes.
1.50 Category 1 CME Credits
www.aad.org | 189
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U112 Histopathology of Scarring Alopecia
Room: 235/236
DIRECTOR Catherine Margaret Stefanato, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to
1. Identify the ways in which short- and long-term safety of
biologic drugs can be properly assessed.
2. Assess the specific data regarding safety of the most widely used
biologics for psoriasis therapy.
3. Analyze the relative risks and benefits of existing biologic drugs
as an aid to therapeutic decision-making.
DESCRIPTION
Biologic therapy for psoriasis has revolutionized our ability to treat
moderate to severe psoriasis. These drugs, when compared to older
systemic agents, demonstrate a superior risk/benefit ratio, based
particularly on their apparently superb safety profiles. However,
much of what is held as gospel regarding biologic safety is based
MONDAY, FEBRUARY 7
on anecdote, misperception, and outright misrepresentation. The
aim of this session is to drill down to the actual available data
on safety. This will allow us to understand these drugs in much
greater depth, allowing practitioners to make better therapeutic
decisions.
1.50 Category 1 CME Credits
190 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
U113 Immunology for Dermatologists
Room: 270
DIRECTOR Delphine J. Lee, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Summarize the well-established models for nevus and
melanoma progression.
2. Assess the current data on tissue and cancer stem cell biology.
3. Develop new insights into the biology of melanocytic
neoplasms and the potential ramifications for diagnosis and
treatment.
DESCRIPTION
The well-established model of melanoma dedifferentiation
from a melanocyte passing through nevus stages and eventually
developing invasive and metastatic characteristics does not mesh
well with the clinical phenomenon. For example, it is difficult to
define invasion as a malignant process since nevi clearly have the
same capacity, explain why the majority of melanomas develop
in normal skin, or explain phenomena such as eruptive nevi.
Tissue and cancer stem cell biology has now come to the research
forefront. The presence of cells with stem cell-like characteristics in
melanomas has major implications for the etiology, diagnosis, and
treatment of melanocytic neoplasias.
1.50 Category 1 CME Credits
U114 Stem Cells in Melanoma and Nevi
Room: 267/268
DIRECTOR James M. Grichnik, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Distinguish the clinical features of different autoimmune
blistering diseases (AIBD).
2. Determine which tests to order for which autoimmune
blistering condition.
3. Identify current evidence for treatment of AIBD and a general
approach to management.
DESCRIPTION
This session will review the distinguishing clinical and pathological
features of the autoimmune blistering diseases and the tests needed
to diagnose them. The evidence for treatment will be reviewed and
a general approach to treatment described based on this and the
guidelines by different dermatologic societies. Case examples will
be used in a lecture/discussion format.
1.50 Category 1 CME Credits
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U115 Medication Use: Improving Adherence
and Compliance
Room: 285
DIRECTOR Steven R. Feldman, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Describe typical patterns of how patients use their medications.
2. List interventions to improve patients’ adherence behavior.
DESCRIPTION
Poor adherence to treatment is nearly ubiquitous. Poor treatment
outcomes and many other puzzling dermatologic phenomena are
mediated by poor use of medication. This session describes how
well people use their medication, relying on evidence obtained
using objective electronic monitors. Practical ways to improve
patients’ use of medication will be discussed. These measures can
help dramatically improve outcomes of treatment for patients with
many chronic skin diseases including acne, atopic dermatitis, and
U116 Utilize Web Sites that Enhance
Your Career
Room: 274
DIRECTOR Helen Mary Torok, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Utilize clinical tools in the diagnosis of lentigo maligna
melanoma.
2. Recognize surgical and histologic pitfalls in the managment of
lentigo maligna melanoma.
DESCRIPTION
The diagnosis and management of lentigo maligna melanoma
in the head and neck region presents multiple challenges due to
variable natural history and clinical presentation, location in a
cosmetically and functionally sensitive area, and unpredictable
subclinical extension beyond recommended excision margins.
The goal of this session is to illustrate the multiple challenges and

MONDAY, FEBRUARY 7
psoriasis. present a comprehensive management approach including: 1)
1.50 Category 1 CME Credits clinical assessment tools; 2) excision techniques and corresponding
tissue grossing methods; 3) histological evaluation of surgical
margins and associated pitfalls.
1.50 Category 1 CME Credits

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 191
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U117 Diagnosis and Management of Unusual U119 New Botulinum Toxins Practice
Skin Tumors Integration
Room: 264 Room: 269
DIRECTOR Erica Lee, M.D. DIRECTOR Joel Schlessinger, M.D.
LEARNING OBjECTIVES LEARNING OBjECTIVES
Following this focus session, the attendee will be able to: Following this focus session, the attendee will be able to:
1. Recognize less commonly encountered non-melanoma skin 1. Discuss new options in botulinum toxins.
cancers. 2. Contrast differences in new botulinum toxins.
2. Discuss the key histopathologic tumor features. 3. Discuss integration of new botulinum toxins into practice.
3. Identify challenges and pitfalls in the management of these
DESCRIPTION
unusual tumors.
There are several new botulinum toxin options either planned or
DESCRIPTION soon to be in use in dermatology practices. How do they compare
This session will review the clinicopathologic features of less to onabotulinumtoxin A? How can practices integrate new
commonly encountered non-melanoma skin cancers including forms of botulinum toxin to their services and what methods are
microcystic adnexal carcinoma, dermatofibrosarcoma protuberans, considered best practices for these products? This course will allow
high-risk squamous cell carcinoma, and extramammary ample discussion among the participants of their usage patterns
Paget disease. Emphasis will be on the early recognition and and how they prepare, dilute, and market new and existing
MONDAY, FEBRUARY 7

management of these tumors. products. Additionally, injection sites and differences in responses
1.50 Category 1 CME Credits will be discussed.
1.50 Category 1 CME Credit

U118 Holy Moly: Religion and the Skin

Room: 263
DIRECTOR Gary J. Brauner, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize dermatitides and traumatic reactive patterns caused
by application of garments or religious paraphernalia or
preparations.
2. Treat dermatoses with understanding of religious restrictions of
use of common dermatologic therapies.
3. Explain the reality of stigmata and religious stigmatization of
cutaneous diseases.
DESCRIPTION
Disparities in delivery of healthcare have made “cultural
competency” not merely a helpful but now a legally-required
remedy. Ethnicity and race are not the only relevant considerations.
Religious practices may cause or prevent cutaneous disease, heavily
weigh the social significance of certain diseases and impact on
delivery of proper dermatologic therapy. This focus session will
highlight such problems; please bring your own as well.
1.50 Category 1 CME Credits

192 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F055 Vitiligo: Problems and Solutions F056 Therapeutic Safety

Room: 255/256/257 Room: 391
DIRECTOR Torello M. Lotti, M.D. DIRECTOR Joel M. Gelfand, M.D., MSCE
SPEAkERS SPEAkERS
Rafael Falabella, M.D. Henry W. Lim, M.D. Macrene Alexiades-Armenakas, M.D., Ph.D.
Pearl E. Grimes, M.D. James J. Nordlund, M.D. Robert E. Kalb, M.D.
Iltefat H. Hamzavi, M.D. Mauro Picardo, M.D. Susan J. Walker, M.D.
Jana Hercogova, M.D., Ph.D.
LEARNING OBjECTIVES
LEARNING OBjECTIVES Following this forum, the attendee will be able to:
Following this forum, the attendee will be able to: 1. Discuss and analyze the methods used to evaluate the safety of
1. Discuss the mechanism of depigmentation. dermatologic therapeutics.
2. Develop a strategy to diagnose vitiligo and related disorders. 2. Rigorously assess the safety of dermatologic therapeutics.
3. Identify a winning approach to treatment, based on the choice
DESCRIPTION
between well-established and new modalities.
This session will focus on the critical appraisal of the safety of
DESCRIPTION dermatologic therapeutics. The process of assessing safety of a
This symposium will review current knowledge on vitiligo. drug or device prior to and after FDA approval will be reviewed.

Presenters will give you the headlines for an efficient
investigational approach to the problem and the critical
knowledge to make your practical choice between innovative and
conventional therapies. Newly available drugs will be discussed.
There will be a question and answer period at the end in which
practicing dermatologists and residents will be encouraged to
actively engage in the discussion.
2.00 Category 1 CME Credits
MONDAY, FEBRUARY 7
Strengths and limitations of our knowledge about risks associated
with therapeutics will be discussed. Recent data evaluating safety
issues associated with isotretinoin, methotrexatate, and dermal
fillers will be discussed as examples. This session is directed to all
physicians who prescribe drugs or use medical devices as well as
individuals who study the risks and benefits of therapeutics.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Safety assessment by FDA: What the Dermatologist
Needs to Know / Dr. Walker
9:30 a.m. Methotrexate Guidelines for Dermatologists:
To Biopsy or not to Biopsy / Dr. Kalb
10:00 a.m. Safety of Dermal Fillers / Dr. Alexiades-Armenakas
10:30 a.m. Current Controveries in Safety of Dermatologic
Therapeutics / Dr. Gelfand

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 193
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F057 Adolescent Dermatology F058 Hair Loss in Women

Room: 252/253/254 Room: 388/389/390
DIRECTOR Robert Silverman, M.D. DIRECTOR Mary Gail Mercurio, M.D.
SPEAkERS SPEAkERS
Kenneth E. Bloom, M.D. Robert L. Epps, M.D. Zoe Diana Draelos, M.D.
Bernard Cohen, M.D. Roselyn E. Epps, M.D. Nazanin Michelle Hanjani, M.D.
Leonard C. Sperling, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to: LEARNING OBjECTIVES
1. Evaluate and manage selected dermatologic disorders in Following this forum, the attendee will be able to:
adolescents. 1. Evaluate and treat common forms of scarring and non-scarring
2. Identify the basic rules that govern consent and confidentiality alopecias in women.
for teens. 2. Identify when evaluation for hyperandrogenism is indicated in
3. Outline interview techniques and hints for the office visit that a woman with androgenetic alopecia.
result in a successful patient encounter. 3. Determine which hair products may cause hair damage and
which are beneficial in women with alopecia.
DESCRIPTION
Successful treatment of skin disease in the adolescent patient DESCRIPTION
MONDAY, FEBRUARY 7

can be a challenge. Teens will present with disorders that reflect A variety of scarring and non-scarring forms of hair loss are
their entry into adulthood and more often than not, they wish common in women. This symposium will focus on select
to be treated as adults. However, in the eyes of the law, in the disorders emphasizing diagnostic clues, therapeutic challenges,
United States, they are still children. Their stage of psychosocial and treatment pearls. There will also be a discussion of hair care
development from early to late adolescence may significantly products in the woman with alopecia.
impact a teen’s concerns and successful approach to solving their 2.00 Category 1 CME Credits
problems.
SCHEDULE
2.00 Category 1 CME Credits
9:00 a.m. Androgenetic Alopecia / Dr. Mercurio
SCHEDULE 9:30 a.m. Alopecia Areata / Dr. Hanjani
9:00 a.m. Adolescent Development - Is It Normal? 10:00 a.m. Cicatricial Alopecia / Dr. Sperling
/ Dr. Silverman 10:30 a.m. Hair Care Products in Women with Alopecia
/ Dr. Draelos

194 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng


For description of session categories and fees see page 37
FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
F059 Case-Based Discussion in Cutaneous
Lymphomas
Room: 278/279/280
DIRECTOR Youn H. Kim, M.D.
SPEAkERS Uma Sundram, M.D., Ph.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Apply appropriate pathologic and clinical diagnostic tools in
cutaneous lymphomas.
2. Order the appropriate staging evaluation and discuss prognosis
and treatment alternatives with the patient.
3. Select and utilize the optimal therapy for the patient with
cutaneous lymphomas.
DESCRIPTION
Using a case-based format, this session will review the most
updated information essential for the proper diagnosis, staging,
and management of patients with cutaneous lymphoma for
the practicing clinicians. It includes an update of the advances
in our understanding of the pathogenetic mechanisms in
cutaneous lymphoma. The session updates the clinical and
pathologic diagnostic methods including how to apply ancillary
tests in the optimal diagnosis. The session concludes with
discussions of current management approaches integrating
expert recommendations, consensus practice guidelines, and
evidence-based options. Included in the treatment updates will
be innovative therapies that are currently under investigation and
available for patient participation.
2.00 Category 1 CME Credits
For the Latest Program Book InFormatIon PLease reFer to
SCIENTIFIC SESSIONS
F060 Immunohistochemistry in Dermatology
Room: 386/387
DIRECTOR Tammie C. Ferringer, M.D.
SPEAkERS
Whitney A. High, M.D.
Jacqueline M. Junkins-Hopkins, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Discuss the use of immunohistochemistry as it pertains to
melanocytic and lymphoid processes.
2. Describe how immunohistochemistry is used in other areas of
dermatopathology.
3. Explain the limitations of immunohistochemistry.
DESCRIPTION
Judicious use of immunohistochemistry can be an adjuvant
tool to traditional morphologic diagnosis. The role in diagnosis
MONDAY, FEBRUARY 7
of melanocytic and lymphoid processes will be discussed with
emphasis on recent advances. Use in diagnostic dilemmas
involving other areas of dermatopathology will also be reviewed.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Immunohistochemistry in Melanocytic Lesions
/ Dr. Ferringer
9:30 a.m. Questions and Answers / Dr. Ferringer
9:40 a.m. Immunohistochemical Potpourri / Dr. High
10:10 a.m. Questions / Dr. High
10:20 a.m. Immunohistochemistry in Lymphoid Infiltrates
/ Dr. Junkins-Hopkins
10:50 a.m. Questions / Dr. Junkins-Hopkins
www.aad.org | 195
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F061 Medical Dermatology Challenge: F062 Ethical Dilemmas in Dermatology

Complex Cases from the Collection of Room: 281/282
Dr. Samuel Moschella DIRECTOR Jack Selwyn Resneck Sr., M.D.
Room: 392
SPEAkERS
DIRECTOR Ruth Ann Vleugels, M.D. Brett M. Coldiron, M.D. Robert M. Portman, J.D.
Dirk Michael Elston, M.D. Theodore Rosen, M.D.
SPEAkERS
Steven R. Feldman, M.D., Ph.D. Stephen Burtis Webster, M.D.
Samuel Leonard Moschella, M.D. Jennifer Tan-Billet, M.D.
Philip E. LeBoit, M.D.
Arturo P. Saavedra- Charles R. Taylor, M.D.
Lauzon, M.D., Ph.D. LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
LEARNING OBjECTIVES
1. Evaluate a practice setup in the context of own ethical
Following this forum, the attendee will be able to:
standards and outside ethical guidelines.
1. Visually identify and diagnose classic and atypical presentations
2. Develop standards for ethical conduct in everyday practice.
of cutaneous manifestations of systemic disease.
3. Explain how the AAD Ethics Committee functions.
2. Select management options for complex medical dermatologic
disease based on the best available evidence from the literature. DESCRIPTION
3. Discuss the use of advanced systemic therapies for the Several ethical dilemmas and problems encountered by
management of refractory dermatologic conditions.
MONDAY, FEBRUARY 7

dermatologists in everyday practice will be presented by

provocative speakers representing each side of the issues. Is it
DESCRIPTION
appropriate for dermatologists to discuss or promote their political
After following patients with complex medical dermatologic
views with patients in the office? Is it ethical for your office to
disease for over fifty years, Dr. Samuel Moschella, along with
bill patients and earn a profit for dermatopathology services done
several colleagues, will share medical dermatology images and
elsewhere? Should dermatologic surgeons, in response to Medicare
discuss clinical clues for identifying complex skin conditions.
payment reduction rules, only excise one lesion daily or send
This session will offer practical tips for diagnosis, appropriate
Mohs closures elsewhere? Also covered will be the functioning of
evaluation, and advanced therapeutic management of patients
the AAD Ethics Committee and how it affects you.
with systemic diseases affecting the skin. Audience self-assessment
2.00 Category 1 CME Credits
will be encouraged through Kodachrome review, and a case-
based approach will be utilized to highlight relevance for the SCHEDULE
dermatology trainee or experienced clinician. Cases discussed 9:00 a.m. Introduction / Dr. Resneck
will include those focusing on granulomatous disease, renal 9:05 a.m. What Does the Ethics Committee Really Do?
disease, lymphoproliferative disease, connective tissue disease, and / Mr. Portman
pediatric disease. 9:15 a.m. Delaying a Repair or Multiple Procedures Is Not
2.00 Category 1 CME Credits Unethical / Dr. Coldiron
9:25 a.m. Insurance Payment Policies Should Not Impact the
SCHEDULE
Number of Surgeries Done in One Day / Dr. Elston
9:00 a.m. Image Session 1 / Dr. Taylor
9:35 a.m. Discussion / Faculty
9:25 a.m. Image Session 2 / Dr. Saavedra-Lauzon
9:45 a.m. You Should Use Your Office to Educate Your Patients
9:45 a.m. Image Session 3 / Dr. Tan-Billet
About Your Political Views / Dr. Rosen
10:05 a.m. Image Session 4 / Dr. Vleugels
9:55 a.m. The Office Is a Place of Healing, Not Politicking
10:25 a.m. Image Session 5 / Dr. Moschella
/ Dr. Webster
10:05 a.m. Discussion / Faculty
10:15 a.m. The Dermatologist Should be Allowed to Bill for Path
Done Elsewhere / Dr. Feldman
10:25 a.m. Slides Read by a Dermatopathologist Should be Billed
by that Person / Dr. LeBoit
10:35 a.m. Discussion / Faculty
10:45 a.m. Answers to Your Burning Ethical Questions / Faculty

196 | amerIcan academy oF dermatoLogy • 68th

69th annuaL meetIng
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

WORkSHOP
9:00 a.m. to 11:00 a.m.
Tuition fee and ticket required for admission.

W010 MOC Self-Assessment: W011 Leading by Advocating for Dermatology

M
O
C
Cosmetic Dermatology Room: 393/394
Room: 288/289/290
DIRECTOR Bruce A. Brod, M.D
DIRECTOR Emmy M. Graber, M.D.
SPEAkERS
LEARNING OBjECTIVES Jack S. Resneck Jr., M.D.
Following this workshop, the attendee will be able to:
LEARNING OBjECTIVES
1. Identify the strengths and weaknesses in his/her cosmetic
Following this workshop, the attendee will be able to:
dermatology knowledge and make improvements as needed.
1. Recognize both the complexities and the realities of taking
2. Demonstrate commitment to lifelong learning and self-
a policy proposal through the process, and effectively and
assessment.
collaboratively work towards the adoption of such policies.
DESCRIPTION 2. Demonstrate effective techniques for addressing opposition
This session will be structured in a question-and-answer format and overcoming obstacles in face-to-face meetings with policy
using an automated response system. It will cover topics in makers and their staff.
cosmetic dermatology.
DESCRIPTION
2.00 Category 1 CME Credits
Ever wonder what goes on in Washington D.C. and where
the myriad policies affecting the practice of dermatology come

New Session for Annual Meeting 2011.
MONDAY, FEBRUARY 7
from? Are you interested in getting involved in the process so
that your voice can be heard during this time of many changes
in health care? Take a hands-on approach to understanding
policymaking in this new Leadership Institute Workshop where
attendees will develop key competencies such as “Managing
Politics and Influencing Others” and “Building and Maintaining
Relationships.” These competencies are also useful in local politics,
managing a practice, working on a hospital staff, and in many
other settings.

Policy-making is a dynamic process, and dermatologists advocate

for the specialty in legislatures, regulatory agencies, and other
venues. Developing long-term relationships, building a reputation
by working constructively with others (even when you disagree),
thinking long-term and recognizing obstacles, forging alliances,
and knowing when to put aside personal politics are all critical
to success. This interactive workshop will demonstrate how
individual dermatologists, working together, can influence the
policy-making process. Led by dermatologists with experience
advocating for dermatology and a national health policy strategist,
participants will both learn the basics of how the system works
and have a chance to develop valuable skills that will help them
further the cause of dermatology at a national or local level.
2.00 Category 1 CME Credits

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 197
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
9:00 a.m. to 12:00 p.m.
Tuition fee and ticket required for admission.

C021 Intermediate Cosmetic Surgery SCHEDULE

Room: 291/292 9:00 a.m. Introduction / Dr. Lawrence
9:05 a.m. The Waiting Room and Exam Room Experience
DIRECTOR Naomi Lawrence, M.D. Before Seeing the Physician / Dr. Goldman
SPEAkERS 9:20 a.m. The Science of Waiting in the Waiting Room
Kimberly J. Butterwick, M.D. Mitchel Paul Goldman, M.D. / Dr. Lawrence
Sue Ellen Cox, M.D. Stephen Howard Mandy, M.D. 9:35 a.m. Questions and Answers / Faculty
Lisa M. Donofrio, M.D. Seth L. Matarasso, M.D. 9:45 a.m. Comprehensive Noninvasive Cosmetic Approach for
Richard Gordon Glogau, M.D. Susan H. Weinkle, M.D. the 30-Year-Old Patient / Dr. Butterwick
David J. Goldberg, M.D., J.D. Christopher B. Zachary, M.D. 10:00 a.m. Comprehensive Noninvasive Cosmetic Approach for
the 40 to 50-Year-Old Patient / Dr. Donofrio
LEARNING OBjECTIVES 10:15 a.m. Comprehensive Noninvasive Cosmetic Approach for
Following this course, the attendee will be able to: the 60+-Year-Old Patient / Dr. Weinkle
1. Utilize a comprehensive noninvasive cosmetic approach to 10:30 a.m. Questions and Answers / Faculty
patients in various age groups. 10:40 a.m. Tips for Using Multiple Toxins / Dr. Matarasso
2. Manage complications, dissatisfied patients, and practice 10:55 a.m. Filler Algorithm: How I Decide What to Use in
management issues. Who and Where / Dr. Cox
3. Demonstrate improvement in scheduling for the cosmetic 11:10 a.m. Don’t Buy That Device! Lasers: What You Really
practice. Need and How to Accomplish It Cost Effectively
MONDAY, FEBRUARY 7

DESCRIPTION / Dr. Zachary

This course will emphasize a comprehensive but noninvasive 11:25 a.m. Questions and Answers / Faculty
approach to cosmetic correction for patients in various age groups. 11:35 a.m. Managing Expectations in the Dissatisfied Cosmetic
We will address the issue of handling different botulinum toxins Patient / Faculty
in the attendee’s clinical practice. As the filler market becomes
more complex, we will address an algorithm for use of multiple
different fillers. The attendee will also learn a reasonable strategy
to evaluate new devices. The lectures will incorporate practice
management issues in cosmetic surgery such as waiting room
dynamics and handling the dissatisfied cosmetic patient.
3.00 Category 1 CME Credits
REFERENCES
1. Carruthers ed. Soft Tissue Augmentation, Procedures in Cosmetic
Dermatology. 2nd ed. Philadelphia: Saunders; 2005.
2. Surgery of the Skin, Procedural Dermatology. Robinson et al
eds. 2nd ed. Philadelphia: Mosby; 2010.

198 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
9:00 a.m. to 12:00 p.m.
Tuition fee and ticket required for admission.

C022 Advanced Practice Management: SCHEDULE

9:00 a.m. Introduction / Dr. Davey
Mini MBA 9:05 a.m. Future Challenges for Dermatologists / Dr. Coldiron
Room: 260/261/262 9:25 a.m. Questions and Answers / Faculty
DIRECTOR William Patrick Davey, M.D. 9:30 a.m. Acquiring Real Estate to Enhance Value and Quality
of Your Practice / Dr. Goldstein
SPEAkERS 9:50 a.m. Questions and Answers / Faculty
Clarence W. Brown, Jr., M.D. Glenn D. Goldstein, M.D. 9:55 a.m. Tips for Hiring/Managing Personnel / Dr. Harmon
Roger I. Ceilley, M.D. Christopher B. Harmon, M.D. 10:15 a.m. Questions and Answers / Faculty
Brett M. Coldiron, M.D. David E. Kent, M.D. 10:20 a.m. Negotiating Contracts / Dr. Brown
Joseph S. Eastern, M.D. 10:40 a.m. Questions and Answers / Faculty
10:45 a.m. Enhancing Operations / Dr. Kent
LEARNING OBjECTIVES 11:05 a.m. The Best Advice I Ever Got / Dr. Ceilley
Following this course, the attendee will be able to: 11:25 a.m. The Best Advice I Ever Got / Dr. Eastern
1. Identify and practice successful management strategies. 11:45 a.m. Final Questions and Answers / Faculty
2. Manage employees and inventory in a dermatology practice.
3. Develop negotiating skills.
DESCRIPTION
Successful dermatology practices excel at dermatologic diagnoses/

MONDAY, FEBRUARY 7
treatments and use excellent practice management. Many
dermatologists are excellent diagnosticians however receive
little training in office management. This session will highlight
some of the office management strategies utilized by successful The best dermatologic
dermatology practices.
3.00 Category 1 CME Credits literature review available!
Save time and stay up-to-
date with DermClips, the
Academy’s literature review
newsletter, featuring:

• Article review from some of the

most popular medical journals.
• Commentary based upon
application to everyday
practice setting
• References for further study
• AMA PRA Category 1 CreditsTM

Visit the Academy

Resource Center
Booth 3623 to subscribe!

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 199
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
9:00 a.m. to 12:00 p.m.
Tuition fee and ticket required for admission.

C023 Advanced Pediatric Dermatology REFERENCES

Room: 293/294 1. Beck LA, Boguniewicz M, Hata T, Schneider LC, Hanifin
J, Gallo R, Paller AS, et al. Phenotype of atopic dermatitis
DIRECTOR Albert C. Yan, M.D. subjects with a history of eczema herpeticum. J Allergy Clin
SPEAkERS Immunol. 2009 Aug;124(2):260-269, 269.e1-7. Epub 2009
Magdalene A. Dohil, M.D. Ashfaq A. Marghoob, M.D. Jun 27.
Anita N. Haggstrom, M.D. Amy S. Paller, M.D. 2. Marghoob AA, Braun R. Proposal for a revised 2-step
Anne W. Lucky, M.D. Mary L. K. Williams, M.D. algorithm for the classification of lesions of the skin using
dermoscopy. Arch Dermatol. 2010 Apr;146(4):426-428.
LEARNING OBjECTIVES 3. Metry D, Heyer G, Hess C, Garzon M, Haggstrom A, et
Following this course, the attendee will be able to: al. Consensus Statement on Diagnostic Criteria for PHACE
1. Recognize infectious complications of atopic dermatitis. Syndrome. Pediatrics. 2009 Nov;124(5):1447-1456. Epub
2. Diagnose pediatric skin lesions more effectively using clinical 2009 Oct 26.
clues and derm(at)oscopy.
3. Select the best treatments for children with pediatric skin SCHEDULE
diseases such as hemangiomas, congenital ichthyoses, and 9:00 a.m. Introductions / Dr. Yan
epidermolysis bullosa. 9:05 a.m. Atopic Dermatitis and Related Infections / Dr. Paller
9:35 a.m. Lumps and Bumps in Children / Dr. Dohil
DESCRIPTION 10:05 a.m. Infantile Hemangiomas / Dr. Haggstrom
MONDAY, FEBRUARY 7

This session will present updates as well as advanced perspectives 10:30 a.m. Questions and Answers / Faculty
regarding a broad range of both common and rare pediatric 10:40 a.m. Insights into Epidermolysis Bullosa / Dr. Lucky
skin disorders. For those seeking a sophisticated examination of 11:00 a.m. Derm(at)oscopy of Pediatric Lesions / Dr. Marghoob
pediatric dermatology issues, a combination of state-of-the-art 11:30 a.m. Insights into Ichthyosis / Dr. Williams
updates (on the infectious complications of atopic dermatitis, 11:55 a.m. Questions and Answers / Faculty
infantile hemangiomas, derm(at)oscopy of pediatric skin lesions),
as well as clinical pearls (epidermolysis bullosa, disorders of
cornification, cutaneous lumps and bumps of childhood) will be
presented.
3.00 Category 1 CME Credits

200 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.

S032 Cutaneous Tumors Benign and Malignant SCHEDULE

9:00 a.m. Introduction / Dr. Russell
Room: 275/276/277
9:05 a.m. How I Approach Merkel Cell Carcinoma / Dr. Nghiem
DIRECTOR Mark A. Russell, M.D. 9:25 a.m. How I Approach Dermatofibrosarcoma Protuberans
/ Dr. Ratner
SPEAkERS
9:45 a.m. How I Approach High-Risk Squamous Cell
Hilary E. Baldwin, M.D. Julia K. Padgett, M.D.
Carcinoma / Dr. Zwald
Anna S. Clayton, M.D. Desiree Ratner, M.D.
10:05 a.m. How I Approach Lipomas / Dr. Clayton
Joseph C. English III, M.D. Susan M. Swetter, M.D.
10:25 a.m. How I Approach Lesions Associated with Syndromes:
Dori Goldberg, M.D. Fiona O’Reilly Zwald, M.D.
Sebaceous Adenoma and Trichilemmoma
Paul Nghiem, M.D., Ph.D.
/ Dr. English
LEARNING OBjECTIVES 10:45 a.m. How I Approach Keloids / Dr. Baldwin
Following this symposium, the attendee will be able to: 11:05 a.m. How I Approach Atypical Nevi / Dr. Swetter
1. Recognize various presentations for benign and malignant 11:25 a.m. How I Approach Giant Congenital Nevi / Dr. Padgett
cutaneous tumors. 11:45 a.m. How I Approach Lentigo Maligna / Dr. Goldberg
2. Utilize the current literature to evaluate the potential clinical
course of such tumors.
3. Develop diagnostic and therapeutic plans for these conditions
based on the best available evidence.

MONDAY, FEBRUARY 7
DESCRIPTION
Frequently, dermatologists must recognize and treat a variety of
benign and malignant cutaneous lesions. These tumors may have
various presentations or associations which complicate diagnosis
and treatment. The speakers will attempt to impart to the
Don’t Be the Last to Know About
audience how they approach patients with these conditions. They Rx Recalls and Warnings!
will share tips to help clinicians recognize these tumors, discuss the
current understanding of the origin and biologic behavior of the
tumors, and present rationales for various proposed treatments. • F
DA required drug alerts e-mailed to
The speakers will relate examples from their own practices and you immediately
experiences to illustrate the difficulties and dilemmas these
FREE
situations may present. • N
o more delays, paper, and Membe
r
3.00 Category 1 CME Credits mailbox clutter Benefit!
• E
ndorsed by major liability carriers
and medical societies
• I mproves patient safety and reduces
physician liability
• R
egistration is FREE and takes only minutes
to complete

Visit the Academy Resource Center Booth 3623

or register today at: www.aad.org/hcnn

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 201
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.

S033 Photodermatology REFERENCES

Room: Auditorium A 1. Krutmann J, Honigsmann H, Elmets CA, eds. Dermatological
Phototherapy and Photodiagnostic Methods. New York: Springer.
DIRECTOR Craig A. Elmets, M.D. 2. Lim HW, Honigsmann H, Hawk JLM, eds. Photodermatology.
SPEAkERS London: Informa Healthcare.
R. Rox Anderson, M.D. Jean T. Krutmann, M.D. SCHEDULE
Sewon Kang, M.D. Marian Elizabeth Northington, M.D. 9:00 a.m. Introduction / Dr. Elmets
LEARNING OBjECTIVES 9:05 a.m. Ultraviolet Radiation and Rheumatic Disease
Following this symposium, the attendee will be able to: / Dr. Callen
1. Develop a systematic approach to the assessment and 9:30 a.m. Photoaging: UVA and Beyond / Dr. Krutmann
management of skin photoaging. 9:55 a.m. Medical Management of Photoaging / Dr. Kang
2. Summarize the management of actinic damage in organ 10:20 a.m. Procedural Options for Photoaging / Dr. Northington
transplant recipients. 10:45 a.m. New Developments in Laser Therapy / Dr. Anderson
3. Discuss the role of ultraviolet radiation in rheumatic diseases. 11:10 a.m. Management of Actinic Damage in the Organ
Transplant Recipient / Dr. Murphy
DESCRIPTION 11:35 a.m. Non-melanoma Skin Cancer and Its
This symposium will review contemporary topics related to Chemoprevention / Dr. Elmets
photodermatology that are of particular interest to the practicing
MONDAY, FEBRUARY 7

dermatologist. This will include the newest developments in

photoaging of the skin. There will be a discussion of the role that
ultraviolet radiation plays in rheumatic diseases. Also, there will
be an update in the latest trends in lasers. New developments in
management of actinic damage in organ transplant recipients and
the chemoprevention of skin cancer will be reviewed.
3.00 Category 1 CME Credits

202 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.

S034 Psoriasis REFERENCES

Room: La Nouvelle Orleans Ballroom 1. Gottlieb A, et al. Guidelines for the management of psoriasis
and psoriatic arthritis. Section 2: Psoriatic Arthritis: Overview
DIRECTOR Boni E. Elewski, M.D. and guidelines of care. J Am Acad Dermatol. 2008; 58: 851-
SPEAkERS 864.
Jeffrey Phillip Callen, M.D. Linda F. Stein, M.D. 2. Gottlieb AB, et al. Phase II, randomised, double-blind placebo-
Alice B. Gottlieb, M.D., Ph.D. Amy J. Theos, M.D. controlled study of ustekinumab, a human interleukin-12/23
Alexandra Boer Antonella Tosti, M.D. monoclonal antibody, in psoriatic arthritis. Lancet. 2009;
Kimball, M.D., M.P.H. Abby S. Van Voorhees, M.D. 373:633-640.
Mark Lebwohl, M.D. 3. Strober B, et al. A series of cirtically challenging case scenarios
in moderate to severe psoriasis: A Delphi consensus approach.
LEARNING OBjECTIVES J Am Acad Dermatol. 2009; 61(Supplement): S1-S42.
Following this symposium, the attendee will be able to:
1. Examine the current treatment of psoriasis and psoriatic SCHEDULE
arthritis in adults and children, and to explore future options. 9:00 a.m. Welcome and Course Overview / Dr. Elewski
2. Identify psoriasis co-morbidities and learn if therapeutic 9:01 a.m. Diagnosing and Treating Patients with Psoriatic
intervention might minimize or prevent certain risk factors. Arthritis / Dr. Gottlieb
3. Manage psoriatic patients in the setting of concurrent disorders 9:22 a.m. New and Emerging Therapies in Psoriasis / Dr. Lebwohl
including alcohol abuse, hepatitis, infections, and cancer 9:45 a.m. Treatment of Children with Psoriasis / Dr. Theos

history. Also, manage the pregnant women with psoriasis.
DESCRIPTION
This symposium reviews the newest therapies for psoriasis and
psoriatic arthritis, with emphasis on special populations including
nail psoriasis and psoriasis in children. There will also be a
discussion of managing psoriasis co-morbidities in the setting of
the biologic agents. Treating patients with concurrent disorders
including hepatitis, alcohol abuse, infections, and cancer will also
be highlighted.
3.00 Category 1 CME Credits
MONDAY, FEBRUARY 7
10:05 a.m. Recognizing and Managing Co-Morbidities in the
Psoriatic Patient / Dr. Callen
10:25 a.m. Panel Discussion / Faculty
10:40 a.m. Psoriasis Is Not the Only Problem: Managing
Treatments in the Presence of Hepatitis, HIV Disease,
Prior Malignancies, and EtOH Abuse
/ Dr. Van Voorhees
11:00 a.m. Management of Psoriasis in Pregnant Women
/ Dr. Kimball
11:15 a.m. Difficult Management Situations: Intertriginous and
Scalp Psoriasis and Management of Mild Psoriasis
/ Dr. Stein
11:30 a.m. Treatment of Nail Psoriasis / Dr. Tosti
11:45 a.m. Panel Discussion / Faculty

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 203
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.

S035 Controversies in Dermatologic Drug REFERENCES

Therapy 1. Wolverton SE, ed, Comprehensive Dermatologic Drug Therapy.
Vol II, London: Elsevier, 2007.
Room: Auditorium B
SCHEDULE
DIRECTOR Stephen E. Wolverton, M.D.
9:00 a.m. What Are Several Controversies Pertaining to Use of
SPEAkERS Physician Extenders in Dermatology? / Dr. Del Rosso
James Q. Del Rosso, D.O. Julie Claire Harper, M.D. 9:30 a.m. What is the Risk of Cardiovascular Disease in
Joel M. Gelfand, M.D., MSCE Neil H. Shear, M.D. Psoriasis and Therapeutic Implications of This Risk?
Kenneth B. Gordon, M.D. / Dr. Gelfand
10:00 a.m. Are Biologics Really Any Better Than Traditional
LEARNING OBjECTIVES
Systemics for Psoriasis? / Dr. Gordon
Following this symposium, the attendee will be able to:
10:30 a.m. What are Several of the Recent Controversies in
1. Develop awareness of both sides of the controversies
Isotretinoin Therapy? / Dr. Harper
concerning various systemic and topical medications.
11:00 a.m. What Are the Pros and Cons of Meeting With
2. Identify several of the controversies that relate to physician
Pharmaceutical Reps? / Dr. Shear
extenders and pharmaceutical representatives.
11:30 a.m. Annoying and Controversial Black Box Warnings for
DESCRIPTION Dermatologic Drugs / Dr. Wolverton
Controversies abound in all aspects of dermatologic drug therapy.
MONDAY, FEBRUARY 7

The speakers will address head on relevant issues in controversies

such as the cardiovascular risks of psoriasis, comparison of
various systemic drugs for psoriasis, discussion of the ever-present
controversies surrounding isotretinoin, and some controversial
black box warnings. Therapy-related controversies surrounding
physician extenders and pharmaceutical representatives are
likewise discussed. Attendees will gain a clear understanding of the
most current factors in these important controversies involving
dermatologic drug therapy.
3.00 Category 1 CME Credits

204 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.

S036 Blistering Disease REFERENCES

Room: 295/296 1. Murrell DF, Amagai M, Barnadas M, et al. Consensus
statement on definitions of disease endpoints and therapeutic
DIRECTOR Dedee F. Murrell, M.D. response for pemphigus. J Am Acad Dermatol. 2008; 58 (June):
SPEAkERS 1043-1046.
Valeria Aoki, M.D. Jose-Manuel Mascaro Jr., M.D. 2. Joly P, Mouquet H, Roujeau JC, et al: A single cycle of
Luca Borradori, M.D. Amit G. Pandya, M.D. rituximab for the treatment of severe pemphigus. N Engl J
Fredric Caux, M.D. David A. Sirois, DMD, Ph.D. Med. 2007 Aug 9;357(6):545-552.
Davis G. Farvolden, M.D. Eli Sprecher, M.D., Ph.D. 3. Rosenbach M, Murrell DF, Bystryn J-C, et al. Comparison of
Pascal Joly, M.D., Ph.D. Victoria P. Werth, M.D. reliability and validity between two outcome instruments for
pemphigus. J Invest Dermatol. 2009; 109: 2404-2410.
LEARNING OBjECTIVES
1. Summarize the criteria for diagnosis of pemphigus, pemphigoid SCHEDULE
and epidermolysis bullosa acquisita. 9:00 a.m. Importance of Patient Support Groups for
2. Evaluate the evidence for therapies for pemphigus and Autoimmune Bullous Disease / Dr. Sirois
pemphigoid. 9:05 a.m. Practical Diagnosis of Pemphigus and Pemphigoid
3. Outline the genetic and environmental factors that predispose / Dr. Mascaro
to development of pemphigus and pemphigoid. 9:25 a.m. Clinical Features and Diagnosis of Epidermolysis
Bullosa Acquisita / Dr. Caux

DESCRIPTION
This session will highlight advances in the diagnosis,
characterization, and therapeutic options related to pemphigus,
pemphigoid and epidermolysis bullosa acquisita. Attendees will
learn about the genetic and environmental factors that predispose
patients to develop pemphigus and pemphigoid. Experienced
international bullous experts will give a critical review of the
evidence for traditional and novel therapies. The key role played
by the patient support group, IPPF, to advance the diagnosis and
management of these orphan diseases will be explained.
3.00 Category 1 CME Credits
MONDAY, FEBRUARY 7
9:35 a.m. Questions and Answers on Diagnosis / Dr. Murrell
9:45 a.m. Lab Testing for Diagnosis of AIBD / Dr. Farvolden
9:55 a.m. Genetic Predisposition Towards Pemphigus and
Pemphigoid / Dr. Sprecher
10:10 a.m. Environmental Triggers to Pemphigus and
Pemphigoid / Dr. Aoki
10:25 a.m. Questions and Answers on Testing and Causes
/ Dr. Murrell
10:35 a.m. Evidence-Based Management of Pemphigus / Dr. Joly
11:05 a.m. Measuring Extent and Activity of Disease in
Pemphigus / Dr. Werth
11:15 a.m. Evidence-Based Management of Bullous Pemphigoid
/ Dr. Borradori
11:35 a.m. Prognosis and Avoiding Complications of Treatment
/ Dr. Pandya
11:50 a.m. Questions and Answers on Treatment / Dr. Murrell

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 205
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.

S037 key Surgical Principles We All REFERENCES

Should know 1. Boyer JD. Zitelli JA, Brodland DG. Undermining in
cutaneous surgery. Dermatol Surg. 2001; 27(1): 75-78.
Room: Auditorium C
2. Dzubow LM. The dynamics of dog-ear formation and
DIRECTOR Christopher James Miller, M.D. correction. J Dermatol Surg Oncol. 1985; 11(7): 722-728.
3. Salasche SJ, Bernstein G, Senkarik M. Surgical Anatomy of the
SPEAkERS
Skin. Norwalk, Connecticut/San Mateo, California: Appleton
Jeremy S. Bordeaux, M.D., M.P.H. Nathaniel J. Jellinek, M.D.
and Lange.
Teris M. Chen, M.D. Joseph Sobanko, M.D.
SCHEDULE
LEARNING OBjECTIVES
9:00 a.m. Improving Surgical Outcomes for Scalpel-Based
Following this symposium, the attendee will be able to:
Surgeries: Striving for Reproducibly Excellent
1. Operate safely and confidently on any area of the body,
Results / Dr. Miller
including high-risk areas, such as the temple, the mandible,
9:05 a.m. Critical Anatomy Made Simple: A Framework to
and the posterior triangle of the neck.
Operate with Confidence and Efficiency, Even in
2. Apply principles of effective surgical design and technique to
“Danger” Zones / Dr. Jellinek
achieve reproducibly excellent surgical results with routine
9:30 a.m. Questions and Answers / Faculty
scalpel-based surgeries.
9:35 a.m. Aesthetic Design of Surgical Reconstruction and
3. Illustrate enhancements in patient perceptions of outcomes
Variations of the Ellipse: Key Principles to Make
with efficient management of common dermatologic
MONDAY, FEBRUARY 7

Scars Less Perceptible / Dr. Bordeaux

procedures.
DESCRIPTION
This practical session will emphasize surgical fundamentals to
help dermatologists who want to perform routine scalpel-based
procedures with greater confidence and efficiency. Comprised of
academic dermatologic surgeons who teach residents, our panel
of speakers will use clinical cases, photos, and videos from their
own practices to illustrate key principles necessary to succeed at
every step of common procedures in any dermatology practice.
Topics have been chosen carefully to allow in-depth coverage of
practical information that will enhance the surgical practice of any
dermatologist. Sufficient time is allotted for panelists to address
audience questions.
3.00 Category 1 CME Credits
10:00 a.m. Taming the Dog Ear: Why They Occur and How to
Deal with Them / Dr. Chen
10:25 a.m. Questions and Answers / Faculty
10:30 a.m. Cysts, Lipomas, and More: Reliable Strategies for
Common Procedures / Dr. Sobanko
10:55 a.m. Questions and Answers / Faculty
11:00 a.m. Excising and Undermining with Confidence:
Why How We Cut Is Just as Important as How
We Stitch / Dr. Miller
11:20 a.m. Overcoming Common Challenges to Placing Deep
and Top Sutures: Keys to Success / Dr. Miller
11:45 a.m. Putting It All Together: Video Presentation and
Questions and Answers / Dr. Miller

206 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
9:00 a.m. to 5:00 p.m.
Tuition fee and ticket required for admission.

C024 Infectious Diseases REFERENCES

Room: 238/239 1. McConeghy KW, Mikolich DJ, LaPlante KL. Agents for the
decolonization of methicillin-resistant Staphylococcus aureus.
DIRECTOR Dirk Michael Elston, M.D. Pharmacotherapy. 2009 Mar;29(3):263-80.
SPEAkERS 2. Hochedez P, Caumes E. Common skin infections in travelers.
Francisco G. Bravo, M.D. Carrie L. Kovarik, M.D. J Travel Med. 2008 Jul-Aug;15(4):252-62.
Nooshin Ketabchi Ronald P. Rapini, M.D. 3. Crum-Cianflone N, Weekes J, Bavaro M. Recurrent
Brinster, M.D. Theodore Rosen, M.D. Community-Associated Methicillin-Resistant Staphylococcus
George W. Elgart, M.D. Kenneth J. Tomecki, M.D. aureus Infections among HIV-Infected Persons: Incidence and Risk
Tammie C. Ferringer, M.D. Stephen K. Tyring, M.D., Ph.D. Factors. AIDS Patient Care STDS. 2009 Jun 16.
Gary Goldenberg, M.D. Karen Warschaw, M.D. SCHEDULE
Whitney A. High, M.D. 9:00 a.m. Unusual Arthropod Assaults from the South
LEARNING OBjECTIVES / Dr. Rapini
Following this course, the attendee will be able to: 9:25 a.m. Tuberculosis / Dr. Bravo
1. Distinguish and diagnose and treat bacterial skin infections. 9:50 a.m. Vaccines to Prevent Infectious Diseases with
2. Interpret and diagnose and treat viral skin infections. Cutaneous / Dr. Tyring
3. Demonstrate and diagnose and treat fungal skin infections. 10:15 a.m. Update on HIV-Related Infectious Skin Disease
/ Dr. Kovarik
DESCRIPTION

The course focuses on important infectious pathogens as well as
new developments in the diagnosis and treatment of infectious
diseases of the skin.
6.00 Category 1 CME Credits
MONDAY, FEBRUARY 7
10:40 a.m. Fungal Infections / Dr. Elgart
11:05 a.m. Bacterial Infections Other than MRSA
/ Dr. Goldenberg
11:30 a.m. How to Handle a MRSA Outbreak / Dr. Elston
2:00 p.m. STDs Other Than Syphilis / Dr. High
2:25 p.m. Dermatologic Threats from Exotic Pets / Dr. Rosen
2:50 p.m. Spirochetes / Dr. Brinster
3:15 p.m. Parasites / Dr. Elston
3:40 p.m. Barnyard Zoonoses / Dr. Ferringer
4:05 p.m. Infections in Patients on Biologic Therapy
/ Dr. Warschaw
4:30 p.m. Leishmaniasis / Dr. Tomecki

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 207
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
9:00 a.m. to 5:00 p.m.
Tuition fee and ticket required for admission.

C025 Fundamentals of Dermoscopy REFERENCES

Room: 271/272/273 1. Johr RH, Stolz, W. Dermoscopy: An Illustrated Self-Assessment
Guide. New York: McGraw Hill; 2010.
DIRECTOR Robert H. Johr, M.D. 2. Marghoob AA, Braun RP, Kopt AW. Atlas of Dermoscopy.
SPEAkERS Taylor and Francis Group; 2005.
Ralph P. Braun, M.D. Ashfaq A. Marghoob, M.D. 3. Menzies SW, Crotty KA, Inguar C, McCarthy, WH. An Atlas
Rainer Hofmann-Wellenhof Scott Menzies, MBBS, Ph.D. of Surface Microscopy of Pigmented Skin Lesions: Dermoscopy.
Harald Kittler, M.D. Wilhelm Stolz, M.D. New York: McGraw Hill; 2003.
Emma Lanuti, M.D. David L. Swanson, M.D. SCHEDULE
LEARNING OBjECTIVES 9:00 a.m. Melanocytic vs. Non-Melanocytic: The Two Step
Following this course, the attendee will be able to: Algorithm / Dr. Braun
1. Use the two-step algorithm when evaluating skin lesions. 9:30 a.m. Local Criteria: Trunk and Extremities Melanocytic
2. Recognize all of the important dermoscopic criteria and Lesions / Dr. Marghoob
patterns. 10:00 a.m. Melanoma-Specific Criteria: Trunk and Extremities
3. Use pattern analysis to evaluate skin lesions. / Dr. Marghoob
10:30 a.m. Pattern Analysis: Case Presentations / Dr. Johr
DESCRIPTION 11:00 a.m. Face, Mucosa, Palms, Soles, Nails, Genitalia
The incidence of melanoma is increasing at an alarming rate. / Dr. Stolz
MONDAY, FEBRUARY 7

Clinicians evaluating patients with pigmented skin lesions should
be very skilled even cutting edge at diagnosis. Dermoscopy is
the standard of care in many countries around the world. It
significantly increases the accuracy of the clinical diagnosis of
melanocytic, non-melanocytic benign and malignant skin lesions.
The ultimate goal is not to miss or misdiagnose important benign
and malignant skin lesions and dermoscopy has been proven to
help reach this goal.
6.00 Category 1 CME Credits
11:30 a.m. Important Vascular Structures / Dr. Kittler
11:45 a.m. Questions and Answers / Faculty
2:00 p.m. Melanocytic Nevi (Congenital, Acquired, Dysplastic,
Blue, Combined) / Mr. Hofmann-Wellenhof
2:15 p.m. Spitzoid Patterns / Dr. Kittler
2:30 p.m. The Many Faces of Melanoma / Dr. Menzies
3:00 p.m. Seborrheic Keratosis, Hemangiomas,
Dermatofibromas / Dr. Swanson
3:15 p.m. Basal Cell and Squamous Cell Carcinoma, Sebaceous
Gland Hyperplasia / Dr. Braun
3:30 p.m. Solar Lentigo, Actinic Keratosis, Lichen Planus
Keratosis, Ink Spot Lentigo / Dr. Stolz
3:45 p.m. University of Miami Resident Case Presentation
/ Dr. Lanuti
4:00 p.m. Case Presentations: Self Assessment / Dr. Johr
4:45 p.m. Questions and Answers / Faculty

208 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
12:00 p.m. to 2:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F063 Young Physician Pearls and Pitfalls: F064 The Approach to the Patient with
A Survival Guide for the First 10 Years Cutaneous T-Cell Lymphoma
Room: 392 Room: 252/253/254
DIRECTOR Brian R. Sperber, M.D., Ph.D. DIRECTOR Peter W. Heald, M.D.
SPEAkERS SPEAkERS
Brian Leach, M.D. Eric Stratman, M.D. Ginette Hinds, M.D.
Maithily Nandedkar, M.D. Nathan Trookman, M.D. Jo-Ann Latkowski, M.D.
Brian Sperber, M.D. Antonio Subtil, M.D.
LEARNING OBjECTIVES LEARNING OBjECTIVES
Following this forum, the attendee will be able to: Following this forum, the attendee will be able to:
1. Effectively manage office staff, minimize clinical and 1. Diagnose mycosis fungoides and recognize the conditions that
administrative errors and use technology in practice. can mimic it clinically and histologically.
2. Prepare for Maintenance of Certification. 2. Classify patient’s cutaneous T-cell lymphoma (CTCL) utilizing
3. Demonstrate how to build and maintain a successful the most modern classification scheme along with clincial and
relationship with the community. histological components.
3. Evaluate and stage a patient with CTCL in order to develop
DESCRIPTION
a prognosis and a set of parameters that will be used to guide

MONDAY, FEBRUARY 7
The first 10 years in practice are both demanding and exhilarating!
therapy.
This session will address some of the most common challenges
faced by the young dermatologist in both private practice and DESCRIPTION
academia, including Maintenance of Certification. We will discuss In this session there will be speakers with expertise in the clinical
strategies for managing a successful office staff, minimizing clinical and histologic findings that are useful in the recognition and
and administrative errors, and building and maintaining a positive classification of cutaneous T-Cell lymphomas (CTCLs). Patients
relationship with community. In addition, we will outline ways will be presented with demonstrative examples of all variants of
to maximize the potential of information technology in your that disease and its mimickers.
practice. The session will close with a panel discussion of practice 2.00 Category 1 CME Credits
pearls and advice for maintaining a healthy work-life balance.
SCHEDULE
2.00 Category 1 CME Credits
12:00 p.m. Diagnosing Mycosis Fungoides (MF) / Dr. Heald
SCHEDULE 12:15 p.m. Recognizing MF in Skin of Color / Dr. Hinds
12:00 p.m. Introduction / Dr. Sperber 12:35 p.m. Diagnosis of MF by Biopsy / Dr. Subtil
12:05 p.m. Maintenance of Certification / Dr. Stratman 1:05 p.m. Distinct Variants of MF/CTCL / Dr. Latkowski
12:20 p.m. The Reality Show of Office Staff / Dr. Leach 1:25 p.m. Non-MF CTCL / Dr. Subtil
12:35 p.m. Technology in the Office / Dr. Nandedkar 1:45 p.m. Staging, Testing, and the Toolbox for MF/CTCL
12:50 p.m. Building your Reputation in the Community / Dr. Heald
/ Dr. Trookman
1:05 p.m. All the Stupid things I’ve Done / Dr. Sperber
1:20 p.m. Practice Pearls and Work-Life Balance
/ Panel Discussion
1:45 p.m. Questions and Answers

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 209
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
12:00 p.m. to 2:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F065 What’s New and Emerging: Therapeutics F066 Merkel Cell Carcinoma: Diagnosis,
Room: 278/279/280 Management, and Controversies
DIRECTOR William Howard Eaglstein, M.D. Room: 281/282

SPEAkERS DIRECTOR Paul Nghiem, M.D., Ph.D.

Leslie Baumann, M.D. Craig A. Elmets, M.D. SPEAkERS
Jeffrey Phillip Callen, M.D. Kenneth A. Katz, M.D. Linda Chung-Chin Wang, M.D., J.D.
LEARNING OBjECTIVES Siegrid S. Yu, M.D.
Following this forum, the attendee will be able to: LEARNING OBjECTIVES
1. Describe current medical methods by sunscreen to prevent Following this forum, the attendee will be able to:
skin cancer. 1. Discuss areas of controversy and consensus regarding the
2. Evaluate and choose agents for cosmetic dermatologic risk factors, incidence, clinical, pathologic, and prognostic
purposes. characteristics of Merkel cell carcinoma.
DESCRIPTION 2. Analyze data linking the Merkel cell polyomavirus and immune
This session is aimed at new and emerging therapies especially evasion by this cancer to outcomes and emerging therapies.
in the areas of medical dermatology, cosmetic dermatology, skin 3. Utilize this information to guide the multi-disciplinary
cancer preventions, and evaluation of therapies. management of representative cases.
MONDAY, FEBRUARY 7

2.00 Category 1 CME Credits DESCRIPTION

SCHEDULE
12:00 p.m. Introduction / Dr. Eaglstein
12:05 p.m. Cosmetic Dermatology / Dr. Baumann
12:30 p.m. Skin Cancer Prevention: Beyond Sunscreens
/ Dr. Elmets
12:55 p.m. Evaluating New Therapeutics / Dr. Katz
1:20 p.m. Medical Dermatology / Dr. Callen
Merkel cell carcinoma (MCC) is a polyomavirus-associated skin
cancer with a higher disease-associated mortality (~46%) than
melanoma (~15%) and an increasing incidence of ~1600 cases/
year in the US. Management is challenging because therapy is
different in nature than for other skin malignancies and is
controversial within the literature. Multi-disciplinary care
involving surgery, radiation and medical oncology is often
indicated. This session will highlight areas of consensus and
controversy in the viral etiology, clinical presentation, staging,
pathology, and management of MCC. Representative and
challenging cases will be presented to highlight treatment options
and relevant data.
2.00 Category 1 CME Credits
SCHEDULE
12:00 p.m. Introduction, Clinical and Prognostic Features
/ Dr. Nghiem
12:30 p.m. Role of Imaging and Radiation Therapy in MCC
Management / Dr. Wang
12:50 p.m. Interactive Management Discussion of Representative
Cases / Dr. Yu
1:30 p.m. New Directions in Prognosis and Therapy of MCC
/ Dr. Nghiem

210 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
12:00 p.m. to 2:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F067 Managing Hair Loss Made Easy F068 Use of Physician Extenders
Room: 388/389/390 Room: 386/387
DIRECTOR Vera H. Price, M.D. DIRECTOR David M. Pariser, M.D.
SPEAkERS Paradi Mirmirani, M.D. SPEAkERS
Paul R. Bergstresser, M.D. Suzanne Olbricht, M.D.
LEARNING OBjECTIVES
Robert David Greenberg, M.D. Abel Torres, M.D.
Following this forum, the attendee will be able to:
1. Recognize salient details of the history. LEARNING OBjECTIVES
2. Assess signs that identify and differentiate the alopecias. Following this forum, the attendee will be able to:
3. Select appropriate therapy, and track response parameters 1. Identify and discuss issues related to the use of non-physician
systematically. clinicians in the practice of dermatology.
2. Recognize the education and dermatologic training afforded
DESCRIPTION
physician extenders specializing in dermatology.
This session will address the critical shortage of dermatologists
3. Summarize the legal and ethical aspects related to the
who are willing to see patients with hair loss. The aim of the
supervision and training of physician extenders in dermatology.
session is to make the management of alopecia areata, cicatricial
alopecia, and androgenetic alopecia easy with a fresh, systematic DESCRIPTION
approach. New advances in these three important conditions will The increasing demand for dermatologic services and undersupply

MONDAY, FEBRUARY 7
be discussed. The session is directed to clinicians, academicians, of dermatologists nationwide contribute to the use of physician
and residents. extenders in many dermatology practices. Speakers will relate how
2.00 Category 1 CME Credits physician extenders are educated, trained, and used in dermatology
practices. Speakers will provide information about hiring, training,
and supervising these professionals. Both a dermatology NP and
PA will discuss their respective professional training and clinical
experience in dermatology. Details will be provided on how
physician extenders are used successfully, what pitfalls to avoid,
how to bill for their services, and what the ethical and legal
implications are in having physician extenders in your practice.
2.00 Category 1 CME Credits
SCHEDULE
12:00 p.m. The AAD’s Policy Statement on the use of Non-
Physician Clinicians / Dr. Olbricht
12:25 p.m. Training of Non-Physician Clinicians in Dermatology
/ Dr. Bergstresser
12:35 p.m. Legal and Liability Concerns / Dr. Torres
12:45 p.m. Supervision of Physician Extenders:
Practical Considerations / Dr. Greenberg
1:25 p.m. Role of Unlicensed Medical Assistants in
a Dermatologic Practice / Dr. Pariser

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 211
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
12:00 p.m. to 2:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F069 Cutaneous Oncology: Multidisciplinary F070 Fungal Infections

Management of Common and Uncommon Room: 255/256/257
Skin Cancers DIRECTOR Aditya K. Gupta, M.D., Ph.D.
Room: 391
SPEAkERS
DIRECTOR Thomas Kupper, M.D. Lawrence F. Eichenfield, M.D. Nathaniel J. Jellinek, M.D.
Boni E. Elewski, M.D. Antonella Tosti, M.D.
SPEAkERS
Sheila Fallon Friedlander, M.D.
Keri S. Chaney, M.D. Chrysalyne Delling Schmults, M.D.
Arturo P. Saavedra- Linda Chung-Chin Wang, M.D., J.D. LEARNING OBjECTIVES
Lauzon, M.D., Ph.D. Andrew Werchniak, M.D. Following this forum, the attendee will be able to:
1. Evaluate treatments for dermatophyte and non-dermatophyte
LEARNING OBjECTIVES
mold onychomycosis.
Following this forum, the attendee will be able to:
2. Assess current treatments for tinea capitis.
1. Discuss the medical and surgical management of melanoma,
3. Discuss the non-medical management of onychomycosis
squamous cell carcinoma, cutaneous T-cell lymphoma, Merkel
including the role of debridement and surgery.
cell carcinoma, and graft-versus-host disease.
2. Identify the variables associated with the risk of recurrence, DESCRIPTION
metastasis, and mortality in these patients. This session reviews the management of onychomycosis in
3. Formulate an effective treatment plan for these common and
MONDAY, FEBRUARY 7

children and adults. Dermatophyte and non-dermatophyte

uncommon skin cancers.
DESCRIPTION
Modern medicine requires the dermatologist to have a greater
familiarity with the multidisciplinary management of common
and uncommon cutaneous skin cancers and associated disorders,
including melanoma, squamous cell carcinoma, cutaneous T-cell
lymphoma, Merkel cell carcinoma, and graft-versus-host disease.
New concepts of pathogenesis, epidemiology, and the spectrum
of clinical presentations will be discussed. The complexities of
staging by clinical-pathological correlation as well as new and
evolving imaging techniques will be reviewed. Practical tips for
optimal management and innovative therapeutic strategies will
be presented using challenging cases seen at the Dana-Farber/
Brigham and Women’s Cancer Center.
2.00 Category 1 CME Credits
infections will be included, as well as the surgical management of
onychomycosis. The current treatment options for tinea capitis
will be presented.
2.00 Category 1 CME Credits
SCHEDULE
12:00 p.m. Pediatric Onychomycosis and Nail Disorders
/ Dr. Eichenfield
12:20 p.m. Tinea Capitis / Dr. Friedlander
12:40 p.m. Update on Onychomycosis Treatment / Dr. Gupta
1:00 p.m. Topical Therapies for Onychomycosis / Dr. Elewski
1:20 p.m. Non-Dermatophyte Molds / Dr. Tosti
1:40 p.m. Surgical Management of Onychomycosis / Dr. Jellinek

212 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

WORkSHOP DISCUSSION GROUP

12:00 p.m. to 2:00 p.m. 12:15 p.m. to 1:45 p.m.
Tuition fee and ticket required for admission. Tuition fee and ticket required for admission.

W012 Dealing with Difficult People and Looking
Forward to It
Room: 288/289/290
DIRECTOR Steven Kenneth Shama, M.D., M.P.H.
LEARNING OBjECTIVES
Following this workshop, the attendee will be able to:
1. Discuss the many reasons why we become upset at various
people or situations.
2. Demonstrate tools and techniques for dealing with these
challenging people/patients.
DESCRIPTION
Difficult people/patients elicit emotions you may prefer not to
have. We’ll find creative ways of dealing with these people, so
you make peace, not war! It takes two people to make situations
“difficult.” What part do you play in this? What can you learn
about yourself and them? Participants will be asked to suggest
difficult scenarios and we’ll generate many different approaches
D021 Dermatology, Diagnosis, and the
Visual Arts
Room: 240
DIRECTOR John E. Wolf Jr., M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Assess the depiction of skin disorders in a variety of art forms.
2. Discuss the use of art interpretation in historical research and
clinical diagnosis.
3. Recognize the impact of skin diseases on famous artists.
DESCRIPTION
Just as the skin often reveals the body’s interior disharmony, art is
a window into the human soul. The visual arts offer many intimate
glimpses of skin diseases and of powerful emotional responses
to those disorders of the flesh. We shall consider artistic works
as diverse as pre-Columbian sculptures, Old Masters, medieval
miniatures, and anonymous tribal art. This lecture will stress the

to solving these frustrating situations. Handouts will be provided
giving “answers” to life’s most frustrating interactions. The session
will be touching, filled with laughter, and incidentally excellent
for risk management. Guaranteed to be memorable, practical, and
life/spirit enriching!
2.00 Category 1 CME Credits
MONDAY, FEBRUARY 7
fact that art interpretation can be a useful tool to refine clinical
diagnostic skills. Finally, for those who may have attended before,
significant new material has been added to the presentation.
1.50 Category 1 CME Credits
D022 Common Dermatologic Diseases with
Myriad Treatments
Room: 241
DIRECTOR Richard B. Odom, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Identify the many therapeutics involved in the management of
more complex or complicated dermatological diseases.
2. Utilize the standard approaches to treatment of extensive or
unusual skin conditions.
3. Demonstrate newer and innovative ideas about treating skin
conditions that are recalcitrant to standard management
schemes.
DESCRIPTION
This discussion group will present newer and innovative ideas and
approaches involved in the management of more extensive and
complex skin diseases. Some treatment modalities are evidence-
based and other schemes are anecdotal but supported with case
reports. Active audience participation will be encouraged and
appreciated.
1.50 Category 1 CME Credits

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 213
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U120 Sexually Transmitted Infections: The
Current Standard of Diagnosis and Care
Room: 235/236
DIRECTOR Whitney A. High, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Summarize the latest diagnostic techniques for sexually
transmitted disease.
2. Identify the latest therapeutic options for treating sexually
transmitted disease.
3. Compare and contrast signs and symptoms of sexually
transmitted diseases as compared to other skin disease that may
affect the genitalia.
DESCRIPTION
This course will seek to review the signs and symptoms of sexually
transmitted disease (STD), and compare and contrast these
conditions to other dermatological illness that may involve the
MONDAY, FEBRUARY 7
U122 High-Risk Squamous Cell Carcinomas:
A Clinical and Pathologic Case Review
Room: 265/266
DIRECTOR David E. Geist, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Identify squamous cell carcinomas (SCC) with high risk
features.
2. Explain the limitations of standard surgical excision for these
tumors.
3. Develop an aggressive management plan for high-risk SCC
including margin-controlled surgery, close monitoring, and
possibly adjuvant therapy.
DESCRIPTION
While some squamous cell carcinomas are amenable to simple
excision, other squamous cell carcinomas carry a heightened
risk of recurrence and metastasis and are said to be high risk.

genitalia. The latest diagnostic techniques will be discussed and Prognostic factors such as depth, histologic grade, perineural
the current therapeutic guidelines for STDs will be reviewed. invasion, location, and immune status have been identified.
1.50 Category 1 CME Credits Mismanagement of these tumors may result in significant
morbidity and mortality. Cases of complicated tumors with good
and poor outcomes will be presented with clinical photos and
U121 Update on Graft-Versus-Host Disease pathology. Strategies for early recognition and multidisciplinary
Room: 283 management will be discussed.
1.50 Category 1 CME Credits
DIRECTOR Jonathan Cotliar, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize indications for and methods of hematopoietic stem
cell transplantation.
2. Recognize the clinical presentation of graft-versus-host disease.
3. Learn about new diagnostic tools and therapeutic options for
graft-versus-host disease.
DESCRIPTION
This session is intended for dermatologists and residents with an
interest in the treatment of graft-versus-host disease. Attendees
will learn about the unique cutaneous complications associated
with hematopoietic stem cell transplantation. This session will
explore indications for and methods of hematopoietic stem
cell transplantation, with an emphasis on new insights into the
pathophysiology of graft-versus-host disease, along with emerging
diagnostic tools and therapeutic modalities.
1.50 Category 1 CME Credits

214 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng


For description of session categories and fees see page 37
FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U123 Forensics in Dermatology
Room: 298/299
DIRECTOR Eve Judith Lowenstein, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Offer an understanding of the areas of forensic science, define
forensic terminology, and describe the forensic exam.
2. Recognize the scope of forensics in dermatology, including
understanding types of wounds and patterns of injury to skin,
hair, and nails.
3. Determine the role of the dermatologist in forensic recognition
of the signs suggestive of murder, torture, abuse, assault,
neglect, self-inflicted injuries, poisonings, and bioterrorism.
DESCRIPTION
Examination of the skin is a critical part of the forensic
examination.The skin may reveal clues to the identity, time of
death or injury, and signs of internal disease or external trauma.
Dermatologists may be called upon to provide their opinions
in forensics cases. It is important for physicians to learn to use
forensic terminology appropriately to describe and document
dermatologic findings, as well as to be able to distinguish between
normal postmortem changes in the skin and signs of disease or
trauma. In this review, we offer an overview of dermatologic
findings in forensic pathology and highlight their significance.
1.50 Category 1 CME Credits
For the Latest Program Book InFormatIon PLease reFer to
SCIENTIFIC SESSIONS
U124 Graft-Versus-Host Disease
Room: 267/268
DIRECTOR Edward W. Cowen, M.D
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize the risk factors associated with graft-versus-host
disease (GVHD).
2. Differentiate between the diagnostic and non-diagnostic
cutaneous features of chronic GVHD.
3. Formulate a treatment plan for the management of cutaneous
GVHD.
DESCRIPTION
Graft-versus-host disease (GVHD) is the major cause of
non-relapse-related morbidity following allogeneic stem cell
transplantation. Although multi-organ involvement is common,
cutaneous GVHD is one of the most frequent presenting features
of both acute and chronic disease. This session will discuss the
MONDAY, FEBRUARY 7
features of both acute and chronic GVHD, with an emphasis on
classification of chronic GVHD based on recent NIH consensus
criteria. Treatment recommendations tailored to the type of
skin involvement will be discussed, as well as the importance
of dermatologic input in a multi-disciplinary approach to
management.
1.50 Category 1 CME Credits
www.aad.org | 215
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U125 Penile Growths U126 Healing the Pyoderma Gangrenosum

Room: 270 Ulcer: Lessons for the PG Clinic
DIRECTOR Giuseppe A. Micali, M.D. Room: 264

LEARNING OBjECTIVES DIRECTOR Laura S. Winterfield, M.D.

Following this focus session, the attendee will be able to:
1. Utilize dermatoscopy in clinical practice beyond the usual
indication for cutaneous pigmented lesions.
2. Recognize those skin conditions in which dermatoscopy may
be more useful.
3. Choose the most appropriate technical devices and
magnifications for each condition.
DESCRIPTION
Dermatoscopy is a noninvasive technique which allows a rapid
and magnified (X10-X1000) in vivo observation of the skin
with the visualization of morphologic features invisible to the
naked eye. Apart from its most common use for the diagnosis
of pigmented skin lesions, it has been demonstrated that
MONDAY, FEBRUARY 7
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize classic and unusual presentations of pyoderma
gangrenosum.
2. Apply an algorithm for the diagnosis and treatment of patients
with pyoderma gangrenosum.
DESCRIPTION
Pyoderma gangrenosum (PG) is an inflammatory ulcerative
condition that causes significant morbidity and can be extremely
challenging to treat. In this session, we will discuss clinical
settings of PG, and the state-of-the-art topical and systemic agents
to suppress inflammation and promote wound healing. Our
experience in using novel anti-inflammatory and biologic agents

dermatoscopy has further applications in dermatology, including and tissue-engineered therapies for PG will be discussed.
inflammatory diseases, parasitoses, hair and nails abnormalities, 1.50 Category 1 CME Credits
and a large variety of other skin conditions. Depending on the
disorder, dermatoscopy may be useful for differential diagnosis,
prognostic evaluation, and monitoring response to treatment.
The aim of this forum is to advance knowledge of dermatoscopy
beyond the traditional indication of pigmented lesions, focusing
on those conditions in which this technique may be useful. The
session is directed to encourage dermatologists to alternative use of
dermatoscopy in clinical practice based on the presenter’s personal
experience, and on literature review.
1.50 Category 1 CME Credits

216 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng


For description of session categories and fees see page 37
FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U127 Interactive Clinical Pathologic Challenge
Room: 285
DIRECTOR Soon Bahrami, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Apply clinical-pathologic correlation more effectively in the
diagnosis of skin diseases.
2. Recognize pitfalls of clinical and microscopic evaluation that
can lead to diagnostic errors.
3. Select appropriate ancillary methods to enhance diagnostic
accuracy.
DESCRIPTION
This session will utilize an interactive approach in the presentation
of a series of unique and challenging cases from an academic
dermatopathology practice. Emphasis will be placed on
correlating clinical and microscopic features to achieve accurate
patient diagnoses. Ancillary testing and potential pitfalls will be
discussed. Neoplastic and inflammatory dermatologic diseases
will be presented in a stepwise “build the case” approach. This
session is directed towards dermatologists with an interest in
dermatopathology, dermatopathologists, and residents and fellows.
1.50 Category 1 CME Credits
U128 Leg Ulcer Quiz for the Astute Dermatologist!
Room: 269
DIRECTOR Alain Brassard, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Identify venous, arterial, diabetic, pyoderma gangrenosum and
unusual leg ulcers.
2. Demonstrate leg ulcer knowledge in an interactive format.
DESCRIPTION
Retention of knowledge is far superior when one participates in
the discussion. This is an interactive session based on the American
TV show, Jeopardy. It is delivered to a group of 60 individuals
maximum, divided in 6 to 10 teams. The game is divided into
five categories: arterial ulcers, venous ulcers, diabetic foot ulcers,
pyoderma gangrenosum and, Unusual ulcers. Each category has
questions and sub-questions. The audience will participate in the
discussion of different leg ulcer case scenarios in a fun and relaxed
atmosphere. The winning team will be congratulated by applause.
1.50 Category 1 CME Credits
For the Latest Program Book InFormatIon PLease reFer to
SCIENTIFIC SESSIONS
U129 Informed Shared Decision Making in
Psoriasis Management
Room: 263
DIRECTOR Jerry Kim Leng Tan, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Define informed shared treatment decision making.
2. Identify the roles of physician and patient in treatment
decisions.
3. Describe means to engage patients in values clarification.
DESCRIPTION
This session is directed at practicing dermatologists and trainees.
Informed shared decision making involves patient-physician
interaction combining patient autonomy and self-determination
with the expert knowledge and guidance of the clinician to fulfill
the mandate of informed choice. However, the myriad options for
moderate to severe psoriasis with differing attributes (risk, benefit,
and cost) requires recognition of patient perspectives, preferences,
MONDAY, FEBRUARY 7
and values. Inadequate training in informed counseling and a lack
of time and resources is unlikely to facilitate informed choice.
Potential solutions include the development of educational
resources and decision aids to inform and engage patients in the
decision-making process.
1.50 Category 1 CME Credits
U130 Sarcoidosis
Room: 274
DIRECTOR Misha Rosenbach, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Diagnose cutaneous sarcoidosis more effectively.
2. Evaluate patients with cutaneous sarcoidosis for systemic
involvement.
3. Manage patients with cutaneous sarcoidosis with a step wise,
multi-agent approach.
DESCRIPTION
Sarcoidosis is a multisystem granulomatous disease of unknown
cause that frequently affects skin. This session will review the
current understanding of cutaneous sarcoidosis, including new
theories about the etiopathogenesis of this poorly understood
entity. During the session we will review how to diagnose
cutaneous sarcoidosis; the broad clinical spectrum and multiple
morphologies of this protean disease will be discussed. We will
then review how to evaluate patients for systemic involvement
once a diagnosis is made. Finally, we will review the treatment
options and present a step wise, practical approach to the
management of these challenging patients.
1.50 Category 1 CME Credits
www.aad.org | 217
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U131 Neurofibromatosis U132 The Year in Review in Pediatric

Room: 242 Dermatology: How Does It Change My
DIRECTOR Amy J. Theos, M.D. Practice?
Room: 284
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to: DIRECTOR Robert Sidbury, M.D.
1. Diagnose patients with neurofibromatosis (NF) type 1 and
LEARNING OBjECTIVES
NF1-like syndrome.
Following this focus session, the attendee will be able to:
2. Discuss the differential diagnosis and approach to patients with
1. Demonstrate practical applications of the latest developments
multiple cafe au lait spots.
in pediatric dermatology.
3. Discuss the role of genetic testing in the workup of patients
2. Review the evolving story of beta-blockade for infantile
with NF1 and its variants.
hemangiomas.
DESCRIPTION
DESCRIPTION
Neurofibromatosis type 1 (NF1) and its variants are disorders
This session will review the most recent advances in
likely to be seen by dermatologists. This session will review the
pathophysiology, diagnosis, and management of common
important clinical features and discuss the management of NF1
pediatric skin conditions. Emphasis will be placed on practical
from a dermatological perspective. The clinical features of a newly
application of these findings to daily clinical experience. Topics
described NF1-like syndrome (Legius syndrome) will be reviewed.
covered will include beta-blockade for infantile hemangiomas,
MONDAY, FEBRUARY 7

The role of genetic testing, which has recently become available,

genetics of alopecia areata and vitiligo, vitamin D and skin disease,
will be discussed. An update on management and clinical
infections and atopic dermatitis as well as issues related to the use
treatment trials will be provided. This session is geared to any
of common medications such as isotretinoin and cantharidin.
dermatologist interested in an update on NF1.
1.50 Category 1 CME Credits
1.50 Category 1 CME Credits

218 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
2:00 p.m. to 5:00 p.m.
Tuition fee and ticket required for admission.

C026 Basic Botulinum Toxin SCHEDULE

Room: 260/261/262 2:00 p.m. Introduction / Dr. Ozog
2:05 p.m. Relevant Anatomy for the Botulinum Toxin User
DIRECTOR David M. Ozog, M.D. / Dr. Wieder
SPEAkERS 2:15 p.m. Questions and Answers / Dr. Wieder
Alastair Carruthers, M.D. Seth L. Matarasso, M.D. 2:19 p.m. Preparing, Dosing, and Injecting Botulinum Toxins
Jean D.A. Carruthers, M.D. Suzan Obagi, M.D. / Dr. Scherschun
Joel Lee Cohen, M.D. Mark G. Rubin, M.D. 2:29 p.m. Questions and Answers / Dr. Scherschun
Dee Anna Glaser, M.D. Lubomira Scherschun, M.D. 2:33 p.m. Botulinum Toxins for Glabella with Video
Christopher B. Harmon, M.D. Roberta D. Sengelmann, M.D. / Dr. Harmon
Derek H. Jones, M.D. Joshua M. Wieder, M.D. 2:43 p.m. Questions and Answers / Dr. Harmon
David Kouba, M.D., Ph.D. 2:47 p.m. Botulinum Toxins for Forehead with Video
/ Dr. Rubin
LEARNING OBjECTIVES 2:57 p.m. Questions and Answers / Dr. Rubin
Following this course, the attendee will be able to: 3:01 p.m. Botulinum Toxins for Peri-orbital Area with Video
1. Utilize FDA-approved reconstituted botulinum toxins safely / Dr. Jones
and with optimal dosing. 3:11 p.m. Questions and Answers / Dr. Jones
2. Treat wrinkle lines of the glabella, forehead, crow’s feet, lower 3:15 p.m. Botulinum Toxins for Lower Face and Neck with
face, and neck. Video / Dr. Matarasso

3. Discuss botulinum toxin treatments comfortably and
confidently with patients.
DESCRIPTION
This session should teach the attendee how to prepare, how to
inject, how to prevent complications, and how to keep patients
satisfied when using botulinum toxins. Luminaries in the field
of cosmetic dermatology will teach the audience tricks and
pearls they have learned over the years in treating botulinum
toxin patients. Both FDA-approved botulinum toxins will be
thoroughly discussed.
3.00 Category 1 CME Credits
MONDAY, FEBRUARY 7
3:25 p.m. Questions and Answers / Dr. Matarasso
3:29 p.m. Botulinum Toxins for Hyperhidrosis / Dr. Glaser
3:39 p.m. Questions and Answers / Dr. Glaser
3:43 p.m. “A Tale of Two Toxins” and Clinical Pearls
/ Dr. Carruthers
3:53 p.m. Questions and Answers / Dr. Carruthers
3:57 p.m. Building a Botulinum Toxin Practice and Clinical
Pearls / Dr. Obagi
4:07 p.m. Questions and Answers / Dr. Obagi
4:11 p.m. Preventing and Managing “Complications”:
Touchups and Other Clinical Pearls / Dr. Cohen
4:21 p.m. Questions and Answers / Dr. Cohen
4:25 p.m. “To Arch or Not to Arch - That is the Question”:
Eyebrow Position and Other Clinical Pearls
/ Dr. Carruthers
4:35 p.m. Questions and Answers / Dr. Carruthers
4:39 p.m. Seven Tips for the Novice Injector: How I Do It
/ Dr. Sengelmann
4:48 p.m. Questions and Answers / Dr. Sengelmann
4:52 p.m. Review of Literature and Off-Label Dermatology Uses
/ Dr. Kouba

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 219
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
COURSE
2:00 p.m. to 5:00 p.m.
Tuition fee and ticket required for admission.
C027 Sclerotherapy
Room: 293/294
DIRECTOR Margaret A. Weiss, M.D.
SPEAkERS
David Michael Duffy, M.D.
Mitchel Paul Goldman, M.D.
Robert A. Weiss, M.D.
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Recognize the anatomy and pathophysiology of superficial
venous disease of the leg.
2. Utilize this information to better perform sclerotherapy of
unwanted veins.
3. Minimize and treat complications from sclerotherapy.
DESCRIPTION
Venous disease of the legs affects millions; many seek symptomatic
MONDAY, FEBRUARY 7
and/or cosmetic relief. This session will cover the treatment of
varicose and telangiectic leg and non-leg veins. Anatomy and the
recognition of common patterns will be supplemented by video
demonstration, including brief Doppler/Duplex examination, a
critical step for dermatologists seeking to expand their treatment
from telangiectasia to larger varicosities. The important advance of
foamed sclerotherapy will be discussed and shown. Complications
will be discussed. This session is intended to benefit the
beginner but will include more advanced techniques to help the
experienced.
3.00 Category 1 CME Credits
SCHEDULE
2:00 p.m. The Old Gray’s Anatomy Ain’t What it Used to Be,
But There’s Still Some Things You Should Know
/ Dr. Weiss
2:15 p.m. Nothing Compares to Watching Video of How to
Perform Sclerotherapy / Dr. Weiss
2:45 p.m. Sclerosing Solutions: Why Polidocanol Will Replace
Hypertonic Saline / Dr. Weiss
3:00 p.m. Navigating Through Turbulence: Avoiding
Complications of Foam and Non-Foam Sclerotherapy
/ Dr. Goldman
3:45 p.m. Questions and Answers / Faculty
4:00 p.m. Only Detergent Solutions Can Foam: How This
Technique is Changing Vein Treatments / Dr. Weiss
4:15 p.m. What About Those Ugly Chest and Hand Veins:
Non-Leg Sclerotherapy / Dr. Weiss
4:35 p.m. Practice Pearls / Dr. Weiss
4:45 p.m. Questions and Answers / Faculty
220 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
C028 Soft Tissue Augumentation
Room: 291/292
DIRECTOR Heidi A. Waldorf, M.D.
SPEAkERS
Vivian Wasserteil Bucay, M.D. Derek H. Jones, M.D.
Cheryl M. Burgess, M.D. Rhoda S. Narins, M.D.
Rebecca L. Fitzgerald, M.D. Hema A. Sundaram, M.D.
Brooke A. Jackson, M.D. Susan H. Weinkle, M.D.
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Identify the clinical characteristics and filling properties of
available filling agents.
2. Design a realistic plan for soft tissue augmentation during a
cosmetic consultation.
3. Demonstrate minimizing risk and manage complications when
they occur.
DESCRIPTION
This session will provide a detailed examination of soft tissue
augmentation. Patient evaluation and aspects of a thorough
consultation will be outlined. The scientific basis and best
practices for use will be reviewed for each product category.
Special considerations for patient subgroups as well as avoiding
and managing complications will be stressed. Both beginner and
experienced injectors should leave with pearls to improve their
practice.
3.00 Category 1 CME Credits
SCHEDULE
2:00 p.m. A Modern Approach to Soft Tissue Augmentation
/ Dr. Waldorf
2:20 p.m. Update on Hyaluronic Acid Filling Agents / Dr. Jones
2:40 p.m. Questions and Answers / Dr. Jones
2:45 p.m. Calcium Hydroxylapatite: A Scientific Approach
/ Dr. Sundaram
3:05 p.m. Questions and Answers / Dr. Sundaram
3:10 p.m. Best Practices for Poly-L-Lactic Acid / Dr. Fitzgerald
3:30 p.m. Questions and Answers / Dr. Fitzgerald
3:35 p.m. Permanent Fillers: How and When / Dr. Burgess
3:50 p.m. Questions and Answers / Dr. Burgess
3:55 p.m. Soft Tissue Augmentation of the Face / Dr. Weinkle
4:10 p.m. Questions and Answers / Dr. Weinkle
4:15 p.m. Augmenting Skin of Color: Special Considerations
/ Dr. Jackson
4:30 p.m. Questions and Answers / Dr. Jackson
4:35 p.m. Managing Filler Complications / Dr. Bucay
4:55 p.m. Questions and Answers / Dr. Bucay
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
2:00 p.m. to 5:00 p.m.
Open admission, no tuition or ticket.

S038 Surgical Pearls S039 Therapeutic and Diagnostic Pearls

Room: 275/276/277 Room: La Nouvelle Orleans Ballroom
DIRECTOR Summer R. Youker, M.D. DIRECTOR Stephen P. Stone, M.D.
SPEAkERS SPEAkERS
Christie Travelute Ammirati, M.D. Kenny J. Omlin, M.D.. Joseph B. Bikowski, M.D. Ronald C. Hansen, M.D.
Jeremy S. Bordeaux, M.D., M.P.H. Jeffrey E. Petersen, M.D. Stuart M. Brown, M.D. Mark Lebwohl, M.D.
Christine Elizabeth Cabell, M.D. Bertrand Richert, M.D., Ph.D.
LEARNING OBjECTIVES
Christopher James Miller, M.D.
Following this symposium, the attendee will be able to:
LEARNING OBjECTIVES 1. Use innovative therapies for patients with complicated
Following this symposium, the attendee will be able to: conditions or common maladies unresponsive to commonly
1. Recognize the difficulties of surgery in special sites and develop effective approaches.
strategies to overcome them. 2. Safely and effectively utilize established medications for off-
2. Identify practical techniques for finessing closures. label uses.
3. Identify useful surgical pearls to take back to your practice. 3. Develop some unusual arrows for the therapeutic and
diagnostic quiver.
DESCRIPTION
This session is directed toward general dermatologists and DESCRIPTION

MONDAY, FEBRUARY 7
dermatologists-in-training who wish to improve their surgical Faculty will present innovative approaches to some treatment-
skills. Key subjects to be covered include tips for surgery on the resistant dermatologic problems, some using newer drugs and
nails, the scalp, and the lower leg; tips for scar refinement; and tips treatments, others reaching back to therapies that worked in the
for achieving the best surgical result possible. This session is not past but may have been forgotten. Off-label and ABM (anecdote-
intended for accomplished dermatologic surgeons. based management) will predominate, with a few evidence-based
3.00 Category 1 CME Credits pearls as well. Target audience is the office-based dermatologist.
Participants are urged to e-mail challenging cases to drspstone@
SCHEDULE
gmail.com in advance of the meeting for discussion by the faculty.
2:00 p.m. Surgery on the Scalp / Dr. Ammirati
3.00 Category 1 CME Credits
2:20 p.m. Surgery on the Lower Leg / Dr. Petersen
2:40 p.m. Questions and Answers / Faculty REFERENCES
2:45 p.m. Optimizing Suture Technique / Dr. Bordeaux 1. Stone SP. Unusual, innovative, and long-forgotten remedies. In
3:05 p.m. Finessing the Standing Cone / Dr. Youker Dermatological Clinics, Theirs, BH: ed. 18:2. 323-338, April
3:25 p.m. Questions and Answers / Faculty 2000
3:30 p.m. Painless Anesthesia and Scar Revision / Dr. Cabell 2. Ely H. Dermatologic therapies you’ve probably never heard of.
4:10 p.m. Questions and Answers / Faculty Dermatological Clinics 1989 Jan;7(1):19-35.
4:15 p.m. Cosmetic Pearls / Dr. Omlin 3. Lebwohl, M. et al. Treatment of Skin Disease. Philadelphia:
4:35 p.m. Easy Flaps and How to Use Them / Dr. Miller Mosby. in press
4:50 p.m. Basic Nail Surgery / Dr. Richert
SCHEDULE
4:55 p.m. Questions and Answers / Faculty
2:00 p.m. Introduction / Dr. Stone
2:05 p.m. Off Label But Not Off the Wall / Dr. Stone
2:35 p.m. More Office Tips / Dr. Lebwohl
3:05 p.m. A Potpourri of Pearls… / Dr. Brown
3:35 p.m. Not in the Textbooks... / Dr. Bikowski
4:05 p.m. Pediatric Dermatological Pearls / Dr. Hansen
4:35 p.m. Questions, Challenges, and Answers from the Faculty
/ Faculty

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 221
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
2:00 p.m. to 5:00 p.m.
Open admission, no tuition or ticket.

S040 Fundamentals of Cutaneous Surgery SCHEDULE

Room: Auditorium B 2:00 p.m. Preoperative Considerations / Dr. Aasi
2:20 p.m. Surgical Instruments and Sutures / Dr. Zwald
DIRECTOR Elizabeth M. Billingsley, M.D. 2:35 p.m. Anesthesia for Cutaneous Surgery / Dr. Kirby
SPEAkERS 2:55 p.m. Questions and Answers / Faculty
Sumaira Zareen Aasi, M.D. Joslyn S. Kirby, M.D. 3:00 p.m. Biopsy and Excision: Techniques and Tips
Christie Travelute Ammirati, M.D. Mollie A. MacCormack, M.D. / Dr. Jacobs
Christine Elizabeth Cabell, M.D. Fiona O’Reilly Zwald, M.D. 3:20 p.m. Suturing Techniques and Finessing the Closure
M. Amanda Jacobs, M.D. / Dr. Ammirati
3:45 p.m. Surgical Dressings and Wound Care
LEARNING OBjECTIVES / Dr. MacCormack
Following this symposium, the attendee will be able to: 4:00 p.m. Questions and Answers / Faculty
1. Evaluate patients preoperatively and effectively plan basic 4:05 p.m. Basics of Nail Biopsies and Nail Surgery
dermatology surgical procedures. / Dr. Billingsley
2. Perform skin and nail biopsies, simple excisions, and layered 4:25 p.m. Recognition and Management of Surgical
closures. Complications / Dr. Cabell
3. Manage common surgical complications. 4:50 p.m. Questions and Answers / Faculty
DESCRIPTION
MONDAY, FEBRUARY 7

This symposium is designed for the dermatologist with little or no

experience in cutaneous surgery, as well as the more experienced
dermatologist wishing to improve surgical judgment, skills, and
outcomes. Preoperative patient evaluation, basic biopsy and
excision techniques, and suturing essentials will be discussed.
Information on suture types, surgical instruments, anesthesia,
and surgical dressings and wound care will be presented. Time
will also be spent discussing the recognition and management of
surgical complications.
3.00 Category 1 CME Credits

222 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
2:00 p.m. to 5:00 p.m.
Open admission, no tuition or ticket.

S041 Clinical Issues in Medical Dermatology SCHEDULE

Room: Auditorium A 2:00 p.m. Introductory Remarks / Dr. Bolognia
2:05 p.m. Pyoderma Gangrenosum: Rx and Dx / Dr. Davis
DIRECTOR Jean L. Bolognia, M.D. 2:35 p.m. Questions and Answers / Dr. Davis
2:40 p.m. Controversies in Contact Dermatitis: From Systemic
SPEAkERS Contact Dermatitis to Implanted Medical Devices
David Eric Cohen, M.D. Christine Ko, M.D. / Dr. Cohen
Edward W. Cowen, M.D. Julie V. Schaffer, M.D. 3:10 p.m. Questions and Answers / Dr. Cohen
Mark D. P. Davis, M.D. 3:15 p.m. Recently Described Disorders: Clinicopathologic
LEARNING OBjECTIVES Correlations / Dr. Ko
Following this symposium, the attendee will be able to: 3:45 p.m. Questions and Answers / Dr. Ko
1. Recognize the clinical spectrum of severe cutaneous drug 3:50 p.m. What’s New in Skin Diseases in
reactions. Immunocompromised Hosts / Dr. Cowen
2. Develop a clinical approach to the diagnosis and treatment of 4:20 p.m. Questions and Answers / Dr. Cowen
pyoderma gangrenosum. 4:25 p.m. Severe Cutaneous Drug Reactions: SJS/TEN, AGEP
3. Recognize newly described dermatologic disorders. and DRESS / Dr. Schaffer
4:55 p.m. Questions and Answers / Dr. Schaffer
DESCRIPTION
The interface between internal medicine and dermatology
continues to play an important role in both the outpatient and

MONDAY, FEBRUARY 7
inpatient settings. This session will update the dermatologist
with regard to newly described dermatologic disorders, severe
cutaneous drug reactions, and the clinical approach to pyoderma
gangrenosum. Controversies in contact dermatitis will be discussed
as well as cutaneous disorders in immunocompromised hosts.
3.00 Category 1 CME Credits
REFERENCES
1. Callen JP, et al. Dermatological Signs of Internal Disease. 4th ed.
Elsevier:London, 2009.
2. Weenig RH, Davis MDP, et al. Skin ulcers misdiagnosed as
pyoderma gangrenosum. N Engl J Med. 2002; 347:1412-1418.
3. Wolf R, et al. Life-threatening acute adverse cutaneous drug
reactions. Clin Dermatol. 2005;23:171-181.

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 223
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
2:00 p.m. to 5:00 p.m.
Open admission, no tuition or ticket.

S042 International Dermatology

Room: 295/296
DIRECTOR Sidney N. Klaus, M.D.
MAKE A WORLD OF DIFFERENCE
SPEAkERS
Noah A. Craft, M.D., Ph.D. James J. Nordlund, M.D.
Roderick J. Hay, M.D. Scott A. Norton, M.D., M.P.H.
Peter Hotez, M.D. Wingfield Ellis Rehmus, M.D.
Carrie L. Kovarik, M.D. Aisha Sethi, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Recognize the range and depth of dermatology problems Find volunteer
worldwide.
2. Assess approaches currently in use to alleviate these problems. opportunities
DESCRIPTION
This symposium will focus on issues that impact on skin disorders
in dermatology
and the dermatologic community worldwide, including emerging that best fit your lifestyle
MONDAY, FEBRUARY 7

and reemerging skin infections, the HIV/AIDS epidemic, societal

disruptions caused by conflict and drought, and global climate
change. It will also examine efforts currently underway by the
international dermatologic community to alleviate these problems Make a difference by
through training programs to enhance the delivery of skin care
at the local level and discuss the possibilities of control or even
volunteering in your
elimination of tropical skin infections.
3.00 Category 1 CME Credits
community or abroad
SCHEDULE
2:00 p.m. Introduction / Dr. Klaus Join the Leadership
2:05 p.m. Emerging Skin Diseases / Dr. Norton
2:25 p.m. Impact of Global Climate Change on Distribution of
Circle for Volunteerism
Skin Diseases / Dr. Rehmus
2:45 p.m. Practice Of Dermatology In Developing Countries
/ Dr. Kovarik
3:05 p.m. Effects of Societal Disruption on Epidemiology of
Skin Disorders / Dr. Sethi
Visit the
3:25 p.m. Enhancing Skin Care in Africa Through Training Academy Resource Center
Programs / Dr. Nordlund
3:45 p.m. How Close Are We to the Control of Tropical Skin Booth 3623
Infections? / Dr. Hotez
4:05 p.m. Role of International Dermatology Organizations today to learn more!
/ Dr. Hay
4:25 p.m. The Role of Dermatology in the Control of HIV/
AIDS / Dr. Craft
4:45 p.m. Questions and Answers / Faculty

224 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
2:00 p.m. to 5:00 p.m.
Open admission, no tuition or ticket.

S043 Melanoma Update SCHEDULE

Room: Auditorium C 2:00 p.m. Introduction / Dr. Friedman
2:05 p.m. Difficult Melanocytic Lesions of Childhood and Their
DIRECTOR Robert J. Friedman, M.D. Management / Dr. Schaffer
SPEAkERS 2:20 p.m. Adjunctive Tools in the Diagnosis of Melanoma
Suephy C. Chen, M.D. Julie V. Schaffer, M.D. / Dr. Rabinovitz
Clay J. Cockerell, M.D. Jennifer A. Stein, M.D. 2:35 p.m. Saving Lives in Melanoma / Dr. Friedman
Harold S. Rabinovitz, M.D. Susan M. Swetter, M.D. 2:50 p.m. Epidemiology of Melanoma: Can We Make a
Darrell S. Rigel, M.D. Steven Q. Wang, M.D. Difference? / Dr. Rigel
Gary S. Rogers, M.D. 3:05 p.m. Causes Of Melanoma: UVR —Yes Or No?
/ Dr.Wang
LEARNING OBjECTIVES 3:20 p.m. A Successful Plan to Prevent Melanoma and its
Following this symposium, the attendee will be able to: / Dr. Swetter
1. Outline the diagnostic and therapeutic management of patients 3:35 p.m. Questions and Answers / Faculty
with melanoma; outline the issues surrounding the epidemic of 3:45 p.m. Clinical Diagnosis of Melanoma / Dr. Stein
melanoma; discuss the diagnostic conundrum associated with 4:00 p.m. The Broad Spectrum of Atypical Nevi and their Risk
melanoma. for Developing Melanoma: Clinical Dermatoscopy
2. Examine the role of UV and the use of sun protective behaviors Imaging Technology / Dr.Chen
in preventing cancers of the skin; gain a better understanding 4:15 p.m. The Toughest Melanocytic Lesions I’ve Diagnosed

MONDAY, FEBRUARY 7
of the role of genetic testing for melanoma risk. / Dr. Cockerell
3. Evaluate new concepts in the diagnosis of melanoma, including 4:30 p.m. The Clinical Management of the Melanoma Patient
dermoscopy, confocal laser microscopy, and computer vision; from Curable In Situ to Thick High-Risk Disease
gain a better understanding of the newest treatments for / Dr. Rogers
advanced melanoma. 4:45 p.m. Questions and Answers / Faculty
DESCRIPTION
The incidence of skin cancer/melanoma continues to rise
throughout the world. Dermatologists are faced each day with
the need to diagnose difficult pigmented lesions and to assess risk
for melanoma in such patients. As the incidence of melanoma
increases, we are challenged by the need to make accurate
diagnoses and treat this relatively common and potentially deadly
malignancy. Those attending this symposium will be exposed
to the teaching of a world-renowned faculty who will present
the most up-to-date and cutting-edge diagnostic and treatment
techniques for melanoma and other atypical pigmented lesions.
The goal is to be able to utilize the information presented and
apply it to everyday patient care.
3.00 Category 1 CME Credits
REFERENCES
1. Rigel, DS, et al, eds. Cancer of the Skin. Philadelphia: Elsevier;
2011.

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 225
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

DISCUSSION GROUP FOCUS SESSION

2:30 p.m. to 4:00 p.m. 2:30 p.m. to 4:00 p.m.
Tuition fee and ticket required for admission. Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

D023 Cutaneous T-Cell Lymphoma U133 Psychodermatology: Not just a Delusion;

Room: 240 ‘Bugs,’ Trichotillomania, and the
DIRECTOR Gary S. Wood, M.D. Morgellons Debate
Room: 235/236
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to: DIRECTOR Gary Goldenberg, M.D.
1. Identify the key clinicopathologic features of cutaneous T-cell
LEARNING OBjECTIVES
lymphoma (CTCL).
Following this focus session, the attendee will be able to:
2. Recognize recent advances in the tumor biology of CTCL.
1. Perform the appropriate evaluation and testing on a patient
3. Apply these advances to improve the management of CTCL
that “sees bugs.“
patients.
2. Manage a patient who says “I have Morgellons disease.”
DESCRIPTION 3. Appropriately evaluate and treat a patient that pulls at hair or
Important advances have been made in our understanding of picks at skin.
utaneous T-cell lymphoma (CTCL) tumor biology that can be
DESCRIPTION
used to improve clinical management. These include our ability to
This session will discuss the approach to a patient who presents with
identify and track the tumor clone, the implications of different
‘bugs on the skin.’ We will “pick apart” the differential diagnoses,
tumor clone homing behaviors, recognition that CTCL tumors
including true infections, delusions (from organic and psychiatric
(T3 lesions) sort into biologically and clinically distinct subsets, the
causes), somatoform disorders, hypochondriasis, and delirium.
MONDAY, FEBRUARY 7

importance of a robust host response and how to best maintain it

We will review appropriate history taking, physical examination,
during therapy, and the role of dysregulated apoptosis in CTCL
and laboratory testing for these patients. Clinical examples will
pathogenesis and therapy. These topics will be addressed following a
be used, and a basic treatment algorithm will be presented. This
brief review of the clinicopathological features of CTCL.
session will feature an open discussion regarding the controversial
1.50 Category 1 CME Credits
term “Morgellons disease.” We will also discuss a basic approach to
trichotillomania, skin picking, and body dysmorphic disorder. This
session is intended for all dermatologists.
D024 PAPA Syndrome, SAPHO, and Acne: Skin
1.50 Category 1 CME Credits
and Bones and Inflammation
Room: 241
DIRECTOR Gerd Plewig, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Explain how interleukin-1 receptor antagonists immediately
improve pyoderma gangrenosum.
2. Discuss these conditions and their treatment options.
DESCRIPTION
Hereditary and acquired inflammatory signs and symptoms
affecting skin, bones, and gut may be seen in PAPA syndrome
(pyogenic arthritis, pyoderma gangrenosum, and acne),
SAPHO syndrome (synovitis, acne, pustulosis [palmoplantaris],
hyperostosis, and osteitis), cryopyrinopathies, and Muckle-
Wells syndrome. This session focuses on important knowledge
of proteins interacting with pyrin. Furthermore acne inversa is
associated with Crohn disease and ulcerative colitis.
1.50 Category 1 CME Credits

226 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng


For description of session categories and fees see page 37
FOCUS SESSION
2:30 p.m. to 4:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U134 Issue in Office Design
Room: 283
DIRECTOR James A. Zalla, M.D.
LEARNING OBjECTIVES
1. Recognize the numerous important issues in design of a
dermatology office.
2. Design functional and efficient front office and clinical space
and patient flow.
3. Apply new ideas and tips to existing office facilities.
DESCRIPTION
This session reflects 35 years of practice experience as applied to
the design of a 10,000 square foot group practice dermatology
office. The space includes general, surgical, and pediatric
dermatology, Mohs surgery, dermatopathology lab, and cosmetic
consultation room. Tips on office design, room sizes and layout,
seating, wall and floor covering, other furnishings, equipment,
lighting, signage, phone, audio, nurse call systems, fire sprinkling
system, soundproofing, and storage recommendations will all be
shared. Time will also be available for questions.
1.50 Category 1 CME Credits
U135 What’s New in Dermatopathology and
Why It’s Important to You
Room: 263
DIRECTOR Gary Goldenberg, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Identify and describe recent clinically relevant studies in
dermatopathology.
2. Evaluate and recognize clinically relevant use of
immunohistochemical stains in dermatopathology.
DESCRIPTION
This focus session is intended to update clinical dermatologists
on a wide spectrum of recent developments in dermatopathology.
The conference will spotlight clinically relevant research. Attention
will be given to inflammatory and neoplastic diseases. Use of
immunohistochemical stains, and their clinical application, will
also be discussed.
1.50 Category 1 CME Credits
For the Latest Program Book InFormatIon PLease reFer to
SCIENTIFIC SESSIONS
U136 Management of Challenging Pigmented
Lesions
Room: 270
DIRECTOR Caroline C. Kim, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Characterize clinical and pathologic features of challenging
pigmented lesions.
2. Identify the most appropriate management strategies for
challenging pigmented lesions.
3. Recognize current diagnostic limitations for certain cases and
formulate practical treatment plans.
DESCRIPTION
Dermatologists are presented with the difficult task of evaluating
and managing patients with challenging pigmented lesions. Through
case examples, this session will review a variety of complex cases and
discuss practical management strategies, including surgical margins,
the role of sentinel lymph node biopsy, and appropriate follow-
MONDAY, FEBRUARY 7
up. Topics to be covered include atypical mole syndrome, atypical
spitz nevi, melanocytic tumors of uncertain malignant potential
(MELTUMP), and childhood melanoma. Current limitations of
histopathological diagnosis in certain pigmented lesions will be
discussed, as well as practical management strategies for such lesions.
This session will be directed towards all general dermatologists.
1.50 Category 1 CME Credits
U137 Developing a Unified Approach to
Investigating Autoimmune Disease
Room: 264
DIRECTOR John Harris, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Categorize autoimmune diseases of the skin with those of other
organ systems.
2. Predict pathogenic mechanisms for autoimmune diseases based
on distribution, symptoms, and evolution of disease.
3. Develop novel treatment strategies based on disease categories
of pathogenesis.
DESCRIPTION
Autoimmune diseases of the skin are numerous and complex. Recent
discoveries in basic and clinical sciences have challenged established
categories of autoimmune disease but provide new insights into
how these diseases manifest in our patients. New discoveries in basic
science will be discussed, as well as clinical characteristics that allow
us to compare and contrast individual autoimmune diseases affecting
the skin or other organ systems. Developing a strategy to categorize
autoimmune diseases provides an opportunity to understand how
these diseases are interrelated, to predict which novel treatments
might benefit our patients, and to better focus clinical and basic
research questions.
1.50 Category 1 CME Credits
www.aad.org | 227
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
FOCUS SESSION
2:30 p.m. to 4:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U138 Digital Imaging and Medical Informatics:
Decision Support for Clinicians and
Teachers
Room: 274
DIRECTOR Arthur Papier, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Discuss digital trends in dermatology and medical information.
2. Summarize advances in health information technology and
imaging, as it relates to teaching and dermatologic care.
3. Define clinical decision support.
DESCRIPTION
Recent healthcare reform legislation includes significant
physician reimbursement for using electronic health records that
meaningfully incorporate decision support. What is decision
support and how can it eventually improve the care dermatologists
deliver? Dermatology as a visual specialty has unique information
MONDAY, FEBRUARY 7
needs when considering the patient visit. During this session
clinical and academic dermatologists will learn of new information
technologies for handheld and desktop computing, and how
technology innovations can aide diagnosis and visual record
keeping. The integration of decision support with teledermatology
and the creation of an educational “feedback loop” for the
referring physician will be described.
1.50 Category 1 CME Credits
228 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
U139 Inherited Cancer Syndromes:
The Role of the Dermatologist
Room: 265/266
DIRECTOR Richard Eric White, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize individuals at risk for inherited cancer syndromes.
2. Apply screening protocols for individuals at risk for inherited
cancer syndromes.
3. Develop referral practices for individuals at risk for inherited
cancer syndromes.
DESCRIPTION
Inherited cancer syndromes account for 5-10% of all malignancies.
Dermatologists routinely manage individuals who are at risk for these
syndromes. This session presents four inherited cancer syndromes:
familial melanoma, muir-torre, hereditary breast and ovarian cancer
and, hereditary leiomyoma renal cell cancer. The ability to recognize
the dermatologic manifestations of these syndromes empowers the
attendee to identify at-risk individuals. The dermatologist has an
essential role in screening, management and referral. The session
participant will learn to obtain a focused pedigree, apply diagnostic
criteria, order screening studies, and provide referrals. The session
will conclude with an overview of genetic counseling.
1.50 Category 1 CME Credits

For description of session categories and fees see page 37
FOCUS SESSION
2:30 p.m. to 4:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U140 Past, Present, and Pearls of Treatment of
Autoimmune Bullous Disease
Room: 269
DIRECTOR Naveed Sami, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Discuss local and systemic therapeutic options available,
including the latest treatments.
2. Formulate a general treatment algorithm and discuss specific
questions the audience may have regarding specific patients.
3. Discuss possible treatment pearls which may help in the
treatment of autoimmune mucocutaneous blistering disease
patients.
DESCRIPTION
Autoimmune mucocutaneous blistering diseases can vary in their
presentation and treatment response. There are very few case
controlled studies on the usage of certain systemic agents. Most
of treatment knowledge has been derived from the experience of
dermatologists over the several decades. This session will attempt to
present the various treatment agents available today. A treatment
algorithm of what could be used in a realistic scenario will be
discussed. Specific treatment pearls will be shared by the presenter
which may help clinicians in the management of their patients.
Specific questions will be addressed in a discussion format.
1.50 Category 1 CME Credits
For the Latest Program Book InFormatIon PLease reFer to
SCIENTIFIC SESSIONS
U141 Skin Signs of Systemic Disease
Room: 242
DIRECTOR Joseph C. English III, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Discuss new skin disease associations with systemic disease.
2. Describe new systemic disease associations with classical skin
signs of internal disease.
3. Examine the need for the interaction of all specialities with
dermatology to enhance patient care.
DESCRIPTION
This session is dedicated to updating practicing dermatologist with
the most current evidence-based dermatology findings concerning
the evaluation and management of skin signs of systemic disease.
Part I is organ system based disease followed by new skin findings.
Part II is classic skin signs followed by a review of new and old
associated systemic diseases.
MONDAY, FEBRUARY 7
1.50 Category 1 CME Credits
U142 Cryosurgical Update
Room: 267/268
DIRECTOR Gloria F. Graham, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Choose the appropriate treatment for benign, premalignant
and malignant skin lesions.
2. Select the best method for specific patients.
3. Identify side effects and their prevention.
DESCRIPTION
The session will present a variety of skin tumors and conditions
amenable to cryosurgery with the goal of achieving improved
cure rate and cosmetic result. Pretreatment of the skin in some
conditions can improve the overall cure rate and cosmetic result.
Selection of technique includes cotton swab, probe, or spray
with or without use of cone or thermocouple needle. Some
newer technology and techniques will be discussed including
cryoimmunology, fractional cryosurgery, and confocal microscopy
as aid in determining tumor depth prior to cryosurgery. A
new device to measure temperature control may prove useful.
Clinicians and residents may find this useful in their practices.
1.50 Category 1 CME Credits
www.aad.org | 229
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
3:00 p.m. to 5:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F071 Advanced Treatment for Chronic Wounds F073 Techniques for Flap Success
Room: 252/253/254 Room: 255/256/257
DIRECTOR Marco Romanelli, M.D. DIRECTOR Ken K. Lee, M.D.
SPEAkERS SPEAkERSs
Francisco Kerdel, M.D. Maria Miteva, M.D. Sumaira Zareen Aasi, M.D.
Severin R. Laeuchli, M.D. Paolo Romanelli, M.D. Andrew J. Kaufman, M.D.
LEARNING OBjECTIVES Steven M. Rotter, M.D.
Following this forum, the attendee will be able to:
LEARNING OBjECTIVES
1. Identify patients who are candidates for advanced treatment in
Following this forum, the attendee will be able to:
chronic wound management.
2. Formulate approaches to therapy for difficult-to-heal wounds. 1. Examine different types of flaps.
3. Compare the safety and efficacy profiles of various advanced 2. Apply different flap designs to various defects.
treatments. 3. Recognize the advantages and limitations of various flaps.
DESCRIPTION DESCRIPTION
This session will give an overview of advanced treatment available This session will provide an in-depth examination of different
for the management of common and atypical chronic wounds. flap types: advancement, transposition, rotation, pedicle, and
Clinical usefulness, appropriateness, and cost-effectiveness of interpolated flaps. The speakers will discuss the advantages
the most recent advances will be covered, including topical and limitations of each of these flaps, as well as offer pearls for
MONDAY, FEBRUARY 7

antimicrobials, active dressings, systemic drugs, medical devices, the proper execution of these flaps. Many examples of various
and tissue engineering. defects closed with different flaps will be shown. Additionally,
2.00 Category 1 CME Credits management of complications will be reviewed.
2.00 Category 1 CME Credits
F072 Medium and Deep Chemical Peeling
Room: 278/279/280
DIRECTOR Harold Joseph Brody, M.D.
SPEAkER Seaver Soon, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Choose and compare photoaging, wrinkles and scarring
indications for medium and deep combination chemical peeling.
2. Utilize exact techniques for medium trichloroacetic acid
chemical peeling and deep regional phenol chemical peeling
in combination on the face.
DESCRIPTION
Dermatologic surgeons can treat photoaging in the form of
hyperpigmentation, moderate to severe wrinkles, actinic keratoses,
and pitted scarring in a cost-effective manner using combinations
of chemical resurfacing techniques. This session will teach exact
techniques for medium depth trichloroacetic acid (TCA) chemical
peeling and regional deep phenol peeling (i.e., around the mouth)
on the photoaged face. Didactic instruction and extensive video
will be used. Superficial peeling will not be emphasized, and
complications will be covered briefly only with respect to medium
and deep peeling. Familiarity with chemical peeling agents in
advance is very helpful.
2.00 Category 1 CME Credits

230 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
3:00 p.m. to 5:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F074 The Use of the Confocal Microscope in a F075 Alopecia CPC

Private Clinical Practice Room: 388/389/390
Room: 391 DIRECTOR Lynne J. Goldberg, M.D.
DIRECTOR Harold S. Rabinovitz, M.D. SPEAkERS
SPEAkERS Michael D. Ioffreda, M.D.
Verena Ahlgrimm-Siess, M.D. Giovanni Pellacani, M.D. Leonard C. Sperling, M.D.
Sara Bassoli, M.D. Susana Puig, M.D. Catherine Margaret Stefanato, M.D.
Joseph Malvehy, M.D. Alon Scope, M.D. LEARNING OBjECTIVES
Scott Menzies, MBBS, Ph.D. Iris Zalaudek, M.D. Following this forum, the attendee will be able to:
Margaret C. Oliviero, NP 1. Develop an appreciation for information that can be obtained
LEARNING OBjECTIVES from a scalp biopsy.
Following this forum, the attendee will be able to: 2. Compare scalp biopsy results with the patients clinical picture,
1. Describe the confocal features of normal skin. maximizing diagnostic accuracy.
2. Differentiate benign and malignant neoplasms of the skin. DESCRIPTION
3. Identify the confocal features of specific neoplasms. This forum features four dermatologists/dermatopathologists with
DESCRIPTION a special interest in alopecia. Each will present patients whose
The reflectance confocal microscope is a new imaging device that biopsies were especially instructive. Histologic clues and pitfalls

MONDAY, FEBRUARY 7
can be used as an aid in the evaluation of diseases of the skin. will be discussed, and pointers as to how to correlate the biopsy
This course will focus on introducing this device, its terminology, report with the patients clinical findings given. Along the way
and basic mechanics. The attention will be on both benign and expect tips on approach to the alopecia patient, clinical findings
malignant melanocytic and non-melanocytic neoplasms of the skin. of various alopecias, where to obtain the biopsy, narrowing down
2.00 Category 1 CME Credits what information you are seeking from the biopsy, and how to
dissect this information from the biopsy report. Presentations will
SCHEDULE be informal, and questions and discussion encouraged. Suitable for
3:00 p.m. Principles and Terminology of Reflectance Confocal both dermatopathologists and dermatologists.
Microscopy (RCM) / Dr. Scope 2.00 Category 1 CME Credits
3:20 p.m. Benign Melanocytic Neoplasms / Dr. Bassoli
3:40 p.m. Melanoma Diagnosis / Dr. Pellacani
4:00 p.m. Reflectance Confocal Microscopy of Non-Melanocytic
Neoplasms / Dr. Ahlgrimm-Siess
4:20 p.m. How the Confocal Microscope is Used Daily in a
Clinical Setting / Ms. Oliviero
4:40 p.m. Unknowns for the Experts / Dr. Malvehy
/ Dr. Puig / Dr. Rabinovitz / Dr. Zalaudek

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 231
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
3:00 p.m. to 5:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F076 Pediatric Dermatology F077 Aesthetic Dermatologic Complications

Room: 386/387 Room: 392
DIRECTOR Mary Wu Chang, M.D. DIRECTOR Ranella J. Hirsch, M.D.
SPEAkERS SPEAkERS
Richard J. Antaya, M.D. Jean D.A. Carruthers, M.D.
Hanspaul Makkar, M.D. Jeffrey S. Dover, M.D.
Karen Wiss, M.D. Roberta D. Sengelmann, M.D.
LEARNING OBjECTIVES LEARNING OBjECTIVES
Following this forum, the attendee will be able to: Following this forum, the attendee will be able to:
1. Recognize the diagnostic methods necessary to distinguish 1. Prevent, evaluate, and manage aesthetic dermatologic
blistering diseases in infancy and early childhood. complications.
2. Identify birthmarks that require specific surgical or medical 2. Develop best practices for optimizing complication outcomes.
management.
DESCRIPTION
3. Discuss examples of unique pediatric dermatoses.
This interactive session will orient the attendee to best practices
DESCRIPTION for the prevention, evaluation, and management of aesthetic
Get out your pencils, its time for a quiz! Four pediatric dermatologic complications. The audience is invited to present
MONDAY, FEBRUARY 7

dermatologists return to bring interesting and informative cases to difficult cases they have encountered for discussion with the panel.
share with the audience for a stimulating and practical session. The 2.00 Category 1 CME Credits
cases will be presented in a pre-test format at the beginning of the
session, followed by discussion. There will be a mix of classic as
well as rare entities. Audience participation is encouraged.
New cases and updates are included this year.
2.00 Category 1 CME Credits
SCHEDULE
3:00 p.m. Introduction / Dr. Chang
3:03 p.m. Photo Quiz / Faculty
3:20 p.m. Discussion of Cases / Faculty
4:45 p.m. Questions and Answers / Faculty

232 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM WORkSHOP
3:00 p.m. to 5:00 p.m. 3:00 p.m. to 5:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat Tuition fee and ticket required for admission.
for only 15 minutes after the official start time.

F078 Epidermolysis Bullosa: Cases and W013 MOC Self-Assessment: Office-Based

Discussion
M
O
C
Safety
Room: 281/282 Room: 288/289/290
DIRECTOR Hillary Johnson-Jahangir, M.D., Ph.D.
DIRECTOR Anne W. Lucky, M.D.
LEARNING OBjECTIVES
SPEAkERS
Following this workshop, the attendee will be able to:
Anna Lee Bruckner, M.D.
1. Identify strengths and weaknesses in one’s knowledge of
Elena Pope, M.D.
issues in patient safety that are relevant to the practice of
LEARNING OBjECTIVES dermatology.
Following this forum, the attendee will be able to: 2. Integrate and apply concepts in patient safety to improve
1. Recognize some of the important issues in the care of patients dermatologic care.
with epidermolysis bullosa.
DESCRIPTION
2. Utilize new strategies for caring for patients with epidermolysis
bullosa. This session will be structured as a question-and-answer format
using an automated response system. Concepts in patient safety
DESCRIPTION that are relevant for dermatologists will be highlighted. Safety
This focus session will provide an opportunity to present cases of
issues important in procedural and medical dermatologic practice
epidermolysis bullosa that illustrate unique features or problems
will be addressed in order to better care for our patients.

with diagnosis and/or treatment. There will be some didactic
discussion of the new classification of epidermolysis bullosa and
updates of research in progress in this field. Participants are
encouraged to submit their cases before the meeting.
2.00 Category 1 CME Credits
MONDAY, FEBRUARY 7
2.00 Category 1 CME Credits
* Self-assessment questions utilized in this session are
the same as those used for Workshop W004 MOC:
Self-Assessment offered at Summer Meeting 2010.
Physicians should not claim CME/MOC credit for
attending this session if they attended Workshop W004
at Summer Meeting 2010.

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 233
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

Represents restricted session in program overviews Represents activities that meet MOC-D
Restricted Session open to dermatologists and corporate M
O
This activity has been approved by the ABD to satisfy
individual members only! A ticket is required for admittance C component 2 of MOC-D

Represents Practice Management Session in program overviews Represents Leadership Institute in program overviews
Practice Management Session open to eligible Leadership Institute — addresses leadership
office staff/registered nurses competencies specific to dermatologists

Represents Patient Safety Session in program overviews Represents Health Information Technology (HIT) in
program overviews
Patient Safety Session
Health Information Technology Sessions

Represents Audience Response System Session

Audience Response System Session

OVERVIEW
MONDAY/TUESDAY, FEBRUARY 7, 8
Courses — 9:00 p.m. to 5:00 p.m.
C029 Dermatology Review. . . . . . . . . . . . . . . . . . . . . .234 C030 Basic Dermatology . . . . . . . . . . . . . . . . . . . . . . .235

COURSE
9:00 a.m. to 5:00 p.m.
MONDAY/TUESDAY, FEBRUARY 7/8

Tuition fee and ticket required for admission.

C029 Dermatology Review SCHEDULE

Room: 243/244/245 Monday, February 7, 2011
9:00 a.m. Introduction / Dr. Rich
DIRECTOR Phoebe Rich, M.D. 9:05 a.m. Advances in Cutaneous T-Cell Lymphoma / Dr. Duvic
9:35 a.m. Bacterial Skin Infection Update: MRSA and More
SPEAkERS
/ Dr. Murakawa
David R. Adams, M.D., Pharm.D George J. Murakawa, M.D.
10:05 a.m. Immunodermatology / Dr. Blauvelt
Pamela S. Allen, M.D. David Michael Pariser, M.D.
10:35 a.m. Questions and Answers / Faculty
Andrew Blauvelt, M.D. Darrell S. Rigel, M.D.
10:45 a.m. Infectious Skin Disease: Viral and More: What’s New!
Jeffrey Phillip Callen, M.D. Janet Louise Roberts, M.D.
/ Dr. Tyring
Clay J. Cockerell, M.D. Theodore Rosen, M.D.
11:15 a.m. Atopic Dermatitis Update / Dr. Simpson
David Eric Cohen, M.D. Eric Lawrence Simpson, M.D.
11:45 a.m. Questions and Answers / Faculty
Raymond L. Cornelison Jr., M.D. Stephen K. Tyring, M.D., Ph.D.
2:00 p.m. Blistering Diseases / Dr. Yancey
Benjamin David Ehst, M.D., Ph.D. Guy F. Webster, M.D., Ph.D.
2:30 p.m. Rheumatic Skin Disease / Dr. Werth
Alfons Krol, M.D. Victoria P. Werth, M.D.
3:00 p.m. Hair Disorders: What’s New! / Dr. Roberts
Henry W. Lim, M.D. Kim B. Yancey, M.D.
3:30 p.m. Dermatologic Emergencies / Dr. Rosen
LEARNING OBjECTIVES 4:00 p.m. Drug Reactions / Dr. Adams
Following this course, the attendee will be able to: 4:35 p.m. Questions And Answers / Faculty
1. Demonstrate an understanding of cutaneous disease by Tuesday, February 8, 2011
reviewing new information concepts, and discoveries from the 9:00 a.m. Pediatric Dermatology Update / Dr. Krol
current literature. 9:30 a.m. Contact Dermatitis Update / Dr. Cohen
2. Integrate and apply cutting edge research and knowledge 10:00 a.m. Dermatolopathology Update / Dr. Cockerell
to improve patient care and to prepare for certification 10:30 a.m. Questions and Answers / Faculty
examinations. 10:35 a.m. Melanoma Update / Dr. Rigel
DESCRIPTION 11:05 a.m. Skin Signs of Systemic Disease / Dr. Callen
This course will provide encapsulated new information in 11:30 a.m. Photodermatology Update / Dr. Lim
a soup- to-nuts coverage of dermatology. World-renowned 2:00 p.m. Skin Manifestations of HIV Disease / Dr. Ehst
dermatologists will summarize their areas of expertise in an 2:30 p.m. Laser Update / Dr. Allen
informative and engaging fashion. This will provide current 3:00 p.m. Botulinum Toxin for Hyperhidrosis Update
information in dermatology that will improve clinical practice and / Dr. Pariser
provide concise information helpful in reviewing for certification 3:30 p.m. Questions and Answers / Faculty
examinations. 3:45 p.m. Nails Update! / Dr. Rich
12.00 Category 1 CME Credits 4:15 p.m. Psoriasis-Biologics Update / Dr. Cornelison
4:45 p.m. Questions and Answers / Faculty
234 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
9:00 a.m. to 5:00 p.m.
Tuition fee and ticket required for admission.

C030 Basic Dermatopathology SCHEDULE

Room: 383/384/385
DIRECTOR Rosalie Elenitsas, M.D.
SPEAkERS
Raymond L. Barnhill, M.D.
Nooshin Ketabchi Brinster, M.D.
Clay J. Cockerell, M.D.
Carrie Ann R. Cusack, M.D.
George W. Elgart, M.D.
Tammie C. Ferringer, M.D.
James E. Fitzpatrick, M.D.
Maxwell A. Fung, M.D.
Jane Margaret Grant-Kels, M.D.
Antoinette Foote Hood, M.D.
Michael D. Ioffreda, M.D.
Hideko Kamino, M.D.
Rossitza Z. Lazova, M.D.
Jason Bok Lee, M.D.
Carlos H. Nousari, M.D.
Ronald P. Rapini, M.D.
Leslie Robinson-Bostom, M.D.
Adam Rubin, M.D.
Andras Schaffer, M.D.
Mary S. Stone, M.D.
Michael Tetzlaff, M.D.
Karen Warschaw, M.D.
Clifton Robert White Jr., M.D.
Caroline S. Wilkel, M.D.
Monday, February 7, 2011
9:00 a.m. Introductory Comments / Elenitsas
9:05 a.m. A Method for Histopathologic Diagnosis of
Inflammatory Skin Diseases / Dr. Fitzpatrick
9:25 a.m. Vacuolar and Lichenoid Dermatitis / Dr. Lee
9:45 a.m. Intraepidermal Vesicular Dermatitis / Dr. Hood
10:10 a.m. Psoriasiform and Spongiotic Dermatitis / Dr. Wilkel
10:25 a.m. Intermission / Faculty
10:40 a.m. Subepidermal Vesicular Dermatitis / Dr. Nousari
11:05 a.m. Nodular and Diffuse Dermatitis (Sweet syndrome and
Granuloma Faciale) / Dr. Grant-Kels
11:35 a.m. Vasculitis / Dr. Stone
11:55 a.m. Questions and Answers / Faculty
12:00 p.m. Lunch / Faculty
2:00 p.m. Fibrohistiocytic Neoplams / Dr. Kamino
2:30 p.m. Fat and Osseous Neoplasms / Dr. Cockerell

MONDAY/TUESDAY, FEBRUARY 7/8

Christine Ko, M.D.
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Recognize the histologic features of common inflammatory
dermatoses.
2. Differentiate the histologic feaures of the common cutaneous
neoplasms.
3. Demonstrate a solid foundation in basic dermatopathology.
DESCRIPTION
This session is designed to offer an overview of the histologic
features of a wide spectrum of cutaneous inflammatory dermatoses
and neoplasms. Criteria used to establish diagnoses and to
differentiate among lesions with similar histopathologic features
will be reviewed. Pattern analysis will be emphasized. Lectures
will be illustrated with clinical and histopathologic photographs.
Syllabus material will be provided.
11.00 Category 1 CME Credits
REFERENCES
1. Elder DE, Elenitsas R, Johnson BL, Murphy GF, Xu X.
Lever’s Histopathology of the Skin. 10th ed. Philadelphia, PA:
Lippincott Williams and Wilkins; 2009
2. Weedon D. Weedon’s Skin Pathology. 3rd ed. Churchill
Livingstone; 2010
3. Ackerman AB, Boer A, Bennin B, Gottlieb GG. Histologic
Diagnosis of Inflammatory Skin Diseases. 3rd ed. New York, NY:
Ardor Scribendi; 2005
2:50 p.m. Metastatic Neoplasms / Dr. Elgart
3:10 p.m. Intermission / Faculty
3:25 p.m. Benign Melanocytic Neoplasms / Dr. Barnhill
3:55 p.m. Malignant Melanocytic Neoplasms / Dr. Fung
4:25 p.m. Pre-malignant and Malignant Epithelial Neoplasms
/ Dr. Cusack
4:55 p.m. Questions and Answers / Faculty
Tuesday, February 8, 2011
9:00 a.m. Panniculitis / Dr. Robinson-Bostom
9:25 a.m. Alopecia / Dr. Ioffreda
9:50 a.m. Nail Histology, Common Inflammatory Skin Disease
and Neoplasms / Dr. Rubin
10:10 a.m. Depositions and Dermal Disorders / Dr. Tetzlaff
10:25 a.m. Intermission / Faculty
10:40 a.m. Practical Immunoperoxidase Staining / Dr. Ferringer
11:10 a.m. Follicular Neoplasms / Dr. Rapini
11:30 a.m. Neural Neoplasms / Dr. White
11:50 a.m. Questions and Answers / Faculty
12:00 p.m. Lunch / Faculty
2:00 p.m. Lymphoma and Pseudolymphoma / Dr. Schaffer
2:30 p.m. Muscle Neoplasms / Dr. Ko
2:50 p.m. Sebaceous Neoplasms / Dr. Lazova
3:15 p.m. Intermission / Faculty
3:30 p.m. Apocrine and Eccrine Neoplasms / Dr. Warschaw
4:00 p.m. Vascular Neoplasms / Dr. Brinster
4:25 p.m. Benign Epithelial Neoplasms and Cysts / Dr. Elenitsas
4:55 p.m. Questions and Answers / Faculty

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 235
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

OVERVIEW
Represents restricted session in program overviews Represents activities that meet MOC-D
Restricted Session open to dermatologists and corporate M
O
This activity has been approved by the ABD to satisfy
individual members only! A ticket is required for admittance C component 2 of MOC-D

Represents Practice Management Session in program overviews Represents Leadership Institute in program overviews
Practice Management Session open to eligible Leadership Institute — addresses leadership
office staff/registered nurses competencies specific to dermatologists

Represents Patient Safety Session in program overviews Represents Health Information Technology (HIT) in
program overviews
Patient Safety Session
Health Information Technology Sessions

Represents Audience Response System Session

Audience Response System Session

TUESDAY, FEBRUARY 8 Courses — 9:00 a.m. to 12:00 p.m.

C031 Advanced Cosmetic Surgery and Aesthetics . . . .245
Discussion Groups — 7:15 a.m. to 8:45 a.m.
D025 Integration of Photodynamic Therapy into C032 Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .246
Your Practice. . . . . . . . . . . . . . . . . . . . . . . . . . . .238
D026 A Practical Approach to Photosensitivity. . . . . . .238 Symposia — 9:00 a.m. to 12:00 p.m.
S044 Therapeutic Hotline . . . . . . . . . . . . . . . . . . . . . .247
Focus Sessions — 7:15 a.m. to 8:45 a.m. S045 Disorders of Mucous Membranes . . . . . . . . . . . .247
U143 Pediatric Surgery . . . . . . . . . . . . . . . . . . . . . . . . .238 S046 Pediatric Dermatology . . . . . . . . . . . . . . . . . . . .248
U144 Serial Screening for Melanoma: Measures That have S047 Managing Melanoma in the Modern
Consistently Achieved Early Detection and Cure 238 Millennium. . . . . . . . . . . . . . . . . . . . . . . . . . . . .249
U145 Advances in Psoriasis. . . . . . . . . . . . . . . . . . . . . .239 S048 Cutaneous Lymphomas. . . . . . . . . . . . . . . . . . . .249
U146 Management of Cutaneous Toxicity in the Era S049 Cosmetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .250
of Targeted Chemotherapy . . . . . . . . . . . . . . . . .239 S050 Organizational Approaches to AIDS/STDs
U147 Dermatological Signs of Child Abuse . . . . . . . . .239 From a Global Perspective. . . . . . . . . . . . . . . . . .250
U148 Lessons Learned from Challenging Pediatric Cases:
Targeted Novel Molecular Therapies . . . . . . . . .239 Forums — 12:00 p.m. to 2:00 p.m.
U149 Overgrowth Syndromes . . . . . . . . . . . . . . . . . . .240 F086 BCC Update and Options of Treatment . . . . . . .251
U150 Skin Cancer Viruses: Bench to Bedside. . . . . . . .240 F087 Nail Disorders in Children . . . . . . . . . . . . . . . . .251
U151 Approach to Non-Scarring Hair Loss in Women . .240 F088 Clinical Trials . . . . . . . . . . . . . . . . . . . . . . . . . . .252
U152 Cutaneous Mucinosis . . . . . . . . . . . . . . . . . . . . .241 F089 Advances in Photomedicine . . . . . . . . . . . . . . . .252
U153 Facing Facial Dermatoses . . . . . . . . . . . . . . . . . .241 F090 Autoimmune Mucocutaneous Blistering
Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .253
Forums — 9:00 a.m. to 11:00 a.m. F091 Supportive Onco-Dermatology:
F079 Update on Alopecia Areata . . . . . . . . . . . . . . . . .241 Dermatologic Reactions in Oncology . . . . . . . . .253
F080 Fractional Laser and Light-Based Technologies . .242 F092 Diagnosing and Monitoring Hair
and Scalp Disease . . . . . . . . . . . . . . . . . . . . . . . .254
F081 Geriatric Dermatology . . . . . . . . . . . . . . . . . . . .242
F082 Managing Office Politics: Private Practice,
Academics, and Everything in Between. . . . . . . .243 Discussion Group — 12:15 p.m. to 1:45 p.m.
TUESDAY, FEBRUARY 8

F083 Psoriasis Therapy in the Age of Biologics . . . . . .243 D027 Differential Diagnosis of Leprosy in
a Non-Endemic Country . . . . . . . . . . . . . . . . . .254
F084 Medical Applications of Topical
Photodynamic Therapy . . . . . . . . . . . . . . . . . . . .243
F085 Autoimmune Blistering Disorders. . . . . . . . . . . .244 Focus Sessions — 12:15 p.m. to 1:45 p.m.
U154 Caring for the Hospitalized Patient: Interesting
Cases from the Inpatient Consultative Service . .255
Workshop — 9:00 a.m. to 11:00 a.m. U155 What’s New in Skin Cancer Prevention . . . . . . .255
W014 Dermoscopy Cases . . . . . . . . . . . . . . . . . . . . . . .244 U156 Finding the Needle in the Haystack:
A Guide to More Effective Patch Testing . . . . . .255
U157 Rosacea Update. . . . . . . . . . . . . . . . . . . . . . . . . .255

236 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

OVERVIEW

U158 Acne: Etiopathogenesis and Treatment 2011. . . .256

U159 An Approach to Cultural
Diversity in Dermatology . . . . . . . . . . . . . . . . . .256
U160 Pigmented Lesions in Pediatric Dermatology . . .257
U161 Actinic Keratoses Update . . . . . . . . . . . . . . . . . .257
U162 Full Facial Approach with Botulinum Toxin
and Hyaluronic Acid: Cases From a
European Practice . . . . . . . . . . . . . . . . . . . . . . . .257
U163 Garden Variety Derm: Identifying and Managing
Exposures to Hazardous Plants and Arthropods in
the Garden . . . . . . . . . . . . . . . . . . . . . . . . . . . . .258
U164 Hypercoagulability, Purpura, and the Skin . . . . .258
U165 The Management of TEN/SJS:
The US Army Burn Unit Experience . . . . . . . . .258

Courses— 2:00 p.m. to 5:00 p.m.

C033 Advanced Surgery . . . . . . . . . . . . . . . . . . . . . . . .259
C034 Skin Resurfacing and Rejuvenation. . . . . . . . . . .259

Symposia — 2:00 p.m. to 5:00 p.m.

S051 Evidence-Based Medicine . . . . . . . . . . . . . . . . . .260
S052 Surgical Complications . . . . . . . . . . . . . . . . . . . .260

Focus Sessions — 2:30 p.m. to 4:00 p.m.

U166 Great Cases in Teledermatology . . . . . . . . . . . . .261
U167 Establishing a Mohs’ Practice:
Pearls for New Surgeons . . . . . . . . . . . . . . . . . . .261
U168 Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .261
U169 Cryosurgery Present and Future . . . . . . . . . . . . .261
U170 Pitfalls in Dermatopathology: When Things Are
Not What They Seem to Be . . . . . . . . . . . . . . . .262
U171 Frontiers of Dermatopathology: Utility,
Methodology, and Interpretation of Current
(and Future) Molecular Testing. . . . . . . . . . . . . .262
U172 Transplant Research in Dermatology . . . . . . . . .262

Forums — 3:00 p.m. to 5:00 p.m.

F093 Psychocutaneous Medicine . . . . . . . . . . . . . . . . .263
F094 Melasma: Advances in the Treatment of a
Therapeutically Challenging Disease . . . . . . . . . .263
F095 Challenges in the Diagnosis and Management of
Lentigo Maligna Melanoma . . . . . . . . . . . . . . . .264
F096 Phototherapy . . . . . . . . . . . . . . . . . . . . . . . . . . .264
TUESDAY, FEBRUARY 8

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 237
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
DISCUSSION GROUP
7:15 a.m. to 8:45 a.m.
Tuition fee and ticket required for admission.
D025 Integration of Photodynamic Therapy into
Your Practice
Room: 240
DIRECTOR Nellie Konnikov, M.D.
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Discuss and teach leprosy.
2. Differentiate leprosy from the endemic dermatologic entities in
practice.
3. Evaluate and appreciate leprosy as a model for other
dermatologic diseases which have systemic overtones.
DESCRIPTION
Since leprosy is not endemic in the U.S., one might feel comfortable
not including it in differential diagnoses. The potential source of disease
in practice is immigrants from highly endemic areas such as Brazil and
India. How can one best be sensitized to this disease and diagnosis?
Why not describe what diseases it can look like in your practice and
then tell you why it is not leprosy? This approach will not only tell
you how to make a diagnosis of leprosy, but will make you realize that
leprosy in many ways can be a model for other dermatologic entities.
1.50 Category 1 CME Credits
D026 A Practical Approach to Photosensitivity
Room: 241
DIRECTOR Robert P. Sarkany, M.D., MBBS
LEARNING OBjECTIVES
Following this discussion group, the attendee will be able to:
1. Clinically assess and create a clinical differential diagnosis for
patients presenting with photosensitivty.
2. Demonstrate which tests to do on which patients and to
understand the principles and diagnostic role of specialist tests
such as photopatch and phototesting.
3. Manage patients with photosensitivity.
DESCRIPTION
The audience will receive the tools to manage photosensitive patients
TUESDAY, FEBRUARY 8
in their own practices. Speakers will interactively discuss how
photosensitive patients present in the general dermatology clinic; how to
clinically assess (history and examination) photosensitive patients to gain
a differential diagnosis in the clinic; which investigations to do in which
clinical scenarios, and particularly in which situations the specialist tests
(phototests, photopatch tests, porphyrin tests etc.) are useful and where
they are needed; create a simple practical framework so dermatologists
can manage photosensitive patients. After the session you should have
the rudiments to manage patients presenting with photosensitive
dermatoses.
1.50 Category 1 CME Credits
238 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U143 Pediatric Surgery
Room: 270
DIRECTOR Annette M. Wagner, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Identify practical tips to improve surgical and laser outcomes in
pediatric patients in their practice.
2. Distinguish and manage common birthmarks that require
surgery using appropriate anesthetic agents and optimal timing.
3. Utilize vascular lasers appropriately in the pediatric population.
DESCRIPTION
The use of lasers and surgical procedures is becoming common
in pediatric dermatology practice. This session will provide
participants with updated information applicable to performing
procedures in children. Practical surgical and laser pearls
to improve outcomes in this population will be discussed.
Controversies and more advanced surgical techniques for the
pediatric dermatologic surgeon will be presented.
1.50 Category 1 CME Credits
U144 Serial Screening for Melanoma:
Measures that have Consistently
Achieved Early Detection and Cure
Room: 265/266
DIRECTOR Ronald Nevin Shore, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Select patients at increased risk of skin cancers for whom serial
screening would be appropriate.
2. Select lesions for which biopsy or monitoring would be
appropriate.
3. Develop an effective serial screening program.
DESCRIPTION
This session is intended to assist practitioners in establishing
or improving office-based, serial screening programs with the
objective being to achieve very high rates of cure for skin cancer,
particularly melanoma, through consistent early detection. The
scientific basis of various measures in our screening program will
be reviewed, including how these relate to the developmental
biology and chronology of melanoma. Those measures that have
been particularly helpful in our program’s achieving 100% survival
from all skin cancers in over 18 years will be discussed, and several
fascinating, new observations on the nature of melanoma will be
described.
1.50 Category 1 CME Credits

For description of session categories and fees see page 37
FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U145 Advances in Psoriasis
Room: 267/268
DIRECTOR Jeffrey M. Weinberg, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Assess the latest clinical data for tumor necrosis factor-
inhibitors.
2. Determine the latest clinical data for T-cell targeted therapies
and antibodies to IL-12/23.
3. Review the latest clinical data for novel oral and biologic
therapies in development for psoriasis.
DESCRIPTION
There are a growing number of new and investigational therapies
for psoriasis. The latest efficacy and safety data for available and
investigational biological agents will be reviewed. In addition,
an update on oral therapies in development will be presented.
Recommendations for appropriate monitoring of patients on these
agents will be discussed.
1.50 Category 1 CME Credits
U146 Management of Cutaneous Toxicity in the
Era of Targeted Chemotherapy
Room: 264
DIRECTOR Milan J. Anadkat, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize the common manifestations of chemotherapy skin
toxicity.
2. Differentiate the varying mechanisms of chemotherapy-induced
cutaneous reactions.
3. Manage patients with cutaneous toxicity due to systemic
chemotherapy.
DESCRIPTION
Systemic chemotherapy has always resulted in varying forms
of cutaneous toxicity. With the advance in molecular targeted
chemotherapy, cutaneous adverse reactions have become a leading
cause of morbidity and dose limitation for afflicted patients. In
this session, dermatologists will learn to recognize the varying
forms of cutaneous toxicity resulting from targeted chemotherapy,
the mechanisms underlying these reactions, and how to manage
these perplexing scenarios.
1.50 Category 1 CME Credits
For the Latest Program Book InFormatIon PLease reFer to
SCIENTIFIC SESSIONS
U147 Dermatological Signs of Child Abuse
Room: 269
DIRECTOR Arnold Pieter Oranje, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize the clinical spectrum of dermatologic signs of child
abuse and formulate a comprehensive differential diagnosis for
the case.
2. Demonstrate the proper diagnosis by choosing an adequate
workup, including an independent double-interdisciplinary
evaluation, to come to the most correct conclusions.
3. Recognize the necessity for cooperation between the forensic
pediatrician and the pediatric dermatologist.
DESCRIPTION
This interactive session will concentrate on the difficult and
unusual cases that one may encounter in consultations when child
abuse is suspected. The problems will be illustrated by several
cases and discussed in a comprehensive manner with input from
everyone present. A multidisciplinary approach is demanded in
cases of suspected child abuse. In the Netherlands, a working
group for forensic pediatrics is active and recommended as the
best approach (Robert AC Bilo, Arnold P Oranje).
1.50 Category 1 CME Credits
U148 Lessons Learned from Challenging
Pediatric Cases: Targeted Novel
Molecular Therapies
Room: 284
DIRECTOR Joyce Teng, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Describe the relevant clinical and management challenges of a
variety of interesting pediatric dermatologic cases.
2. Discuss targeted molecular diagnostic and therapeutic
approaches for several challenging dermatologic conditions.
TUESDAY, FEBRUARY 8
3. Outline other potential molecular therapies and novel
application of light based treatments.
DESCRIPTION
In this session, several challenging pediatric vascular, neoplastic,
and genetic dermatoses will be presented. The session will review
some of the difficulties in both diagnosis and management
from the dermatologic perspectives. It intends to educate the
attendee about developing novel therapeutic concepts to manage
challenging dermatologic conditions based on recent developments
in molecular biology.
1.50 Category 1 CME Credits
www.aad.org | 239
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U149 Overgrowth Syndromes U151 Approach to Non-Scarring Hair Loss

Room: 283 in Women
DIRECTOR Kristen P. Hook, M.D. Room: 235/236

LEARNING OBjECTIVES DIRECTOR Jeffrey Donovan, M.D.

Following this focus session, the attendee will be able to: LEARNING OBjECTIVES
1. Identify distinguishing characteristics of overgrowth syndromes Following this focus session, the attendee will be able to:
to aid in diagnosis. 1. Identify important features from a patient’s history and clinical
2. Determine appropriate workup and clinical monitoring. examination that help differentiate causes of non-scarring hair
3. Discuss appropriate treatment and referral options. loss in women.
2. Complete appropriate investigations to further assess the cause
DESCRIPTION of hair loss.
Overgrowth syndromes can be defined by the type of soft 3. Select appropriate treatments based on the type of hair loss.
tissue hypertrophy and the presence of vascular malformations.
Distinguishing characteristics of syndromes and diagnostic features DESCRIPTION
Concerns about hair loss are common among women. Although
will be identified. Appropriate workup and clinical monitoring
the diagnosis can sometimes be immediately evident, at other
recommendations will be discussed, as well as recent knowledge times making the correct diagnosis can be aided by a systematic
regarding potential complications. Referral and treatment options approach. This session is designed to assist participants to perform
will be mentioned in brief. a focused history and clinical examination. The participant will
1.50 Category 1 CME Credits know when and which blood tests to order as part of a workup
and when to consider a scalp biopsy. Appropriate treatments will
be reviewed along with discussion of their efficacy and potential
side effects.
U150 Skin Cancer Viruses: Bench to Bedside 1.50 Category 1 CME Credits
Room: 274
DIRECTOR Sarah T. Arron, M.D., Ph.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Define viruses associated with skin cancer.
2. Describe molecular mechanisms for viral carcinogenesis.
DESCRIPTION
Over 15% of human cancers are caused by viruses. When a new
virus is discovered in cancer, researchers must demonstrate an
epidemiologic association as well as a molecular mechanism for
carcinogenesis. We will review the evidence for three viruses
associated with skin cancer: HHV-8 and Kaposi’s sarcoma,
HPV and squamous cell carcinoma, and MCPyV and Merkel
TUESDAY, FEBRUARY 8

cell carcinoma. This session will introduce dermatologists to

techniques for viral discovery, viral mechanisms for carcinogenesis,
and potential antiviral therapies for cancer.
1.50 Category 1 CME Credits

240 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng


For description of session categories and fees see page 37
FOCUS SESSION
7:15 a.m. to 8:45 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U152 Cutaneous Mucinosis
Room: 242
DIRECTOR Raymond L. Cornelison Jr., M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Demonstrate how to defuse the potential frustration that both
the physician and the patient may bring to the office.
2. Utilize words, gestures and tonality to encourage memorable
and meaningful interactions.
DESCRIPTION
This session will bring together both physician practitioners and a
patient with a chronic skin disease to present both the physicians
and the patients perspective. Medical training has taught physicians
to fix the human body but not necessarily how to heal patients. The
objective of this session is to make physicians aware of their intense
impact on the life of the patient and to explore the many ways that
the physician can facilitate the moments of joy, inspiration, and
deep personal satisfaction that can take place during an office visit.
This session will be unforgettable, guaranteed!
1.50 Category 1 CME Credits
U153 Facing Facial Dermatoses
Room: 263
DIRECTOR Joseph B. Bikowski, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Perform a complete differential diagnosis of facial dermatoses.
2. Diagnose and treat the common and not so common facial
dermatoses.
DESCRIPTION
This session emphasizes evaluation of facial dermatoses including
differential diagnosis and medical management. This will include
presentation and discussion of: an innovative new acne grading
system, isotretinoin treatment pearls, unusual presentations of
rosacea, Demodex dermatitis, Pityrosporum folliculitis, and
unusual contact dermtitis.
1.50 Category 1 CME Credits
For the Latest Program Book InFormatIon PLease reFer to
SCIENTIFIC SESSIONS
FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
F079 Update on Alopecia Areata
Room: 238/239
DIRECTOR Elise Olsen, M.D.
SPEAkERS Jerry Shapiro, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Discuss the most recent information on the etiology of alopecia
areata.
2. Use microscopic evaluation of hair bulbs obtained by hair pull,
dermoscopic evaluation of the scalp and scalp biopsy to help
make the diagnosis.
3. Summarize the many effective treatments available for the
various subtypes of alopecia areata.
DESCRIPTION
This forum is one of an annual series covering an update on
various hair loss conditions. This year we will focus on alopecia
areata. We will cover new information on the etiology as well
as educate the attendee on how to use the microscopic hair
examination, dermoscopic examination of the scalp and scalp
biopsy to help make the diagnosis of alopecia areata. We will also
present a practical and thorough review of therapeutic options and
camouflage techniques for alopecia areata.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Diagnosis of Alopecia Areata / Dr. Olsen
9:20 a.m. Etiological Factors in Alopecia Areata / Dr. Shapiro
9:40 a.m. Skin Directed Therapy, Part I (Steroids, Minoxidil)
/ Dr. Dr. Olsen
10:00 a.m. Skin Directed Therapy, Part II (Anthralin, Sensitizers,
Newer Agents, Camouflage Methods) / Dr. Shapiro
10:20 a.m. Systemic Agents / Dr. Olsen
10:40 a.m. Case Presentations and Discussion / Faculty
TUESDAY, FEBRUARY 8
www.aad.org | 241
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F080 Fractional Laser and Light-Based F081 Geriatric Dermatology

Technologies Room: 388/389/390
Room: 252/253/254 DIRECTOR Wendy E. Roberts, M.D.
DIRECTOR Jill S. Waibel, M.D. SPEAkERS Robert A. Norman, D.O.
SPEAkERS LEARNING OBjECTIVES
R. Rox Anderson, M.D. Roy Geronemus, M.D. Following this forum, the attendee will be able to:
Henry H. L. Chan, M.D. E. Victor Ross Jr., M.D. 1. Recognize the need for an experience in geriatric dermatology.
LEARNING OBjECTIVES 2. Identify dermatologic issues in the geriatric patient.
Following this forum, the attendee will be able to: 3. Categorize and summarize new treatments in geriatric
1. Evaluate the current indications, limitations, and potential for dermatology.
fractional laser and light-based devices. DESCRIPTION
2. Gain insight into advanced techniques for optimal patient The total geriatric population stands at 12.4%. By the year 2050
results in both medical and aesthetic arenas. 1 in 5 people in the US will be age 65 and older. It becomes
3. Discuss new fractional technologies and update on the latest increasingly important for the dermatologist to have experience in
research in fractional lasers and light-based technology. managing dermatologic issues in this age group. We will discuss
DESCRIPTION emerging trends in geriatric dermatology as well as the recognition
This session is directed at both potential and experienced users and management of disorders of older patients.
of fractional laser and light technologies. Using evidence-based 2.00 Category 1 CME Credits
approaches our dynamic panel will examine current applications, SCHEDULE
and the strengths and weaknesses of fractional light. A review of 9:00 a.m. Geriatric Dermatology Update / Dr. Roberts
the practical aspects of fractional lasers will help clinicians in daily 10:00 a.m. Issues in Geriatric Dermatology / Dr. Norman
practice on aspects such as physics, parameters, complications and
patient selection. We will also explore the use fractional light
around the world in patients with skin of color. The session will
end with a global view of the future of fractional light.
2.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Highlights from Fractional Laser Literature
and Experience: Indications, Parameters and
Complications / Dr. Waibel
9:20 a.m. Physics, Strengths and Weakness of Fractional Lasers
and Light-Based Technology / Dr. Ross
9:40 a.m. Maximizing Aesthetic and Medical Results with
Fractional Lasers / Dr. Geronemus
10:00 a.m. Fractional Laser Light-Based Technologies in Skin of
Color: A View from Around the World / Dr. Chan
TUESDAY, FEBRUARY 8

10:20 a.m. Emerging Fractional Research and Technologies:

The Future of Light / Dr. Anderson
10:40 a.m. Questions and Panel Discussion / Faculty

242 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F082 Managing Office Politics: F084 Medical Applications of Topical

Private Practice, Academics, and Photodynamic Therapy
Everything in Between Room: 386/387
Room: 393/394 DIRECTOR Rolf-Markus Szeimies, M.D.
DIRECTOR Margaret E. Parsons, M.D. SPEAkERS
SPEAkERS Robert Bissonnette, M.D. Colin A. Morton, M.D.
Philip L. Bailin, M.D. Percy M. Lehmann, M.D. Luis A. Torezan, M.D.
Susan H. Weinkle, M.D. LEARNING OBjECTIVES
LEARNING OBjECTIVES Following this forum, the attendee will be able to:
Following this forum, the attendee will be able to: 1. Evaluate the use, limitations and potential of topical
1. Identify the skill sets for understanding and navigating small to photodynamic therapy for premalignant, malignant, and
large organizations. inflammatory skin conditions.
2. Summarize the political realities of medical practice. 2. Recognize practical aspects of the therapy and select
DESCRIPTION appropriate patients.
Success in any leadership role requires a skill set of understanding 3. Select treatment conditions for particular situations and handle
and navigating an organization. The skill set we all need will be specific therapy-related side effects and complications.
reviewed and reflected in different environments: office, clinic, DESCRIPTION
academic, and organized medicine. Our speakers bring experience This session is directed at both potential and experienced users of
that will demonstrate political skills and how the finesse of
photodynamic therapy (PDT). Using evidence-based approaches,
utilizing those skills has helped them succeed as leaders in their
practice settings. current applications of topical PDT for non-melanoma skin
2.00 Category 1 CME Credits cancer and inflammatory skin conditions will be examined. The
speakers will present treatment details and expected outcomes, and
discuss side effects and complications and how to cope with them.
F083 Psoriasis Therapy in the Age of Biologics 2.00 Category 1 CME Credits
Room: 281/282 SCHEDULE
DIRECTOR Robert E. Kalb, M.D. 9:00 a.m. Update on Photosensitizers and Light Sources
/ Dr. Szeimies
LEARNING OBjECTIVES 9:20 a.m. Topical PDT for Actinic Keratosis / Dr. Torezan
Following this forum, the attendee will be able to: 9:40 a.m. Topical PDT for Bowen’s Disease and Basal Cell
1. Differentiate among the available treatments for moderate to
Carcinoma / Dr. Morton
severe psoriasis.
10:00 a.m. Questions and Answers / Faculty
2. Illustrate optimal therapy with conventional systemic agents
and phototherapy. 10:10 a.m. Topical PDT for Inflammatory Skin Conditions
3. Recognize situations where individual biologic therapies may / Dr. Bissonnette
have advantages. 10:30 a.m. Side Effects of Topical PDT and How to Manage
Them / Dr. Lehmann
DESCRIPTION 10:50 a.m. Audience Questions for all Panelists / Faculty
TUESDAY, FEBRUARY 8

The goal of this session is to update and review the treatment

of moderate to severe psoriasis. Topics to be covered include
phototherapy, conventional systemic therapy, and biologic
therapy. Guidelines and practical tips for each treatment option
will be covered. There is special emphasis on literature published
in the past 12 months. Cost, insurance regulations, prior
authorization requirements, and physician administered therapy
will all be discussed. The session is designed to facilitate the
treatment of moderate to severe psoriasis in the typical private
practice dermatology office.
2.00 Category 1 CME Credits

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 243
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM WORkSHOP
9:00 a.m. to 11:00 a.m. 9:00 a.m. to 11:00 a.m.
Ticket required for admission, no tuition fee. Ticket holds seat Tuition fee and ticket required for admission.
for only 15 minutes after the official start time.

F085 Autoimmune Blistering Disorders W014 Dermoscopy Cases

Room: 391 Room: 343
DIRECTOR Neil J. Korman, M.D., Ph.D. DIRECTOR Giuseppe Argenziano, M.D.
LEARNING OBjECTIVES SPEAkERS Iris Zalaudek, M.D.
Following this forum, the attendee will be able to:
LEARNING OBjECTIVES
1. To describe the clinical features that aid in diagnosis of
Following this workshop, the attendee will be able to:
pemphigus, bullous and mucous membrane pemphigoid.
1. Utilize dermoscopy with confidence under routine conditions.
2. To learn about the limited evidence based medicine available
2. Identify and interpret the most important dermoscopy criteria.
to treat these conditions.
3. Develop a practical approach for the diagnosis of pigmented
3. To understand and appreciate the practical therapeutic
lesions and melanoma.
approaches that are utilized to treat the autoimmune blistering
diseases. DESCRIPTION
Dermoscopy is an in vivo method that has been reported to be
DESCRIPTION
useful for the early recognition of melanoma. It uses an immersion
This session will present the latest information on the diagnosis
technique and optical magnification. Taken together, these optical
and treatment of patients with pemphigus, bullous pemphigoid
means allow the visualization of structures up to the dermis. This
and mucous membrane pemphigoid. Attendees will learn about
session will provide a review of the most important dermoscopic
the relatively limited but latest evidence available supporting
criteria for diagnosing melanoma, as well as clinical scenarios
the use of different therapeutic approaches. After discussing
and case examples where the use of dermoscopy and specific
the evidence, we will then discuss a practical approach to the
management rules will help clinicians improving skin cancer
treatment of patients with autoimmune blistering diseases
screening in the routine patient.
including appropriate screening and follow up laboratory studies.
2.00 Category 1 CME Credits
2.00 Category 1 CME Credits
SCHEDULE
SCHEDULE
9:00 a.m. Dermoscopy to Examine Patients NOT Lesions!
9:00 a.m. Test / Dr. Korman
/ Dr. Argenziano
10:00 a.m. Relevant Clinical Scenarios Using Dermoscopy
/ Dr. Zalaudek
10:30 a.m. Dermoscopy Quiz for the Audience / Dr. Argenziano
TUESDAY, FEBRUARY 8

244 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
9:00 a.m. to 12:00 p.m.
Tuition fee and ticket required for admission.

C031 Advanced Cosmetic Surgery and REFERENCES

Aesthetics 1. Carruthers J, Carruthers A. Botulinum toxin A in the mid and
lower face and neck. Dermatol Clin. 2004;22:151-158.
Room: 255/256/257
2. Fincher EF, Moy RL. Cosmetic blepharoplasty. Dermatol Clin.
DIRECTOR Hayes B. Gladstone, M.D. 2005;23:431-442.
3. Klein AW. Techniques for soft tissue augmentation: an “A to
SPEAkERS
Z.” Am J Clin Dermatol. 2006;7:107-120.
Murad Alam, M.D. Basil Hantash, M.D., Ph.D.
Joel Lee Cohen, M.D. Ronald L. Moy, M.D. SCHEDULE
Edgar Fincher, M.D., Ph.D. Rebecca Clare Tung, M.D. 9:00 a.m. My Approach to the Cosmetic Patient / Dr. Fincher
Helen Horn Fincher, M.D. Robert A. Weiss, M.D. 9:15 a.m. The Latest Techniques for Cellulite Treatment
Mitchel Paul Goldman, M.D. Christopher B. Zachary, M.D. / Dr. Goldman
9:30 a.m. Advanced Botulinum Toxin Injection Techniques
LEARNING OBjECTIVES
/ Dr. Cohen
1. Define the specific technical aspects of these advanced cosmetic
9:45 a.m. Advanced Facial Augmentation Techniques
procedures.
/ Dr. Tung
2. Determine which advanced cosmetic procedures are
10:00 a.m. Panel Discussion / Faculty
appropriate for specific cosmetic conditions.
10:10 a.m. Advanced Ablative Fractional Resurfacing Techniques
3. Evaluate cosmetic conditions more effectively.
/ Dr. Zachary
DESCRIPTION 10:25 a.m. Advances in Radiofrequency Rejuvenation
As the population ages it has become more sophisticated about / Dr. Hantash
rejuvenation options. Dermatologists must be familiar with, and 10:40 a.m. Advances in Ultrasound Tightening and Less Invasive
be able to perform, more advanced cosmetic procedures to meet Contouring / Dr. Alam
the public’s expectations. Dermatologic surgeons have been leaders 10:55 a.m. Panel Discussion / Faculty
in minimally invasive aesthetic procedures. This session will focus 11:05 a.m. Advanced Techniques in Leg Vein Therapy
onkey points of advanced techniques of common rejuvenation / Dr. Weiss
procedures, such as botulinum toxin, fillers, and lasers, as well as 11:20 a.m. Advanced Techniques In Liposuction / Dr. Fincher
highlight advanced cosmetic procedures, including blepharoplasty, 11:35 a.m. Blepharoplasty Pearls / Dr. Moy
face-lifts, and liposuction. In addition to other learning objectives, 11:47 a.m. Face-lift Highlights / Dr. Gladstone
key steps of these procedures will be reviewed and practice pearls
from the individual speakers will be shared.
3.00 Category 1 CME Credits

TUESDAY, FEBRUARY 8

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 245
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
9:00 a.m. to 12:00 p.m.
Tuition fee and ticket required for admission.

C032 Lasers REFERENCES

Room: 275/276/277 1. Kauvar ANB, ed. Principles and Practices of Cutaneous Laser
Surgery. New York: Taylor and Francis; 2005.
DIRECTOR Arielle N. B. Kauvar, M.D.
SCHEDULE
SPEAkERS 9:00 a.m. Introduction / Dr. Kauvar
Tina S. Alster, M.D. E. Victor Ross Jr., M.D. 9:05 a.m. Laser Treatment of Pigmented Lesions and Tattoos
R. Rox Anderson, M.D. Elizabeth Tanzi, M.D. / Dr. Uebelhoer
Mathew M. Avram, M.D. Nathan S. Uebelhoer, D.O. 9:20 a.m. Laser Treatment of Vascular Lesions / Dr. Dierickx
Christine C. Dierickx, M.D. Christopher B. Zachary, M.D. 9:40 a.m. Laser and Light Treatment of Acne / Dr. Ross
Melanie C. Grossman, M.D. 9:55 a.m. Laser Hair Removal / Dr. Grossman
LEARNING OBjECTIVES 10:20 a.m. Non-ablative Fractional Resurfacing / Dr. Tanzi
Following this course, the attendee will be able to: 10:40 a.m. Ablative Fractional Resurfacing / Dr. Alster
1. Apply advanced laser techniques for the treatment of 11:00 a.m. Skin Tightening / Dr. Zachary
pigmented lesions, vascular lesions, unwanted hair, and acne. 11:15 a.m. Non-invasive Fat Reduction and Body Contouring
2. Recognize and differentiate the advantages and disadvantages / Dr. Avram
of skin resurfacing with non-ablative and ablative fractional 11:30 a.m. What’s on the Horizon in Deviced-based Treatments?
devices. / Dr. Anderson
3. Describe the current devices for body contouring and fat
reduction and recognize future directions in cutaneous laser
surgery.
DESCRIPTION
This intermediate-level course is designed for dermatologists with
a basic understanding of cutaneous laser surgery. Attendees will
learn the most advanced techniques for the treatment of facial
photodamage, scars, vascular and pigmented lesions, acne and
unwanted hair. An in-depth review of ablative and non-ablative
fractional skin resurfacing, skin tightening devices, and non-
invasive fat reduction and body contouring treatments will provide
the audience with the most recent information to enhance clinical
outcomes. A presentation on the future of cutaneous laser surgery
will provide a glimpse into the direction of evolving technology.
3.00 Category 1 CME Credits
TUESDAY, FEBRUARY 8

246 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.

S044 Therapeutic Hotline S045 Disorders of Mucous Membranes

Room: 271/272/273 Room: 291/292
DIRECTOR Theodore Rosen, M.D. DIRECTOR Rochelle R. Torgerson, M.D., Ph.D.
SPEAkERS SPEAkERS
Glynis R. Ablon, M.D. Darrell S. Rigel, M.D. Alison June Bruce, MBChB Lynette J. Margesson, M.D.
Erin E. Boh, M.D., Ph.D. Noah S. Scheinfeld, M.D., J.D. Libby Edwards, M.D. Ginat W. Mirowski, DMD, M.D.
Scott W. Fosko, M.D. Kenneth J. Tomecki, M.D. Nasim Fazel, M.D. Bethanee Jean Schlosser, M.D., Ph.D.
LEARNING OBjECTIVES LEARNING OBjECTIVES
Following this symposium, the attendee will be able to: Following this symposium, the attendee will be able to:
1. Utilize latest topical therapeutic agents. 1. Develop an approach to the evaluation of patients with oral
2. Apply new cosmetic innovations. and vulvovaginal complaints.
3. Identify therapeutics for skin cancer, infections, and psoriatic 2. Diagnose and manage some of the more common oral and
arthritis. vulvovaginal diseases.
3. Identify the diagnostic and treatment dilemmas encountered in
DESCRIPTION
challenging cases of oral and vulvovaginal diseases.
This session is designed to expand therapeutic horizons
by highlighting new, relevant information and innovative DESCRIPTION
interventions. Subject matter will be diverse, including: skin The diagnosis and management of mucous membrane diseases
cancer, cosmetic dermatology, cutaneous infections, psoriatic is the realm of the dermatologist. This session will simplify the
arthritis, cutaneous surgery, and topical therapeutics. This session evaluation of such patients by presenting a logical and thorough
will be clinically germane and almost immediately applicable to approach to the oral and vulvar examinations. A case-based
daily patient care. format will be used to explore the diagnosis and management
3.00 Category 1 CME Credits of frequently encountered mucous membrane diseases as well as
rarer, more challenging mucous membrane disorders. Ultimately
REFERENCES
a well-learned approach to patients with mucous membrane
1. Atanaskova A, Tomecki KJ. Innovative management of
complaints can make management of both common and rare
recurrent furunculosis. Dermatol Clin. 2010;28:479-487.
diseases rewarding.
2. Swanson N, et al. Imiquimod 2.5% and 3.75% for the
3.00 Category 1 CME Credits
treatment of actinic keratoses. J Am Acad Dermatol.
2010;62:582-590. REFERENCES
3. Rigel DS. Trends in dermatology: Melanoma incidence. Arch 1. Eisen D, Lynch DP, eds. The Mouth: Diagnosis and Treatment.
Dermatol. 2010;146:318. Philadelphia: Mosby.
2. Lynch PJ, Edwards L. Genital Dermatology. Churchill-
SCHEDULE
Livingstone.
9:00 a.m. What’s New in Melanoma Therapy? / Dr. Rigel
9:30 a.m. What’s New in Cosmetic Dermatology? / Dr. Ablon SCHEDULE
10:00 a.m. What’s New in Cutaneous Infection Therapeutics? 9:00 a.m. Oral Examination and Common Findings
/ Dr. Tomecki / Dr. Torgerson
TUESDAY, FEBRUARY 8

10:30 a.m. Modern Management of Psoriatic Arthritis / Dr. Boh 9:15 a.m. Gingival Lumps and Bumps / Dr. Mirowski
11:00 a.m. Antibiotics and Cutaneous Surgery: 2010 / Dr. Fosko 9:35 a.m. Ulcerative Oral Lesions / Dr. Fazel
11:30 a.m. What’s New in Topical Therapeutics? / Dr. Scheinfeld 9:55 a.m. Challenging Oral Cases / Dr. Bruce
10:20 a.m. Questions and Answers: Oral Cases / Faculty
10:30 a.m. Vulvar Examination and Common Findings
/ Dr. Torgerson
10:45 a.m. The “Lichens” / Dr. Margesson
11:05 a.m. Vulvar Manifestations of Systemic Disease
/ Dr. Schlosser
11:25 a.m. Challenging Vulvar Cases / Dr. Edwards
11:50 a.m. Questions and Answers: Vulvar Cases / Faculty

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 247
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.

S046 Pediatric Dermatology REFERENCES

Room: 260/261/262
DIRECTOR Anthony J. Mancini, M.D.
SPEAkERS
Joanna M. Burch, M.D. Pearl C. Kwong, M.D.
Elizabeth Alvarez Connelly, M.D. Moise L. Levy, M.D.
Jonathan A. Dyer, M.D. Elena Pope, M.D.
Anita N. Haggstrom, M.D. Robert Sidbury, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Recognize and treat common and atypical exanthems and
bacterial skin infections in the pediatric patient.
2. Determine when to evaluate the child with recalcitrant
dermatitis for other potential disorders.
3. Utilize a variety of clinical pearls to perform surgical procedures
and laser therapy in non-sedated children.
DESCRIPTION
We will review evolving observations about pathogenesis,
associations, and treatments for infantile hemangiomas, as well
as several common and atypical exanthems in children, focusing
on clinical presentation and diagnosis. We will be updated on
methicillin-resistant Staphylococcus aureus infections in children and
review the contemporary classification of epidermolysis bullosa.
Additionally, we will learn about features which should point to
possible underlying nutritional deficiency, immunodeficiency, or
syndrome in the child with recalcitrant dermatitis. Conditions
which may present with an eruption in the diaper area will be
reviewed, and we’ll learn some procedural pearls for performing
surgery and laser therapy in non-sedated children.
3.00 Category 1 CME Credits
TUESDAY, FEBRUARY 8
1. Haggstrom AN, Drolet BA, Baselga E, Chamlin SL,
Garzon MC, Horii KA, et al. Prospective study of infantile
hemangiomas: clinical characteristics predicting complications
and treatment. Pediatrics. 2006;118:882-887.
2. Fine JD, Eady RA, Bauer EA, Bauer JW, et al. The
classification of inherited epidermolysis bullosa (EB): Report
of the 3rd International Consensus Meeting on Diagnosis and
Classification of Epidermolysis Bullosa. J Am Acad Dermatol.
2008;58:931-950.
3. Paller AS, Mancini AJ. Hurwitz Clinical Pediatric Dermatology.
3rd ed. London: Elsevier; 2006.
SCHEDULE
9:00 a.m. Introduction / Dr. Mancini
9:05 a.m. Infantile Hemangiomas: Emerging Observations
/ Dr. Haggstrom
9:30 a.m. The Child with Recalcitrant Dermatitis: When to
Worry / Dr. Levy
9:50 a.m. Exanthems in Children: An Update / Dr. Dyer
10:15 a.m. Diaper Dermatitis: More than Meets the Eye?
/ Dr. Kwong
10:35 a.m. Questions and Answers / Faculty
10:45 a.m. Pediatric Bacterial Infections / Dr. Sidbury
11:10 a.m. Epidermolysis Bullosa: An Update for the
Dermatologist / Dr. Pope
11:35 a.m. Pediatric Procedural Pearls / Dr. Burch
11:55 a.m. Questions and Answers / Faculty

248 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM
9:00 a.m. to 12:00 p.m.
Open admission, no tuition or ticket.

S047 Managing Melanoma in the Modern S048 Cutaneous Lymphomas

Millennium Room: 295/296
Room: 293/294 DIRECTOR Madeleine Duvic, M.D.
DIRECTOR Hensin Tsao, M.D., Ph.D. SPEAkERS
SPEAkERS Joan Guitart, M.D. Alain H. Rook, M.D.
Keith Flaherty Kenneth Yee Tsai, M.D. Youn H. Kim, M.D. Gary S. Wood, M.D.
Allan C. Halpern, M.D. Jennifer Wargo, M.D. Ellen J. Kim, M.D.

LEARNING OBjECTIVES LEARNING OBjECTIVES

Following this symposium, the attendee will be able to:
1. Recognize high-risk individuals and high-risk lesions through
modern technologies.
2. Define the molecular targets that define subclasses of
melanoma and their treatments.
3. Describe current advances in melanoma immunotherapy.
DESCRIPTION
Current melanoma practice relies heavily on visual description:
skin type, lesion morphology, and histopathology. In this
symposium, we will explore recent advances in molecular genetics,
cancer genomics, imaging modalities, and immunobiology and
how these gains can be leveraged to identify (1) individuals most
susceptible to melanoma; (2) high-risk pigmented lesions; (3)
molecular subclasses within melanocytic tumors; (4) novel targeted
treatments; and (5) new immunoltherapeutic approaches. For
decades, melanoma has remained impenetrable on many fronts.
Now, with the current molecular revolution, this disease may
finally become comprehensible and conquerable.
3.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Personal Risk Profiling in Melanoma / Dr. Tsao
9:35 a.m. Update on Imaging Modalities for Pigmented Lesions
/ Dr. Halpern
10:10 a.m. Molecular Pathology for Melanoma Classification
/ Dr. Tsai
10:45 a.m. Update on Targeted Therapies for Melanoma
/ Mr. Flaherty
11:20 a.m. Modern Melanoma Immunotherapy / Dr. Wargo
Following this symposium, the attendee will be able to:
1. Describe and understand the pathogenesis and current
categorization of cutaneous lymphomas.
2. Order appropriate studies for staging cutaneous lymphomas.
3. Select appropriate stage-specific treatments for cutaneous
lymphomas.
DESCRIPTION
This is an overview of the most commonly encountered
cutaneouslymphomas. Speakers will review the current status of
cutaneous B-cell lymphoma (CBCLs), CD30+ lymphoproliferative
disorders, CD8+ and NK/NKT cell lymphomas, mycosis
fungoides, and Sézary syndrome. The speakers will review
diagnosis based on specific serologic and molecular markers,
current staging systems, and stage-specific treatments.
3.00 Category 1 CME Credits
REFERENCES
1. Kim EJ, et al. Immunopathogenesis and therapy of cutaneous
T cell lymphoma. J Clin Invest. , 2005;115(4): 7.
2. Senff NJ, Noordijk EM, Yim YH. et al. EORTC and ISCL
consensus recommendations for the management of cutaneous
B-cell lymphomas. Blood. Jun 20, 2008.
3. Horwitz SM, Olsen EA, Duvic M. et al. Review: treatment
of mycosis fungoides and Sézary syndrome: a stage-based
approach. J Natl Compr Canc Netw. 2008 Apr;6(4):436-442.
SCHEDULE
9:00 a.m. Introduction / Dr. Duvic
9:05 a.m. Everything You Need to Make the Diagnosis of
Cutaneous Lymphomas / Dr. Wood
9:30 a.m. Cutaneous B-Cell Lymphomas: Classifications,
Staging, and Treatment / Dr. Kim
TUESDAY, FEBRUARY 8

11:50 a.m. Questions and Answers / Faculty
10:00 a.m. Sorting Out CD30+ Lymphoproliferative Disorders
/ Dr. Duvic
10:30 a.m. Cytotoxic and Assorted Uncommon Peripheral T-Cell
Lymphomas / Dr. Guitart
11:00 a.m. Diagnosis, Staging, and Treatment of Mycosis
Fungoides / Dr. Kim
11:30 a.m. Combined Immunotherapy for Sézary Syndrome and
What to Do Next / Dr. Rook

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 249
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

RESTRICTED SYMPOSIUM SYMPOSIUM

9:00 a.m. to 12:00 p.m. 9:00 a.m. to 12:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat for Open admission, no tuition or ticket.
only 15 minutes after the official start time for eligible categories.

S049 Cosmetics S050 Organizational Approaches to AIDS/STDs

Room: Auditorium A From a Global Perspective
DIRECTOR Mary P. Lupo, M.D. Room: 278/279/280

SPEAkERS DIRECTOR Toby A. Maurer, M.D.

Diane S. Berson, M.D. Rashmi Sarkar, M.D.
Vic A. Narurkar, M.D. Susan H. Weinkle, M.D.
Wendy E. Roberts, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Apply cosmetic procedures into a medical dermatology
practice.
2. Demonstrate that dermatology is a broad and diverse
specialty that works best when both medical and cosmetic
and procedural treatments are used together.
3. Identify which procedures are best to treat common medical
problems such as acne, skin cancer, and melsma.
DESCRIPTION
Dermatology is one of the most diverse medical specialties.
Often, medical conditions and diseases are difficult to control
with pharmaceutical agents alone. Advances in cosmetic
procedures over the past years have improved their safety and
efficacy, and there may be a purpose and benefit to use some of
these procedures for medical conditions. This symposium will
review common medical dermatological conditions and advise
a strategy to incoporate cosmetic procedures to improve patient
outcomes.
3.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. Welcome: How Cosmetics Fit in a Medical
Dermatological Practice. / Dr. Lupo
9:05 a.m. The Complete Dermatologist / Dr. Lupo
9:25 a.m. Cosmetics and Cosmeceuticals for Acne and Roscea
Patients / Dr. Berson
10:00 a.m. Practical Applications of the Robert’s Skin Typing
System and Its Usefulness in Cosmetic Procedure
Choices / Dr. Roberts
TUESDAY, FEBRUARY 8
SPEAkERS
Erin H. Amerson, M.D. Scott A. Norton, M.D., M.P.H.
Jennifer Cafardi, M.D. Marcio Soares Serra, M.D.
Carrie L. Kovarik, M.D.
LEARNING OBjECTIVES
Following this symposium, the attendee will be able to:
1. Summarize the new guidelines to treatment of HIV and its
impact on dermatology.
2. Recognize the new dermatologic issues of HIV/AIDS.
3. Discuss the impact of dermatology in the global fight against
HIV/AIDS.
DESCRIPTION
HIV/AIDS continues to be an important and ever-expanding area
of dermatology with national and international implications.
The role of dermatologists in HIV/AIDS continues and evolves.
We will address how these roles are important and changing.
We will also be hearing about the new treatment guidelines in
HIV/AIDS and examine how this may change dermatologic
practice and manifestations. Early detection in Kaposi’s sarcoma
remains an issue globally. New thoughts on Kaposi’s sarcoma as
they emerge in the US and globally will also be addressed.
3.00 Category 1 CME Credits
SCHEDULE
9:00 a.m. AIDS/STDs- Hot Topics, New Issues / Dr. Maurer

10:30 a.m. Cosmetics to Enhance Laser Results / Dr. Narurkar

10:55 a.m. Advances in Cosmeceuticals for Aging and Skin
Cancer Prevention / Dr. Weinkle
11:20 a.m. Cosmetic Treatment of Pigment Disorders / Dr. Sarkar

250 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
12:00 p.m. to 2:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F086 BCC Update and Options of Treatment F087 Nail Disorders in Children
Room: 391 Room: 392
DIRECTOR Alvaro Enrique Acosta, M.D. DIRECTOR Antonella Tosti, M.D.
SPEAkERS SPEAkERS
Alina G. Bridges, D.O. Bianca Maria Piraccini, M.D.
Jorge Alberto Garcia-Zuazaga, M.D. Bertrand Richert, M.D., Ph.D.
Priya S. Zeikus, M.D. Martin N. Zaiac, M.D.
LEARNING OBjECTIVES LEARNING OBjECTIVES
Following this forum, the attendee will be able to: Following this forum, the attendee will be able to:
1. Identify the basal cell carcinoma risk factors for recurrence. 1. Diagnose onychomycosis and inflammatory nail disorders and
2. Examine what evidence is available regarding risks and benefits select appropriate medical treatment.
of specific therapies. 2. Select correct approach to nail pigmentation (melanonychia)
3. Utilize specific cases to categorize each case according to its risk in children.
factors and choose the appropriate therapy. 3. Manage nail surgical procedures in childhood.
DESCRIPTION DESCRIPTION
New insights into the pathology of basal cell carcinoma (BCC), This session is designed for general dermatologists who want to
clinical recurrence BCC risk factors, and an evidence-based improve their skill in the diagnosis and treatment of nail disorders
approach to therapy will be reviewed. The case discussion will be in children. The faculty will discuss common and uncommon nail
interactive and the attendees will have the opportunity to choose disorders including nail psoriasis, melanonychia, onychomycosis,
the best BCC treatment, according to an evidence-based approach. in-growing toenails, lichen planus, and genetic diseases.
This forum is directed toward residents, fellows, dermatologists, and 2.00 Category 1 CME Credits
dermatologic surgeons.
SCHEDULE
2.00 Category 1 CME Credits
12:00 p.m. In-growing Toenails / Dr. Richert
12:30 p.m. Clinical Cases / Dr. Zaiac
1:00 p.m. Infective Disorders / Dr. Piraccini
1:30 p.m. Nail Pigmentation / Dr. Tosti

TUESDAY, FEBRUARY 8

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 251
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
12:00 p.m. to 2:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F088 Clinical Trials F089 Advances in Photomedicine

Room: 252/253/254
DIRECTOR Alexandra Boer Kimball, M.D., M.P.H.
SPEAkERS
Maria B. Alora-Palli, M.D. Jeffrey J. Crowley, M.D.
Annie Chiu, M.D. Wingfield Ellis Rehmus, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Design clinical trials and surveys.
2. Interact effectively with the institutional review board and
understand basic regulatory responsiblities.
3. Demonstrate how to develop clinical trials with an appreciation
of logistics, training staff, budgeting and contracting issues.
DESCRIPTION
In the first half of this session, experienced clinical trialists in
dermatology will introduce participants to the basics of designing
clinical trials including how to think about sample size, trial
design, eligiblility criteria, endpoints, good clinical practice and
institutional review board (IRB) submissions. The second hour
will cover practical aspects of managing trials including staffing,
recruitment and budgeting, and how to design surveys effectively.
2.00 Category 1 CME Credits
SCHEDULE
12:00 p.m. Designing Clinical Trials: Considerations and
Practical Tips / Dr. Kimball
12:24 p.m. Good Clinical Practice: An Introduction to What You
Need to Know / Dr. Rehmus
12:48 p.m. What the IRB Is Looking for: How to Make
Submissions Easier / Dr. Alora-Palli
1:12 p.m. Practical Office Considerations: Staffing, Logistics and
Budgeting / Dr. Crowley
1:36 p.m. Survey Design: Basic Principles / Dr. Chiu
TUESDAY, FEBRUARY 8
Room: 386/387
DIRECTOR Henry W. Lim, M.D.
SPEAkERS
Alexander V. Anstey, M.D. Mina Yaar, M.D.
Harvey Lui, M.D. Michael D. Zanolli, M.D.
Gillian M. Murphy, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Summarize recent advances in photodermatoses, photoaging,
and photoprotection.
2. Describe the use of phototherapy and biologics in psoriasis.
3. Outline emerging new developments in photomedicine.
DESCRIPTION
New developments in photomedicine will be discussed by leading
experts in the field. New developments in photodermatoses will
be presented, followed by presentation of advances in photoaging
and photoprotection. The role of phototherapy and biologics in
the management of psoriasis will be discussed. The session will
conclude with a presentation on what is new on the horizon in
photomedicine.
2.00 Category 1 CME Credits
SCHEDULE
12:00 p.m. Introduction / Dr. Lim
12:05 p.m. What’s New in Photodermatoses? / Dr. Anstey
12:25 p.m. What’s New in Photoaging? / Dr. Yaar
12:45 p.m. What’s New in Photoprotection? / Dr. Murphy
1:05 p.m. Phototherapy and Biologics in Psoriasis / Dr. Zanolli
1:25 p.m. What’s New on the Horizon in Photomedicine?
/ Dr. Lui
1:45 p.m. Questions and Answers / Faculty

252 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng


For description of session categories and fees see page 37
FORUM
12:00 p.m. to 2:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
F090 Autoimmune Mucocutaneous Blistering
Disorders
Room: 238/239
DIRECTOR Michael J. Camilleri, M.D.
SPEAkERS
Alina G. Bridges, D.O. Julia S. Lehman, M.D.
Lawrence E. Gibson, M.D. John Joseph Zone, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Diagnose and treat autoimmune mucocutaneous blistering
disorders.
2. Recognize atypical presentations of autoimmune
mucocutaneous blistering disorders.
3. Manage autoimmune mucocutaneous blistering disorders in
special situations.
DESCRIPTION
Autoimmune mucocutaneous blistering disorders (AMBD)
are a group of inflammatory dermatoses characterized by an
autoimmune reaction to epithelial adhesive proteins, resulting in
widespread mucocutaneous blistering. The session will start off
with a detailed overview of the diagnosis and treatment of these
disorders. Other subjects discussed include AMBD in pregnancy
and children, systemic disorders associated with AMBD,
IgA-mediated AMBD, and Pneumocystis carinii pneumonia
(PCP) prophylaxis in dermatology patients on systemic
immunosuppressive agents. This session is particularly directed
towards general and pediatric dermatologists involved in the care
of AMBD patients.
2.00 Category 1 CME Credits
SCHEDULE
12:00 p.m. The Diagnosis and Treatment of Autoimmune
Mucocutaneous Blistering Disorders / Dr. Camilleri
12:30 p.m. Autoimmune Mucocutaneous Blistering Disorders in
Pregnancy and Children / Dr. Bridges
12:50 p.m. Systemic Disorders Associated with Autoimmune
Mucocutaneous Blistering Disorders / Dr. Gibson
1:10 p.m. IgA-mediated Autoimmune Mucocutaneous Blistering
Disorders / Dr. Zone
1:30 p.m. PCP Prophylaxis in Dermatology Patients on
Systemic Corticosteroids and Other Systemic
Immunosuppressive Agents / Dr. Lehman
1:45 p.m. Questions and Answers / Faculty
For the Latest Program Book InFormatIon PLease reFer to
SCIENTIFIC SESSIONS
F091 Supportive Onco-Dermatology:
Dermatologic Reactions in Oncology
Room: 388/389/390
DIRECTOR Mario E. Lacouture, M.D.
SPEAkERS
Milan J. Anadkat, M.D. Heidi H. Kong, M.D.
Jeffrey Phillip Callen, M.D. Patricia L. Myskowski, M.D.
Jennifer N. Choi, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to:
1. Recognize the importance of supportive onco-dermatology
through an understanding of the incidence, impact on quality
of life-and clinical presentation of dermatologic toxicities to
cancer therapies.
2. Examine mechanisms involved in dermatologic conditions in
oncology and therapies, including targeted agents, cytotoxic
chemotherapy, radiotherapy, and therapeutic transplants.
3. Apply mechanistically-based interventions in supportive onco-
dermatology in order to minimize the impact on quality of life
and maximize clinical outcome.
DESCRIPTION
Novel medical, surgical, and radiation regimens have led to
improved quality of life and longer survival times, resulting in
millions of individuals living with a diagnosis of cancer. Despite
these achievements, dermatologic conditions in oncology are
noteworthy for their high frequency, impact on quality of life,
and negative effect on anticancer therapy administration. Optimal
care dictates that dermatologic events must be addressed early
and effectively, in order to minimize physical and psychosocial
discomfort, and to ensure consistent cancer regimens. This
introduction to supportive onco-dermatology provides the basis
for the understanding and management of dermatologic events in
the oncology setting.
2.00 Category 1 CME Credits
SCHEDULE
12:00 p.m. Dermatology in the Cancer Patient/Survivor
TUESDAY, FEBRUARY 8
/ Dr. Lacouture
12:10 p.m. Cytotoxic Chemotherapy-Induced Dermatologic
Toxicities / Dr. Anadkat
12:40 p.m. Topical Therapy-Induced Dermatologic Toxicities
/ Dr. Myskowski
1:00 p.m. Targeted Therapy-Induced Dermatologic Toxicities
/ Dr. Lacouture
1:20 p.m. Radiation Therapy-Induced Dermatologic Toxicities
/ Dr. Choi
1:40 p.m. Paraneoplastic Dermatoses / Dr. Callen
www.aad.org | 253
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM DISCUSSION GROUP

12:00 p.m. to 2:00 p.m. 12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat Tuition fee and ticket required for admission.
for only 15 minutes after the official start time.

F092 Diagnosing and Monitoring Hair and D027 Differential Diagnosis of Leprosy in a
Scalp Disease Non-Endemic Country
Room: 281/282 Room: 240
DIRECTOR Lidia Rudnicka, M.D., Ph.D. DIRECTOR Samuel Leonard Moschella, M.D.
SPEAkERS LEARNING OBjECTIVES
Elise Olsen, M.D. Catherine Margaret Stefanato, M.D. Following this discussion group, the attendee will be able to:
Jerry Shapiro, M.D. Iris Zalaudek, M.D. 1. Discuss and teach leprosy.
2. Review how to differentiate leprosy from the endemic
LEARNING OBjECTIVES
dermatologic entities in practice.
Following this forum, the attendee will be able to:
3. Evaluate and appreciate leprosy as a model for other
1. Diagnose hair and scalp diseases more efficiently.
dermatologic diseases which have systemic overtones.
2. Choose adequate techniques for differential diagnosis
of hair loss. DESCRIPTION
3. Monitor treatment efficacy in hair loss. Since leprosy is not endemic in the U.S., one might feel
comfortable not including it in differential diagnoses. The
DESCRIPTION
potential source of disease in practice is immigrants from highly
The session will focus on new methods and techniques, which
endemic areas such as Brazil and India.How can one best be
aid differential diagnosis, assessment of disease activity and
sensitized to this disease and diagnosis? Why not describe what
monitoring treatment efficacy in common hair and scalp disorders.
diseases it can look like in your practice and then tell you why it
New imaging techniques (i.e. trichoscopy, reflectance confocal
is not leprosy? This approach will not only tell you how to make
microscopy, digital photographing) and recently developed
a diagnosis of leprosy, but will make you realize that leprosy in
evaluation scales are gaining popularity in dermatological practice.
many ways can be a model for other dermatologic entities.
In many diseases, however, histopathology remains the gold
1.50 Category 1 CME Credits
standard diagnostic procedure. This session will concentrate on
selecting adequate diagnostic techniques for different clinical
situations related to hair loss and scalp diseases. The session is
designed for dermatology residents and dermatologists who treat
patients with hair loss.
2.00 Category 1 CME Credits
SCHEDULE
12:00 p.m. The Value Of Histopathology in Diagnosing and
Monitoring Hair Loss / Dr. Stefanato
12:24 p.m. Global Assessment Of Hair Loss Patterns and Density
in the Central Scalp / Dr. Olsen
12:48 p.m. Diagnosing And Monitoring Alopecia Areata
/ Dr. Shapiro
1:12 p.m. The Value Of Dermoscopy in Diagnosing Scalp
Tumors / Dr. Zalaudek
TUESDAY, FEBRUARY 8

1:36 p.m. The Value of Trichoscopy in Diagnosing and

Monitoring Hair and Scalp Diseases / Dr. Rudnicka

254 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng


For description of session categories and fees see page 37
FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U154 Caring for the Hospitalized Patient:
Interesting Cases from the Inpatient
Consultative Service
Room: 270
DIRECTOR Lauren C. Hughey, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Formulate a comprehensive differential diagnosis for the
hospitalized patient with skin disease.
2. Analyze consult cases to arrive at proper diagnosis by choosing
appropriate work-up.
3. Select treatment options for the hospitalized patient.
DESCRIPTION
This interactive session will concentrate on both common
and unusual cases one may encounter in the hospital on the
dermatology consultation service. Several cases will be presented
as unknowns and discussed in a comprehensive manner with
audience participation while working through the differential
diagnosis, workup, and treatment plan for each case.
1.50 Category 1 CME Credits
U155 What’s New in Skin Cancer Prevention?
Room: 235/236
DIRECTOR Maryam Mandana Asgari, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Examine the most promising supplements and drugs for skin
cancer prevention.
2. Summarize current understanding of skin cancer
chemoprevention.
3. Identify putative novel skin cancer risk factors.
DESCRIPTION
When your skin cancer patients ask you what else they can do
(other than sun protection) to prevent future skin cancers, what
do you tell them? This session aims to increase your knowledge
of current chemopreventative agents, and highlight the most
promising supplements and drugs — all using evidence-based
literature.
1.50 Category 1 CME Credits
For the Latest Program Book InFormatIon PLease reFer to
SCIENTIFIC SESSIONS
U156 Finding the Needle in the Haystack:
A Guide to More Effective Patch Testing
Room: 263
DIRECTOR Kalman L. Watsky, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Diagnose patients with dermatitis more effectively.
2. Demonstrate improvements in patch-testing technique for
patients with suspected allergic contact dermatitis.
3. Select optimum treatments and/or avoidance strategies for
patients with allergic contact dermatitis.
DESCRIPTION
This focus session for practicing clinicians will address the
diagnostic and therapeutic problems posed by patients with
suspected allergic contact dermatitis. Using clinical case
examples from a referral private practice, participants will review
the differential diagnosis and therapeutic alternatives for these
patients. Special attention will be paid to patch testing with
an extended series of allergens to aid in the evaluation of this
challenging group of disorders.
1.50 Category 1 CME Credits
U157 Rosacea Update
Room: 265/266
DIRECTOR Lisa E. Maier, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Identify the various subtypes of rosacea.
2. Examine current theories regarding rosacea etiology.
3. Develop a therapeutic plan for patients with rosacea.
DESCRIPTION
Rosacea is a common and chronic inflammatory skin disease that
results in significant clinical and emotional morbidity. Rosacea
phenotypes are clinically heterogeneous. These various subtypes
TUESDAY, FEBRUARY 8
will be discussed in detail. The session will address the many
theories regarding the pathophysiology of this disease. In this
session, we will focus on medical treatment and will discuss how
to choose appropriate therapy for each subtype of rosacea. We will
not address lasers and surgical techniques in detail.
1.50 Category 1 CME Credits
www.aad.org | 255
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U158 Acne: Etiopathogenesis and Treatment
2011
Room: 269
DIRECTOR F. William Danby, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize the endocrinological and physiological events that
lead to the physical initiation of the comedo.
2. Discuss the contribution to acnegenesis of classic endogenous
hormone sources, exogenous dietary hormones, and other
hormonally active molecules in the environment.
3. Manage acne with a view towards active reduction of long-term
hormonal stimulation.
DESCRIPTION
The session starts with a brief review of traditional endocrinological
biochemistry; a classic review of the anatomy of the pilosebaceous
unit; and a fresh look at the molecular pathophysiology and cellular
dynamics of acne. The several sources of endogenous sex and growth
hormones, the dietary and other sources of the same hormones,
and the possible impact of environmental hormones are considered.
Therapeutic approaches to minimize the hormonal drive of
acnegenicity will be detailed. The rationale for appropriately targeted
therapy, as driven by pathogenetic / acnegenic considerations, will
be highlighted. The session is directed at residents, acne therapists,
and acne researchers.
1.50 Category 1 CME Credits
TUESDAY, FEBRUARY 8
256 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
U159 An Approach to Cultural Diversity in
Dermatology
Room: 285
DIRECTOR Christina L. Chung, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Diagnose cutaneous disease more effectively in patients with
skin of color.
2. Identify cultural differences in skin care practices.
3. Develop a more culturally sensitive approach to the
management of ethnic skin.
DESCRIPTION
From the inner cities to rural areas, dermatologists are
increasingly treating cutaneous disease in skin of color. The
clinical presentation of skin disorders in these patients can vary
significantly from that seen in skin types I-III. Additionally,
patients with skin of color often hail from cultures whose skin
and hair care practices and perceptions of beauty are different
from what is perceived as the “American standard.” This session
provides insight into some of these issues and promotes an
awareness among practitioners with the goal of providing practical
and superior care to a culturally diverse group of patients.
1.50 Category 1 CME Credits
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U160 Pigmented Lesions in Pediatric U162 Full Facial Approach with Botulinum
Dermatology Toxin and Hyaluronic Acid:
Room: 274 Cases From a European Practice
DIRECTOR Kara N. Shah, M.D., Ph.D. Room: 267/268

LEARNING OBjECTIVES DIRECTOR Ricardo R. Ruiz-Rodriguez, M.D.

Following this focus session, the attendee will be able to:
1. Appropriately manage Spitz nevi and atypical Spitz tumors in
children.
2. Evaluate and manage children with large congenital
melanocytic nevi with respect to concerns regarding melanoma
and neurocutaneous melanosis.
3. Discuss the epidemiology of melanoma in children.
DESCRIPTION
This session will review current recommendations for the
evaluation and management of several controversial pigmented
lesions in children, including Spitz nevi, atypical Spitz tumors,
and large congenital melanocytic nevi. In addition, recent data
on the epidemiology of melanoma in children will be reviewed.
This session is geared towards pediatric dermatologists and general
dermatologists with an interest in pigmented lesions in children.
1.50 Category 1 CME Credits
U161 Actinic keratoses Update
Room: 283
DIRECTOR Linda Susan Marcus, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Define actinic keratoses.
2. Discuss various modalities and their appropriate place in the
treatment of actinic keratosis.
3. Discuss the prevention of actinic keratosis and new horizons in
treatment and prevention.
DESCRIPTION
The importance of the updated definition of actinic keratosis
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Define the techniques to achieve natural results by using
botulinum toxin and hyaluronic acid.
2. Recognize the cosmetic needs of each patient.
DESCRIPTION
Results using botulinum toxin (BT) can significantly be
improved by:
1. The use of lower doses in mid-lower face and also in the
frontal region.
2. The combination of superficial and deep injections.
3. The tendency for full-face treatments with BT.
4. The microlift procedure.
5. The use of advanced indications.
6. The adjunctive usage with other rejuvenating techniques.
Filling of lines, folds and furrows, and re-establishing volume
and contours with hyaluronic acid preparations may follow in a
second step producing natural and long-lasting results. Multiple
before and after photos and videos will be shown to describe the
techniques to achieve natural looking results.
1.50 Category 1 CME Credits
TUESDAY, FEBRUARY 8

as the earliest stage in the development of skin cancer will be

discussed. Pathogenesis and etiology will be reviewed. There will
be an overview of the current treatment modalities including
topical therapies, photodynamic therapy, curettage, shave,
excision, and cryosurgery. Newer experiemental regimens and
combination therapy, as well as preventive measures, will be
included. This topic will continue to evolve since the number
of actinic keratoses has multiplied due to the aging population
and continued social trends which have increased sun exposure.
Audience participation is encouraged.
1.50 Category 1 CME Credits

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 257
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37
FOCUS SESSION
12:15 p.m. to 1:45 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U163 Garden Variety Derm: Identifying and
Managing Exposures to Hazardous Plants
and Arthropods in the Garden
Room: 284
DIRECTOR Julian J. Trevino, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Identify the plants and arthropods discussed.
2. Recognize the cutaneous manifestations associated with
exposures to various plants and arthropods.
3. Select the most appropriate therapy and/or preventative
measures for the various plant/arthropod exposures.
DESCRIPTION
Cutaneous manifestations resulting from exposures to plants
and arthropods in the outdoor environment are commonly
encountered in medical dermatology practice. These range from
minor annoyances to severe, life-threatening situations. The most
recent entomologic and botanical classification for the arthropods
and plants discussed will be reviewed. The epidemiology and
pathogenesis of the adverse cutaneous reactions to various
plants and arthropods will be presented. The range of clinical
manifestations seen in plant and arthropod exposures will be
emphasized. Strategies for prevention and management of the
adverse cutaneous reactions will be discussed.
1.50 Category 1 CME Credits
TUESDAY, FEBRUARY 8
258 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
U164 Hypercoagulability, Purpura, and the Skin
Room: 264
DIRECTOR Kathryn Schwarzenberger, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Recognize and diagnose purpuric disorders in skin.
2. Recognize newer diagnoses associated with purpura.
3. Evaluate patients with purpura and hypercoagulable disorders.
DESCRIPTION
This focus session is intended to help dermatologists at all levels
become better able to recognize and evaluate purpuric disorders.
Clinical clues to the diagnosis of purpura will be discussed, as will
newer diseases characterized by purpura. Diseases associated with
hypercoagulability, diagnostic tools, and new diagnostic tests will
all be discussed.
1.50 Category 1 CME Credits
U165 The Management of TEN/SjS:
The US Army Burn Unit Experience
Room: 242
DIRECTOR Jeffrey Scott Henning, D.O.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Explain the current thinking in the pathophysiology of SJS and
TEN.
2. Using evidence-based medicine, discuss the different
interventional medication approaches, fluid managment. and
supportive care with respect to SJS and TEN.
3. Describe the US Army Burn Unit’s approach to wound care of
SJS and TEN.
DESCRIPTION
The session will cover the Brooke Army Medical Center Burn
Unit’s extensive experience with SJS/TEN and advances in
medical treatment. It will include new treatment strategies in
wound care and therapeutics. The discussion will focus on the
experience with >75 patients in the past 4 years with SJS/TEN.
Wound care management with standard non-interventional versus
interventional wound care, fluid management and interventions
such as steroids, IVIG and cyclosporine. The session will discuss
new advances in the pathogenesis and basic science mechanisms of
TEN and SJS. Our vast experience with wound care management
will be highlighted.
1.50 Category 1 CME Credits
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

COURSE
2:00 p.m. to 5:00 p.m.
Tuition fee and ticket required for admission.

C033 Advanced Surgery C034 Skin Resurfacing and Rejuvenation

Room: 255/256/257
DIRECTOR TBD
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Determine how to select appropriate repair options for surgical
defects on the face and ears.
2. Identify techniques to improve the design and execution of
intermediate, complex, adjacent tissue transfer and skin graft
closures.
3. Examine the challenges associated with the use of advanced
surgical techniques when repairing surgical defects on the face.
DESCRIPTION
This course will focus on the repair of surgical defects on the face,
eyelids, ears, and lips. Speakers will focus on how to plan and
execute anatomic site-specific repair options. Attendees should
have experience with reconstructive procedures.
3.00 Category 1 CME Credits
Room: 260/261/262
DIRECTOR Ashish Bhatia, M.D.
SPEAkERS
Jeffrey T. S. Hsu, M.D.
LEARNING OBjECTIVES
Following this course, the attendee will be able to:
1. Assess aging skin and potential improvement with resurfacing
and rejuvenation modalities.
2. Compare various resurfacing and rejuvenation modalities,
including those for skin of color.
3. Select appropriate candidates for skin resurfacing and
rejuvenation.
DESCRIPTION
This is a comprehensive course on skin resurfacing and
rejuvenation. Traditional therapies including chemical peels and
resurfacing will be discussed. In addition, the latest technology
including non-ablative lasers, as well as erbium, CO2, and
fractional lasers will be covered in detail. The course will also focus
on the adjunctive use of topicals, botulinum toxin, and fillers for
skin rejuvenation along with resurfacing. Finally, the course will
cover how to select patients and treatments for optimal results,
including appropriate therapy for skin of color and how to prevent
and treat complications.
3.00 Category 1 CME Credits

TUESDAY, FEBRUARY 8

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 259
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

SYMPOSIUM RESTRICTED SYMPOSIUM

2:00 p.m. to 5:00 p.m. 2:00 p.m. to 5:00 p.m.
Open admission, no tuition or ticket... Ticket required for admission, no tuition fee. Ticket holds seat for
only 15 minutes after the official start time for eligible categories.

S051 Evidence-Based Medicine S052 Surgical Complications

Room: 278/279/280 Room: 271/272/273
DIRECTOR Michael E. Bigby, M.D. DIRECTOR Hugh M. Gloster Jr., M.D.
SPEAkERS SPEAkERS
Brett M. Coldiron, M.D. Christine Elizabeth Cabell, M.D. Ann G. Neff, M.D.
Robert Paul Dellavalle, M.D., Ph.D. Christopher B. Harmon, M.D. Bertrand Richert, M.D., Ph.D.
Dirk Michael Elston, M.D. Girish S. Munavalli, M.D., M.H.S. Elizabeth Tanzi, M.D.
LEARNING OBjECTIVES LEARNING OBjECTIVES
Following this symposium, the attendee will be able to: Following this symposium, the attendee will be able to:
1. Explain what evidence-based medicine (EBM) is and is not, its 1. Demonstrate the necessary steps to prevent complications.
strengths and its limitations.
2. Promptly diagnose complications.
2. Identify opportunities and approaches to facilitate the teaching
of EBM as the foundation for lifelong learning and knowledge 3. Select the best management strategies for complications.
sharing. DESCRIPTION
3. Describe how the use of EBM can positively impact clinical Any physician who performs cutaneous surgery should be
outcomes using real-world clinical scenarios. prepared to treat surgical complications, which are unavoidable
DESCRIPTION even in the best hands. Therefore, dermatologic surgeons should
The session will be helpful in expanding physician knowledge be familiar with potential complications in order to provide better
of evidence-based medicine EBM, how it can be effectively and service to patients and to minimize the risk of suboptimal results.
confidently incorporated into daily practice, and will promote Experienced cutaneous surgeons will discuss the prevention,
the utility and benefit of EBM as the foundation for learning diagnosis, and management of complications that may occur
and scientific inquiry at any career stage. This session will also following popular cosmetic procedures, nail procedures, and the
foster the Academy’s initiative and key priority of quality patient reconstruction of surgical defects.
care by highlighting the importance of EBM for dermatology 3.00 Category 1 CME Credits
by demonstrating how clinical findings work collectively to
enhance the body of evidence and medical knowledge, and can REFERENCES
be harnessed to achieve superior patient outcomes and ongoing 1. Gloster H, ed. Complications in Cutaneous Sugery. 1st ed.
medical education. New York: Springer Verlag, 2008.
3.00 Category 1 CME Credits
SCHEDULE
REFERENCES 2:00 p.m. Introduction / Dr. Gloster
1. Bigby M, Williams H. Evidence-based dermatology. In: Rook’s
2:05 p.m. Complications of Nail Procedures / Dr. Richert
Textbook of Dermatology. 8th ed. Edited by: Tony Burns,
2:20 p.m. Infection and Dehiscence / Dr. Cabell
Stephen Breathnach, Neil Cox and Christopher Griffiths,
Blackwell Publishing; 2009. 2:35 p.m. Botulinum Toxin and Fillers / Dr. Harmon
2. Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman 2:50 p.m. Lasers / Dr. Tanzi
B, Bowman M. Strength of recommendation taxonomy 3:05 p.m. Periorbital Complications / Dr. Neff
(SORT): a patient-centered approach to grading evidence in the 3:20 p.m. Sclerotherapy / Dr. Munavalli
medical literature. Am Fam Physician. 2004;69:548-56. http:// 3:35 p.m. Bleeding and Necrosis / Dr. Gloster
TUESDAY, FEBRUARY 8

www.aafp.org/afp/200 3:50 p.m. Questions and Answers / Dr. Gloster

SCHEDULE
2:00 p.m. EBM: What It Is and Isn’t, Its Strengths and
Weaknesses / Dr. Bigby
2:30 p.m. Teaching EBM As The Foundation For Lifelong
Learning / Dr. Dellavalle
3:00 p.m. Using EBM in Dealing with Insurance Companies
And Payors / Dr. Moody
3:30 p.m. Using EBM in Guidelines Development / Dr. Elston
4:00 p.m. Using EBM in Health Care Policy Decisions
/ Dr. Coldiron
4:30 p.m. Questions and Answers / Faculty

260 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng


For description of session categories and fees see page 37
FOCUS SESSION
2:30 p.m. to 4:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.
U166 Great Cases in Teledermatology
Room: 265/266
DIRECTOR Hon S. Pak, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Outline how teledermatology can be leveraged to augment
traditional dermatologic care in a large healthcare setting.
2. Analyze interesting dermatologic cases from all over the world.
3. Assess some of the unique challenges in managing cases using
teledermatology.
DESCRIPTION
This session will briefly discuss how teledermatology is being
used in a large region of the United States. The session will also
discuss how teledermatology is now incorporated in one of the
largest dermatology residency programs. Most of the session will
be presenting interesting dermatology cases to include common
and rare skin diseases including but not limited to pediatric and
infectious diseases. We will also discuss some unique aspects of
managing skin disease with teledermatology.
1.50 Category 1 CME Credits
U167 Establishing a Mohs Practice: Pearls for
New Surgeons
Room: 242
DIRECTOR Monika Srivastava, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Develop a dermatologic surgery practice, including Mohs
surgery.
2. Prepare appropriate documentation for surgical procedures and
teaching tools for assistants.
3. Apply proper surgical codes, including the use of modifiers.
DESCRIPTION
The purpose of this session is to help new dermatologists and
dermatologic surgeons develop an efficent surgical practice.
The overview will include setup of examination rooms, surgical
instruments, procedure documentation, and teaching guidelines
for assistants. This session will also review the setup of a Mohs
laboratory, including proper CLIA certification. Lastly, proper
coding for surgical procedures, including the use of modifiers, will
be explored.
1.50 Category 1 CME Credits
For the Latest Program Book InFormatIon PLease reFer to
SCIENTIFIC SESSIONS
U168 Psoriasis
Room: 267/268
DIRECTOR Stephanie L. Mehlis, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Evaluate topical, phototherapy, and systemic therapy and their
relative efficacies in the treatment of psoriasis.
2. Identify the relevant risks of treatment options and their
clinical importance.
3. Discuss the relationship of comorbidities and psoriasis and
examine how these impact treatment decisions.
DESCRIPTION
Understanding the nature of psoriasis as a systemic disease
and the magnitude of therapeutic options can be challenging
to the practicing dermatologist. This session will be a case-
based, interactive approach to discuss difficult issues facing the
practitioner in the treatment of psoriasis.
1.50 Category 1 CME Credits
U169 Cryosurgery Present and Future
Room: 235/236
DIRECTOR William Abramovits, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Assess how cryosurgery works to selectively destroy lesional
skin while preserving surrounding healthy tissues.
2. Identify lesions and patients for whom cryosurgery may be the
treatment of choice.
3. Select equipment to optimize the performance of cryosurgery.
DESCRIPTION
When cryosurgery is skillfully performed, the cure rates for many
types of skin cancers, pre-malignant and benign lesions should
be high, the peri- and post-operative morbidity should be minor,
and the cosmetic result gratifying. Cryosurgery is very operator-
TUESDAY, FEBRUARY 8
dependent; it requires fundamental knowledge in the physics of
cryobiology, skin anatomy and physiology, pathology, and the
clinical acumen that is to be expected only from a dermatologist.
I will present the proper selection of lesions, patients, and
technique. New information to be presented: the most recent
literature on the subject will be critically reviewed as will the latest
instrumentation and equipment.
1.50 Category 1 CME Credits
www.aad.org | 261
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FOCUS SESSION
2:30 p.m. to 4:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

U170 Pitfalls in Dermatopathology: When U171 Dermatopathology: Utility, Methodology,

Things are Not What They Seem to Be and Interpretation of Current (and Future)
Room: 269 Molecular Testing
DIRECTOR Aleodor A. Andea, M.D. Room: 264

LEARNING OBjECTIVES DIRECTOR Gregory A. Hosler, M.D., Ph.D.

Following this focus session, the attendee will be able to:
1. Recognize a variety of dermatopathology cases that are prone to
be misdiagnosed.
2. Identify histological features that are useful in preventing
pitfalls in diagnosis.
3. Determine appropriate ancillary studies that help arrive at the
correct diagnosis.
DESCRIPTION
This session is directed towards residents, dermatologists with an interest
in dermatopathology, and dermatopathologists who enjoy challenging
cases. Pitfalls in the diagnosis of cutaneous neoplasms that may result
in diagnostic errors with significant clinical impact will be presented.
The session focuses on histological mimickers: skin malignancies that
resemble reactive conditions or benign neoplasms, benign conditions
that masquerade as malignancies, and tumors that are prone to be
mistaken for other types of cutaneous malignancies. The audience will
be presented with the salient features of each entity and with tips to
avoid misdiagnosis.
1.50 Category 1 CME Credits
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. List current molecular tests (and tests on the horizon) used in
dermatopathology.
2. Recognize the current applications and limitations of each test.
3. Describe the methodologies of these various molecular tests.
DESCRIPTION
Only few molecular tests are utilized and currently available in the field
of dermatopathology. This is changing, however, and expansion in
this area is inevitable. Current commonly used tests include B-cell and
T-cell gene rearrangement analysis for diagnosing lymphoma, surrogate
analysis of defects in mismatch repair genes for Muir-Torre syndrome
by immunohistochemistry, and an increasing battery of molecular tests
for infectious disease. Other methodologies are still in their infancy with
respect to application in dermatopathology, but show great promise.
Examples include comparative genomic hybridization and FISH
for diagnosing melanocytic lesions and microarray technologies for
diagnosing and potentially treating melanoma.
1.50 Category 1 CME Credits

Lowest-Price Guaranteed! U172 Transplant Research in Dermatology

Room: 263
DIRECTOR Richard August Clark, M.D.
LEARNING OBjECTIVES
Following this focus session, the attendee will be able to:
1. Categorize cutaneous transplant biomaterials according to their
through Henry Schein components and their potential use.
2. Assess the benefits and deficiency of autologous and allogeneic skin
transplant biomaterials in context of the clinical need.
3. List several new skin substitutes that are undergoing evaluation in
From discounts on medical and surgical clinical trials.
TUESDAY, FEBRUARY 8

supplies to generic and brand-name DESCRIPTION

pharmaceuticals — you won’t find Large acute cutaneous wounds and chronic ulcers may be candidates
better prices! for cutaneous skin transplants. Currently several options are available:
autologous flaps or grafts; decellularized allografts; cultured allogeneic
keratinocytes applied by sprays or in sheets; and complex biological
dressing composed of acellular or cellular engineered scaffolds. Proper
Stop by the Academy matching of available biomaterial with clinical need is of paramount
importance in obtaining the best outcome in a cost-effective way.
Resource Center Booth 3623 Transplant biomaterials will be categorized according to their components,
and learn how to take advantage of potential use, benefits and deficiencies, and several new skin substitutes
this money-saving benefit! that are undergoing evaluation in clinical trials will be described.
1.50 Category 1 CME Credits
262 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
3:00 p.m. to 5:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F093 Psychocutaneous Medicine F094 Melasma: Advances in the Treatment of

Room: 238/239 a Therapeutically Challenging Disease
DIRECTOR Thelda M. Kestenbaum, M.D. Room: 252/253/254
DIRECTOR Pearl E. Grimes, M.D.
SPEAkERS
Caroline Scott Koblenzer, M.D. SPEAkERS
John Y. M. Koo, M.D. Henry H. L. Chan, M.D. Marta I. Rendon, M.D.
Amit G. Pandya, M.D. Rashmi Sarkar, M.D.
LEARNING OBjECTIVES
Following this forum, the attendee will be able to: LEARNING OBjECTIVES
1. Recognize and treat common psychocutaneous disorders. Following this forum, the attendee will be able to:
2. Assess the appropriate use and side effects of psychotropic 1. Succinctly review new data on the pathogenesis of melasma.
medications. 2. Discuss treatments including topical agents, cosmeceuticals,
peels, microdermabrasion, and laser modalities.
DESCRIPTION 3. Determine risk/benefit ratios for procedures.
This session should provide an overview of common
psychocutaneous disorders that present to all dermatologists so that DESCRIPTION
appropriate treatment can be rendered. The use of psychotropic Melasma is indeed a global disorder of major cosmetic significance.
medications and their side effects will be discussed. Recognition of It negatively impacts quality of life. This forum will review the most
the many presentations of obsessive-compulsive disorder (OCD) recent advances in the pathogenesis and treatment of melasma.
will be enhanced. A heightened awareness of the high prevalence 2.00 Category 1 CME Credits
of psychological diseases that present to the dermatologist and a REFERENCES
comfort in their treatment will hopefully be attained. 1. Grimes PE. Aesthetics and Cosmetic Surgery for Darker Skin
2.00 Category 1 CME Credits Types. Philadelphia, PA: Lippincott Williams and Wilkins;
SCHEDULE 2007.
3:00 p.m. Introduction / Dr. Kestenbaum 2. Halder RM. Dermatology and Dermatological Therapy of
3:05 p.m. Psychopharmacology for Dermatologists / Dr. Koo Pigmented Skin. Boca Raton, FL. Taylor and Francis
3:50 p.m. Delusions and Dysesthesias / Dr. Koblenzer Group; 2006.
4:20 p.m. Obsessive-Compulsive Disorder in Dermatology 3. Tosti A, Grimes PE, de Padova MP. Color Atlas of Chemical
/ Dr. Kestenbaum Peels. Berlin: Springer-Verlag; 2006.
4:45 p.m. Questions and Answers / Dr. Kestenbaum SCHEDULE
3:00 p.m. Advances on the Pathogens Of Melasma / Dr. Grimes
3:20 p.m. Topical Agents / Dr. Pandya
4:10 p.m. The South Asia Experience / Dr. Sarkar
4:25 p.m. Laser Modalities / Dr. Chan
4:45 p.m. Superficial Resurfacing Procedures / Dr. Rendon
4:50 p.m. Questions and Answers / Faculty
TUESDAY, FEBRUARY 8

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 263
 SCIENTIFIC SESSIONS
For description of session categories and fees see page 37

FORUM
3:00 p.m. to 5:00 p.m.
Ticket required for admission, no tuition fee. Ticket holds seat
for only 15 minutes after the official start time.

F095 Challenges in the Diagnosis and F096 Phototherapy

Management of Lentigo Maligna Room: 386/387
Melanoma DIRECTOR Heidi Tewich Jacobe, M.D.
Room: 281/282
SPEAkERS
DIRECTOR Vicki J. Levine, M.D. James Ferguson, M.D. John Lyndon McLeod Hawk, M.D.
Iltefat H. Hamzavi, M.D. Henry W. Lim, M.D.
SPEAkERS
Isaac Brownell, M.D., Ph.D. Kishwer S. Nehal, M.D. LEARNING OBjECTIVES
Klaus J. Busam, M.D. Jennifer A. Stein, M.D. Following this forum, the attendee will be able to:
1. Identify with coding and reimbursement issues involved in the
LEARNING OBjECTIVES
practice of phototherapy.
Following this forum, the attendee will be able to:
2. Describe the basic principles of photobiology and
1. Utilize clinical tools in the diagnosis of lentigo maligna
photoimmunology as they apply to the use of ultraviolet
melanoma.
radiation in the treatment of skin disease.
2. Recognize surgical and histologic pitfalls in the management of
3. Examine the indications and contraindications for different
lentigo maligna melanoma.
types of phototherapy and how to manage phototherapy
3. Evaluate the role of nonsurgical treatments.
patients.
DESCRIPTION
DESCRIPTION
The diagnosis and management of lentigo maligna melanoma
This forum is designed for practitioners considering incorporating
in the head and neck region presents multiple challenges due to
phototherapy into their therapeutic armamentarium. Topics
variable natural history and clinical presentation, location in a
include the basics of phototherapy coding and reimbursement, basic
cosmetically and functionally sensitive area, and unpredictable
concepts of photobiology and immunology pertinent to the use of
subclinical extension beyond recommended excision margins. The
this modality, and how-tos regarding indications and regimens for
goal of this session is to illustrate the multiple challenges and present
the major modalities (UVB, NBUVB, PUVA, and PDT).
a comprehensive management approach including: 1) clinical
2.00 Category 1 CME Credits
assessment tools; 2) excision techniques and corresponding tissue
grossing methods; 3) histologic evaluation of surgical margins and SCHEDULE
associated pitfalls; and 4) role of nonsurgical alternatives. 3:00 p.m. Phototherapy Basics: Getting Started / Dr. Lim
2.00 Category 1 CME Credits 3:20 p.m. Photodynamic Therapy / Dr. Hamzavi
3:45 p.m. Questions and Answers / Dr. Jacobe
SCHEDULE
3:50 p.m. Phototherapy for Psoriasis / Dr. Ferguson
3:00 p.m. Alternative Treatments Of Lentigo Maligna
4:10 p.m. Phototherapy for Atopic Dermatitis and Pruritic Skin
Melanoma / Dr. Levine
Disorders / Dr. Hawk
3:30 p.m. The Natural History and Diagnostic Tools in Lentigo
4:30 p.m. Questions and Answers / Dr. Jacobe
Maligna Melanoma / Dr. Stein
4:35 p.m. Phototherapy for Sclerosing Skin Conditions
4:00 p.m. The Pathologic Evaluation of Lentigo Maligna
/ Dr. Jacobe
Melanoma / Dr. Busam
4:55 p.m. Session Summary and Questions and Answers
4:30 p.m. Radiation Therapy in the Treatment Of Lentigo
/ Dr. Jacobe
Maligna Melanoma / Dr. Brownell
TUESDAY, FEBRUARY 8

264 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

ACNE REGIMEN
REDEFINED

EPIDUO GEL: A VISIBLE DIFFERENCE*

® 1

Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5%—A unique fixed-dose

combination developed for the first-line treatment of inflammatory and comedonal lesions

www.epiduo.com/hcp

*In a phase 3 clinical trial of 1670 patients, median reduction in inflammatory lesions was 70% and median reduction in
comedonal lesions was 62% at week 12.

Important Safety Information

Epiduo® Gel is a retinoid and antimicrobial combination product indicated for the topical treatment of acne vulgaris in patients 12 years
and older. The most common adverse events associated with use of Epiduo® Gel are erythema, scaling, dryness, stinging and burning.
In addition, in clinical trials, adverse events reported in greater than 1% of patients treated with the Gel included contact dermatitis
and skin irritation. Excessive exposure to sunlight and sunlamps should be avoided during treatment, and use of sunscreen products
and protective clothing is recommended. Concomitant use of irritating topical products (like products containing resorcinol, salicylic acid
or sulfur) should be avoided. Epiduo® Gel has not been tested in pregnant or nursing women, or with the elderly. Pregnancy Category C.
Please see brief summary of Prescribing Information on next page.
08-ETL-1256 Epiduo Asize Brief text only:Layout 1
EPIDUO™ Rx only
(adapalene and benzoyl peroxide) Gel 0.1% / 2.5%
For Topical Use Only
Not For Ophthalmic, Oral, or Intravaginal Use.
BRIEF SUMMARY
INDICATIONS AND USAGE
EPIDUO Gel is a combination of adapalene, a retinoid, and benzoyl peroxide,
and is indicated for the topical treatment of acne vulgaris in patients 12 years
of age and older.
CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
Ultraviolet Light and Environmental Exposure: Avoid exposure to sunlight and
sunlamps. Wear sunscreen when sun exposure cannot be avoided.
Erythema, scaling, dryness, and stinging/burning may occur with use of
EPIDUO Gel.
ADVERSE REACTIONS
Observed local adverse reactions in patients treated with EPIDUO Gel were
erythema, scaling, dryness, stinging, and burning. Other most commonly
reported adverse events (≥1%) in patients treated with EPIDUO Gel were dry
skin, contact dermatitis, application site burning, application site irritation,
skin irritation.
DRUG INTERACTIONS
Exercise caution in using preparations containing sulfur, resorcinol, or
salicylic acid, medicated or abrasive soaps and cleansers and products with
high concentrations of alcohol or astringents in combination with EPIDUO Gel.
Concomitant use of topical products with a strong drying effect can increase
irritation. Use with caution.
Pregnancy
Pregnancy Category C. There are no well-controlled trials in pregnant
women treated with EPIDUO Gel. Animal reproduction studies have not
been conducted with the combination gel or benzoyl peroxide. Furthermore,
such studies are not always predictive of human response; therefore,
EPIDUO Gel should be used during pregnancy only if the potential benefit
justifies the risk to the fetus.
No teratogenic effects were observed in rats treated with oral doses of 0.15
to 5.0 mg adapalene/kg/day, up to 25 times (mg/m22/day) the maximum
recommended human dose (MRHD) of 2 grams of EPIDUO Gel. However,
teratogenic changes were observed in rats and rabbits when treated with oral
doses of ≥ 25 mg adapalene/kg/day representing 123 and 246 times MRHD,
respectively. Findings included cleft palate, microphthalmia, encephalocele
and skeletal abnormalities in rats; and umbilical hernia, exophthalmos and
kidney and skeletal abnormalities in rabbits.
Dermal teratology studies conducted in rats and rabbits at doses of 0.6-6.0 mg
adapalene/kg/day [25-59 times (mg/m22) the MRHD] exhibited no fetotoxicity
and only minimal increases in supernumerary ribs in both species and delayed
ossification in rabbits.
Nursing Mothers
It is not known whether adapalene or benzoyl peroxide is excreted in human
milk following use of EPIDUO Gel. Because many drugs are excreted in human
milk, caution should be exercised when EPIDUO Gel is administered to a
nursing woman.
Pediatric Use
Safety and effectiveness of EPIDUO Gel in pediatric patients under the age of
12 have not been established.
Geriatric Use
Clinical studies of EPIDUO Gel did not include sufficient numbers of subjects
aged 65 and over to determine whether they respond differently from younger
subjects.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No carcinogenicity, photocarcinogenicity, genotoxicity, or fertility studies were
conducted with EPIDUO Gel.
Carcinogenicity studies with adapalene have been conducted in mice at topical
doses of 0.4, 1.3, and 4.0 mg/kg/day (1.2, 3.9, and 12 mg/m22/day), and in rats
Reference: 1. Gollnick HPM, Draelos Z, Glenn MJ, et al; Adapalene–BPO Study Group. Adapalene–benzoyl peroxide, a unique fixed-dose combination topical gel
for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol. 2009;161(5):1180-1189.
Galderma is a registered trademark.
©2010 Galderma Laboratories, L.P.
Galderma Laboratories, L.P.
14501 N. Freeway
Fort Worth, TX 76177
EPI-317 Printed in USA 01/10 www.epiduo.com/hcp
12/22/08 4:12 PM Page 1
at oral doses of 0.15, 0.5, and 1.5 mg/kg/day (0.9, 3.0, and 9.0 mg/m22/day).
In terms of body surface area, the highest dose levels are 9.8 (mice) and
7.4 times (rats) the MRHD of 2 grams of EPIDUO Gel. In the rat study, an
increased incidence of benign and malignant pheochromcytomas in the
adrenal medulla of male rats was observed.
No significant increase in tumor formation was observed in rodents
topically treated with 15-25% benzoyl peroxide carbopol gel (6-10 times the
concentration of benzoyl peroxide in EPIDUO Gel) for two years. Rats received
maximum daily applications of 138 (males) and 205 (females) mg benzoyl
peroxide/kg. In terms of body surface area, these levels are 27-40 times
the MRHD. Similar results were obtained in mice topically treated with 25%
benzoyl peroxide carbopol gel for 56 weeks followed by intermittent treatment
with 15% benzoyl peroxide carbopol gel for rest of the 2 years study period,
and in mice topically treated with 5% benzoyl peroxide carbopol gel for
two years.
The role of benzoyl peroxide as a tumor promoter has been well established
in several animal species. However, the significance of this finding in humans
is unknown.
In a photocarcinogenicity study conducted with 5% benzoyl peroxide
carbopol gel, no increase in UV-induced tumor formation was observed in
hairless mice topically treated for 40 weeks.
No photocarcinogenicity studies were conducted with adapalene. However,
animal studies have shown an increased tumorigenic risk with the use of
pharmacologically similar drugs (e.g., retinoids) when exposed to UV
irradiation in the laboratory or sunlight. Although the significance of these
findings to humans is not clear, patients should be advised to avoid or minimize
exposure to either sunlight or artificial irradiation sources.
Adapalene did not exhibit mutagenic or genotoxic effects in vitro (Ames test,
Chinese hamster ovary cell assay, mouse lymphoma TK assay) or in vivo
(mouse micronucleus test).
Bacterial mutagenicity assays (Ames test) with benzoyl peroxide has provided
mixed results, mutagenic potential was observed in a few but not in a
majority of investigations. Benzoyl peroxide has been shown to produce
single-strand DNA breaks in human bronchial epithelial and mouse epidermal
cells, it has caused DNA-protein cross-links in the human cells, and has
also induced a dose-dependent increase in sister chromatid exchanges in
Chinese hamster ovary cells. In rat oral studies, 20 mg adapalene/kg/day
(120 mg/m22/day; 98 times the MRHD based on mg/m22/day comparison) did
not affect the reproductive performance and fertility of F0 males and females,
or growth, development and reproductive function of F1 offspring.
No fertility studies were conducted with benzoyl peroxide.
PATIENT COUNSELING INFORMATION
– Advise patients to cleanse the area to be treated with a mild or soapless
cleanser; pat dry. Apply EPIDUO Gel as a thin layer, avoiding the eyes, lips
and mucous membranes.
– Advise patients not to use more than the recommended amount and not to
apply more than once daily as this will not produce faster results, but may
increase irritation.
– EPIDUO Gel may cause irritation such as erythema, scaling, dryness,
stinging or burning.
– Advise patients to minimize exposure to sunlight, including sunlamps.
Recommend the use of sunscreen products and protective apparel, (e.g.,
hat) when exposure cannot be avoided.
– EPIDUO Gel may bleach hair and colored fabric.
Marketed by:
GALDERMA LABORATORIES, L.P.
Fort Worth, Texas 76177 USA
Manufactured by:
Galderma Production Canada Inc.
Baie d’Urfé, QC, H9X 3S4 Canada
Made in Canada.
GALDERMA is a registered trademark.
Revised: December 2008
P51356-0
 POSTER EXHIBITS

ELECTRONIC POSTER EXHIBITS POSTER DISCUSSION SESSIONS

Ticket required for admission, no tuition fee. Ticket holds seat
Location for only 15 minutes after the official start time.
Ernest N. Morial Convention Center, Hall E
The Poster Discussion Sessions will be held on the following dates
Hours and times in the Ernest N. Morial Convention Center.

Friday, February 4 ................................ 7:00 a.m. - 7:00 p.m. PD01 Surgery

Saturday, February 5, 2011
Saturday, February 5 ............................ 7:00 a.m. - 7:00 p.m. 7:15 a.m. to 8:45 a.m.

Sunday, February 6 .............................. 7:00 a.m. - 7:00 p.m. PD02 Clinical Dermatology
Saturday, February 5, 2011
Monday, February 7 ............................. 7:00 a.m. - 7:00 p.m.
7:15 a.m. to 8:45 a.m.
Tuesday, February 8 ............................ 7:00 a.m. - 12:00 p.m.
PD03 Acne
Sunday, February 6, 2011
Poster Exhibit Task Force 12:15 p.m. to 1:45 p.m.
Brian Berman, M.D., Ph.D., Chair
Carrie Ann R. Cusack, M.D. PD04 Psoriasis
Vincent Anthony DeLeo, M.D. Sunday, February 6, 2011
Peter G. Ehrnstrom, M.D. 12:15 p.m. to 1:45 p.m.
Tammie C. Ferringer, M.D.
Gary Goldenberg, M.D. PD05 Cancer
Barbara M. Mathes, M.D. Monday, February 7, 2011
Adam Rubin, M.D. 7:15 a.m. to 8:45 a.m.

POSTER EXHIBITS
Eduardo D. Poletti-Vazquez, M.D.
Samuel John Reck, M.D. PD06 Internal Medicine
Julia Tzu, M.D. Monday, February 7, 2011
Molly Wanner, M.D. 7:15 a.m. to 8:45 a.m.

The AAD Would Like to Congratulate

the 2011 World Congress Poster Exhibit
Scholarship Recipients!
A listing of the 2011 scholarship recipients will
be available in the Program-At-A-Glance.

For more information about World Congress Poster Exhibit Scholarships,

or to submit an application for the 2012 AAD Annual Meeting, visit
www.aad.org/scholarshipopportunities/#ampes.

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 265
 POSTER EXHIBITS
DESCRIPTION
These highly interactive sessions will feature the authors of a select
group of poster exhibits, whose findings are of particular relevance
to dermatologists, discussing important issues raised in their
research. Moderator(s) will then lead a discussion in which the
individuals attending the session will be given the opportunity to
ask questions and share their opinions on the topic.
DISCUSSION FORMAT
For more information, see pages 112, 154, and 187.
PD01: SURgERy
P100
The use of Mohs micrographic surgery for the treatment of
nonmelanoma skin cancers in the Medicare population
P101
Association between Mohs surgery wait times and surgical defect
size in patients with squamous cell or basal cell carcinoma of the
skin
P102
POSTER EXHIBITS
Safety during dermatologic procedures and surgeries: A survey of
physician injuries and prevention strategies
P103
Skin assessment by high-frequency ultrasound is a useful and
reliable method to quantify photoaging in skin
P104
Melanocyte-keratinocyte transplantation in the treatment of
vitiligo: The experience of an academic medical center in the
United States
P105
Association of facial skin aging and vitamin D levels in healthy
middle-aged white women
P106
Cryosurgery followed by imiquimod 3.75% to treat actinic
keratosis
P107
A novel high-power bipolar RF technology for noninvasive body
contouring
266 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
PD02: CLINICAL DERMATOLOgy
P200
Survey of bacterial diversity on infant skin over the first year of life
P201
Baby sun protection products: A competitive assessment of eye
mildness, SPF:PFA ratio, stability, and antimicrobial robustness
P202
A large study of 826 patients confirms the safety and effectiveness
of doxycycline monohydrate 40-mg capsules for the treatment of
papulopustular rosacea
P203
Lymphoma among patients with atopic dermatitis treated with
topical corticosteroids and/or topical calcineurin inhibitors
P204
A six-year retrospective review of drug reaction with eosinophilia
and systemic symptoms (DRESS)
P205
A survey of mortality in patients admitted to intensive care with
skin disorders
P206
Cutaneous epithelial to mesenchymal transition is mediated by
TGF-β and TNF-α synergism: implications for scleroderma
P207
Simvastatin inhibits transforming growth factor-β1-induced
collagen type I, CTGF, and α-SMA expression in keloid fibroblasts
PD03: ACNE
P300
Clindamycin plus tretinoin gel: Treatment of acne patients with all
six Fitzpatrick skin types
P301
Tretinoin microsphere 0.1% gel for acne patients
P302
Faropenem is effective for inflammatory acne
P303
High degree of safety, efficacy, tolerability, lower relapse rates, and
improved quality of life associated with high-dose isotretinoin
therapy
P304
Managing mild to moderate acne in adolescents: Cutaneous
tolerability benefits of tretinoin gel (0.05%) in a study
subpopulation of 983 subjects aged 10 to <18 years
 POSTER EXHIBITS

P305 PD05: CANCER

Exacerbation of facial acne vulgaris after consuming pure
chocolate
P306
Meta-analysis of randomized controlled trials using 5% benzoyl
peroxide and clindamycin versus 2.5% benzoyl peroxide and
clindamycin topical treatments in acne
P500
High clinical response rate of Sézary syndrome with immune
modifying therapies: Prognostic markers of response
P501
Risk factors associated with the developement of a second
melanoma associated with nevus

PD04: PSORIASIS P502

P400
The effect of tumor necrosis factor-alpha inhibitors on the risk of
myocardial infarction in patients with psoriasis
P401
Determining the extent to which clinically effective treatment,
ustekinumab or etanercept, reverses the molecular disease profile
of psoriatic skin: Comparisons of lesional, non-lesional, and
normal skin
P402
Improvement in nail psoriasis is associated with improved efficacy
outcomes in hand and/or foot psoriasis in adalimumab-treated
patients: Subanalysis of REACH
Significantly higher Breslow score of melanomas detected by
patients’ self-examination compared to melanomas detected during
annual dermatology check-up
P503
Application of a filtration and isolation by size technique for the
detection of circulating tumor cells in cutaneous melanoma
P504
Using standardized patients and moulage to assess students’ ability
to detect melanomas
P505
Characterizing regression in melanomas: a population-based study

POSTER EXHIBITS
P506
P403 Prognosis and risk factors of local recurrence in cutaneous melanoma
Ustekinumab demonstrates rapid onset of efficacy in the treatment
of moderate to severe psoriasis P507
Effectiveness of photodynamic therapy in Bowen disease: An
P404 observational and descriptive study in 50 patients
Cause-specific mortality in patients with severe psoriasis:
A population-based cohort study
PD06: INTERNAL MEDICINE
P405
The safety of tumor necrosis factor antagonists in patients with P600
psoriatic disease: A systematic review and meta-analysis of Tumour necrosis factor-alpha promoter -308G/A (TNFα -308G/
randomized controlled trials A) polymorphism in Mexican patients with alopecia areata

P406
A pooled analysis of phase III, randomized, placebo-controlled
clinical trials of the anti-interleukin 12/23 monoclonal antibody,
ABT-874
P407
Gene expression profiling in psoriatic scalp hair follicles: Clobetasol
propionate shampoo 0.05% normalizes psoriasis disease markers
P601
Vulvo-cervico-vaginal manifestations and evaluation of Papanicolaou
smears in pemphigus vulgaris and pemphigus foliaceus
P602
Analysis of the reactivity of indirect immunofluorescence in
patients with pemphigus foliaceus and pemphigus vulgaris using
rat bladder epithelium as a substrate

P603
A study of 383 patients of tungiasis in Haiti

P604
Antiphospholipid antibody syndrome triggered by levamisole-
tainted cocaine: Case report and review of the literature

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 267
 POSTER EXHIBITS
P605
Diagnostic guidelines for cellulitis: Recommendations based on
a retrospective analysis of cellulitis admissions to Massachusetts
General Hospital
P606
Expression of pro-inflammatory protein s100a12 (EN-RAGE) in
Behçet’s disease and its association with disease activity
ACNE
P700
Antimicrobial peptide-DNA complexes and type I interferon are
implicated in initial pathogenesis of rosacea
P701
“Got sick, got a gift’’: a new tool for optimizing adherence to acne
therapy
P702
The combination of salicylic acid peel with 5% benzoyl peroxide
and 1% clindamycin lotion in a treatment of acne vulgaris:
A randomized double-blind placebo-controlled study
P703
POSTER EXHIBITS
Unexpected benefits of topical dapsone or clindamycin/benzoyl
peroxide in combination with tazarotene in treatment of
comedonal acne
P704
Adapalene-benzoyl peroxide combination relative to vehicle is
quickly effective in the treatment of acne among a Hispanic
population
P705
Subcision-suction method: A new highly effective treatment of
atrophic acne scars and other depressed scars of the face
P706
Topical triggers for perioral dermatitis
P707
Clinical proof of concept evaluation of the effectiveness and
tolerance of a facial product on subjects with rosacea
P708
Medication adherence among acne patients: A review
P709
The efficacy of adapalene-benzoyl peroxide fixed-dose combination
increases with the number of baseline acne lesions
P710
Effective 6-month maintenance management of acne with
adapalene-benzoyl peroxide fixed-dose combination
268 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
P711
Should anti-oxidants be prescribed in acne vulgaris?
P712
Efficacy and tolerability of 5% sodium L-ascorbyl-2-phosphate
lotion, as maintenance therapy, for moderate to severe acne in
comparison with 0.1% adapalene gel
P713
In vitro percutaneous absorption of tretinoin into the dermis of
human skin
P714
No BPO-induced degradation of tretinoin when benzoyl peroxide is
combined with an optimized formulation of tretinoin gel (0.05%)
P715
The treatment of acne: Driver of resistance in resident commensal
flora?
P716
Studies of the dermal tolerability of a prescription benzoyl
peroxide 5.3% topical emollient foam
P717
Adapalene lotion 0.1% shows comparable tolerability to adapalene
cream 0.1% in a split-face comparison
P718
Fixed-dose adapalene-benzoyl peroxide gel is synergistically
efficacious in the treatment of acne vulgaris: a meta-analysis of
studies in 3,855 patients
P719
The use of autologous platelet gel enhances the efficacy of skin
needling for the treatment of acne scarring
P720
Clinical effects and tolerance of a composition containing benzoyl
peroxide and capryloyl salicylic acid (C8-LHA) on acne
P721
Psychological effects of acne in adolescents
P722
Fractionated erbium laser during oral isotretinoin treatment
P723
Rosacea fulminans: Personal experience
P724
Patient satisfaction with benzoyl peroxide 5.3% emollient foam in
clinical practice
 POSTER EXHIBITS

P725 P810
A clinical study evaluating the dermatologic benefits of topical Clinical benefits of topical application of Artemisia abrotanum
bakuchiol (UP256) cream on facial acne (southernwood) on photodamaged skin

P726 P811
Three-dimensional full-sized silicone-based facial replicas for A synthetic NF-kB inhibitor has significant anti-aging benefits on
teaching outcome measures in acne photodamaged facial skin

P727 P812
The usefulness of adapalene outside of acne vulgaris A purified feverfew extract increases skin’s antioxidant and cellular
detoxification defenses by activating the antioxidant response
element promoter
AgINg/gERIATRICS
P813
P800 Anti-wrinkle activity of retinol is enhanced by a Myrtus communis
Regulation of extracellular matrix protein expression by NF-kB: extract
Link between inflammation and aging
P814
P801 Pollution doubles skin damage from solar UV
The anti-aging effects of poly-gamma glutamic acid on broad-band
ultraviolet B-induced photoaging skin in a mice model P815
Ability of topical formulation containing botanical antioxidants
P802 to mitigate synergistic skin damaging effects of UV radiation and
Clinical, instrumental and histological changes with a 120-day oral environmental aggressors and improve skin barrier
supplementation with marine protein, concentrated acerola (vitamin
C), grape seed extract (procyanidins), and tomato extract (lycopene) P816

P803
Persistence of nasolabial fold correction with a hyaluronic acid
dermal filler: Results of an 18-month study extension
P804
Assessment of the onset, spread, efficacy and pain upon injection of
abobotulinumtoxina and onabotulinumtoxina for the treatment of
dynamic frontalis rhytids using a novel frontalis activity measure
POSTER EXHIBITS
Clinical evaluation of an antioxidant gel cream containing
vitamin C, ferulic acid, and phloretin on photo-damaged skin
P817
Adverse reaction of temporary fillers used for treating facial aging
P818
Hydrophobically-modified polymer gentle facial cleansers provide
gentle cleansing in sensitive skin subjects

P805 P819
Hydroxydecyl ubiquinoyl dipalmitoyl glycerate (idebenone Myrtus communis extract enhances the tolerability and efficacy of
complex): A new and effective topical antioxidant for the high retinol facial moisturizer
treatment of premature skin aging associated with cellular
oxidative stress P820
Clinical evaluation of a topical retinol treatment to address signs
P806 of aging on the hands, neck, and décolletage
Clinical evaluation of an antioxidant cream containing resveratrol,
ferulic acid, and vitoptin on photo-damaged skin P821
Clinical evaluation of a mineral powder foundation SPF 25 in
P807 improving the appearance of women with photodamaged skin
Facial skin aging and association with blood markers of oxidative stress
P822
P808 Reduction in skin barrier perturbation by hydrophobically-
Clinical evidence of a new anti-sagging cosmetic cream modified polymers
demonstrated by digital image analysis
P823
P809 The invitro effects of Artemisia abrotanum (southernwood) on
A double-blind, placebo-controlled study demonstrated the anti- restoring skin balance
aging efficacy of a hexylresorcinol and ascorbic acid-2 glucoside-
containing product.

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 269
 POSTER EXHIBITS

ARTS, HISTORy, AND HUMANITIES OF P1009

Specificity of two groups of “stratum corneum autoantibodies” in
DERMATOLOgy normal sera and their clinical significance in psoriasiform lesions

P900 P1010
The moon children of Kuna Yala: Albinism in San Blas Islands of The complexing proteins of botulinum neurotoxin type A bind to
Panama: Review, directions in research and aid neuronal as well as non-neuronal cells

P901 P1011
American women in dermatology Investigation into lipolytic compounds

P902 P1012
Women in American dermatology: Clinicians Photostability of sunscreen combinations containing avobenzone
exposed to natural and artificial UV light
P903
Women in American dermatology: Physician scientists P1013
Confocal Raman and IR spectroscopic studies of SDS permeation
in skin and interaction with stratum corneum lipids
BASIC SCIENCE
P1014
P1000 Effects of chemistry on the rheological properties of hyaluronic
IL-17A-mediated inflammation in cutaneous lupus erythematosus acid (HA) fillers

P1001 P1015
Is there a role for complexing proteins in pharmaceutical Down-regulation of cathelicidin activity for management of
botulinum neurotoxin formulations? rosacea-related symptoms and hyperirritable skin
POSTER EXHIBITS

P1002 P1016
Ex vivo evaluation of an autologous model of bioengineered Novel techniques to characterize skin barrier and assess product
human skin effects on stratum corneum health

P1003 P1017
Development of a bioengineered substitute of the human skin Deposition and penetration profile of soybean oil in the stratum
using an alternative cell source corneum from liquid skin cleansers

P1004 P1018
Erbb2 activation of PI3K/Akt signaling and inhibition of Attenuation of Nocardia brasiliensis through serial in vitro cultures
thrombospondin 1 is necessary for keratinocyte migration

P1005 CLINICAL DERMATOLOgy AND OTHER

Correlation of skin barrier function and sebaceous lipids on the
face of women from three populations in the US CUTANEOUS DISORDERS
P1006 P1100
Quantification of light depolarization as a potential tool for Comparative efficacy of continuous and intermittent use of epinastine
differentiation of benign and malignant skin lesions for chronic urticaria in an 8-week randomized, multicenter, parallel-
group study
P1007
NT201 (Merz, Germany) and botulinum toxin (Allergan, USA) P1101
have equivalent potency Inhalant abuse

P1008 P1102
Identification of extracellular proteases produced by Nocardia The safety and efficacy of etanercept for the treatment of discoid
brasiliensis in a THP-1 macrophage monolayer lupus erythematosus

P1103
Role of oligomers in amyloidogenesis in primary cutaneous
amyloidosis

270 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 POSTER EXHIBITS

P1104 P1118
A pediatric hemangioma of the nasal tip: The Cyrano nose Lower patient weight does not increase risk of developing
doxycyline-resistant microorganisms in patients taking doxycycline
P1105 monohydrate 40-mg capsules (30 mg immediate release/10 mg
Comparison of clinico-epidemiological features of cutaneous delayed release beads) for up to 9 months
adverse drug reactions in children and adults
P1119
P1106 Improved QoL in rosacea patients treated with doxycycline
Hyperferritinemia: A potentially useful marker in a number of monohydrate 40-mg capsule-containing regimens
critical dermatological conditions associated with macrophage
activation syndrome P1120
Efficacy of doxycycline monohydrate 40-mg capsules for rosacea is
P1107 not correlated with baseline severity or body weight
Bilateral idiopathic auricular ossificans: A case report
P1121
P1108 Three cases of necrobiosis lipoidica treated with photodynamic therapy
Diabetic dermopathy: Pathognomonic of diabetes mellitus
P1122
P1109 Hereditary angioedema: By the way of a case
Livedo reticularis as the first manifestation of a cholesterol
embolism P1123
Uncommon side effects of isotretinoin therapy: Paronychia and
P1110 pyogenic granuloma
Gluteal nodules in twelve patients treated with depot somatostatin
analogs P1124
Case of extensive inguinal hidradenitis suppurativa

POSTER EXHIBITS
P1111
Prevalence of necrobiosis lipoidica in patients served in a third P1125
level hospital in Mexico Histiocytoid Sweet syndrome with neutropenia in association with
acute myeloid leukemia
P1112
Delusional infestation: Analysis of ‘matchbook’ sign specimens and P1126
biopsy results Histiocytoid Sweet’s syndrome in a patient with a history of
pseudomyxoma peritonei
P1113
An open label study to evaluate the efficacy of re-treatment of P1127
patients with psoriasis who have previously been treated with A rare breast lesion in 3 patients: Furthering our knowledge on
etanercept nodular mucinosis of the breast

P1114 P1128
Myelodysplastic syndrome presenting as interstitial granulomatous Fluoroscopy-induced morphea
dermatitis
P1129
P1115 Segmental cherry angiomas associated with extragenital lichen
Further evaluation of cutaneous irritation caused by topical sclerosus: A report of 2 cases
medications using a novel technique
P1130
P1116 Generalized granuloma annulare: A therapeutic challenge; our
Sneddon’s syndrome experience in 12 patients

P1117 P1131
Intertriginous xanthomas in a two-year-old girl with type II The dermatologic manifestation of hyperandrogenism:
hyperlipidemia A retrospective chart review.

P1132
Atypical, incapacitating nodules in a woman with paraplegia:
Treatment with shave excision

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 271
 POSTER EXHIBITS

P1133 P1148
Skin phototype makes a difference in the severity and management Acute generalized exanthematous pustulosis (AGEP)
of skin
P1149
P1134 Orlistat-induced bullous leukocytoclastic vasculitis
Doxycycline monohydrate 40-mg capsule-containing regimens:
Effectiveness and safety in the treatment of papulopustular rosacea P1150
Trichilemmal horn
P1135
The influence of variable distorted cognition and behavior for the P1151
treatment of skin problems Granuloma gluteale adultorum

P1136 P1152
An open-label study of naftifine hydrochloride 1% gel in the Intertriginous granular parakeratosis: A case report and review of
treatment of seborrheic dermatitis of the scalp the literature

P1137 P1153
Subcutaneous fat necrosis/panniculitis and polyarthritis associated Hidradenitis suppurativa disease amelioration with ustekinumab
with acinar cell carcinoma of the pancreas: A rare presentation of therapy
PPP syndrome
P1154
P1138 Gender differences exist in the presentation and management of
Delusional infestation: A report of three cases with unusual most of the major skin toxicities associated with epidermal growth
pathogens factor receptor inhibitors

P1139 P1155
POSTER EXHIBITS

Lipoatrophia semicircularis Adult xanthogranuloma in hematologic malignancy

P1140 P1156
A case of subcutaneous sarcoidosis (Darier-Roussy) misdiagnosed Bullous drug eruption associated with nitrofurantoin
as erythema nodosum
P1157
P1141 Keratosis obturans
Adult Ehlers-Danlos patient with disseminated xanthogranulomas
P1158
P1142 Cutaneous co-infection with both herpes simplex virus and
Cutaneous metastatic Crohn’s disease: A rare case report and tuberculosis in a HIV-infected patient presenting as a refractory
review exophytic perianal tumor

P1143 P1159
Progressive macular hypomelanosis in a pediatric patient Photodynamic therapy for the treatment of cutaneous sarcoidosis:
A case study
P1144
A case of granuloma annulare induced by adalimumab P1160
Unusual presentation of erythema elevatum diutinum
P1145
Ulcerated sarcoidosis P1161
Pigmentary demarcation lines
P1146
Case report: Pseudoporphyria in a 56-year-old man as a result of P1162
finasteride intake Dermoscopic findings of cutaneous renal cell carcinoma

P1147 P1163
Intralymphatic granulomas as a pathogenic factor in cheilitis Eccrine spiradenoma: Not just another painful nodule
granulomatosa/Melkersson-Rosenthal syndrome: Report of a case
with immunohistochemical and molecular studies P1164
Linear lichen sclerosus along the Blaschko’s line

272 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 POSTER EXHIBITS

P1165 CONNECTIvE TISSUE DISEASES

Melanocytic nevus over a blue nevus
P1200
P1166 Zosteriform keloidal morphea
Polydactyly
P1201
P1167 Mutation in the topoisomerase I gene and abnormal topoisomerase
Sweet’s syndrome: Case report I activity in a patient with severe systemic sclerosis (scleroderma)

P1168 P1202
Non-Hodgkin natural killer T-cell lymphoma with cutaneous Extragenital lichen sclerosus treated with desoximetasone and
involvement: Immediate response to induction treatment calcitriol

P1169 P1203
Cutis verticis gyrata secondary to congenital nevus Rare cutaneous manifestation in patients with lupus erythematosus

P1170 P1204
A case of eccrine poroma of the buttock A novel defect in fibrillin-1 deposition by dermal fibroblasts
clinically presenting as acquired cutis laxa is reversible with
P1171 dexamethasone and losartan treatment
Glomus tumor presenting as mobile nodule on the knee
P1205
P1172 A case of nevus anelasticus
A novel foam vehicle is consistently preferred by patients for
dermatological conditions P1206
Linear cutaneous lupus erythematosus: Report of two cases

POSTER EXHIBITS
P1173
Febrile ulceronecrotic Mucha-Habermann disease: A case report P1207
and review of the literature Amicrobial pustulosis of the folds associated with autoimmune
disorders: Case series
P1174
Erosive pustular dermatosis of the scalp mimicking cutaneous P1208
extension of metastatic breast carcinoma Ulcerative dermatomyositis: A case series

P1175 P1209
An open label study of the tolerability of sodium sulfacetamide Interstitial granulomatous dermatitis in a patient with lupus
10%, sulfur 5% emollient foam in rosacea patients with a history erythematosus
of sensitivity to metronidazole
P1210
P1176 Relapsing polychondritis: Diagnosis after rare neurologic
Long lasting discoid lupus erythematosus leading to basal cell complication
carcinoma in a Haitian patient
P1211
P1177 Exacerbation by ibuprofen in subacute lupus erythematosus
Interesting cases from Stony Brook University
P1212
P1178 Clinical and histological features of 65 patients with cutaneous
Multiple eccrine hidrocystomas of uncommon presentation lupus erythematosus

P1179 P1213
Polypoid dermatofibroma Amyopathic dermatomyositis developed into dermatomyositis after
12 years: Case report
P1180
Fixed drug eruption caused by bisoprolol P1214
Case report: Chronic cutaneous lupus erythematosus associated
P1181 with Hashimoto thyroiditis
An unusual presentation of striate lichen

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 273
 POSTER EXHIBITS

DERMATITIS, ATOPIC P1312

P1300
Infective endocarditis in children with atopic dermatitis
P1301
A 5-year randomized study to investigate the safety of
pimecrolimus cream 1% in the treatment of mild to moderate
atopic dermatitis in infants: Clinical safety
P1302
Natural PPAR alpha agonist evaluation on in vitro and ex vivo
models of atopic dermatitis
A novel lipid-rich moisturizing body wash reduces clinical ashiness
in skin of color subjects
P1313
An open label study evaluating a hyaluronic acid-ceramide based
prescription emollient foam in the treatment of mild to moderate
eczema
P1314
Bilateral comparison study of pimecrolimus cream 1% and a
ceramide-hyaluronic acid based emollient foam in the treatment of
patients with atopic dermatitis

P1303 P1315
An over-the-counter moisturizer is as clinically effective as, Long-term efficacy of alitretinoin in 3 patients with chronic hand
and more cost-effective than, prescription barrier creams in the eczema
treatment of children with mild to moderate atopic dermatitis:
A randomized, controlled trial P1316
From bench to bedside: An evaluation of a ceramide-hyaluronic
P1304 acid based emollient foam in barrier-compromised patients
Topical therapeutic effect of Korean red ginseng and its genuine
constituents in an atopic dermatitis mouse model P1317
Filaggrin mutations in atopic dermatitis among the Chinese
P1305
Barrier disruption revealed physiological differences in dry and P1318
POSTER EXHIBITS

normal skin Report of 2 cases of chronic atopic dermatitis treated with

adalimumab
P1306
Delivery of a pseudo-ceramide to atopic skin is related to objective P1319
and subjective improvement Health behavior models: A framework for studying adherence in
children with atopic dermatitis
P1307
Hydration potential of a new body moisturizer P1320
Effect of moisturizer containing pseudo-ceramide on barrier
P1308 function and sensitivity of atopic skin
Irritation potential and cosmetic acceptability of a new body
moisturizer P1321
Effect of a pseudo-ceramide containing moisturizer on quality of
P1309 life of patients with atopic dermatitis
Sunflower oleodistillate: A topical PPAR-α agonist developed for
atopic dermatitis P1322
A novel finding in atopic dermatitis: Film-producing Staphylococcus
P1310 epidermidis as an etiology
A 5-year randomized study to investigate the safety of
pimecrolimus cream 1% in the treatment of mild to moderate P1323
atopic dermatitis in infants: Immunological parameters Irritation potential and cosmetic acceptability of a new body wash

P1311 P1324
Physicians’ perceptions of an eczema action plan for atopic The Epic study: Evaluating skin barrier emulsion in the clinic for
dermatitis AD; results across subgroups by distribution of dermatitis

274 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 POSTER EXHIBITS

DERMATITIS, CONTACT, ALLERgIC DERMATOPATHOLOgy

AND IRRITANT P1500
Neutrophilic urticaria: Descriptive study of 32 patients
P1400
Autoimmune progesterone dermatitis in a patient with endometriosis P1501
Cerebral autosomal dominant arteriopathy with subcortical
P1401 infarcts and leukoencephalopathy (CADASIL): The importance of
Atypical perniosis the cutaneous biopsy in the diagnosis

P1502
P1402 Defining the histopathological features of the high-risk squamous
Severe chronic hand eczema treated with alitretinoin cell carcinoma

P1403 P1503
Are Caucasians and African Americans different in erythema and Atypical angiolymphoid hyperplasia with eosinophilia mimicking
other skin irritation responses? A clinical investigation with a cutaneous lymphoma
topical product and blank control
P1504
Cutaneous endometriosis
P1404
Pustular form of eosinophilic, polymorphic, and pruritic eruption P1505
of radiotherapy with glioblastoma A case of glomangiopericytoma-type myopericytoma on the nose tip

P1405 P1506
The impact of TNF-alpha polymorphisms in patients with chronic Bullous eosinophilic cellulitis
irritant contact dermatitis
P1507
Cutaneous intravascular extramedullary hematopoiesis
P1406

POSTER EXHIBITS
Patch testing with supplemental allergens in conjunction with the P1508
standard series yields more reactions than the standard series alone Multiple palisaded encapsulated neuromas

P1407 P1509
Cutaneous photoallergic effect of cyamemazine: A case report Lymphangioma-like pattern evolution in a case of classic Kaposi’s sarcoma

P1408 P1510
Erythema grading in light and dark skin: A meta-analysis of 20 Lipomembranous panniculitis
modified cumulative irritancy tests performed in 2004 - 2008 with P1511
Caucasian and African American subjects Correlation between clinical and histological diagnoses

P1409 P1512
Cefoxitin-induced delayed onset infusion phlebitis: A case report Localized cutaneous eruption with enlarged histiocytes induced by
subcutaneous granulocyte-macrophage colony-stimulating factor
injections

P1513
Pitfalls in the diagnosis of cutaneous Rosai-Dorfman disease:
Report on 2 cases

P1514
Hypocellular plaque-like CD34-positive dermal fibroma
(medallion-like dermal dendrocyte hamartoma)

P1515
Cutaneous epitheloid angiomatous nodule and epitheloid hemangioma:
Distinct entities on the epitheloid vascular tumors spectrum?

P1516
Varicella-zoster virus brachioplexitis associated with granulomatous
vasculopathy

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 275
 POSTER EXHIBITS

P1517 P1611
Annular elastolytic giant-cell granuloma Evaluation of the pituitary-adrenal axis function in patients on
topical steroid therapy
P1518
Importance of histopathological diagnosis of acroangiodermatitis P1612
New model into how non-ionic surfactants alter cleanser solution
properties to create skin compatible cleanser
DERMATOPHARMACOLOgy/
COSMECEUTICALS P1613
Skin penetration of tretinoin in three concentrations as an agent
for superficial chemical peeling
P1600
Simple vasoconstriction may be a primary anti-inflammatory
mechanism of topical corticosteroids
P1614
Doxycycline in contemporary dermatologic practice
P1601
Muckel-Wells syndrome: Good response with anakinra
P1615
Clinical improvements in facial photo-aged skin using a novel oak
quercetin topical preparation
P1602
Evidence-based topical skin rejuvenation
P1616
Comparison of clinical improvements in facial photo-aging of
P1603
a topical system containing a bi-mineral complex and stabilized
International CO-validation of a new international quality of life
retinol versus a series of professional chemical peels
instrument specific to physical appearance: BeautyQoL

P1604 P1617
A regimen approach for improving facial photo-aging with topical
Biomimetic signalling technology mimics healing current in skin
POSTER EXHIBITS

application of a zinc-copper galvanic couple and natural extracts

P1605
Regulation of skin barrier function and inflammation by patented
P1618
Respecting patient choice: Potential pitfalls in prescribing
natural peptides

P1606 P1619
20% alpha/poly hydroxy acid cream improves the symptoms of
Classic Kaposi´s sarcoma treated with topical imiquimod: One
recalcitrant hyperkeratosis
case report and review

P1607 P1620
Clinical methodology to demonstrate positive benefits that are
Bioequivalence of two formulations of tretinoin emollient cream
perceivable from body wash cleansers with controlled normal use
(0.05%)
and home use procedure
P1608
Comparing the effectiveness of an oatmeal cream versus a
P1621
Efficacy and tolerability of antioxidant complex treatment in fine
prescription device cream in improving skin moisturization and
lines, wrinkles, and photodamaged skin
barrier function in moderate to severe dry skin

P1609 P1622
Associating surfactant to hydrophobically-modified polymers
Clinical improvements in skin barrier properties with topical
reduces the surfactant dynamics and reduces the aggressiveness of
application of formulations containing natural southernwood
a cleanser
P1610
Cleansers with hydrophobically modified polymers demonstrate
improved mildness and skin barrier integrity

276 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 POSTER EXHIBITS

DIgITAL/ELECTRONIC TECHNOLOgy EDUCATION AND COMMUNITy SERvICE

P1700 P1800
Nevi dermoscopic structure changes during pregnancy related to Educating hair professionals for skin cancer prevention: A baseline
location survey of skin cancer knowledge, attitudes, and behaviors among
hair professionals in Houston, Texas
P1701
Langerhans cells and melanocytes share similar morphologic P1801
features under in vivo reflectance confocal microscopy: A challenge Dermhub: A comprehensive dermatology focused patient
for melanoma diagnosis education resource and social community

P1702 P1802
Teledermoscopy of pigmented lesions: A pilot study Detection of violative advertising in dermatology-related
promotional materials
P1703
Aneurysmal dermatofibromas clinically mimicking malignant P1803
melanomas: Colorimetric analysis from conventional digital Getting the word out: A fast intervention to educate nonmedical
photographs skin care professionals at salons and spas in southern California
about tanning bed usage and skin cancer
P1704
Pilot clinical study for non invasive diagnosis of non-melanoma P1804
skin cancer Examining the associations among family history, knowledge, and
sunscreen use in adolescents
P1705
Dermoscopic features of skin lesions in mastocytosis: A study of P1805
the Spanish Network on Mastocytosis in a series of 127 patients Melanoma preventive behavior in Polish population

POSTER EXHIBITS
P1706 P1806
Confocal and histologic correlation of linear dots on dermoscopy Scarce statistics: The need for epidemiology education in medicine
of pigmented Bowen’s disease
P1807
P1707 Nanotechnology and dermatology education in the United States:
Detection of subclinical acantholysis in pemphigus by reflectance Data from a pilot survey
confocal microscopy
P1808
P1708 Use of health lay workers for melanoma detection in underserved
The use of ImageJ with semi-automatic segmentation by active communities
contours: A new method of digital planimetry
P1809
P1709 Developing an observed structured teaching exam for dermatology
Dermoscopy of clear cell acanthoma residents at OUHSC

P1810
Improving your bottom line: Corporate structure, tax reduction,
and benefit planning for today’s dermatologist

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 277
 POSTER EXHIBITS

EPIDEMIOLOgy AND HEALTH SERvICES gENODERMATOSES

ADMINISTRATION P2000
Recognition of congenital syndromes with subtle expression or late
P1900 penetrance: Presentation of tuberous sclerosis complex in adults
Perception of dermatologists´ quality of life
P2001
P1901 Epidermolytic hyperkeratosis in a newborn with a heterozygous
Melanoma cancer registry reporting practices of US dermatologists
187F mutation in the KRT1 gene
P1902 P2002
A survey of skin conditions and concerns in South Asian
Extending the phenotypic spectrum of keratitis-ichthyosis-deafness
Americans: Results of a community-based survey
syndrome: Report of a patient with GJB2 (g12R) connexin 26
mutation and unusual clinical findings
P1903
Translation into Brazilian-Portuguese language, cross-cultural
P2003
adaptation and validation of a disease-specific quality of life
Ectodermal dysplasia associated to B-cell lymphoma resulting from
questionnaire: Acne-specific quality of life questionnaire (Acne-
mutation of the p63 gene
QoL)
P2004
P1904 Recessive dystrophic epidermolysis bullosa with squamous cell
Occupational skin disorders: A health services analysis of workers’
carcinoma
compensation cases, 2004-2008
P2005
P1905 Transgrediens lesions in patients with pachyonychia congenita
Survey “Buen Rayito” about healthy sun exposure habits in
POSTER EXHIBITS

teenagers through a Web platform in Spain

P2006
Muir-Torre syndrome: Surgical management and cancer screening
P1906 guidelines
Study of prevalence and characteristics of melanocytic nevi in 8- to
10-year-old children in southern Spain and analysis of associated
P2007
factors
Hailey-Hailey disease successfully treated with topical
5-fluorouracil
P1907
Desirable traits in academic dermatology mentors
P2008
A novel mutation (p. Lys199Asn) in KRT5 resulting in different
P1908 epidermolysis bullosa simplex phenotypes of a Chinese family
Clinical interpretation of ItchyQol using an anchor-based
technique
P2009
Reed’s syndrome: Familial cutaneous and uterine leiomyomatosis
P1909
Linkage of multi-generation families afflicted with psoriasis in the
P2010
Newfoundland and Labrador Founder population
Old syndromes, new perspectives: Brooke-Spiegler syndrome
P1910 P2011
Deficiency of vitamin D in healthy people from a Mediterranean
Focal dermal hypoplasia: Report of a Taiwanese case and literature
region
reviews

P2012
Collodion baby: Presentation of a clinical case with good outcome

278 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 POSTER EXHIBITS

P2013 HAIR AND NAIL DISORDERS

Variable expression of incontinentia pigmenti in two sisters
P2014
Pigmentary incontinence, type 2, male newborn surviving 29 days:
Case report
P2100
A Japanese piebald patient with auburn hair color caused by a
novel mutation p.P832L in the KIT gene and a homozygous
variant p.I120T in the MC1R gene

P2015 P2101
A report of epidermolysis bullosa simplex with mottled Association betweenTLR9 gene polymorphisms and susceptibility
pigmentation in three generations of a family to alopecia areata in Korean population

P2016 P2102
Cutaneous manifestations of cobalamin C deficiency Hirsutism in Algeria: Etiological study

P2017 P2103
A subtle nevus of Ota in a neurofibromatosis type 1 patient Clinical study on 88 cases of Korean twenty-nail dystrophy

P2018 P2104
The gray zone Nail changes in patients with graft-versus-host disease

P2019 P2105
A novel PORCN mutation in focal dermal hypoplasia A man with frontal fibrosing alopecia

P2020 P2106
Pseudoxanthoma elasticum Ten bright white fingernails in two young healthy patients

POSTER EXHIBITS
P2021 P2107
Case report: GAPO syndrome A new classification system for grading the severity of onychomycosis:
Onychomycosis Area Severity Index Score (OASIS)
P2022
Metabolic implications from a cutaneous sign P2108
Activity of TDT 067 (terbinafine in transferosomes) against agents
P2023 of onychomycosis, as determined by minimum inhibitory and
Angiofibroma rating scale in tuberous sclerosis complex fungicidal concentration

P2024 P2109
A case of Kindler syndrome A case of short anagen syndrome: Successfully controlled with
topical minoxidil and systemic cyclosporine as combination
P2025 therapy
Unilateral Darier’s disease following Blaschko’s lines
P2110
P2026 Effect of TDT 067 (terbinafine in transferosomes) on the
Acrodermatitis enteropathica: Report of two cases morphology and ultrastructure of dermatophytes known to cause
onychomycosis
P2027
Multiple familial trichoepithelioma

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 279
 POSTER EXHIBITS

IMMUNODERMATOLOgy AND P2214

Case report: Dermatitis herpetiformis associated with Grave’s
BLISTERINg DISORDERS disease

P2200 P2215
Erythema multiforme in the setting of lupus erythematosus Porphyria cutanea tarda : Report of 5 cases with different
(so-called Rowell’s syndrome): A reappraisal based on a systematic precipitating factors and review of the literature
review of the worldwide literature

P2201 INFECTION — BACTERIAL AND

Evaluation of Trypanosoma cruzi reactivity in a Brazilian endemic
area of fogo selvagem (endemic pemphigus foliaceus) PARASITIC
P2202 P2300
Spectrum of patients with autoimmune bullous dermatoses from Mycobacterium haemophilum infection of the skin and soft tissue in
immunocompromised patients: How to enhance yield of positive
an outpatient clinic in Brazil
culture
P2203 P2301
Imunohistochemical profile of FOXP3 regulatory T cells in Simultaneous primary and secondary syphilis
endemic pemphigus foliaceus
P2302
P2204 Unresolving abscess on the finger of a diabetic patient
Regional audit of bullous pemphigoid
P2303
Epidemiological features of leprosy patients studied over a period
P2205 of 10 years in the dermatology center “Dr Ladislao de la Pascua”
Anti-laminin γ1 pemphigoid with a linear IgA bullous dermatosis-
P2304
POSTER EXHIBITS

like presentation: A case report and literature review

Clinical and laboratory investigations in patients with scabies
P2206
Epidermolysis bullosa pruriginosa: Novel compound heterozygote P2305
A case report and rare side effect of low-dose clofazimine in the
splice site mutations
treatment of lepromatous leprosy
P2207 P2306
Bullous lupus erythematosus as a cutaneous manifestation of A case of disseminated Mycobacterium chelonae
systemic lupus
P2307
P2208 Lues maligna
Mechanical forces exacerbate vancomycin-induced linear IgA
P2308
bullous dermatosis “Racket” lesion reaction in a dimorphic tuberculoid leprosy patient
P2209 P2309
A case of coma blisters in a non-pressure dependent distribution New World cutaneous leishmaniasis imported into Spain

P2210 P2310
Bullous pemphigoid associated with acquired hemophilia A: Atypical secondary syphilis: A case report and review of
A case report uncommon presentations of secondary syphilis

P2312
P2211 The fundamental role of the “ten tasks to prevent disability in
Cicatricial pemphigoid: A series of 5 cases from Singapore Buruli ulcer”

P2212 P2312
Burn-induced pemphigus Botryomycosis: Great response to sulfamethoxazole-trimethoprim

P2313
P2213 Primary cutaneous nocardiosis due to Nocardia transvalensis in an
Hailey-Hailey syndrome immunocompetent patient.

280 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 POSTER EXHIBITS

P2314 P2412
Confocal microscopy of cutaneous larva migrans Transmission electron microscopy for the definitive diagnosis of
disseminated cutaneous histoplasmosis
P2315
Case report of photodynamic therapy failure in the treatment of P2413
cutaneous leishmaniasis: 24 months of clinical and histotological Pityriasis versicolor treated with ketoconazole 2% foam
follow-up
P2414
P2316 Comparison of keratinase activity produced by different fungi
Mycobacterium marinum infection in an aquarium keeper under the induction of hair substrate
P2317 P2415
Clinical manifestations of Buruli ulcer An open-label study of naftifine hydrochloride 1% gel in the
treatment of tinea versicolor
P2318
Ecthyma gangrenosum in a patient with HIV/AIDS P2416
Bilateral tinea nigra palmaris: A case report of multiple lesions
P2319
Metastatic tuberculosis: Case report P2417
Subcutaneous phaeohyphomycosis (mycotic cysts)

P2418
INFECTION — FUNgAL Chromoblastomycosis: A good treatment response of itraconazole
combined with terbinafine
P2400
Majocchi granuloma on hand succesfully treated with griseofulvin

P2401 INFECTION — vIRAL

Chronic granulomatous disease (CGD) in a sexagenarian
P2500

POSTER EXHIBITS
P2402
Candidal intertrigo in hospitalized patients: Etiology, risk factors, Clinical analysis of solid organ transplant recipients with herpetic
and association with systemic candidiosis infection reveals favorable, intermediate, and poor prognosis
cluster-based organ systems involvement
P2403
Cutaneous sporotrichosis in Jilin Province, northeast China: A P2501
report of 457 cases Cutaneous HPV-related immune reconstitution associated disease
(IRAD) in HIV: An under-recognised phenomenon
P2404
Disseminated cutaneous histoplasmosis in patient infected with
human immunodeficiency virus P2502
Drug-resistant herpes simplex virus in HIV-infected patients
P2405
How is laser effective in treatment of onychomycosis? P2503
Acquired epidermodysplasia verruciformis associated with
P2406
Disseminated zygomycosis heralded by a subtle cutaneous finding transplan related immunosuppression

P2407 P2504
A case of cutaneous mucormycosis mimicking sporotrichosis Dermatological manifestations in coinfected patients by hepatitis
C virus and HIV: A prospective and comparative study
P2408
A double-blind, randomized, placebo-controlled study evaluating
the efficacy and safety of naftifine hydrochloride 2% cream and P2505
placebo applied daily for 2 weeks in patients with tinea cruris Clinical profile of sexually transmitted infections in HIV
seropositive patients
P2409
A double-blind, randomized, placebo-controlled study evaluating P2506
the efficacy and safety of naftifine hydrochloride 2% cream, Acyclovir-resistant herpes simplex virus treated with IV foscarnet
naftifine hydrochloride 1% cream, and placebo in tinea pedis and topical cidofovir
P2410
Scedosporium apiospermum skin infection successfully treated P2507
with voriconazole A case of disseminated varicella presenting with abdominal pain
and petiechiae treated with IVIG
P2411
Cutaneous blastomycosis: A case report and review of the literature
For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 281
 POSTER EXHIBITS

P2508 P2610
Case of varicella zoster infection in adult: A disease with increasing Disseminated cutaneous gout: A rapid onset of disease
incidence
P2611
P2509 Dermatologic capecitabine reactions: A case report and review of
Severe primary herpetic gingivostomatitis in a 17-year-old the literature
immunocompetent teenager
P2612
P2510 Scars worsening and thickening as a initial sign of systemic
Disseminated herpes zoster and aseptic meningitis in an sarcoidosis
immunocompetent patient

P2511 LyMPHOMA, CUTANEOUS/MyCOSIS

Complete resolution of chronic multiple verruca vulgaris treated
with quadrivalent human papillomavirus (HPV) vaccine FUNgOIDES
P2512 P2700
Hand-foot-mouth disease: A pre school concern Defining early mycosis fungoides: Validation of a diagnostic
algorithm proposed by the International Society for Cutaneous
Lymphomas (ISCL)
INTERNAL MEDICINE DERMATOLOgy P2701
Programmed death 1 expression in mycosis fungoides and Sézary
P2600
syndrome
Cutaneous vasculitis associated with solid organ malignancies: The
Mayo Clinic experience, 1996-2009
P2702
POSTER EXHIBITS

Hypopigmented mycosis fungoides treated with narrow band

P2601
UVB: A 10-year retrospective study
Low prevalence of necrolytic acral erythema in patients with
chronic hepatitis C virus infection
P2703
Low-dose electron beam radiation to localized symptomatic CTCL
P2602
lesions further improves clinical responses to romidepsin
Telangiectasia macularis eruptiva perstans in a patient with
gastrointestinal stromal tumor
P2704
Analysis of supernumerary clonal gamma TCR gene
P2603
rearrangements in cutaneous T-cell lymphoma (CTCL)
Is minocycline a safe treatment for acne?

P2604 P2705
Psoralen plus ultraviolet A light may be associated with clearing of
Calciphylaxis ulcers treated with sodium thiosulfate
peripheral blood disease in advanced cutaneous T-cell lymphoma
P2605
Cutaneous manifestations of abdominal arteriovenous fistulas
P2706
Mycosis fungoides among veterans exposed to Agent Orange used
in the Vietnam war: Clinicopathologic and genotypic analysis
P2606
Cutaneous amyloidosis: Report of two clinical cases
P2707
Unusual presentation in two cases of primary cutaneous B- cell
P2607
lymphoma
Amicrobial pustulosis associated with anti-interferon gamma
antibodies
P2708
Primary cutaneous aggressive epidermotropic CD8+ cytotoxic
P2608
T-cell lymphoma showing less pronounced epidermotropism
Scar sarcoidosis associated with systemic sarcoidosis: A case report

P2609 P2709
Withdrawn
Sorafenib-induced severe hand-foot skin reaction

282 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 POSTER EXHIBITS

P2710 P2808
Case of mycosis fungoides with atypical immunophenotype Melanoma opportunistic screening: facilitators, barriers and
performance toward detection and recognition by third year
P2711 medical students.
Erythroderma and pruritus of one year of evolution
P2809
P2712 Clinical and dermatoscopic follow-up of acquired melanocytic
CD56 negative extranodal NK/T cell lymphoma, nasal-type with nevi in organ transplant recipients: A preliminary study
cytotoxic T-cell phenotype
P2810
P2713 Sensitivity of pre operative PET/CT imaging for the detection of
Panniculitic-like T-cell lymphoma of unusual presentation
metastatic melanoma in patients with AJCC stage 0 to stage IIC
P2714 P2811
Hemophagocytic syndrome as a complication in a patient with
An unusual manifestation of a metastatic melanoma
Sézary syndrome
P2812
P2715 Amelanotic lentigo maligna: Case report
Primary cutaneous peripheral T-cell lymphoma: Unspecified type
P2813
Performance of an adjuvant melanoma detection tool compared to
MELANOMA AND PIgMENTED LESIONS physicians

P2800 P2814
The insulin-like growth factor-1 receptor involvement in Retrospective study of melanoma in Bay Pines veterans population
melanoma invasion

POSTER EXHIBITS
P2815
P2801 Large dendritic cells in pigmented basal cell carcinoma on
Distance to specialist services and relationship to Breslow thickness reflectance confocal microscopy (RCM)
at presentation of patients with malignant melanoma
P2816
P2802 A case series of fourteen patients with melanoma in situ,
C.A.S.H. as a method for teaching dermoscopy lentiginous type, treated with topical imiquimod therapy reveals
the need for individualized regimens for successful treatment
P2803
Clinical presentation of thin melanoma: A prospective multi- P2817
center study Scalp metastasis of ocular melanoma

P2804 P2818
Circulating benign nevus cells detected by ISET technique: Epiluminescence microscopy of pigmented skin lesions in Brazil’s
Warning for melanoma molecular diagnosis southern area: The region of highest incidence region of melanoma

P2805 P2819
Animal-type malignant melanoma: A case report and discussion Comparing diagnostic sensitivity and specificity for pigmented
lesions in clinical dermatologists vs. a multispectral digital
P2806 dermascopy system
Dermoscopy and in situ hybridization for the diagnosis of
melanoma in the context of a nondiagnostic histology: A pilot P2820
study Pigmented epithelioid melanocytoma (animal type melanoma)

P2807
Prognostic indicators and nature of invasion of lentigo maligna
melanoma compared to superficial spreading melanoma

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 283
 POSTER EXHIBITS

NON-MELANOMA SkIN CANCER P2914

A case of bowenoid papulosis
P2900
A 2-year perspective on the efficacy of capecitabine in tumor P2915
reduction for transplant patients Metastatic eccrine porocarcinoma presenting as painful lesions

P2901 P2916
Bowen’s disease associated with HPV in the finger treated with Primary cutaneous lymphoepithelioma-like carcinoma
immunomodulator
P2917
P2902 A case of Merkel cell carcinoma concurrent with Bowen’s disease
The prevalence of non-melanoma skin cancer associated with UV
nail light exposure P2918
Basal cell carcinoma arising from an epidermal cyst
P2903
Basal cell carcinoma with myoepithelial and neuroendocrine P2919
differentiation Giant squamous cell carcinoma on the palm associated with
human papillomavirus infection
P2904
Multiple squamous cell carcinoma on the hand P2920
Cylindroma with an adjacent basal cell carcinoma: An unusual
P2905 collision tumor
Photodynamic therapy of actinic keratoses with a 5-aminolevulinic
acid-contaninig self-adhesive patch: Short-and long-term (12 P2921
months) efficacy and tolerability Dermoscopic features of vascular patterns in a basal cell carcinoma
of hand: Case report
POSTER EXHIBITS

P2906
Regional audit on squamous cell carcinoma excision margin
PEDIATRIC DERMATOLOgy
P2907
Occurrence of second primary malignancies in Asian patients with P3000
nonmelanoma skin cancer A retrospective review of scalp hyperkeratosis and alopecia in
children of color
P2908
Skin cancer after organ transplantation: Analysis of a controlled P3001
sample from one hospital in Madrid Transient myeloproliferative disorder-associated cutaneous
pustulosis
P2909
Malignant nodular hidradenoma P3002
Investigation of recreational, acute solar UVR exposure: Effects on
P2910 skin of Hispanic and Caucasian children
A large angiosarcoma involving the scalp in a healthy male
P3003
P2911 Kwashiorkor attributed to rice milk in a child with atopic
Merkel cell carcinoma: 4 cases dermatitis and food allergies

P2912 P3004
Scrotal extramammary Pagets disease presenting with histological What is different in skin physiology in neonates and young
features of Bowen disease children of different age groups compared to adults? A randomized
in vivo study
P2913
Primary eccrine ductal carcinoma masquerading as metastatic P3005
squamous cell carcinoma Venous malformations: Age of presentation and tissue type
involvement

284 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 POSTER EXHIBITS

P3006 P3019
Assessment of infant skin development in three regions: New Porokeratotic eccrine ostial and dermal duct nevus treated with a
Jersey, Mumbai, and Beijing combination erbium/CO2 laser: A case and review

P3007 P3020
Quality of life impact of chronic pruritus in children versus adults: Case report: Olmsted syndrome associated with polyp of the
A pilot study external ear

P3008 P3021
Utility of the methotrexate polyglutamate assay in pediatric Midline scalp mass in an infant
patients with inflammatory skin diseases treated with methotrexate
P3022
P3009 Lupus erythematosus profundus presenting as morphea-like lesions
Outpatient visits by children with psoriasis in the United States: involving bilateral malar areas of a 12-year-old Philippine boy with
1979 to 2007 a negative ANA

P3010
The Edmonton Protocol: Safety and efficacy of propanolol in 48
pediatric patients with hemangiomas of infancy
P3011
Erythrokeratoderma variabilis in a Native American
P3012
A case of benign cephalic histiocytosis with clinical and
histological features of juvenile xanthogranuloma on follow-up:
P3023
Beradinelli-Seip congenital lipodystrophy: A case report
P3024
A 3- year-old boy with erythrokeratodermia progressiva
symmetrica (Gottron’s syndrome): a rare erythrokeratoderma
treated with acitretin
P3025
Pityriasis rubra pilaris exuberant type III in children

POSTER EXHIBITS
Additional support for a unifying concept
P3026
P3013 Haemophagocytic lymphohistiocytosis
Impaired skin barrier function in mild and moderate diaper
dermatitis P3027
EB nevi
P3014
Accidental poisoning including near-fatal and fatal toxicity, due to P3028
topical exposure to transdermal patches in children Diffuse cutaneous mastocytosis in the lactating

P3015 P3029
Idiopathic eruptive macular pigmentation: A diagnostic challenge Local hygiene of pediatric vulvovaginitis

P3016 P3030
Albright’s hereditary osteodystrophy associated with additional Acute accidental poisoning by percutaneous absorption in the
material on chromosome 4 pediatric age group

P3017 P3031
Diagnosis and management of pediatric diffuse cutaneous Is the functional skin adaptation complete and competent in
mastocytosis infancy?

P3018 P3032
Uniformity of inorganic, ultraviolet filters in films: Spreadability of Langerhans cell histiocytosis in an infant with penile lesions:
children’s sunscreens A case report

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 285
 POSTER EXHIBITS

P3033 P3109
Becker nevus with ipsilateral breast and areolar hypoplasia The responses to photodynamic therapy in histopathologic
subtypes of precancerous disesases
P3034
Appearance of lush fixed pigmented erythema in a child after use P3110
of phenobarbital Sunscreen use and sun exposure in a population of Japanese
females
P3035
Telangiectasia macularis eruptiva perstans P3111
Facial rejuvenation using novel topical aminolevulinic acid ester
P3036
A case of neonatal lupus erythematosus with cutaneous and P3112
cardiac involvement. UVB-induced apoptosis and autophagy in HaCat cells

P3113
PHOTOBIOLOgy, PHOTOTHERAPy AND Bowen’s disease treated with PDT using ALA in nanostructured
vehicle and two light deliveries: A case report
PHOTOSENSITIvITy DISEASES
P3114
P3100 Alpha-glucosylrutin plus licochalcone A: Enhanced protective
Efficacy of PUVA and narrowband UVB phototherapy for efficacy in PLE
hypopigmented mycosis fungoides
P3115
P3101 Mechanisms to protect skin cells from UV damage
Micronized sunscreen particles were not shown to penetrate
beyond the stratum corneum on human skin in vivo
POSTER EXHIBITS

P3102
PIgMENTARy DISORDERS AND vITILIgO
Pilot trial of deferasirox in the treatment of porphyria cutanea
P3200
tarda
Dendritic cells: Ultrastructural and immunophenotypical changes
upon narrow band-UVB in vitiligo skin
P3103
Comprehensive evaluation of a sunscreen containing only
P3201
inorganic UV filters
Development and validation of a vitiligo-specific health-related
quality of life (VHRQoL) instrument
P3104
The relevance of high SPF products: High SPF sunscreens help
P3202
compensate for under-application
Vitiligo and serological markers: Results from a case-control study
in a Spanish population
P3105
COP1 protein decreases in parallel with differentiation and after
P3203
UVB irradiation in normal human skin
Serum homocysteine is associated with extent of vitiligo vulgaris
P3106 P3204
A comparative study of UVA-1 phototherapy versus betamethasone
The histopathological characteristics in male melasma:
valerate 0.1% cream for chronic vesicular hand eczema
Comparison with female melasma and lentigo
P3107 P3205
A different idea for genital protection in phototherapy units
Is there an association between vitiligo and adrenal insufficiency?
A study with 32 patients
P3108
Change of cathepsin K activity in human skin in vivo after chronic
ultraviolet damage

286 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 POSTER EXHIBITS

P3206 P3305
Case report: Autologous non-cultured melanocyte-keratinocyte Effect of ustekinumab on cardiovascular events: Results from
transplantation procedure in an African American male with post- pooled phase 2 and 3 psoriasis trials
burn injury hypopigmentation.
P3306
Calcipotriene foam is an effective treatment for plaque-type psoriasis
P3207
Comparison of novel skin lightening cream targeting melanogenesis P3307
on multiple-levels to triple combination cream: A preliminary Efficacy and safety of ABT-874 versus methotrexate in patients
melasma study with moderate to severe psoriasis

P3208 P3308
A comparative study of a combination of serial superficial peels Oral apremilast is active in the treatment of moderate to severe
and a topical regimen versus topical regimen in the treatment of plaque psoriasis
postinflammatory hyperpigmentation
P3309
Anxiety in patients with psoriasis
P3209
Multi-ethnic clinical evaluation of a product regimen on P3310
improving photo-damaged skin Resource utilization and costs associated with switching from
etanercept to adalimumab versus dose escalating with etanercept in
P3210 patients with psoriasis
Post-botulinum toxin depigmentation
P3311
P3211 A comparison of the classic versus the linear-scaling method
Hydroquinone free skin brightening with novel cream calculations of the psoriasis area and severity index as evaluation of
plaque psoriasis in patients treated with tasocitinib (CP-690,550)
P3212 P3312

A rare complication of a common procedure
PSORIASIS AND OTHER
PAPULOSqUAMOUS DISORDERS
P3300
Obesity, waist circumference, weight change, and the risk of
psoriasis (PS) and psoriatic arthritis (PSA) in US women
P3301
Pro-inflammatory and anti-inflammatory cytokines and bone
mineral density in psoriatic arthritis
P3302
A global approach to psoriatic patients through PASI score and
Skindex-29
P3303
Pooled safety and efficacy results from two phase III trials
comparing briakinumab with etanercept and placebo for the
treatment of moderate to severe psoriasis
P3304
An evaluation of the effect of tasocitinib (CP-690,550), an oral
Janus kinase inhibitor, on pruritus in patients with plaque psoriasis
POSTER EXHIBITS
Long-term safety and efficacy of ABT-874 for the treatment of
moderate to severe psoriasis. Interim analysis from an open-label
extension study
P3313
Imiquimod-induced psoriasis: A case report, review of the
literature, and pathophysiologic mechanism
P3314
Behavioral factors that associate with psoriasis expression amongst
monozygotic twins
P3315
Sustained improvement in skin disease-specific quality of life in
patients with moderate to severe psoriasis receiving ustekinumab
maintenance therapy: Long-term results from Phoenix 1
P3316
Safety and efficacy of two regimens involving clobetasol spray,
0.05% and calcitriol ointment, 3 µg/g for moderate plaque psoriasis
P3317
Quality of life under treatment with fumaric acid ester in patients
with severe psoriasis vulgaris: A prospective evaluation

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 287
 POSTER EXHIBITS
P3318
Tasocitinib (CP-690,550), an oral Janus kinase inhibitor,
significantly improves the symptoms of moderate-to-severe
psoriasis with early onset of efficacy
P3319
Efficacy and safety of alefacept in combination with narrow-band
UVB compared to alefacept alone in subjects with moderate to
severe psoriasis: Results of the Canadian Alefacept Phototherapy
Psoriasis Study
P3320
Long-term efficacy and safety of maintenance versus intermittent
infliximab therapy for moderate-to-severe plaque-type psoriasis:
The RESTORE2 trial
P3321
PSOLAR: Update of a multicenter registry of patients with psoriasis
who are candidates for systemic therapy including biologics
P3322
Etanercept therapy for moderate to severe plaque psoriasis with
involvement of the scalp
P3323
A randomized, double-blind, placebo-controlled study to evaluate
the efficacy of ammonium lactate lotion 12% (Lac-Hydrin®)
and halobetasol propionate ointment 0.05% (Ultravate®) in the
treatment and maintenance of psoriasis
POSTER EXHIBITS
P3324
Flare of pustular psoriasis after initiating ustekinumab therapy
P3325
Copper and ceruloplasmin as markers of severity in psoriasis
P3326
The efficacy of retreatment with adalimumab in moderate-to-
severe psoriasis following treatment interruption after 33 weeks or
>3 years of 40 mg every-other-week dosing
P3327
A quantitative comparison of RhoA and RhoB expression in psoriasis
P3328
Adalimumab treatment of psoriasis patients following suboptimal
responses to etanercept, methotrexate, or phototherapy: Efficacy
across subgroups in an open-label study
P3329
Rapid response of nail psoriasis to clobetasol 8% nail lacquer
P3330
The itch severity item: Mediation modeling and measurement
characteristics from a phase 2b trial of tasocitinib (CP-690,550),
an oral Janus kinase inhibitor, in patients with plaque psoriasis
288 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
P3331
Tasocitinib (CP-690,550), an oral Janus kinase inhibitor,
consistently improves the clinical signs of moderate-to-severe
psoriasis in different body regions
P3332
Comparison of psoriasis sign and symptom reduction and
complete clearance with adalimumab versus etanercept
P3333
Health care outcomes associated with continuous use of
adalimumab versus continuous and intermittent use of etanercept
in patients with psoriasis
P3334
Persistent impairment of work productivity and activity in patients
with longer disease duration of psoriasis with hand/foot involvement
P3335
Chemical compatibility of calcipotriene 0.005% foam in
combination with topical steroids
P3336
The long-term safety of adalimumab: An analysis of all adalimumab
exposure in all moderate to severe psoriasis clinical trials
P3337
Improved quality of life with apremilast (APR) in the treatment of
psoriasis: Results from a phase 2b randomized controlled study
P3338
ESPRIT: Interim results from a 10-year postmarketing surveillance
registry of adalimumab treatment for moderate to severe psoriasis
P3339
ABT-874 versus etanercept and placebo in patients with moderate
to severe chronic plaque psoriasis: Efficacy and safety results
P3340
Efficacy and safety of adalimumab in treatment of moderate
to severe hidradenitis suppurativa: Results from the placebo-
controlled portion of a phase II, randomized, double-blind study
P3341
Adalimumab provides health-related quality-of-life benefits for
patients with psoriasis with suboptimal response to etanercept,
methotrexate, or phototherapy
P3342
Effects of ABT-874 treatment on health-related quality of life and
work productivity and activity impairment in patients with psoriasis
P3343
Bilateral comparison study on the order of application of
combination clobetasol proprionate spray and calcitriol ointment
in the treatment of plaque psoriasis
 POSTER EXHIBITS

P3344 P3357
ABT-874 versus methotrexate in moderate to severe psoriasis: Efficacy and safety outcomes for psoriasis patients who interrupt,
Effects on health-related quality-of-life outcomes then resume, adalimumab therapy

P3345 P3358
Sustained efficacy of ustekinumab for the treatment of moderate to Ustekinumab use and experience outside of the clinical trial setting:
severe psoriasis in initial responders continuing with maintenance A comprehensive, retrospective chart review of a small, private
therapy through year 3 practice

P3346
Ustekinumab improves overall skin response and health-related
quality of life in a subset of moderate to severe psoriasis patients
with psoriatic arthritis: Analysis of PHOENIX 1 and 2
P3347
Successful treatment of moderate to severe plaque psoriasis of the
scalp with clobetasol propionate spray, 0.05%
P3348
Safety and bioavailability of two calcipotriene formulations in
subjects with mild to moderate plaque-type psoriasis
P3349
Analysis of vitamin D analogs for treatment of psoriasis
P3350
Fatigue outcomes following withdrawal from and retreatment
with adalimumab among patients maintained on adalimumab for
moderate to severe psoriasis
P3359
Is progesterone also pro-psoriasis? Two case reports
P3360
Health-related quality-of-life outcomes in patients with moderate to
severe psoriasis treated with ABT-874 versus etanercept or placebo
P3361
Health-related quality of life in patients with moderate to severe
psoriasis: Effects of treatment with ABT-874 versus etanercept or
placebo
P3362
Achieving long-term sustained response is associated with
improvements in patient-reported outcomes in patients with
psoriasis treated with ABT-874
P3363
A case of inverse psoriasis responding to botulinum toxin type-A

POSTER EXHIBITS
P3364
P3351 Dermoscopy can be useful in differentiating scalp psoriasis from
Joint pain improvement in patients on etanercept therapy for seborrheic dermatitis
moderate to severe psoriasis
P3365
P3352 Treatment with calcitriol ointment 3 µg/g for 26 – 52 weeks
NF-kB cutaneous expression under cyclosporine effect in patients resulted in stable or improved plaque psoriasis disease severity in
with plaque psoriasis most patients

P3353 P3366
Efficacy of adalimumab is consistent across body weight in Combination therapy with cyclosporine A and an anti-TNFα
patients with moderate-to-severe psoriasis: Subanalysis of REVEAL agent (adalimumab) in the treatment of severe psoriasis

P3354
Adalimumab for severe palmo-plantar psoriasis: An open-label
pilot trial in nine patients
P3355
Resource utilization and costs associated with adalimumab or
etanercept for moderate to severe psoriasis in a real-world setting
P3367
A case of generalized annular lichen planus
P3368
Developing a symptom-based patient-reported outcome
instrument for use in regulated psoriasis clinical trials

P3356
Efficacy and safety results of ABT-874 versus etanercept and placebo
in patients with moderate to severe chronic plaque psoriasis

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 289
 POSTER EXHIBITS

P3369 P3405
Prevalence of metabolic syndrome in Thai psoriasis-patients at a Comparison study of evolving monopolar radiofrequency
tertiary care center technologies on face and body
P3370 P3406
Concomitant treatment with adalimumab and narrow band UVB
Adjunctive measures to reduce discomfort of Botox Cosmetic®
for severe plaque psoriasis: Report of 3 cases

P3371 P3407
An isomorphic response of psoriasis in tattoo Safety and efficacy evaluation of a novel technology in transdermal
delivery of glycolic acid as skin conditioning agent
P3372
Population pharmacokinetics of tasocitinib (CP-690,550) in
patients with moderate-to-severe plaque psoriasis
SURgERy — DERMATOLOgIC
P3373
Determination of genetic markers for responsiveness to alefacept P3500
(Amevive®) Preoperative assessment of extramammary Paget disease using
conventional fluorescence diagnosis
P3374
A recalcitrant acrodermatitis continua of Hallopeau successfully P3501
treated with etanercept Compared therapeutic efficacy between melamine foam sponge
and cotton wool bud in the cryotherapy of viral wart:
P3375 A comparative split-lesion study
Psoriasiform dermatitis with hyperkeratosis due to zinc deficiency

P3376 P3502
Psoriasis and non-alcoholic fatty liver disease: A review Malignant fibrous histiocytoma in the setting of chronic
lymphocytic leukemia and non-Hodgkin lymphoma
POSTER EXHIBITS

SURgERy — COSMETIC P3503

P3400
A phase II, randomized, double-blind clinical trial comparing
safety and efficacy of a metallic cannula vs. a standard needle for
dermal filler injections (hyaluronic acid gel) for the treatment of
nasogenian folds
P3401
Comparison of duration of action and onset of formulations of
botulinum toxin type A (BoNTA) in the forehead
P3402
Motives for cosmetic procedures in Saudi women
P3403
Onset and durability of response of abobotulinumtoxina for
reduction of glabellar lines in patients with skin of color
P3404
Facial lipoatrophy secondary to lupus profundus: Treatment with
large particle hyaluronic acid
Pigmented dermatofibrosarcoma protuberans treated with Mohs
micrographic surgery
P3504
The art and science of surgical margins for the dermatopathologist
P3505
Reducing the pain of lidocaine administration by controlling angle
of injection
P3506
The efficacy and safety of new total combination techniques
compared with classic sequential combination therapy with
punch, fractional and long-pulsed Er-YAG laser for the treatment
of acne scars
P3507
Mohs micrographic surgery for the treatment of cellular
neurothekeoma and review of its use in surgical management of
benign tumors

290 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 POSTER EXHIBITS

P3508 P3606
Simple algorithms for calculating the total operative area for Deep dermis remodeling with a micro-ablative fractional carbon
proper coding of rhombic transposition flaps dioxide laser in a vectorial pass technique: 24 months of follow up

P3509 P3607
Treatment of massive rhinophyma by decortication Permanent tattoos after parenteral over-the-counter iron injections
for anemia: A case report
P3510
Atypical infiltrative cutaneous lesion on a finger P3608
Acanthosis nigricans of the lips treated with carbon dioxide laser
P3511 ablation
Quantifying and characterizing adverse events in dermatologic
surgery P3609
Intense pulsed light therapy or Q-switched laser for solar lentigo
P3512 evaluated by skin physiological examination and reflectance-mode
A review of sutures and other skin closure materials confocal microscopy

P3513 P3610
A case of foreign body granulomas following soft-tissue The new fashion vectorial way to improve fat remodeling and
augmentation of the buttocks by a non-licensed practitioner sculping the face using noninvasive in-motion selective ultrasound
(Accent Ultra): 12 months of follow-up
P3514
Treatment of trichoepitheliomas on a patient with Brooke-Spiegler
syndrome WOUND HEALINg AND ULCERS
P3700
SURgERy — LASER

POSTER EXHIBITS
A modern hydrogen peroxide cream for wound healing

P3600 P3701
A comparative study: 30% trichloroacetic acid vs ultrapulse CO2 Complications of electrodesiccation for the removal of cutaneous
laser in treatment of xanthelasma palpebrarum neurofibromas

P3601 P3702
Successful treatment of upper and lower extremity port-wine stains A comparison of facial wound healing agents following removal of
using high-fluence pulsed dye laser therapy initiated in infancy dermatosis papulosa nigra in an African American population

P3602 P3703
Axillary sweating decreased by laser hair removal with the diode Effect of a combination of a propyl-betaine and polyhexanide-
810-nm system containing irrigation solution on methicillin-resistant
Staphylococcus aureus (MRSA) biofilms in porcine model
P3603
Long-term data for low-energy intense pulsed light for hair P3704
removal at home Post-procedural wound healing efficacy and safety in a clinical
setting: A comparison of topical antibiotic ointment versus skin
P3604 protectant ointment
Clinical evaluation of a new fractionated bipolar radiofrequency
device for the treatment of photoaging P3705
Topical dapsone gel as a novel treatment for atrophie blanche
P3605 ulcerations
Clinicohistological study of low fluence, multiple pass Q-switched
Nd:YAG laser treatment for melasma in Asian skin

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 291
 3 8 A c a d e m
th
y A r t E x h i b i t

The 38th Annual Art Exhibit of the American Academy of Dermatology will be
presented in the Ernest N. Morial Convention Center (Lobby E). This ever popular
attraction presents works created by Academy members and their family members.

Entry Requirements Interested Academy members should note the following entry requirements:

1. Eligibility The completed application form and check in US funds

Artwork by any member of the American Academy of Dermatology, spouse must be received by December 20, 2010.
or child, through 22 years old. A duplicate must be attached to the back or underside of each art piece.
Copies of the application form are acceptable for additional entries.
2. Hanging Fees
$20.00 per item. Make checks payable to the American Academy 6. Liability and Indemnification
of Dermatology. Checks must be in US funds. Checks drawn in non-US funds Care will be exercised in handling and carrying objects; however, all entries
will be returned and artwork will not be permitted to be displayed are accepted with the understanding that no liability for loss, damage, or
injury is assumed by the Academy or its agents. Artists may wish to insure
3. Categories their artwork while it is at the exhibition, and in transit.
Artists must declare a media. Ribbons will be awarded in the following
categories: 7. Judging
If the number of entries warrant it, 1st, 2nd, 3rd, and Honorable Mention
will be given in each category.
• Mixed Media • Oil Paintings • Arts and Crafts
• Water Color • Acrylic Paintings • Photography 8. Acknowledgements
• Drawings and Prints • Sculpture • Art in Dermatologic Photography The Academy is grateful to the chair and members of the Art Exhibit Task Force
4. Limitations and Special Instructions for their work in organizing and administering the 38th Annual Art Exhibit.
Entries will be limited to a total of eight for the show; four pieces only
Nancy Linsey Wong, MD Chair
will be accepted in any one media. All entries will be received in hand at
Kathleen Marie Ting, MD Member
the Ernest N. Memorial Convention Center on Friday, February 4 from 3:00 p.m.
Linwood G. Bradford, MD Member
until 4:30 p.m. and should be picked up Monday, February 7 between 5:00 p.m.
Yulianna E Russak, MD Member
and 6:00 p.m. Please no early pickups.
Paul Benedetto, MD Resident Member
All artwork must be ready for hanging, framed or stretched
and with hanging wire. 9. Art Exhibit Hours
5. Applications/Information Saturday, February 5
Sunday, February 6
7:00 a.m. to 5:00 p.m.
7:00 a.m. to 5:00 p.m.
Complete the application on the next page and send to:
Monday, February 7 7:00 a.m. to 5:00 p.m.
Nancy Wong
970 Palo Alto Ave
Palo Alto, CA 94301
 Attach this stub to the back of the art piece. Enclose this stub with entry fee made payable to the
American Academy of Dermatology and mail prior to December 20, 2010
American Academy of Dermatology
38th Annual Art Exhibit to: Nancy Wong, M.D., 970 Palo Alto Ave, Palo Alto, CA 94301
FEBRUARY 5-7, 2011 HANGING FEE OF $20.00 PER ARTICLE.
NEW ORLEANS, LA

ARTIST
ARTIST q Member q Spouse/partner q Child

ADDRESS
ADDRESS
CITY
CITY
STATE ZIP

STATE ZIP TITLE

PHONE MOBILE E-MAIL

TITLE
MEDIUM (Check the most appropriate designation):
q Mixed Media q Oil q Acrylics
MEDIUM q Drawing & Prints q Water Color q Photography
q Scuplture q Arts & Crafts q Arts in Derm Photo
Price if for sale: $_______________ q Not for sale q 12 & under q 13-19
Height______in. x Width______in. of art
Attach this stub to art piece. Price if for sale: $_________________ q Not for sale
All artwork must be ready for hanging. Artists may donate the proceeds of any sale in support of Academy Programs/Activities. Please
contact Jan Edgar, Director of Development, in Room C33 at the Miami Beach Convention
Center, or after the meeting, at (847)240-1037, jedgar@aad.org.

NEW! The Academy invites artists to donate their work for a silent auction with proceeds LIABILITY AND INDEMNIFICATION
benefiting the AAD Camp Discovery Endowment. Sunday, February 6, 2011, 9 a.m. – 3:00 Care will be exercised in handling and carrying objects; however, all entries
p.m., Winners will be announced at the Art Exhibit at 3:30 p.m. on Sunday.
are accepted with the understanding that no liability for loss, damage, or
SILENT AUCTION AGREEMENT injury is assumed by the Academy or its agents. Artists may wish to insure
their artwork while it is at the exhibition, and in transit.
I, _____________________________________, wish to contribute the item/s listed
below to the silent auction held during The American Academy of Dermatology Annual The undersigned does hereby agree to protect, indemnify, hold harmless and
Meeting. defend the Academy, its officers, directors, agents, members, servants, and
employees from and against any and all claims, liabilities, losses, damages
and expenses, resulting from the participation in the Academy Art Exhibit.
ITEM DESCRIPTION

ART ENTRY DATE/TIME: 3:00 p.m. – 4:30 p.m.

VALUE MINIMUM BID Friday, February 4, 2011

DONOR SHOULD BE LISTED AS ART REMOVAL DATE/TIME: 5:00 p.m. – 6:00 p.m.
Monday, February 7, 2011
ADDRESS

CITY
SIGNATURE
STATE ZIP
DATE
PHONE MOBILE E-MAIL

SIGNATURE DATE

All donors must attend the silent Auction. Items that do not receive bids will be returned
to the donor.
Your in-kind contribution may be tax deductible. We will send you a letter acknowledging
your contribution and the value you have placed on the item(s) or service(s) donated. It is
the sole responsibility of the donor to determine the value of the contribution in accordance
with IRS regulations. Donors are encouraged to consult their legal and financial advisers for
additional information.
 Our mission is to advocate
on behalf of individuals
with skin disease.

This is accomplished in the following ways:

The Coalition of Skin Diseases supports the growth of member organizations

through the sharing of mutual concerns.

The Coalition of Skin Diseases increases the pace of discovery of a cure while
improving the quality of life for those affected.

The Coalition of Skin Diseases also works closely with the National Institute
of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to coordinate
research efforts for all skin diseases. Members of the Coalition meet annually
with members of Congress and testify when selected before the appropriations
committees to educate Congress and the public on the seriousness of skin
diseases while stressing the need for increased medical funding.

Patient Support Organizations

Basal Cell Carcinoma Nevous Syndrome/Gorlin Syndrome

(BCCNS Life Support Network)

Cicatricial Alopecia Research Foundation (CARF)

Cutaneous Lymphoma Foundation

Dystrophic Epidermolysis Bullosa (DebRA of America, Inc.)

Foundation for Ichthyosis and Related Skin Types (F.I.R.S.T.)

International Hyperdihrosis Society

International Pemphigus Pemphigoid Foundation (IPPF)

National Alopecia Areata Foundation (NAAF)

National Eczema Association (NEA)

National Foundation For Ectodermal Dysplasias (NFED)

National Psoriasis Foundation (NPF)

Nevus Outreach, Inc.

Pachyonychia Congenita Project (PC PROJECT)

PXE International

The Sturge-Weber Foundation (SWF)

Vitiligo Support International (VSI)

Xeroderma Pigmentosum Society, Inc.

4301 Connecticut Avenue, NW, Suite 404, Washington, DC 20008-2369

Tel: (202) 243-0115
info@coalitionofskindiseases.org www.coalitionofskindiseases.org
 For moderate to severe plaque psoriasis

Introducing a real
sharpshooter
NEW spray nozzle more precisely hits a
range of plaques on the body and scalp
• Efficacy of Clobex® Spray confirmed in multiple clinical
trials totaling more than 2000 patients1-3
—An average of 80% of patients clear or almost
clear at 4 weeks1,2

NEW NOZZLE!
Important Safety Information
CLOBEX® (clobetasol propionate) Spray, 0.05%, is a super-high potent topical corticosteroid formulation
indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface
area (BSA) in patients 18 years of age or older.
Clobetasol propionate has been shown to suppress the HPA axis at the lowest doses tested.
Clobetasol propionate spray should not be used in the treatment of rosacea or perioral dermatitis
and should not be used on the face, groin or axillae.
In controlled clinical trials, the following adverse reactions have been reported: burning, pruritus,
hyperpigmentation, infections and infestations, nasopharyngitis, upper respiratory tract infection,
and skin and subcutaneous tissue disorders.
Treatment should be limited to 4 weeks. Treatment beyond 2 weeks should be limited
to localized lesions of moderate to severe plaque psoriasis that have not sufficiently
improved after the initial 2 weeks of treatment with CLOBEX® Spray, 0.05%.
CLOBEX® Spray, 0.05%, should not exceed 50 g (59 mL or 2 fl oz) per week.
CLOBEX® Spray, 0.05%, is not recommended for use on anyone
younger than 18 years of age. Pregnancy Category C.
Please see adjacent page for brief summary of Prescribing Information.

Log on to www.psoriasispro.com
CLOBEX
®
the incidence of pups with cysts on the kidney at higher dose levels during the preweaning period. The weights
of the epididymides and testes were significantly reduced at higher dosages. Despite these changes, there
(clobetasol propionate) Spray, 0.05% were no effects on the mating and fertility of the offspring.
Rx Only There are no adequate and well-controlled studies of the teratogenic potential of clobetasol propionate in
BRIEF SUMMARY pregnant women. CLOBEX® (clobetasol propionate) Spray, 0.05% should be used during pregnancy only if
INDICATIONS AND USAGE: CLOBEX® (clobetasol propionate) Spray, 0.05% is a super-high potent topical the potential benefit justifies the potential risk to the fetus.
corticosteroid formulation indicated for the treatment of moderate to severe plaque psoriasis affecting up to Nursing Mothers: Systemically administered corticosteroids appear in human milk and could suppress
20% body surface area (BSA) in patients 18 years of age or older (see PRECAUTIONS). Treatment should be growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known
limited to 4 consecutive weeks. The total dosage should not exceed 50 g (59 mL or 2 fl. oz.) per week. whether topical administration of corticosteroids could result in sufficient systemic absorption to produce
Before prescribing for more than 2 weeks, any additional benefits of extending treatment to 4 weeks should detectable quantities in breast milk. Because many drugs are excreted in human milk, caution should be
be weighed against the risk of HPA axis suppression. exercised when CLOBEX® (clobetasol propionate) Spray, 0.05% is administered to a nursing woman.
Patients should be instructed to use CLOBEX® (clobetasol propionate) Spray, 0.05% for the minimum amount Pediatric Use: Use in patients under 18 years of age is not recommended, because safety has not been
of time necessary to achieve the desired results (see PRECAUTIONS). established and because numerically high rates of HPA axis suppression were seen with other clobetasol
Use in patients under 18 years of age is not recommended because safety has not been established and propionate topical formulations. Safety and effectiveness in pediatric patients treated with CLOBEX®
because numerically high rates of HPA axis suppression were seen with other clobetasol propionate (clobetasol propionate) Spray, 0.05% have not been established (see PRECAUTIONS: General).
topical formulations (see PRECAUTIONS: Pediatric Use). Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults
CONTRAINDICATIONS: CLOBEX® (clobetasol propionate) Spray, 0.05% is contraindicated in patients who are of HPA axis suppression and Cushing’s syndrome when they are treated with topical corticosteroids. They are
hypersensitive to clobetasol propionate, to other corticosteroids, or to any ingredient in this preparation. therefore also at greater risk of glucocortisteroid insufficiency during and/or after withdrawal of treatment.
PRECAUTIONS: Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants
General: Clobetasol propionate is a highly potent topical corticosteroid that has been shown to and children.
suppress the HPA axis at the lowest doses tested. HPA axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial
In studies evaluating the potential for hypothalamic-pituitary-adrenal (HPA) axis suppression, using the hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal
Cosyntropin Stimulation Test, CLOBEX® (clobetasol propionate) Spray, 0.05% demonstrated rates of suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation.
suppression that were comparable after 2 and 4 weeks of twice-daily use (19% and 15-20%, respectively), in Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
adult patients with moderate to severe plaque psoriasis (≥ 20%BSA). In these studies, HPA axis suppression Geriatric Use: Clinical studies of CLOBEX® (clobetasol propionate) Spray, 0.05% did not include sufficient
was defined as serum cortisol level ≤18 g/dL 30-min post cosyntropin stimulation. (See CLINICAL numbers of patients aged 65 and over to adequately determine whether they respond differently than younger
PHARMACOLOGY). patients. In the two Phase 3 studies, 21 of the 240 patients (9%) were over the age of 65. In general, dose
Patients with acute illness or injury may have increased morbidity and mortality with intermittent HPA axis selection for an elderly patient should be made with caution, usually starting at the low end of the dosing
suppression. Patients should be instructed to use CLOBEX® (clobetasol propionate) Spray, 0.05% for the range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant
minimum amount of time necessary to achieve the desired results (see INDICATIONS AND USAGE). disease or other drug therapy.
Systemic absorption of topical corticosteroids has caused reversible adrenal suppression with the ADVERSE REACTIONS: In controlled, clinical trials with CLOBEX® (clobetasol propionate) Spray, 0.05%,
potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing’s the most common adverse reaction was burning at the site of application [40% of subjects treated with
syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of CLOBEX® (clobetasol propionate) Spray, 0.05% and 47% of subjects treated with Spray Vehicle]. Other
topical corticosteroids while on treatment. commonly reported adverse reactions for CLOBEX® (clobetasol propionate) Spray, 0.05% and Spray Vehicle,
HPA axis suppression has not been evaluated in psoriasis patients treated with CLOBEX® (clobetasol respectively, are noted in Table 2.
propionate) Spray, 0.05% who are less than 18 years old. Pediatric patients may be more susceptible to Table 2 - Commonly Occurring Adverse Events
systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios (see
PRECAUTIONS: Pediatric Use). The potential increase in systemic exposure does not correlate with any proven Clobetasol Propionate Vehicle
benefit, but may lead to an increased potential for hypothalamic-pituitary-adrenal (HPA) axis suppression. Adverse Reaction 0.05% Spray Spray
Conditions which increase systemic absorption include the application of the more potent steroids, use over (N=120) (N=120)
large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients applying a
topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence System Organ Class
of adrenal suppression (see laboratory tests below). If adrenal suppression is noted, an attempt should be
made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. General disorders and administration site conditions 50 (42%) 56 (47%)
Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, Application site atrophy 0 (0%) 1 (1%)
signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic
corticosteroids. For information on systemic supplementation, see prescribing information for those products. Application site burning 48 (40%) 56 (47%)
If irritation develops, CLOBEX® (clobetasol propionate) Spray, 0.05% should be discontinued and appropriate
therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure Application site dryness 2 (2%) 0 (0%)
to heal rather than noting a clinical exacerbation, as with most topical products not containing corticosteroids. Application site irritation 1 (1%) 0 (0%)
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should
be instituted. If a favorable response does not occur promptly, use of CLOBEX® (clobetasol propionate) Spray, Application site pain 1 (1%) 2 (2%)
0.05% should be discontinued until the infection has been adequately controlled.
CLOBEX® (clobetasol propionate) Spray, 0.05% should not be used in the treatment of rosacea or Application site pigmentation changes 1 (1%) 0 (0%)
perioral dermatitis, and should not be used on the face, groin, or axillae. Application site pruritus 4 (3%) 3 (3%)
Information for Patients: Patients using topical corticosteroids should receive the following information and
instructions: Infections and infestations 17 (14%) 12 (10%)
• This medication is to be used as directed by the physician and should not be used longer than the Influenza 0 (0%) 2 (2%)
prescribed time period.
• This medication should not be used for any disorder other than that for which it was prescribed. Nasopharyngitis 6 (5%) 3 (3%)
• The treated skin area should not be bandaged, otherwise covered, or wrapped so as to be occlusive
unless directed by the physician. Pharyngitis streptococcal 1 (1%) 0 (0%)
• Patients should wash their hands after applying the medication. Upper respiratory tract infection 10 (8%) 2 (2%)
• Patients should report any signs of local or systemic adverse reactions to the physician.
• Patients should inform their physicians that they are using CLOBEX® (clobetasol propionate) Spray, 0.05% Skin and subcutaneous tissue disorders 4 (3%) 2 (2%)
if surgery is contemplated.
• This medication is for external use only. It should not be used on the face, underarms, or groin area. Eczema asteatotic 2 (2%) 0 (0%)
Also avoid contact with the eyes and lips.
• As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement Other adverse events occurred at rates less than 1.0%. Most local adverse events were rated as mild to
is seen within 2 weeks, contact the physician. moderate and they are not affected by age, race or gender. The following additional local adverse reactions
• Patients should not use more than 50 g (59 mL or 2 fl. oz.) per week of CLOBEX® (clobetasol propionate) Spray, 0.05%. have been reported with topical corticosteroids. They may occur more frequently with the use of occlusive
Instructions to the Pharmacist: dressings and higher potency corticosteroids, including clobetasol propionate. These reactions are listed in an
1. Remove the spray pump from the wrapper approximate decreasing order of occurrence: folliculitis, acneiform eruptions, hypopigmentation, perioral
2. Remove and discard the cap from the bottle dermatitis, allergic contact dermatitis, secondary infection, striae and miliaria.
3. Keeping the bottle vertical, insert the spray pump into the bottle and turn clockwise until well-fastened Systemic absorption topical corticosteroids has produced hypothalamic-pituitary-adrenal (HPA) axis
4. Dispense the bottle with the spray pump inserted suppression manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
Laboratory Tests: The cosyntropin stimulation test may be helpful in evaluating patients for HPA axis suppression. OVERDOSAGE: Topically applied CLOBEX® (clobetasol propionate) Spray, 0.05% can be absorbed in sufficient
Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term animal studies have not been performed amount to produce systemic effects. (See PRECAUTIONS).
to evaluate the carcinogenic potential of clobetasol propionate. DOSAGE AND ADMINISTRATION: CLOBEX® (clobetasol propionate) Spray, 0.05% should be sprayed directly
Clobetasol propionate was negative in the in vitro mammalian chromosomal aberration test and in the in vivo onto the affected skin areas twice daily and rubbed in gently and completely. (See INDICATIONS AND USAGE).
mammalian erythrocyte micronucleus test. CLOBEX® (clobetasol propionate) Spray, 0.05% contains a super-high potent topical corticosteroid;
The effect of subcutaneously administered clobetasol propionate on fertility and general reproductive toxicity therefore treatment should be limited to 4 weeks. Treatment beyond 2 weeks should be limited to
was studied in rats at doses of 0, 12.5, 25, and 50 g/kg/day. Males were treated beginning 70 days before localized lesions of moderate to severe plaque psoriasis that have not sufficiently improved after the
mating and females beginning 15 days before mating through day 7 of gestation. A dosage level of less than initial 2 weeks of treatment with CLOBEX® (clobetasol propionate) Spray, 0.05%.
12.5 g/kg/day clobetasol propionate was considered to be the no-observed-effect-level (NOEL) for paternal The total dosage should not exceed 50 g (59 mL or 2 fluid ounces) per week because of the potential for the
and maternal general toxicity based on decreased weight gain and for male reproductive toxicity based on drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
increased weights of the seminal vesicles with fluid. The female reproductive NOEL was 12.5 g/kg/day (ratio Therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks,
of animal dose to proposed human dose of 0.03 on a mg/m2/day basis) based on reduction in the numbers reassessment of diagnosis may be necessary.
of estrous cycles during the pre-cohabitation period and an increase in the number of nonviable embryos at Use in pediatric patients younger than 18 years is not recommended because of the potential for HPA axis
higher doses. suppression (see PRECAUTIONS: Pediatric Use).
Pregnancy: Teratogenic effects: Pregnancy Category C. Unless directed by physician, CLOBEX® (clobetasol propionate) Spray, 0.05% should not be used with
Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at occlusive dressings.
relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application HOW SUPPLIED: CLOBEX® (clobetasol propionate) Spray, 0.05% is supplied in a white HDPE bottle with a
to laboratory animals. white polypropylene cap and white LDPE liner in the following sizes:
Clobetasol propionate is absorbed percutaneously, and when administered subcutaneously it was a significant 2 fl oz/59 mL NDC 0299-3849-02
teratogen in both the rabbit and the mouse. Clobetasol propionate has greater teratogenic potential than 4.25 fl oz/125 mL NDC 0299-3849-04
steroids that are less potent. Store under controlled room temperature conditions of 20˚C - 25˚C (68˚F - 77˚F) with excursions permitted
The effect of clobetasol propionate on pregnancy outcome and development of offspring was studied in the rat. between 15˚C and 30˚C (59˚F and 86˚F). Do not freeze, refrigerate or store above 30˚C. Spray is flammable;
Clobetasol propionate was administered subcutaneously to female rats twice daily (0, 12.5, 25, and 50 keep away from heat or flame.
g/kg/day) from day 7 of presumed gestation through day 25 of lactation or day 24 presumed gestation for US Patent Nos: 5,972,920; 5,990,100 and foreign patents pending.
those rats that did not deliver a litter. The maternal NOEL for clobetasol propionate was less than Marketed by: GALDERMA LABORATORIES, L.P., Fort Worth, Texas 76177 USA
12.5 g/kg/day due to reduced body weight gain and feed consumption during the gestation period. The Manufactured by: CPL, Mississauga, Ontario, Canada L5N 6L6, Made in Canada.
reproductive NOEL in the dams was 25 g/kg/day (ratio of animal dose to proposed human dose of 0.07 on GALDERMA is a registered trademark.
a mg/m2/day basis) based on prolonged delivery at a higher dose level. The no-observed-adverse-effect-level www.psoriasispro.com
(NOAEL) for viability and growth in the offspring was 12.5 g/kg/day (ratio of animal dose to proposed human 2003739-0906
dose of 0.03 on a mg/m2/day basis) based on incidence of stillbirths, reductions in pup body weights on days Revised: September 2006
1 and 7 of lactation, increased pup mortality, increases in the incidence of umbilical hernia, and increases in

References: 1. Clobex® Spray Prescribing Information. September 2006. Galderma Laboratories, L.P. 2. Koo JYM. Relevance of the COBRA Trial in current psoriasis practice. Cutis. 2007;80(suppl 5):4-11.
3. Menter A, Abramovits W, Colón LE, Johnson LA, Gottschalk RW. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the
treatment of moderate to severe plaque psoriasis. J Drugs Dermatol. 2009;8:52-57.
© 2010 Galderma Laboratories, L.P.
GALDERMA and CLOBEX are registered trademarks.
Galderma Laboratories, L.P., 14501 N. Freeway, Fort Worth, TX 76177
CLO-604 Printed in USA 04/10
 EIGHT STRENGTHS
for More Precise SOLODYN Dosing

SOLODYN Tablets 45 mg, 90 mg, and 135 mg formulations are also available for patients weighing 99–109 lbs (45–49 kg), 187–212 lbs (85–96 kg), and
277–300 lbs (126–136 kg), respectively.

SOLODYN is indicated to treat only inflammatory
lesions of non-nodular moderate to severe acne
vulgaris in patients 12 years of age and older.
SOLODYN did not demonstrate any effect on
non-inflammatory lesions. Safety of SOLODYN
has not been established beyond 12 weeks
of use. This formulation of minocycline has not
been evaluated in the treatment of infections. To
reduce the development of drug-resistant bacteria
as well as to maintain the effectiveness of other
antibacterial drugs, SOLODYN should be used
only as indicated.
Important Safety Information for SOLODYN Tablets
• The most commonly reported side effects were • In rare cases, photosensitivity has been reported.
headache, fatigue, dizziness, and pruritus.
• Should not be used during pregnancy nor by
• Minocycline, like other tetracyclines, can cause individuals of either gender who are attempting to
fetal harm when administered to a pregnant conceive a child; concurrent use of tetracyclines
woman. with oral contraceptives may render oral
contraceptives less effective.
• Tetracycline drugs should not be used during tooth
development (last half of pregnancy and up to • This drug is contraindicated in persons who have
8 years of age) as they may cause permanent shown hypersensitivity to any of the tetracyclines.
discoloration of teeth.
• Safety beyond 12 weeks of use has
• Pseudomembranous colitis has been reported with not been established.
nearly all antibacterial agents and may range from
mild to life-threatening; therefore, it is important
to consider this diagnosis in patients who present
with diarrhea subsequent to the administration of
antibacterial agents.
• Central nervous system side effects, including
light-headedness, dizziness, and vertigo, have
been reported with minocycline therapy.

See following pages for Brief Summary of Full Prescribing Information.

SOLODYN is a registered trademark of Medicis Pharmaceutical Corporation.
SOL 10-028 03/30/11 Now with Greater Dosing Precision
BRIEF SUMMARY
(see package insert for full
prescribing information)
SOLODYN®
(minocycline HCl, USP) Extended Release
Tablets
Rx Only
KEEP OUT OF REACH OF CHILDREN
INDICATIONS AND USAGE
Indication
SOLODYN is indicated to treat only
inflammatory lesions of non-nodular
moderate to severe acne vulgaris in
patients 12 years of age and older.
Limitations of Use
SOLODYN did not demonstrate any effect
on non-inflammatory acne lesions. Safety
of SOLODYN has not been established
beyond 12 weeks of use. This formulation
of minocycline has not been evaluated in
the treatment of infections.
To reduce the development of drug-
resistant bacteria as well as to maintain the cases, consideration should be given to
effectiveness of other antibacterial drugs,
SOLODYN should be used only as indicated protein supplementation, and treatment
(see Warnings and Precautions).
CONTRAINDICATIONS
This drug is contraindicated in persons
who have shown hypersensitivity to any of
the tetracyclines.
WARNINGS AND PRECAUTIONS
Teratogenic Effects
A. MINOCYCLINE, LIKE OTHER
TETRACYCLINE-CLASS ANTIBIOTICS,
CAN CAUSE FETAL HARM WHEN
ADMINISTERED TO A PREGNANT
WOMAN. IF ANY TETRACYCLINE IS USED
DURING PREGNANCY OR IF THE PATIENT
BECOMES PREGNANT WHILE TAKING
THESE DRUGS, THE PATIENT SHOULD
BE APPRISED OF THE POTENTIAL
HAZARD TO THE FETUS.
SOLODYN should not be used during
pregnancy or by individuals of either
gender who are attempting to conceive
a child (see Nonclinical Toxicology & Use
in Specific Populations).
B. THE USE OF DRUGS OF THE
TETRACYCLINE-CLASS DURING
TOOTH DEVELOPMENT (LAST HALF OF Central nervous system side effects
PREGNANCY, INFANCY, AND CHILDHOOD including light-headedness, dizziness or
UP TO THE AGE OF 8 YEARS) MAY
CAUSE PERMANENT DISCOLORATION
OF THE TEETH (YELLOW-GRAY-BROWN). symptoms should be cautioned about
This adverse reaction is more common
during long-term use of the drug but
has been observed following repeated
short-term courses. Enamel hypoplasia
has also been reported. TETRACYCLINE
DRUGS, THEREFORE, SHOULD NOT BE
USED DURING TOOTH DEVELOPMENT.
C. All tetracyclines form a stable calcium has been associated with the use
complex in any bone-forming tissue. A
decrease in fibula growth rate has been been reported to cause or precipitate
observed in premature human infants
given oral tetracycline in doses of 25
mg/kg every 6 hours. This reaction was manifestations include headache and
shown to be reversible when the drug
was discontinued.
Results of animal studies indicate that in infants. Although signs and symptoms
tetracyclines cross the placenta, are
found in fetal tissues, and can cause
retardation of skeletal development
on the developing fetus. Evidence of
embryotoxicity has been noted in animals exists. Patients should be questioned for
treated early in pregnancy (see Use in visual disturbances prior to initiation of Laboratory Monitoring
Specific Populations). treatment with tetracyclines and should be Periodic laboratory evaluations of organ
routinely checked for papilledema while on systems, including hematopoietic, renal
Pseudomembranous Colitis
treatment. Concomitant use of isotretinoin and hepatic studies should be performed.
Pseudomembranous colitis has been and minocycline should be avoided because Appropriate tests for autoimmune syndromes
reported with nearly all antibacterial isotretinoin, a systemic retinoid, is also should be performed as indicated.
agents and may range from mild known to cause pseudotumor cerebri. ADVERSE REACTIONS
to life-threatening. Therefore, it is
important to consider this diagnosis Autoimmune Syndromes Clinical Trial Experience
Tetracyclines have been associated with the
in patients who present with diarrhea Because clinical trials are conducted under
subsequent to the administration of development of autoimmune syndromes. prescribed conditions, adverse reaction
antibacterial agents. The long-term use of minocycline in the rates observed in the clinical trial may not
treatment of acne has been associated reflect the rates observed in practice.
Treatment with antibacterial agents with drug-induced lupus-like syndrome,
alters the normal flora of the colon and The following table summarizes selected
autoimmune hepatitis and vasculitis.
may permit overgrowth of clostridia. adverse reactions reported in clinical trials
Sporadic cases of serum sickness have
Studies indicate that a toxin produced by at a rate of ≥1% for SOLODYN.
presented shortly after minocycline
Clostridium difficile is a primary cause of use. Symptoms may be manifested by Selected Treatment-Emergent Adverse
“antibiotic-associated colitis”. fever, rash, arthralgia, and malaise. In Reactions in at least 1% of Clinical
symptomatic patients, liver function tests, Trial Subjects
After the diagnosis of pseudomembranous
ANA, CBC, and other appropriate tests
colitis has been established, therapeutic Adverse Reactions SOLODYN PLACEBO
should be performed to evaluate the (1 mg/kg) N=364
measures should be initiated. Mild
patients. Use of all tetracycline-class drugs N=674 (%) (%)
cases of pseudomembranous colitis
should be discontinued immediately.
usually respond to discontinuation of At least one treatment- 379 (56) 197 (54)
the drug alone. In moderate to severe Photosensitivity emergent event
Photosensitivity manifested by an Headache 152 (23) 83 (23)
management with fluids and electrolytes, exaggerated sunburn reaction has been Fatigue 62 (9) 24 (7)
observed in some individuals taking Dizziness 59 (9) 17 (5)
with an antibacterial drug clinically effective tetracyclines. This has been reported Pruritus 31 (5) 16 (4)
against Clostridium difficile colitis. rarely with minocycline. Patients should Malaise 26 (4) 9 (3)
Hepatotoxicity minimize or avoid exposure to natural or Mood alteration 17 (3) 9 (3)
artificial sunlight (tanning beds or UVA/B
Post-marketing cases of serious liver injury, Somnolence 13 (2) 3 (1)
treatment) while using minocycline. If
including irreversible drug-induced hepatitis Urticaria 10 (2) 1 (0)
patients need to be outdoors while using
and fulminant hepatic failure (sometimes Tinnitus 10 (2) 5 (1)
fatal) have been reported with minocycline minocycline, they should wear loose-fitting Arthralgia 9 (1) 2 (0)
use in the treatment of acne. clothes that protect skin from sun exposure Vertigo 8 (1) 3 (1)
and discuss other sun protection measures Dry mouth 7 (1) 5 (1)
Metabolic Effects with their physician.
Myalgia 7 (1) 4 (1)
The anti-anabolic action of the tetracyclines
may cause an increase in BUN. While Serious Skin/Hypersensitivity Postmarketing Experience
this is not a problem in those with normal Reaction Adverse reactions that have been reported
renal function, in patients with significantly Post-marketing cases of anaphylaxis with minocycline hydrochloride use in a
impaired function, higher serum levels of and serious skin reactions such as variety of indications include:
tetracycline-class antibiotics may lead to Stevens-Johnson syndrome and erythema Skin and hypersensitivity reactions:
azotemia, hyperphosphatemia, and acidosis. multiforme have been reported with fixed drug eruptions, balanitis, erythema
If renal impairment exists, even usual oral minocycline use in treatment of acne. multiforme, Stevens-Johnson syndrome,
or parenteral doses may lead to excessive Tissue Hyperpigmentation anaphylactoid purpura, photosensitivity,
systemic accumulations of the drug Tetracycline-class antibiotics are known pigmentation of skin and mucous
and possible liver toxicity. Under such to cause hyperpigmentation. Tetracycline membranes, hypersensitivity reactions,
conditions, lower than usual total doses therapy may induce hyperpigmentation in angioneurotic edema, anaphylaxis.
are indicated, and if therapy is prolonged,many organs, including nails, bone, skin,
serum level determinations of the drug Autoimmune conditions: polyarthralgia,
eyes, thyroid, visceral tissue, oral cavity pericarditis, exacerbation of systemic lupus,
may be advisable. (teeth, mucosa, alveolar bone), sclerae and
pulmonary infiltrates with eosinophilia,
Central Nervous System Effects heart valves. Skin and oral pigmentation transient lupus-like syndrome.
has been reported to occur independently
Central nervous system: pseudotumor
of time or amount of drug administration,
cerebri, bulging fontanels in infants,
vertigo have been reported with minocycline whereas other tissue pigmentation has
been reported to occur upon prolonged decreased hearing.
therapy. Patients who experience these
administration. Skin pigmentation includes Endocrine: thyroid discoloration, abnormal
driving vehicles or using hazardous diffuse pigmentation as well as over sites thyroid function.
machinery while on minocycline therapy. of scars or injury.
Oncology: papillary thyroid cancer.
These symptoms may disappear during Development of Drug Resistant
therapy and usually rapidly disappear Oral: glossitis, dysphagia, tooth
Bacteria
when the drug is discontinued. discoloration.
Bacterial resistance to the tetracyclines
Benign Intracranial Hypertension may develop in patients using SOLODYN, Gastrointestinal: enterocolitis, pancreatitis,
Pseudotumor cerebri (benign intracranial therefore, the susceptibility of bacteria hepatitis, liver failure.
hypertension) in adults and adolescents associated with infection should be Renal: reversible acute renal failure.
considered in selecting antimicrobial
therapy. Because of the potential for Hematology: hemolytic anemia,
of tetracyclines. Minocycline has
drug-resistant bacteria to develop during thrombocytopenia, eosinophilia.
pseudotumor cerebri, the hallmark the use of SOLODYN, it should be used only Preliminary studies suggest that use of
of which is papilledema. Clinical as indicated. minocycline may have deleterious effects
on human spermatogenesis (see Nonclinical
Superinfection
blurred vision. Bulging fontanels have been As with other antibiotic preparations, use Toxicology).
associated with the use of tetracyclines of SOLODYN may result in overgrowth of DRUG INTERACTIONS
nonsusceptible organisms, including fungi.
Anticoagulants
of pseudotumor cerebri resolve after If superinfection occurs, the antibiotic
Because tetracyclines have been shown
discontinuation of treatment, the possibility should be discontinued and appropriate
to depress plasma prothrombin activity,
for permanent sequelae such as visual therapy instituted.
patients who are on anticoagulant therapy
loss that may be permanent or severe
may require downward adjustment of their
anticoagulant dosage.
Penicillin
Since bacteriostatic drugs may interfere
with the bactericidal action of penicillin, it is
advisable to avoid giving tetracycline-class
drugs in conjunction with penicillin.
Methoxyflurane
The concurrent use of tetracycline and
methoxyflurane has been reported to result
in fatal renal toxicity.
Antacids and Iron Preparations
Absorption of tetracyclines is impaired by
antacids containing aluminum, calcium
or magnesium and iron-containing
preparations.
Low Dose Oral Contraceptives
In a multi-center study to evaluate the
effect of SOLODYN on low dose oral
contraceptives, hormone levels over one
menstrual cycle with and without
SOLODYN 1 mg/kg once-daily were
measured. Based on the results of this
trial, minocycline-related changes in
estradiol, progestinic hormone, FSH and
LH plasma levels, of breakthrough
bleeding, or of contraceptive failure, can
not be ruled out. To avoid contraceptive
failure, female patients are advised to use
a second form of contraceptive during
treatment with minocycline.
Drug/Laboratory Test Interactions
False elevations of urinary catecholamine
levels may occur due to interference with
the fluorescence test.
USE IN SPECIFIC POPULATIONS
Pregnancy
Teratogenic Effects: Pregnancy category D
(see Warnings and Precautions)
SOLODYN should not be used during
pregnancy. If the patient becomes pregnant
while taking this drug, the patient should be
apprised of the potential hazard to the fetus
and stop treatment immediately.
There are no adequate and well-controlled
studies on the use of minocycline in
pregnant women. Minocycline, like other
tetracycline-class drugs, crosses the
placenta and may cause fetal harm when
administered to a pregnant woman.
Rare spontaneous reports of congenital
anomalies including limb reduction have
been reported with minocycline use in
pregnancy in post-marketing experience.
Only limited information is available
regarding these reports; therefore, no
conclusion on causal association can
be established.
Minocycline induced skeletal malformations
(bent limb bones) in fetuses when
administered to pregnant rats and rabbits in
doses of 30 mg/kg/day and 100 mg/kg/day,
respectively, (resulting in approximately
3 times and 2 times, respectively, the
systemic exposure to minocycline
observed in patients as a result of use of
SOLODYN). Reduced mean fetal body
weight was observed in studies in which
minocycline was administered to pregnant
rats at a dose of 10 mg/kg/day (which
resulted in approximately the same level of
systemic exposure to minocycline as that
observed in patients who use SOLODYN).
Minocycline was assessed for effects on evaluate the carcinogenic potential of contains minocycline hydrochloride
peri- and post-natal development of rats in minocycline. A structurally related equivalent to 65 mg minocycline, supplied
a study that involved oral administration to compound, oxytetracycline, was found as follows:
pregnant rats from day 6 of gestation to produce adrenal and pituitary tumors
through the period of lactation (postpartum in rats. NDC 99207-463-30 Bottle of 30
day 20), at dosages of 5, 10, or 50 Mutagenesis—Minocycline was not The 80 mg extended release tablets are
mg/kg/day. In this study, body weight gain mutagenic in vitro in a bacterial reverse gray, unscored, coated, and debossed
was significantly reduced in pregnant mutation assay (Ames test) or CHO/HGPRT with “DYN-080” on one side. Each tablet
females that received 50 mg/kg/day mammalian cell assay in the presence contains minocycline hydrochloride
(resulting in approximately 2.5 times the or absence of metabolic activation. equivalent to 80 mg minocycline, supplied
systemic exposure to minocycline observed Minocycline was not clastogenic in vitro as follows:
in patients as a result of use of SOLODYN). using human peripheral blood lymphocytes
No effects of treatment on the duration of NDC 99207-466-30 Bottle of 30
or in vivo in a mouse micronucleus test.
the gestation period or the number of live The 90 mg extended release tablets are
pups born per litter were observed. Gross Impairment of Fertility—Male and
yellow, unscored, coated, and debossed
external anomalies observed in F1 pups female reproductive performance in
with “DYN-090” on one side. Each tablet
(offspring of animals that received rats was unaffected by oral doses of
contains minocycline hydrochloride
minocycline) included reduced body size, minocycline of up to 300 mg/kg/day (which
equivalent to 90 mg minocycline, supplied
improperly rotated forelimbs, and reduced resulted in up to approximately 40 times the
as follows:
size of extremities. No effects were level of systemic exposure to minocycline
observed in patients as a result of use of NDC 99207-461-30 Bottle of 30
observed on the physical development,
behavior, learning ability, or reproduction SOLODYN). However, oral administration of NDC 99207-461-10 Bottle of 100
100 or 300 mg/kg/day of minocycline to
of F1 pups, and there was no effect on
male rats (resulting in approximately 15 to The 105 mg extended release tablets are
gross appearance of F2 pups (offspring
of F1 animals). 40 times the level of systemic exposure to purple, unscored, coated, and debossed
minocycline observed in patients as a result with “DYN-105” on one side. Each tablet
Nursing Mothers of use of SOLODYN) adversely affected contains minocycline hydrochloride
Tetracycline-class antibiotics are excreted spermatogenesis. Effects observed at 300 equivalent to 105 mg minocycline, supplied
in human milk. Because of the potential for mg/kg/day included a reduced number as follows:
serious adverse effects on bone and tooth of sperm cells per gram of epididymis,
development in nursing infants from the NDC 99207-467-30 Bottle of 30
an apparent reduction in the percentage
tetracycline-class antibiotics, a decision of sperm that were motile, and (at 100 The 115 mg extended release tablets are
should be made whether to discontinue and 300 mg/kg/day) increased numbers green, unscored, coated, and debossed
nursing or discontinue the drug, taking into of morphologically abnormal sperm cells. with “DYN-115” on one side. Each tablet
account the importance of the drug to the Morphological abnormalities observed in contains minocycline hydrochloride
mother (see Warnings and Precautions). sperm samples included absent heads, equivalent to 115 mg minocycline,
misshapen heads, and abnormal flagella. supplied as follows:
Pediatric Use
SOLODYN is indicated to treat only Limited human studies suggest that NDC 99207-464-30 Bottle of 30
inflammatory lesions of non-nodular minocycline may have a deleterious effect
moderate to severe acne vulgaris The 135 mg extended release tablets are
on spermatogenesis.
in patients 12 years and older. pink (orange-brown), unscored, coated,
SOLODYN should not be used by individuals and debossed with “DYN-135” on one
Safety and effectiveness in pediatric
patients below the age of 12 has not of either gender who are attempting to side. Each tablet contains minocycline
conceive a child. hydrochloride equivalent to 135 mg
been established.
HOW SUPPLIED/STORAGE AND minocycline, supplied as follows:
Use of tetracycline-class antibiotics below
the age of 8 is not recommended due to HANDLING NDC 99207-462-30 Bottle of 30
How Supplied
the potential for tooth discoloration (see NDC 99207-462-10 Bottle of 100
Warnings and Precautions). SOLODYN (minocycline HCl, USP) Extended
Release Tablets are supplied as aqueous Storage
Geriatric Use film coated tablets containing minocycline Store at 25ºC (77ºF); excursions are
Clinical studies of SOLODYN did not hydrochloride equivalent to 45 mg, 55 mg, permitted to 15º-30ºC (59º-86ºF)
include sufficient numbers of subjects aged 65 mg, 80 mg, 90 mg, 105 mg, 115 mg [See USP Controlled Room Temperature].
65 and over to determine whether they or 135 mg minocycline, are supplied Handling
respond differently from younger subjects. as follows.
Keep out of reach of children
Other reported clinical experience has not
identified differences in responses between The 45 mg extended release tablets are Protect from light, moisture, and
the elderly and younger patients. In general, gray, unscored, coated, and debossed excessive heat.
dose selection for an elderly patient should with “DYN-045” on one side. Each tablet Dispense in tight, light-resistant container
be cautious, usually starting at the low end contains minocycline hydrochloride with child-resistant closure.
of the dosing range, reflecting the greater equivalent to 45 mg minocycline, supplied
as follows:
frequency of decreased hepatic, renal, or U.S. Patent 5,908,838* and Patents Pending
cardiac function, and concomitant disease NDC 99207-460-30 *90 mg is also covered by U.S. Patents
Bottle of 30 7,541,347 and 7,544,373
or other drug therapy. NDC 99207-460-10 Bottle of 100
OVERDOSAGE Manufactured for:
The 55 mg extended release tablets are Medicis, The Dermatology Company
In case of overdosage, discontinue pink, unscored, coated, and debossed
medication, treat symptomatically and Scottsdale, AZ 85256
with “DYN-055” on one side. Each tablet
institute supportive measures. Minocycline contains minocycline hydrochloride August 2010
is not removed in significant quantities by equivalent to 55 mg minocycline, supplied
hemodialysis or peritoneal dialysis. as follows: 17110163
NONCLINICAL TOXICOLOGY
NDC 99207-465-30 Bottle of 30
Carcinogenesis, Mutagenesis,
The 65 mg extended release tablets are
Impairment of Fertility
blue, unscored, coated, and debossed
Carcinogenesis—Long-term animal with “DYN-065” on one side. Each tablet
studies have not been performed to
 TECHNICAL EXHIBITS

TECHNICAL EXHIBIT HourS

Saturday, February 5 . . . . . . . . . . . . . . . . . 10:00 a.m. – 5:00 p.m.
Sunday, February 6. . . . . . . . . . . . . . . . . . . 10:00 a.m. – 5:00 p.m.
Monday, February 7 . . . . . . . . . . . . . . . . . . 10:00 a.m. – 5:00 p.m.

The American Academy of Dermatology invites you to visit the technical exhibits as part of your educational experience at the Annual
Meeting. The products displayed in the technical exhibits area and the uses suggested by the manufacturers do not represent an
endorsement by nor imply that the products have been evaluated or approved by the American Academy of Dermatology.

For your convenience, the technical exhibiting companies are listed alphabetically and by the products/services they offer. They are
identified by the following codes:
Associations, Foundations, and Medical Societies Office Equipment and Supplies
Clothing Other Medical Equipment and Supplies
Computer Software and Hardware Pharmaceutical
Cosmetics and Skin Care Photographic Equipment and Imaging Services
Disposable Medical Supplies Phototherapy Supplies and Equipment
EMR/EHR Systems Practice Management
Laboratory Services Publishing and Educational Materials
Laser and Laser Supplies Surgical Instruments
Market Research
Medical Lighting Equipment A listing by product/services can be found beginning on page 330.

The Academy strives to provide complete, accurate, and timely Acuderm, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3221
information, and regrets any inadvertent errors or omissions. 5370 NW 35th Terrace,
Ft. Lauderdale, FL 33309
TECHNICAL EXHIBITS

Phone: (954)733-6935, Fax: (954)486-3602

Email: cust-service@acuderm.com
ALpHABETICAL DIrECTory of
EXHIBITINg CompANIES Product Category: Disposable Medical Supplies, Other Medical
Companies confirmed as of August 12, 2010 Equipment and Supplies, Surgical Instruments

3gen, LLC/DermLite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 321 ADVANCE/merion matters . . . . . . . . . . . . . . . . . . . . . . . . 2622

31521 Rancho Viejo Rd, #104 2900 Horizon Drive
King of Prussia, PA 19406
San Juan Capistrano, CA 92675
Phone: (800)355-5627, Fax: (610)270-3185
Phone: (949)481-6384, Fax: (949)240-7492 Email: mmarx@advanceweb.com
Email: info@3genllc.com
Product Category: Publishing and Educational Materials
Product Category: Office Equipment and Supplies, Other Medical
Equipment and Supplies, Photographic Equipment and Imaging Advanced Bio-Technologies, Inc . . . . . . . . . . . . . . . . . . . . 311
Services 1100 Satellite Blvd NW
Suwanee, GA 30024
A Phone: (678)684-1426, Fax: (678)684-1422
Abbott . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2721 Email: info@advancedbiotech.com
200 Abbott Park Rd
Abbott Park, IL 60064 Product Category: Cosmetics and Skin Care, Pharmaceutical
Phone: (847)937-6100
Advanced Skin & Hair Inc . . . . . . . . . . . . . . . . . . . . . . . 1467
Product Category: Pharmaceutical 12121 Wilshire Blvd, Suite 1012
Los Angeles, CA 90025
AccessDermatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2367
Phone: (310)442-9700, Fax: (310)943-1540
Calle Provenza 388
Barcelona, 08025 Email: salesteam@revivogen.com
Spain
Phone: (34)-93-4592220, Fax: (34)-93-4581535 Product Category: Cosmetics and Skin Care
Email: service@prous.com

Product Category: Publishing and Educational Materials

298 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 TECHNICAL EXHIBITS

Aeph International Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . 1971 American Board of Dermatology . . . . . . . . . . . . . . . . . . . 3716

Office 404, 4th Floor 1 Ford Place
Albany House 324/326 Detroit, MI 48202
London, WIB 3HH Phone: (313)874-1089, Fax: (313)872-3221
United Kingdom Email: maguiar@hfhs.org
Phone: (44)207504-1323, Fax: (44)207504-1322
Email: revyouth_service@hotmail.com Product Category: Associations, Foundations, and Medical Societies

Product Category: Other Medical Equipment and Supplies American Society for Dermatologic Surgery . . . . . . . . . . 1033
5550 Meadowbrook Dr, Ste 120
Aerolase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2065 Rolling Meadows, IL 60008
777 Old Saw Mill River Rd Phone: (847)956-0900
Tarrytown, NY 10591 Email: mjones@asds.net
Phone: (914)345-8300, Fax: (914)345-8303
Email: information@aerolase.com Product Category: Associations, Foundations, and Medical Societies

Product Category: Laser and Laser Supplies American Society for mohs Surgery . . . . . . . . . . . . . . . . 3719
5901 Warner Ave., PMB 391
Aesthetic guide, The . . . . . . . . . . . . . . . . . . . . . . . . . . . 1371 Huntington Beach, CA 92649
120 Vantis, Suite 470 Phone: (800)616-2767, Fax: (714)379-6272
Aliso Viejo, CA 92656 Email: execdir@mohssurgery.org
Phone: (949)830-5409, Fax: (949)830-8944
Product Category: Associations, Foundations, and Medical Societies
Email: info@miinews.com
Amgen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2141, 2632
Product Category: Publishing and Educational Materials, Market
Research One Amgen Center Drive, M/S 36-1-A
Thousand Oaks, CA 91320

TECHNICAL EXHIBITS
Allergan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 641 Phone: (800)262-6436
2525 Dupont Drive Email: amgen@amgen.com
Irvine, CA 92612
Phone: (714)246-4500, Fax: (714)246-4971 Product Category: Pharmaceutical

Product Category: Cosmetics and Skin Care Anthony products/gio pelle . . . . . . . . . . . . . . . . . . . . . . 3613
7740 Records St
Alma Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2357 Indianapolis, IN 46226
485 Half Day Road, Suite 100 Phone: (800)428-1610, Fax: (317)543-3289
Buffalo Grove, IL 60089 Email: customerse@anthonyproducts.com
Phone: (224)377-2128, Fax: (646)805-1312
Email: marketing@almalasers.com Product Category: Cosmetics and Skin Care, Medical Lighting
Equipment, Other Medical Equipment and Supplies, Surgical
Product Category: Laser and Laser Supplies, Other Medical Instruments
Equipment and Supplies
Apira Science . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3929
Alopecia Areata & Eczema resource Sharing Alliance . . . 3934 100 Bayview Circle #2200
14 Mitchell Blvd Newport Beach, CA 92660
San Rafael, CA 94903 Phone: (949)854-9900, Fax: (949)854-9922
Phone: (415)472-3780, Fax: (415)472-5343
Email: info@naaf.org
Product Category: Laser and Laser Supplies
Product Category: Associations, Foundations, and Medical Societies
Applisonix Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1473
3 Pekeris St
American Academy of Dermatology . . . . . . . . . . . . . . . . . 3623
930 E Woodfield Rd Rehovot, 76702
Schaumburg, IL 60173 Israel
Phone: (866)503-SKIN (7546), Fax: (847)240-1859 Phone: (972)8-936-3604, Fax: (972)-8-936-3614
Email: mrc@aad.org Email: sharon@applisonix.com

Product Category: Associations, Foundations, and Medical Societies Product Category: Laser and Laser Supplies

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 299
 TECHNICAL EXHIBITS

Astellas pharma uS, Inc . . . . . . . . . . . . . . . . . . . . . . . . . 2031 Beijing Syntech Laser Co, Ltd . . . . . . . . . . . . . . . . . . . . . 4041
3 Parkway North 5F, No 1 Building, No 65 Jiancaicheng West Road
Deerfield, IL 60015 Xisanqi, Haidian District
Phone: (847)317-8000, Fax: (847)317-5953 Beijing, 100096
China
Product Category: Pharmaceutical Phone: (86)10-8293-9866x215, Fax: (86)10-8293-0928
Email: lina@syntechlaser.com
Auriga International . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2411
Avenue Victor Hugo 32 Product Category: Laser and Laser Supplies, Medical Lighting
Braine-L’Alleud, B-1420 Equipment
Belgium
Phone: (32)2-384-5377, Fax: (32)2-384-1397 Big C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 662
Email: fabienne@auriga-int.com 20655 S Western Ave #116
Torrance, CA 90501
Product Category: Cosmetics and Skin Care, Pharmaceutical Phone: (888)668-2442, Fax: (310)618-9996
Email: sales@bigc.com
Aurora Diagnostics-DErmDX . . . . . . . . . . . . . . . . . . . . . . 3755
11025 RCA Center Drive, Suite 300 Product Category: Photographic Equipment and Imaging Services,
Palm Beach Gardens, FL 33410 Other Medical Equipment and Supplies
Phone: (561)626-5512, Fax: (561)626-4530
Email: Info@auroradx.com Biodermis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 460
6000 S Eastern Ave, Ste 9-D
Product Category: Computer Software and Hardware, EMR/EHR Las Vegas, NV 89119
Systems, Laboratory Services Phone: (800)374-3376, Fax: (702)260-4646
Email: sales@biodermis.com
Austrian Bidding Committee WCD 2015 . . . . . . . . . . . . . 3715
MCI Berlin Office,Markgrafenstr 56 Product Category: Cosmetics and Skin Care, Other Medical
Berlin, 10117 Equipment and Supplies
TECHNICAL EXHIBITS

Germany
Phone: (49)3020-4590, Fax: (49)3020-45950 Biopelle, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2211
Email: biddingcommittee@wcd2015.com 780 W 8 Mile Road
Ferndale, MI 48220
Product Category: Associations, Foundations, and Medical Societies Phone: (866)424-6735, Fax: (877)548-7100

Avantik Biogroup . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3628 Product Category: Cosmetics and Skin Care

32 Commerce St
Springfield, NJ 07081 Biopsy Diagnostics, pC . . . . . . . . . . . . . . . . . . . . . . . . . 1771
Phone: (888)392 8411, Fax: (973)232-0076 122 Riverwalk Blvd, Ste A
Ridgeland, SC 29936
Product Category: Laboratory Services, Other Medical Equipment Phone: (843)379-2939, Fax: (843)379-2949
and Supplies Email: carla@bx-dx.com

Axia medical Solutions . . . . . . . . . . . . . . . . . . . . . . . . . 3253 Product Category: Laboratory Services

2015 Camino Vida Roble, Ste L
Carlsbad, CA 92011 bioskin gmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3842
Phone: (866)494-4466, Fax: (760)931-8266 Burchardstrasse 17
Email: customerservic@axiamedical.com Hamburg, 20095
Germany
Product Category: Cosmetics and Skin Care, Laboratory Services, Phone: (49)40-60-68-97-0, Fax: (49)40-60-68-97-30
Pharmaceutical Email: info@bioskin.de

Product Category: Cosmetics and Skin Care, Pharmaceutical

B Boiron . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1368
Beiersdorf Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 625
6 Campus Blvd
187 Danbury Road Newtown Square, PA 19073
Wilton, CT 06897 Phone: (610)325-7464, Fax: (610)325-7480
Phone: (203)563-5800, Fax: (203)563-5800
Product Category: Pharmaceutical
Product Category: Cosmetics and Skin Care

300 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 TECHNICAL EXHIBITS

Brazilian Society of Dermatological Surgery . . . . . . . . . . 1874 CareCredit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218

Rua Mato Grosso 306-cj 1411 2995 Red Hill Ave, Ste 100
Sao Paulo, SP 01239-040 Costa Mesa, CA 92626
Brazil Phone: (800)300-3046, Fax: (866)874-4093
Phone: (55)11-2114-6388, Fax: (55)11-2114-6389 Email: tseymour@carecredit.com
Email: sbcd@sbcd.org.br
Product Category: Practice Management
Product Category: Associations, Foundations, and Medical
Societies Caris DX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3841
6655 North MacArthur Blvd
Brazilian Society of Dermatology . . . . . . . . . . . . . . . . . . 1872 Irving, TX 75039
Avenida Rio Branco, 39-18 Andar Phone: (214)277-8700, Fax: (214)596-2280
Rio De Janeiro, RJ 20090-000 Email: clientservices@carisdx.com
Brazil
Phone: (55)21 -2253-6747, Fax: (55)21-2253-6747 Product Category: Laboratory Services
Email: sbd@sbd.org.br
Centocor ortho Biotech Inc . . . . . . . . . . . . . . . . . . . . . . . 1440
Product Category: Associations, Foundations, and Medical 800 Ridgeview Drive
Societies Horsham, PA 19044
Phone: (610)651-6000, Fax: (215)325-4087
Brymill Cryogenic Systems . . . . . . . . . . . . . . . . . . . . . . . 1764
105 Windermere Ave Product Category: Pharmaceutical
Ellington, CT 06029
Phone: (860)875-2460, Fax: (860)872-2371 Chemotechnique Diagnostics/Dormer Laboratories . . . . . . 2126
91 Kelfield Street, Unit 5
Product Category: Other Medical Equipment and Supplies, Office Toronto, ON M9W 5A3
Equipment and Supplies Canada

TECHNICAL EXHIBITS
Phone: (416)242-6167, Fax: (416)242-9487
Buffalo filter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3840
Email: info@dormer.com
595 Commerce Drive
Buffalo, NY 14228
Phone: (716)835-7000, Fax: (716)835-3414 Product Category: Cosmetics and Skin Care, Disposable Medical
Email: smoke-info@buffalofilter.com Supplies, Other Medical Equipment and Supplies, Pharmaceutical

Product Category: Disposable Medical Supplies, Laser and Laser ChopSaver . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1266
Supplies, Other Medical Equipment and Supplies, Surgical P.O. Box 20692
Instruments Indianapolis, IN 46220
Phone: (317)259-1447, Fax: (317)259-1447
Business Enterprise SrL . . . . . . . . . . . . . . . . . . . . . . . . . 764 Email: info@chopsaver.com
Via Pantelleria, 98
Trapani, IT 91100 Product Category: Cosmetics and Skin Care
Italy
Phone: (39)0923567818, Fax: (39)0923560354
Email: ben@ben.it Chromogenex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3354
Units 1 and 2 Heol Rhosyn, Dafen
Product Category: Other Medical Equipment and Supplies Llanelli, South Wales SA14 8QG
United Kingdom
Phone: (44)1554-755444; Fax: (44)1554-755333
C Email: sgeers@chromogenex.com
Canfield Imaging Systems . . . . . . . . . . . . . . . . . . . . . . . . 341
253 Passaic Ave Clarisonic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1866
Fairfield, NJ 07004 13222 SE 30th St, Ste A1
Phone: (800)815-4330, Fax: (973)276-0339 Bellevue, WA 98005
Email: info@canfieldsci.com Phone: (425)463-3787
Email: samold@clarisonic.com

Product Category: Cosmetics and Skin Care

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 301
 TECHNICAL EXHIBITS

ClearfX Skin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1775 Conmed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1134

12358 Tiara St 525 French Rd
Valley Village, CA 91607 Utica, NY 13502
Phone: (818)430-9953 Phone: (800)448-6506, Fax: (800)438-3051
Email: info@conmed.com
Product Category: Cosmetics and Skin Care, Other Medical
Equipment and Supplies Product Category: Office Equipment and Supplies

Clinique Laboratories LLC . . . . . . . . . . . . . . . . . . . . . . . . . 327 Conrex pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . 315

767 5th Avenue 5121 West Chester Pike
New York, NY 10153 Newton Square, PA 19038
Phone: (212)572-3800 Phone: (610)355-2454, Fax: (610)355-2453
Email: info@seshaskin.com
Product Category: Cosmetics and Skin Care
Product Category: Cosmetics and Skin Care
CNH pillow Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1666
802 Orange St Coolibar, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1565
Abilene, TX 79601 2401 Edgewood Ave South
Phone: (325)672-2162, Fax: (325)677-2410 St. Louis Park, MN 55426
Email: cnhpillow@yahoo.com Phone: (800)926-6509, Fax: (952)922-1455
Email: service@coolibar.com
Product Category: Other Medical Equipment and Supplies
Product Category: Clothing
Coalition of Skin Diseases . . . . . . . . . . . . . . . . . . . . . . . 3712
4301 Connecticut Ave N W, Suite 404 CoolTouch Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 845
Washington, DC 20008 9085 Foothills Blvd
Phone: (202) 243-0115 Roseville, CA 95747
TECHNICAL EXHIBITS

Email: romerocm@earthlink.net Phone: (800)378-7222, Fax: (916)677-1901

Email: service@newstarlasers.com
Product Category: Association, Foundations and Medical Societies
Product Category: Laser and Laser Supplies
Cobalt medical Supply . . . . . . . . . . . . . . . . . . . . . . . . . . 3913
P O Box 367 Coria Laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3341
Pequannock, NJ 07440 3810 Hulen Steet
Phone: (888)350-3790, Fax: (201)465-3041 Fort Worth, TX 76107
Email: sales@cobaltmed.com Phone: (817)302-3890

Product Category: Disposable Medical Supplies, Medical Lighting Cortex Technology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2464
Equipment, Office Equipment and Supplies, Other Medical Smedevaenget 10
Equipment and Supplies, Surgical Instruments Hadsund, 9560
Denmark
CoLabs International . . . . . . . . . . . . . . . . . . . . . . . . . . . 1975 Phone: (45)9857-4100, Fax: (45)9857-2223
7251 W Lake Mead #300 Email: cortex@cortex.dk
Las Vegas, NV 89128
Phone: Fax: (702)947-2550 Product Category: Other Medical Equipment and Supplies
Email: info@klenskin.com

Product Category: Cosmetics and Skin Care Cosmetic Ingredient review . . . . . . . . . . . . . . . . . . . . . . 2417
1101 17th Street NW, Suite 412
Compulink . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1573 Washington, DC 20036
2645 Townsgate Rd Phone: (202)331-0651, Fax: (202)331-0088
Westlake Village, CA 91361 Email: cirinfo@cir-safety.org
Phone: (800)456-4522, Fax: (208)979-7789
Email: sales@compulinkadvantage.com Product Category: Cosmetics and Skin Care, Publishing and
Educational Materials
Product Category: Computer Software and Hardware, EMR/EHR
Systems, Practice Management

302 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

© Clinique Laboratories, LLC

The power to even skin tone with results

equal to a leading prescription ingredient.
Clinique Even Better Clinical Dark Spot Corrector.
Dermatologist-developed to be safe, comfortable.Yet in clinical trials our serum
was comparable to a leading prescription ingredient with a 53% improvement in
evening skin tone.
In 4 weeks, all skin tones enjoy a more uniform radiance. At 12 weeks, see a visible
reduction in dark spots, age spots, traces of acne past.
Apply twice a day. Never forget the sunscreen. And results are guaranteed.
Visit Clinique Booth 327 to see clinical results for all skin tones.
Use your smart phone
to scan this code or visit
m.clinique.com/evenbetter
for a special offer
when you discover
Even Better Clinical.
 TECHNICAL EXHIBITS

Cosmetic Surgery Times/Dermatology Times . . . . . . . . . . 1132 Cutis and Cosmetic Dermatology . . . . . . . . . . . . . . . . . . 2117
485F US Hwy 1 S, Suite 100 7 Century Drive, Ste 302
Iselin, NJ 08830 Parsippany, NJ 07054
Phone: (732)346-3089, Fax: (732)596-0016 Phone: (973)206-3434
Email: aammon@advanstar.com
Product Category: Publishing and Educational Materials
Product Category: Publishing and Educational Materials
Cynosure Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2921
Courage + Khazaka electronic gmbH . . . . . . . . . . . . . . . 2752 5 Carlisle Rd
Mathias-Brüeggen-Str. 91 Westford, MA 01886
Cologne, NRW 50829 Phone: (978)256-4200, Fax: (978)256-6556
Germany Email: info@cynosure.com
Phone: (49)221-9564990, Fax: (49)221-9564991
Email: info@courage-khazaka.de Product Category: Laser and Laser Supplies

Product Category: Photographic Equipment and Imaging Services

D
Croda/Sederma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 559 Daavlin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2929, 2941
300-A Columbus Circle 205 W Bement St.
Bryan, OH 43506
Edison, NJ 08837
Phone: (800)322-8546, Fax: (419)636-1739
Phone: (732)417-0800, Fax: (732)417-0804
Email: sales@daavlin.com
Email: marketing-usa@croda.com
Product Category: Phototherapy Supplies and Equipment
Product Category: Cosmetics and Skin Care

Cryosurgery Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1668 Dalos Biopharma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 864

TECHNICAL EXHIBITS

421 S Lynnhaven Rd, Ste 101

5829 Old Harding Pike
Virginia Beach, VA 23452
Nashville, TN 37205
Phone: (757)631-2114, Fax: (757)631-2115
Phone: (615)354-0414, Fax: (615)354-0466
Email: info@crysosurgeryinc.com Product Category: Cosmetics and Skin Care, Pharmaceutical

Product Category: Other Medical Equipment and Supplies

DEKA medical, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3353
665 Third Street, Ste 20
CuremD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1568 San Francisco, CA 94107
55 Broad Street Phone: (877)844-5552, Fax: (415)358-8800
New York, NY 10004 Email: info@dekamedinc.com
Phone: (212)509-6200, Fax: (212)509-6206
Email: Skye.yang@curemd.com Product Category: Laser and Laser Supplies

Product Category: EMR/EHR Systems, Practice Management Delasco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3021

608 13th Ave
Cu-Tech, L .L .C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3741 Council Bluffs, IA 51501
333 US Highway 46 West Phone: (800)831-6273, Fax: (800)320-9612
Email: questions@delasco.com
Mountain Lake, NJ 07046
Phone: (973)331-1620, Fax: (973)331-1622 Product Category: Cosmetics and Skin Care, Disposable Medical
Email: broche@cu-tech.com Supplies, Laser and Laser Supplies, Medical Lighting Equipment,
Other Medical Equipment and Supplies, Pharmaceutical,
Product Category: Pharmaceutical Publishing and Educational Materials, Surgical Instruments

Cutera . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1333 Derm101 .com . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2525

3240 Bayshore Blvd 350 W 43 ST, Ste 31E
Brisbane, CA 94005 New York, NY 10036
Phone: (415)657-5500 Phone: (212)448-0083, Fax: (212)448-0552
Email: customerservice@derm101.com
Product Category: Laser and Laser Supplies, Office Equipment
and Supplies Product Category: Publishing and Educational Materials

304 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 REVOLUTIONARY NEW DEVICE MEASURES
HAIR LOSS, HAIR GROWTH, AND HAIR
BREAKAGE.
How can you possibly manage a patient with hair loss – when you can’t even measure how much hair the patient has?
Well, now you can…. thanks to HairCheck® – a new diagnostic tool based on published Trichometer technology. 1, 2

For the very first time, you’ll be able to

measure hair… quickly and easily.

HairCheck® simultaneously measures the number of hairs and their

diameters, generates a single value and displays it as the Hair Mass Index (HMI).

The HairCheck® method can be learned in 20 minutes or less and requires no formal training.
No hair is cut; no hair is damaged. The actual bundle measurement takes less than 10 minutes.

If it can’t be measured, it can’t be managed!

WITH HAIRCHECK® YOU’LL BE ABLE TO:

• Measure your hair loss patient’s response to hair growth products.
• Measure hair loss and growth with scientific accuracy and confidence.
• Detect very early balding in young men who appear to have no loss.
• Detect and quantify hair breakage – a commonly under-appreciated cause of hair
loss in women.3

Add hair loss diagnostics to your practice, and bill as a

“cosmetic” service.
TO MEASURE HMI

Visit us at Booth #866 -- AAD 2011 annual meeting

For more information call 1-800-233-7453
or visit
www.haircheck.com

HairCheck® is a mechanical hair-measuring device. The diagnosis and treatment of hair loss requires evaluation by a medical
professional, and should not be based on HairCheck® data alone.
1. Cohen BH. The cross section trichometer: A new device for measuring hair quantity, hair loss, and hair growth. Derm Surg 2008; 34:900-910.
2. Cohen BH. The cross section trichometer, In Unger WP, Shapiro R, Unger R, et al. Hair Transplantation, Fifth Edition. Informa Healthcare: New York
3. Cohen BH. Hair breakage: an under appreciated cause of hair loss in women. Hair Transplant Forum Internat. May/June ,2008.
 TECHNICAL EXHIBITS

Derma medical Systems . . . . . . . . . . . . . . . . . . . . . . . . . . 827 Dermatology World . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3718

5275 Toscana Way #146 930 East Woodfield Rd
San Diego, CA 92122 Schaumburg, IL 60173
Phone: (858)625-0621, Fax: (858)625-9219 Phone: (847)240-1770, Fax: (847)330-8907
Email: usa@dermamedicalsystems.com Email: cdeguide@aad.org

Product Category: Photographic Equipment and Imaging Services, Product Category: Publishing and Educational Materials
Phototherapy Supplies and Equipment
Dermik . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3321
Dermablend . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1917 55 Corporate Drive
575 Fifth Avenue, 20th Floor Bridgewater, NJ 08807
Phone: (800)207-8049
New York, NY 10017
Phone (877)900-6700
Product Category: Pharmaceutical
Product Category: Cosmetics and Skin Care Dermpath Diagnostics . . . . . . . . . . . . . . . . . . . . . 1035, 3031
7111 Fairway Drive, Ste 400
DErmAdoctor, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 658 Palm Beach Gardens, FL 33418
1901 McGee Street Phone: (866)467-SKIN(7546), Fax: (214)975-1301
Kansas City, MO 64108 Email: bmccarley@dermpathdiagnostics.
Phone: (816)472-5700, Fax: (816)472-5752
Email: service@dermadoctor.com Product Category: Laboratory Services

Product Category: Cosmetics and Skin Care Dermresources, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . 1870

2270 LaVista Ave
Dermalis Distribuidora de productos para a Saude LTD . . . 3257 College Office Park
Rue Vintede Setembro, 2304-sala 402 Pensacola, FL 32504
TECHNICAL EXHIBITS

Caxias do Sul, RS 95020-450 Phone: (877)692-0171, Fax: (850)494-9644

Brasil Email: admin@dermresources.com
Phone: (55)54-3025-5440, Fax: (55)54-3025-5440
Email: eventos@dermalis.com.br
Product Category: Practice Management, Publishing and
Educational Materials
Product Category: Cosmetics and Skin Care
doc2mD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 663
Dermanaut . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3918
11025 RCA Center Drive, Ste 300
440 Burroughs, Suite 315
Detroit, MI 48202 Palm Beach Gardens, FL 33410
Phone: (734)604-8214 Phone: (877)770-3111, Fax: (561)904-7820
Email: jon@dermanaut.com Email: sales@doc2md.com

Product Category: Computer Software and Hardware, EMR/EHR Product Category: Computer Software and Hardware, EMR/EHR
Systems Systems, Laboratory Services

Dermatology foundation . . . . . . . . . . . . . . . . . . . . . . . . . 2740 Docs Duds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1767

1560 Sherman Avenue, Ste 870 92 Half Mile Road
Evanston, IL 60201 Red Bank, NJ 07701
Phone: (847)328-2256, Fax: (847)328-0509 Phone: (732)219-0060, Fax: (732)583-8183
Email: dfgen@dermatologyfoundation.org Email: wgreer@docsduds.com

Product Category: Associations, Foundations, and Medical Product Category: Clothing

Societies
D-path Dermatopathology . . . . . . . . . . . . . . . . . . . . . . . . . 210
Dermatologyoutlines .com . . . . . . . . . . . . . . . . . . . . . . . . . 971 142 Collins Street
30100 Telegraph Rd, Ste 408
Memphis, TN 38112-3814
Bingham Farms, MI 48025
Phone: (248)646-0325, Fax: (248)646-3119 Phone: (866)957-0425, Fax: (901)271-2699
Email: Dermoutsales@gmail.com Email: r.compagna@gipath.com

Product Category: Publishing and Educational Materials Product Category: Laboratory Services

306 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 TECHNICAL EXHIBITS

Dr . russo Skincare Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . 3555 Ellis Instruments, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . 2624

43 Devonshire St 21 Cook Ave
London, W19 7AL Madison, NJ 07940
United Kingdom Phone: (800)218-9082, Fax: (973)593-9277
Phone: (44)0870-243-2230, Fax: (44)20-7323-1220 Email: cellis@nac.net
Email: info@drrussoskincare.com
Product Category: Disposable Medical Supplies, Surgical
Product Category: Cosmetics and Skin Care Instruments

Dusa pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . 2249 Ellman International . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 759

25 Upton Drive 3333 Royal Ave
Wilmington, MA 01887 Oceanside, NY 11572
Phone: (978)657-7500, Fax: (978)657-9193 Phone: (516)594-3333, Fax: (516)569-0054
Email: cs-dept@dusapharma.com Email: ellman@ellman.com

Product Category: Pharmaceutical Product Category: Other Medical Equipment and Supplies,
Surgical Instruments
Dynamis Skin Science,Inc . . . . . . . . . . . . . . . . . . . . . . . . 221
261 Old York Rd, Ste 427 ELoN Hair, Nails and Skin . . . . . . . . . . . . . . . . . . . . . . . . 823
Jenkintown, PA 19046 38 Church Avenue
Phone: (877)682-7949, Fax: (877)657-0658 Wareham, MA 02571
Email: ilkrader@dynamisscience.com Phone: (800)414-3566, Fax: (508)291-2200
Email: info@ilovemynails.com
Product Category: Cosmetics and Skin Care, Pharmaceutical
Product Category: Cosmetics and Skin Care, Pharmaceutical

Elorac, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 459

E 100 Fairway Drive, Suite 134
Eclipsemed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3649

TECHNICAL EXHIBITS
Vernon Hills, IL 60061
16850 Dallas Parkway Phone: (847)362-8200, Fax: (847)362-8394
Dallas, TX 75248 Email: cgabanski@eloracpharma.com
Phone: (972)380-2911, Fax: (972)380-2953
Email: sales@eclipsemed.com Product Category: Pharmaceutical

Product Category: Laser and Laser Supplies, Other Medical Elsevier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2620, 1433
Equipment and Supplies, Surgical Instruments 1600 JFK Blvd Suite 1800
Philadelphia, PA 19103
eDerm Systems/Integrated Dermatology . . . . . . . . . . . . . 3352 Phone: (215)239-3490, Fax: (215)239-3494
902 Clint Moore Rd, Suite 226 Email: jhayes@elsevier.com
Boca Raton, FL 33487
Phone: (561)449-6900 Product Category: Publishing and Educational Materials
Email: info@edermsystems.com
EltamD Skincare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2457
Product Category: EMR/EHR Systems 2055 Luna Rd, # 126
Carrollton, TX 75006
Edge Systems Corporation . . . . . . . . . . . . . . . . . . . . . . . 3833 Phone: (800)633-8872, Fax: (972)385-7930
2277 Redondo Ave Email: info@eltamd.com
Signal Hill, CA 90755
Phone: (800)603-4996, Fax: (562)597-0148 Product Category: Cosmetics and Skin Care
Email: sales@edgesystem.net
Envy medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1365
Product Category: Cosmetics and Skin Care, Other Medical 31340 Via Colinas, Ste 101
Equipment and Supplies Westlake Village, CA 91362
Phone: (888)848-3633, Fax: (818)874-1195
Eleme medical/osuris medical uSA . . . . . . . . . . . . . . . . . 414
10 Al Paul Lane, Suite 102 Product Category: Cosmetics and Skin Care, Other Medical
Merrimack, NH 03054 Equipment and Supplies
Phone: (603)816-1920, Fax: (603)882-4762
Email: info@elememedical.com

Product Category: Laser and Laser Supplies

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 307
 TECHNICAL EXHIBITS

Ethicon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1365B fotona Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2165

1415 1st Street S, Ste 5
European Academy of Dermatology and Venereology . . . . 3717 Willmar, MN 56201
12, via delle scuole Phone: (888)550-4113, Fax: (320)235-4000
Lugano, 6900 Email: info@fotona.us
Switzerland
Phone: (41)91973-4520 Product Category: Cosmetics and Skin Care, Laser and Laser
Email: office@eadv.org Supplies

Product Category: Associations, Foundations, and Medical

Societies g
galderma Laboratories, Lp . . . . . . . . . . . . . . . . . . . . . . . 1841
Expeditor Systems, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . 2750 14501 North Freeway
4090 Nine McFarland Drive Fort Worth, TX 76177
Alpharetta, GA 30004 Phone: (817)961-5000
Phone: (770)441-0405 Email: letty.hall@galderma.com
Email: mmiller@expeditor.com
Product Category: Pharmaceutical
Product Category: Other Medical Equipment and Supplies
garnier Skincare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1816
575 Fifth Avenue, 15th FL
f New York, NY 10017
fallene Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 521 Phone: (800)370-1925
2555 Industry Lane
West Norristown, PA 19403 Product Category: Cosmetics and Skin Care
Phone: (800)332-5536, Fax: (610)630-6202
TECHNICAL EXHIBITS

Email: info@fallene.com general project uSA . . . . . . . . . . . . . . . . . . . . . . . . . . . 4033

via della Gora 15/19
Product Category: Cosmetics and Skin Care Montespertoli Florence, 50025
Italy
ferndale Laboratories, Inc . . . . . . . . . . . . . . . . . . . . . . . . 1533 Phone: (39)0571675076, Fax: (39)0571675077
780 W Eight Mile Rd Email: info@generalproject.com
Ferndale, MI 48220
Product Category: Other Medical Equipment and Supplies, Laser
Product Category: Pharmaceutical and Laser Supplies, Medical Lighting Equipment, Phototherapy
Supplies and Equipment
foamix Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831
PO Box 4038 global pathology Laboratory Services . . . . . . . . . . . . . . . . 865
Weizman Science Park 16250 NW 59th Ave, Ste 201
Ness Ziona, 74140 Miami Lakes, FL 33014
Israel Phone: (305)825-4422, Fax: (305)779-5387
Phone: (972)8-9316233, Fax: (972)8-9474356 Email: pattya@globalpathlab.com
Email: yaffa@foamix.co.il
Product Category: Laboratory Services
Product Category: Cosmetics and Skin Care, Pharmaceutical
gloprofessional . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3953
fotofinder Systems, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . 258 600 W Bayaud Ave
9693 Gerwig Lane, Ste S Denver, CO 80223
Columbia, MD 21046 Phone: (800)232-0398, Fax: (800)306-9047
Phone: (888)501-0805, Fax: (443)283-3869 Email: customerservicegroup@gloprofessional.com
Email: info@fotofinder-systems.com Product Category: Cosmetics and Skin Care

Product Category: Photographic Equipment and Imaging Services

308 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 TECHNICAL EXHIBITS

graceway pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . 2131 Hill Laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2746

222 Valley Creek Blvd, Ste 300 3 N Bacton Hill Rd
Exton, PA 19341 Frazer, PA 19355
Phone: (267)948-0400 Phone: (877)445-5020, Fax: (610)647-6297
Email: info@gracewaypharma.com Email: info@hilllabs.com

Product Category: Pharmaceutical Product Category: Office Equipment and Supplies, Medical
Lighting Equipment, Other Medical Equipment and Supplies,
group Health permanente . . . . . . . . . . . . . . . . . . . . . . . . 2071 Phototherapy Supplies and Equipment
320 Westlake Ave N, Ste 100
Seattle, WA 98109 Hill Top research Corporation . . . . . . . . . . . . . . . . . . . . 1465
Phone: (800)543-9323, Fax: (206)877-0652 6088 Main Street
Email: vanassen.j@ghc.org Miamiville, OH 45147
Phone: (513)831-3114, Fax: (513)831-1217
Product Category: Practice Management Email: info@hill-top.com

Product Category: Cosmetics and Skin Care, Laboratory Services,

H Pharmaceutical
Haircheck . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 866
12188 SW 128th St Hironic Co ., LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326
Miami, FL 33186 #913 Sicox Tower, 513-14
Phone: (800)233-7453, Fax: (305)253-6696 Sangdaewon-Dong-Jeongwon-Gu
Email: info@haircheck.com Sungnam, 462-120
Korea
Product Category: Other Medical Equipment and Supplies Phone: (82)31-777-9711, Fax: (82)31-777-9713
Email: export@hironic.com

TECHNICAL EXHIBITS
Henry Schein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3829
135 Duryea Road Product Category: Laser and Laser Supplies, Other Medical
Melville, NY 11747 Equipment and Supplies, Phototherapy Supplies Equipment,
Phone: (800)P-Schein, Fax: (800)329-9109 Surgical Instruments
Email: medsls@henryschein.com
Histopath Lab pA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1164
Product Category: Clothing, Computer Software and Hardware, 2671 W Norvell Bryant Hwy
Cosmetics and Skin Care, Disposable Medical Supplies, EMR/ Lecanto, FL 34461
EHR Systems, Laboratory Services, Medical Lighting Equipment, Phone: (352)527-1344
Office Equipment and Supplies, Pharmaceutical, Practice
Management, Surgical Instruments Product Category: Laboratory Services

Herbalix restoratives . . . . . . . . . . . . . . . . . . . . . . . . . . . 3917 Hoya ConBio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1133

P.O. Box 65346 47733 Fremont Blvd
Port Ludlow, WA 98365 Fremont, CA 94538
Phone: (866)387-4222, Fax: (360)437-0442 Phone: (510)445-4500, Fax: (510)445-4550
Email: info@herbalix.com Email: info@conbio.com

Product Category: Cosmetics and Skin Care Product Category: Laser and Laser Supplies

Hill Dermaceuticals, Inc . . . . . . . . . . . . . . . . . . . . . . . . . 1965 HrA research . . . . . . . . . . . . . . . . . . . . . . .2113, 626, 1765

2650 S. Mellonville Ave 400 Lanidex Plaza
Sanford, FL 32773 Parsippany, NJ 07054
Phone: (800)344-5707, Fax: (407)649-9213 Phone: (973)240-1200, Fax: (973)463-1888
Email: mariMaria@hillderm.com Email: kdibiase@hraresearch.com

Product Category: Pharmaceutical Product Category: Market Research

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 309
 TECHNICAL EXHIBITS

I Iredale mineral Cosmetics . . . . . . . . . . . . . . . . . . . . . . . . 351

Images En Dermatologie . . . . . . . . . . . . . . . . . . . . . . . . . . 972 51 Church St
2 Rue Sainte Marie Great Barrington, MA 01230
Courbevoie, FR 92418 Phone: (800)762-1132
France Email: info@janeiredale.com
Phone: (33)146-67-62-83, Fax: (33)146-67-63-10
Email: egiroudun@edimark.fr Product Category: Cosmetics and Skin Care

Product Category: Publishing and Educational Materials IrIDEX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2621

1212 Terra Bella Avenue
Informa Healthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2526 Mountain View, CA 94043
Telephone House, 69-77 Paul St Phone: (800)388-4747, Fax: (650)962-0486
London Surrey, EC2A 4LQ
United Kingdom Product Category: Laser and Laser Supplies
Phone: (44)020-3377 3590
iS Clinical by Innovative Skincare . . . . . . . . . . . . . . . . . . 664
Product Category: Publishing and Educational Materials 312 Western Avenue
Glendale, CA 91201
Innovaderm research Inc . . . . . . . . . . . . . . . . . . . . . . . . 1268 Phone: (888)804-4447, Fax: (818)638-8768
1851 Sherbrooke St, E., Ste 502 Email: info@isclinical.com
Montreal, QC H2K 4L5
Canada Product Category: Cosmetics and Skin Care
Phone: (514)521-4285, Fax: (514)906-0659
Email: amgaulin@innovaderm.ca Italy Bidding Committee for WCD 2015 . . . . . . . . . . . . . . 3713
via Lucilio 60
Product Category: Pharmaceutical, Cosmetics and Skin Care Rome, 00136
TECHNICAL EXHIBITS

Italy
Innovative optics, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . 3533 Phone: (39)06-35530-202, Fax: (39)06-35530-268
6812 Hemlock Ln Email: rome2015wcd@triumphgroup.it
Maple Grove, MN 55369
Phone: (763)425-7789, Fax: (763)425-6689 Product Category: Associations, Foundations, and Medical
Email: tom@innovativeoptics.com Societies

Product Category: Laser and Laser Supplies

J
Intendis, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 441 Jan marini Skin research . . . . . . . . . . . . . . . . . . . . . . . 2947
PO Box 1941 6951 Via Del Oro
Morristown, NJ 07962-1941 San Jose, CA 95119
Phone: (866)463-3634, Fax: (973)966-3378 Phone: (408)362-0130, Fax: (408)362-0140
Email: jamesm.felker@janmarini.com
Product Category: Pharmaceutical
Product Category: Cosmetics and Skin Care
International Society of Dermatology . . . . . . . . . . . . . . . 3818
2323 N State St, #30 Johns Hopkins emedical Dermatology review . . . . . . . . . 1774
Bunnell, FL 32110 122 West 26th Street, Ste 1100
Phone: (386)437-4405, Fax: (386)437-4427 New York, NY 10001-6867
Email: info@intsocderm.org Phone: (646)336-6495, Fax: (646)336-6497
Email: gmorse@dkbmed.com
Product Category: Associations, Foundations, and Medical
Societies, Publishing and Educational Materials Product Category: Publishing and Educational Materials

310 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 Is Your Skin On
The System?

Dramatic improvement in the

appearance of:
• fine lines, wrinkles, photoaging
• acne
• rosacea
• skin discoloration
...and so much more!

CLEANSE REJUVENATE RESURFACE HYDRATE PROTECT

Step 1 Step 2 Step 3 Step 4 Step 5

SKIN CARE MANAGEMENT SYSTEM ™

Exclusively by JAN MARINI SKIN RESEARCH ®

JANMARINI SKIN RESEARCH®

For the science behind your beautiful skin... T (800) 347-2223 F (408) 362-0140 JanMarini.com
© Jan Marini Skin Research, Inc. 4/10 - SCMSB001
 TECHNICAL EXHIBITS

Johnson & Johnson CpC . . . . . . . . . . . . . . . . . . . . . . . . . 1640 L

199 Grandview Rd Laboratoires Serobiologiques/Div . of Cognis . . . . . . . . . . . 259
Skillman, NJ 08558 2270 Argentia Rd
Phone: (866)4AVEENO, Fax: (908)874-1123 Missisauga, ON L5N 6H9
Canada
Product Category: Cosmetics and Skin Care Phone: (416)843-6371, Fax: (905)542-7588
Email: sean.maguire@cognis.com
Johnson & Johnson Consumer products - Baby . . . . . . . . 1258
199 Grandview Rd Product Category: Cosmetics and Skin Care
Skillman, NJ 08558
Phone: (866)4AVEENO, Fax: (908)874-1123 La roche-posay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1920
575 Fifth Avenue, 20th Floor
Product Category: Cosmetics and Skin Care New York, NY 10017
Phone: (888)LRP-LABO
Johnson & Johnson r & D . . . . . . . . . . . . . . . . . . . . . . . . 1456
Product Category: Cosmetics and Skin Care

Laser Network, The . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 458

K 19336 Goddard Ranch Ct., Ste 203
Kaiser permanente . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 926
Morrison, CO 80465
1800 Harrison St, 7th Floor Phone: (866)597-6895, Fax: (303)697-1811
Oakland, CA 94612 Email: info@thelasertrader.com
Phone: (800)777-4912, Fax: (510)625-5487
Email: mdrecruitment.tpmg@kp.org Product Category: Laser and Laser Supplies

Product Category: Practice Management Laser Safety Industries, LLC . . . . . . . . . . . . . . . . . . . . . . 2269

6311 Cambridge Street
TECHNICAL EXHIBITS

Kao Brands Company . . . . . . . . . . . . . . . . . . . . . . . . . . . 2121 Minneapolis, MN 55416

2535 Spring Grove Ave Phone: (952)405-6947, Fax: (952)405-6949
Cincinnati, OH 45214 Email: info@lasersafetyindustries.co
Phone: (513)455-5352
Email: jill.gerke@kaobrands.com Product Category: Laser and Laser Supplies, Other Medical
Equipment and Supplies
Product Category: Cosmetics and Skin Care
LASErINg SrL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3055
Kentek Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2465 Via Staffette Partigiane, 54
1 Elm Street Modena, 41122
Pittsfield, NH 03263 Italy
Phone: (603)223-4900, Fax: (603)223-7441 Phone: (39)059-450999, Fax: (39)059-311096
Email: info@kenteklaserstore.com Email: lasering@lasering.it

Product Category: Laser and Laser Supplies

Product Category: Disposable Medical Supplies, Laser and Laser
Supplies
LASErVISIoN uSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1168
595 Phalen Blvd
Kiehl’s Since 1851 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1911 St. Paul, MN 55130
435 Hudson St Phone: (651)357-1800, Fax: (651)357-1830
New York, NY 10014 Email: info@lasersafety.com
Phone: (917)606-2763
Email: ccannella@kiehls-usa.com Product Category: Laser and Laser Supplies

312 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 TECHNICAL EXHIBITS

Leo pharma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611 L’oreal paris . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1810

Industriparken 55 575 Fifth Avenue, 26th Floor
Ballerup, 2750 New York, NY 10017
Denmark
Phone: (45)44945888 Product Category: Cosmetics and Skin Care

Product Category: Pharmaceutical L’oreal Vichy Laboratories . . . . . . . . . . . . . . . . . . . . . . . 1921

575 Fifth Avenue, 20th Floor
Levia-Lerner medical Devices, Inc . . . . . . . . . . . . . . . . . . 2171 New York, NY 10017
1545 Sawtelle Blvd, Ste 36 Phone: (212)984-5030
Los Angeles, CA 90025
Product Category: Cosmetics and Skin Care
Phone: (310)914-0091, Fax: (310)914-0095
Email: info@mylevia.com
Lpg Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3453
2753 Route des Dolines BP 243
Product Category: Phototherapy Supplies and Equipment
0690S Antipolis Cedex
France
Lexington International, LLC . . . . . . . . . . . . . . . . . . . . . . . 968 Phone: (33)492-38-3900
777 Yamato Rd, Ste 105
Boca Raton, FL 33431 Product Category: Other Medical Equipment and Supplies
Phone: (561)314-2430, Fax: (561)892-0747
Email: las@hairmax.com Lucid, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3247
2320 Brighton Henrietta TL Rd
Product Category: Laser and Laser Supplies, Other Medical Rochester, NY 14623
Equipment and Supplies Phone: (585)239-9800, Fax: (585)239-9806
Email: colleen@lucid-tech.com
LightStim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 216
3189 Red Hill Ave Ste C Product Category: Laboratory Services, Other Medical Equipment

TECHNICAL EXHIBITS
Costa Mesa, CA 92626 and Supplies, Photographic Equipment and Imaging Services
Phone: (800)298-4010, Fax: (714)884-3603
Email: info@lightstim.com Lumenis, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2331
5302 Betsy Ross Drive
Product Category: Phototherapy Supplies and Equipment Santa Clara, CA 95054
Phone: (408)764-3824, Fax: (408)764-3660
LIgHTWAVE Technologies . . . . . . . . . . . . . . . . . . . . . . . . 2415 Email: jscott@lumenis.com
1734 W Williams Dr., #10
Phoenix, AZ 85027 Product Category: Laser and Laser Supplies
Phone: (866)999-6954, Fax: (602)548-8818
Email: cristina@mylightwave.com Lutronic Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3813
51 Everett Drive, A-50
Product Category: Cosmetics and Skin Care, Other Medical Princeton Junction, NJ 08550
Equipment and Supplies Phone: (609)275-1565, Fax: (609)275-3800

Lippincott, Williams & Wilkins . . . . . . . . . . . . . . . . . . . . . 922 Product Category: Laser and Laser Supplies
110 Kramer Court
Mandeville, LA 70471 m
Phone: (504)377-7518 marina medical Instruments, Inc . . . . . . . . . . . . . . . . . . . 853
Email: jay.walton@wolterskluwer.com 955 Shotgun Rd
Sunrise, FL 33326
Product Category: Publishing and Educational Materials Phone: (954)924-4418, Fax: (954)924-4419
Email: alexbarron@marinamedical.com
Locks of Love . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1566
234 Southern Blvd Product Category: Surgical Instruments
West Palm Beach, FL 33405
Phone: (561)833-7332, Fax: (561)833-7962 mcgraw-Hill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2027
Email: lauren@locksoflove.org 2 Penn Plaza, 23rd Floor
New York, NY 10121
Product Category: Associations, Foundations, and Medical Phone: (800)262-4729
Societies
Product Category: Publishing and Educational Materials

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 313
 TECHNICAL EXHIBITS

mD Solar Sciences . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1569 medimetriks pharmaceuticals, Inc . . . . . . . . . . . . . . . . . 1664

128 East Avenue 363 Route 46 West
Norwalk, CT 06851 Fairfield, NJ 07004
Phone: (203)857-0095, Fax: (203)286-1484 Phone: (973)882-7512, Fax: (973)882-7502
Email: info@mdsolarsciences.com Email: info@medimetriks.com

Product Category: Clothing and Cosmetics and Skin Care Product Category: Pharmaceutical

medCo Data, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 563 mednet Technologies, Inc . . . . . . . . . . . . . . . . . . . . . . . . 2225

1410 N West Shore Blvd, Ste 710 1975 Linden Blvd, Ste 407
Tampa, FL 33607 Elmont, NY 11003
Phone: (813)321-1550, Fax: (813)321-1555 Phone: (516)285-2200, Fax: (516)285-1685
Email: info@medcodata.com Email: info@mednet-tech.com
Product Category: Computer Software and Hardware, EMR/EHR Product Category: Computer Software and Hardware, Practice
Systems, Office Equipment and Supplies, Practice Management Management, Publishing and Educational Materials

medelita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154 mELA Sciences,Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211

1046 Calle Recodo, Suite D 50 S Buckhout St, Suite 1
San Clemente, CA 92673 Irvington, NY 10533
Phone: (877)987-7979, Fax: (949)542-4101
Phone: (914)591-3783, Fax: (914)591-3701
Email: contact.us@medelita.com
Email: info@melasciences.com
Product Category: Clothing, Other Medical Equipment
Product Category: Other Medical Equipment and Supplies,
and Supplies
Photographic Equipment and Imaging Services

medesthetics magazine . . . . . . . . . . . . . . . . . . . . . . . . . 2466 mentor Worldwide LLC . . . . . . . . . . . . . . . . . . . . . . . . . . 1359

TECHNICAL EXHIBITS

7628 Densmore Ave 201 Mentor Drive

Van Nuys, CA 91406 Santa Barbara, CA 93111
Phone: (818)782-7328, Fax: (818)782-2913 Phone: (800)525-8773, Fax: (805)870-6002
Product Category: Publishing and Educational Materials
Product Category: Computer Software and Harware,
Cosmetics and Skin Care, Disposable Medical Supplies,
medical Illumination International . . . . . . . . . . . . . . . . . 2275 Practice Management, Other Medical Equipment and Supplies,
547 Library St Pharmaceutical, Surgical Instruments
San Fernando, CA 91340
Phone: (818)838-3025, Fax: (818)838-3625 merge and Skin Inc . magazine . . . . . . . . . . . . . . . . . . . . 3823
Email: cs@medillum.com 336 Gundersen Dr, St A
Carol Stream, IL 60188
Product Category: Medical Lighting Equipment
Phone: (630)344-6064, Fax: (630)597-0118
medical protective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 829 Email: cmckown@allured.com
5814 Reed Road
Fort Wayne, IN 46835 Product Category: Publishing and Educational Materials
Phone: (800)463-3776, Fax: (866)417-5068
Email: Nancy.Stahulak@medpro.com merz pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
4215 Tudor Lane
Product Category: Practice Management Greensboro, NC 27410
Phone: (888)MERZUSA, Fax: (336)856-0107
medicis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2741 Email: info@merzusa.com
7720 N Dobson Rd
Scottsdale, AZ 85256 Product Category: Cosmetics and Skin Care, Pharmaceutical
Phone: (602)808-8800, Fax: (602) 808-0822
Email: customer_service@medicis.com

Product Category: Pharmaceutical

314 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

MDSolarSciences – a physician-led company committed to saving
lives and providing a safer and healthier time in the sun.
Scientific Advisory Board – 50 highly-regarded medical and
scientific professionals, behavioral and educational specialists
support MDSolarSciences’ commitment to advancing the
science of sun protection.
MDSolarSciences Sunscreens – a line of lotion, gels, body
spray and sports stick, meet the strictest guidelines using
safer ingredients for both children and adults, as well as
the environment. Sunscreens provide high level, broad spectrum
UVA and UVB protections; Ease of application and fast absorption;
Moisture balanced compounds to keep skin soft and prevent drying;
Water resistant formulas.
SolarSciences Sportswear – a line of 50+ stylish, comfortable sun
protective clothing and hats designed for children, teens and adults.
SolSciOptiX – a line of UV400 screened sunglasses and ski goggles,
available for adults, teens and children. Optional polarizing lenses
also available.
SolAlert – personalized UV sensors measure the UV index, a card for
adults and a wrist-band for children.
SolEDUCATE – a series of highly informative educational materials for
safer fun-in-the-sun rounds out the integrated UV protection system.
 TECHNICAL EXHIBITS

mesoestetic uSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2561 mJD patient Communications . . . . . . . . . . . . . . . . . . . . . 3040

16311 Ventura Blvd, Ste 1210 4915 St Elmo Ave, Ste 306
Encino, CA 91436 Bethesda, MD 20814
Phone: (818)783-6881 Phone: (301)657-8010, Fax: (301)657-8023
Email: kristy@mjdpc.com
Product Category: Cosmetics and Skin Care
Product Category: Computer Software and Hardware, Office
micro4, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1665 Equipment and Supplies, Practice Management
7118, I-40 West, Bldg. D
Amarillo, TX 79106 mmr Technologies, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . 2265
Phone: (800)235-1856, Fax: (806)463-7021 1400 N Shoreline Blvd A5
Email: sales@micro4.com Mountain View, CA 94043
Phone: (650)962-9620, Fax: (650)962-9647
Product Category: Computer Software and Hardware, EMR/EHR Email: support@elan2.com
Systems, Practice Management
Product Category: Other Medical Equipment and Supplies
microsurgery Instruments, Inc . . . . . . . . . . . . . . . . . . . . . . 867
PO Box 1378 modernizing medicine, Inc . . . . . . . . . . . . . . . . . . . . . . . 973
Bellaire, TX 77402-1378 330 South Federal Highway
Phone: (713)664-4707, Fax: (713)664-8873 Boynton Beach, FL 33435
Email: microusa@microsurgeryusa.com Phone: (866)799-2146 ext.201
Email: info@modernizingmedicine.com
Product Category: Medical Lighting Equipment, Other Medical
Equipment and Supplies, Surgical Instruments Product Category: EMR/EHR Systems

midmark Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . 3121 moleSafe uSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1069

TECHNICAL EXHIBITS

60 Vista Drive 328 W St Georges Ave

Versailles, OH 45380 Linden, NJ 07036
Phone: (800)643-6275, Fax: (800)365-8631 Phone: (877)665-3723
Email: info@midmark.com
Product Category: Photographic Equipment and Imaging Services
Product Category: Medical Lighting Equipment, Office
Equipment and Supplies monique mathieu LLC/gernetic . . . . . . . . . . . . . . . . . . . . 3751
2601 NE 11th Court
miltex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1844 Ft Lauderdale, FL 33304
589 Davies Drive Phone: (954)537-0732, Fax: (954)537-1505
York, PA 17402 Email: info@monique-mathieu.us
Phone: (866)854-8300, Fax: (866)854-8400
Email: customerservice@miltex.com Product Category: Clothing, Cosmetics and Skin Care

Product Category: Surgical Instruments mTI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3641

3655 West Ninigret Dr
miramar Labs, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1675 Salt Lake City, UT 84104
445 Indio Way Phone: (800)924-4655, Fax: (801)952-0548
Sunnyvale, CA 94085 Email: matthewbaker@mti.net
Phone: (480)940-8700, Fax: (408)940-8795
Email: info@miramarlabs.com Product Category: Medical Lighting Equipment, Office
Equipment and Supplies, Other Medical Equipment and Supplies
Product Category: Other Medical Equipment and Supplies

316 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 Make your own
liquid nitrogen !

No more depending
on delivery
services.

You can make

your own liquid
nitrogen in your
office.

• Clean
• Reliable
• On-Demand
• Safe

Come see us in New Orleans,

AAD Booth Number 2265
For information on how to make your own
liquid nitrogen with the award winning
elan2 Liquid Nitrogen Generators:
Web: www.elan2.com
Email: sales@elan2.com
Phone: (847) 740-8701
 TECHNICAL EXHIBITS

N NexTech . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2157
5550 W. Executive Dr, Ste 350
National Biological Corporation . . . . . . . . . . . . . . . . . . . 3229
Tampa, FL 33609
23700 Mercantile Road
Phone: (813)425-9200, Fax: (813)425-9292
Beachwood, OH 44122 Email: websales@nextech.com
Phone: (800)338-5045, Fax: (216)765-0271
Email: Info@PhototherapyExperts.com Product Category: Computer Software and Hardware, EMR/EHR
Systems, Practice Management
Product Category: Laser and Laser Supplies, Photographic
Equipment and Imaging Services, Phototherapy Supplies and Nextgen Healthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1165
Equipment 795 Horsham Road
Horsham, PA 19044
National Library of medicine . . . . . . . . . . . . . . . . . . . . . 3825 Phone: (215)657-7010
c/o NN/LMSCR@Ham-TMC Library Email: dzampitella@nextgen.com
1133 John Freeman Blvd
Product Category: EMR/EHR Systems, Practice Management
Houston, TX 77030
Phone: (888)346-3656, Fax: (301)402-1384 NIA24 / Niadyne Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1265
Email: custserv@nlm.nih.gov 2530 Meridian Pkwy, Ste 200
RTP, NC 27713
Product Category: Publishing and Educational Materials, Phone: (866)Niadyne, Fax: (919)806-4850
Computer Software and Hardware Email: ejones@niadyne.com

Neocutis, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3155 Product Category: Cosmetics and Skin Care

3053 Fillmore Street #140
San Francisco, CA 94123 NoIr Laser Shield . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2327
Phone: (866)636-2884, Fax: (313)664-0668 6155 Pontiac Trail
Email: contactus@neocutis.com South Lyon, MI 48178
Phone: (734)769-5565, Fax: (734)769-1708
TECHNICAL EXHIBITS

Product Category: Cosmetics and Skin Care Email: david.bothner@noirlaser.com

Product Category: Laser and Laser Supplies

NeoStrata Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1855
307 College Road East
Princeton, NJ 08540
Phone: (800)225-9411, Fax: (800)636-7872 o
Email: CUSTSVC@neostrata.com obagi medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2011
3760 Kilroy Airport Way
Product Category: Cosmetics and Skin Care Long Beach, CA 90806
Phone: (562)628-1007, Fax: (562)628-1008
Neutraderm, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 359 Email: lisae@obagi.com
20660 Nordhoff St
Product Category: Pharmaceutical
Chatsworth, CA 91311
Phone: (818)534-3180, Fax: (818)534-3192 oculo-plastik Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3821
Email: zoec@neutraderm.com 200 Sauve West
Montreal, QC H3L 1Y9
Product Category: Cosmetics and Skin Care Canada
Phone: (514)381-3292, Fax: (514)381-1164
Neutrogena . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 941 Email: sales@oculoplastik.com
5760 West 96th Street
Los Angeles, CA 90045 Product Category: Laser and Laser Supplies
Phone: (310)337-2171, Fax: (310)337-2110
Email: dfoster@its.jnj.com

Product Category: Cosmetics and Skin Care

318 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 not just another pretty face

prevent

protect

optimize

correct balance

clear

restore

lighten

Others follow. Obagi leads. Others promise. Obagi delivers.

From acne to aging, from hyperpigmentation to inflammation, Obagi Medical brings value others don’t
because Obagi delivers results others can’t. When choosing an aesthetics partner, choose wisely.
Nothing works like Obagi because nothing else is Obagi.

Make your practice not just another practice. Call (800) 311-4469 for special offers on becoming an Obagi practice today.

Obagi is a registered trademark of OMP, Inc. Distributed by OMP, Inc. ©2010 Obagi Medical Products, Inc. All rights reserved. 05/10 www.obagi.com
 TECHNICAL EXHIBITS

officite, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3655

3010 Highland Parkway, Ste 625
p
pacific World Corporation . . . . . . . . . . . . . . . . . . . . . . . 1270
Downers Grove, IL 60515
25800 Commerce Centre Dr
Phone: (800)908-2483, Fax: (630)230-2301
Email: sales@officite.com Lake Forest, CA 92630
Phone: (949)598-2400 X274, Fax: (949)598-2424
Product Category: Computer Software and Hardware, Practice Email: Smurphy@pwcosmetics.com
Management
Product Category: Cosmetics and Skin Care
omnipath Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . 3941
8211 Remmet Avenue paladin Labs Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 851
Canoga Park, CA 91304 100 Alexis Nihon Ste 600
Phone: (818)251-3800, Fax: (818)251-3810 Montreal, QC H4M 2P2
Email: nicole@omnipathdiagnostics.com Canada
Phone: (866)340-1112, Fax: (514)340-7836
Product Category: Laboratory Services Email: customerservicepaladin@paladin-labs.com
on Call medical Coats . . . . . . . . . . . . . . . . . . . . . . . . . . . 659 Product Category: Pharmaceutical
620 Franklin Ave
Baltimore, MD 21221
palomar medical Technologies, Inc . . . . . . . . . . . . . . . . . 811
Phone: (410)574-2657, Fax: (410)574-6307
Email: customerservice@aetnashirt.com 15 Network Drive
Burlington, MA 01803
Product Category: Clothing Phone: (781)993-2300, Fax: (781)993-2330
Email: info@palomarmedical.com
onset Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2170
400 Highland Corporate Drive Product Category: Laser and Laser Supplies, Other Medical
Cumberland, RI 02864 Equipment and Supplies, Surgical Instruments
TECHNICAL EXHIBITS

Phone: (888)713-8154
Email: info@onsettx.com pathLogix Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . 1973
470 Nautilus Street, Ste 306
Product Category: Pharmaceutical La Jolla, CA 92037
Phone: (888)454-5000, Fax: (858)454-2003
ontos, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 527 Email: jerry@pathlogix.com
PO Box 89
Chehalis, WA 98532
Phone: (888)469-7546, Fax: (888)469-7953 Product Category: Computer Software and Hardware
Email: md@4myskin.com
pCA Skin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2531
Product Category: Cosmetics and Skin Care, Pharmaceutical 6710 East Camelback Road, Ste 230
Scottsdale, AZ 85251
ortho Dermatologics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1240 Phone: (800)PCA.SKIN, Fax: (480)946-5690
5760 West 96th Street Email: info@pcaskin.com
Los Angeles, CA 90045
Phone: (310)410-5813 Product Category: Cosmetics and Skin Care
Email: chahn1@its.jnj.com
person and Covey, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . 2547
Product Category: Pharmaceutical 616 Allen Avenue
Glendale, CA 91201
Phone: (800)423-2341
Email: helpdesk@personandcovey.com

Product Category: Cosmetics and Skin Care, Pharmaceutical

320 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 Sean Doherty, MD
before after
Come and visit
TH
PALOMAR BOO

811
Lux1540 ™ :
Consumer Marketing THE FIRST FRACTIONAL
LASER FDA CLEARED FOR
TREATING STRIAE
Millions of women worldwide have stretch marks.
Not one woman wants them.

Until now there were no good options for stretch mark treatment.
Since the U.S. Food and Drug Administration cleared Palomar’s
fractional laser for treating stretch marks, you now have an
excellent aesthetic solution.

The Lux1540 Fractional laser handpiece can improve

Introducing Scars1.com the unsightly color and skin texture associated with
& Stretchmarks1.com stretch marks, leaving smoother, better-looking skin
Consumers can learn about the benefits of with no downtime.
fractional non-ablative laser treatments at
Scars1.com and Stretchmarks1.com, part of
the Body1 network of health education sites.
With over 250,000 visitors per month to the
Body1 network, these consumer sites can
help drive prospective consumers to your See why physicians have chosen
practice.
Lux1540 at www.palomarmedical.com.

Results may vary and are not guaranteed.

©2010 Palomar Medical Technologies, Inc. Palomar is a registered trademark, and Lux1540
is a trademark of Palomar Medical Technologies, Inc. ALL RIGHTS RESERVED.
Palomar Medical Technologies, Inc. 15 Network Drive, Burlington, MA 01803 USA
from light comes beauty www.palomarmedical.com USA: 1-800-PALOMAR
 TECHNICAL EXHIBITS

pharmaceutical Specialties, Inc . (pSI) . . . . . . . . . . . . . . . 964 pierre fabre Dermo Cosmetique uSA . . . . . . . . . . . . . . . 2311
1620 Industrial Dr. NW 9 Campus Drive, 2nd Fl
Rochester, MN 55901 Parsippany, NJ 07054
Phone: (507)288-8500, Fax: (507)288-7603 Phone: (973)355-8000
Email: order@psico.com Email: info@genesispharm.com

Product Category: Cosmetics and Skin Care Product Category: Pharmaceutical

pharmaDerm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3041 pollogen Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1075

210 Park Avenue 6 Kaufman St POB 50320
Florham Park, NJ 07932 Tel-Aviv, 6801
Phone: (866)337-6001 Israel
Email: tracey.miller@nycomed.us.com Phone: (972)3-510-4157, Fax: (972)3-510-4112
Email: info@pollogen.com
Product Category: Pharmaceutical
Product Category: Cosmetics and Skin Care, Laser and Laser
photocure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 667 Supplies, Other Medical Equipment and Supplies
Hoffsveien 48
Oslo, NO-0377 practical Dermatology . . . . . . . . . . . . . . . . . . . . . . . . . . 2553
Norway c/o Bryn Mawr Communications, LLC
Phone: (47)22 06 2210, Fax: (47)22 06 2218 Wayne, PA 19087
Email: info@photocure.no Phone: (484)581-1800

Product Category: Computer Software and Hardware, Practice

Product Category: Cosmetics and Skin Care
Management, Publishing and Educational Materials
photomedex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 419
practice flow Solutions . . . . . . . . . . . . . . . . . . . . . . . . . . 358
TECHNICAL EXHIBITS

147 Keystone Drive 7742 Spalding Drive, Ste 368

Montgomeryville, PA 18936 Norcross, GA 30092
Phone: (800)366-4758, Fax: (215)619-3211 Phone: (678)983-0229, Fax: (678)935-0186
Email: cust@photomedex.com Email: brooks@practiceflowsolutions.com

Product Category: Cosmetics and Skin Care, Laser and Laser Product Category: Practice Management
Supplies, Phototherapy Supplies and Equipment
procter and gamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
physician Endorsed, LLC . . . . . . . . . . . . . . . . . . . . . . . . 1269 1 P and G Plaza
950 So Pine Island Rd Suite A-150 Cincinnati, OH 45202
Plantation, FL 33324 Phone: (513) 983-1100
Phone: (954)318-6060, Fax: (954)318-6065 Email: miller.c.3@pg.com
Email: emilybd@bellsouth.net
Product Category: Cosmetics and Skin Care
Product Category: Clothing
promius pharma, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . 3933
200 Somerset Corporate Blvd
phytoCeuticals, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 567 Bridgewater, NJ 08807
37 Midland Avenue Phone: (908)429-4500, Fax: (908)429-4579
Elmwood Park, NJ 07407 Email: rdurso@promiuspharma.com
Phone: (201)791-2255, Fax: (201)791-2310
Email: info@phyto-ceutical.com Product Category: Pharmaceutical

Product Category: Cosmetics and Skin Care, Pharmaceutical propath . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 451

1355 River Bend Drive
Dallas, TX 75247
Phone: (800)258-1253, Fax: (214)237-1844
Email: marketing@propath.com

Product Category: Laboratory Services

322 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 TECHNICAL EXHIBITS

pSp: plastic Surgery practice . . . . . . . . . . . . . . . . . . . . 3630 revision Skincare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 410

7101 College Blvd. Ste 400 9019 Premier Row
Overland Park, KS 66210 Dallas, TX 75247
Phone: (913)894-6923, Fax: (913)864-6932 Phone: (800)385-6652, Fax: (214)630-1806
Email: scho@thisisamg.com Email: info@revisionskincare.com
Product Category: Publishing and Educational Materials
Product Category: Cosmetics and Skin Care

robbins Instruments Inc . . . . . . . . . . . . . . . . . . . . . . . . . . 833

Q 2 North Passaic Ave
Quanta System SpA . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3847 Chatham, NJ 07928
VIA IV Novembre 116 Phone: (973)635-8972, Fax: (973)635-8732
Solbiate Olona, 21058 Email: info@robbinsinstruments.com
Italy
Phone: (39)0331-376797, Fax: (39)0331367815 Product Category: Disposable Medical Supplies, Surgical
Email: quanta@quantasystem.com Instruments, Other Medical Equipment and Supplies

Product Category: Laser and Laser Supplies rockwell Laser Industries . . . . . . . . . . . . . . . . . . . . . . . . 317
7754 Camargo Road
Quantel Derma gmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . 2364 Cincinnati, OH 45243
AM Wolfsmantel 46 Phone: (800)945-2737
Erlangen, Bavaria, 90158 Email: customerservice@rli.com
Germany
Phone: (49)9131-94088-0, Fax: (49)9131-94088-99 Product Category: Computer Software and Hardware, Disposable
Email: info@quantel-derma.com Medical Supplies, Laser and Laser Supplies, Other Medical
Equipment and Supplies, Publishing and Educational Materials
Product Category: Laser and Laser Supplies
TECHNICAL EXHIBITS

rogaine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1556
Quantificare, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2115
1180 Rte des Dolines, Athena B, BP 40051
Sopia-Antipolis, Cedex, 06901
France
S
Sandstone medical Technologies . . . . . . . . . . . . . . . . . . 2221
Phone: (33)4 92 91 5420, Fax: (33)4 92 91 95 00
Email: info@quantificare.com 105 Citation Court
Homewood, AL 35209
Product Category: Computer Software and Hardware, Phone: (205)290-8251, Fax: (205)290-4269
Photographic Equipment and Imaging Services Email: sandstonemike@bellsouth.net

Quintessence Skin Science/revitalight . . . . . . . . . . . . . . 2426 Product Category: Laser and Laser Supplies
c/o International Cosmeceuticals Inc.
PO Box 226425 SanovaWorks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 758
Miami, FL 33222 377 Park Ave South, 6th Floor
Phone: (888)876-1138, Fax: (305)591-6869 New York, NY 10016
Email: info@qskinscience.com Phone: (212)213-5436 x4333, Fax: (212)213-5435
Email: mary.altamirano@pceny.com
Product Category: Cosmetics and Skin Care
Product Category: Publishing and Educational Materials

r Scar Heal, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 765

352G 150th Ave
ra medical Systems, Inc . . . . . . . . . . . . . . . . . . . . . . . . . 1854
Madeira Beach, FL 33708
2270-L Camino Vida Roble
Phone: (727)397-7227, Fax: (727)398-7227
Carlsbad, CA 92011
Email: sales@scarheal.com
Phone: (760)804-1648, Fax: (760)804-1657
Email: mburstein@ramed.com Product Category: Cosmetics and Skin Care
Product Category: Laser and Laser Supplies

324 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 TECHNICAL EXHIBITS

Sciton . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2019 SkinCeuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1824

925 Commerical Street 3402 Miller Road
Palo Alto, CA 94303 Garland, TX 7541
Phone: (650)493-9155, Fax: (650)493-9146 Phone: (800)811-1660; Fax (972)926-2950
Email: information@sciton.com
Product Category: Cosmetics and Skin Care
Product Category: Laser and Laser Supplies
Skin Disease Education foundation . . . . . . . . . . . . . . . . 2520
Sesderma Laboratory . . . . . . . . . . . . . . . . . . . . . . . . . . . 1170 5635 Fishers Lane, Ste 6000
15951 SW 41st St #300 Rockville, MD 20852
Davie, FL 33331 Phone: (240)221-4405, Fax: (240) 221-4400
Phone: (800)796-0996, Fax: (954)835-4654 Email: terrie@sdefderm.com
Email: customerservice@sesvaliausa.com
Product Category: Publishing and Educational Materials
Product Category: Cosmetics and Skin Care

Shantel medical Supply . . . . . . . . . . . . . . . . . . . . . . . . . 3632 Skin of mine Dot .Com . . . . . . . . . . . . . . . . . . . . . . . . . . 1275

400 Columbus Avenue, Ste 5S
5600 Peck Rd
Valhalla, NY 10595
Arcadia, CA 91006
Phone: (914)495-3310, Fax: (914)801-5354
Phone: (626)358-7530, Fax: (626)599-8171 Email: feedback@skinofmine.com
Email: info@shantel.com
Product Category: Computer Software and Hardware
Product Category: Cosmetics and Skin Care
Skinmedica, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 511
Skin & Aging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 930 5909 Sea Lion Place, Ste H
83 General Warren Blvd, Ste 100 Carlsbad, CA 92010
Malvern, PA 19355 Phone: (866)867-0110, Fax: (760)448-3601

TECHNICAL EXHIBITS
Phone: (610)560-0500, Fax: (610)560-0501 Email: info@skinmedica.com

Product Category: Cosmetics and Skin Care, Publishing and Product Category: Cosmetics and Skin Care, Pharmaceutical
Educational Materials,
Smart practice (an Allerderm Affiliate) . . . . . . . . . . . . . . 1852
Skin & Allergy News . . . . . . . . . . . . . . . . . . . . . . . . . . . 2522 3400 E McDowell Road
60-B Columbia Road Phoenix, AZ 85008
Morristown, NJ 07960 Phone: (800)878-3837, Fax: (602)225-0245
Email: info@allerderm.com
Phone: (973)290-8200, Fax: (973)290-8250
Email: l.kalish@elsevier.com
Product Category: Cosmetics and Skin Care, Disposable Medical
Supplies
Product Category: Cosmetics and Skin Care, Publishing and
Educational Materials Smartpractice Canada . . . . . . . . . . . . . . . . . . . . . . . . . . 1850
2175 29th Street NE, Unit 90
Skin & Cancer Associates/Advanced Dermatology mgmt . . . 2210 Calgary, AB T1Y 7H8
1111 Park Centre Blvd, Ste 300 Canada
Miami Gardens, FL 33169 Phone: (866)903-2673, Fax: (866)903-2672
Phone: (305)623-5595, Fax: (305)623-1937 Email: info@allergeaze.com
Email: d.tomlinson@admcorp.com
Product Category: Other Medical Equipment and Supplies
Product Category: Practice Management
Society of Dermatology physician Assistants . . . . . . . . . . 3547
Skin Cancer foundation, The . . . . . . . . . . . . . . . . . . . . . . 847 P.O. Box 701461
149 Madison, Suite 901 San Antonio, TX 78270
Phone: (800)380-3992
New York, NY 10016
Email: sdpa@dermpa.org
Phone: (212)725-5176, Fax: (212)725-5751
Email: vbarlow@skincancer.org Product Category: Associations, Foundations, and Medical
Societies
Product Category: Associations, Foundations, and Medical
Societies

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 325
 TECHNICAL EXHIBITS

Solta medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 411 Stiefel Laboratories, Inc . . . . . . . . . . . . . . . . . . . . . . . . . 2341

25881 Industrial Blvd c/o GSK
Hayward, CA 94545 RTP, NC 27709
Phone: (510)782-2286, Fax: (510)782-2287 Phone: (800)366-8900
Email: info@solta.com
Product Category: Pharmaceutical, Cosmetics and Skin Care
Product Category: Laser and Laser Supplies, Medical Lighting
Equipment Strata pathology Services . . . . . . . . . . . . . . . . . . . . . . . 1065
One Cranberry Hill, Ste 303
Sound Surgical Technologies . . . . . . . . . . . . . . . . . . . . . 1470 Lexington, MA 02139
357 S McCaslin Blvd, Ste 100 Phone: (800)325-7284, Fax: (617)252-6563
Louisville, CO 80027 Email: clientservices@pathsrv.com
Phone: (888)471-4777, Fax: (720)294-2948
Product Category: Laboratory Services
Email: info@vaser.com

Product Category: Other Medical Equipment and Supplies Summers Labs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3529
103 G.P. Clement Drive
Sperian protection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3819 Collegeville, PA 19426
10 Thurber Blvd Phone: (610)454-1471, Fax: (610)454-1475
Smithfield, RI 02917 Email: info@sumlab.com
Phone: (800)500-4739, Fax: (401)232-1832 Product Category: Cosmetics and Skin Care
Email: srajguru@sperianprotection.com
Product Category: Laser and Laser Supplies
TECHNICAL EXHIBITS

Time. It’s all about time.

It’s time for Strata Pathology Services.
Unsurpassed
in customer service Strata Pathology Services is a leading comprehensive pathology laboratory
dedicated to providing both you and your patients with the ultimate in
diagnostic services.
Unrivaled
in diagnostic expertise Our local team of nationally renowned pathologists, friendly and
knowledgeable office staff and dedicated couriers recognize that the best in
patient care can only be achieved by working together with you toward one
Expert common goal: your patients’ needs.
Dermatopathology
Services As a privately owned, state-of-the-art laboratory, we are uniquely
qualified to offer you an unsurpassed level of personalized service.
877-872-8223 Our professionals will work closely with your office staff to tailor a program
to fit your practice’s needs.

326 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 TECHNICAL EXHIBITS

Sun precautions, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3541 T

2815 Wetmore Ave taberna pro medicum . . . . . . . . . . . . . . . . . . . . . . . . . . . 1864
Everett, WA 98201 Im Dorf 15a
Phone: (800)882-7860, Fax: (425)303-0836 Lueneburg, NI 21335
Email: customerservice@sunprecautions Germany
Product Category: Clothing, Cosmetics and Skin Care Phone: (49)4131-401555, Fax: (49)4131-401755
Email: info@tpm-online.de
Sun products Corporation (All Laundry Detergent) . . . . . . 2629
60 Danbury Road Product Category: Office Equipment and Supplies
Wilton, CT 06897
Phone: (800)298-240 Tanda Skincare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2068
11-380 Jamieson Parkway
Email: consumer.relations@sunproducts
Cambridge, ON N3C4N4
Product Category: Cosmetics and Skin Care Canada
Phone: (519)651-1177, Fax: (519)651-2277
Sunday Afternoons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2365 Email: sarah.tarle@pharoslife.com
716 South Pacific Highway
Talent, OR 97540 Product Category: Cosmetics and Skin Care, Phototherapy
Phone: (888)874-2642, Fax: (541)535-9988 Supplies and Equipment
Email: hats@sundayafternoons.com
TeleVox . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3535, 1233
Product Category: Clothing 3709 Lakeside Drive South, Ste B
Mobile, AL 36693
SurgiTel/general Scientific Corp . . . . . . . . . . . . . . . . . . . 2111 Phone: (800)644-4266, Fax: (251)633-2420
77 Enterprise Dr Email: info@televox.com
Ann Arbor, MI 48103
Product Category: Computer Software and Hardware, Laboratory
Phone: (800)959-0153, Fax: (734)662-0520

TECHNICAL EXHIBITS
Services, Practice Management, Other Medical Equipment
Email: info@surgitel.com and Supplies
Product Category: Surgical Instruments
ThermoTek, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
1200 Lakeside Pkwy, #200
Sybaritic, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1572 Flower Mound, TX 75028
9220 James Ave, S Phone: (972)874-4949, Fax: (972)874-4945
Minneapolis, MN 55431 Email: thermotek@thermotekusa.com
Phone: (952)888-8282
Email: info@sybaritic.com Product Category: Laser and Laser Supplies, Other Medical
Equipment and Supplies
Product Category: Cosmetics and Skin Care, Laser and Laser
Supplies, Other Medical Equipment and Supplies Tiemann-Bernsco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1865
25 Plant Ave
Syneron and Candela . . . . . . . . . . . . . . . . . . . . . . . . . . . 3515 Hauppauge, NY 11788
Phone: (800)843-6266, Fax: (800)577-6050
3 Goodyear
Email: sales@georgetiemann.com
Irvine, CA 92818
Phone: (949)716-6670, Fax: (949)716-6555 Product Category: Disposable Medical Supplies, Laser and Laser
Email: info@candelalaser.com Supplies, Medical Lighting Equipment, Other Medical Equipment
and Supplies, Surgical Instruments
Product Category: Laser and Laser Supplies
Tilley Endurables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1264
Syris Scientific . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1564 900 Don Mills Road
22 Shaker Road Toronto, ON M3C 1VC
Gray, ME 04039 Canada
Phone: (207)657-7050, Fax: (207)657-7051 Phone: (800)555-2160
Email: safesun@tilley.com
Email: wcyr@syrisscientific.com
Product Category: Clothing
Product Category: Medical Lighting Equipment
Tissue Techniques pathology Labs . . . . . . . . . . . . . . . . . 1169

for the lAtest ProgrAm Book informAtion PleAse refer to www.aad.org | 327
 TECHNICAL EXHIBITS

13016 Bee Street, Ste 100 unilever . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 431

Dallas, TX 75234-6158 700 Sylvan Street
Phone: (972)241-6277, Fax: (972)241-4747 Englewood Cliffs, NJ 07632
Email: tissuetech@juno.com Phone: (201)567-8000, Fax: (201)894-2869
Email: comments@unilever.com
Product Category: Laboratory Services
Product Category: Cosmetics and Skin Care
TKL research, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3549
365 W Passaic St upsher-Smith Laboratories, Inc . . . . . . . . . . . . . . . . . . . . 2319
Rochelle Park, NJ 07662 6701 Evenstad Dr
Phone: (201)587-0500 x3389, Fax: (201)336-1511 Maple Grove, MN 55369
Email: pmierzwa@tklresearch.com Phone: (763)315-2000, Fax: (763)315-2244
Email: uslinfo@upsher-smith.com
Product Category: Pharmaceutical Product Category: Pharmaceutical
Topix pharmaceuticals Inc . . . . . . . . . . . . . . . . . . . . . . . 2149 uVBIoTEK, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
174 Route 109 3 Depot Street
West Babylon, NY 11704 PO Box 430
Phone: (800)445-2595, Fax: (631)794-2310 Hudson Falls, NY 12839
Email: cust.service@topixpharm.com Phone: (518)747-3310 x101, Fax: (518)747-2294
Email: gary@uvbiotek.com
Product Category: Cosmetics and Skin Care
Product Category: Phototherapy Supplies and Equipment
Triangle Biomedical Sciences . . . . . . . . . . . . . . . . . . . . 1769
3014 Croasdaile Drive
Durham, NC 27705 V
Valeant pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . 3441
Phone: (919)384-9393, Fax: (919)384-9595
3801 Hulen Street
TECHNICAL EXHIBITS

Email: service@trianglebiomedical.com Fort Worth, TX 76107

Phone: (817)302-3834, Fax: (817)302-3890
Product Category: Other Medical Equipment and Supplies
Email: kinerasesupport@valeant.com
Triax pharmaceuticals, LLC . . . . . . . . . . . . . . . . . . . . . . 1955 Product Category: Cosmetics and Skin Care, Pharmaceutical
11 Commerce Dr
Cranford, NJ 07016 Valeo pharma Corp . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3650
Email: info@triaxpharma.com 16667 Hymus Boulevard
Product Category: Pharmaceutical Kirkland, QC H9H 4R9
Canada
Phone: (514)693-8833, Fax: (514)694-0865
u Email: rousseau@valeopharma.com
ulthera, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1070
Product Category: Pharmaceutical
2150 S Country Club Drive #27
Mesa, AZ 85210
Vancouver 2015 World Congress of Dermatology Bid . . . 3745
2590 Granville St #104
ultralite Enterprises, Inc . . . . . . . . . . . . . . . . . . . . . . . . . 2421
Vancouver, BC V6H 3H1
390 Farmer Court
Canada
Lawrenceville, GA 30046
Phone: (770)963-0594, Fax: (770)995-7171 Product Category: Associations, Foundations, and Medical
Email: ultralit@bellsouth.net Societies

Product Category: Phototherapy Supplies and Equipment Venus Concept Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
Building 62 HaHermesh Str
ultraShape NA Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2064 Karmiel, 21652
2603 Camino Ramon, 2nd Floor Israel
San Ramon, CA 94583 Phone: (972)4958-9393, Fax: (972)4958-9494
Phone: (925)362-8947, Fax: (925)362-8492 Email: liat@venus-concept.com
Email: info@ultrashape.com
Product Category: Laser and Laser Supplies, Other Medical
Product Category: Laser and Laser Supplies Equipment and Supplies, Phototherapy Supplies and Equipment

328 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 TECHNICAL EXHIBITS

ViraCor-IBT Laboratories . . . . . . . . . . . . . . . . . . . . . . . . 2630

11274 Renner Blvd
y
yaupon Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 565
Lenexa, KS 66219 259 N. Radnor-Chester Rd.
Phone: (800)637-0370, Fax: (913)492-7145 Radnor, PA 19087
Email: diagnostictesting@ibtlabs.com Phone: (610)975-9290 Fax: (610)975-9012
Product Category: Laboratory Services Email:pmorrris@yaupontherapeutics.com

Viscot medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2175 Product Category: Pharmaceutical

32 West Street
East Hanover, NJ 07936 yodle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2551
Phone: (973)887-9273, Fax: (973)887-3961 50 W 23rd Street, Ste 401
Email: romola@viscot.com New York, NY 10010
Phone: (877)276-5104, Fax: (646)753-6312
Product Category: Disposable Medical Supplies Email: info@yodle.com

VmV HypoALLErgENICS . . . . . . . . . . . . . . . . . . . . . . . . 3812 young pharmaceuticals, Inc . . . . . . . . . . . . . . . . . . . . . . 3241

16 West 16th St Unit 5GN 1840 Berlin Turnpike
New York, NY 10011 Wethersfield, CT 06109
Phone: (212)217-2762, Fax: (347)368-0529 Phone: (860)529-7919, Fax: (860)529-6801
Email: ccvrowell@vmvgroup.com Email: info@youngpharm.com

Product Category: Cosmetics and Skin Care Product Category: Cosmetics and Skin Care, Computer Software
and Hardware, Pharmaceutical

W
Wallaroo Hat Company . . . . . . . . . . . . . . . . . . . . . . . . . . 2557 Z
1880 S Flatiron Ct, E Zimmer medizin Systems . . . . . . . . . . . . . . . . . . . . . . . . 2214
Boulder, CO 80301 25 Mauchly Suite 300
TECHNICAL EXHIBITS

Phone: (303)494-5949, Fax: (303)245-8720 Irvine, CA 92618

Email: info@wallaroohats.com Phone: (800)327-3576, Fax: (949)727-2154
Email: info@zimmerusa.com
Product Category: Clothing
Product Category: Cosmetics and Skin Care, Other Medical
Warner Chilcott . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 965 Equipment and Supplies, Laser and Laser Supplies
100 Enterprise Drive
Rockaway, NJ 07866 ZipChart . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 661
Phone: (800)521-8813 29043 N 59th Street
Cave Creek, AZ 85331
Product Category: Pharmaceutical Phone: (866)344-3549, Fax: (866)246-2104
Email: customercare@zipchart.com
Wiley-Blackwell . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2521
350 Main Street Product Category: EMR/EHR Systems
Malden, MA 02148
Phone: (800)532-5954, Fax: (781)338-8552
Email: jeelliot@wiley.com

Product Category: Publishing and Educational Materials

330 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting

 TECHNICAL EXHIBITS
proDuCT CATEgory DIrECTory of
EXHBITINg CompANIES
ASSoCIATIoNS, fouNDATIoNS, AND
mEDICAL
Alopecia Areata & Eczema Resource Sharing Alliance . . . . . . 3934
American Academy of Dermatology. . . . . . . . . . . . . . . . . . . 3623
American Board of Dermatology . .. . . . . . . . . . . . . . . . . . . . 3716
American Society for Dermatologic Surgery . . . . . . . . . . . . . . 1033
American Society for Mohs Surgery . . . . . . . . . . . . . . . . . . . . 3719
Bidding Committee Austria for WCD 2015 . . . . . . . . . . . . . 3715
Brazilian Society of Dermatological Surgery . . . . . . . . . . . . . . 1874
Brazilian Society of Dermatology . . . . . . . . . . . . . . . . . . . . . . 1872
Coalition of Skin Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . 3712
Dermatology Foundation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2740
European Academy of Dermatology and Venereology . . . . . . 3717
International Society of Dermatology. . . . . . . . . . . . . . . . . . . 3818
Italy Bidding Committee for WCD 2015 . . . . . . . . . . . . . . . 3713
Locks of Love . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1566
Skin Cancer Foundation, The . . . . . . . . . . . . . . . . . . . . . . . . . 847
Society of Dermatology Physician Assistants . . . . . . . . . . . . . 3547
Vancouver 2015 World Congress of Dermatology Bid . . . . . . 3745
TECHNICAL EXHIBITS
CLoTHINg
Coolibar, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1565
Docs Duds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1767
Henry Schein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3829
Medelita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
Monique Mathieu LLC/Gernetic . . . . . . . . . . . . . . . . . . . . . . 3751
On Call Medical Coats . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 659
Physician Endorsed, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . 1269
Sun Precautions, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3541
Sunday Afternoons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2365
Tilley Endurables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1264
Wallaroo Hat Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2557
CompuTEr SofTWArE AND HArDWArE
Aurora Diagnostics-DERMDX . . . . . . . . . . . . . . . . . . . . . . . 3755
Clinix Medical Information Services . . . . . . . . . . . . . . . . . . . 3646
Compulink . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1573
Dermanaut . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3918
doc2MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 663
Henry Schein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3829
MedCo Data, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 563
Mednet Technologies, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . 2225
Mentor Worldwide, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1359
Micro4, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1665
MJD Patient Communications . . . . . . . . . . . . . . . . . . . . . . . 3040
National Library of Medicine . . . . . . . . . . . . . . . . . . . . . . . . . 3825
NexTech . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2157
Officite, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3655
332 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
PathLogix Corporation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1973
Practical Dermatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2553
Prime Clinical Systems, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . 3928
Quantificare, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2115
Rockwell Laser Industries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317
Skin of Mine Dot.Com . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1275
TeleVox . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1233, 3535
Young Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . 3241
CoSmETICS AND SKIN CArE
Advanced Bio-Technologies, Inc. . . . . . . . . . . . . . . . . . . . . . . 311
Advanced Skin & Hair Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . 1467
Allergan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 641
Anthony Products/Gio Pelle . . . . . . . . . . . . . . . . . . . . . . . . . . 3613
Auriga International . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2411
Axia Medical Solutions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3253
Beiersdorf Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 625
Biodermis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 460
Biopelle, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2211
BioSkin GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3842
Chemotechnique Diagnostics/Dormer Laboratories . . . . . . . . 2126
ChopSaver . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1266
Clarisonic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1866
ClearFX Skin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1775
Clinique Laboratories LLC. . . . . . . . . . . . . . . . . . . . . . . . . . . . 327
CoLabs International . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1975
Conrex Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 315
Cosmetic Ingredient Review. . . . . . . . . . . . . . . . . . . . . . . . . . 2417
Croda/Sederma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 559
Dalos BioPharma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 864
Delasco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3021
Dermablend . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
DERMAdoctor, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 658
Dermalis Distribuidora de Productos para a Saude LTD . . . . 3257
Dr. Russo Skincare Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3555
Dynamis Skin Science, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . 221
Edge Systems Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . 3833
ELON Hair, Nails and Skin . . . . . . . . . . . . . . . . . . . . . . . . . . . 823
EltaMD Skincare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2457
Envy Medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1365
Fallene Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 521
Foamix Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831
Fotona Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2165
Garnier Skincare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1816
gloProfessional . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3953
Henry Schein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3829
Herbalix Restoratives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3917
Hill Top Research Corporation . . . . . . . . . . . . . . . . . . . . . . . 1465
Innovaderm Research Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . 1268
Iredale Mineral Cosmetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 351
iS Clinical by Innovative Skincare . . . . . . . . . . . . . . . . . . . . . . 664
Jan Marini Skin Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2947
Johnson & Johnson Consumer Products-Baby . . . . . . . . . . . . 1258
Johnson & Johnson CPC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 941
Kao Brands Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2121

Kiehl’s since 1851. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1911
Laboratoires Serobiologiques/Div. of Cognis . . . . . . . . . . . . . . 259
La Roche-Posay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1920
LIGHTWAVE Technologies . . . . . . . . . . . . . . . . . . . . . . . . . 2415
L’Oreal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1810
L’Oreal Vichy Laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . 1921
Mentor Worldwide, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1359
Merz Pharmaceuticals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
Mesoestetic USA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2561
Monique Mathieu LLC/Gernetic . . . . . . . . . . . . . . . . . . . . . . 3751
Neocutis, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3155
NeoStrata Company. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1855
Neutraderm, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 359
Neutrogena . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 941
NIA24 / Niadyne Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1265
Ontos, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 527
Pacific World Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . 1270
PCA Skin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2531
Person and Covey, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2547
Pharmaceutical Specialties, Inc. (PSI) . . . . . . . . . . . . . . . . . . . . 964
Photocure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 667
PhotoMedex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 419
PhytoCeuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 567
Pollogen Ltd. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1073
Procter and Gamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
Quintessence Skin Science /Revitalight . . . . . . . . . . . . . . . . . 2426
Revision Skincare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 410
Scar Heal, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 765
Sesderma Laboratory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1170
Shantel Medical Supply . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3632
Skin & Aging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 930
SkinCeuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1824
SkinMedica, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 511
Smart Practice (an Allerderm Affilialiate) . . . . . . . . . . . . . . . . 1852
Stiefel Laboratories, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2341
Summers Labs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3529
Sun Precautions, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3541
Sun Products Corporation (All Laundry Detergent). . . . . . . . 2629
Sybaritic, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1572
Tanda Skincare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2068
Topix Pharmaceuticals Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . 2149
Unilever . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 431
Valeant Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3341
VMV HYPOALLERGENICS . . . . . . . . . . . . . . . . . . . . . . . . 3812
Young Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . 3241
Zimmer Medizin Systems. . . . . . . . . . . . . . . . . . . . . . . . . . . . 2214
DISpoSABLE mEDICAL SuppLIES
Acuderm, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3221
Buffalo Filter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3840
Chemotechnique Diagnostics/Dormer Laboratories . . . . . . . . 2126
Cobalt Medical Supply . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3913
Delasco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3021
for the lAtest ProgrAm Book informAtion PleAse refer to
TECHNICAL EXHIBITS
Ellis Instruments, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2624
Henry Schein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3829
Kentek Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2465
Mentor Worldwide, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1359
Robbins Instruments Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 833
Rockwell Laser Industries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317
Smart Practice (an Allerderm Affiliate) . . . . . . . . . . . . . . . . . . 1852
Tiemann-Bernsco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1865
Viscot Medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2175
Emr/EHr SySTEmS
Aurora Diagnostics-DERMDX . . . . . . . . . . . . . . . . . . . . . . . 3755
Clinix Medical Information Services . . . . . . . . . . . . . . . . . . . 3646
Compulink. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1573
Cure MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1568
Dermanaut . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3918
doc2MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 663
eDerm Systems/Integrated Dermatology . . . . . . . . . . . . . . . . 3352
Henry Schein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3829
MedCo Data, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 563
Micro4, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1665
Modernizing Medicine, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . 363
NexTech . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2157
NextGen Healthcare. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1165
Prime Clinical Systems, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . 3928
TECHNICAL EXHIBITS
ZipChart . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 661
LABorATory SErVICES
Aurora Diagnostics-DERMDX . . . . . . . . . . . . . . . . . . . . . . . 3755
Avantik Biogroup . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3628
Axia Medical Solutions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3253
Biopsy Diagnostics, PC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1771
Caris DX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3841
Dermpath Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . 1035, 3031
doc2MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 663
D-Path Dermatopathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210
Global Pathology Laboratory Services . . . . . . . . . . . . . . . . . . . 865
Henry Schein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3829
Hill Top Research Corporation . . . . . . . . . . . . . . . . . . . . . . . 1465
Histopath Lab PA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1164
Lucid, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3247
OmniPath Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3941
ProPath . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 451
Strata Pathology Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1065
TeleVox . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1233, 3535
Tissue Techniques Pathology Labs . . . . . . . . . . . . . . . . . . . . . 1169
ViraCor-IBT Laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . 2630
www.aad.org | 333
 TECHNICAL EXHIBITS
LASEr AND LASEr SuppLIES
Aerolase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2065
Alma Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2357
Apira Science . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3929
Applisonix Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1473
Beijing Syntech Laser Co, Ltd . . . . . . . . . . . . . . . . . . . . . . . . 4041
Buffalo Filter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3840
CoolTouch Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 845
Cutera . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1333
Cynosure Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2921
DEKA Medical, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3353
Delasco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3021
Eclipsemed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3649
Eleme Medical/Osuris Medical USA . . . . . . . . . . . . . . . . . . . . 414
Fotona Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2165
General Project USA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4033
Hironic Co., LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326
Hoya ConBio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1133
Innovative Optics, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3533
IRIDEX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2621
Kentek Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2465
Laser Network, The . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 458
Laser Safety Industries, LLC. . . . . . . . . . . . . . . . . . . . . . . . . . 2269
LASERING SRL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3055
LASERVISION USA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1168
Lexington International, LLC . . . . . . . . . . . . . . . . . . . . . . . . . 968
TECHNICAL EXHIBITS
Lumenis, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2331
Lutronic Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3813
National Biological Corporation . . . . . . . . . . . . . . . . . . . . . . 3229
NoIR Laser Shield . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2327
Oculo-Plastik Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3821
Palomar Medical Technologies, Inc. . . . . . . . . . . . . . . . . . . . . 811
PhotoMedex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 419
Pollogen Ltd. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1073
Quanta System SPA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3847
Quantel Derma GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2364
Ra Medical Systems, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . 1854
Rockwell Laser Industries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317
Sandstone Medical Technologies . . . . . . . . . . . . . . . . . . . . . . 2221
Sciton . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2019
Solta Medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 411
Sperian Protection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3819
Sybaritic, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1572
Syneron and Candela . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3515
ThermoTek, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
Tiemann-Bernsco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1865
UltraShape NA Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2064
Venus Concept Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
Zimmer Medizin Systems. . . . . . . . . . . . . . . . . . . . . . . . . . . . 2214
334 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
mArKET rESEArCH
Aesthetic Guide, The . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1371
HRA Research . . . . . . . . . . . . . . . . . . . . . . . . . . . 626, 1765, 2113
mEDICAL LIgHTINg EQuIpmENT
Anthony Products/Gio Pelle . . . . . . . . . . . . . . . . . . . . . . . . . . 3613
Beijing Syntech Laser Co, Ltd . . . . . . . . . . . . . . . . . . . . . . . . 4041
Cobalt Medical Supply . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3913
Delasco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3021
General Project USA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4033
Henry Schein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3829
Hill Laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2746
Medical Illumination International . . . . . . . . . . . . . . . . . . . . 2275
Microsurgery Instruments, Inc. . . . . . . . . . . . . . . . . . . . . . . . . 867
Midmark Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3121
MTI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3641
Solta Medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 411
Syris Scientific . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1564
Tiemann-Bernsco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1865
offICE EQuIpmENT AND SuppLIES
3Gen, LLC/DermLite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 321
Brymill Cryogenic Systems. . . . . . . . . . . . . . . . . . . . . . . . . . . 1764
Cobalt Medical Supply . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3913
Conmed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1134
Cutera . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1333
Henry Schein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3829
Hill Laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2746
MedCo Data, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 563
Midmark Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3121
MJD Patient Communications . . . . . . . . . . . . . . . . . . . . . . . 3040
MTI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3641
taberna pro medicum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1864
oTHEr mEDICAL EQuIpmENT AND
SuppLIES
3Gen, LLC/DermLite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 321
Acuderm, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3221
Aeph International Ltd. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1971
Alma Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2357
Anthony Products/Gio Pelle . . . . . . . . . . . . . . . . . . . . . . . . . . 3613
Avantik Biogroup . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3628
Big C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 662
Biodermis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 460
Brymill Cryogenic Systems. . . . . . . . . . . . . . . . . . . . . . . . . . . 1764
Buffalo Filter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3840
Business Enterprise SRL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 764
Chemotechnique Diagnostics/Dormer Laboratories . . . . . . . . 2126
ClearFX Skin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1775
CNH Pillow Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1666
Cobalt Medical Supply . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3913
Cortex Technology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2464
Cryosurgery Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1668

Delasco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3021
Eclipsemed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3649
Edge Systems Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . 3833
Ellman International . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 759
Envy Medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1365
Expeditor Systems, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2750
General Project USA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4033
Haircheck. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 866
Henry Schein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3829
Hill Laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2746
Hironic Co., LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326
Laser Safety Industries, LLC. . . . . . . . . . . . . . . . . . . . . . . . . . 2269
Lexington International, LLC . . . . . . . . . . . . . . . . . . . . . . . . . 968
LIGHTWAVE Technologies . . . . . . . . . . . . . . . . . . . . . . . . . 2415
LPG Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3453
Lucid, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3247
Medelita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
MELA Sciences, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211
Mentor Worldwide, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1359
Microsurgery Instruments, Inc. . . . . . . . . . . . . . . . . . . . . . . . . 867
Miramar Labs, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1673
MMR Technologies, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . 2265
MTI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3641
Palomar Medical Technologies, Inc. . . . . . . . . . . . . . . . . . . . . 811
Pollogen Ltd. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1073
Robbins Instruments Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 833
Rockwell Laser Industries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317
SmartPractice Canada . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1850
Sound Surgical Technologies . . . . . . . . . . . . . . . . . . . . . . . . . 1470
Sybaritic, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1572
TeleVox . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1233, 3535
ThermoTek, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
Tiemann-Bernsco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1865
Triangle Biomedical Sciences . . . . . . . . . . . . . . . . . . . . . . . . . 1769
Ulthera, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1070
Venus Concept Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
Zimmer Medizin Systems. . . . . . . . . . . . . . . . . . . . . . . . . . . . 2214
pHArmACEuTICAL
Abbott . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2721
Advanced Bio-Technologies, Inc. . . . . . . . . . . . . . . . . . . . . . . 311
Amgen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2141, 2632
Astellas Pharma US, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2031
Auriga International . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2411
Axia Medical Solutions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3253
BioSkin GmbH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3842
Boiron . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1368
Centocor Ortho Biotech . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1440
Chemotechnique Diagnostics/Dormer Laboratories . . . . . . . . 2126
Cu -Tech, L.L.C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3741
Dalos BioPharma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 864
Delasco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3021
Dermik . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3321
Dusa Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2249
Dynamis Skin Science, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . 221
ELON Hair, Nails and Skin . . . . . . . . . . . . . . . . . . . . . . . . . . . 823
Elorac, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 459
for the lAtest ProgrAm Book informAtion PleAse refer to
TECHNICAL EXHIBITS
Ferndale Laboratories, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . 1533
Foamix Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831
Galderma Laboratories, LP. . . . . . . . . . . . . . . . . . . . . . . . . . . 1841
Graceway Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . 2131
Henry Schein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3829
Hill Dermaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . 1965
Hill Top Research Corporation . . . . . . . . . . . . . . . . . . . . . . . 1465
Innovaderm Research Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . 1268
Intendis, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 441
Leo Pharma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611
Medicis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2741
Medimetriks Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . 1664
Mentor Worldwide, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1359
Merz Pharmaceuticals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
Obagi Medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2011
Onset Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2170
Ontos, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 527
Ortho Dermatologics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1240
Paladin Labs Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 851
Person and Covey, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2547
PharmaDerm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3041
PhytoCeuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 567
Pierre Fabre Dermo Cosmetique USA . . . . . . . . . . . . . . . . . . 2311
Promius Pharma, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3933
SkinMedica, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 511
Stiefel Laboratories, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2341
TECHNICAL EXHIBITS
TKL Research, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3549
Triax Pharmaceuticals, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . 1955
Upsher-Smith Laboratories, Inc. . . . . . . . . . . . . . . . . . . . . . . 2319
Valeant Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3341
Valeo Pharma Corp. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3650
Warner Chilcott . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 965
Yaupon Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 565
Young Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . 3241
pHoTogrApHIC EQuIpmENT AND
ImAgINg SErVICES
3Gen, LLC/DermLite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 321
Big C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 662
Canfield Imaging Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . 341
Courage + Khazaka electronic GmbH . . . . . . . . . . . . . . . . . . 2752
Derma Medical Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 827
Fotofinder Systems, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 258
Lucid, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3247
MELA Sciences, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211
MoleSafe USA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1069
National Biological Corporation . . . . . . . . . . . . . . . . . . . . . . 3229
Quantificare, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2115
pHoToTHErApy SuppLIES AND
EQuIpmENT
Daavlin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2929, 2941
Derma Medical Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 827
www.aad.org | 335
 TECHNICAL EXHIBITS
General Project USA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4033
Hill Laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2746
Hironic Co., LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326
Levia-Lerner Medical Devices, Inc. . . . . . . . . . . . . . . . . . . . . 2171
LightStim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 216
National Biological Corporation . . . . . . . . . . . . . . . . . . . . . . 3229
PhotoMedex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 419
Tanda Skincare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2068
Ultralite Enterprises, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . 2421
UVBIOTEK, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
Venus Concept Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
prACTICE mANAgEmENT
CareCredit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218
Clinix Medical Information Services . . . . . . . . . . . . . . . . . . . 3646
Compulink. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1573
DermResources, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1870
Group Health Permanente . . . . . . . . . . . . . . . . . . . . . . . . . . . 2071
Henry Schein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3829
Kaiser Permanente . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 926
MedCo Data, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 563
Medical Protective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 829
Mednet Technologies, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . 2225
Mentor Worldwide, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1359
Micro4, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1665
TECHNICAL EXHIBITS
MJD Patient Communications . . . . . . . . . . . . . . . . . . . . . . . 3040
NexTech . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2157
NextGen Healthcare. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1165
Officite, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3655
Practical Dermatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2553
Practice Flow Solutions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 358
Prime Clinical Systems, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . 3928
Skin and Cancer Associates/Advanced Dermatology Mgmt . . 2210
TeleVox . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1233, 3535
Yodle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2551
336 | AmericAn AcAdemy of dermAtology • 69th AnnuAl meeting
puBLISHINg AND EDuCATIoNAL
mATErIALS
AccessDermatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2367
ADVANCE/Merion Matters . . . . . . . . . . . . . . . . . . . . . . . . . 2622
Aesthetic Guide, The . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1371
Cosmetic Ingredient Review. . . . . . . . . . . . . . . . . . . . . . . . . . 2417
Cosmetic Surgery Times/Dermatology Times . . . . . . . . . . . . 1132
Cutis and Cosmetic Dermatology . . . . . . . . . . . . . . . . . . . . . 2117
Delasco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3021
Derm101.com . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2525
DermatologyOutlines.com . . . . . . . . . . . . . . . . . . . . . . . . . . . . 971
Dermatology World . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3718
DermResources, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1870
Elsevier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1433, 2620
Images En Dermatologie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 972
Informa Healthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2526
International Society of Dermatology. . . . . . . . . . . . . . . . . . . 3818
Johns Hopkins eMedical Dermatology Review . . . . . . . . . . . 1774
Lippincott, Williams & Wilkins. . . . . . . . . . . . . . . . . . . . . . . . 922
McGraw-Hill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2027
Medesthetics Magazine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2466
Mednet Technologies, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . 2225
Merge and Skin Inc. Magazine . . . . . . . . . . . . . . . . . . . . . . . . 3823
National Library of Medicine . . . . . . . . . . . . . . . . . . . . . . . . . 3825
Practical Dermatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2553
PSP: Plastic Surgery Practice . . . . . . . . . . . . . . . . . . . . . . . . . 3630
Rockwell Laser Industries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317
SanovaWorks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 758
Skin & Aging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 930
Skin & Allergy News . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2522
Skin Disease Education Foundation . . . . . . . . . . . . . . . . . . . . 2520
Wiley-Blackwell . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2521
SurgICAL INSTrumENTS
Acuderm, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3221
Anthony Products/Gio Pelle . . . . . . . . . . . . . . . . . . . . . . . . . . 3613
Buffalo Filter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3840
Cobalt Medical Supply . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3913
Delasco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3021
Eclipsemed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3649
Ellis Instruments, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2624
Ellman International . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 759
Henry Schein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3829
Hironic Co. LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326
Marina Medical Instruments, Inc. . . . . . . . . . . . . . . . . . . . . . . 853
Microsurgery Instruments, Inc. . . . . . . . . . . . . . . . . . . . . . . . . 867
Mentor Worldwide, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1359
Miltex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1844
Palomar Medical Technologies, Inc. . . . . . . . . . . . . . . . . . . . . 811
Robbins Instruments Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 833
SurgiTel/General Scientific Corp . . . . . . . . . . . . . . . . . . . . . . 2111
Tiemann-Bernsco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1865
 IN MEMORY

The Academy acknowledges with sorrow the passing of the following members. (As of June 11, 2010)

ASSOCIATE Ngo Thanh Hien, M.D. lIFE MEMBERS lIFE MEMBERS

Sidney E. Thompson, M.D.
Fayetteville, NC
March 14, 2010
FEllOwS
Christopher l. Feucht, M.D.
Chesapeake, VA
April 17, 2010
Daniel M. Ingraham, D.O.
Colleyville, TX
June 22, 1999
Hugh Robert Bailey, M.D.
Liberty, MO
October 15, 2009
w. David Jacoby Jr., M.D.
Tucson, AZ
November 25, 2009
Minneapolis, MN (CONTINuED) (CONTINuED)
January 1, 2010 Hubert M. Brown, M.D. Frederick Helm, M.D.
Dayton, OH Amherst, NY
July 1, 2008 May 7, 2009
HONORARY
Herschel S. Zackheim, M.D. lee Carrick, M.D. Joachim J. Herzberg, M.D.
Helena, MT Naples, FL Bremen, Germany
March 3, 2009 February 4, 2010 December 21, 2009
J. Graham Smith Jr., M.D. Robert T. Carson Jr., M.D. Paul Hirsch, M.D. J.D.
Mobile, AL Oxnard, CA Beverly Hills, CA
May 18, 2010 January 18, 2010 October 14, 2009
Harry J. Hurley, M.D. Julius l. Danto, M.D. James J. Jambor, M.D.
West Chester, PA Albuquerque, NM Dodge City, KS
July 27, 2009 September 21, 2009 January 31, 2010
Thomas linwood Day, M.D. Norman B. Kanof, M.D.
INTERNATIONAl New York, NY New York, NY
FEllOwS December 4, 2008 February 14, 2010
Juan T. Espinosa, M.D.

Craig S. Schauder, M.D.
Cornelius, NC
January 19, 2010
Charles Edwin Reaves, M.D.
Charlotte, NC
September 16, 2009
David Cooper, M.D., Ph.D.
Canton, OH
June 23, 2009
Ingrid R. E. Albert, M.D.
Creve Coeur, MO
July 23, 2009
Cuenca, Ecador
December 8, 2009
Kim Chye Yee, M.D.
Kuala Lumpur, Malaysia
September 16, 2009
Maria E. M. Cafe, M.D.
Belo Horizonte, Brazil
February 1, 2010
lIFE MEMBERS
Eugene P. Alexander, M.D.
San Angelo, TX
March 17, 2010
IN MEMORY
louis A. Fragola Jr., M.D. Robert James Keiper, M.D.
Riverside, RI Long Beach, CA
May 25, 2009 April 23, 2007
lawton C. Gerlinger Jr., M.D. Mohammed Shafi Khan, M.D.
Miamisburg, OH Audubon, PA
November 3, 2009 October 31, 2008
Robert G. German, M.D. Albert M.
Fulton, IL Kligman, M.D., Ph.D.
November 5, 2009 Philadelphia, PA
February 9, 2010
william Albert S.
Gibson, M.D. william Edward laur, M.D.
Glenshaw, PA Amarillo, TX
January 1, 2009 April 20, 2010

Harry M. Humeniuk, M.D. william Eugene Amos, M.D. J.M. Goodman, M.D. Joseph Mann lehman, M.D.
Sylvania, OH Phoenix, AZ Toronto, ON Lubbock, TX
May 11, 2010 July 1, 2009 December 10, 2009 July 31, 2009

John C. Ansel, M.D. James Claire Andrews, M.D. Howard E. Goody, M.D., Ph.D. Grace V. lindsay, M.D.
Little Rock, AR Bremerton, WA Philadelphia, PA Loma Linda, CA
August 8, 2009 August 31, 2009 August 27, 2009 January 6, 2010

Marie-France Jacob Jim Baral, M.D. C. walter Hassel Jr., M.D. Cyrus w. loo, M.D.
Demierre, M.D. New York, NY Pequea, PA Honolulu, HI
Boston, MA May 25, 2010 March 23, 2010 January 27, 2010
April 13, 2010

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 337
 IN MEMORY

lIFE MEMBERS lIFE MEMBERS

(CONTINuED) (CONTINuED)
Herbert lionel Albert Shapiro, M.D.
Manashaw, M.D. Palm Beach Gardens, FL
Encinitas, CA March 12, 2010
April 23, 2007
Alfred J. Shapiro, M.D.
Richard Masters, M.D. Jupiter, FL
Belmont, MA December 13, 2009
March 22, 2009
Jesus Trujillo Valencia, M.D.
Robert Joseph Mexicali, Mexico
McNamara, M.D. January 1, 2006
Oakland, CA
May 15, 2010 lillian S. Vlalukin, M.D.
McLean, VA
John Edward Milner, M.D. November 26, 2005
Seattle, WA
February 24, 2010 Hugh Samuel wiley, M.D.
Centennial, CO
william Bradley September 2, 2009
Moores, M.D.
Carmel, IN
August 23, 2009
IN MEMORY

Ervin Novak, M.D.

Kalamazoo, MI
January 25, 2010

Sidney Olansky, M.D.

Atlanta, GA
December 28, 2007

Neville Pereyo-
Torrellas, M.D.
Ponce, Puerto Rico
October 10, 2009

Samuel John Randall Jr., M.D.

Charlotte, NC
September 13, 2009

Harvey Curtis Roys Jr., M.D.

Seattle, WA
January 3, 2009

Manly Rubin, M.D.

Minneapolis, MN
January 16, 2010

338 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 HONORS AND AwARDS

PAST PRESIDENTS 1989 Edgar B. Smith, M.D.* 1980 Gordon C. Sauer, M.D.*
1990 J. Graham Smith Jr., M.D.* 1981 James H. Graham, M.D.
1938 Howard Fox, M.D.*
1991 Stephen B. Webster, M.D. 1982 Samuel L. Moschella, M.D.
1939 Paul A. O’Leary, M.D.*
1992 Wilma F. Bergfeld, M.D. 1983 Victor D. Newcomer, M.D.*
1940 Harry R. Foerster, M.D.*
1993 Mark V. Dahl, M.D. 1984 Denny L. Tuffanelli, M.D.
1941 Richard S. Weiss, M.D.*
1994 Peyton E. Weary, M.D.* 1985 Harry L. Wechsler, M.D.*
1946 George M. MacKee, M.D.*
1995 Rex A. Amonette, M.D. 1986 Milton Orkin, M.D.*
1947 Edward A. Oliver, M.D.*
1996 W. Mitchell Sams Jr., M.D. 1987 Edward A. Krull, M.D.*
1948 Clyde L. Cummer, M.D.*
1997 Roger I. Ceilley, M.D. 1988 Marvin A. Chernosky, M.D.*
1949 Francis E. Senear, M.D.*
1998 Lynn A. Drake, M.D. 1989 Frederick D. Malkinson, M.D.
1950 Earl D. Osborne, M.D.*
1999 Darrell S. Rigel, M.D. 1990 Diane R. Baker, M.D.
1951 Donald M. Pillsbury, M.D.*
2000 Richard K. Scher, M.D. 1991 Paul M. Lazar, M.D.*
1952 C. Guy Lane, M.D.*
2001 Ronald G. Wheeland, M.D. 1992 Peter J. Lynch, M.D.
1953 Michael H. Ebert, M.D.*
2002 Fred F. Castrow II, M.D. 1993 W. Mitchell Sams Jr., M.D.
1954 Fred D. Weidman, M.D.*
2003 Raymond L. 1994 Lawrence A. Norton, M.D.*
1955 Arthur C. Curtis, M.D.*
Cornelison Jr., M.D. 1995 Alan R. Shalita, M.D.
1956 George M. Lewis, M.D.*
2004 Boni E. Elewski, M.D. 1996 Paul S. Russell, M.D.
1957 Nelson P. Anderson, M.D.*
2005 Clay J. Cockerell, M.D. 1997 Antoinette F. Hood, M.D.
1957 Arthur G. Schoch, M.D.*
2006 Stephen P. Stone, M.D. 1998 Richard K. Scher, M.D.
1958 James R. Webster, M.D.*
2007 Diane R. Baker, M.D. 1999 Roy S. Rogers III, M.D.
1958 Everett R. Seale, M.D.*
2008 C. William Hanke, M.D. 2000 Marianne N.
1959 Anthony C. Cipollaro, M.D.*
2009 David M. Pariser, M.D. O’Donoghue, M.D.
1960 Francis W. Lynch, M.D.*
2010 William D. James, M.D. 2001 Boni E. Elewski, M.D.
1961 Wiley M. Sams, M.D.*
2002 Neil A. Swanson, M.D.
HONORS AND AwARDS

1962 J. Walter Wilson, M.D.*

2003 Joseph L. Jorizzo, M.D.
1963 Robert R. Kierland, M.D.*
1964 Clinton W. Lane, M.D.*
PAST VICE PRESIDENTS 2004 Jeffrey P. Callen, M.D.
1946 Everett C. Fox, M.D.* 2005 Bruce H. Thiers, M.D.
1965 Carl T. Nelson, M.D.*
1949 Frank C. Combes, M.D.* 2006 William P. Coleman III, M.D.
1966 Herman Beerman, M.D.*
1950 Francis W. Lynch, M.D.* 2007 Henry W. Lim, M.D.
1967 Clarence S. Livingood, M.D.*
1951 James L. Pipkin, M.D.* 2008 James S. Taylor, M.D.
1968 Stanley E. Huff, M.D.*
1956 Samuel Becker, M.D.* 2009 Evan R. Farmer, M.D.
1969 Walter C. Lobitz Jr., M.D.*
1958 Everett R. Seale, M.D.* 2010 Andrew P. Lazar, M.D.
1970 Edward C. Cawley, M.D.*
1971 J. Lamar Callaway, M.D.* 1959 Norman M. Wrong, M.D.*
1972 Walter B. Shelley, M.D.* 1961 Thomas Butterworth, M.D.*
1963 Louis H. Winer, M.D.*
PAST
1973 John R. Haserick, M.D.*
1974 Frederick A.J. Kingery, M.D. 1964 Frederick J. Szymanski, M.D.* SECRETARY-TREASuRERS
1975 Rudolf L. Baer, M.D.* 1965 Harry L. Arnold Jr., M.D.* 1938-1941 Clyde L. Cummer, M.D.,
1976 Harry L. Arnold Jr., M.D.* 1966 Rees B. Rees, M.D.* Treasurer*
1977 John M. Shaw, M.D.* 1968 Otis F. Jillson, M.D.* 1938-1941 Earl D. Osborne, M.D.,
1978 Rees B. Rees, M.D.* 1969 Victor H. Witten, M.D.* Secretary*
1979 Robert W. Goltz, M.D. 1970 Hermann Pinkus, M.D.* 1946-1949 Earl D. Osborne, M.D.*
1980 Alfred W. Kopf, M.D. 1971 Harold N. Cole Jr., M.D.* 1950-1953 John E. Rauschkolb, M.D.*
1981 Harold O. Perry, M.D. 1972 John L. Fromer, M.D.* 1954-1957 James R. Webster, M.D.*
1982 John H. Epstein, M.D. 1973 Margaret A. Storkan, M.D.* 1958-1962 Robert R.
1983 John S. Strauss, M.D. 1974 Adolph Rostenberg Jr., M.D.* Kierland, M.D.*
1984 Richard L. Dobson, M.D. 1975 Herbert Mescon, M.D.* 1963-1967 Stanley E. Huff, M.D.*
1985 Clayton E. Wheeler Jr., M.D.* 1976 Harold O. Perry, M.D. 1968 Robert Pommerening, M.D.*
1986 Samuel L. Moschella, M.D. 1977 Morris Waisman, M.D.* 1969-1973 Frederick A.J.
1987 Richard B. Odom, M.D. 1978 Donald J. Birmingham, M.D.* Kingery, M.D.
1988 G. Thomas Jansen, M.D.* 1979 Richard L. Dobson, M.D. 1974-1976 John M. Shaw, M.D.*

*Deceased
340 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

1977-1979 Walter G. Larsen, M.D.
1980-1982 Franklin Pass, M.D.
1983-1985 G. Thomas Jansen, M.D.*
1986-1988 Stephen B. Webster, M.D.
1989-1991 Paul S. Russell, M.D.
1992-1994 Fred F. Castrow II, M.D.
1995-1997 Darrell S. Rigel, M.D.
1998-2000 June K. Robinson, M.D.
2001-2003 Clay J. Cockerell, M.D.
2004-2006 David M. Pariser, M.D.
2007-2009 Mary E. Maloney, M.D.
HONORARY MEMBERS
1939 Andrew Biddle, M.D.*
William T. Corlett, M.D.*
William A. Pusey, M.D.*
Charles J. White, M.D.*
1949 Fred Wise, M.D.*
1958 Clyde L. Cummer, M.D.*
1968 Henry E. Michelson, M.D.*
Donald M. Pillsbury, M.D.*
Marion B. Sulzberger, M.D.*
1969 Charles C. Dennie, M.D.*
Harry R. Foerster, M.D.*
Hamilton Montgomery, M.D.*
1972 Herman Beerman, M.D.*
Clark W. Finnerud, M.D.*
1974 Samuel Ayres Jr. M.D.*
J. Lamar Callaway, M.D.*
Everett C. Fox, M.D.*
Clinton W. Lane, M.D.*
Wiley M. Sams, M.D.*
Richard L. Sutton Jr., M.D.*
J. Walter Wilson, M.D.*
1975 Robert R. Kierland, M.D.*
Francis W. Lynch, M.D.*
J. Lewis Pipkin, M.D.*
Samuel J. Zakon, M.D.*
1978 Clarence S. Livingood, M.D.*
Adolph Rostenberg Jr., M.D.*
1979 Harry L. Arnold Jr., M.D.*
Stanley E. Huff, M.D.*
Frederick A. J. Kingery, M.D.
John M. Shaw, M.D.*
1980 Rudolf L. Baer, M.D.*
Walter C. Lobitz Jr., M.D.*
1981 Hermann Pinkus, M.D.*
Naomi C. Kanof, M.D.*
1982 Rees B. Rees, M.D.*
1983 William Montagna, Ph.D.*
1984 Harold O. Perry, M.D.
For the Latest Program Book InFormatIon PLease reFer to
HONORS AND AwARDS
Walter B. Shelley, M.D.*
1987 Edward P. Cawley, M.D.*
Robert W. Goltz, M.D.
Clayton E. Wheeler Jr., M.D.*
1989 John A. Kenney Jr., M.D.*
Aaron B. Lerner, M.D.*
1991 Harvey Blank, M.D.*
Thomas B.
Fitzpatrick, M.D., Ph.D.*
Peyton E. Weary, M.D.*
1992 William M. Narva, M.D.
Perry Robins, M.D.
Eugene J. Van Scott, M.D.
1993 J. B. Howell, M.D.*
G. Thomas Jansen, M.D.*
1997 Edward A. Krull, M.D.*
J. Graham Smith Jr., M.D.*
John S. Strauss, M.D.
1999 E. William Rosenberg, M.D.
2000 Philip C. Anderson, M.D.*
Richard L. Dobson, M.D.
James H. Graham, M.D.
Alfred W. Kopf, M.D.
2001 Victor D. Newcomer, M.D.*
Herschel S. Zackheim, M.D.*
2002 Bradford W. Claxton, CAE
Mark V. Dahl, M.D.
Harry J. Hurley, M.D.*
Peter J. Lynch, M.D.
2003 Stephen W. Clark
John H. Epstein, M.D.
Paul M. Lazar, M.D.*
Cheryl K. Nordstedt
Edgar B. Smith, M.D.*
2004 Mark A. Everett, M.D.*
Samuel L. Moschella, M.D.
Paul S. Russell, M.D.
2005 Rex A. Amonette, M.D.
David R. Bickers, M.D.
Robert A. Briggaman, M.D.
Irwin M. Freedberg, M.D.*
Gloria F. Graham, M.D.
Richard B. Odom, M.D.
Richard K. Scher, M.D.
2006 Fred F. Castrow II, M.D.
George W. Hambrick Jr., M.D.
Coleman Jacobson, M.D.
2007 A. Bernard Ackerman, M.D.*
Wilma F. Bergfeld, M.D.
Marshall L. Blankenship, M.D.
Nancy B. Esterly, M.D.
Roy S. Rogers III, M.D.
Stephen B. Webster, M.D.
2008 Marie-Louise Johnson, M.D.
Walter G. Larsen, M.D.
Jerome Z. Litt, M.D.
Lawerence A. Norton, M.D.*
W. Mitchell Sams Jr., M.D.
Beverly B. Sanders Jr., M.D.*
Alan R. Shalita, M.D.
Frances J. Storrs, M.D.
2009 Lynn A. Drake, M.D.
James D. Maberry, M.D.
Arthur L. Norins, M.D.
Darrell S. Rigel, M.D.
E. Dorinda Shelley, M.D.
Ronald G. Wheeland, M.D.
J. Graham Smith Jr., M.D.*
2010 Gerd Plewig, M.D.
Jean D.A. Carruthers, M.D.
THE GOlD MEDAl
1962 Henry E. Michelson, M.D.*
1963 Stephen Rothman, M.D.*
1966 Donald M. Pillsbury, M.D.*
HONORS AND AwARDS
1967 Marion B. Sulzberger, M.D.*
1972 J. Lamar Callaway, M.D.*
1975 Clarence S. Livingood, M.D.*
1978 Rudolf L. Baer, M.D.*
1984 Walter C. Lobitz Jr., M.D.*
1986 Naomi M. Kanof, M.D.*
1987 Rees B. Rees, M.D.*
1989 Harvey Blank, M.D.*
1990 Peyton E. Weary, M.D.*
1991 Robert W. Goltz, M.D.
1992 Walter B. Shelley, M.D.*
1993 Clayton E. Wheeler Jr., M.D.*
1995 John S. Strauss, M.D.
1996 Edward A. Krull, M.D.*
1997 G. Thomas Jansen, M.D.*
1998 Harold O. Perry, M.D.
1999 E. William Rosenberg, M.D.
2000 Alfred W. Kopf, M.D.
2001 John A. Kenney Jr., M.D.*
2002 Mark V. Dahl, M.D.
2003 Edgar B. Smith, M.D.*
2004 Paul S. Russell, M.D.
2005 Rex A. Amonnette, M.D.
2006 Coleman Jacobson, M.D.
2007 Stephen B. Webster, M.D.
2008 Frances J. Storrs, M.D.
2009 J. Graham Smith Jr., M.D.*
*Deceased
www.aad.org | 341
 HONORS AND AwARDS

MARION B. SulZBERGER 1978 Henry Kaplan, M.D. MARION B. SulZBERGER, M.D.,

1979 Emil Frei III, M.D. MEMORIAl AwARD AND
INTERNATIONAl 1979 Gerald Weissmann, M.D.
lECTuRESHIP 1980 Howard Green, M.D.
lECTuRESHIP
Sponsored by Miles Pharmaceuticals 1980 Eugene J. Van Scott, M.D. (Lila Gruber Fund Award of the AAD)
(Formerly Miles Pharmaceuticals 1981 Howard M. Temin, Ph.D. 1984 Stephen I. Katz, M.D., Ph.D.
Lectureship) 1982 Werner Bollag, M.D. 1985 Robert A. Briggaman, M.D.
1982 Michael B. Sporn, M.D. 1986 Gerald S. Lazarus, M.D.
1965 Marion B. Sulzberger, M.D.*
1983 Stanley Cohen, Ph.D. 1987 Douglas R. Lowy, M.D.
1966 Eugene M. Farber, M.D.*
1983 Wallace Clark Jr., M.D.* 1988 John A. Parrish, M.D.
1967 Herman Beerman, M.D.*
1984 Margaret L. Kripke, Ph.D. 1989 Eugene A. Bauer, M.D.
1968 Walter C. Lobitz Jr., M.D.*
1984 Robert C. Gallo, M.D. 1990 Thomas T. Provost, M.D.
1969 Carl T. Nelson, M.D.*
1985 J. Michael Bishop, M.D. 1991 Kirk D. Wuepper, M.D.*
1970 Alfred W. Kopf, M.D.
1985 Harald zur Hausen, M.D. 1992 David R. Bickers, M.D.
1971 Richard K. Winkelmann, M.D.
1986 Thomas A. Waldmann, M.D. 1993 Jouni J. Uitto, M.D.
1972 Harvey Blank, M.D.* 1995 Thomas J. Lawley, M.D.
1987 Philip Leder, M.D.
1973 Walter B. Shelley, M.D.* 1996 Luis A. Diaz, M.D.
1988 Robert T. Schimke, M.D.
1974 Rees B. Rees, M.D.* 1997 Wilma F. Bergfeld, M.D.
1989 Stuart H. Yuspa, M.D.
1975 Harry L. Arnold Jr., M.D.* 1998 Ervin H. Epstein Jr., M.D.
1990 Robert A. Weinberg, M.D.
1976 Rudolf L. Baer, M.D.* 1999 Barbara A. Gilchrest, M.D.
1991 Lance A. Liotta, M.D.
1977 Robert W. Goltz, M.D. 2000 Paul R. Bergstresser, M.D.
1992 Arnold J. Levine, Ph.D.
1978 Richard L. Dobson, M.D. 2001 John R. Stanley, M.D.
1993 Erkki Ruoslahti, M.D.
1979 Thomas B. Fitzpatrick, M.D.* 2002 R. Rox Anderson, M.D.
1995 Francis S. Collins, M.D., Ph.D.
1980 Aaron B. Lerner, M.D. 2003 Robert L. Modlin, M.D.
1996 Burt Vogelstein, M.D.
HONORS AND AwARDS

1981 Hermann Pinkus, M.D.* 2004 Paul Khavari, M.D., Ph.D.

1997 Edward E. Harlow Jr., Ph.D.
1983 Howard I. Maibach M.D. 2005 Michael J. Detmar, M.D.
1998 Mary-Claire King, Ph.D.
1984 J. Graham Smith Jr., M.D.* 2006 Gary S. Wood, M.D.
1999 Richard D. Klausner, M.D.
1985 John H. Epstein, M.D. 2007 Kim B. Yancey, M.D.
2000 Alfred G. Knudson, M.D.
1986 Harold O. Perry, M.D. 2008 John A. McGrath, M.D.
2001 David M. Livingston, M.D.
1987 John S. Strauss, M.D. 2009 Kevin D. Cooper, M.D.
2002 Douglas R. Lowy, M.D.
1988 Samuel L. Moschella, M.D. 2010 Andrzej A. Dlugosz, M.D.
2003 Stanley Koesmeyer, M.D.
1989 Irwin M. Braverman, M.D.
2004 Eric S. Lander, Ph.D.
1990 Richard B. Odom, M.D.
2005 Steven A.
1991 G. Thomas Jansen, M.D.* ClARENCE S. lIVINGOOD, M.D.,
Rosenberg, M.D., Ph.D.
1992 Edgar B. Smith, M.D.*
2006 Carol W. Greider, Ph.D. AwARD AND lECTuRESHIP
2007 Errol C. Friedburg, M.D. 1993 John S. Strauss, M.D.
2008 Ian H. Frazer, M.D. 1994 Irwin M. Freedberg, M.D.*
lIlA GRuBER MEMORIAl 1995 M. Roy Schwarz, M.D.
2009 John Mendelsohn, M.D.
CANCER RESEARCH AwARD 2010 Michael R. Stratton, M.D. 1996 Philip C. Anderson, M.D.*
AND lECTuRESHIP 1997 Bradford W. Claxton
1998 Edward A. Krull, M.D.*
1972 Sol Spiegelman, Ph.D.
1999 Mark V. Dahl, M.D.
1973 Professor Jacques Monod 2000 Capt. Jeffrey S. Ashby
1974 Robert A. Good, M.D., Ph.D. 2001 Lowell A. Goldsmith, M.D.
1974 Judah Folkman, M.D. 2002 Klaus Wolff, M.D.
1975 H. Sherwood Lawrence, M.D. 2003 Marcus A. Conant, M.D.
1975 K. Frank Austen, M.D. 2004 Harry J. Hurley, M.D.*
1976 Charles Heidelberger, Ph.D. 2005 Peyton E. Weary, M.D.*
1976 James E. Cleaver, Ph.D. 2006 Steven R.
1977 Frederic E. Mohs, M.D.* Feldman, M.D., Ph.D.
1977 Bert W. O’Malley, M.D. 2007 Antoinette F. Hood, M.D.
1978 Hermann Pinkus, M.D.*
*Deceased

342 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 HONORS AND AwARDS

2008 Barbara A. Gilchrest, M.D. EVERETT C. FOX RESIDENTS/ 2009 Cynthia Harrington, M.D., Ph.D.
2009 Roderick J. Hay, M.D. 2009 Adam Friedman, M.D.
2010 James J. Leyden, M.D.
FEllOwS AwARD 2010 Zakiya Rice, M.D.
(formerly Henry Stelwagon Award) 2010 Grainne O’Regan, M.B.B.Ch., MBA
1970 Dirk W.R. Suringa, M.D.
EuGENE J. VAN SCOTT 1971 James J. Leyden, M.D.
AwARD FOR INNOVATIVE 1972 Mark V. Dahl, M.D.
1973 James A. Yeckley, M.D. MASTERS IN DERMATOlOGY
THERAPY OF THE SKIN AND
1974 Sheldon J. Segal, M.D. 1984 Rudolf L. Baer, M.D.*
PHIllIP FROST lEADERSHIP 1975 Bruce U. Wintroub, M.D. 1985 Harold O. Perry, M.D.
lECTuRE 1976 Robert T. Matheson, M.D. 1985 Clarence S. Livingood, M.D.*
2008 Douglas R. Lowy, M.D. 1977 David A. Norris, M.D. 1985 Harvey Blank, M.D.*
2009 John J. Voorhees, M.D. 1978 David J. Atherton, M.D. 1986 Rees B. Rees, M.D.*
2010 R. Rox Anderson, M.D. 1979 Daniel N. Sauder, M.D. 1987 Walter B. Shelley, M.D.*
1980 Ellen Fithian, M.D. 1987 J. Lamar Callaway, M.D.*
1981 Kristin M. Leiferman, M.D. 1987 Harry L. Arnold Jr., M.D.*
THOMAS G. PEARSON, 1982 Larry L. Peterson, M.D. 1988 Herman Beerman, M.D.*
E.D.D., MEMORIAl 1983 Lela A. Lee, M.D. 1988 Walter C. Lobitz Jr., M.D.*
1984 Francisco Tausk, M.D. 1989 Alexander A. Fisher, M.D.*
EDuCATION AwARD 1986 William S. Sawchuk, M.D. 1989 Richard L. Sutton Jr., M.D.*
2003 Mary E. Maloney, M.D. 1987 James T. Elder, M.D. 1990 Thomas B. Fitzpatrick, M.D., Ph.D.*
2004 Elizabeth I. McBurney, M.D. 1988 Ponciano D. Cruz, M.D. 1990 Robert W. Goltz, M.D.
2005 Roy S. Rogers III, M.D. 1989 William D. Ju, M.D. 1991 John H. Epstein, M.D.
2006 Jean L. Bolognia, M.D. 1990 Kathleen A. David-Bajar, M.D. 1991 G. Thomas Jansen, M.D.*

HONORS AND AwARDS

2007 Thomas L. Ray, M.D. 1991 Linda Cecilia 1992 Richard L. Dobson, M.D.
2008 Jeffrey P. Callen, M.D. Chung-Honet, M.D. 1992 Samuel L. Moschella, M.D.
2009 Peter J. Lynch, M.D. 1992 Nouha D. Hultsch, M.D. 1993 Clayton E.Wheeler Jr., M.D.*
2010 Maria L. Chanco Turner, M.D. 1993 M. Peter Marinkovich, M.D. 1993 Irwin M. Braverman, M.D.
1995 Deirdre Murrell, M.D. 1994 Albert M. Kligman, M.D.*
1996 Zelmira Lazarova, M.D. 1994 Lowell A. Goldsmith, M.D.
EVERETT C. FOX, M.D., 1997 Thomas N. Darling, M.D. 1994 Alfred W. Kopf, M.D.
MEMORIAl lECTuRESHIP 1998 Edel Ann O’Toole, M.D. 1995 Marie-Louise
1994 Harry J. Hurley, M.D.* 1999 Paul S. Yamauchi, M.D., Ph.D. Johnson, M.D., Ph.D.
1995 G. Thomas Jansen, M.D.* 2000 Sumayah Jamal, M.D., Ph.D. 1995 John A. Kenney Jr., M.D.*
1996 William M. Narva, M.D. 2001 Nicole F. Hayre, M.D. 1996 Eugene Farber, M.D.*
1997 Victor D. Newcomer, M.D.* 2002 Eli Sprecher, M.D., Ph.D. 1996 J.B. Howell, M.D.*
1998 Elizabeth I. McBurney, M.D. 2003 Helen S. Young, M.D. 1997 Victor D. Newcomer, M.D.*
1999 Maria L. Chanco Turner, M.D. 2003 Otobia Dimson, M.D. 1997 Eugene J. Van Scott, M.D.
2000 Donald P. Lookingbill, M.D. 2004 Christopher Miller, M.D. 1998 John S. Strauss, M.D.
2001 Irwin H. Braverman, M.D. 2004 Emme Guttman, M.D. 1998 Aaron B. Lerner, M.D.
2002 Rex A. Amonette, M.D. 2005 Amy E. Adams, M.D., Ph.D. 1999 Harry J. Hurley, M.D.*
2003 Gloria F. Graham, M.D. 2005 Shasa Hu, M.D. 1999 Peyton E. Weary, M.D.*
2004 Jeffrey P. Callen, M.D. 2006 Marina O’Kane, MB, 2003 J. Graham Smith Jr., M.D.*
2005 Roy S. Rogers III, M.D. M.R.C.P.U.K., B.S. 2003 Frances J. Storrs, M.D.
2006 Samuel L. Moschella, M.D. 2006 Gregory J. 2004 A. Bernard Ackerman, M.D.*
2007 William D. James, M.D. Fulchiero Jr., M.D., M.S.B.E. 2005 Stephen I. Katz, M.D., Ph.D.
2008 Jean L. Bolognia, M.D. 2007 M. Pressley, M.D., B.Sc. 2006 Mark V. Dahl, M.D.
2009 Frances J. Storrs, M.D. 2007 Richard B. Warren, M.D., 2007 Jon M. Hanifin, M.D.
2010 Libby Edwards, M.D. M.B.Ch.B. (Hons) 2008 Nancy Esterly, M.D.
2008 Jason Clark 2009 Edward A. Krull, M.D.*
2008 Mary Bennett, M.D. 2010 James J. Nordlund, M.D.
*Deceased
For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 343

Committees are listed alphabetically.
All events are held at the Morial Convention Center (MCC) or Hilton Riverside (HR) unless otherwise indicated.
Academic Dermatology leadership Program luncheon
MCC - Room 350 . . . . . . . . . . .Saturday, February 5 - 12:00 p.m.
Academy Former Presidents Advisory Committee
MCC - Room 342 . . . . . . . . . . .Saturday, February 5 - 12:00 p.m.
Access to Dermatologic Care Task Force
MCC - Room 337 . . . . . . . . . . . . .Friday, February 4 - 10:00 a.m.
Advisory Board Executive Committee Meeting
MCC - Room 349 . . . . . . . . . . . . Monday, February 7 - 8:00 a.m.
Advisory Board General Business Meeting
MCC - Room 383/384/385. . . . . .Sunday, February 6 - 2:30 p.m.
Advisory Board Reference Committee Executive Session
MCC - Room 349 . . . . . . . . . . . . . Friday, February 4 - 4:00 p.m.
Advisory Board Reference Committee Hearing
MCC - Room 350 . . . . . . . . . . . . . Friday, February 4 - 2:00 p.m.
Annual Meeting Evaluation Task Force
MCC - Room 338 . . . . . . . . . . . . Friday, February 4 - 12:00 p.m.
Art Exhibit Task Force
MCC - Art Exhibit Hall D/E. . . . . Friday, February 4 - 2:00 p.m.
Board of Directors Meeting
MCC - Room 395/396 . . . . . . . . Saturday, February 5 - 7:00 a.m.
Board Orientation
MCC - Room 349 . . . . . . . . . . . Thursday, February 3 - 7:00 a.m.
Bylaws Committee
MCC - Room 337 . . . . . . . . . . . . Monday, February 7 - 7:00 a.m.
Camp Discovery Committee
MCC - Room 339 . . . . . . . . . . . .Saturday, February 5 - 3:30 p.m.
Career Development Fair
HR - Grand Salon ABC . . . . . . . . . Friday, February 4 - 5:00 p.m.
Carrier Policy and Medical liability Task Force
MCC - Room 338 . . . . . . . . . . . . . .Friday, February 4 - 8:00 a.m.
Clinical Guidelines and Research Committee
MCC - Room 342 . . . . . . . . . . . . Friday, February 4 - 12:00 p.m.
CME Program Review and Evaluation Task Force
MCC - Room 337 . . . . . . . . . . . . . .Friday, February 4 - 7:30 a.m.
Coalition of Skin Diseases
HR - Melrose . . . . . . . . . . . . . . . Monday, February 7 - 11:30 a.m.
Coding and Reimbursement Task Force
MCC - Room 338 . . . . . . . . . . . .Saturday, February 5 - 2:00 p.m.
Congressional Policy Committee
MCC - Room 342 . . . . . . . . . . . . . .Friday, February 4 - 8:00 a.m.
Core Curriculum Task Force
HR - Eglinton and Winton . . . . . . .Friday, February 4 - 9:30 a.m.
Corporate Partner Circle Meeting
HR - Belle Chasse . . . . . . . . . . . . . .Friday, February 4 - 7:00 a.m.
Corporate Partner Recognition Reception
HR - Versailles Ballroom . . . . . . . .Sunday, February 6 - 5:00 p.m.
For the Latest Program Book InFormatIon PLease reFer to
COMMITTEE MEETINGS
Corporate Relations Task Force Meeting
HR - Chequers. . . . . . . . . . . . . . . Monday, February 7 - 7:00 a.m.
Council on Communications
MCC - Room 339 . . . . . . . . . . . . .Sunday, February 6 - 5:00 p.m.
Council on Education
MCC - Room 342 . . . . . . . . . . . . Monday, February 7 - 2:00 p.m.
Council on Government Affairs, Health Policy, and Practice
MCC - Room 356 . . . . . . . . . . . . Monday, February 7 - 9:30 a.m.
Council on Member Services
MCC - Room 342 . . . . . . . . . . . . Monday, February 7 - 9:00 a.m.
Dermatopathology Task Force
MCC - Room 337 . . . . . . . . . . . . . Friday, February 4 - 2:00 p.m.
DermCAC
HR - Belle Chasse . . . . . . . . . . . Thursday, February 3 - 2:00 p.m.
Dermlex Task Force
MCC - Room 342 . . . . . . . . . . . . Saturday, February 5 - 9:00 a.m.
Development Committee Meeting
HR - Belle Chasse . . . . . . . . . . . . . Friday, February 4 - 3:00 p.m.
COMMITTEE MEETINGS
Dialogues in Dermatology Editorial Board
HR - Cambridge . . . . . . . . . . . . . . .Friday, February 4 - 7:30 a.m.
Distance learning and Enduring Materials Committee
MCC - Room 350 . . . . . . . . . . . . .Sunday, February 6 - 2:00 p.m.
Diversity Task Force Meeting
MCC - Room 337 . . . . . . . . . . . . Saturday, February 5 - 8:00 a.m.
Education and Volunteer Abroad Committee
MCC - Room 349 . . . . . . . . . . .Saturday, February 5 - 12:00 p.m.
Ethics Committee
MCC - Room 337 . . . . . . . . . . . Monday, February 7 - 12:00 p.m.
Grassroots Advocacy Committee
HR - Chequers. . . . . . . . . . . . . . . .Sunday, February 6 - 2:00 p.m.
Health Care Delivery Committee
MCC - Room 337 . . . . . . . . . . . .Saturday, February 5 - 1:00 p.m.
Health Care Finance Committee
MCC - Room 338 . . . . . . . . . . . .Saturday, February 5 - 4:00 p.m.
History Committee
MCC - Room 356 . . . . . . . . . . . .Saturday, February 5 - 2:00 p.m.
HVO Steering Committee Meeting
MCC - Room 338 . . . . . . . . . . . . Saturday, February 5 - 7:00 a.m.
Interdisciplinary and Postgraduate Education Task Force
MCC - Room 339 . . . . . . . . . . . . Saturday, February 5 - 7:30 a.m.
International Affairs Committee
MCC - Room 338 . . . . . . . . . . . . .Sunday, February 6 - 2:00 p.m.
International Members Reception
HR - Grand Salon D . . . . . . . . . . . Friday, February 4 - 5:00 p.m.
International Scholarship Reception and Dinner
HR - Versailles Ballroom . . . . . . Thursday, February 3 - 6:00 p.m.
www.aad.org | 345
 COMMITTEE MEETINGS
Intersociety liaison Committee
MCC - Room 339 . . . . . . . . . . . . Monday, February 7 - 2:00 p.m.
Investment Committee
MCC - Room 338 . . . . . . . . . . . . Monday, February 7 - 7:00 a.m.
JAAD Assistant/Associate Editors Meeting
HR - Rosedown . . . . . . . . . . . . . . .Sunday, February 6 - 4:00 p.m.
JAAD Editorial Board Meeting
HR - Rosedown . . . . . . . . . . . . . .Saturday, February 5 - 4:00 p.m.
leaders in Giving Recognition Reception
HR - Rosedown . . . . . . . . . . . . . . . Friday, February 4 - 5:00 p.m.
leadership Advisory Board Meeting
MCC - Room 338 . . . . . . . . . . . . Monday, February 7 - 3:30 p.m.
leadership and Mentoring Reception
HR - Jefferson . . . . . . . . . . . . . . . .Sunday, February 6 - 5:00 p.m.
leadership Development Steering Committee
MCC - Room 342 . . . . . . . . . . . . .Sunday, February 6 - 2:00 p.m.
Maintenance of Certification Committee
MCC - Room 350 . . . . . . . . . . . . .Sunday, February 6 - 3:30 p.m.
Media Appreciation luncheon
MCC - Room 393/394 . . . . . . .Saturday, February 5 - 12:00 p.m.
Medical Informatics Committee
MCC - Room 339 . . . . . . . . . . . Saturday, February 5 - 11:00 a.m.
Medical Student Core Curriculum work Group
COMMITTEE MEETINGS
MCC - Room 356 . . . . . . . . . . . . .Sunday, February 6 - 1:00 p.m.
Melanoma/Skin Cancer Committee
MCC - Room 349 . . . . . . . . . . . . .Sunday, February 6 - 3:15 p.m.
Membership Committee
MCC - Room 356 . . . . . . . . . . . . . .Friday, February 4 - 9:00 a.m.
Needs Assessment and Program Evaluation Committee
MCC - Room 338 . . . . . . . . . . . Monday, February 7 - 10:00 a.m.
Needs Assessment Task Force
MCC - Room 357 . . . . . . . . . . . .Saturday, February 5 - 2:00 p.m.
Organizational Structure Committee
MCC - Room 349 . . . . . . . . . . . . .Friday, February 4 - 10:00 a.m.
Pamphlets Editorial Board
MCC - Room 339 . . . . . . . . . . . . .Sunday, February 6 - 2:00 p.m.
Patient Advocate Task Force
HR - Durham . . . . . . . . . . . . . . . .Sunday, February 6 - 4:00 p.m.
Patient Safety and Quality of Care Committee
MCC - Room 356 . . . . . . . . . . . . Friday, February 4 - 12:00 p.m.
Performance Measurement Task Force
HR - Ascot . . . . . . . . . . . . . . . . . . .Sunday, February 6 - 2:00 p.m.
Poster Exhibit Task Force
MCC - Room 339 . . . . . . . . . . . . .Friday, February 4 - 11:30 a.m.
Practice Management Task Force
MCC - Room 339 . . . . . . . . . . . . . .Friday, February 4 - 9:00 a.m.
Quality Assurance/Quality Improvement Task Force
HR - Cambridge . . . . . . . . . . . . . . Friday, February 4 - 1:30 p.m.
346 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
2011 Recognition luncheon
MCC - Room 393/394 . . . . . . . . Friday, February 4 - 12:00 p.m.
Regional Course work Group
MCC - Room 339 . . . . . . . . . . . . Monday, February 7 - 7:30 a.m.
Regulatory Policy Committee
MCC - Room 338 . . . . . . . . . . . . . Friday, February 4 - 3:00 p.m.
Resident Reception
HR - Napoleon Ballroom. . . . . . . . Friday, February 4 - 5:00 p.m.
Residents/Fellows Committee Meeting
HR - Melrose . . . . . . . . . . . . . . . Thursday, February 3 - 5:30 p.m.
Scientific Assembly Committee Meeting
MCC - Room 356 . . . . . . . . . . . . Monday, February 7 - 4:30 p.m.
Self - Assessment Task Force
MCC - Room 339 . . . . . . . . . . . . . Sunday, February 6 - 7:30 a.m.
Sharing Mentoring Experiences
MCC - Room 393/394 . . . . . . . . . .Friday, February 4 - 7:30 a.m.
SkinPAC and Dermatology Advocacy Network Reception
HR - Jefferson . . . . . . . . . . . . . . . . Friday, February 4 - 5:00 p.m.
SkinPAC Board of Advisors Meeting
HR - Eglinton and Winton . . . . . . Friday, February 4 - 2:30 p.m.
Sports Committee
MCC - Room 337 . . . . . . . . . . . .Saturday, February 5 - 5:30 p.m.
State Dermatology Society Executives Conference
MCC - Room 338 . . . . . . . . . . . Thursday, February 3 - 8:00 a.m.
State Dermatology Society leadership Breakfast
HR - Melrose . . . . . . . . . . . . . . . . . .Friday, February 4 - 8:00 a.m.
State Policy Committee
MCC - Room 357 . . . . . . . . . . . . .Friday, February 4 - 10:00 a.m.
State Society Development Task Force
MCC - Room 357 . . . . . . . . . . . . . Friday, February 4 - 2:00 p.m.
Strategy Committee
MCC - Room 349 . . . . . . . . . . . Thursday, February 3 - 2:00 p.m.
Sulzberger Institute for Dermatologic Education Committee
MCC - Room 339 . . . . . . . . . . . . . Friday, February 4 - 2:30 p.m.
Telemedicine Task Force
HR - Eglinton and Winton . . . . . Monday, February 7 - 9:00 a.m.
Volunteer Fair
HR - Court Assembly . . . . . . . . . . Friday, February 4 - 5:00 p.m.
Volunteerism Committee
MCC - Room 350 . . . . . . . . . . . . Monday, February 7 - 7:30 a.m.
workforce Task Force
MCC - Room 357 . . . . . . . . . . . . Monday, February 7 - 8:00 a.m.
world Congress Fund Review Task Force
MCC - Room 357 . . . . . . . . . . . . . .Friday, February 4 - 7:30 a.m.
Young Physician and New Member welcome Reception
HR - Versailles Ballroom . . . . . . . . Friday, February 4 - 5:00 p.m.
Young Physicians Committee
MCC - Room 342 . . . . . . . . . . . . . Sunday, February 6 - 7:30 a.m.
 ANCIllARY GROuPS AND REuNIONS
Groups are listed alphabetically.
All events are held at the Hilton Riverside (HR) unless otherwise indicated.
Albert Einstein College of Medicine - Dermatology Alumni
HR - Port . . . . . . . . . . . . . . . . . . .Saturday, February 5 - 6:00 p.m.
Alumni Reception for university of Chicago Dermatology
HR - Melrose . . . . . . . . . . . . . . . .Saturday, February 5 - 6:00 p.m.
American Contact Dermatitis Society - 22nd Annual Meeting
General Session
New Orleans Marriott . . . . . . . . Thursday, February 3 - 7:00 a.m.
American Contact Dermatitis Society - Annual Meeting
Committee
New Orleans Marriott . . . . . . .Wednesday, February 2 - 1:00 p.m.
American Contact Dermatitis Society - Board of Directors
Meeting
New Orleans Marriott . . . . . . .Wednesday, February 2 - 6:00 p.m.
American Contact Dermatitis Society - Breakfast Symposium
New Orleans Marriott . . . . . . . . Thursday, February 3 - 7:30 a.m.
American Contact Dermatitis Society - Editorial Board
New Orleans Marriott . . . . . . . . . . .Friday, February 4 - 7:00 a.m.
American Contact Dermatitis Society - Poster and Scientific
Exhibits
New Orleans Marriott . . . . . . . . Thursday, February 3 - 7:00 a.m.
American Contact Dermatitis Society - Reception
New Orleans Marriott . . . . . . . . Thursday, February 3 - 5:00 p.m.
American Contact Dermatitis Society - Roundtable lunch
New Orleans Marriott . . . . . . . Thursday, February 3 - 12:00 p.m.
American Israel Society of Dermatologists (AISD)
HR - Belle Chasse . . . . . . . . . . . . .Sunday, February 6 - 5:30 p.m.
American Society for Mohs Surgery Board Meeting
HR - Durham . . . . . . . . . . . . . . . . Friday, February 4 - 6:00 p.m.
American Society for Mohs Surgery Fellow Exam
HR - Elmwood . . . . . . . . . . . . . . . Friday, February 4 - 4:00 p.m.
For the Latest Program Book InFormatIon PLease reFer to
American Society for Muslims in Dermatology
Cleopatra Mediterraneon Restaurant - 2701 Manhattan Blvd,
Harvey, LA . . . . . . . . . . . . . . . . . . . Friday, February 4 - 7:30 p.m.
Association of Military Dermatologists
National WWII Museum . . . . . . . Monday, February 7 - 6:00 p.m.
Association of Professors of Dermatology (APD) Board of
Directors Meeting
HR - Melrose . . . . . . . . . . . . . . . . Saturday, February 5 - 7:00 a.m.
Association of Surgical Faculty
HR - Magnolia. . . . . . . . . . . . . . .Sunday, February 6 - 12:00 p.m.
Atlantic Derm Exec Committee Meeting
HR - Norwich . . . . . . . . . . . . . . . . Friday, February 4 - 5:00 p.m.
Atopic Dermatitis ERG Meeting
HR - Jasperwood . . . . . . . . . . . . . . Friday, February 4 - 4:00 p.m.
Boston university Dermatology Alumni Reunion
HR - Grand Salon 21, 24 . . . . . .Saturday, February 5 - 6:00 p.m.
ANCIllARY GROuPS & REuNIONS
Brown university Department of Dermatology Residency
Reunion
Windsor Court - 300 Gravier Street . Saturday, February 5 - 6:00 p.m.
Canadian Dermatology Foundation Board Meeting
HR - Norwich . . . . . . . . . . . . . . . .Sunday, February 6 - 2:00 p.m.
Canadian Professors of Dermatology
HR - Newberry . . . . . . . . . . . . . . . .Friday, February 4 - 7:00 a.m.
Case School of Medicine - Alumni Reunion for Residents,
Fellows and Faculty
HR - Prince of Wales . . . . . . . . . . . Friday, February 4 - 5:30 p.m.
CDA Board of Directors
HR - Chequers. . . . . . . . . . . . . . . . Sunday, February 6 - 7:00 a.m.
CDA Bulletin Committee
HR - Trafalgar . . . . . . . . . . . . . . . . Sunday, February 6 - 8:00 a.m.
www.aad.org | 347
 ANCIllARY GROuPS AND REuNIONS
CDA Dermatology Surgery Committee
HR - Newberry . . . . . . . . . . . . . . Saturday, February 5 - 7:00 a.m.
CDA Education Committee
HR - Warwick . . . . . . . . . . . . . . . . Sunday, February 6 - 8:00 a.m.
CDA Humanitarian Committee
HR - Durham . . . . . . . . . . . . . . . . Sunday, February 6 - 7:00 a.m.
CDA Industry Committee Meeting
HR - Norwich . . . . . . . . . . . . . . . . .Friday, February 4 - 8:00 a.m.
CDA Pharmacy and Therapeutics Committee
HR - Ascot . . . . . . . . . . . . . . . . . . Saturday, February 5 - 7:00 a.m.
CDA Planning Committee
HR - Warwick . . . . . . . . . . . . . . . Saturday, February 5 - 8:30 a.m.
CDA Reception
HR - Grand Ballroom A . . . . . . . .Sunday, February 6 - 6:30 p.m.
CDA Sun Awareness Program Committee
HR - Norwich . . . . . . . . . . . . . . . . Sunday, February 6 - 8:00 a.m.
CDA wCD 2015 Bid Meeting
HR - Norwich . . . . . . . . . . . . . . . . Friday, February 4 - 2:00 p.m.
Christian Medical Association Dermatology Section
HR - Melrose . . . . . . . . . . . . . . . . . Sunday, February 6 - 7:00 a.m.
ANCIllARY GROuPS & REuNIONS
Cicatricial Alopecia Research Foundation Scientific Advisors
Meeting
HR - Elmwood . . . . . . . . . . . . . . Saturday, February 5 - 7:00 a.m.
Clinics in Dermatology Editorial Board Meeting
Windsor Court - 300 Gravier Street . . .Sunday, February 6 - 7:30 a.m.
Cook County/Rush Reunion
HR - Ascot . . . . . . . . . . . . . . . . . . .Sunday, February 6 - 5:30 p.m.
Cooper university Hospital Dermatology Reunion
HR - Warwick . . . . . . . . . . . . . . . . Friday, February 4 - 6:00 p.m.
Council for Nail Disorders - 15th Annual Meeting
New Orleans Marriott . . . . . . . Thursday, February 3 - 11:00 a.m.
Council for Nail Disorders - Board of Trustees
New Orleans Marriott . . . . . . . . Thursday, February 3 - 5:00 p.m.
348 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
Council for Nail Disorders - Exhibits
New Orleans Marriott . . . . . . . Thursday, February 3 - 11:00 a.m.
Council of Dermatology Editors
Windsor Court - 300 Gravier Street . .Monday, February 7 - 7:30 a.m.
Cutaneous lymphoma Foundation Medical Advisory Board
HR - Newberry . . . . . . . . . . . . . . Friday, February 4 - 12:00 p.m.
Dartmouth Dermatology Reunion
HR - Steering . . . . . . . . . . . . . . . . . Friday, February 4 - 5:00 p.m.
Dermatoepidemiology Expert Resource Group (ERG) Meeting
HR - Cambridge . . . . . . . . . . . . . . Sunday, February 6 - 7:00 a.m.
Dermatology Foundation Annual Meeting of Membership and
Award Presentation
HR - Versailles Ballroom . . . . . . .Saturday, February 5 - 5:30 p.m.
Dermatology Foundation Annual Meeting Reception
HR - Napoleon Ballroom. . . . . . .Saturday, February 5 - 6:30 p.m.
Dermatology Foundation Board of Trustees Meeting
HR - Magnolia. . . . . . . . . . . . . . . Saturday, February 5 - 8:00 a.m.
Dermatology Foundation Medical and Scientific Meeting (Day 1)
HR - Fountain . . . . . . . . . . . . . Wednesday, February 2 - 8:00 a.m.
Dermatology Foundation Medical and Scientific Meeting (Day 2)
HR - Fountain . . . . . . . . . . . . . . Thursday, February 3 - 8:00 a.m.
Dermatology Foundation Project Awareness Committee Meeting
HR - Durham . . . . . . . . . . . . . . . Monday, February 7 - 9:00 a.m.
Dowling Club Reunion
HR - Compass . . . . . . . . . . . . . . .Saturday, February 5 - 6:30 p.m.
Duke uNC Reunion
HR - Jasperwood . . . . . . . . . . . . . .Sunday, February 6 - 6:00 p.m.
Emory univeristy School of Medicine
HR - Cambridge . . . . . . . . . . . . . . Friday, February 4 - 6:00 p.m.
FIRST Medical and Scientific Advisory Board Meeting
HR - Jasperwood . . . . . . . . . . . . . Saturday, February 5 - 7:00 a.m.
 ANCIllARY GROuPS AND REuNIONS
Foundation for International Dermatologic Education Board of
Directors Meeting
HR - Durham . . . . . . . . . . . . . . . Saturday, February 5 - 8:00 a.m.
Foundation for International Dermatologic Education Reception
HR - Pelican . . . . . . . . . . . . . . . . . Friday, February 4 - 6:00 p.m.
Gay and lesbian Dermatology Specialists Association
Reception
500 Chartres Street - 2nd Floor . . . Friday, February 4 - 8:00 p.m.
Geisinger Medical Center Reunion
HR - Newberry . . . . . . . . . . . . . . .Sunday, February 6 - 5:30 p.m.
GRAPPA
HR - Fountain . . . . . . . . . . . . . . . Sunday, February 6 - 11:30 a.m.
Hackney - Norins Society Board Meeting
HR - Newberry . . . . . . . . . . . . . .Saturday, February 5 - 5:30 p.m.
Harvard Dermatology House Officers Club Reception
HR - Jasperwood . . . . . . . . . . . . . . Friday, February 4 - 7:30 p.m.
Hemangioma Investigators Group
HR - Norwich . . . . . . . . . . . . . . Thursday, February 3 - 7:30 a.m.
Henry Ford Hospital - Alumni Reunion
HR - Oak Alley . . . . . . . . . . . . . . . Friday, February 4 - 6:00 p.m.
History of Dermatology Society Annual Banquet and Zakon
lecture
Restaurant August -
301 Tchoupitoulas Street . . . . . . Thursday, February 3 - 7:00 p.m.
History of Dermatology Society lunch
Windsor Court -
300 Gravier Street . . . . . . . . . . Thursday, February 3 - 12:00 p.m.
History of Dermatology Society Ogden Museum Tour
Ogden Museum -
925 Camp Street . . . . . . . . . . . Thursday, February 3 - 10:00 a.m.
History of Dermatology Society Seminar
Windsor Court -
300 Gravier Street . . . . . . . . . . . Thursday, February 3 - 1:30 p.m.
For the Latest Program Book InFormatIon PLease reFer to
Indiana university School of Medicine Hackney -Norins Society
HR - Grand Salon 6. . . . . . . . . . .Saturday, February 5 - 6:30 p.m.
International Academy of Cosmetic Dermatology Board of
Directors Meeting
Windsor Court -
300 Gravier Street . . . . . . . . . . . . Saturday, February 5 - 8:00 a.m.
International Confocal working Group
HR - Grand Ballroom A . . . . . . Thursday, February 3 - 1:00 p.m.
International Dermoscopy Society
HR - Grand Ballroom A . . . . . . Thursday, February 3 - 1:00 p.m.
International Journal of Dermatology - Editorial Board Meeting
HR - Jasperwood . . . . . . . . . . . . .Sunday, February 6 - 12:00 p.m.
International Society for Digital Imaging of the Skin
HR - Grand Ballroom A . . . . . . Thursday, February 3 - 1:00 p.m.
International Society of Dermatology - Board of Directors
HR - Marlborough AB. . . . . . . . Monday, February 7 - 11:00 a.m.
International Society of Dermatology - Committee Meetings
HR - Belle Chasse . . . . . . . . . . . . Monday, February 7 - 2:00 p.m.
International Society of Dermatology - Executive Committee
HR - Ascot . . . . . . . . . . . . . . . . . . Monday, February 7 - 8:00 a.m.
ANCIllARY GROuPS & REuNIONS
International Society of Dermatology - Reception
HR - Jefferson . . . . . . . . . . . . . . . Monday, February 7 - 5:30 p.m.
International Transplant Skin Cancer Collaborative Membership
Meeting
HR - Grand Ballroom B . . . . . . Thursday, February 3 - 4:00 p.m.
Iowa Dermatological Society Reunion
HR - Jasperwood . . . . . . . . . . . . .Saturday, February 5 - 6:00 p.m.
IPPF Medical Advisory Board Meeting
HR - Fountain . . . . . . . . . . . . . . . Saturday, February 5 - 7:00 a.m.
ISDS Board of Directors Meeting
HR - Eglinton and Winton . . . . . .Sunday, February 6 - 5:15 p.m.
ITSCC Board of Directors Meeting
HR - Ascot . . . . . . . . . . . . . . . . . . . .Friday, February 4 - 7:00 a.m.
www.aad.org | 349
 ANCIllARY GROuPS AND REuNIONS

Jefferson Medical College Reunion
HR - Marlborough B . . . . . . . . . . .Sunday, February 6 - 5:30 p.m.
Johns Hopkins Reunion
HR - Oak Alley . . . . . . . . . . . . . .Saturday, February 5 - 6:00 p.m.
Journal of Cutaneous Medicine and Surgery Editorial Board
Meeting
HR - Prince of Wales . . . . . . . . . . Saturday, February 5 - 7:00 a.m.
logical Images, Inc. Editorial Reception
HR - Eglinton and Winton . . . . .Saturday, February 5 - 5:00 p.m.
Mayo Clinic Dermatology Alumni O’leary Society Reception
and Dinner
Brennan’s Restaurant -
Contact slavin.nancy@mayo.edu . . . . Saturday, February 5 - 6:15 p.m.
Medical College of VA/VA Commonwealth university
HR - Durham . . . . . . . . . . . . . . .Saturday, February 5 - 5:30 p.m.
Medical Dermatology Society Annual Meeting
HR - Jefferson . . . . . . . . . . . . . . Thursday, February 3 - 1:00 p.m.
Medical Dermatology Society Annual Meeting Reception
HR - Oak Alley . . . . . . . . . . . . . Thursday, February 3 - 6:00 p.m.
Medical university of South Carolina
ANCIllARY GROuPS & REuNIONS
National Eczema Association Scientific Advisory Committee
HR - Cambridge . . . . . . . . . . . . . .Sunday, February 6 - 4:00 p.m.
National Medical Association’s Annual Dermatology
Meeting Reception
HR - River . . . . . . . . . . . . . . . . . .Saturday, February 5 - 6:30 p.m.
National Psoriasis Foundation Medical Board Meeting
HR - Rosedown . . . . . . . . . . . . Thursday, February 3 - 12:00 p.m.
National Psoriasis Foundation Partner’s Reception
HR - Melrose . . . . . . . . . . . . . . . . . Friday, February 4 - 5:30 p.m.
New York university School of Medicine
HR - Grand Salon 19. . . . . . . . . .Saturday, February 5 - 6:30 p.m.
North American Clinical Dermatologic Society Board Meeting
HR - Steering . . . . . . . . . . . . . . . . Saturday, February 5 - 8:00 a.m.
North American Contact Dermititis Group
HR - Cambridge . . . . . . . . . . . Wednesday, February 2 - 8:00 a.m.
North American Hair Research Society
HR - Magnolia. . . . . . . . . . . . . . . Friday, February 4 - 12:00 p.m.
Northwestern university Department of Dermatology/university
of Illinois/Rush/Cook County Reunion
HR - Grand Salon 10, 7 . . . . . . .Saturday, February 5 - 6:30 p.m.

Invitation to Follow . . . . . . . . . . . . Friday, February 4 - 6:00 p.m.

Ohio State university Dermatology Reunion
Merkel Cell Carcinoma Multicenter Interest Group HR - Fountain . . . . . . . . . . . . . . .Saturday, February 5 - 5:30 p.m.
HR - Ascot . . . . . . . . . . . . . . . . . . . Friday, February 4 - 5:00 p.m.
Oregon Health and Science university Alumni Reunion
Mount Sinai School of Medicine Reception for Alumni HR - Magnolia. . . . . . . . . . . . . . . .Sunday, February 6 - 6:30 p.m.
and Friends
PDA Executive Committee Meeting
HR - Magnolia. . . . . . . . . . . . . . .Saturday, February 5 - 6:00 p.m.
HR - Ascot . . . . . . . . . . . . . . . . .Saturday, February 5 - 12:00 p.m.
NAHRS Task Force Breakfast Meeting
Penn Medicine Alumni Reception
HR - Cambridge . . . . . . . . . . . . . Monday, February 7 - 7:00 a.m.
HR - Fountain . . . . . . . . . . . . . . . .Sunday, February 6 - 6:00 p.m.
Nanodermatology Society
Photomedicine Society Annual Board of Directors Meeting
HR - Magnolia. . . . . . . . . . . . . . . . Friday, February 4 - 5:30 p.m.
HR - Melrose . . . . . . . . . . . . . . Thursday, February 3 - 12:00 p.m.
National Alopecia Areata Foundation Scientific Advisory
Photomedicine Society Annual Meeting
Council lunch Meeting
HR - Elmwood . . . . . . . . . . . . . Thursday, February 3 - 7:00 a.m.
HR - Prince of Wales . . . . . . . . .Saturday, February 5 - 12:00 p.m.

350 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 ANCIllARY GROuPS AND REuNIONS
Rofeh Ohr Society
HR - Trafalgar . . . . . . . . . . . . . . . . Friday, February 4 - 5:00 p.m.
Rofeh Ohr Society
HR - Trafalgar . . . . . . . . . . . . . . . Saturday, February 5 - 7:00 a.m.
Roger williams Department of Dermatology and Skin Surgery
Reunion
HR - Bridge . . . . . . . . . . . . . . . . .Saturday, February 5 - 6:00 p.m.
Rush/Cook County Reunion
HR - Ascot . . . . . . . . . . . . . . . . . . .Sunday, February 6 - 5:30 p.m.
Saint louis university Alumni Reception
HR - Newberry . . . . . . . . . . . . . . . Friday, February 4 - 5:00 p.m.
SIu Dermatology Alumni Reception
HR - Trafalgar . . . . . . . . . . . . . . .Saturday, February 5 - 5:30 p.m.
Skin and Allergy News Editorial Advisory Board Meeting
HR - Fountain . . . . . . . . . . . . . . . . Sunday, February 6 - 6:30 a.m.
Skin Cancer Foundation Photobiology luncheon
HR - Durham . . . . . . . . . . . . . . .Sunday, February 6 - 12:00 p.m.
Skin of Color Society Annual Reception
HR - Magnolia. . . . . . . . . . . . . . Thursday, February 3 - 6:00 p.m.
Skin of Color Society Annual Scientific and Business Meeting
HR - Jasperwood . . . . . . . . . . . . Thursday, February 3 - 2:00 p.m.
SKINmed Editorial Board Meeting
Windsor Court - 300 Gravier Street . Sunday, February 6 - 12:00 p.m.
Society for Investigative Dermatology Meetings
HR - Norwich . . . . . . . . . . . . . . . Saturday, February 5 - 7:00 a.m.
Society for Pediatric Dermatology Resident Reception
HR - Fountain . . . . . . . . . . . . . . . . Friday, February 4 - 5:00 p.m.
Spanish Academy of Dermatology - Academia Espanola De
Dermatologia Y Venereologia
HR - Grand Ballroom A . . . . . . .Saturday, February 5 - 6:00 p.m.
SPD Executive Committee Meeting
HR - Jasperwood . . . . . . . . . . . . . Friday, February 4 - 12:00 p.m.
For the Latest Program Book InFormatIon PLease reFer to
SPD Pre-AAD Meeting
HR - Napoleon Ballroom. . . . . . Thursday, February 3 - 9:00 a.m.
SuNY Downstate Medical Center Reunion
HR - Melrose . . . . . . . . . . . . . . . . .Sunday, February 6 - 6:00 p.m.
The O’leary Society Board Meeting
HR - Durham . . . . . . . . . . . . . . .Saturday, February 5 - 3:30 p.m.
uCSD Dermatology Alumni Reunion - Dr. Howard and Barbara
Milstein Reunion
HR - Grand Salon 3. . . . . . . . . . .Saturday, February 5 - 6:00 p.m.
univeristy of British Columbia Department of Dermatology and
Skin Science Alumni and Friends
HR - Belle Chasse . . . . . . . . . . . .Saturday, February 5 - 5:00 p.m.
university of California San Francisco Alumni Reunion
HR - Grand Ballroom B . . . . . . . .Sunday, February 6 - 6:30 p.m.
university of California, Davis, Department of Dermatology
Alumni
HR - Grand Salon 12. . . . . . . . . .Saturday, February 5 - 6:00 p.m.
university of California, Irvine Annual Alumni Meeting
HR - Grand Salon 18. . . . . . . . . .Saturday, February 5 - 6:00 p.m.
university of Cincinnati Alumni Reception
ANCIllARY GROuPS & REuNIONS
HR - Prince of Wales . . . . . . . . . . .Sunday, February 6 - 5:30 p.m.
university of louisville Reunion
HR - Cambridge . . . . . . . . . . . . .Saturday, February 5 - 5:00 p.m.
university of Maryland Reunion
HR - Pelican . . . . . . . . . . . . . . . .Saturday, February 5 - 5:30 p.m.
university of Miami Alumni Reunion
HR - Grand Salon 16, 13 . . . . . .Saturday, February 5 - 6:30 p.m.
university of Minnesota Dermatology Alumni Reunion
HR - Steering . . . . . . . . . . . . . . . .Saturday, February 5 - 5:45 p.m.
university of Rochester Alumni Reception
HR - Eglinton and Winton . . . . . . Friday, February 4 - 6:30 p.m.
university of Southern California Dermatology Reunion
HR - Starboard . . . . . . . . . . . . . .Saturday, February 5 - 6:00 p.m.
www.aad.org | 351
 ANCIllARY GROuPS AND REuNIONS
university of Tennesee
HR - Grand Salon 15. . . . . . . . . .Saturday, February 5 - 6:00 p.m.
university of utah, Department of Dermatology Reunion
HR - Grand Salon 9. . . . . . . . . . .Saturday, February 5 - 6:00 p.m.
university of Virginia Reunion
HR - Prince of Wales . . . . . . . . . .Saturday, February 5 - 6:30 p.m.
university of washington Dermatology Division Reception
HR - Chequers. . . . . . . . . . . . . . .Saturday, February 5 - 5:30 p.m.
uS Consortium for Cutanous lymophomas Meeting
HR - Grand Salon A . . . . . . . . . Thursday, February 3 - 7:00 a.m.
uSClC Board of Directors Breakfast
HR - Jasperwood . . . . . . . . . . . . . . .Friday, February 4 - 7:00 a.m.
uSF Dermatology Alumni Reception
HR - Grand Salon 4. . . . . . . . . . .Saturday, February 5 - 5:30 p.m.
uT Southwestern Medical Center Reunion
HR - Elmwood . . . . . . . . . . . . . . .Sunday, February 6 - 5:30 p.m.
Vanderbilt Dermatology Alumni Reunion
Loews New Orleans - LaFourche . . Friday, February 4 - 5:30 p.m.
wake Forest university School of Medicine - Department of
Dermatology
ANCIllARY GROuPS & REuNIONS
HR - Ascot . . . . . . . . . . . . . . . . . .Saturday, February 5 - 5:00 p.m.
washington university Barnes - Jewish Hospital Dermatology
Alumni Reunion
HR - Kabacoff . . . . . . . . . . . . . . .Saturday, February 5 - 5:30 p.m.
352 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
wayne State university, Dermatology Alumni Reception
HR - Norwich . . . . . . . . . . . . . . .Saturday, February 5 - 7:00 p.m.
wDS Annual luncheon
HR - Grand Ballroom BCD . . . .Sunday, February 6 - 12:00 p.m.
wDS Board of Directors Meeting
HR - Jefferson . . . . . . . . . . . . . . . . Sunday, February 6 - 6:30 a.m.
wDS Center
HR - Marlborough A . . Thursday, February 3 - Sunday, February 6
wDS Committee Meetings
HR - Marlborough B . . .Friday, February 4 – Saturday, February 5
weill Medical College of Cornell university Reunion
Ritz-Carlton New Orleans - Crescent
View Room . . . . . . . . . . . . . . . . .Saturday, February 5 - 6:00 p.m.
wisconsin Reunion
Marshfield Clinics
Medical College of wisconsin -Milwaukee
university of wisconsin - Madison
HR - Elmwood . . . . . . . . . . . . . .Saturday, February 5 - 5:30 p.m.
Xeroderma Pigmentation Expert Resource Group
HR - Elmwood . . . . . . . . . . . . .Saturday, February 5 - 12:00 p.m.
Yale Alumni Reunion
HR - Grand Salon 4,7 . . . . . . . . . .Sunday, February 6 - 6:00 p.m.
 Discover it the ZIANA® Effect

ZIANA Gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older.
Important Safety Information for ZIANA Gel
• The most commonly reported adverse events were nasopharyngitis, pharyngolaryngeal pain,
dry skin, cough, and sinusitis.
• Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported
with the use of topical clindamycin. ZIANA Gel should be discontinued if significant diarrhea occurs.
Systemic absorption of clindamycin has been demonstrated following topical use of this product.
• If a reaction suggesting sensitivity or chemical irritation occurs, use of the medication should be discontinued.
• Avoid exposure to sunlight and sunlamps. Patients with sunburn should not use the product. Use with caution in patients who require
considerable sun exposure due to occupation or who are inherently sensitive to the sun. Avoid excessive exposure to the sun, cold, and
wind, which can irritate skin. Daily use of sunscreen and protective clothing are recommended.
• Keep away from eyes, mouth, angles of nose, and mucous membranes.
• This drug is contraindicated in patients with regional enteritis, ulcerative colitis, or history of antibiotic-associated colitis.
• Concomitant use of topical medications with a strong drying effect can increase skin irritation. Use with caution.

See reverse side for a Brief Summary of the Full Prescribing Information.

ZIANA is a registered trademark of Medicis Pharmaceutical Corporation.

ZNA 09-026AR 12/30/11
PATIENT INFORMATION
ZIANA® (ZEE-AH-NA)
(clindamycin phosphate 1.2% and tretinoin
0.025%) Gel
IMPORTANT: Not for mouth, eye, or vaginal
use.
Read the Patient Information that comes with
ZIANA® Gel before you start using it and each time
you get a refill. There may be new information.
This leaflet does not take the place of talking with
your doctor about your acne or treatment.
What is ZIANA® Gel?
ZIANA® Gel is an antibiotic and retinoid combination
medicine used for the skin treatment of acne in
patients 12 years and older.
Who should not use ZIANA® Gel?
Do not use ZIANA® Gel if you:
• have Crohn’s Disease
• have Ulcerative Colitis
• have developed colitis with past antibiotic use
Tell your doctor:
• if you are pregnant or planning to become
pregnant. It is not known if ZIANA® Gel may
harm your unborn baby.
• if you are breastfeeding. ZIANA® Gel may pass
through your milk and may harm your baby.
• about all the medicines and skin products
you use:
• ZIANA® Gel should not be used with
erythromycin-containing products.
• Avoid medicated or abrasive soaps and
cleansers, soaps and cosmetics that have a Talk to your doctor about any side effect that
strong drying effect, and skin products that
contain alcohol, astringents, spices or lime.
These products may cause increased skin
irritation if used with ZIANA® Gel.
How should I use ZIANA® Gel?
Use ZIANA® Gel exactly as prescribed. It may
take some time for you to see improvement of 59 to 86°F (15 to 30°C). Do not freeze.
your acne with ZIANA® Gel. Your doctor will tell
you how long to use ZIANA® Gel.
At bedtime:
• Wash your face gently with a mild soap and reach of children
warm water.
• Pat the skin dry.
• Apply a pea-size amount of ZIANA® Gel to your
fingertip and spread it over your face. Gently, other than those listed in patient information
smooth it into your skin. Do not get ZIANA® Gel
in your eyes or mouth, on your lips, on the
corners of your nose, or on open wounds.
In the morning: This leaflet summarizes the most important
• Apply a sunscreen and reapply during the day information about ZIANA® Gel. If you would like
as needed. more information, talk with your doctor. You can
also ask your pharmacist or doctor for information
• Do not apply ZIANA® Gel more than once a day about ZIANA® Gel that is written for healthcare
professionals.
• Do not use too much ZIANA® Gel. Too much
ZIANA® Gel may irritate your skin. If you have questions about ZIANA® Gel you can
also call: 1-800-900-6389 (this is a toll-free
• Do not wash your face more than 2 to 3 times a number) between 10:00 a.m. and 4:00 p.m.
day. Washing your face too often or scrubbing it Eastern Time, Monday through Friday.
may make your acne worse.
What are the ingredients in ZIANA® Gel?
Avoid:
Active Ingredients: clindamycin phosphate 1.2%
• excessive exposure to the sun, cold, and and tretinoin 0.025%
wind. Weather extremes can dry and burn the
Inactive Ingredients: purified water USP,
skin. Always use a sunscreen on ZIANA® Gel
glycerin USP, carbomer 981 NF, methylparaben
treated skin, even on cloudy days. Use other
NF, polysorbate 80 NF, edetate disodium USP,
protective clothing such as a hat when you are
citric acid USP, propylparaben NF, butylated
in the sun.
hydroxytoluene NF, and tromethamine USP.
• the use of sunlamps and tanning booths
If your face becomes sunburned, stop Manufactured for:
ZIANA® Gel until your skin has healed. Medicis, The Dermatology Company
Scottsdale, AZ 85256
What are possible side effects with By: Contract Pharmaceuticals Limited Niagara
ZIANA® Gel? Buffalo, NY 14213
• Skin irritation. ZIANA® Gel may cause skin
irritation such as dryness, redness, peeling, U.S. Patent 5,721,275
burning, or stinging. Stop ZIANA® Gel and call U.S. Patent 6,387,383
your doctor if your skin becomes very red,
swollen, blistered, or crusted. 09-0052 (Folded)
• Change in skin color. ZIANA Gel may cause a
® 09-0054 (Flat)
temporary skin color change (lighter or darker).
• Colitis. This occurs rarely. Stop ZIANA® Gel and
call your doctor if you develop severe watery
diarrhea, or bloody diarrhea.
bothers you or that does not go away.
These are not all the side effects with ZIANA® Gel.
Ask your doctor or pharmacist for more
information.
How should I store ZIANA® Gel?
• Store ZIANA® Gel at room temperature,
• Keep ZIANA® Gel away from heat and light.
• Keep the tube tightly closed.
• Keep ZIANA® Gel and all medicines out of the
General information about ZIANA® Gel
Medicines are sometimes prescribed for purposes
leaflet. Do not use ZIANA® Gel for a condition for
which it was not prescribed. Do not give ZIANA®
Gel to other people, even if they have the
same symptoms you have. It may harm them. 013009
 SUBJECT INDEX

How To USE THE SUBJECT INDEX

The subject index has been updated to help the attendees better plan their educational activities. The index is divided into nine different primary
topics with subtopics listed alphabetically under these primary topics.

THE prImary TopICS arE:

• Basic Science of Dermatology • Clinical Dermatology • Therapeutics – Non-Surgical
• Dermatopathology • Surgery • Socioeconomic and Practice Issues
• Diagnostic Methods • Epidemiology

BaSIC SCIENCE Genetics and Biochemistry, including Basic principles of

Basic methodologies in Skin research
C012 Structure and Function of the Skin, 105
D010 Recent Advances in Skin Biology and Skin Disease, 133
F051 Controversies in Vitamin D, 179
F088 Clinical Trials, 253
S018 Late-Breaking Research, 126
S024 Residents and Fellows Symposium, 159
U038 Nanotechnology, 114
U045 Non-cultured Epidermal Suspension in Vitiligo:
From Lab to Clinic, 116
U058 From Stem to Skin: Precursor Cells That Have a lot of Potential, 136
Cutaneous physiology, including wound Healing, Immunology,
Cancer Biology, Itch, pigmentation, and angiogenesis
Genetics, DNa, Transcription, Translation, and proteins
C012 Structure and Function of the Skin, 105
D010 Recent Advances in Skin Biology and Skin Disease, 133
F019 Journal Watching, 101
F051 Controversies in Vitamin D, 179
U073 Amyloidosis: Changing Our View in Dermatology, 154
microbiology
C012 Structure and Function of the Skin, 105
C023 Advanced Pediatric Dermatology, 200
F051 Controversies in Vitamin D, 179
S031 Tropical Dermatology, 173
U038 Nanotechnology, 114
U041 Uncommon Cutaneous Infections: Clinical and Histologic
Features, 114

SUBJECT INDEX
C012 Structure and Function of the Skin, 105 U052 Diseases of Male Genitalia, 134
C029 Dermatology Review, 234 U150 Skin Cancer Viruses: Bench to Bedside, 241
D010 Recent Advances in Skin Biology and Skin Disease, 133 pharmacology
D012 Aging Skin: Mechanism-Based Rejuvenation, 144 F051 Controversies in Vitamin D, 179
D020 When Does Chronic Dermatitis Become Cutaneous F091 Supportive Onco-Dermatology: Dermatologic Reactions in
T-Cell Lymphoma?, 188 Oncology, 254
S001 Disorders of Pigmentation, 75 S016 Drug Actions, 125
U037 Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS), 99 S035 Controversies in Dermatologic Drug Therapy, 204
U060 Stress, the Nervous System, and Cutaneous Immunity, 137 U038 Nanotechnology, 114
U090 Angiogenesis and Clinical Dermatology, 166 U061 Calciphylaxis, 144
U097 Immunostimulatory Treatment of Skin Cancer, 168 U075 Drug Safety: Do No Harm, 155
U113 Immunology for Dermatologists, 190 U087 Fulfilling Great Expectations: Caring for New Mothers and
U121 Update on Graft-Versus-Host Disease, 214 Mothers-to-Be, 165
U137 Developing a Unified Approach to Investigating Autoimmune U096 Medical Therapies and How They Work, 169
Disease, 227 U101 Pediatric Drug Eruptions, 175
U172 Transplant Research in Dermatology, 264 U115 Medication Use: Improving Adherence and Compliance, 191
U118 Holy Moly: Religion and the Skin, 192
Embryology
C012 Structure and Function of the Skin, 105 photophysics and photobiology, including Lasers
F051 Controversies in Vitamin D, 179 C012 Structure and Function of the Skin, 105
F009 Photobiology for Dermatologists, 80
U171 Dermatopathology: Utility, Methodology, and Interpretation of
F077 Aesthetic Dermatologic Complications, 232
Current (and Future) Molecular Testing, 262
F080 Fractional Laser and Light-Based Technologies, 242
General Cellular Biology, including apoptosis, Cell Cycle and Cell F084 Medical Applications of Topical Photodynamic Therapy, 244
Cycle regulation, Second messenger Systems, receptor Biology, F089 Advances in Photomedicine, 253
Stem Cells S033 Photodermatology, 202
C012 Structure and Function of the Skin, 105 S034 Psoriasis, 203
D023 Cutaenous T-Cell Lymphoma, 226 U033 Electrolysis: When Laser isn’t the Answer, 98
F048 Psoriasis as a Systemic Disease, 178 U038 Nanotechnology, 114
U089 Lasers 101, 166
S022 Acne and Rosacea, 142
U096 Medical Therapies and How They Work, 167
U037 Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS), 99
U058 From Stem to Skin: Precursor Cells that Have a lot of Potential, 136 Structure and Function of Skin, including Basement
U096 Medical Therapies and How They Work, 167 membrane Zone
U113 Immunology for Dermatologists, 190 C012 Structure and Function of the Skin, 105
U121 Update on Graft-Versus-Host Disease, 214 D010 Recent Advances in Skin Biology and Skin Disease, 133
U158 Acne: Etiopathogenesis and Treatment 2011, 256 F025 Dramatic Oral Disease, 118

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 353
 SUBJECT INDEX
U005 High-Yield “Power Hour” for Residents, 66
U036 Subcutaneous Fat in Dermatology, 98
U083 Hair Highlights: Common and Challenging Hair Loss F012 Update on Genetic Skin Disease, 82
Disorders, 157
U114 Stem Cells in Melanoma and Nevi, 190
BaSIC SCIENCE oF DErmaToLoGy
anatomy
C012 Structure and Function of the Skin, 105
U036 Subcutaneous Fat in Dermatology, 98
W004 MOC Self-Assessment: Procedural Dermatology, 121
Biochemistry
C012 Structure and Function of the Skin, 105
F051 Controversies in Vitamin D, 179
U061 Calciphylaxis, 144
Cell Biology
C012 Structure and Function of the Skin, 105
F051 Controversies in Vitamin D, 179
U090 Angiogenesis and Clinical Dermatology, 166
Connective Tissues
C012 Structure and Function of the Skin, 105
D010 Recent Advances in Skin Biology and Skin Disease, 133
D012 Aging Skin: Mechanism-Based Rejuvenation, 144
Genetics
C012 Structure and Function of the Skin, 105
D010 Recent Advances in Skin Biology and Skin Disease, 133
F012 Update on Genetic Skin Disease, 82
SUBJECT INDEX
F050 What’s New in Immunomodulation, 179
S015 Advanced Pediatric Dermatology, 125
S036 Blistering Disease, 205
U073 Amyloidosis: Changing Our View in Dermatology, 154
U088 Hereditary Diseases of the Epidermis, 165
Immunology
C007 Immunology, 79
C012 Structure and Function of the Skin, 105
C029 Dermatology Review, 234
D010 Recent Advances in Skin Biology and Skin Disease, 133
D014 Advances in Pemphigus and Pemphigoid, 154
D020 When Does Chronic Dermatitis Become Cutaneous T-Cell U157 Rosacea Update, 256
Lymphoma?, 188
F050 What’s New in Immunomodulation, 179
S036 Blistering Disease, 205
U084 Climate Change, Allergy, and the Skin, 157
U096 Medical Therapies and How They Work, 169
U097 Immunostimulatory Treatment of Skin Cancer, 168
U126 Healing the Pyoderma Gangrenosum Ulcer: Lessons for the PG U104 Cosmeceuticals: Topical Therapies for Treating
Clinic, 216
U137 Developing a Unified Approach to Investigating Autoimmune
Disease, 227
Inflammation
C007 Immunology, 79
C012 Structure and Function of the Skin, 105
D020 When Does Chronic Dermatitis Become Cutaneous T-Cell Histologic Features, 114
Lymphoma?, 188
F048 Psoriasis as a Systemic Disease, 178
F091 Supportive Onco-Dermatology: Dermatologic Reactions in
Oncology, 254
S016 Drug Actions, 125
U096 Medical Therapies and How They Work, 169
U097 Immunostimulatory Treatment of Skin Cancer, 168
U164 Hypercoagulability, Purpura, and the Skin, 259
354 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
molecular Biology/Genetics
C012 Structure and Function of the Skin, 105
F048 Psoriasis as a Systemic Disease, 178
F051 Controversies in Vitamin D, 179
U158 Acne: Etiopathogenesis and Treatment 2011, 256
pathophysiology
F048 Psoriasis as a Systemic Disease, 178
S016 Drug Actions, 125
S036 Blistering Disease, 205
U041 Uncommon Cutaneous Infections: Clinical and
Histologic Features, 114
U096 Medical Therapies and How They Work, 169
U101 Pediatric Drug Eruptions, 175
U158 Acne: Etiopathogenesis and Treatment 2011, 256
photobiology
C012 Structure and Function of the Skin, 105
D012 Aging Skin: Mechanism-Based Rejuvenation, 144
F009 Photobiology for Dermatologists, 80
F051 Controversies in Vitamin D, 179
S033 Photodermatology, 202
U019 Sun, Drugs and Invervention: How to Prevent Non-Melanoma
Skin Cancer, 87
U096 Medical Therapies and How They Work, 169
physiology
C012 Structure and Function of the Skin, 105
F051 Controversies in Vitamin D, 179
U036 Subcutaneous Fat in Dermatology, 98
CLINICaL DErmaToLoGy
acne and related Disorders
C012 Structure and Function of the Skin, 105
D024 PAPA-Syndrome, SAPHO, and Acne: Skin and Bones and
Inflammation, 226
F029 Acne and Rosacea Update, 120
F045 Rosacea, 150
U002 Management of Post-Acne Scarring, 65
U011 Medical and Aesthetic Dermatology in Skin of Color, 68
U153 Facing Facial Dermatoses, 242
U158 Acne: Etiopathogenesis and Treatment 2011, 256
aging/Geriatrics
D012 Aging Skin: Mechanism-Based Rejuvenation, 144
F004 Geriatric Dermatology: Advanced Cases, 70
F081 Geriatric Dermatology, 243
S012 Aging Gracefully, 93
the Aging Face, 176
Bacterial
C029 Dermatology Review, 234
U027 Practical Approaches to Medical and Cosmetic Dermatology in
Patients with Skin of Color, 95
U041 Uncommon Cutaneous Infections: Clinical and
U120 Sexually Transmitted Infections: The Current Standard of Diagnosis
and Care, 214
Black Skin
S001 Disorders of Pigmentation, 75
U011 Medical and Aesthetic Dermatology in Skin of Color, 68
U077 Hair Disease and the African American Patient, 155
U159 An Approach to Cultural Diversity in Dermatology, 257
 SUBJECT INDEX

Bullous Dermatoses Clinical research

C012 Structure and Function of the Skin, 105
C029 Dermatology Review, 234
D014 Advances in Pemphigus and Pemphigoid, 154
F024 Evaluation and Management of Hemangiomas, 117
F078 Epidermolysis Bullosa: Cases and Discussion, 232
F086 BCC Update and Options of Treatment, 251
S036 Blistering Disease, 205
U027 Practical Approaches to Medical and Cosmetic Dermatology in Know, 145
Patients with Skin of Color, 95
Clinical Dermatology
C014 Coding, Documentation and Practice Management, 123
C019 Hair and Nails, 138
C029 Dermatology Review, 234
D003 Selected Topics in Medical Dermatology, 84
D010 Recent Advances in Skin Biology and Skin Disease, 133
D015 Urticaria and Angioedema, 163
D022 Common Dermatologic Diseases with Myriad Treatments, 213
D025 Integration of Photodynamic Therapy into Your Practice, 239
F005 Board Blitz, 71
F008 Decreasing Iatrogenic Problems in Your Practice, 72
F014 Challenging Diagnostic Cases for Advanced Practitioners:
PA/NP I, 83
F017 Resident Jeopardy, 100
F018 Atopic Dermatitis, 100
F021 FDA Presents: Information for Dermatologists, 102
F034 From the Dermatology Rheumatology Clinics: Practical Tips and D010 Recent Advances in Skin Biology and Skin Disease, 133
Advances in Management, 130
F036 Careers in Academic Dermatology, 131
F057 Adolescent Dermatology, 194
D010 Recent Advances in Skin Biology and Skin Disease, 133
D012 Aging Skin: Mechanism-Based Rejuvenation, 144
F092 Diagnosing and Monitoring Hair and Scalp Disease, 255
S036 Blistering Disease, 205
U017 Clinical Trials for the Private Practitioner, 86
U018 Outcomes Research in Dermatology, 86
U066 Compliance in Pharmaceutical Development: What You Need to
U108 Safety of Biologic Therapies: What’s the Real Story?, 177
Collagen Vascular Disorders
C029 Dermatology Review, 234
D013 Challenging Pediatric Dermatology Cases, 154
S019 Rheumatologic Dermatology, 139
S033 Photodermatology, 202
U056 Recommended Screening Practices in Medical Dermatology, 136
Collagen Vascular Disorders - Dermatomyositis
D003 Selected Topics in Medical Dermatology, 84
D010 Recent Advances in Skin Biology and Skin Disease, 133
S019 Rheumatologic Dermatology, 139
U056 Recommended Screening Practices in Medical Dermatology, 136
U059 Potpourri of CPC, 136
U109 Pediatric Connective Tissue, 189
Collagen Vascular Disorders - Lupus Erythematosus
D003 Selected Topics in Medical Dermatology, 84
S019 Rheumatologic Dermatology, 139
U056 Recommended Screening Practices in Medical Dermatology, 136
U059 Potpourri of CPC, 136

SUBJECT INDEX
F091 Supportive Onco-Dermatology: Dermatologic Reactions in U109 Pediatric Connective Tissue, 189
Oncology, 254
F092 Diagnosing and Monitoring Hair and Scalp Disease, 255 Collagen Vascular Disorders - Scleroderma
F094 Melasma: Advances in the Treatment of Therapeutically D010 Recent Advances in Skin Biology and Skin Disease, 133
Challenging Disease, 265 S019 Rheumatologic Dermatology, 139
S001 Disorders of Pigmentation, 75 U056 Recommended Screening Practices in Medical Dermatology, 136
S011 Therapeutics, 93 U059 Potpourri of CPC, 136
S019 Rheumatologic Dermatology, 139 U109 Pediatric Connective Tissue, 189
S027 Contact and Occupational Dermatitis, 170 Collagen Vascular Disorders - Vasculitis
S051 Evidence-Based Medicine, 261 D010 Recent Advances in Skin Biology and Skin Disease, 133
U011 Medical and Aesthetic Dermatology in Skin of Color, 68 S019 Rheumatologic Dermatology, 139
U035 Paraneoplastic Dermatoses, 98 U027 Practical Approaches to Medical and Cosmetic Dermatology in
U036 Subcutaneous Fat in Dermatology, 98 Patients with Skin of Color, 95
U050 Viral Exanthem Update, 134 U056 Recommended Screening Practices in Medical Dermatology, 136
U051 Therapy for Lipodermatosclerosis, Venous Ulceration, and Atrophie U059 Potpourri of CPC, 136
Blanche, 134 U109 Pediatric Connective Tissue, 189
U056 Recommended Screening Practices in Medical Dermatology, 136
U059 Potpourri of CPC, 136 Cosmetics
U093 Notes of a Therapeutic Iconoclast, 167 C027 Sclerotherapy, 220
U096 Medical Therapies and How They Work, 167 D012 Aging Skin: Mechanism-Based Rejuvenation, 144
U103 Drug Reaction Update 2011, 176 F005 Board Blitz, 71
U105 Advances in Fat Transfer and Liposuction for Correction of F094 Melasma: Advances in the Treatment of Therapeutically
Lipodystrophy: The USC Experience, 176 Challenging Disease, 265
U123 Forensics in Dermatology, 215 U011 Medical and Aesthetic Dermatology in Skin of Color, 68
U132 The Year In Review in Pediatric Dermatology: How Does It U036 Subcutaneous Fat in Dermatology, 98
Change My Practice?, 218 U046 Social Media and Dermatology: How Twitter and Facebook Will
U141 Skin Signs of Systemic Disease, 229 Help You and Your Practice, 116
U147 Dermatological Signs of Child Abuse, 240 U049 Avoiding Complications and Maximizing Results in Cutaneous
U152 Cutaneous Mucinosis, 242 Laser Surgery, 134
U153 Facing Facial Dermatoses, 242 U055 Practical Approaches to Cosmeceuticals, 135
U155 What’s New in Skin Cancer Prevention?, 255 U104 Cosmeceuticals: Topical Therapies for Treating the Aging
U157 Rosacea Update, 256 Face, 176
U159 An Approach to Cultural Diversity in Dermatology, 257 U105 Advances in Fat Transfer and Liposuction for Correction of
Lipodystrophy: The USC Experience, 176
W010 MOC Self-Assessment: Cosmetic Dermatology, 197

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 355
 SUBJECT INDEX

Diseases of Connective Tissue U082 P

ractical and Realistic Office Mycology for the Epidemiology,
C003 Pediatric Dermatology, 73 Diagnosis, and Treatment of Human Mycoses, 157
F034 From the Dermatology Rheumatology Clinics: Practical Tips and U120 Sexually Transmitted Infections: The Current Standard of Diagnosis
Advances in Management, 130 and Care, 214
S011 Therapeutics, 93
General Dermatology
U152 Cutaneous Mucinosis, 242
C014 Coding, Documentation, and Practice Management, 123
Eczemas C017 Advanced Dermoscopy, 128
C029 Dermatology Review, 234 D010 Recent Advances in Skin Biology and Skin Disease, 133
S011 Therapeutics, 93 F004 Geriatric Dermatology: Advanced Cases, 70
S027 Contact and Occupational Dermatitis, 170 F005 Board Blitz, 71
U074 Eczema Centers: World Experiences, 154 F008 Decreasing Iatrogenic Problems in Your Practice, 72
U096 Medical Therapies and How They Work, 167 F081 Geriatric Dermatology, 243
S009 Advanced Medical Dermatology, 92
Eczemas - atopic U035 Paraneoplastic Dermatoses, 98
C003 Pediatric Dermatology, 73 U046 Social Media and Dermatology: How Twitter and Facebook
C007 Immunology, 79 Will Help You and Your Practice, 116
D010 Recent Advances in Skin Biology and Skin Disease, 133 U061 Calciphylaxis, 144
D013 Challenging Pediatric Dermatology Cases, 154 U081 Medical and Surgical Practice, 156
D020 When Does Chronic Dermatitis Become Cutaneous T-Cell U103 Drug Reaction Update 2011, 176
Lymphoma?, 188
U123 Forensics in Dermatology, 215
F018 Atopic Dermatitis, 100
U132 The Year in Review in Pediatric Dermatology: How Does It
F031 Food Allergy and Dermatology, 121 Change My Practice?, 218
S016 Drug Actions, 125 U147 Dermatological Signs of Child Abuse, 240
S025 New Emerging Therapies, 168 U153 Facing Facial Dermatoses, 242
S027 Contact and Occupational Dermatitis, 170 U157 Rosacea Update, 256
U074 Eczema Centers: World Experiences, 154
U163 Garden Variety Derm: Identifying and Managing Exposures to
U132 The Year in Review in Pediatric Dermatology: How Hazardous Plants and Arthropods in the Garden, 258
Does It Change My Practice?, 218
Genital Disorders
Eczemas - Contact C009 Dermatologic Syndromes and Genetic Disorders, 90
C005 Basic Contact Dermatitis, 74
SUBJECT INDEX

F002 Erosive Vulvar Diseases: Approach to Diagnosis, Differential

C010 Advanced Contact Dermatitis, 90 Diagnosis, and Treatment, 69
D010 Recent Advances in Skin Biology and Skin Disease, 133 U022 Vulvar Dermatoses, 87
D020 When Does Chronic Dermatitis Become Cutaneous T-Cell U120 Sexually Transmitted Infections: The Current Standard of Diagnosis
Lymphoma?, 188 and Care, 214
D024 PAPA Syndrome, SAPHO, and Acne: Skin and Bones and U121 Update on Graft-Versus-Host Disease, 214
Inflammation, 226
U147 Dermatological Signs of Child Abuse, 240
F018 Atopic Dermatitis, 100
S016 Drug Actions, 125 Genodermatoses
S025 New Emerging Therapies, 168 C012 Structure and Function of the Skin, 105
S027 Contact and Occupational Dermatitis, 170 C029 Dermatology Review, 234
U073 Amyloidosis: Changing Our View in Dermatology, 154 F012 Update on Genetic Skin Disease, 82
U074 Eczema Centers: World Experiences, 154 F078 Epidermolysis Bullosa: Cases and Discussion, 233
U132 The Year in Review in Pediatric Dermatology: How Does It F092 Diagnosing and Monitoring Hair and Scalp Disease, 255
Change My Practice?, 218 U027 Practical Approaches to Medical and Cosmetic Dermatology in
Patients with Skin of Color, 95
Eczemas - miscellaneous
U034 Pediatric Hyperhidrosis and Ectodermal Dysplasia: To Sweat or
D010 Recent Advances in Skin Biology and Skin Disease, 133 Not to Sweat?, 98
D020 When Does Chronic Dermatitis Become Cutaneous T-Cell
U067 Twists and Splits: How to Approach Hair Shaft Disorders, 146
Lymphoma?, 188
U106 What’s That? Syndrome Update, 176
F018 Atopic Dermatitis, 100
U131 Neurofibromatosis, 218
S016 Drug Actions, 125
S025 New Emerging Therapies, 168 Hair Disorders
S027 Contact and Occupational Dermatitis, 170 C012 Structure and Function of the Skin, 105
U074 Eczema Centers: World Experiences, 154 C019 Hair and Nails, 138
U123 Forensics in Dermatology, 215 C029 Dermatology Review, 234
U132 The Year in Review in Pediatric Dermatology: How Does It D011 Women With Hair Loss, 144
Change My Practice?, 218 F012 Update on Genetic Skin Disease, 82
F058 Hair Loss in Women, 194
Endocrine Diseases
F067 Managing Hair Loss Made Easy, 211
F051 Controversies in Vitamin D, 179
F079 Update on Alopecia Areata, 242
U158 Acne: Etiopathogenesis and Treatment 2011, 256
F092 Diagnosing and Monitoring Hair and Scalp Disease, 255
Fungal S002 Alopecia: Work up and Treatment, 75
F070 Fungal Infections, 212 U011 Medical and Aesthetic Dermatology in Skin of Color, 68
U041 Uncommon Cutaneous Infections: Clinical and Histologic U067 Twists and Splits: How to Approach Hair Shaft Disorders, 146
Features, 148 U077 Hair Disease and the African American Patient, 155

356 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SUBJECT INDEX

Herpes Viruses U148 L essons Learned from Challenging Pediatric Cases: Targeted Novel
U062 Herpes Simplex and Varicella Zoster Virus, 144 Molecular Therapies, 240
U165 The Management of TEN/SJS: The US Army Burn Unit
Human Immunodeficiency Virus Experience, 259
C029 Dermatology Review, 234
U090 Angiogenesis and Clinical Dermatology, 166 malignancy/Tumors
U105 Advances in Fat Transfer and Liposuction for Correction of C007 Immunology, 79
Lipodystrophy: The USC Experience, 176 C017 Advanced Dermoscopy, 128
F005 Board Blitz, 71
Human papillomavirus F074 The Use of the Confocal Microscope in a Private Clinical
U071 Warts, 147 Practice, 230
U090 Angiogenesis and Clinical Dermatology, 166 F095 Challenges in the Diagnosis and Management of Lentigo
U147 Dermatological Signs of Child Abuse, 240 Maligna Melanoma, 264
S032 Cutaneous Tumors Benign and Malignant, 201
Infections S033 Photodermatology, 202
C003 Pediatric Dermatology, 73 U008 Recognition and Management of High-Risk Skin Cancer, 67
C029 Dermatology Review, 234 U035 Paraneoplastic Dermatoses, 98
D025 Integration of Photodynamic Therapy into Your Practice, 239 U065 Dermoscopy: It’s Time for a Quiz, 145
D027 Differential Diagnosis of Leprosy in a Non-Endemic Country, 255 U090 Angiogenesis and Clinical Dermatology, 166
U041 Uncommon Cutaneous Infections: Clinical and Histologic U100 Current Management of Skin Cancer in Transplant Patients, 175
Features, 114 U117 Diagnosis and Management of Unusual Skin Tumors, 192
U082 Practical and Realistic Office Mycology for the Epidemiology, U121 Update on Graft-Versus-Host Disease, 214
Diagnosis and Treatment of Human Mycoses, 157 U122 High-Risk Squamous Cell Carcinomas: A Clinical and Pathologic
U084 Climate Change, Allergy, and the Skin, 157 Case Review, 214
U120 Sexually Transmitted Infections: The Current Standard of Diagnosis U144 Serial Screening for Melanoma: Measures that have Consistently
and Care, 214 Achieved Early Detection and Cure, 239
U132 The Year in Review in Pediatric Dermatology: How Does It Change U155 What’s New in Skin Cancer Prevention?, 255
My Practice?, 218 malignancy/Tumors - Epithelial Tumors
Infestations/Bites C012 Structure and Function of the Skin, 105
C003 Pediatric Dermatology, 73 D010 Recent Advances in Skin Biology and Skin Disease, 133

SUBJECT INDEX
D024 PAPA Syndrome, SAPHO, and Acne: Skin and Bones and F059 Case-Based Discussion in Cutaneous Lymphomas, 195
Inflammation, 226 F086 BCC Update and Options of Treatment, 251
U163 Garden Variety Derm: Identifying and Managing Exposures to F091 Supportive Onco-Dermatology: Dermatologic Reactions
in Oncology, 254
Hazardous Plants and Arthropods in the Garden, 258
S043 Melanoma Update, 225
Inflammatory Disorders U008 Recognition and Management of High-Risk Skin Cancer, 67
C003 Pediatric Dermatology, 73 U019 Sun, Drugs, and Invervention: How to Prevent Non-Melanoma
C019 Hair and Nails, 138 Skin Cancer, 87
D020 When Does Chronic Dermatitis Become Cutaneous T-cell U029 Skin Cancer in Patients with Non-Melanoma Hodgkin’s
Lymphoma?, 188 Lymphoma, 96
F001 Advanced Medical Dermatology, 69 U065 Dermoscopy: It’s Time for a Quiz, 145
S036 Blistering Disease, 205 U078 Case-Based Approach to Lentigo Maligna, 156
U035 Paraneoplastic Dermatoses, 98 U090 Angiogenesis and Clinical Dermatology, 166
U096 Medical Therapies and How They Work, 167
U096 Medical Therapies and How They Work, 167
U097 Immunostimulatory Treatment of Skin Cancer, 168
U125 Penile Growths, 216
U136 Management of Challenging Pigmented Lesions, 227
U137 Developing a Unified Approach to Investigating Autoimmune
U144 Serial Screening for Melanoma: Measures That Have Consistently
Disease, 227 Achieved Early Detection and Cure, 239
Internal medicine U155 What’s New in Skin Cancer Prevention?, 255
F001 Advanced Medical Dermatology, 69 malignancy/Tumors - Lymphoma/mycosis Fungoides
F027 Practical Approaches to Patient Problems, 119 C012 Structure and Function of the Skin, 105
S009 Advanced Medical Dermatology, 92 D010 Recent Advances in Skin Biology and Skin Disease, 133
S036 Blistering Disease, 205 D020 When Does Chronic Dermatitis Become Cutaneous T-Cell
U061 Calciphylaxis, 144 Lymphoma?, 188
U121 Update on Graft-Versus-Host Disease, 214 F059 Case-Based Discussion in Cutaneous Lymphomas, 195
U141 Skin Signs of Systemic Disease, 229 F086 BCC Update and Options of Treatment, 251
U164 Hypercoagulability, Purpura, and the Skin, 259 F091 Supportive Onco-Dermatology: Dermatologic Reactions
in Oncology, 254
Literature Update/what’s New S043 Melanoma Update, 225
F004 Geriatric Dermatology: Advanced Cases, 70 S047 Managing Melanoma in the Modern Millennium, 250
F022 Coding and Office Management, 102 U008 Recognition and Management of High-Risk Skin Cancer, 67
F076 Pediatric Dermatology, 232 U029 Skin Cancer in Patients with Non-Melanoma Hodgkin’s
F081 Geriatric Dermatology, 243 Lymphoma, 96
F083 Psoriasis Therapy in the Age of Biologics, 244 U059 Potpourri of CPC, 136
U036 Subcutaneous Fat in Dermatology, 98 U063 Dermatoscopy, 145

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 357
 SUBJECT INDEX

U065 Dermoscopy: It’s Time for a Quiz, 145 S009 Advanced Medical Dermatology, 92
U078 Case-Based Approach to Lentigo Maligna, 156 S011 Therapeutics, 93
U090 Angiogenesis and Clinical Dermatology, 166 W004 MOC Self-Assessment: Procedural Dermatology, 121
U096 Medical Therapies and How They Work, 167
U097 Immunostimulatory Treatment of Skin Cancer, 168 occupational Dermatology
U136 Management of Challenging Pigmented Lesions, 227 S027 Contact and Occupational Dermatitis, 170
U144 Serial Screening for Melanoma: Measures that have Consistently U163 Garden Variety Derm: Identifying and Managing Exposures to
Achieved Early Detection and Cure, 239 Hazardous Plants and Arthropods in the Garden, 258
U155 What’s New in Skin Cancer Prevention?, 225 oculocutaneous Disorders
C012 Structure and Function of the Skin, 105
malignancy/Tumors - melanoma and pigmented Lesions
C012 Structure and Function of the Skin, 105 oral/mucous membrane Disorders
C017 Advanced Dermoscopy, 128 F002 Erosive Vulvar Diseases: Approach to Diagnosis, Differential
C029 Dermatology Review, 234 Diagnosis, and Treatment, 69
D010 Recent Advances in Skin Biology and Skin Disease, 133 S036 Blistering Disease, 205
F059 Case-Based Discussion in Cutaneous Lymphomas, 195
F074 The Use of the Confocal Microscope in a Private Clinical other
Practice, 230 C014 Coding, Documentation, and Practice Management, 123
F086 BCC Update and Options of Treatment, 251 U035 Paraneoplastic Dermatoses, 98
F091 Supportive Onco-Dermatology: Dermatologic Reactions in papulosquamous Disorders
Oncology, 254 C009 Dermatologic Syndromes and Genetic Disorders, 90
F095 Challenges in the Diagnosis and Management of Lentigo Maligna F024 Evaluation and Management of Hemangiomas, 117
Melanoma, 264
S016 Drug Actions, 125
S011 Therapeutics, 93
S025 New Emerging Therapies, 168
S043 Melanoma Update, 225
U032 Chronic Inflammatory Hand and Foot Dermatoses, 97
U008 Recognition and Management of High-Risk Skin Cancer, 67
U029 Skin Cancer in Patients with Non-Melanoma Hodgkin’s U080 Uncommon Neonatal Dermatosis, 156
Lymphoma, 96 pediatric Dermatology
U065 Dermoscopy: It’s Time for a Quiz, 145 C003 Pediatric Dermatology, 73
U078 Case-Based Approach to Lentigo Maligna, 156 C029 Dermatology Review, 234
U090 Angiogenesis and Clinical Dermatology, 166
SUBJECT INDEX

D013 Challenging Pediatric Dermatology Cases, 154

U096 Medical Therapies and How They Work, 167 F005 Board Blitz, 71
U097 Immunostimulatory Treatment of Skin Cancer, 168 F012 Update on Genetic Skin Disease, 82
U125 Penile Growths, 216 F027 Practical Approaches to Patient Problems, 119
U136 Management of Challenging Pigmented Lesions, 227 F076 Pediatric Dermatology, 232
U144 Serial Screening for Melanoma: Measures that have Consistently
F078 Epidermolysis Bullosa: Cases and Discussion, 233
Achieved Early Detection and Cure, 239
S011 Therapeutics, 93
U155 What’s New in Skin Cancer Prevention?, 225
S015 Advanced Pediatric Dermatology, 125
U160 Pigmented Lesions in Pediatric Dermatology, 258
S036 Blistering Disease, 205
malignancy/Tumors - other U030 Treatment of Pediatric Psoriasis, 96
C012 Structure and Function of the Skin, 105 U034 Pediatric Hyperhidrosis and Ectodermal Dysplasia: To Sweat or
D010 Recent Advances in Skin Biology and Skin Disease, 133 Not to Sweat?, 98
F059 Case-Based Discussion in Cutaneous Lymphomas, 195 U048 Challenging Cases in Pediatric Dermatology, 117
F086 BCC Update and Options of Treatment, 251 U101 Pediatric Drug Eruptions, 175
F091 Supportive Onco-Dermatology: Dermatologic Reactions in U109 Pediatric Connective Tissue, 189
Oncology, 254 U132 The Year in Review in Pediatric Dermatology: How Does It Change
S043 Melanoma Update, 225 My Practice?, 218
U008 Recognition and Management of High-Risk Skin Cancer, 67 U143 Pediatric Surgery, 239
U029 Skin Cancer in Patients with Non-Melanoma Hodgkin’s U147 Dermatological Signs of Child Abuse, 240
Lymphoma, 96 U149 Overgrowth Syndromes, 241
U065 Dermoscopy: It’s Time for a Quiz, 145
U160 Pigmented Lesions in Pediatric Dermatology, 258
U078 Case-Based Approach to Lentigo Maligna, 156
U090 Angiogenesis and Clinical Dermatology, 166 photosensitivity Diseases
U096 Medical Therapies and How They Work, 167 C029 Dermatology Review, 234
U097 Immunostimulatory Treatment of Skin Cancer, 168 D026 A Practical Approach to Photosensitivity, 239
U136 Management of Challenging Pigmented Lesions, 227 F006 Vitiligo, 71
U144 Serial Screening for Melanoma: Measures That Have Consistently F009 Photobiology for Dermatologists, 80
Achieved Early Detection and Cure, 239
U155 What’s New in Skin Cancer Prevention?, 225 pigmentary abnormalities/Vitiligo
C012 Structure and Function of the Skin, 105
Nail Disorders F094 Melasma: Advances in the Treatment of a Therapeutically
C017 Advanced Dermoscopy, 128 Challenging Disease, 265
C019 Hair and Nails, 138 S001 Disorders of Pigmentation, 75
C029 Dermatology Review, 234 U011 Medical and Aesthetic Dermatology in Skin of Color, 68
F004 Geriatric Dermatology: Advanced Cases, 70 U086 Melasma: Pathogenesis and Treatment, 165
F070 Fungal Infections, 212

358 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SUBJECT INDEX

pruritus
F083 Psoriasis Therapy in the Age of Biologics, 244
DErmaTopaTHoLoGy
S025 New Emerging Therapies, 168 advanced
C016 Advanced Self-Assessment of Dermatopathology, 127
psoriasis U091 Challenging Cases in Dermatopathology, 166
C012 Structure and Function of the Skin, 105 U135 What’s New in Dermatopathology and Why It’s Important
C029 Dermatology Review, 234 to You, 227
F001 Advanced Medical Dermatology, 69
F035 Practical Aspects of Biologic Therapy, 131 Basic
F048 Psoriasis as a Systemic Disease, 178 C030 Basic Dermatopathology, 235
F056 Therapeutic Safety, 193 F011 Dermatopathology Made Simple, 81
S009 Advanced Medical Dermatology, 92 U061 Calciphylaxis, 144
S011 Therapeutics, 93 U135 What’s New in Dermatopathology and Why It’s Important
S016 Drug Actions, 125 to You, 227
U030 Treatment of Pediatric Psoriasis, 96
Clinical-pathologic Correlations
U095 Biologic Drugs for Psoriasis: Do We Use Them Enough?, 167
F005 Board Blitz, 71
U096 Medical Therapies and How They Work, 167
F027 Practical Approaches to Patient Problems, 119
U108 Safety of Biologic Therapies: What’s the Real Story?, 177
U059 Potpourri of CPC, 136
U129 Informed Shared Decision making in Psoriasis Management, 217
U091 Challenging Cases in Dermatopathology, 166
U135 What’s New in Dermatopathology and Why It’s Important
to You, 227 U127 Interactive Clinical-Pathologic Challenge, 217
U168 Psoriasis, 263 Dermatopathologic Findings in the perforating Disorders,
psychocutaneous Disorders atrophies, and other Disorders of Dermal Connective Tissue,
U133 Psychodermatology: Not Just a Delusion; Bugs, Trichotillomania, Including Degenerative Disorders
and the Morgellons Debate, 226 C030 Basic Dermatopathology, 235
U147 Dermatological Signs of Child Abuse, 240 C06A Basic-Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
Sexually Transmitted C06C Basic Self-Assessment of Dermatopathology, 89
U041 Uncommon Cutaneous Infections: Clinical and Histologic C06D Basic Self-Assessment of Dermatopathology, 99
Features, 114 C06E Basic Self-Assessment of Dermatopathology Discussion, 122
U120 Sexually Transmitted Infections: The Current Standard of Diagnosis

SUBJECT INDEX
S007 Gross and Microscopic Dermatology, 106
and Care, 214 W003 MOC Self-Assessment: Dermatopathology, 104
U147 Dermatological Signs of Child Abuse, 240
Dermatopathologic Findings in Various Benign and malignant
Sunscreens
Cutaneous Neoplasms and Neoplastic Diseases, Including
F009 Photobiology for Dermatologists, 80
U019 Sun, Drugs, and Invervention: How to Prevent Non-Melanoma Cutaneous Lymphomas
Skin Cancer, 87 C030 Basic Dermatopathology, 235
U104 Cosmeceuticals: Topical Therapies for Treating the C06A Basic-Self-Assessment of Dermatopathology, 64
Aging Face, 176 C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
Tattoos C06D Basic Self-Assessment of Dermatopathology, 99
C032 Lasers, 247 C06E Basic Self-Assessment of Dermatopathology Discussion, 122
Transplant medicine F011 Dermatopathology Made Simple, 81
F043 Role of Dermatologist in Management of Skin Disease in Solid F060 Immunohistochemistry in Dermatology, 195
Organ Transplant Recipients, 149 F064 The Approach to the Patient with Cutaneous T-Cell
U008 Recognition and Management of High-Risk Skin Cancer, 67 Lymphoma, 209
U019 Sun, Drug, and Invervention: How to Prevent Non-Melanoma S007 Gross and Microscopic Dermatology, 106
Skin Cancer, 87 U020 Challenging Diagnostic Cases for Advanced Practitioners:
U100 Current Management of Skin Cancer in Transplant Patients, 175 PA/NP II, 87
U059 Potpourri of CPC, 136
Ulcers U097 Immunostimulatory Treatment of Skin Cancer, 168
F007 Management of Difficult Wounds, 72 U116 Utilize Web Sites That Enhance Your Career, 191
U051 Therapy for Lipodermatosclerosis, Venous Ulceration, and Atrophie U135 What’s New in Dermatopathology and Why It’s Important
Blanche, 134 to You, 227
Urticaria U170 Pitfalls in Dermatopathology: When Things Are Not What They
D015 Urticaria and Angioedema, 159 Seem to Be, 263
F031 Food Allergy and Dermatology, 121 W003 MOC Self-Assessment: Dermatopathology, 104
W008 Basic Dermoscopy, 182
Viral
C029 Dermatology Review, 234 Dermatopathologic Findings in Various Connective Tissue
U071 Warts, 147 Diseases and other rheumatologic Disease
U120 Sexually Transmitted Infections: The Current Standard of Diagnosis C030 Basic Dermatopathology, 235
and Care, 214 C06A Basic-Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 359
 SUBJECT INDEX
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
S007 Gross and Microscopic Dermatology, 106
U020 Challenging Diagnostic Cases for Advanced Practitioners: Dermatopathologic Findings in Various Non-Infectious Ulcerative
PA/NP II, 87
U059 Potpourri of CPC, 136
U076 Immunofluorescence in Dermatopathology, 155
U135 What’s New in Dermatopathology and Why It’s Important C06C Basic Self-Assessment of Dermatopathology, 89
to You, 227
W003 MOC Self-Assessment: Dermatopathology, 104
Dermatopathologic Findings in Various Cutaneous Drug reactions
C06A Basic-Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
S007 Gross and Microscopic Dermatology, 106
U020 Challenging Diagnostic Cases for Advanced Practitioners: C06C Basic Self-Assessment of Dermatopathology, 89
PA/NP II, 87
W003 MOC Self-Assessment: Dermatopathology, 104
Dermatopathologic Findings in Various Developmental Cysts and
other malformations
C06A Basic-Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
S007 Gross and Microscopic Dermatology, 106
W003 MOC Self-Assessment: Dermatopathology, 104
SUBJECT INDEX
Dermatopathologic Findings in Various Genodermatoses
C024 Infectious Diseases, 207
C06A Basic-Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
S007 Gross and Microscopic Dermatology, 106
Dermatopathologic Findings in Various Infections, Infestations,
and Bites
C030 Basic Dermatopathology, 235
C06A Basic-Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
S007 Gross and Microscopic Dermatology, 106
U010 The Tzanck Smear Test: Reintroducing Our Good Old Friend!, 67
U020 Challenging Diagnostic Cases for Advanced Practitioners:
PA/NP II, 87
U041 Uncommon Cutaneous Infections: Clinical and Histologic Vasculopathy, and purpura
Features, 114
Dermatopathologic Findings in Various metabolic and Systemic
Diseases, including the mucinoses
C030 Basic Dermatopathology, 235
C06A Basic-Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
S007 Gross and Microscopic Dermatology, 106
U005 High-Yield “Power Hour” for Residents, 66
U020 Challenging Diagnostic Cases for Advanced Practitioners: W003 MOC Self-Assessment: Dermatopathology, 104
PA/NP II, 87
360 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
U059 Potpourri of CPC, 136
W003 MOC Self-Assessment: Dermatopathology, 104
Diseases
C06A Basic-Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
S007 Gross and Microscopic Dermatology, 106
Dermatopathologic Findings in Various Non-Neoplastic adnexal
Diseases
C030 Basic Dermatopathology, 235
C06A Basic-Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
F011 Dermatopathology Made Simple, 81
S007 Gross and Microscopic Dermatology, 106
W003 MOC Self-Assessment: Dermatopathology, 104
Dermatopathologic Findings in Various papulosquamous Disorders
C030 Basic Dermatopathology, 235
C06A Basic-Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
F011 Dermatopathology Made Simple, 81
S007 Gross and Microscopic Dermatology, 106
U020 Challenging Diagnostic Cases for Advanced Practitioners:
PA/NP II, 87
U135 What’s New in Dermatopathology and Why It’s Important
to You, 227
W003 MOC Self-Assessment: Dermatopathology, 104
Dermatopathologic Findings in Various Types of panniculitis and
Disorders of the Subcutaneous Fat
C030 Basic Dermatopathology, 235
C06A Basic-Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
F011 Dermatopathology Made Simple, 81
S007 Gross and Microscopic Dermatology, 106
Dermatopathologic Findings in Various Types of Vasculitis,
C030 Basic Dermatopathology, 235
C06A Basic-Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
F011 Dermatopathology Made Simple, 81
S007 Gross and Microscopic Dermatology, 106
U061 Calciphylaxis, 144
U076 Immunofluorescence in Dermatopathology, 155
U164 Hypercoagulability, Purpura, and the Skin, 259

Dermatopathologic Findings in Various Vesicobullous Disorders
C030 Basic Dermatopathology, 235
C06A Basic Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
F090 Autoimmune Mucocutaneous Blistering Disorders, 254
S007 Gross and Microscopic Dermatology, 106
S025 New Emerging Therapies, 168
S036 Blistering Disease, 205
U010 The Tzanck Smear Test: Reintroducing Our Good Old Friend!, 67
U020 Challenging Diagnostic Cases for Advanced Practitioners:
PA/NP II, 87
U114 Stem Cells in Melanoma and Nevi, 190
W003 MOC Self-Assessment: Dermatopathology, 104
Dermatopathologic Findings of Hair and Nails, Including alopecia
C019 Hair and Nails, 138
C030 Basic Dermatopathology, 235
C06A Basic Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
F042 Hair and Nail Clinicopathologic Correlations, 149
F067 Managing Hair Loss Made Easy, 211
F075 Alopecia CPC, 231
F092 Diagnosing and Monitoring Hair and Scalp Disease, 255
S007 Gross and Microscopic Dermatology, 106
S028 Nails, 171
U033 Electrolysis: When Laser Isn’t the Answer, 98
U083 Hair Highlights: Common and Challenging Hair PA/NP II, 87
Loss Disorders, 157
U125 Penile Growths, 216
W003 MOC Self-Assessment: Dermatopathology, 104
Dermatopathologic Findings of oral and anogenital Diseases
C06A Basic Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
F025 Dramatic Oral Disease, 118
S007 Gross and Microscopic Dermatology, 106
U022 Vulvar Dermatoses, 87
Dermatopathology
C014 Coding, Documentation, and Practice Management, 123
C029 Dermatology Review, 234
C030 Basic Dermatopathology, 235
F011 Dermatopathology Made Simple, 81
F092 Diagnosing and Monitoring Hair and Scalp Disease, 255
F095 Challenges in the Diagnosis and Management of Lentigo Maligna C06A Basic Self-Assessment of Dermatopathology, 64
Melanoma, 264
U043 Dermatopathology Challenges Encountered by the Mohs C06C Basic Self-Assessment of Dermatopathology, 89
Surgeon, 115
U135 What’s New in Dermatopathology and Why It’s Important C06E Basic Self-Assessment of Dermatopathology Discussion, 122
to You, 227
Dermatopathology artifacts
C06A Basic Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
S007 Gross and Microscopic Dermatology, 106
For the Latest Program Book InFormatIon PLease reFer to
SUBJECT INDEX
Dermatopathology Differential Diagnosis: Invisible Dermatoses
C06A Basic Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
S007 Gross and Microscopic Dermatology, 106
Dermatopathology Differential Diagnosis: Dermatologic Diseases
with Diffuse Infiltrates
C030 Basic Dermatopathology, 235
C06A Basic Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
F064 The Approach to the Patient with Cutaneous T-Cell
Lymphoma, 209
S007 Gross and Microscopic Dermatology, 106
U170 Pitfalls in Dermatopathology: When Things Are Not What They
Seem to Be, 263
W003 MOC Self-Assessment: Dermatopathology, 104
Dermatopathology Differential Diagnosis: Dermatologic Diseases
with Interface Dermatitis
C030 Basic Dermatopathology, 235
C06A Basic Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
SUBJECT INDEX
S007 Gross and Microscopic Dermatology, 106
U020 Challenging Diagnostic Cases for Advanced Practitioners:
U170 Pitfalls in Dermatopathology: When Things Are Not What They
Seem to Be, 263
W003 MOC Self-Assessment: Dermatopathology, 104
Dermatopathology Differential Diagnosis: Dermatologic Diseases
with Nodular Inflammation or Infiltrates
C030 Basic Dermatopathology, 235
C06A Basic Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
S007 Gross and Microscopic Dermatology, 106
U020 Challenging Diagnostic Cases for Advanced Practitioners:
PA/NP II, 87
U170 Pitfalls in Dermatopathology: When Things Are Not What They
Seem to Be, 263
Dermatopathology Differential Diagnosis: Dermatologic Diseases
with perivascular Infiltrates
C06B Basic Self-Assessment of Dermatopathology, 80
C06D Basic Self-Assessment of Dermatopathology, 99
F011 Dermatopathology Made Simple, 81
S007 Gross and Microscopic Dermatology, 106
Dermatopathology Stains, Including Histochemistry,
Immunohistochemistry, and Immunofluorescence
C030 Basic Dermatopathology, 235
F025 Dramatic Oral Disease, 118
F060 Immunohistochemistry in Dermatology, 195
S007 Gross and Microscopic Dermatology, 106
www.aad.org | 361
 SUBJECT INDEX
U037 Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS), 99
U076 Immunofluorescence in Dermatopathology, 155
U135 What’s New in Dermatopathology and Why It’s Important SkILLS
to You, 227
U139 Inherited Cancer Syndromes: The Role of the Dermatologist, 228
U171 Dermatopathology: Utility, Methodology, and Interpretation of Consultant, and Health Care System Communications
Current (and Future) Molecular Testing, 262
W003 MOC Self-Assessment: Dermatopathology, 104
Disorders of pigmentation
C06A Basic Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
F055 Vitiligo: Problems and Solutions, 135
U086 Melasma: Pathogenesis and Treatment, 165
Histology of the Skin
C030 Basic Dermatopathology, 235
C06A Basic Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
F052 Advanced Dermatopathology, 180
U059 Potpourri of CPC, 136
Immunopathology
S036 Blistering Disease, 205
patient Care and the Dermatopathologist: patient Safety Issues
SUBJECT INDEX
C06A Basic Self-Assessment of Dermatopathology, 64
C06B Basic Self-Assessment of Dermatopathology, 80
C06C Basic Self-Assessment of Dermatopathology, 89
C06D Basic Self-Assessment of Dermatopathology, 99
C06E Basic Self-Assessment of Dermatopathology Discussion, 122
S014 Patient Safety and Quality, 124
W013 MOC Self-Assessment: Office-Based Safety, 233
Self-assessment
C016 Advanced Self-Assessment of Dermatopathology, 127
F076 Pediatric Dermatology, 232
W005 MOC Self-Assessment: Pediatric Dermatology, 133
DIaGNoSTIC mETHoDS
microbiology
U082 Practical and Realistic Office Mycology for the Epidemiology, Practice, 118
Diagnosis, and Treatment of Human Mycoses, 157
patch Testing
D026 A Practical Approach to Photosensitivity, 239
EpIDEmIoLoGy
Epidemiology
F048 Psoriasis as a Systemic Disease, 178
F051 Controversies in Vitamin D, 179
F056 Therapeutic Safety, 193
S042 International Dermatology, 224
U018 Outcomes Research in Dermatology, 86
U082 Practical and Realistic Office Mycology for the Epidemiology,
Diagnosi, and Treatment of Human Mycoses, 157
U132 The Year in Review in Pediatric Dermatology: How Does It Change F093 Psychocutaneous Medicine, 265
My Practice?, 218
U155 What’s New in Skin Cancer Prevention?, 255
362 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
INTErpErSoNaL aND CommUNICaTIoN
Non-patient Communication, Including Staff, Colleague,
C014 Coding, Documentation, and Practice Management, 123
C022 Advanced Practice Management: Mini MBA, 199
D007 Leading from Conflict to Resolution, 113
F008 Decreasing Iatrogenic Problems in Your Practice, 72
F022 Coding and Office Management, 102
F030 Managing Online Reputation, 120
F032 Multidisciplinary Preventive Networking in Occupational Contact
Dermatitis, 129
F046 Leading Your Team by Coaching and Mentoring, 150
F047 Managing an Efficient Practice, 177
F063 Young Physician Pearls and Pitfalls: A Survival Guide for
the First 10 Years, 209
S004 When Bad Things Happen to Good Doctors, 76
S005 Leading from Your Vision to Exceptional Service, 77
S013 Leading Others for Peak Performance, 94
U006 International Teledermatology Overview, 66
U012 Leading with your Strengths, 68
U046 Social Media and Dermatology: How Twitter and Facebook Will
Help You and Your Practice, 116
W002 Dermatology Speaker Development, 104
W012 Dealing with Difficult People and Looking Forward to It, 213
patient Communication
C001 Volunteers Abroad Course: Beginner, 57
C002 Volunteers Abroad Course: Advanced, 58
C014 Coding, Documentation and Practice Management, 123
C021 Intermediate Cosmetic Surgery, 198
D009 Educate Your Patients and Improve Outcomes, 133
F008 Decreasing Iatrogenic Problems in Your Practice, 72
F020 Volunteerism and Humanitarianism, 101
F022 Coding and Office Management, 102
F025 Dramatic Oral Disease, 118
F030 Managing Online Reputation, 120
F067 Managing Hair Loss Made Easy, 211
S004 When Bad Things Happen to Good Doctors, 76
S008 Consultative Dermatology for the Hospitalized Patient, 91
S027 Contact and Occupational Dermatitis, 119
U009 Phototherapy and Photochemotherapy: Nuances and Peals for the
Practicing Clinician, 67
U012 Leading with Your Strengths, 68
U026 Teledermatology 101: Integrating Teledermatology into Your
U038 Nanotechnology, 114
U046 Social Media and Dermatology: How Twitter and Facebook Will
Help You and Your Practice, 116
U079 Dermatologic Disease in Asians, 156
U087 Fulfilling Great Expectations: Caring for New Mothers and
Mothers-to-Be, 165
U115 Medication Use: Improving Adherence and Compliance, 191
U118 Holy Moly: Religion and the Skin, 192
U129 Informed Shared Decision Making in Psoriasis Management, 217
W012 Dealing with Difficult People and Looking Forward to It, 213
mEDICaL DErmaToLoGy
adult psychocutaneous Disease
U052 Diseases of Male Genitalia, 134
U083 Hair Highlights: Common and Challenging Hair Loss Disorders, 157
 SUBJECT INDEX

adult adnexal Diseases F020 Volunteerism and Humanitarianism, 101

F010 Hidradenitis Suppurativa: An Update, 81 F023 Psoriasis Guidelines; Implementing Them in Your Practice, 103
S022 Acne and Rosacea, 142 F067 Managing Hair Loss Made Easy, 211
U002 Management of Post-Acne Scarring, 65 F092 Diagnosing and Monitoring Hair and Scalp Disease, 255
U014 When Acne Really Isn’t Acne, 85 U061 Calciphylaxis, 144
U021 Acne in the Adult Female Patient, 87 U079 Dermatologic Disease in Asians, 156
U052 Diseases of Male Genitalia, 134 U083 Hair Highlights: Common and Challenging Hair Loss
U083 Hair Highlights: Common and Challenging Hair Loss Disorders, 157
Disorders, 157 U128 Leg Ulcer Quiz for the Astute Dermatologist!, 217
U139 Inherited Cancer Syndromes: The Role of the Dermatologist, 228
adult Collagen Vascular Disorders and other rheumatologic U154 Caring for the Hospitalized Patient: Interesting Cases from the
Disease Inpatient Consultative Service, 256
F019 Journal Watching, 101 W006 MOC Self-Assessment: Contact Dermatology, 151
F034 From the Dermatology Rheumatology Clinics: Practical Tips and
Advances in Management, 130 adult patient Care: In-office and ancillary Diagnostics
F054 Dermatologic Health of Women, 181 D011 Women With Hair Loss, 144
U020 Challenging Diagnostic Cases for Advanced Practitioners: D026 A Practical Approach to Photosensitivity, 239
PA/NP II, 87 F023 Psoriasis Guidelines; Implementing Them in Your Practice, 103
U031 Dermatomyositis, 97 F092 Diagnosing and Monitoring Hair and Scalp Disease, 255
U056 Recommended Screening Practices in Medical Dermatology, 136 S049 Cosmetics, 251
U130 Sarcoidosis, 217 U010 The Tzanck Smear Test: Reintroducing our Good Old Friend!, 67
U079 Dermatologic Disease in Asians, 156
adult Disorders of Cornification and keratinization U083 Hair Highlights: Common and Challenging Hair Loss
D019 Enhancing Observational Skills, 188 Disorders, 157
F012 Update on Genetic Skin Disease, 82 U144 Serial Screening for Melanoma: Measures that have Consistently
U102 From Pigment to PUPP (or PEP): What to Expect When Your Achieved Early Detection and Cure, 239
Patient Is Expecting, 175
adult patient Care: Non-Surgical office-Based procedures
adult patient Care: assessment Skills, plan Formulation, F084 Medical Applications of Topical Photodynamic Therapy, 244
and patient recommendations U010 The Tzanck Smear Test: Reintroducing Our Good Old Friend!, 67
D001 Pregnancy Dermatoses: Moving Towards a Better U083 Hair Highlights: Common and Challenging Hair Loss
Understanding, 64

SUBJECT INDEX
Disorders, 157
D019 Enhancing Observational Skills, 188
D022 Common Dermatologic Diseases with Myriad Treatments, 213 adult patient Care: patient Safety Issues
D026 A Practical Approach to Photosensitivity, 239 F020 Volunteerism and Humanitarianism, 101
F012 Update on Genetic Skin Disease, 82 F023 Psoriasis Guidelines; Implementing Them in Your Practice, 103
F020 Volunteerism and Humanitarianism, 101 S014 Patient Safety and Quality, 124
F023 Psoriasis Guideline; Implementing Them in Your Practice, 103 S035 Controversies in Dermatologic Drug Therapy, 204
F032 Multidisciplinary Preventive Networking in Occupational Contact U009 Phototherapy and Photochemotherapy: Nuances and Peals for the
Dermatitis, 129 Practicing Clinician, 67
F054 Dermatologic Health of Women, 181 U038 Nanotechnology, 114
F061 Medical Dermatology Challenge: Complex Cases from the U068 Electrosurgery Update, 146
Collection of Dr. Samuel Moschella, 196 U075 Drug Safety: Do No Harm, 155
S022 Acne and Rosacea, 142 U087 Fulfilling Great Expectations: Caring for New Mothers and
S034 Psoriasis, 203 Mothers-to-Be, 165
S041 Clinical Issues in Medical Dermatology, 223 U108 Safety of Biologic Therapies: What’s the Real Story?, 177
U009 Phototherapy and Photochemotherapy: Nuances and Peals for the U110 Review of Dermatological Adverse Reactions, 189
Practicing Clinician, 67 U112 Histopathology of Scarring Alopecia, 190
U014 When Acne Really Isn’t Acne, 85 U129 Informed Shared Decision Making in Psoriasis Management, 217
U016 Sports Dermatology: Skin Infections in Athletes, 85 U139 Inherited Cancer Syndromes: The Role of the Dermatologist, 228
U026 Teledermatology 101: Integrating Teledermatology into Your adult patient Care: population Health and preventive Care
Practice, 89 C001 Volunteers Abroad Course: Beginner, 57
U056 Recommended Screening Practices in Medical Dermatology, 136 C002 Volunteers Abroad Course: Advanced, 58
U079 Dermatologic Disease in Asians, 156 F020 Volunteerism and Humanitarianism, 101
U087 Fulfilling Great Expectations: Caring for New Mothers and F023 Psoriasis Guidelines; Implementing them in Your Practice, 103
Mothers-to-Be, 165 F032 Multidisciplinary Preventive Networking in Occupational Contact
U105 Advances in Fat Transfer and Liposuction for Correction of Dermatitis, 129
Lipodystrophy: The USC Experience, 176 F054 Dermatologic Health of Women, 181
U128 Leg Ulcer Quiz for the Astute Dermatologist!, 217 F065 What’s New and Emerging: Therapeutics, 210
U129 Informed Shared Decision Making in Psoriasis Management, 217 U075 Drug Safety: Do No Harm, 155
U139 Inherited Cancer Syndromes: The Role of the Dermatologist, 228
W006 MOC Self-Assessment: Contact Dermatology, 151 atrophies, perforating Disorders, and Disorders of Dermal
Connective Tissue
adult patient Care: History Taking and physical Diagnosis C025 Fundamentals of Dermoscopy, 208
C004 Diagnosis and Therapeutics: The Fundamentals, 74 D006 Serologic Testing for Connective Tissue Diseases, 94
D001 Pregnancy Dermatoses: Moving Towards a Better U052 Diseases of Male Genitalia, 134
Understanding, 64
U139 Inherited Cancer Syndromes: The Role of the Dermatologist, 228
D026 A Practical Approach to Photosensitivity, 239

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 363
 SUBJECT INDEX

Benign and malignant Cutaneous Neoplasms, including Cutaneous Disorders of Subcutaneous Fat
Lymphomas U020 Challenging Diagnostic Cases for Advanced Practitioners:
D023 Cutaenous T-Cell Lymphoma, 226 PA/NP II, 87
F064 The Approach to the Patient with Cutaneous T-Cell U036 Subcutaneous Fat in Dermatology, 98
Lymphoma, 209
Eczematous Dermatoses
F065 What’s New and Emerging-Therapeutics, 210
C029 Dermatology Review, 234
F066 Merkel Cell Carcinoma: Diagnosis, Management, and
D001 Pregnancy Dermatoses: Moving Towards a Better
Controversies, 210
Understanding, 64
F084 Medical Applications of Topical Photodynamic Therapy, 244
F018 Atopic Dermatitis, 100
S006 Approach to Pigmented Lesions, 78
F032 Multidisciplinary Preventive Networking in Occupational Contact
S048 Cutaneous Lymphomas, 250
Dermatitis, 129
U003 Management of High-Risk Squamous Cell Carcinoma (SCC), 65
F096 Phototherapy, 266
U015 Merkel Cell Carcinoma, 85
S016 Drug Actions, 125
U019 Sun, Drugs, and Invervention: How to Prevent Non-Melanoma
Skin Cancer, 87 S027 Contact and Occupational Dermatitis, 170
U020 Challenging Diagnostic Cases for Advanced Practitioners: U009 Phototherapy and Photochemotherapy: Nuances and Pearls for the
PA/NP II, 87 Practicing Clinician, 67
U053 Through the Looking Glass: The Use of Dermoscopy in the U020 Challenging Diagnostic Cases for Advanced Practitioners:
Management of the Pigmented Lesion Patient, 135 PA/NP II, 87
U113 Immunology for Dermatologists, 190 U038 Nanotechnology, 114
U116 Utilize Web Sites That Enhance Your Career, 191 U115 Medication Use: Improving Adherence and Compliance, 191
U144 Serial Screening for Melanoma: Measures That Have Consistently U156 Finding the Needle in the Haystack: A Guide to More Effective
Achieved Early Detection and Cure, 239 Patch Testing, 256
U171 Dermatopathology: Utility, Methodology, and Interpretation of W006 MOC Self-Assessment: Contact Dermatology, 151
Current (and Future) Molecular Testing, 262 Immunobullous Diseases
W008 Basic Dermoscopy, 182 C015 Internal Medicine, 127
W014 Dermoscopy Cases, 244 C024 Infectious Diseases, 207
Disorders Due to Light, Trauma, and other physical agents C029 Dermatology Review, 234
F084 Medical Applications of Topical Photodynamic Therapy, 244 F025 Dramatic Oral Disease, 118
U151 Approach to Non-scarring Hair Loss in Women, 241 F090 Autoimmune Mucocutaneous Blistering Disorders, 254
SUBJECT INDEX

S015 Advanced Pediatric Dermatology, 125

Disorders of Hair and Nails S036 Blistering Disease, 205
C019 Hair and Nails, 138 U005 High-Yield “Power Hour” for Residents, 66
C023 Advanced Pediatric Dermatology, 200 U010 The Tzanck Smear Test: Reintroducing Our Good Old Friend!, 67
C029 Dermatology Review, 234 U020 Challenging Diagnostic Cases for Advanced Practitioners:
D011 Women With Hair Loss, 144 PA/NP II, 87
F012 Update on Genetic Skin Disease, 82 U037 Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS), 99
F042 Hair and Nail Clinicopathologic Correlations, 149 U038 Nanotechnology, 114
F058 Hair Loss in Women, 194 U076 Immunofluorescence in Dermatopathology, 155
F067 Managing Hair Loss Made Easy, 211 U114 Stem Cells in Melanoma and Nevi, 190
F070 Fungal Infections, 212 U140 Past, Present, and Pearls of Treatment of Autoimmune Bullous
F079 Update on Alopecia Areata, 242 Disease, 229
F087 Nail Disorders in Children, 252
F092 Diagnosing and Monitoring Hair and Scalp Disease, 255 Infections, Infestations, and Bites
S009 Advanced Medical Dermatology, 92 C002 Volunteers Abroad Course: Advanced, 58
S028 Nails, 171 C015 Internal Medicine, 127
S034 Psoriasis, 203 C018 Dermatologic Drug Safety and Efficacy, 137
U011 Medical and Aesthetic Dermatology in Skin of Color, 68 F083 Psoriasis Therapy in the Age of Biologics, 244
U027 Practical Approaches to Medical and Cosmetic Dermatology in S031 Tropical Dermatology, 173
Patients with Skin of Color, 95 S050 Organizational Approaches to AIDS/STD From a Global
U033 Electrolysis: When Laser isn’t the Answer, 98 Perspective, 251
U083 Hair Highlights: Common and Challenging Hair Loss U010 The Tzanck Smear Test: Reintroducing our Good Old Friend!, 67
Disorders, 157 U016 Sports Dermatology: Skin Infections in Athletes, 85
U118 Holy Moly: Religion and the Skin, 192 U020 Challenging Diagnostic Cases for Advanced Practitioners:
PA/NP II, 87
Disorders of pigmentation U038 Nanotechnology, 114
C017 Advanced Dermoscopy, 128 U041 Uncommon Cutaneous Infections: Clinical and Histologic
S001 Disorders of Pigmentation, 75 Features, 114
S021 Skin of Color, 141 U052 Diseases of Male Genitalia, 134
U009 Phototherapy and Photochemotherapy: Nuances and Pearls for the U094 Dermatologic Manifestations of HIV and AIDS, 167
Practicing Clinician, 67
U133 Psychodermatology: Not Just a Delusion; Bugs, Trichotillomania,
U011 Medical and Aesthetic Dermatology in Skin of Color, 68
and the Morgellons Debate, 226
U052 Diseases of Male Genitalia, 134
U163 Garden Variety Derm: Identifying and Managing Exposures to
U079 Dermatologic Disease in Asians, 156 Hazardous Plants and Arthropods in the Garden, 258
U086 Melasma: Pathogenesis and Treatment, 165
U113 Immunology for Dermatologists, 190

364 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SUBJECT INDEX

medical Therapy U124 Graft-Versus-Host Disease, 215

C001 Volunteers Abroad Course: Beginner, 57 U130 Sarcoidosis, 217
C004 Diagnosis and Therapeutics: The Fundamentals, 74 U141 Skin Signs of Systemic Disease, 229
C015 Internal Medicine, 127
C023 Advanced Pediatric Dermatology, 200 Non-Infectious Disorders of macrophages and Langerhans Cells
F010 Hidradenitis Suppurativa: An Update, 81 U130 Sarcoidosis, 217
F020 Volunteerism and Humanitarianism, 101 oral and anogenital Diseases
F023 Psoriasis Guidelines; Implementing Them in Your Practice, 103 F002 Erosive Vulvar Diseases: Approach to Diagnosis, Differential
F025 Dramatic Oral Disease, 118 Diagnosis, and Treatment, 69
F035 Practical Aspects of Biologic Therapy, 131 F025 Dramatic Oral Disease, 118
F065 What’s New and Emerging: Therapeutics, 210 S045 Disorders of Mucous Membranes, 248
F079 Update on Alopecia Areata, 242 U022 Vulvar Dermatoses, 87
S001 Disorders of Pigmentation, 75 U028 Oral Ulcers, 95
S003 Hot Topics, 76 U052 Diseases of Male Genitalia, 134
S009 Advanced Medical Dermatology, 92 U140 Past, Present, and Pearls of Treatment of Autoimmune Bullous
S022 Acne and Rosacea, 142 Disease, 229
S035 Controversies in Dermatologic Drug Therapy, 204
S039 Therapeutic and Diagnostic Pearls, 221 papulosquamous Dermatoses
S041 Clinical Issues in Medical Dermatology, 223 D001 Pregnancy Dermatoses: Moving Towards a Better
S044 Therapeutic Hotline, 248 Understanding, 64
U013 Vitamin D and Dermatology, 68 F025 Dramatic Oral Disease, 118
U016 Sports Dermatology: Skin Infections in Athletes, 85 F035 Practical Aspects of Biologic Therapy, 131
U021 Acne in the Adult Female, 87 F096 Phototherapy, 266
U023 Highlights from JAAD, 88 S016 Drug Actions, 125
U038 Nanotechnology, 114 S034 Psoriasis, 203
U052 Diseases of Male Genitalia, 134 U009 Phototherapy and Photochemotherapy: Nuances and Pearls for the
U075 Drug Safety: Do No Harm, 155 Practicing Clinician, 67
U079 Dermatologic Disease in Asians, 156 U020 Challenging Diagnostic Cases for Advanced Practitioners: PA/NP
U083 Hair Highlights: Common and Challenging Hair Loss II, 87
Disorders, 157 U032 Chronic Inflammatory Hand and Foot Dermatoses, 97
U087 Fulfilling Great Expectations: Caring for New Mothers and U035 Paraneoplastic Dermatoses, 98

SUBJECT INDEX
Mothers-to-Be, 165 U112 Histopathology of Scarring Alopecia, 190
U093 Notes of a Therapeutic Iconoclast, 167 U115 Medication Use: Improving Adherence and Compliance, 191
U094 Dermatologic Manifestations of HIV and AIDS, 167 U129 Informed Shared Decision Making in Psoriasis Management, 217
U095 Biologic Drugs for Psoriasis: Do We Use Them Enough?, 167 U145 Advances in Psoriasis, 240
U101 Pediatric Drug Eruptions, 175
U109 Pediatric Connective Tissue, 189 pruritus
U110 Review of Dermatological Adverse Reactions, 189 C015 Internal Medicine, 127
U112 Histopathology of Scarring Alopecia, 190 D001 Pregnancy Dermatoses: Moving Towards a Better
U121 Update on Graft-Versus-Host Disease, 214 Understanding, 64
U124 Graft-Versus-Host Disease, 215 F038 Itch, 132
U128 Leg Ulcer Quiz for the Astute Dermatologist!, 217 U052 Diseases of Male Genitalia, 134
U129 Informed Shared Decision Making in Psoriasis Management, 217 Ulcerating Dermatoses
U130 Sarcoidosis, 217 D016 Photodermatology, 159
U133 Psychodermatology: Not Just a Delusion; Bugs, Trichotillomania, F023 Psoriasis Guidelines: Implementing them in Your Practice, 103
and the Morgellons Debate, 226
F071 Advanced Treatment for Chronic Wounds, 230
U140 Past, Present, and Pearls of Treatment of Autoimmune Bullous
S041 Clinical Issues in Medical Dermatology, 223
Disease, 229
U051 Therapy for Lipodermatosclerosis, Venous Ulceration, and Atrophie
U145 Advances in Psoriasis, 240
Blanche, 134
U154 Caring for the Hospitalized Patient: Interesting Cases from the
Inpatient Consultative Service, 256 U052 Diseases of Male Genitalia, 134
U157 Rosacea Update, 256 U128 Leg Ulcer Quiz for the Astute Dermatologist!, 217
U165 The Management of TEN/SJS: The US Army Burn Unit Ultraviolet Light Therapy and other physical Treatment modalities
Experience, 259 D008 PUVA and Phototherapy Beyond Psoriasis, 113
metabolic and Systemic Diseases D026 A Practical Approach to Photosensitivity, 239
C015 Internal Medicine, 127 F023 Psoriasis Guidelines: Implementing them in Your Practice, 103
F061 Medical Dermatology Challenge: Complex Cases from the F084 Medical Applications of Topical Photodynamic Therapy, 244
Collection of Dr. Samuel Moschella, 196 F096 Phototherapy, 266
F091 Supportive Onco-Dermatology: Dermatologic Reactions in S001 Disorders of Pigmentation, 75
Oncology, 254 S033 Photodermatology, 202
S041 Clinical Issues in Medical Dermatology, 223 U009 Phototherapy and Photochemotherapy: Nuances and Pearls for the
U020 Challenging Diagnostic Cases for Advanced Practitioners: Practicing Clinician, 67
PA/NP II, 87 U033 Electrolysis: When Laser Isn’t the Answer, 98
U021 Acne in the Adult Female, 87 U038 Nanotechnology, 114
U083 Hair Highlights: Common and Challenging Hair Loss U087 Fulfilling Great Expectations: Caring for New Mothers and
Disorders, 157 Mothers-to-Be, 165
U109 Pediatric Connective Tissue, 189 U142 Cryosurgical Update, 229

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 365
 SUBJECT INDEX

Urticarial Dermatoses and Erythemas Cutaneous Disorders of the Newborn

D015 Urticaria and Angioedema, 159 C023 Advanced Pediatric Dermatology, 200
F026 Chronic Urticaria and Angioedema: What’s New in Pathogenesis F003 Case-Based Challenges in Pediatric Dermatology, 70
and Treatment, 118 F037 Systemic Evaluation of Cutaneous Findings in Infants and
U020 Challenging Diagnostic Cases for Advanced Practitioners: Children: What’s New and What’s True?, 132
PA/NP II, 87 U080 Uncommon Neonatal Dermatosis, 156
Vasculitis, Vasculopathy and purpura Disorders of Non-Infectious macrophages and Langerhans Cells
C015 Internal Medicine, 127 U020 Challenging Diagnostic Cases for Advanced Practitioners:
F019 Journal Watching, 101 PA/NP II, 87
U020 Challenging Diagnostic Cases for Advanced Practitioners:
PA/NP II, 87 Ectodermal Dysplasia
U128 Leg Ulcer Quiz for the Astute Dermatologist!, 217 U007 Ectodermal Dysplasias, 66
U164 Hypercoagulability, Purpura, and the Skin, 259 U020 Challenging Diagnostic Cases for Advanced Practitioners:
PA/NP II, 87
U034 Pediatric Hyperhidrosis and Ectodermal Dysplasia: To Sweat or
mISCELLaNEoUS TopICS Not to Sweat?, 98

art Eczematous Eruptions

U107 Dermatology in Cinema, 177 C023 Advanced Pediatric Dermatology, 200
F003 Case-Based Challenges in Pediatric Dermatology, 70
Controversies F018 Atopic Dermatitis, 100
F051 Controversies in Vitamin D, 179 F039 Treating Severe Skin Disease in Children, 147
F056 Therapeutic Safety, 193 S046 Pediatric Dermatology, 249
S010 Surviving Healthcare Reform, 92 U009 Phototherapy and Photochemotherapy: Nuances and Pearls for the
S035 Controversies in Dermatologic Drug Therapy, 204 Practicing Clinician, 67
S051 Evidence-Based Medicine, 261 U020 Challenging Diagnostic Cases for Advanced Practitioners:
U042 The Vices of Devices in Dermatology, 115 PA/NP II, 87
U046 Social Media and Dermatology: How Twitter and Facebook Will U115 Medication Use: Improving Adherence and Compliance, 191
Help You and Your Practice, 116
U055 Practical Approaches to Cosmeceuticals, 135 Hereditary Disorders of Cornification and keratinization
SUBJECT INDEX

U061 Calciphylaxis, 144 C009 Dermatologic Syndromes and Genetic Disorders, 90

C023 Advanced Pediatric Dermatology, 200
Environment Issues F012 Update on Genetic Skin Disease, 82
U040 Military Unique Dermatology, 114 U020 Challenging Diagnostic Cases for Advanced Practitioners:
Geographic (Global) Dermatology PA/NP II, 87
S036 Blistering Disease, 205 U038 Nanotechnology, 114
S042 International Dermatology, 224 medical Therapy Issues in the pediatric patient
U040 Military Unique Dermatology, 114 C001 Volunteers Abroad Course: Beginner, 57
miscellaneous F003 Case-Based Challenges in Pediatric Dermatology, 70
C014 Coding, Documentation, and Practice Management F039 Treating Severe Skin Disease in Children, 147
F028 What You Need to Know About Coding But Were Afraid F061 Medical Dermatology Challenge: Complex Cases from the
to Ask, 119 Collection of Dr. Samuel Moschella, 196
F036 Careers in Academic Dermatology, 131 F078 Epidermolysis Bullosa: Cases and Discussion, 233
S004 When Bad Things Happen to Good Doctors, 76 S022 Acne and Rosacea, 142
U040 Military Unique Dermatology, 114 S039 Therapeutic and Diagnostic Pearls, 221
U046 Social Media and Dermatology: How Twitter and Facebook will S046 Pediatric Dermatology, 249
Help You and Your Practice, 116 U048 Challenging Cases in Pediatric Dermatology, 117
U072 Pediatric Dermatologic Surgery in the Outpatient Setting: Tricks of
the Trade, 147
pEDIaTrIC DErmaToLoGy U075 Drug Safety: Do No Harm, 155
U083 Hair Highlights: Common and Challenging Hair Loss
Benign Neoplasms, pediatric Cutaneous malignancy, and Tumor
Disorders, 157
Syndromes of Childhood U087 Fulfilling Great Expectations: Caring for New Mothers and
C023 Advanced Pediatric Dermatology, 200 Mothers-to-Be, 165
F003 Case-Based Challenges in Pediatric Dermatology, 70 U101 Pediatric Drug Eruptions, 175
F037 Systemic Evaluation of Cutaneous Findings in Infants and U109 Pediatric Connective Tissue, 189
Children: What’s New and What’s True?, 132 U147 Dermatological Signs of Child Abuse, 240
S020 Birthmarks, 140 U148 Lessons Learned from Challenging Pediatric Cases: Targeted Novel
U020 Challenging Diagnostic Cases for Advanced Practitioners: Molecular Therapies, 240
PA/NP II, 87
U113 Immunology for Dermatologists, 190 Normal Skin Variants and Developmental anomalies
U143 Pediatric Surgery, 239 C023 Advanced Pediatric Dermatology, 200
U171 Dermatopathology: Utility, Methodology, and Interpretation of S020 Birthmarks, 140
Current (and Future) Molecular Testing, 262 S025 New Emerging Therapies, 168

366 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SUBJECT INDEX

pediatric adnexal Diseases, Including acne Vulgaris pediatric patient Care: assessment Skills, plan Formulation, and
S022 Acne and Rosacea, 142 patient/Family recommendations
U014 When Acne Really Isn’t Acne, 85 F003 Case-Based Challenges in Pediatric Dermatology, 70
U083 Hair Highlights: Common and Challenging Hair Loss F057 Adolescent Dermatology, 194
Disorders, 157 F078 Epidermolysis Bullosa: Cases and Discussion, 233
S015 Advanced Pediatric Dermatology, 125
pediatric Collagen Vascular Disorders and other U009 Phototherapy and Photochemotherapy: Nuances and Pearls for the
rheumatologic Disease Practicing Clinician, 67
U020 Challenging Diagnostic Cases for Advanced Practitioners: U048 Challenging Cases in Pediatric Dermatology, 117
PA/NP II, 87 U072 Pediatric Dermatologic Surgery in the Outpatient Setting: Tricks of
pediatric Disorders Due to Light, Trauma, and other the Trade, 147
physical agents pediatric patient Care: History Taking and physical Diagnosis
C009 Dermatologic Syndromes and Genetic Disorders, 90 F057 Adolescent Dermatology, 194
U009 Phototherapy and Photochemotherapy: Nuances and Pearls for the
pediatric Disorders of Hair and Nails
Practicing Clinician, 67
C023 Advanced Pediatric Dermatology, 200 U083 Hair Highlights: Common and Challenging Hair Loss
F006 Vitiligo, 71 Disorders, 157
F012 Update on Genetic Skin Disease, 82
F070 Fungal Infections, 212 pediatric patient Care: In-office and ancillary Diagnostics
F087 Nail Disorders in Children, 252 U010 The Tzanck Smear Test: Reintroducing Our Good Old Friend!, 67
U067 Twists and Splits: How to Approach Hair Shaft Disorders, 146 U083 Hair Highlights: Common and Challenging Hair Loss
U083 Hair Highlights: Common and Challenging Hair Loss Disorders, 157
Disorders, 157 U109 Pediatric Connective Tissue, 189

pediatric Disorders of pigmentation pediatric patient Care: Non-Surgical office-Based procedures

F003 Case-Based Challenges in Pediatric Dermatology, 70 S046 Pediatric Dermatology, 249
F037 Systemic Evaluation of Cutaneous Findings in Infants and U010 The Tzanck Smear Test: Reintroducing Our Good Old Friend!, 67
Children: What’s New and What’s True?, 132 U038 Nanotechnology, 114
F087 Nail Disorders in Children, 252 U072 Pediatric Dermatologic Surgery in the Outpatient Setting:
S001 Disorders of Pigmentation, 75 Tricks of the Trade, 147
U083 Hair Highlights: Common and Challenging Hair Loss

SUBJECT INDEX
S020 Birthmarks, 140
Disorders, 157
U009 Phototherapy and Photochemotherapy: Nuances and Pearls for the
Practicing Clinician, 67 pediatric patient Care: patient Safety Issues
U020 Challenging Diagnostic Cases for Advanced Practitioners: U038 Nanotechnology, 114
PA/NP II, 87 U075 Drug Safety: Do No Harm, 155
U113 Immunology for Dermatologists, 190 U087 Fulfilling Great Expectations: Caring for New Mothers and
Mothers-to-Be, 165
pediatric Exanthematous Diseases and Hypersensitivity Syndromes
U020 Challenging Diagnostic Cases for Advanced Practitioners: pediatric patient Care: population Health and preventive Care
PA/NP II, 87 F051 Controversies in Vitamin D, 179
U050 Viral Exanthem Update, 134 U075 Drug Safety: Do No Harm, 155
U101 Pediatric Drug Eruptions, 175
pediatric psychocutaneous Disease
pediatric Infections, Infestations, and Bites U083 Hair Highlights: Common and Challenging Hair Loss
C023 Advanced Pediatric Dermatology, 200 Disorders, 157
F003 Case-Based Challenges in Pediatric Dermatology, 70 pediatric Subcutaneous Fat Disorders
S046 Pediatric Dermatology, 249 F003 Case-Based Challenges in Pediatric Dermatology, 70
U038 Nanotechnology, 114 U020 Challenging Diagnostic Cases for Advanced Practitioners:
U094 Dermatologic Manifestations of HIV and AIDS, 167 PA/NP II, 87
U142 Cryosurgical Update, 229
pediatric Ulcerating Dermatoses and wound Care
pediatric metabolic and Systemic Diseases, Including Endocrine F078 Epidermolysis Bullosa: Cases and Discussion, 233
Disorders and the Skin U038 Nanotechnology, 114
D026 A Practical Approach to Photosensitivity, 239 U128 Leg Ulcer Quiz for the Astute Dermatologist!, 217
F051 Controversies in Vitamin D, 179
F061 Medical Dermatology Challenge: Complex Cases from the Ultraviolet Light Therapy and other physical Treatment modalities
Collection of Dr. Samuel Moschella, 196 in the pediatric patient
U109 Pediatric Connective Tissue, 189 D026 A Practical Approach to Photosensitivity, 239
F003 Case-Based Challenges in Pediatric Dermatology, 70
pediatric oral and anogenital Dermatoses U009 Phototherapy and Photochemotherapy: Nuances and Pearls for the
F025 Dramatic Oral Disease, 118 Practicing Clinician, 67
U038 Nanotechnology, 114
pediatric papulosquamous Disorders U142 Cryosurgical Update, 229
F039 Treating Severe Skin Disease in Children, 147
U009 Phototherapy and Photochemotherapy: Nuances and Pearls for the Vascular Disorders of Infancy and Childhood, Including
Practicing Clinician, 67 Hemangiomas and malformations
U020 Challenging Diagnostic Cases for Advanced Practitioners: C023 Advanced Pediatric Dermatology, 200
PA/NP II, 87 F003 Case-Based Challenges in Pediatric Dermatology, 70

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 367
 SUBJECT INDEX

F012 Update on Genetic Skin Disease, 82 F020 Volunteerism and Humanitarianism, 101
F019 Journal Watching, 101 F032 Multidisciplinary Preventive Networking in Occupational Contact
F024 Evaluation and Management of Hemangiomas, 117 Dermatitis, 129
F037 Systemic Evaluation of Cutaneous Findings in Infants and F046 Leading Your Team by Coaching and Mentoring, 150
Children: What’s New and What’s True?, 132 F047 Managing an Efficient Practice, 177
F039 Treating Severe Skin Disease in Children, 147 F062 Ethical Dilemmas in Dermatology, 196
F049 Laser Pearls, 178 F063 Young Physician Pearls and Pitfalls: A Survival Guide for the
S015 Advanced Pediatric Dermatology, 125 First 10 Years, 209
S020 Birthmarks, 140 S005 Leading from Your Vision to Exceptional Service, 77
S046 Pediatric Dermatology, 249 U056 Recommended Screening Practices in Medical Dermatology, 136
U020 Challenging Diagnostic Cases for Advanced Practitioners: U087 Fulfilling Great Expectations: Caring for New Mothers and
PA/NP II, 87 Mothers-to-Be, 165
U089 Lasers 101, 166 U092 Opening Your Own Practice: Blunders and Breakthroughs, 166
U090 Angiogenesis and Clinical Dermatology, 67 U098 HIT EMRs and Documenting Clinical Care: Pitfalls and
U132 The Year in Review in Pediatric Dermatology: How Does It Promises, 174
Change My Practice?, 218 W008 Basic Dermoscopy, 182
U149 Overgrowth Syndromes, 241
Teach and Facilitate Learning of others
Vasculitic Disorders of Childhood C001 Volunteers Abroad Course: Beginner, 57
F003 Case-Based Challenges in Pediatric Dermatology, 70 C002 Volunteers Abroad Course: Advanced, 58
D009 Educate Your Patients and Improve Outcomes, 133
Vesicobullous Disorders of Childhood D017 Churning Out the Learning, 173
C023 Advanced Pediatric Dermatology, 200 D018 Practice Tips and Surgical Gems, 173
F003 Case-Based Challenges in Pediatric Dermatology, 70 D019 Enhancing Observational Skills, 188
F078 Epidermolysis Bullosa: Cases and Discussion, 233 D020 When Does Chronic Dermatitis Become Cutaneous T-Cell
F090 Autoimmune Mucocutaneous Blistering Disorders, 254 Lymphoma?, 188
S036 Blistering Disease, 205 D021 Dermatology, Diagnosis, and the Visual Arts, 213
U010 The Tzanck Smear Test: Reintroducing our Good Old Friend!, 67 F020 Volunteerism and Humanitarianism, 101
U020 Challenging Diagnostic Cases for Advanced Practitioners: F044 Dermatology Teaching and Education Group, 150
PA/NP II, 87 S005 Leading from Your Vision to Exceptional Service, 77
U114 Stem Cells in Melanoma and Nevi, 190 S023 Teledermatology, 143
SUBJECT INDEX

U004 Advances in Web-Based Medical Education: How Best to Teach

praCTICE-BaSED LEarNING aND U006
Dermatology, 66
International Teledermatology Overview, 66
ImproVEmENT U012 Leading with Your Strengths, 68
U038 Nanotechnology, 114
access, assess, and Incorporate Evidence-Based resources to U040 Military Unique Dermatology, 114
Improve practice U046 Social Media and Dermatology: How Twitter and Facebook will
D009 Educate Your Patients and Improve Outcomes, 133 Help You and Your Practice, 116
D018 Practice Tips and Surgical Gems, 173 U087 Fulfilling Great Expectations: Caring for New Mothers and
D026 A Practical Approach to Photosensitivity, 239 Mothers-to-Be, 165
F008 Decreasing Iatrogenic Problems in Your Practice, 72 U129 Informed Shared Decision Making in Psoriasis Management, 217
F032 Multidisciplinary Preventive Networking in Occupational Contact U154 Caring for the Hospitalized Patient: Interesting Cases from the
Dermatitis, 129 Inpatient Consultative Service, 256
F052 Advanced Dermatopathology, 180
F056 Therapeutic Safety, 193 Use Technology to Improve practice
F088 Clinical Trials, 253 C002 Volunteers Abroad Course: Advanced, 58
S051 Evidence-Based Medicine, 261 D018 Practice Tips and Surgical Gems, 173
U033 Electrolysis: When Laser Isn’t the Answer, 98 F008 Decreasing Iatrogenic Problems in Your Practice, 72
U056 Recommended Screening Practices in Medical Dermatology, 136 F013 EHR Implementation, Maintenance and Lessons Learned, 82
U069 Half-Truths, Lie, and Statistics: Understanding Medical Statistics F022 Coding and Office Management, 102
for the Practitioner, 146 F030 Managing Online Reputation, 120
U087 Fulfilling Great Expectations: Caring for New Mothers and F047 Managing an Efficient Practice, 177
Mothers-to-Be, 165 F063 Young Physician Pearls and Pitfalls: A Survival Guide for the First
U105 Advances in Fat Transfer and Liposuction for Correction of 10 Years, 209
Lipodystrophy: The USC Experience, 176 S023 Teledermatology, 143
U171 Dermatopathology: Utility, Methodology, and Interpretation of U004 Advances in Web-Based Medical Education: How Best to Teach
Current (and Future) Molecular Testing, 262 Dermatology, 66
U006 International Teledermatology Overview, 66
participate in activities to assess and Improve Quality practice U026 Teledermatology 101: Integrating Teledermatology into Your
C014 Coding, Documentation, and Practice Management, 123 Practice, 89
C022 Advanced Practice Management: Mini MBA, 199 U038 Nanotechnology, 114
D009 Educate Your Patients and Improve Outcomes, 133 U046 Social Media and Dermatology: How Twitter and Facebook will
D018 Practice Tips and Surgical Gems, 173 Help You and Your Practice, 116
D021 Dermatology, Diagnosis, and the Visual Arts, 213 U092 Opening Your Own Practice: Blunders and Breakthroughs, 166
D026 A Practical Approach to Photosensitivity, 239 U098 HIT EMRs and Documenting Clinical Care: Pitfalls
F008 Decreasing Iatrogenic Problems in Your Practice, 72 and Promises 174
F015 Ethical Economics in Dermatology and Dermatologic Surgery, 83 U134 Issues in Office Design, 227

368 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SUBJECT INDEX

U138 D igital Imaging and Medical Informatics: Decision Support for Cutaneous oncology
Clinicians and Teachers, 228 F019 Journal Watching, 101
U171 Dermatopathology: Utility, Methodology, and Interpretation of F069 Cutaneous Oncology: Multidisciplinary Management of Common
Current (and Future) Molecular Testing, 262 and Uncommon Skin Cancers, 212
W008 Basic Dermoscopy, 182 F084 Medical Applications of Topical Photodynamic Therapy, 244
F095 Challenges in the Diagnosis and Management of Lentigo Maligna
Melanoma, 264
proCEDUraL DErmaToLoGy S017 Therapeutic Decision Making in Cutaneous Oncology, 126
anesthesia and monitoring S026 Cutaneous Oncology, 169
C021 Intermediate Cosmetic Surgery, 198 U003 Management of High-Risk Squamous Cell Carcinoma (SCC), 65
D018 Practice Tips and Surgical Gems, 173 U020 Challenging Diagnostic Cases for Advanced Practitioners:
F041 Finessing Facial Reconstruction, 148 PA/NP II, 87
W004 MOC Self-Assessment: Procedural Dermatology, 121 U026 Teledermatology 101: Integrating Teledermatology into Your
Practice, 89
Basic Surgical Skills, Biopsy, Techniques, and Excisional Surgery U038 Nanotechnology, 114
D018 Practice Tips and Surgical Gems, 173 U078 Case-Based Approach to Lentigo Maligna, 156
F033 Introduction to Oral Dermatology, 130 U097 Immunostimulatory Treatment of Skin Cancer, 168
S037 Key Surgical Principles We All Should Know, 206 U116 Utilize Web Sites that Enhance Your Career, 191
S038 Surgical Pearls, 221 U117 Diagnosis and Management of Unusual Skin Tumors, 192
S046 Pediatric Dermatology, 249 U122 High-Risk Squamous Cell Carcinomas: A Clinical and Pathologic
U001 Tricks of the Blade, 65 Case Review, 214
U039 Good Closures Gone Bad: A Story of Blood, Pus, and Tears, 114 U144 Serial Screening for Melanoma: Measures That Have Consistently
U045 Non-cultured Epidermal Suspension in Vitiligo: From Lab to Achieved Early Detection and Cure, 239
Clinic, 116 U150 Skin Cancer Viruses: Bench to Bedside, 241
U057 Procedural Safety in Dermatology, 136 U161 Actinic Keratoses Update, 258
U083 Hair Highlights: Common and Challenging Hair Loss W008 Basic Dermoscopy, 182
Disorders, 157 W014 Dermoscopy Cases, 244
U143 Pediatric Surgery, 239
Dermabrasion and microdermabrasion
Botulinum Toxin and Chemodenervation S021 Skin of Color, 141
C011 The State of the Art of Aesthetic Dermatology: Live Patient U020 Challenging Diagnostic Cases for Advanced Practitioners:

SUBJECT INDEX
Demonstration, 91 PA/NP II, 87
C013 Advanced Botulinum Toxin: Live Patient Demonstration, 122
C020 LPD: Application of Our Aesthetic Toolbox for the Treatment of Dressings and postoperative Care
Medical and Dermatologic Disorders, 139 D018 Practice Tips and Surgical Gems, 173
C021 Intermediate Cosmetic Surgery, 198 U001 Tricks of the Blade, 65
C026 Basic Botulinum Toxin, 219 U038 Nanotechnology, 114
C029 Dermatology Review, 234 U039 Good Closures Gone Bad: A Story of Blood, Pus, and Tears, 114
F019 Journal Watching, 101 Electrosurgery
F077 Aesthetic Dermatologic Complications, 232 D018 Practice Tips and Surgical Gems, 173
S038 Surgical Pearls, 221 U020 Challenging Diagnostic Cases for Advanced Practitioners:
S049 Cosmetics, 251 PA/NP II, 87
U011 Medical and Aesthetic Dermatology in Skin of Color, 68 U068 Electrosurgery Update, 146
U025 A Personalized Planner for Rejuvenation, 88 U161 Actinic Keratoses Update, 258
U038 Nanotechnology, 114
U119 New Botulinum Toxins Practice Integration, 192 Flap reconstruction
U162 Full Facial Approach with Botulinum Toxin and Hyaluronic Acid: C033 Advanced Surgery, 260
Cases From a European Practice, 258 F016 Advances in Dermatologic Surgery, 84
F041 Finessing Facial Reconstruction, 148
Chemical peeling S038 Surgical Pearls, 221
C020 LPD: Application of Our Aesthetic Toolbox for the Treatment of U001 Tricks of the Blade, 65
Medical and Dermatologic Disorders, 139 U020 Challenging Diagnostic Cases for Advanced Practitioners:
C021 Intermediate Cosmetic Surgery, 198 PA/NP II, 87
F072 Medium and Deep Chemical Peeling, 230 U026 Teledermatology 101: Integrating Teledermatology into Your
S021 Skin of Color, 141 Practice, 89
U011 Medical and Aesthetic Dermatology in Skin of Color, 68 U070 Getting Started with Interpolation Flaps, 146
U020 Challenging Diagnostic Cases for Advanced Practitioners: U111 Reconstruction in Dermatologic Surgery: An Introductory and
PA/NP II, 87 Review Session, 189
U025 A Personalized Planner for Rejuvenation, 88 W004 MOC Self-Assessment: Procedural Dermatology, 121
U079 Dermatologic Disease in Asians, 156
U161 Actinic Keratoses Update, 258 Graft reconstruction
C033 Advanced Surgery, 260
Cryosurgery U001 Tricks of the Blade, 65
F086 BCC Update and Options of Treatment, 251 U020 Challenging Diagnostic Cases for Advanced Practitioners:
U052 Diseases of Male Genitalia, 134 PA/NP II, 87
U142 Cryosurgical Update, 229 U045 Non-cultured Epidermal Suspension in Vitiligo: From Lab to
U155 What’s New in Skin Cancer Prevention?, 255 Clinic, 116
U161 Actinic Keratoses Update, 258 U111 Reconstruction in Dermatologic Surgery: An Introductory and
U169 Cryosurgery Present and Future, 261 Review Session, 189
For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 369
 SUBJECT INDEX

Hair Transplantation and Scalp reduction
C019 Hair and Nails, 138
F016 Advances in Dermatologic Surgery, 84
U011 Medical and Aesthetic Dermatology in Skin of Color, 68
Instrumentation
F041 Finessing Facial Reconstruction, 148
S025 New Emerging Therapies, 168
S049 Cosmetics, 251
U020 Challenging Diagnostic Cases for Advanced Practitioners: F071 Advanced Treatment for Chronic Wounds, 230
PA/NP II, 87
U038 Nanotechnology, 114
Lasers
C021 Intermediate Cosmetic Surgery, 198
C029 Dermatology Review, 234
C032 Lasers, 247
C034 Skin Resurfacing and Rejuvenation, 259
D002 Appropriate Uses of Lasers, 64
F010 Hidradenitis Suppurativa: An Update, 81
F016 Advances in Dermatologic Surgery, 84
F049 Laser Pearls, 178
F054 Dermatologic Health of Women, 181
F077 Aesthetic Dermatologic Complications, 232
F080 Fractional Laser and Light-Based Technologies, 242
S001 Disorders of Pigmentation, 75
S021 Skin of Color, 141
S022 Acne and Rosacea, 142
S033 Photodermatology, 202
U002 Management of Post-Acne Scarring, 65
U005 High-Yield “Power Hour” for Residents, 66
SUBJECT INDEX
S040 Fundamentals of Cutaneous Surgery, 222
U020 Challenging Diagnostic Cases for Advanced Practitioners:
PA/NP II, 87
W004 MOC Self-Assessment: Procedural Dermatology, 121
phlebology
C027 Sclerotherapy, 220
D016 Photodermatology, 159
F016 Advances in Dermatologic Surgery, 84
U026 Teledermatology 101: Integrating Teledermatology into Your
Practice, 89
photodynamic Therapy
F077 Aesthetic Dermatologic Complications, 232
F084 Medical Applications of Topical Photodynamic Therapy, 244
U038 Nanotechnology, 114
U161 Actinic Keratoses Update, 258
preoperative patient Evaluation and Documentation
C020 LPD: Application of Our Aesthetic Toolbox for the Treatment of
Medical and Dermatologic Disorders, 139
C021 Intermediate Cosmetic Surgery, 198
C028 Soft Tissue Augumentation, 220
D018 Practice Tips and Surgical Gems, 173
U025 A Personalized Planner for Rejuvenation, 88
U072 Pediatric Dermatologic Surgery in the Outpatient Setting:
Tricks of the Trade, 147
U075 Drug Safety: Do No Harm, 155
procedural management of Benign Subcutaneous Lesions
D018 Practice Tips and Surgical Gems, 173

U020 Challenging Diagnostic Cases for Advanced Practitioners: F077 Aesthetic Dermatologic Complications, 232
PA/NP II, 87
U025 A Personalized Planner for Rejuvenation, 88
U026 Teledermatology 101: Integrating Teledermatology into Your U142 Cryosurgical Update, 229
Practice, 89
U033 Electrolysis: When Laser Isn’t the Answer, 98
U036 Subcutaneous Fat in Dermatology, 98
U038 Nanotechnology, 114
U044 Tumescent Liposuction, Lasers, and New Devices:
A State-of-the -Art Liposuction Practice, 115
U049 Avoiding Complications and Maximizing Results in Cutaneous
Laser Surgery, 134
U085 Emerging Laser and Aesthetic Technology, 158
U089 Lasers 101, 166
U143 Pediatric Surgery, 239
U161 Actinic Keratoses Update, 258
W004 MOC Self-Assessment: Procedural Dermatology, 121
mohs micrographic Surgery
F016 Advances in Dermatologic Surgery, 84
U003 Management of High-Risk Squamous Cell Carcinoma (SCC), 65
U008 Recognition and Management of High-Risk Skin Cancer, 67
U020 Challenging Diagnostic Cases for Advanced Practitioners:
PA/NP II, 87
U043 Dermatopathology Challenges Encountered by the Mohs C011 The State of the Art of Aesthetic Dermatology: Live Patient
Surgeon, 115
U070 Getting Started with Interpolation Flaps, 146
U122 High-Risk Squamous Cell Carcinomas: A Clinical and Pathologic Medical and Dermatologic Disorders, 139
Case Review, 214
U134 Issue in Office Design, 227
U167 Establishing a Mohs’ Practice: Pearls for New Surgeons, 262
Nail Surgery
C019 Hair and Nails, 138
F042 Hair and Nail Clinicopathologic Correlations, 149
F070 Fungal Infections, 212
S028 Nails, 171
S038 Surgical Pearls, 221
U105 Advances in Fat Transfer and Liposuction for Correction of
Lipodystrophy: The USC Experience, 176
U143 Pediatric Surgery, 239
Scar revision
C033 Advanced Surgery, 260
S038 Surgical Pearls, 221
U002 Management of Post-Acne Scarring, 65
U020 Challenging Diagnostic Cases for Advanced Practitioners:
PA/NP II, 87
Skin Cancer in the organ Transplant recipient
F084 Medical Applications of Topical Photodynamic Therapy, 244
S033 Photodermatology, 202
U003 Management of High-Risk Squamous Cell Carcinoma (SCC), 65
U008 Recognition and Management of High-Risk Skin Cancer, 67
U142 Cryosurgical Update, 229
Skin Structure and Surgical anatomy
F016 Advances in Dermatologic Surgery, 84
S037 Key Surgical Principles We All Should Know, 206
Tissue augmentation (Fillers and Fat Transplant)
Demonstration, 91
C020 LPD: Application of Our Aesthetic Toolbox for the Treatment of
C021 Intermediate Cosmetic Surgery, 198
C028 Soft Tissue Augumentation, 220
F019 Journal Watching, 101
F056 Therapeutic Safety, 193
F077 Aesthetic Dermatologic Complications, 232
U002 Management of Post-Acne Scarring, 65
U011 Medical and Aesthetic Dermatology in Skin of Color, 68
U025 A Personalized Planner for Rejuvenation, 88
U044 Tumescent Liposuction, Lasers, and New Devices:
A State-of-the-Art Liposuction Practice, 115

370 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SUBJECT INDEX

U054 B
uilding Beauty: Understanding Facial Proportions, Phi, and the W009 MOC Self-Assessment B, 183
Use of Volumizing Soft Tissue Fillers, 135 W010 MOC Self-Assessment: Cosmetic Dermatology, 197
U105 Advances in Fat Transfer and Liposuction for Correction of W013 MOC Self-Assessment Office-based Safety, 233
Lipodystrophy: The USC Experience, 176 professional Development
U162 Full Facial Approach with Botulinum Toxin and Hyaluronic Acid: C008 Derm Exam Prep Course: Refresher, 79
Cases From a European Practice, 258 C014 Coding, Documentation, and Practice Management, 123
W004 MOC Self-Assessment: Procedural Dermatology, 121 D007 Leading from Conflict to Resolution, 113
Tumescent Liposuction D021 Dermatology, Diagnosis, and the Visual Arts, 213
F008 Decreasing Iatrogenic Problems in Your Practice, 72
U105 Advances in Fat Transfer and Liposuction for Correction of
F020 Volunteerism and Humanitarianism, 101
Lipodystrophy: The USC Experience, 176
F030 Managing Online Reputation, 120
wound Healing and wound Care F036 Careers in Academic Dermatology, 131
D018 Practice Tips and Surgical Gems, 173 F040 Resident Transitions, 148
F071 Advanced Treatment for Chronic Wounds, 230 F046 Leading Your Team by Coaching and Mentoring, 150
U001 Tricks of the Blade, 65 F063 Young Physician Pearls and Pitfalls: A Survival Guide for the First
U038 Nanotechnology, 114 10 Years, 209
U051 Therapy for Lipodermatosclerosis, Venous Ulceration, and Atrophie F082 Managing Office Politics: Private Practice, Academics, and
Everything in Between, 244
Blanche, 134
S004 When Bad Things Happen to Good Doctors, 76
U128 Leg Ulcer Quiz for the Astute Dermatologist!, 217 S005 Leading from Your Vision to Exceptional Service, 77
U172 Transplant Research in Dermatology, 264 S013 Leading Others for Peak Performance, 94
U012 Leading with Your Strengths, 68
proFESSIoNaLISm aND maINTENaNCE oF U024 Leading Confidently through Powerful Communication, 88
U047 Mini - MBA for the Dermatologist, 116
CErTIFICaTIoN W012 Dealing with Difficult People and Looking Forward to It, 213

Ethics and Ethical Conduct Sensitivity to a Diverse patient population

C014 Coding, Documentation, and Practice Management, 123 C001 Volunteers Abroad Course: Beginner, 57
C021 Intermediate Cosmetic Surgery, 198 C002 Volunteers Abroad Course: Advanced, 58
D004 Dealing with Disappointing Outcomes and Medical Mistakes, 84 C021 Intermediate Cosmetic Surgery, 198
D005 Dermatoethics: Contemporary Issues in Ethics and D009 Educate Your Patients and Improve Outcomes, 133

SUBJECT INDEX
Professionalism, 94 F020 Volunteerism and Humanitarianism, 101
F008 Decreasing Iatrogenic Problems in Your Practice, 72 F057 Adolescent Dermatology, 194
F015 Ethical Economics in Dermatology and Dermatologic Surgery, 83 S004 When Bad Things Happen to Good Doctors, 76
F020 Volunteerism and Humanitarianism, 101 U011 Medical and Aesthetic Dermatology in Skin of Color, 68
F030 Managing Online Reputation, 120 U046 Social Media and Dermatology: How Twitter and Facebook Will
F046 Leading Your Team by Coaching and Mentoring, 150 Help You and Your Practice, 116
F062 Ethical Dilemmas in Dermatology, 196 U118 Holy Moly: Religion and the Skin, 192
S004 When Bad Things Happen to Good Doctors, 76 U129 Informed Shared Decision Making in Psoriasis Management, 217
U038 Nanotechnology, 114 U159 An Approach to Cultural Diversity in Dermatology, 257
U046 Social Media and Dermatology: How Twitter and Facebook Will W012 Dealing with Difficult People and Looking Forward to It, 213
Help You and Your Practice, 116 Teamwork
U129 Informed Shared Decision Making in Psoriasis Management, 217 C002 Volunteers Abroad Course: Advanced, 58
Leadership C014 Coding, Documentation, and Practice Management, 123
D007 Leading from Conflict to Resolution, 113 D007 Leading from Conflict to Resolution, 113
F046 Leading Your Team by Coaching and Mentoring, 150 F008 Decreasing Iatrogenic Problems in Your Practice, 72
F063 Young Physician Pearls and Pitfalls: A Survival Guide for the First F046 Leading Your Team by Coaching and Mentoring, 150
10 Years, 209 F063 Young Physician Pearls and Pitfalls: A Survival Guide for the First
F082 Managing Office Politics: Private Practice, Academics, and 10 Years, 209
Everything in Between, 244 S005 Leading from Your Vision to Exceptional Service, 77
S004 When Bad Things Happen to Good Doctors, 76 U012 Leading with Your Strengths, 68
S005 Leading from Your Vision to Exceptional Service, 77 U024 Leading Confidently Through Powerful Communication, 88
S013 Leading Others for Peak Performance, 94 U026 Teledermatology 101: Integrating Teledermatology into Your
S029 Lessons from Great Leaders, 172 Practice, 89
U012 Leading with Your Strengths, 68 U064 Helping You Meet Component 4 of MOC, 145
U024 Leading Confidently through Powerful Communication, 88 U129 Informed Shared Decision Making in Psoriasis Management, 217
U046 Social Media and Dermatology: How Twitter and Facebook Will U154 Caring for the Hospitalized Patient: Interesting Cases from the
Help You and Your Practice, 116 Inpatient Consultative Service, 256
U047 Mini - MBA for the Dermatologist, 116 Volunteerism and Social Consciousness
W007 Effective Communication, 181 C001 Volunteers Abroad Course: Beginner, 57
participation in moC program C002 Volunteers Abroad Course: Advanced, 58
C008 Derm Exam Prep Course: Refresher, 79 F020 Volunteerism and Humanitarianism, 101
U064 Helping You Meet Component 4 of MOC, 145 F040 Resident Transitions, 148
W001 MOC Self-Assessment A, 72 S023 Teledermatology, 143
W004 MOC Self-Assessment: Procedural Dermatology, 121 U006 International Teledermatology Overview, 66
U038 Nanotechnology, 114

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 371
 SUBJECT INDEX

SoCIoECoNomIC aND praCTICE ISSUES Quality assurance

D009 Educate Your Patients and Improve Outcomes, 133
Coding S014 Patient Safety and Quality, 124
C014 Coding, Documentation and Practice Management, 123
F022 Coding and Office Management, 102 risk management/malpractice
F028 What You Need to Know About Coding But Were Afraid C021 Intermediate Cosmetic Surgery, 198
to Ask, 119 F008 Decreasing Iatrogenic Problems in Your Practice, 72
F063 Young Physician Pearls and Pitfalls: A Survival Guide for the First
Computers 10 Years, 209
F047 Managing an Efficient Practice, 177 F068 Use of Physician Extenders, 211
F063 Young Physician Pearls and Pitfalls: A Survival Guide for the First U098 HIT EMRs and Documenting Clinical Care: Pitfalls and
10 Years, 209 Promises, 174
S030 Electronic Health Record (EHR): Physician Demonstration W012 Dealing with Difficult People and Looking Forward to It, 213
Symposium, 172
U046 Social Media and Dermatology: How Twitter and Facebook Will
Help You and Your Practice, 116 SUrGEry
U098 HIT EMRs and Documenting Clinical Care: Pitfalls and advanced
Promises, 174 C013 Advanced Botulinum Toxin: Live Patient Demonstration, 122
U138 Digital Imaging and Medical Informatics: Decision Support for C031 Advanced Surgery, 245
Clinicians and Teachers, 228 C031 Advanced Cosmetic Surgery and Aesthetics, 246
Cost Containment C033 Advanced Surgery, 260
C022 Advanced Practice Management: Mini MBA, 199 F016 Advances in Dermatologic Surgery, 84
F041 Finessing Facial Reconstruction, 148
Education F073 Techniques for Flap Success, 230
C021 Intermediate Cosmetic Surgery, 198 U025 A Personalized Planner for Rejuvenation, 88
D009 Educate Your Patients and Improve Outcomes, 133 U054 Building Beauty: Understanding Facial Proportions, Phi, and the
F046 Leading Your Team by Coaching and Mentoring, 150 Use of Volumizing Soft Tissue Fillers, 135
U004 Advances in Web-Based Medical Education: How Best to Teach U105 Advances in Fat Transfer and Liposuction for Correction of
Dermatology, 66 Lipodystrophy: The USC Experience, 176
Ethics anesthesia
SUBJECT INDEX

C014 Coding, Documentation, and Practice Management, 123 S040 Fundamentals of Cutaneous Surgery, 222
D005 Dermatoethics: Contemporary Issues in Ethics and U143 Pediatric Surgery, 239
Professionalism, 94
F057 Adolescent Dermatology, 194 Basic/Intermediate
C021 Intermediate Cosmetic Surgery, 198
F063 Young Physician Pearls and Pitfalls: A Survival Guide for the First
10 Years, 209 F016 Advances in Dermatologic Surgery, 84
F073 Techniques for Flap Success, 230
Government S040 Fundamentals of Cutaneous Surgery, 222
F021 FDA Presents: Information for Dermatologists, 102 U001 Tricks of the Blade, 65
S010 Surviving Healthcare Reform, 92 U039 Good Closures Gone Bad: A Story of Blood, Pus, and Tears, 114
U040 Military Unique Dermatology, 114 U111 Reconstruction in Dermatologic Surgery: An Introductory and
U098 HIT EMRs and Documenting Clinical Care: Pitfalls and Review Session, 189
Promises, 174 U143 Pediatric Surgery, 239
managed Care Complications and prevention of
C014 Coding, Documentation, and Practice Management, 123 C021 Intermediate Cosmetic Surgery, 198
C022 Advanced Practice Management: Mini MBA, 199 C028 Soft Tissue Augumentation, 220
F073 Techniques for Flap Success, 230
miscellaneous F077 Aesthetic Dermatologic Complications, 232
C014 Coding, Documentation, and Practice Management, 123 S040 Fundamentals of Cutaneous Surgery, 222
F036 Careers in Academic Dermatology, 131 S052 Surgical Complications, 262
S010 Surviving Healthcare Reform, 92 U011 Medical and Aesthetic Dermatology in Skin of Color, 68
U046 Social Media and Dermatology: How Twitter and Facebook Will U025 A Personalized Planner for Rejuvenation, 88
Help You and Your Practice, 116 U039 Good Closures Gone Bad: A Story of Blood, Pus, and Tears, 114
office
management/marketing U049 Avoiding Complications and Maximizing Results in Cutaneous
C014 Coding, Documentation, and Practice Management, 123 Laser Surgery, 134
C021 Intermediate Cosmetic Surgery, 198 U119 New Botulinum Toxins Practice Intergration, 192
C022 Advanced Practice Management: Mini MBA, 199 Cosmetic Surgery
F022 Coding and Office Management, 102 C011 The State of the Art of Aesthetic Dermatology: Live Patient
F046 Leading Your Team by Coaching and Mentoring, 150 Demonstration, 91
F047 Managing an Efficient Practice, 177 C013 Advanced Botulinum Toxin: Live Patient Demonstration, 122
F063 Young Physician Pearls and Pitfalls: A Survival Guide for the First C020 LPD: Application of Our Aesthetic Toolbox for the Treatment of
10 Years, 209 Medical and Dermatologic Disorders, 139
F068 Use of Physician Extenders, 211 C021 Intermediate Cosmetic Surgery, 198
U046 Social Media and Dermatology: How Twitter and Facebook Will C027 Sclerotherapy, 220
Help You and Your Practice, 116 C028 Soft Tissue Augumentation, 220
U092 Opening Your Own Practice: Blunders and Breakthroughs, 166 F005 Board Blitz, 71

372 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 SUBJECT INDEX

F016
U011
Advances in Dermatologic Surgery, 84
Medical and Aesthetic Dermatology in Skin of Color, 68
U025 A Personalized Planner for Rejuvenation, 88
U036 Subcutaneous Fat in Dermatology, 98
U054 Building Beauty: Understanding Facial Proportions, Phi, and the F020 Volunteerism and Humanitarianism, 101
Use of Volumizing Soft Tissue Fillers, 135
U085 Emerging Laser and Aesthetic Technology, 158
U105 Advances in Fat Transfer and Liposuction for Correction of Perspective, 251
Lipodystrophy: The USC Experience, 176
W004 MOC Self-Assessment: Procedural Dermatology, 121
Dermabrasion/peels
C021 Intermediate Cosmetic Surgery, 198
Lasers
C021 Intermediate Cosmetic Surgery, 198
C029 Dermatology Review, 234
C032 Lasers, 247
C034 Skin Resurfacing and Rejuvenation, 259
F016 Advances in Dermatologic Surgery, 84
F077 Aesthetic Dermatologic Complications, 232
F080 Fractional Laser and Light-Based Technologies, 242
S001 Disorders of Pigmentation, 75
U002 Management of Post-Acne Scarring, 65
U025 A Personalized Planner for Rejuvenation, 88
U036 Subcutaneous Fat in Dermatology, 98
U049 Avoiding Complications and Maximizing Results in Cutaneous Perspective, 251
Laser Surgery, 134
U085 Emerging Laser and Aesthetic Technology, 158
U143 Pediatric Surgery, 239
SySTEmS-BaSED praCTICE
accessing Non-physician patient Services outside of your Field to
Benefit your patients, including advocacy
S008 Consultative Dermatology for the Hospitalized Patient, 91
S050 Organizational Approaches to AIDS/STDs From a Global
U033 Electrolysis: When Laser Isn’t the Answer, 98
U046 Social Media and Dermatology: How Twitter and Facebook Will
Help You and Your Practice, 116
U129 Informed Shared Decision Making in Psoriasis Management, 217
U154 Caring for the Hospitalized Patient: Interesting Cases from the
Inpatient Consultative Service, 256
practice management and the Business of Dermatology, including
office regulation and accreditation
C014 Coding, Documentation, and Practice Management, 123
C022 Advanced Practice Management: Mini MBA, 199
F008 Decreasing Iatrogenic Problems in Your Practice, 72
F022 Coding and Office Management, 102
F028 What You Need to Know About Coding But Were Afraid
to Ask, 119
F047 Managing an Efficient Practice, 177
F068 Use of Physician Extenders, 211
S010 Surviving Healthcare Reform, 92
S050 Organizational Approaches to AIDS/STDs From a Global
U047 Mini - MBA for the Dermatologist, 116
U064 Helping You Meet Component 4 of MOC, 145
U092 Opening Your Own: Practice - Blunders and Breakthroughs, 166

W004 MOC Self-Assessment: Procedural Dermatology, 121
Liposuction
U105 Advances in Fat Transfer and Liposuction for Correction of reporting requirements
Lipodystrophy: The USC Experience, 176
micrographic Surgery
F016 Advances in Dermatologic Surgery, 84
Sclerotherapy
C027 Sclerotherapy, 220
F016 Advances in Dermatologic Surgery, 84
U025 A Personalized Planner for Rejuvenation, 88
SUBJECT INDEX
U167 Establishing a Mohs’ Practice: Pearls for New Surgeons, 262
responsibility for population Health, including
F020 Volunteerism and Humanitarianism, 101
F032 Multidisciplinary Preventive Networking in Occupational Contact
Dermatitis, 129
S050 Organizational Approaches to AIDS/STDs From a Global
Perspective, 251
U038 Nanotechnology, 114
U087 Fulfilling Great Expectations: Caring for New Mothers and
Mothers-to-Be, 165

Surgery Teaming with other providers of Care to Benefit your patients

C020 LPD: Application of Our Aesthetic Toolbox for the Treatment of C002 Volunteers Abroad Course: Advanced, 58
Medical and Dermatologic Disorders, 139 F025 Dramatic Oral Disease, 118
F005 Board Blitz, 71 F046 Leading Your Team by Coaching and Mentoring, 150
F016 Advances in Dermatologic Surgery, 84 F060 Immunohistochemistry in Dermatology, 195
S005 Leading from Your Vision to Exceptional Service, 77
F073 Techniques for Flap Success, 230
S017 Therapeutic Decision Making in Cutaneous Oncology, 126
F095 Challenges in the Diagnosis and Management of Lentigo Maligna
S050 Organizational Approaches to AIDS/STDs From a Global
Melanoma, 264
Perspective, 251
U001 Tricks of the Blade, 65 U004 Advances in Web-Based Medical Education: How Best to Teach
U029 Skin Cancer in Patients with Non-Melanoma Hodgkin’s Dermatology, 66
Lymphoma, 96 U006 International Teledermatology Overview, 66
U143 Pediatric Surgery, 239 U083 Hair Highlights: Common and Challenging Hair Loss
Surgical repair methods Disorders, 157
F016 Advances in Dermatologic Surgery, 84 Utilize practice Services to Improve your practice,
F073 Techniques for Flap Success, 230 Including advocacy
U001 Tricks of the Blade, 65 C014 Coding, Documentation, and Practice Management, 123
U081 Medical and Surgical Practice, 156 C021 Intermediate Cosmetic Surgery, 198
U111 Reconstruction in Dermatologic Surgery: An Introductory and S005 Leading from Your Vision to Exceptional Service, 77
Review Session, 189 S050 Organizational Approaches to AIDS/STDs From a Global
W004 MOC Self-Assessment: Procedural Dermatology, 121 Perspective, 251

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 373
 SUBJECT INDEX
U026 T
eledermatology 101: Integrating Teledermatology into Your U090 Angiogenesis and Clinical Dermatology, 166
Practice, 89
U064 Helping You Meet Component 4 of MOC, 145
U092 Opening Your Own Practice: Blunders and Breakthroughs, 166
U134 Issues in Office Design, 227
THErapEUTICS
antifungals
F070 Fungal Infections, 212
Corticosteroids
D014 Advances in Pemphigus and Pemphigoid, 154
F004 Geriatric Dermatology: Advanced Cases, 70
Dermatopharmacology
F056 Therapeutic Safety, 193
S035 Controversies in Dermatologic Drug Therapy, 204
U017 Clinical Trials for the Private Practitioner, 86
U096 Medical Therapies and How They Work, 167
U108 Safety of Biologic Therapies: What’s the Real Story?, 177
Drug reactions
C029 Dermatology Review, 234
F001 Advanced Medical Dermatology, 69
F004 Geriatric Dermatology: Advanced Cases, 70
F005 Board Blitz, 71
U101 Pediatric Drug Eruptions, 175
U103 Drug Reaction Update 2011, 176
U121 Update on Graft-Versus-Host Disease, 214
U146 Management of Cutaneous Toxicity in the Era of Targeted Skin Cancer, 87
SUBJECT INDEX
Chemotherapy, 240
U165 The Management of TEN/SJS: The US Army Burn Unit U096 Medical Therapies and How They Work, 167
Experience, 259
Gene Therapy and DNa Vaccination
F012 Update on Genetic Skin Disease, 82
Immunosuppression/Cytotoxic Therapy
D014 Advances in Pemphigus and Pemphigoid, 154
F053 Autoimmune Disease Update, 180
S016 Drug Actions, 125
S036 Blistering Disease, 205
U095 Biologic Drugs for Psoriasis: Do We Use Them Enough?, 167
U096 Medical Therapies and How They Work, 167
U109 Pediatric Connective Tissue, 189
U168 Psoriasis, 263
miscellaneous
D022 Common Dermatologic Diseases with Myriad Treatments, 213
D026 A Practical Approach to Photosensitivity, 239
F053 Autoimmune Disease Update, 180
S008 Consultative Dermatology for the Hospitalized Patient, 91
U036 Subcutaneous Fat in Dermatology, 98
U158 Acne: Etiopathogenesis and Treatment 2011, 256
U165 The Management of TEN/SJS: The US Army Burn Unit
Experience, 259
U172 Transplant Research in Dermatology, 264
outcomes analysis
U018 Outcomes Research in Dermatology, 86
phototherapy
S001 Disorders of Pigmentation, 75
S033 Photodermatology, 202
U168 Psoriasis, 263
phototherapy - other
F009 Photobiology for Dermatologists, 80
F051 Controversies in Vitamin D, 179
374 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng
U096 Medical Therapies and How They Work, 167
U108 Safety of Biologic Therapies: What’s the Real Story?, 177
phototherapy - pUVa
F009 Photobiology for Dermatologists, 80
U090 Angiogenesis and Clinical Dermatology, 166
U096 Medical Therapies and How They Work, 167
U108 Safety of Biologic Therapies: What’s the Real Story?, 177
phototherapy - UVa
F009 Photobiology for Dermatologists, 80
U090 Angiogenesis and Clinical Dermatology, 166
U096 Medical Therapies and How They Work, 167
U108 Safety of Biologic Therapies: What’s the Real Story?, 177
phototherapy - UVB
F009 Photobiology for Dermatologists, 80
S001 Disorders of Pigmentation, 75
U090 Angiogenesis and Clinical Dermatology, 166
U096 Medical Therapies and How They Work, 167
U108 Safety of Biologic Therapies: What’s the Real Story?, 177
radiation Therapy
F095 Challenges in the Diagnosis and Management of Lentigo Maligna
Melanoma, 264
retinoids
S035 Controversies in Dermatologic Drug Therapy, 204
U019 Sun, Drugs and Invervention: How to Prevent Non-Melanoma
U025 A Personalized Planner for Rejuvenation, 88
U104 Cosmeceuticals: Topical Therapies for Treating the Aging Face, 176
Spa Treatments
S012 Aging Gracefully, 93
Therapeutics and Non-surgical
D010 Recent Advances in Skin Biology and Skin Disease, 133
D015 Urticaria and Angioedema, 163
D022 Common Dermatologic Diseases with Myriads of Treatments, 213
F004 Geriatric Dermatology: Advanced Cases, 70
F021 FDA Presents: Information for Dermatologists, 102
F051 Controversies in Vitamin D, 179
F056 Therapeutic Safety, 193
F079 Update on Alopecia Areata, 242
F081 Geriatric Dermatology, 243
S001 Disorders of Pigmentation, 75
S033 Photodermatology, 202
S044 Therapeutic Hotline, 248
U019 Sun, Drug, and Invervention: How to Prevent Non-Melanoma
Skin Cancer, 87
U090 Angiogenesis and Clinical Dermatology, 166
U093 Notes of a Therapeutic Iconoclast, 167
U095 Biologic Drugs for Psoriasis: Do We Use Them Enough?, 167
U096 Medical Therapies and How They Work, 167
U097 Immunostimulatory Treatment of Skin Cancer, 168
U104 Cosmeceuticals: Topical Therapies for Treating the Aging Face, 176
U148 Lessons Learned from Challenging Pediatric Cases: Targeted Novel
Molecular Therapies, 240
U158 Acne: Etiopathogenesis and Treatment 2011, 256
Topical Nonsteroidal Therapy
S001 Disorders of Pigmentation, 75
U172 Transplant Research in Dermatology, 264
 FaCULTy INDEX

aBBrEVIaTIoNS
affil............................... affiliate
anat ............................. anatomy
asst ............................ assistant
assoc ......................... associate
Biochem ................ Biochemistry
Biol................................ Biology
Br .................................. Branch
Canc .............................. cancer
Chem ........... chemical/chemistry
Chf.................................... chief
Chmn .......................... chairman
Clin...................... clinic/clinical
Col................................. college
Cons ......................... consultant
Cosm .......................... cosmetic
Ctr .................................. center
Dept ......................... department
Derm....................... dermatology
Dermpath ........ dermatopathology
Dir ................................ director
Dis ............................. disease(s)
Div ................................ division
Emer ............................ emeritus
Environ ................ environmental
Exper ..................... experimental
Fac ................................ Facility
Fel .................................. Fellow
Fndtn ....................... Foundation
Gen ............................... general
Hd .................................... head
Hlth ................................ health
Hosp ............................ hospital
Immunol ................. Immunology
Infect ......................... Infectious
Info .......................... Information
Inst .............................. Institute
Instr ........................... Instructor
Int................................. Internal
Invest ...................... Investigator
Lect ............................. Lecturer
med ................ medical/medicine
microbiol ............... microbiology
Nat’l ............................ national
No ...................... north/northern
occup’l .................. occupational
ophthalmal ......... ophthalmology
otolaryngol .......... otolaryngology
parasit .................... Parasitology
path ........................... Pathology
ped ............................ Pediatrics
pharmacol ........... Pharmacology
phys ....................... Physician(s)
physiol ..................... Physiology
plast ............................... Plastic
podiat ........................... Podiatry
prev ........................... Preventive
prof ............................ Professor
prog ............................ Program
psych ........................ Psychiatry
radiol ........................ radiology
res .............................. resident
rsch ........................... research
Sch ................................. school
Sci................................ science
Sect ............................... section
Sen ................................. senior
So...................... south/southern
St ..................................... state
Surg ................. surgery/surgeon
Svc ................................ service
Syphilol ................... syphilology
Trop .............................. tropical
U ............................... university
Va ......... Veterans administration
Vasc ............................ Vascular
Venereol ................. Venereology
Vet............................. Veterinary

a anadkat, milan J., m.D., 79, 239, 253

andea, aleodor a., m.D., 262
Bandow, Grace D., m.D., 119
Bardan, antoanella, m.D., Dermpath, Dallas, TX,
aasi, Sumaira Zareen, m.D., Asst Prof, Yale School anderson, Bryan Erik, m.D., Asst Prof, Dept Derm, 64, 80, 89, 99, 122

FaCULTy INDEX
of Medicine, 222, 230 Penn St U, Hershey, PA, 74, 94, 170 Barnhill, raymond L., m.D., Clin Prof, Dept Derm
ablon, Glynis r., m.D., Asst Clin Prof, U CA, anderson, r. rox, m.D., Prof Derm, Harvard Med and Path, U Miami, Miami, FL, 235
Los Angeles, CA, 247 Sch, Boston, MA, 178, 202, 242, 246 Baselga, Eulalia, m.D., Barcelona, Spain, 189
abramovits, william, m.D., Prof Derm, U Med Ctr, anstey, alexander V., m.D., 252 Bassoli, Sara, m.D., 231
Baylor, Clin Asst Prof, U TX SW Med Sch, Dallas, antaya, richard J., m.D., Assoc Prof, Dept Derm Battle, Eliot Franklin, m.D., Asst Clin Prof, Dept
TX, 261 Yale U Sch Med, New Haven, CT, 232 Derm, Howard U, Washington, DC, 141
acosta, alvaro Enrique, m.D., Prof, Dept Derm, aoki, Valeria, m.D., Rsch Invest, Dept Derm, Baumann, Leslie, m.D., Prof Clin Derm, Dir Cosm
U Natl and Natl Canc Inst, Bogota, Colombia, 251 U Sao Paulo, Sao Paulo, Brazil, 205 Derm, U Miami, Miami, FL, 210
adams, Brian Burke, m.D., m.p.H., Assoc Prof, Dir arbiser, Jack L., m.D.,, ph.D., Assoc Prof, Dept Bayliss, Susan Joy, m.D., Prof Derm and Ped,
VA, Dept Derm, U Cincinnati, Cincinnati, OH, 85 Derm, Emory U, Atlanta, GA, 166 Washington U, St Louis, MO, 90
adams, David r., m.D., pharm.D., Assoc Prof argenziano, Giuseppe, m.D., Dept Derm, Second Beissert, Stefan, m.D., Muenster, Germany, 139
Derm, Penn St Hershey Med Ctr, Hershey, PA 189, U Naples, Naples, Italy, 128, 182, 244 Belazarian, Leah T., m.D., Asst Prof of Med and
234 armstrong, april w., m.D., 74, 89 Pediatrics, University of Massachusetts, Worcester,
aftergut, kent Stuart, m.D., 83 arron, Sarah T., m.D., ph.D., 149, 240 MA, 117
ahlgrimm-Siess, Verena, 231 asgari, maryam mandana, m.D., 255 Bellet, Jane S., m.D., 98
alam, murad, m.D., Chf, Sect Cut and Aesth Surg, avram, mathew m., m.D., Dir, Massachusttes Benabio, Jeffrey a. V., m.D., 116
Dept Derm, NW U, Chicago, IL, 102, 178, 245 Gen Hosp Laser and Cosm Ctr, Harvard Med Sch, Bercovitch, Lionel Gordon, m.D., Clin Prof Derm,
albertini, John G., m.D., Skin Surg Ctr, Boston, MA, 98, 246 Warren Alpert Sch Med Brown U, Providence, RI, 94
Winston-Salem, NC, 259 Berg, Daniel, m.D., Assoc Prof, Derm, U WA,
alexiades-armenakas, macrene, m.D., Seattle, WA, 58
ph.D., 168, 193
alexis, andrew F., m.D., Asst Clin Prof, Columbia B Berger, Timothy G., m.D., Prof Clin Derm, UCSF,
San Francisco, CA, 127
U, St Lukes-Roosevelt, New York, NY, 95, 141 Babel, Dennis E., ph.D., 157
Bergfeld, wilma Fowler, m.D., Hd Dermpath, Dept
allen, pamela S., m.D., 234 Bahrami, Soon, m.D., 217
Derm, Cleveland Clin, Cleveland, OH, 75
alora-palli, maria B., m.D., 252 Bailin, philip Lawrence, m.D., Chmn Dept Derm,
Bergman, James, Asst Prof, Dept Peds, MEO
alster, Tina S., m.D., Dir, Washington Inst Derm Cleveland Clin Fndtn, Cleveland, OH, 243
(Derm) UCSD, San Diego, CA, 121
Laser Surg, Clin Prof,Georgetown U, Washington, Baker, Diane romayne, m.D., Clin Prof, Dept
Bergstresser, paul r., m.D., Dept Derm, U TX
DC, 178, 246 Derm, OR Hlth Sci U, Portland, OR, 118
Med Ctr, Dallas, TX, 211
altman, David J., m.D.,, ph.D., Clarence, NY, 174 Baker, James, 100, 118
Berk, David, m.D., 90, 119
amerson, Erin H, m.D., 250 Baldwin, Hilary E., m.D., Assoc Prof Clin Derm,
Berman, Brian, m.D., ph.D., Prof Derm and Int
ammirati, Christie Travelute, m.D., Assoc Prof, SUNY, Brooklyn, NY, 104, 201
Med, U Miami, Miami, FL, 168
Dept Derm, Pennstate HMC, Hershey, PA, 79, 121,
221-222

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 375
 FaCULTy INDEX

Bernhard, Jeffrey D., m.D., Prof, Div Derm, U MA Brown, Stuart m., m.D., Clin Prof Derm, U TX Chang, mary wu, m.D., Assoc Clin Prof, Dept
Med Sch, Worcester, MA, 127, 132 Hlth Sci Ctr, Dallas, TX, 221 Derm/Ped, U CT, Dir Pediatric Dermatology of New
Bernstein, Eric F., m.D., Clinical Associate Professor, Brownell, Isaac, m.D., ph.D., 264 England, West Hartford, CT, 101, 232
Department of Dermatology, University of Browning, John C., m.D., 175 Chavez López, Guadalupe, m.D., 57
Pennsylvania, PA, 134 Bruce, alison June, mB.Ch.B., Derm, Mayo Clin, Chen, Suephy C., m.D., Dept Derm, Emory U,
Berson, Diane S., m.D., Asst Prof Derm, Weill Med Rochester, MN, 247 Atlanta, GA 86, 159, 225
Col of Cornell U, NY, NY, 250 Bruckner, anna Lee, m.D., 125, 147, 233 Chen, Teris m., m.D., Res, Dept Derm, U CO,
Bhatia, ashish, m.D., Asst Prof of Clin Bucay, Vivian wasserteil, m.D., 220 Aurora, CO, 206
Dermatology, Northwestern U Sch Med, Chicago, Buka, robert L., m.D., Mt. Sinai Sch Med, New Chiu, annie, m.D., Med Stud, Dept Derm, Stanford
IL, 102, 259 York, NY, 166 U, Palo Alto, CA, 252
Bigby, michael E., m.D., Assoc Prof, Dept Derm, Burch, Joanna m., m.D., 248 Choi, Jennifer N., m.D., 253
Harvard Med Sch, Boston, MA, 260 Burdick, anne E., m.D., m.p.H., Professor, Chung, Christina L., m.D., 256
Bikowski, Joseph B., m.D., Clin Asst Prof Derm, Department of Dermatology, Associate Dean for Chung, Connie m., m.D., 146
OH State U, Columbus, OH and Director, Bikowski TeleHealth, University of Miami, Miami, FL, 143 Clark, rachael, m.D.,, ph.D., 105
Skin Care Center, Sewickley, PA, 221, 241 Burgess, Cheryl m., m.D., Asst Clin Prof, Dept Clark, richard august, m.D., Prof, Dept Derm,
Billingsley, Elizabeth m., m.D., Prof Derm, Penn St Derm, Georgetown U Hosp, Washington, DC, 220 Sch Med, SUNY, Stonybrook U, 105, 262
Hershey Med Ctr, Hershey, PA, 121, 222 Burgin, Susan, m.D., Asst Prof, Dept. of Derm, Beth Claveau, Joel, m.D., FABD, FRCPC, Assoc Prof
Bissonnette, robert, m.D., Innovaderm Research, Israel Med Ctr, Harvard Med Sch, Boston, Derm, Melanoma and Skin Cancer Clinic, CHUQ,
Montreal, Canada, 97, 243 MA, 69, 74 Hôtel-Dieu de Québec, Canada, 145
Blauvelt, andrew, m.D., Prof, Dept Derm, OHSU, Burkemper, Nicole m., m.D., 79 Clayton, anna S., m.D., Asst. Clin. Prof., Div. of
Portland, OR, 79, 179, 234 Busam, klaus J., m.D., Professor, Cornell Derm., Vanderbilt Univ. Medical Center, Nashville,
Bloom, kenneth E., m.D., 83, 102, 147, 194 University; Attending, Dermpath, Memorial TN, 201
Blume-peytavi, Ulrike, m.D., 138 Sloan-Kettering Canc Ctr, New York, NY, 264 Cockerell, Clay J., m.D., Clin Prof, Dermpath, U
Boh, Erin E., m.D., ph.D.Assoc Prof, Dept Derm, Butterwick, kimberly J., m.D., Priv Pract Derm, TX SW, Dallas, TX, 64, 80, 89, 99, 122, 123, 149,
Tulane U Sch Med, New Orleans, LA, 247 La Jolla, CA, 91, 115, 198 169, 225, 234, 235
Bolognia, Jean L., m.D., Prof, Dept Derm, Yale U, Buzney, Elizabeth a., m.D., 130 Cohen, Bernard, m.D., Vol Prof, Dept Derm, U
New Haven, CT, 75, 127, 172, 223 Miami, Coral Gables, FL, 133, 194
Bordeaux, Jeremy S., m.D., m.p.H., Asst Prof, Dept Cohen, David Eric, m.D., Vice Chair Dept of Derm,
of Derm, Case Western Reserve University, Univ C NYU School of Medicine, New York, NY, 74, 168,
FaCULTy INDEX

Hosp Case Med Ctr, Cleveland, OH, 146, 206, 221 223, 234
Cabell, Christine Elizabeth, m.D., Dir Derm Surg,
Borradori, Luca, 205 Cohen, Frank,
Geisinger Wyoming Valley Med Ctr, Wilkes Barre,
Brandenburg, Stephan, J.D., Director from the Cohen, Joel Lee, m.D., Dir, AboutSkin Dermatology,
PA, 221-222, 260
Berufsgenossenschaft für Gesundheitsdienst und Englewood Colorado; Asst Prof Univ of Colorado
Cabo, Horacio antonio, m.D., Prof. Dr. Horacio
Wohlfahrtspflege, 129 Dept Dermatology, 122, 219, 245
Cabo. Buenos Aires, Argentina, 128, 145
Brandt, Fredric S., m.D., Coral Gables, FL and Coldiron, Brett m., m.D., Clin Asst Prof Derm, U
Cafardi, Jennifer, m.D., 250
New York, NY, 122 Cincinnati, Cincinnati, OH, 124, 169, 196, 199, 260
Callen, Jeffrey phillip, m.D., Prof Med (Derm), Div
Brassard, alain, m.D., 217 Colegio, oscar, m.D., ph.D., 149
Derm, Scho Med, U Louisville, Louisville, KY, 93,
Braverman, Irwin m., m.D., Prof, Dept Derm, Yale Coleman, kyle, m.D., 122
101, 137, 179, 181, 202, 203, 210, 234, 253
Med Sch, New Haven, CT, 188 Coleman, william p., m.D., Clin Prof, Dept
Callender, Valerie D., m.D., Clin Asst Prof, Dept
Bravo, Francisco G., m.D., Prof Derm and Path, Derm, Hlth Sci Ctr, Tulane U, New Orleans, LA, 91,
Derm, Howard U Col Med, Washington, DC, 68, 141
Cayetano Heredia U, Lima, Peru, 207 122, 139
Callis-Duffin, kristina patrice, m.D., Asst Prof,
Braun, ralph p., m.D., Dept Derm, U Hosp Zürich, Colven, roy mitchell, m.D., Asst Prof, Div Derm,
Dept of Derm, U of Utah, Salt Lake City, UT, 127
Zürich, Switzerland, 128, 182, 208 U WA, Seattle, WA, 143
Camilleri, michael J., m.D., 253
Brauner, Gary J., m.D., Assoc Clin Prof Derm, Comfere, Nneka I., m.D., 104
Cappel, mark a., m.D., 106
Mt Sinai Sch Med, New York, NY, 192 Connelly, Elizabeth alvarez, m.D., Asst Prof of
Carlos, Casey, m.D., 58
Bree, alanna Flath, m.D., Asst Prof of Derm and Derm and Ped, U of Miami, Dept of Derm, Div Ped
Carruthers, alastair, m.D., Clin Prof Derm, U
Ped, Baylor College of Med/Texas Children’s Hosp, Derm, 73, 248
British Columbia, Vancouver, Canada, 91, 219
Houston, TX, 66 Connolly, m. kari, m.D., Assoc Prof, Dept Derm,
Carruthers, Jean D.a., m.D., Clin Prof, Dept Ophth,
Brewer, Jerry D., m.D., 96 UCSF, San Francisco, CA, 139
U BC, Vancouver, Canada, 139, 219, 232
Bridges, alina G., Do, Asst Prof, Dept Derm, Mayo Conroy, michael p., m.D., 106
Carucci, John a., m.D.,, ph.D., Chf, Mohs Surg,
Clinic, Rochester, MN, 251, 253 Cook, Denise, m.D., 102
Cornell U, New York, NY, 259
Brinster, Nooshin ketabchi, m.D., 235 Cook, Joel, m.D., Assoc Prof, Dept Derm, Med U
Carville, James, 162
Brod, Bruce a., m.D., 151, 197 SC, Charleston, SC, 259
Casparian, Jacques michael, m.D., 124
Brody, Harold Joseph, m.D., Clin Prof, Dept Derm, Cooper, kevin D., m.D., Prof Dept Derm, Univ
Caux, Fredric, 205
Sch Med, Emory U, Atlanta, GA, 139, 230 Hosp Case Med Ctr CWRU, Cleveland, OH, 79,
Ceilley, roger I., m.D., Clinical Prof Derm, U IA,
Brouha, Brook L., m.D., 122 167, 178
West Des Moines, IA, 169, 173, 199
Brown, Clarence william, Jr m.D., 199 Cordoro, kelly m., m.D., Asst Prof, Adult and Ped
Chan, Henry H. L., m.D., Hon Clin Assoc Prof,
Brown, marc D., m.D., Prof, Dept Derm, Sch Med, Derm, UCSF, San Francisco, CA, 96, 147
HKU and CUHK, Hong Kong, China, 178,
U Rochester, Rochester, NY, 149 Cornelison, raymond L., m.D., Prof and Chmn,
242, 263
OUHSC, Dept Derm, Oklahoma City, OK, 234, 241
Chaney, keri S., m.D., 212

376 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 FaCULTy INDEX

Cotliar, Jonathan, m.D., Asst Clin Prof,Division of Donofrio, Lisa m., m.D., Asoc Clin Prof, Dept Derm, English, Joseph C., m.D., Asst Prof Derm, Dept
Dermatology,David Geffen School of Medicine at Yale U Sch Med, New Haven, CT, Asst Clin Prof, Derm, U Pittsburgh, Pittsburgh, PA 127, 201, 229
UCLA, Los Angeles, CA, 214 Dept Derm, Tulane U, New Orleans, LA, 139, 198 Epps, robert, m.D., 194
Cotsarelis, George, m.D., Assoc Prof, Dept Derm, Donovan, Jeffrey, m.D., 240 Epps, roselyn E., m.D., Chf, Div Derm, Children’s
Sch Med, U PA, Philadelphia, PA, 75, 105, 149 Dover, Jeffrey S., m.D., Assoc Clin Prof, Dept Natl Med Ctr, Washington, DC, 194
Cowen, Edward w., m.D., Staff Clinician, Derm Br, Derm, Yale Med Sch, and Skin Care Physicians, Estrada-Castanon, roberto a., m.D., 57
Natl Canc Inst, NIH, Bethesda, M.D., 215, 223 Chestnut Hill, MA, 178, 232
Cox, Sue Ellen, m.D., Medical Director, Aesthetic Draelos, Zoe Diana, m.D., Invest, Dermatology
Solutions, Chapel Hill, NC, 198 Consulting Services, High Point, NC, 93, 194 F
Craft, Noah a., m.D.,, ph.D., 57, 173, 224 Drake, Lynn annette, m.D., Lect, Dept Derm, Falabella, rafael, m.D., Clin Prof, Chmn,Dept
Crowley, Jeffrey J., m.D., 252 Harvard Med Sch, Boston, MA, 144 Derm, U Del Valle, Cali, Colombia, 193
Cruz, ponciano D., m.D., Prof and Vice Chmn, Drolet, Beth ann, m.D., Prof, Derm Ped, Med Col Farris, patricia, m.D., Metairie, LA, 91, 93, 122,
Dept Derm, U TX SW, Dallas, TX, 150 WI, Milwaukee, WI, 132 139, 181
Cunningham, Bari B., m.D., Assoc Prof Derm and Duffy, David michael, m.D., Clin Prof, Med Derm, Farvolden, Davis G., m.D., 205
Ped, U CA, San Diego, CA, 93 USC, Los Angeles, CA, 220 Fazel, Nasim, m.D., Asst Prof, UC Davis
Curiel-Lewandrowski, Clara N., m.D., Asst Prof, Duncan, Lyn m., m.D., Asst Prof Path, Harvard Med Sacramento, CA Dept Derm, U CA, Sacramento,
Derm, Univ. Arizona, Arizona Cancer Center, Sch, Dir Dermpath, Boston, MA, 127 CA, 247
Tucson, AZ, 78 Dutz, Jan p., m.D., Assoc Prof, Dept Derm and Feldman, mary melinda, m.D., 87
Cusack, Carrie ann r., m.D., 235 Skin Science, U British Columbia, Vancouver, Feldman, Steven r., m.D., ph.D., Prof Dept Derm,
Canada,139, 180 Wake Forest U, Winston-Salem, NC 103, 120, 122,
Duvic, madeleine, m.D., Prof Med and Derm, Derm 191, 196
Fenton, matthew, ph.D., 121
D Dept, M.D. Anderson Cancer Ctr, Houston, TX, 249
Dyer, Jonathan a., m.D., Asst Prof, Dept Derm Ped, Ferguson, James, m.D., 264
Danby, F. william, m.D., Asst Prof, Dept Med, Sect Ferringer, Tammie C., m.D., Assoc, Derm,
U MO, Columbia, MO, 143, 248
Derm, Dartmouth Med Sch, NH, 256 Dermpath, Geisinger Med Ctr, Danville, PA
Daniel, C. ralph, m.D., Clin Prof Derm, U MS, 106, 127, 195, 207, 235
Jackson, Ms, Clin Assoc Prof Derm, U AL, Fett, Nicole, m.D., 136
Birminham, AL, 171 E Fincher, Edgar, m.D., ph.D., Clin Instr The David
Darling, Thomas N., m.D., ph.D., Assoc Prof, Dept Eaglstein, william Howard, m.D., Emeritus Geffen School of Medicine at UCLA, 245

FaCULTy INDEX
Derm, USUHS, Bethesda, MD, 105 Chairman University of Miami, 210 Fincher, Helen Horn, m.D., 245
Davey, william patrick, m.D., Clin Prof, U KY, Eastern, Joseph S., m.D., Clin Asst Prof, UM. D. Fiorentino, David Franklin, m.D., ph.D., Asst Prof,
Lexington KY, 102, 199 NJ and Seton Hall U, Newark, NJ, 119, 199 Dept Derm, Sch Med, Stanford U, Stanford, CA,
Davidson, Lesly Salgado, m.D., 98 Edison, karen E., m.D., Assoc Prof and Chmn, 137, 139, 180
Davis, mark D. p., m.D., Prof, Dept Derm, Mayo Dept Derm, U Missouri, Columbia, MO, 133 Fisher, Emily J., m.D., 114
Clin, Rochester, MN, 127, 223 Edwards, Libby, m.D., Chf, Div Derm, Carolinas Fitzgerald, rebecca L., m.D., 91, 139, 220
Davis, Thomas L., m.D., Asst Clin Prof, Dept Derm, Med Ctr, Charlotte, NC, 247 Fitzpatrick, James E., m.D., Prof, Dept Derm, U
U TX Med Sch, San Antonio, TX, 122 Ehrlich, alison, m.D., Dir Clin Rsch, Assoc Clin CO Hlth Sci Ctr, Denver, CO, 122, 235
Del rosso, James Q., Do, Derm Res Director, Valley Prof, Dept Derm, George Washington U, Flaherty, keith, 249
Hosp Med Center, Las Vegas, NV, 120, 142, 204 Washington DC., 74 Flynn, Timothy C., m.D., Clin Prof, U NC, Chapel,
DeLeo, Vincent anthony, m.D., Chmn, Derm, St. Ehst, Benjamin David, m.D., ph.D., 234 NC, 135, 139
Luke’s-Roosevelt and Beth Israel Med Ctrs, New Eichenfield, andrew, Chf Ped Rheumatology, Mt. Fosko, Scott w., m.D., Prof, Chmn, Dept Derm,
York, NY, 74, 90 Sinai Med Ctr, New York, NY, 73 St. Louis U, St Louis, MO, 247
Deliduka, Steven B., m.D., 72, 183 Eichenfield, Lawrence F., m.D., Chf Ped and Adol Fox, Lindy peta, m.D., Asst Prof Derm, UCSF,
Dellavalle, robert paul, m.D., ph.D., Chf VA Derm Derm, Prof Ped Med Derm, U CA, Rady Child San Francisco, CA, 69
Svc and Assoc Prof, Derm Dept, U CO, Denver, Hosp, San Diego, CA, 121, 159, 212 Frieden, Ilona J., m.D., Prof Derm Peds, University
CO, 260 Elenitsas, rosalie, m.D., Assoc Prof Derm, Dept of California, San Francisco, CA, 75, 76, 82, 132
Desai, Seemal, m.D., 98 Derm, U PA, Philadelphia, PA, 122, 235 Friedlander, Sheila Fallon, m.D., Clin Prof, Med/
DeVan, marsheila, 88 Elewski, Boni E., m.D., Prof Derm, U AL, Ped Derm, UCSD/Rady Children’s Hosp, San Diego,
Di Nardo, anna, m.D., ph.D., 179 Birmingham, AL, 93, 137, 203, 212 CA, 73, 125, 212
Diaz, Luis a., m.D., Prof and Chmn, Dept Derm, Elgart, George w., m.D., Dir Dermpath, U Miami, Friedman, adam, J., m.D., 71, 148
U NC, Chapel Hill, NC, 154 Miami, FL, 180, 207, 235 Friedman, robert J., m.D., Clin Assoc Prof, Dept
Dierickx, Christine C., m.D., Dir Laser Center Ellis, Charles N., m.D., Prof and Assoc Chmn, Dept Derm, NYU Med Ctr, New York, NY, 169, 225
Boom, Belgium, 246 Derm, U MI Sch Med, Ann Arbor, MI, 123 Fung, maxwell a., m.D., Assoc Prof, Derm and Path,
DiGiovanna, John J., m.D., Dir Dermpharm Div, Ellison, Sandra, 68, 77, 94 Dept Derm,U CA Davis, Sacramento, CA, 235
Dept Derm, Brown U, Providence, RI, 105 Elmets, Craig a., m.D., Prof, Chmn, Dept Derm,
Dinehart, Scott m., m.D., Clin Prof, UAMS Dept U AL, Birmingham, AL, 101, 202, 210
Derm, Little Rock, AR, 123 Elston, Dirk michael, m.D., Director, Dept of G
Dintiman, Brenda Jean, m.D., 120 Dermatology, Geisinger Med Ctr, Danville, PA, 102, Gallo, richard L., m.D., ph.D., Prof and Chf, Derm,
Dinulos, James G., m.D., 176 127, 137, 196, 207, 260 U CA, San Diego, CA., 126
Dohil, magdalene a., m.D., Asst Clin Prof, Ped Garcia-Zuazaga, Jorge alberto, m.D., Director, UH
Derm, U CA, San Diego, CA, 73, 200 Westlake Skin Cancer and Mohs Surgery Program.
Dolev, Jacqueline C., m.D., 66 Univ Hospitals Case Med Ctr, 251

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 377
 FaCULTy INDEX

Garg, amit, m.D., Asst Prof, Dept Derm, Boston Graham-Brown, robin a. C., m.D., FRCP Harris, John, m.D., ph.D., 227
U Sch of Med, Boston, MA, 69, 100, 119 FRCPCH, Con/Sr Lect, Dept Derm, U Hosp Harvey, Valerie m., m.D., 141
Garmyn, marjan, prof, 80 Leicester, Leicester, UK, 70 Hashimoto, Takashi, m.D., 165
Garton, kyle J., m.D., 122 Grando, Sergei a., m.D., ph.D., UC Irvine, CA, 99 Hata, Tissa r., m.D., 68
Garzon, maria Cecilia, m.D., Assoc Prof Clin Derm Granstein, richard D., m.D., Chmn, Dept Derm, Hawk, John Lyndon mcLeod, m.D., Prof Derm
Clin Ped, Columbia U, New York, NY, 117, 132 Weill Med Col, Cornell U, New York, NY, 137 Photobiol, St John’s Inst Derm, London, UK, 80,
Gaspari, anthony a., m.D., Prof, Dept Derm, Sch Grant-kels, Jane margaret, m.D., Prof, Chmn, Dept 159, 264
Med, U M.D., Baltimore, MD, 90, 179 Derm, Dir Dermpath, Sch Med, U CT, Farmington, Hay, roderick J., m.D., 224
Gathers, raechele Cochran, m.D., 141 CT, 235 Haynes, Harley a., m.D., Dir Clin Derm, BWH,
Geist, David E., m.D., 214 Greaves, malcolm w., m.D., ph.D., Natl Skin Ctr, Prof Derm, Harvard Med Sch, Boston, MA, 66
Gelfand, Joel m., m.D., mSCE, Asst Prof, Med Dir Clin Singapore, 70 Heald, peter w., m.D., Prof Derm, Yale U, New
Studies Unit, Dept Derm, U PA, Philadelphia, PA, 125, Greenberg, robert David, m.D., Private Practice, Haven, CT, 209
194, 204 Vernon, CT, 211 Hebert, adelaide a., m.D., Prof Derm and Ped,
Gelmetti, Carlo, m.D., 134 Greenway, Hubert T., m.D., Chmn Derm, Hd Skin U TX, Houston, TX, 125
Gerami, pedram, m.D., Asst Prof Derm/Dermpath and Canc Ctr, Scripps Clin, La Jolla, CA, 84 Heffernan, michael p., m.D., Assoc Prof, Wright
Northwestern Univ Feinberg School of Med, 122 Grichnik, James m., m.D., ph.D., Assc Prof, Div State U, Dayton, OH, 79, 119
Geronemus, roy G., m.D., Clin Prof Derm, NYU Derm, Duke U Med Ctr, Durham, NC, 78, 128, 190 Henning, Jeffrey Scott, Do, 143, 258
Med Ctr, New York, NY, 178, 242 Grimes, pearl E., m.D., Clin Prof, Div Derm, Herbert, Courtney r., m.D., m.p.H., 82
Gibson, Lawrence E., m.D., Prof, Dept Derm, Mayo UCLA, Los Angeles, CA, 75, 193, 263 Hercogova, Jana, m.D., ph.D., Prof, Chmn, Dept
Clin, Mayo Fndtn, Rochester, MN, 106, 253 Grob, Jean-Jacques, m.D., 78 Derm, Charles U, Prague, Czech Republich, 193
Gilchrest, Barbara ann, m.D., Prof and Chmn, Grossman, melanie C., m.D., Assoc Clin, Dept Herman, alysa r., m.D., 70
Dept Derm, Boston U, Boston, MA, 172 Derm, Columbia U, New York, NY, 246 Heymann, warren r., m.D., Hd, Div Derm, Prof
Gilliam, anita C., m.D., ph.D., Dermatopathology, Palo Guitart, Joan, m.D., Prof of Derm and Path, Med, UM.D.NJ-RWJMS, CaM.D.en, NJ, 127
Alto Foundation Medical Group, Palo Alto CA, 127 Northwestern U, Chicago, IL, 249 High, whitney a., m.D., Asst Prof, Depts of Derm
Girardi, michael, m.D., Assoc Prof, Dept Derm, Yale Gupta, aditya k., m.D., ph.D., Prof, Div Derm, and Path , U of Colorado, Denver, CO, 104, 127,
U, New Haven, CT, 79 U Toronto, Toronto, Canada, 212 195, 207, 214
Gladstone, Hayes B., m.D., Assoc Prof, Derm/ Hill, Samantha, m.D., 79
Otolaryngol, Dir, Div Derm Surg, Stanford U, Hinds, Ginette, m.D., 209
Stanford, CA, 245 H Hinshaw, molly a., m.D., Asst Prof of Derm and
FaCULTy INDEX

Glaser, Dee anna, m.D., Prof, Dept Derm, St. Louis Dermpath, U of WI Sch of Med and Public Health,
Haber, robert S., m.D., Asst Prof, Dept Derm,
U, St. Louis, MO, 139, 219 Madison, WI, 104
CWRU Sch Med, Cleveland, OH, 138
Glogau, richard Gordon, m.D., Clin Prof Derm, Hirsch, ranella J., m.D., 232
Haggstrom, anita N., m.D., 140, 200, 248
UCSF, San Francisco, CA, 198 Hivnor, Chad, m.D., 114
Halder, rebat m., m.D., Prof and Chmn, Dept
Gloster, Hugh m., m.D., Assoc Prof, Dept Derm, Hofbauer, Gunther FL, m.D., 87
Derm, Howard U, Washington, DC, 71, 75
U Cincinnati Col Med, Cincinnati, OH, 260 Hofmann-wellenhof, rainer, 128, 208
Hale, Elizabeth k., m.D., 168
Gohara, mona amira, m.D., 141 Holness, D. Linn, m.D., Dir, Div Occup Med,
Halem, monica L., m.D., 126
Goldberg, David J., m.D., JD, Clin Prof, Derm, U Toronto, Toronto, Canada, 129
Hall, John Charles, m.D., Assoc Prof Med, UMKC,
Mount Sinai Sch of Med, New York, NY, 139, Honda, kord S., m.D., 127
Truman Med Ctr, Kansas City, MO, 144
179, 198 Hood, antoinette Foote, m.D., Eastern Virginia
Halpern, allan C., m.D., Chf, Derm Svc, MSKCC,
Goldberg, Dori, m.D., 156, 201 Medical School, Norfolk, VA, 148, 235
New York, NY, 78, 249
Goldberg, Gerald, m.D., Assoc Clin Prof, Sect Derm, Hook, kristen, m.D., 240
Hamzavi, Iltefat H., m.D., M.D.,Sr Staff Phys, Henry
U of AZ HSC, Tucson, AZ, 166 Hordinsky, maria k., m.D., Prof and Hd, Dept
Ford Hospital, Detroit, MI, 141, 181, 193, 264
Goldberg, Lynne J., m.D., Assoc Prof Derm and Derm, U MN, Minneapolis, MN, 138
Haneke, Eckart, Prof, Inst Derm Klinikk , Sandvika,
Path, Boston U Sch of Med, Boston, MA, 180, 231 Horii, kimberly a., m.D., Asst Prof Ped Children
Norway, 171
Goldenberg, Gary, m.D., 119, 207, 226-227 Mercy Hosp, Kansas City, MO, 117
Hanifin, Jon m., m.D., Prof Derm, OHSU, Portland,
Goldman, mitchel paul, m.D., Assoc Clin Prof, Hornyak, Thomas J., m.D., ph.D., Invest, Derm Br,
OR, 121
Derm/Med, UC, San Diego, CA, 198, 220, 245 Ctr for Cancer Rsch, NCI, NIH, Bethesda, MD, 105
Hanjani, Nazanin michelle, m.D., 194
Goldsmith, Lowell a., m.D., Clin Prof, Dept Derm, Hosler, Gregory a., m.D., ph.D., 262
Hanke, C. william, m.D., Clin Prof, Sch Med, IN
Sch Med, U NC, Chapel Hill, NC, 101 Hotez, peter, m.D., 224
U, Indianapolis, IN, 124, 172
Goldstein, Glenn D., m.D., 177, 199 Hruza, George J., m.D., Clin Assoc Prof Derm/
Hansen, Christopher B., m.D., 139
Goodman, Gregory J., m.D., Sr Lect, Monash U, Otolaryngol, St Louis U, St Louis, MO, 101
Hansen, ronald C., m.D., Chf, Ped Derm, Phoenix
Dept Comm Med, Chf Surg Skin Care Fndtn, Vic, Hsu, Jeffrey T. S., m.D., 259
Children’s Hosp, Phoenix, AZ, Prof Derm and Ped,
Australia, 65 Hu, Shasa, m.D., 187
U AZ, Tucson, AZ, 221
Gordon, kenneth B., m.D., Chf Div Derm, Evanston Hughey, Lauren C., m.D., Asst Prof, Dept Derm, U
Hantash, Basil, m.D., ph.D., 245
NW Hlth, Assoc Prof Dept Derm, Northwestern, of AL, Birmingham, AL, 255
Harmon, Christopher B., m.D., Clin Instr, U AL,
Chicago, IL, 125, 137, 204 Hurley, m. yadira, m.D., Asst Prof, Dir Div Dermpath,
Birmingham, AL, 199, 219, 260
Gottlieb, alice B., m.D., ph.D., Chair, Derm-in- Dept Derm, St. Louis U, St. Louis, MO, 79
Harper, Julie Claire, m.D., Clin Assoc Prof, Dept
Chief, Tufts-NEMC, Boston, MA, 203 Hwang, Sam T., m.D., ph.D., M.D./Ph.D., Sr.
Derm, U AL Med Ctr, Birmingham, AL, 120, 204
Graber, Emmy m., m.D., 197 Invest., Derm Br, NCI, Bethesda, MD, 188
Graber, Emmy, m.D., 197
Graham, Gloria F., m.D., Clin Assoc Prof Derm,
Wake Forest U Sch Med, Winston-Salem, NC, 229

378 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 FaCULTy INDEX

I kaufman, Joely anne, m.D., Assistant Professor of

Clinical Dermatology University of Miami Miller
krutmann, Jean, Prof Hd, Clin Phot Derm, U
Duesseldorf, Duesseldorf, Germany, 202
Introcaso, Camille E., m.D., 57
School of Medicine; Miami, FL, 70 kundu, roopal Vashi, m.D., 141, 156
Ioffreda, michael D., m.D., Assoc Prof, Dept Derm,
kaufmann, mark D., m.D., Assoc Clin Prof, Dept kupper, Thomas, m.D., Chair, Dep Derm, Brigham
Col Med, PA St, Hershey, PA, 231, 235
Derm, Mt Sinai School of Med, New York, NY, 172 and Womens Hosp, Boston, MA, 160, 212
Izakovic, Jan, m.D., 112
kauvar, arielle N. B., m.D., Clin Assoc Prof Derm, kwong, pearl C., m.D., Asst Prof, Dept Derm,
NYU Sch Med, New York, NY, 246 U Pittsburgh, Pittsburgh, PA, 248
kelly, Nancy, 57 kyei, angela, m.D., 148
J kent, David E., m.D., Clin Inst, Div Derm, Derm
Jackson, Brooke a., m.D., Asst Clin Prof, Dept Med, Med Col GA, Augusta, GA, 84, 199
Derm, Sch Med, Northwestern, Chicago, IL, 220
Jackson, J. mark, m.D., Assoc Clin Prof, Med/
kerdel, Francisco, m.D., Cedars Med Center,
Miami, FL, 92, 230
L
Lacouture, mario E., m.D., Asst Prof, Dept Derm,
Derm, U Louisville Div Derm, Louisville, KY, 137 keri, Jonette Elizabeth, m.D., ph.D., 142, 164
Northwestern U, Chicago, IL, 131, 253
Jackson-richards, Diane m., m.D., 155 kestenbaum, Thelda m., m.D., Assoc Prof, Div
Laeuchli, Severin r., m.D., 230
Jacob, Sharon E., m.D., Assistant Professor Derm, U KS, Kansas City, KS, 263
Landau, marina, m.D., Dept Derm, Wolfson Med
Medicine and Pediatrics (Dermatology), UCSD, 74 kim, Caroline C., m.D., 227
Ctr, Holon, Israel, 139
Jacobe, Heidi Tewich, m.D., Asst Prof, U TX SW kim, Ellen J., m.D., Asst Prof, Dept Derm, U of PA
Langley, richard G. B., m.D., Assoc Prof Dir Rsch
Med Ctr, Dallas, TX, 139, 180, 264 Sch of Med, Philadelphia, PA, 249
Dalhousie Med Sch, Halifax, Nova Scotia, Canada, 131
Jacobs, m. amanda, m.D., 222 kim, Jenny J., m.D., ph.D., M.D., Ph.D., Associate
Lanuti, Emma, m.D., 208
James, william D., m.D., Prof, Dept Derm, U PA, Prof, Div Derm, David Geffen Sch of Med UCLA,
Larralde, margarita m., m.D., 156
Philadelphia, PA, 143, 160 Los Angeles, CA, 142
Latkowski, Jo-ann, m.D., Asst Prof, Dept Derm,
Jellinek, Nathaniel J., m.D., Asst Prof, Dept Derm, kim, youn H., m.D., Prof, Derm Dept, Stanford U
NYU Sch Med, 209
Brown Med Sch, Providence, RI, 171, 206, 212 Med Sch, Stanford, CA, 195, 249
Law, robert, m.D., 155
Jemec, Gregor B. E., m.D., 81 kimball, alexandra Boer, m.D., m.p.H., Assoc Prof,
Lawrence, Naomi, m.D., Hd, Procedural Derm, Asst
John, Swen m, m.D., 129 Harvard Med Sch, Boston, MA, 203, 252
Pro, Med Cooper U Hosp, Marlton, NJ, 139, 198
Johnson, Carl a., m.D., 83 kirby, Joslyn S., m.D., 94, 146, 222
Lazova, rossitza Z., m.D., Assoc Prof, Dept Derm,
Johnson, Douglas w., m.D., Asst Clin Prof, Dept kirsner, robert S., m.D., ph.D., Vice Chair and
Sch Med, Yale U, New Haven, CT, 235
Med, U of Hawaii Sch of Med, 101, 179 Stiefel Prof, Dept Derm, Sch Med, U Miami, Miami,
Leach, Brian C., m.D., Prof, Dept Derm and Path,
Johnson-Jahangir, Hillary, m.D., ph.D., 124, FL, 145

FaCULTy INDEX
UCSF, San Francisco, CA, 209
126, 233 kittler, Harald, m.D., Assoc Prof, Derm, Med U
LeBoit, philip E., m.D., Prof, Dept Derm and Path,
Johr, robert H., m.D., Clin Prof Derm Ped, Dir Pgt Vienna, Vienna, Austria, 128, 208
UCSF, San Francisco, CA, 196
Lsn, U Miami, Miami, FL, 128, 208 klaus, Sidney N., m.D., 224
Lebwohl, mark, m.D., Prof and Chmn, Dept Derm,
Joly, pascal, m.D., ph.D, 205 knobler, Elizabeth H., m.D., Asst Clin Prof Derm,
Mt Sinai Sch Med, New York, NY, 93, 137, 169,
Jones, Derek H., m.D., Assoc Clin Prof, Div Derm, Columbia-Pres Med Ctr, New York, NY, 126
203, 221
David Geffen Sch Med, UCLA, Los Angeles, CA, ko, Christine, m.D., Asst Prof, Dept Derm, Yale U,
Lee, Delphine J., m.D., ph.D., 159, 190
219, 220 New Haven, CT, 81, 180, 223, 235
Lee, Erica, m.D., 192
Jorizzo, Joseph L., m.D., Prof and Fmr Chmn, Dept koblenzer, Caroline Scott, m.D., Clin.Prof.Derm.
Lee, Jason Bok, m.D., 235
Derm, Wake Forest U, Winston-Salem, NC, 84 University of Pennsylvania, Philadelphia, PA, 263
Lee, ken k., m.D., Dir Derm Surg, Assoc Prof
Junkins-Hopkins, Jacqueline m., m.D., Assc Prof Dept kong, Heidi H., m.D., Assoc Clin Invest, Derm Br,
Derm/Surg/Otolaryngol, OHSU, Portland, OR,
Derm, UPENN, Philadelphia, PA, 136, 180, 195 Natl Inst Hlth, Bethesda, MD, 105, 176, 253
230, 259
konnikov, Nellie, m.D., Clinical Prof Derm, BU
Lee, m. Christine, m.D., Asst Clin Prof, Dept Derm
School of Medicine, Boston, MA 238
Surg, UCSF; Dir, East Bay Laser and Skin Care Ctr,
k koo, John y. m., m.D., Prof, Vice Chmn Derm,
UCSF, San Francisco, CA, 263
Walnut Creek, CA, 158
kalb, robert E., m.D., Clin Assoc Prof, Derm Dept, Lee, robert a., m.D., ph.D., Clinical Instructor,
kouba, David, m.D., ph.D., 219
St U NY Schl Med, Buffalo, NY, 193, 243 University of Pennsylvania, Philadelphia, PA, 81
kovarik, Carrie L., m.D., Asst Prof, Dept Derm,
kamino, Hideko, m.D., Assoc Prof Derm and Path, Lehman, Julia S., m.D., 253
U Penn, Philadelphia PA, 57-58, 122, 143, 207,
Dir Dermpath, NYU Med Ctr, New York, NY, 235 Lehmann, percy m., m.D., 243
224, 250
kang, Sewon, m.D., Prof, Dept Derm, U MI, Leichter, Carl martin, m.D., Oceanside, NY, 102
kowalczyk, andrew, Assoc Prof of Derm and Cell
Ann Arbor, MI, 202 Leonardi, Craig L., m.D., Assoc Clin Prof, Dept
Bio, Emory U, Atlanta, GA, 105
kantor, Jonathan, m.D., 57 Derm, St. Louis U, St Louis, MO, 92, 103, 125
kraemer, kenneth Howard, m.D., Chf, DNA Repair
kaplan, Daniel H., m.D., 131 Leone, Giovanni, m.D., 80
Sect, NCI, Bethesda, MD, 105
katsambas, andreas D., m.D., Assoc Prof, Chmn Leshin, Barry, m.D., Dept Derm, Wake Forest U
kramer, Jesse m., m.D., 123
Derm, U Athens, Athens, Greece, 165 Sch Med, Winston-Salem, NC, 177
krasner, Brett D., m.D., 82
katz, kenneth a., m.D., 210 Levine, Norman, m.D., No academic affiliation, 167
krol, alfons, m.D., Prof and Dir, Ped Derm OHSU,
katz, Stephen I., m.D., ph.D., Dir, NIAMS, NIH, Levine, Vicki J., m.D., 264
Portland, OR, 234
Bethesda, MD, 133 Levitt, Jacob, m.D., Asst Clin Prof, Dept of Derm,
kroshinsky, Daniela, m.D., 91
kaufman, andrew J., m.D., 230 The Mount Sinai Med Ctr, New York, NY, 136
krueger, James G., m.D., ph.D., Prof and Lab Hd
Levy, moise L., m.D., Prof Derm and Ped, Baylor
Invest Derm, Rockefeller U, New York, NY, 105, 125
Col Med, TX Children’s Hosp, Houston, TX, 73,
133, 140, 248

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 379
 FaCULTy INDEX

Leyden, James Joseph, m.D., Emer Prof, Dept marcus, Linda Susan, m.D., 257 moody, Brent r., m.D., Town and Country,
Derm, U PA, Philadelphia, PA, 142 margesson, Lynette J., m.D., Asst Prof OBGYN and MO, 260
Libecco, James Frederick, m.D., 178 Med (Derm), Dartmouth Med Sch, Hanover, NH, 247 morison, warwick L., m.D., Prof, Dept Derm, Johns
Liedtka, Jane E., m.D., 102 marghoob, ashfaq a., m.D., Assoc Prof, Memorial Hopkins U, Baltimore, MD, 113
Lien, mary H., m.D., 157 Sloan-Kettering, New York, NY, 73, 78, 128, 140, morrison, Lynne H., m.D., Assoc Prof, Dermatology
Lim, Henry w., m.D., Chmn and C.S. Livingood 182, 200, 208 Dept, Oregon Health Sciences University, Portland,
Chr, Derm, Henry Ford Hosp, MI, 80, 93, 103, 172, marks, Victor James, m.D., Assoc, Geisinger Med OR, 95
179, 193, 234, 252, 264 Ctr, Danville, PA, 77, 94, 172, 177 morton, Colin a., m.D., M.B.Ch.B., F.R.C.P.(UK),
Lin, Jennifer y., m.D., 83, 136 marmur, Ellen S., m.D., Asst Clin Prof, Dept Derm, Cons, Dept. of Derm, Stirling, Scotland, 243
Linden, kenneth G., m.D., Assoc Prof, Dept Derm, Sch Med, Mt. Sinai, New York, NY, 135 moschella, Samuel Leonard, m.D., Sr. Consult,
UC Irvine, CA, 179 martin, Elizabeth Shannon, m.D., Clinical Lahey Clin, Burlington, MA, 196, 254
Linder, Jennifer Lung, m.D., 176 Volunteer Faculty, Univ of AL, 68 mostow, Eliot N., m.D., Prof and Chr, NEOUCOM,
Lindstrom, Jill a., m.D., 102 martinez, Juan-Carlos, m.D., 189 Akron, OH; Asst Clin Prof, Case Western Reserve U,
Linehan, w. marston, m.D., 161 martini, mary C., m.D., 135 Cleveland, OH, 72
Ling, mark r., m.D., ph.D., Med Dir, Medaphase, mascaro, Jose-manuel, 205 moul, Danielle k., m.D., 84
Inc, Clin Prof Derm, Emory U Sch Med, 177 matalin, mary, 162 mowad, Christen m., m.D., Assoc Prof, Geisinger
Lio, peter a., m.D., 74, 83, 100, 132 matarasso, Seth L., m.D., Clin Prof Derm, UCSF, Medical Center, 74, 151
Lipworth, adam D., m.D., 167 San Francisco, CA, 91, 122, 198, 219 moy, ronald L., m.D., Clin Prof, Div Derm, Sch
maurer, Toby a., m.D., Assoc Prof, UCSF, Chf,
Lober, Clifford warren, m.D., JD, Clin Assoc Prof, Med, UCLA, Dir Derm Surg, VA West, Los Angeles,
Div Derm, U So FL, Tampa, FL, 83, 102, 120 Derm, San Francisco Gen Hosp, San Francisco, CA, CA, 122, 161, 245
Lotti, Torello m., m.D., Prof and Chf, Derm Dept, 58, 132, 250 munavalli, Girish S., m.D., m.H.S., Clin Inst, Dept
Florence U, Florence, Italy, 193 mcClellan, Scott D., m.D., 122 Derm, Sch Med, Johns Hopkins U, Baltimore,
Lowenstein, Eve Judith, m.D., ph.D., Chf Derm, mcDaniel, David H., m.D., Asst Clin Prof, Derm, MD, 260
Brookdale Hosp Med Ctr, Dir Clin Res, Assoc Prof, Plast Surg, E VA Med Sch, VA Beach, VA, 93 murakawa, George J., m.D., Clin Prof, Int Med, MI
Dept Derm, Suny Downstate, Brooklyn, NY, 215 mckoy, karen, m.D., m.p.H., Asst Clin Prof in State U, Lansing, MI, 234
Lucas, Jennifer, m.D., 71, 148 Derm, Harvard Med Sch, Lahey Clin, Burlington, murase, Jenny Eileen, m.D., 165
Lucky, anne w., m.D., Prof Derm and Peds, MA, 58, 66 murphy, Gillian m., m.D., Dept Derm, Beaumont
mcmichael, amy J., m.D., Assoc Prof, Dept Derm,
Cincinnati Children’s Hosp, Cincinnati, OH, 200, 233 Hosp, Dublin, Ireland, 80, 202, 252
Lui, Harvey, m.D., Prof/Chmn, Derm and Skin Sci, Sch Med, Wake Forest U, Winston-Salem, NC, 138 murrell, Dedee F., m.D., Prof and Hd, Dept Derm,
FaCULTy INDEX

U British Columbia, Vancouver, Canada, 75, 252 mcNiff, Jennifer madison, m.D., Prof Dept Derm St George Hosp, U NSW, Sydney, Australia, 180,
Lupi, omar, m.D., ph.D., Assoc Prof Derm, and Path, Yale U, New Haven, CT, 127, 180 205
UNI-RIO, Prof Derm, Federal U, Rio de Janeiro, mehlis, Stephanie L., m.D., 261 mutasim, Diya F., m.D., Chmn, Dept Derm, U
BRAZIL, 154 mehta, Sheetal, m.D., 131 Cincinnati, Cincinnati, OH, 94
Lupo, mary p., m.D., Clin Prof Derm, Tulane U menter, alan, m.D., Chair, Psoriasis Research Unit, myskowski, patricia L., m.D., Memorial
Med Sch, New Orleans, LA, 91, 122, 139, 250 Baylor Research Institute, Dallas, TX, 103 Sloan-Kettering Cancer Ctr, New York, NY, 253
menzies, Scott, Assoc Prof Med, U Sydney, Sydney,
Australia, 78, 128, 208, 231
m mercurio, mary Gail, m.D., Assoc Prof Derm, N
U Rochester, Rochester, NY, 194
macCormack, mollie a., m.D., 222 Nandedkar, maithily a., m.D., 82, 209
metry, Denise w., m.D., Asst Prof, Dept Derm and
macFarlane, Deborah, m.D., m.p.H. Assoc Prof Narins, rhoda S., m.D., Clin Prof Dept Derm,
Ped, Baylor Col Med, Houston, TX, 125, 140
Derm and Plastic Surgery, MD Anderson Cancer NYU Med Ctr, New York, NY, 139, 220
micali, Giuseppe a., m.D., Chmn, Dept Derm,
Center, Houston, TX, 126 Narurkar, Vic a., m.D., Assoc Clin Prof Derm, UC
Catania U, Catania, Italy, 216 Davis Med School, Sacramento, CA 250
mackool, Bonnie T., m.D., 155 miller, alexander, m.D., Assoc Clin Prof, Dept Nasir, adnan, m.D., ph.D., Clin Asst Prof, Dept
maibach, Howard Ira, m.D., Prof, UCSF Med Sch, Derm, U CA, Irvine, CA, 83, 102 Derm, UNC, Chapel Hill, NC, 114
San Francisco, CA, 129 miller, Christopher James, m.D., Dept Derm, U of Nathanson, Nir, m.D., ph.D., 114
maier, Lisa E., m.D., 142, 255 Pennsylvania, Philadelphia, PA, 138, 149, 206, 221 Nedorost, Susan T., m.D., Assoc Prof Dept Derm,
makkar, Hanspaul, m.D., 174, 232 miller, Jeffrey J., m.D., Assoc Prof, Dept Derm, Sch Med, Case Western Reserve U, Cleveland, OH,
maloney, mary E., m.D., Prof, Med Sch, U MA, Penn State Col Med, Hershey, PA, 94, 116 74, 151, 170
Worcester, MA, 76, 113, 172 miller, Lloyd S., m.D., ph.D., 79, 105 Neff, ann G., m.D., 260
miller, oliver Fred, m.D., Emer, Chmn, Dept Derm, Nehal, kishwer S., m.D., 264
malvehy, Joseph, m.D., Melanoma Unit, Hosp Clin,
Geisinger Clin, Danville, PA, 72, 94 Neuburg, marcy, m.D., Prof, Dept Derm, Med Coll
Barcelona, SPAIN, 128, 182, 231
ming, michael E., m.D., Asst Prof., Dept Derm, of WI, Milwaukee, WI, 149
mancini, anthony J., m.D., Assoc Prof, Ped and
UPA, Philadelphia, PA, 163 Nghiem, paul, m.D., ph.D. Assoc Prof, Derm/Med,
Derm, Northwestern U, Chicago, IL, 73, 248
mirmirani, paradi, m.D., The Permanente Medical U of Washington, Seattle, OR, 169, 201, 210
mandy, Stephen Howard, m.D., Clin Prof, Dept Group, Vallejo, CA and Asst Clin Prof, U CA San Nguyen, Tri H., m.D., Assoc Prof, Derm. Univ of TX
Derm, Sch Med, U Miami, Miami, FL, 198 Francisco, San Francisco, CA, 146, 211 Mel Sch-Houston, TX, 124, 148, 259
mirowski, Ginat w., Dm.D., m.D., Assoc Prof Derm, Nikkels, arjen F., m.D., ph.D., 144
Northwestern, Chicago, IL, 69, 130, 247 Nixon, rosemary L., m.D., 129
moiin, ali, m.D., Clin Associate Prof, Div Derm, Nopper, amy J., m.D., Assoc Prof Univ MO-Kansas
Wayne St U, Detroit, MI, 134 City, and Chf Sect Ped Derm, Children’s Mercy
monheit, Gary D., m.D., Assoc Clin Prof, Dept Der, Hosp, Kansas City, MO, 117
U AL, Birmingham, AL, 91, 139

380 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 FaCULTy INDEX

Nordlund, James J., m.D., Prof Clin Derm, Dept parsley, william millard, m.D., Dept Derm, rehmus, wingfield Ellis, m.D., Asst Clin Prof
Derm, Wright State Sch Med, Dayton, OH, 57, 71, U Louisville, Louisville, KY, 138 Derm, Stanford U, Koror, Palau, 57, 224, 252
193, 224 parsons, margaret E., m.D., Asst Clin Prof, Dept reichenberg, Jason S., m.D., 226
Norman, robert a., Do, m.p.H, m.B.a., Assoc Prof, Derm, UC-Davis, Sacramento, CA, 243 rendon, marta I., m.D., The Dermatology and
Aesthetic Center, Boca Raton, FL, 263
Dept Derm, Nova So East U, Ft. Lauderdale, FL patel, rishi r., m.D., 127
resneck, Jack Selwyn, Sr., m.D., Private Practice,
Private Practice Tampa, FL, 70, 242 patel, Tejesh Surenda, m.D., 132
Shreveport, LA, 196
Northington, marian Elizabeth, m.D., Asst. pellacani, Giovanni, m.D., 128, 231 resneck, Jack S., Jr., m.D., Assoc Prof of Dermatol-
Professor of Dermatology Birmingham, AL, 202 petersen, Jeffrey E., m.D., Associate Professor of ogy and Health Policy, UCSF Sch of Med, San
Norton, Scott a., m.D., m.p.H., Derm Dept, Dermatology, Wright State University, Indianapolis, Francisco, CA, 92, 197
Uniformed Services Univ, Bethesda, MD, 57-58, IN, 119, 134, 221 reyter, Ilya, m.D., 176
132, 173, 224, 250 petersen, marta J., m.D., Prof, Dept Derm, U UT, rich, phoebe, m.D., Clin Prof, Dept of Derm
Nouri, keyvan, m.D., Prof, Dir Derm Surg, Salt Lake City, UT, 127 OHSU and Private Practice Portland, OR, 171, 234
U Miami, Miami, FL, 112, 178 picardo, mauro, m.D., 193 richard, Gabriele FAC MG, Genedx Inc.,
Gaithersburg, M.D., Adjunct Assoc Prof, 82
Nousari, Carlos H., m.D., Prof, Dept Derm, U piliang, melissa, m.D., 75, 114
richert, Bertrand, m.D., ph.D., Clin Prof, Dept of
Miami, Miami, FL, Dir, Inst Immunofluor, piraccini, Bianca maria, m.D., 171, 251
Derm, University of Liege, Belgium, 171, 221, 251, 260
Dermpath Diag, Pompano Beach, FL, 235 pittelkow, mark r., m.D., Prof, Dept Derm, Mayo ricotti, Carlos, m.D., 92, 122
Clin, Rochester, MN, 124 rigel, Darrell S., m.D., Clin Prof Derm, New York
plewig, Gerd, m.D., Prof, Dept Derm, U Munich,
o Munich, Germany, 226
Univ Med Ctr, New York, NY, 93, 149, 169, 172,
225, 234, 247
obagi, Suzan, m.D., 219 poblete-Lopez, Christine, m.D., 113, 121 rigopoulos, Demetrios G., m.D., 171
odom, richard B., m.D., Prof Clin Derm, U CA, pomeranz, miriam keltz, m.D., Asst Prof, Dept ring, Johannes, m.D., Prof, Dir Dept Derm/Allergy,
San Francisco, CA, 213 Derm, NYU and Bellevue, New York, NY, 175 Tech, U Munich, Bavaria, Germany, 157
o’Donoghue, marianne N., m.D., Assoc Prof Derm, roberts, Janet Louise, m.D., Clin Prof Derm,
pope, Elena, m.D., 233, 248
Rush U Med Ctr, Chicago, IL, 181 OHSU, Portland, OR, 234
portman, robert m., JD, 196
oh, Dennis H., m.D., ph.D., 105, 159 roberts, wendy E., m.D., Asst Clin Prof Med, Loma
pourciau, Crystal, m.D., 140 Linda U Med Ctr, Loma Linda, CA, 242, 250
olasz, Edit B., m.D., ph.D., 149 powell, Douglas L., m.D., 170 robinson, June k., m.D., Prof Clin Derm, NW U,
olbricht, Suzanne, m.D., Chf Derm, Lahey Clin, powell, Frank C., m.D., Con Derm, Reg Ctr Derm, Chicago, IL, 169, 181
Assoc Prof Derm, Harvard MS, Boston, MA, 76, Mater Hosp, Dublin, Ireland, 150 robinson-Bostom, Leslie, m.D., Assoc Prof Derm,
93, 211 powell, Julie, m.D., Asst Clin Prof, Ped Derm, Dir Div Dermpath, Brown Med Sch, Providence,

FaCULTy INDEX
oliviero, margaret Skin and Canc Assoc, Plantation, U Montreal, Montreal, Canada, 117 RI, 235
FL, 128, 230 pratt, melanie D., m.D., Clin Prof, U Ottawa, Can, 90 rogers, Gary S., m.D., Dir Derm Surg and Oncol,
olsen, Elise, m.D., Prof Derm and Onc, price, Vera H., m.D., FrCp(C), Prof, Dept Derm,
Tufts U Sch Med, Boston, MA, 225
Department Derm, Duke U Med Ctr, Durham, rogers, roy Steele, m.D., Prof Derm, Mayo Clin
UCSF, San Francisco, CA, 211
NC, 75, 241, 254 Col of Med, Rochester, MN, 118
prok, Lori D., m.D., 104 rohrer, Thomas E., m.D., Skincare Phys of Chestnut
omlin, kenny J., m.D., 221 prose, Neil, m.D., Prof Derm, Ped, Duke U Med Hill, Boston U, Boston, MA, 91, 122
oranje, arnold pieter, m.D., Erasmus MC, Pediatric Ctr, Durham, NC, 57, 64, 159 romanelli, marco, m.D., Ph.D., Asst Prof, Dept
Dermatology, Rotterdam, the Netherlands, 239 prussick, ronald B., m.D., 167 Derm, U Pisa, Pisa, Italy, 230
otberg, Nina, m.D., 138 puig, Susana, m.D., 128, 231 romanelli, paolo, m.D., AssocProf, Dept Derm/
otley, Clark C., m.D., Chair, Div of Derm Surg, Prof puttgen, katherine B., m.D., 133, 147 dermpath, Miller Sch Med, U Miami, Miami, FL,
of Derm, Mayo Clin Col of Med, Rochester, MN, 67 92, 164, 230
owen, Cindy, m.D., 137 rook, alain H., m.D., Rook, Alain H, M.D.,
ozog, David m., m.D., 219 Q U Penn, Dept Derm, Philadelphia, PA, 249
Qureshi, abrar a., m.D., m.p.H., Co-Dir, Dept rosen, Theodore, m.D., Prof, Dept Derm, Baylor
Derm, Brigham and Women’s Hosp, Harvard Med Col Med, Houston, TX, 93, 169, 196, 207, 234, 247
p Sch, Boston, MA, 130 rosenbach, misha, m.D., 69, 217
padgett, Julia k., m.D., Asst Prof, Dept Derm, rosenberg, Steven p., m.D., Clin Prof, U Miami,
UVA, Charlottesville, VA, 201 Chm Derm, Good Sam/St Mary, W. Palm Beach, 83
pak, Hon S., m.D., Asst Prof Derm, USUHS, r ross, E. Victor, m.D., Dir Cosm and Laser Derm
rabinovitz, Harold S., m.D., Clin Prof, Dept Derm, Scripps Clin, San Diego, CA, 84, 242, 246
Bethesda, MD, 143, 261
Sch Med, U Miami, Miami. FL, 128, 149, 182, 225, rotter, Steven m., m.D., 230
paller, amy S., m.D., Prof and Chmn, Dept Derm, ruben, Beth S., m.D., Assoc Prof, Depts. of Derm
231
Prof, Dept Ped, Sch Med, Northwestern U, Chicago, radhika, atit, ph.D., 105 and Path, Dermpath Svc, UC San Francisco, CA,
IL, 82, 125, 132, 150, 200 rapini, ronald p., m.D., Prof and Chmn, Dept 149, 171, 180
pandya, amit G., m.D., Prof, Dept Derm, U TX SW Derm, U TX, Houston, TX, 127, 207, 235 rubin, adam, m.D., Div, Dermpath, Dept, Derm,
Med Ctr, Dallas, TX, 75, 101, 141, 148, 205, 263 ratner, Desiree, m.D., Assoc Clin Prof, Dept Derm, U Pennsylvania, Philadelphia, PA, 149, 171, 235
papadopoulos, Diamondis, m.D., 84 Columbia U Med Ctr, New York, NY, 126, 201 rubin, mark G., m.D., Asst Clin Prof, Div Derm,
papier, arthur, m.D., Batavia, NY, 228 reese, Vail C., m.D., Asst Clin Prof Derm, UCSF, U CA, San Diego, CA, 219
pariser, David michael, m.D., Prof, Dept Derm, San Francisco, CA, 177 rucker wright, Dakara, m.D., 140
E VA Med Sch, Norfolk, VA, 172, 211, 234 rudnicka, Lidia, m.D., ph.D., 254
parsad, Davinder, m.D., 116 ruiz-rodriguez, ricardo r., m.D., 257
rumm, peter, m.D., m.p.H., 102
russell, mark a., m.D., Assoc Prof, Dept of Derm,
U of VA, Charlottesville, VA 201

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 381
 FaCULTy INDEX

S Shah, kara N., m.D., ph.D., Asst Prof of Ped and

Derm, Univ Penn Sch Med and Childrens Hosp of
Stasko, Thomas, m.D., Assoc Prof Med (Derm),
Vanderbilt U Med Ctr, Nashville, TN, 149
Saag, kenneth, m.S.C.E., 137
Philadelphia, Philadelphia, PA, 257 Stefanato, Catherine margaret, m.D., Consultant
Saavedra-Lauzon, arturo p., m.D., ph.D., 83,
Shama, Steven kenneth, m.D., m.p.H., New Eng- Dermpath, St John’s Inst Derm, London, UK, 190,
130, 196, 212
land Baptist Hospital and Beth Israel Deaconess 231, 254
Sachs, Dana Lynn, m.D., 93
Medical Center, Brookline/Boston, MA, 104, 213 Stein, Jennifer a., m.D., 169, 225, 264
Sami, Naveed, m.D., 229
Shapiro, Jerry, m.D., Clin Prof, Derm, U British Stein, Linda F., m.D., Dir Derm Rsch Henry Ford
Sarkany, robert p., m.D., mBBS, FrCp, Dir,
Columbia, Vancouver, Canada, Adj Prof Derm, Hosp, Detroit, MI, 93, 203
Photo Bio, St. John’s, London, UK, 238
NYU, New York City, NY, 241, 254 Stolz, wilhelm, m.D., Prof, Hd, Dept Derm, Clin
Sarkar, rashmi, m.D., Asst Prof, Skin Spec, Dept
Shay, Daniel, J.D., 82 Muenchen-Schwabing, Munich, Germany, 128,
Derm, Sardarjung Hosp, Vardhman Mahavir Med
Shear, Neil H., m.D., Prof and Chair, Dept Derm, 182, 208
Col, New Delhi, India, 250, 263
U Toronto, Toronto, Ontario, CANADA, 137, 204 Stone, mary S., m.D., Prof Derm and Path, U IA
Sasseville, Denis, m.D., Royal Victoria Hospital,
Sheth, pranav B., m.D., Group Health Associates, Col Med, Iowa City, IA, 122, 235
Montreal, Canada, 90
Trihealth, 100 Stone, Stephen p., m.D., Prof Clin Med, Div
Schachner, Lawrence a., m.D., Prof and Chmn,
Shinkai, kanade, m.D., ph.D., 69, 87 Derm, SIU Sch Med, Springfield, IL, 221
Dept Derm, Sch Med, U Miami, Miami, FL, 154
Shore, ronald Nevin, m.D., 238 Storrs, Frances J., m.D., Prof Emerita, Dept
Schaefer, Stephanie, m.D., 57
Shwayder, Tor a., m.D., Faap, Dir, Ped Derm, Derm, OR Hlth Sci U, Portland, OR, 90
Schaffer, andras, m.D., 235
Henry Ford Hosp, Detroit, MI, 140 Stratman, Erik Joseph, m.D., Dir, Div of
Schaffer, Julie V., m.D., Asst Prof, Dept Derm and
Sidbury, robert, m.D., Asst Prof, Div Derm, Dept Education, Marshfield Clin, Marshfield, WI,
Ped, NYU, New York, NY, 82, 127, 139, 223, 225
Ped, Sch Med, U WA, Seattle, WA, 73, 218, 248 170, 209
Scheinfeld, Noah S., m.D., JD, Asst Clin Prof,
Silverberg, Nanette Blythe, m.D., Dir Ped Derm, Strober, Bruce Elliot, m.D., ph.D. Asst Prof, Dept
CUMC, New York, NY, 247
St Luke’s Roosevelt Hosp Ctr, Clin Asst Prof, Derm, Sch Med, NY U, New York, NY, 92,
Scheinman, pamela L., m.D., Assoc Clin Prof of
Columbia, New York, NY, 179 125, 168
Derm, Tufts Med Ctr, 74
Silverman, robert, m.D., Clin Assoc Prof, Dept Stuetz, anton, ph.D. 162
Scheman, andrew J., m.D., Assoc Prof Clin
Ped and Derm, U VA, Charlottesville, VA, 194 Subtil, antonio, m.D., mBa, Asst Prof, Dermpath,
Derm, NW U Med Ctr, Chicago, IL, 170
Silvestri, Dianne Louise, m.D., 170 Yale, New Haven, CT, 209
Scher, richard k., m.D., Prof Derm, U NC,
Simpson, Eric Lawrence, m.D., Asst Prof, Derm, Sundaram, Hema a., m.D., 220
Chapel Hill, North Carolina; Prof Emer Derm,
Oregon Hlth Sci U, 100, 234 Sundram, Uma, m.D., ph.D., 195
Columbia U, New York, NY, 171
Sirois, David, D.m.D., ph.D, 205 Swanson, David L., m.D., Asst Prof, Dept Derm,
FaCULTy INDEX

Scherschun, Lubomira, m.D., 219

Sluzevich, Jason C., m.D., Mayo Clinic Mayo Clinic, Scottsdale, AZ, 208
Schlessinger, Joel, m.D., 192
Florida, 97 Swerlick, robert, m.D., Assoc Prof, Dept Derm,
Schlosser, Bethanee Jean, m.D., ph.D., 69,
Smith, kevin C., m.D., Niagara Falls, Canada, 120 Emory U, Atlanta VA Hosp, Atlanta, GA, 79,
130, 247
Smith, Stacy r., m.D., Div Derm, UCSD, La 124, 127
Schmults, Chrysalyne Delling, m.D., Dir, Mohs
Jolla, CA, 115 Swetter, Susan m., m.D., Assoc Prof, Dept Derm,
Micrographic Surgery, Brigham and Women’s
Sobanko, Joseph, m.D., 206 Stanford U Sch Med, Stanford, CA, 169, 201, 225
Hosp, Boston, MA, 65, 212
Solish, Nowell J., m.D., Asst Prof Derm, U Swick, Brian L., m.D., 104
Schwarzenberger, kathryn, m.D., Assoc Prof,
Toronto, Toronto, Canada, 91, 122 Szeimies, rolf-markus, m.D., Assoc Prof, Dept
Univ Vermont, Burlington, VT, 258
Soon, Seaver, m.D., 84, 126, 230 Derm, U Hosp Regensburg, Regensburg,
Scope, alon, m.D., 78, 128, 231
Soter, Nicholas arthur, m.D., Prof Derm, NYU Germany, 243
Seckin, Deniz, m.D., 67
Sch Med, New York, NY, 118, 159 Szepietowski, Jacek C, m.D., 132
Selim, m angelica, Dermpath, Duke U, Durham,
Sotile, mary, ph.D., 123
NC, 101
Sotile, wayne, ph.D., Clin, Wake Forest,
Sellheyer, klaus, m.D., Assoc Dermpath, Nelson
Winston-Salem, NC, 123 T
Dermpath Assoc, Atl, Georgia,Adj Staff, Cleveland Taback, Bret, m.D., 126
Soyer, H. peter, m.D., FaCD, Prof and Chmn,
Clin Fdtn, 166 Tan, Jerry kim Leng, m.D., 217
Derm Group, U, Brisbane, Australia, 128
Sengelmann, roberta D., m.D., Assoc Prof Derm Tan-Billet, Jennifer, m.D., 196
Spellman, mary C., m.D., 145
and Otolaryngol, Dir, Derm Surg, Washington U, Tannous, Zeina S., m.D., 115
Spencer, James m., m.D., Clin Prof, Dept Derm,
St. Louis, MO, 219, 232 Tanzi, Elizabeth, m.D., Co-Dir, Washington Inst
Mt Sinai Sch Med, New York, NY, 169, 179
Serra, marcio Soares, m.D., Asst Prof, FED U of Derm Laser Surg and Clin Instr, Dept Derm,
Sperber, Brian r., m.D., ph.D., 209
ST, Rio De Janeiro, 250 Johns Hopkins Med Ctr, 246, 260
Sperling, Leonard C., m.D., Chmn, Dept Derm,
Sethi, aisha, m.D., 58, 173, 224 Tarbox, michelle B., m.D., 71
Uniformed Svc U, Bethesda, MD, 138, 194, 231
Seykora, John T., m.D., Asst Prof, Dept Derm, U Taylor, Charles r., m.D., Assoc Prof Derm,
Sprecher, Eli, m.D., ph.D., Derm, Rambam Med
PA, Philadelphia, PA, 105, 127, 149 Harvard U, Boston, MA, 67, 196
Ctr, Haifa, Israel, 82, 205
Seymour, paul, 113, 150 Taylor, James Selwyn, m.D., Hd Occ Derm,
Srivastava, monika, m.D., 261
Stalder, Jean Francois, m.D., 154 Cleveland Clin, Cleveland, OH, 74, 90, 124
Stanley, John roger, m.D., Chmn and Prof, Dept Teng, Joyce, m.D., 239
Derm, Sch Med, U PA, Philadelphia, PA, 105 Tetzlaff, michael, m.D., 235
Tharp, michael D., m.D., Prof/Chmn Derm, Rush
U Med Ctr, Chicago, IL, 76, 131

382 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 FaCULTy INDEX

Theos, amy J., m.D., Asst Prof Derm, U AL Med Voorhees, John James, m.D., Prof and Chmn, wolf, John E., m.D., Prof and Chmn, Dept Derm,
Ctr, Birmingham, AL, 203, 218 Dept Derm, Med Sch, U MI, Ann Arbor, MI, 144 Baylor Col Med, Houston, TX, 213
Thiboutot, Diane m., m.D., Prof, Dept Derm, Col wolverton, Stephen E., m.D., Prof Clin Derm,
Med, PA St, Hershey, PA, 105, 120, 142, 181 Dept Derm, IN U Med Ctr, Indianapolis, IN, 204
Thiers, Bruce Harris, m.D., Prof and Chmn, Dept w wood, Gary S., m.D., M.D., Prof and Chmn,
wagner, annette m., m.D., Asst Prof Ped Derm, Dept Derm, U WI and VA, Madison, WI,
Derm, Med U SC, Charleston, SC, 88, 93
NW U, Chicago, IL, 238 226, 249
Thompson, Curtis T., m.D., 138 waibel, Jill S., m.D., 242 wright, Teresa S., m.D., 133
Tierney, Emily, m.D., 81 waldorf, Heidi a., m.D., Assoc Clin Prof, Dept
Tom, wynnis L., m.D., 73, 147 Derm, Sch Med, Mt Sinai, New York, NY, 220
Tomecki, kenneth J., m.D., Vice Chairman, Dept walker, Susan J., m.D., 102, 193 X
Derm, Cleveland Clinic, Cleveland, OH, 76, 187, wang, alun, m.D., 127 Xu, Lisa, m.D., 140
207, 247 wang, Linda Chung-Chin, m.D., JD, 85, 210, 212 yaar, mina, m.D., Prof Dept Derm, Boston U,
Torelo, antonio, m.D., 168 wang, Steven Q., m.D., Memorial Sloan Kettering Boston, MA, 252
Torezan, Luis a., m.D., 243 Cancer Center, NY, 128, 225
Torgerson, rochelle r., m.D., ph.D., Asst Prof wang, Timothy S., m.D., 126
Derm, Mayo Clin Col of Med, Rochester, wargo, Jennifer, m.D., 249 y
MN, 247 warschaw, karen, m.D., Mayo Clinic Arizona, yag-Howard, Cyndi Jill, m.D., Derm Private Prac 65
Torok, Helen mary, m.D., 191 Scottsdale, AZ, 106, 207, 235 yan, albert C., m.D., Asst Prof. Dept Peds and
Torres, abel, m.D., Prof, Dept Derm, Loma Linda warshaw, Erin m., m.D., Chf Derm, Mpls VA, Derm, U Penn/Children’s Hosp, Philadelphia, PA,
U, Loma Linda, CA, 211 Assoc Prof, U MN, Minneapolis, MN, 74, 151 73, 200
Torres, Vicente, m.D., 142 washenik, ken, m.D., ph.D., Med Dir, Bosley; yancey, kim B., m.D., Prof and Chmn, Dept
Tosti, antonella, m.D., Prof, Dept Derm, Bologna Fac, NYU Dept Derm, New York, NY, 75, 168 Derm, Med Col WI, Milwaukee, WI, 105, 172,
U, Bologna, Italy, 70, 92, 138, 171, 203, 212, 251 wasserman, Justin, m.D., 173 234
Tran, kien T., m.D., ph.D., 122 watsky, kalman L., m.D., Clin Prof Dept Derm, yang, Fei-Shiuann Clarissa, m.D., 83
Travers, Jeffrey B., m.D., ph.D., Prof and Chmn Yale U, New Haven, CT, 255 yosipovitch, Gil, m.D., Prof, Dept Derm, Wake
Dept Derm, Sch Med, IN U, Indianapolis, IN, watson, alice C., m.D., 124 Forest, U, Winston-Salem, NC, 132
79, 159 webster, Guy F., m.D., ph.D., Jefferson Med Col, youker, Summer r., m.D., Asst Prof, Dept Derm,
Treat, James r., m.D., 70, 73 Philadelphia, PA, 120, 142, 168, 234 Saint Louis U, St. Louis, MO, 76, 79, 121, 221
Trevino, Julian J., m.D., Assoc Professor, webster, Stephen Burtis, m.D., Gundersen yu, Siegrid S., m.D., 210
Wright State U Sch of Med, Dir WSU Lutheran Med Ctr, La Crosse, WI, 196
Immunodermatology Lab, 258 weinberg, Jeffrey m., m.D., Asst Clin Prof,

FaCULTy INDEX
Trookman, Nathan, m.D., 209 Columbia U, New York, NY, 239 Z
Tsai, kenneth yee, m.D., 249 weinkle, Susan H., m.D., Asst Clin Prof, Dept Zachary, Christopher B., m.D., Prof and Chmn,
Tsao, Hensin, m.D., ph.D., Assoc Prof, Dept Derm, Derm, U S FL, Bradenton, FL, 91, 139, 198, 220, Dept Derm, U CA, Irvine, CA, 198, 245-246
Harvard Med Sch, Boston, MA, 101, 105, 249 243, 250 Zaenglein, andrea L., m.D., Assoc Prof, Derm and
Tsao, Sandy Sharon, m.D., Assoc Prog Dir weiss, margaret a., m.D., Asst Prof Derm, Johns Ped, Penn State, MS Hershey Med Ctr, Hershey,
DermSurg, Dept Derm, MA Gen Hosp, Boston, Hopkins U, Baltimore, MD, 220 PA, 58, 142
MA, 88 weiss, robert J., m.D., 139 Zaiac, martin N., m.D., Greater Miami Skin and
Tucker, Stephen Brent, m.D., 168 weiss, robert a., m.D., Assoc Prof, Dept Derm, Laser, Miami, FL, 92, 251
Tung, rebecca Clare, m.D., Derm Surg, Johns Hopkins U Sch Med, Baltimore, MD, 220, 245 Zalaudek, Iris, m.D., Dept Derm, Med U, Graz,
Cleveland Clin Fndtn, Cleveland, OH, 245 weiss, Stefan C., m.D., 86 Austria, 128, 231, 244, 254
Tyring, Stephen k., m.D., ph.D., Prof Dept werchniak, andrew, m.D., Instr Derm, Med Sch, Zalla, James a., m.D., Assoc Clin Prof, U
Derm, U Texas Hlth Sci Ctr, Houston, TX 147, Harvard U, Boston, MA, 212 Cincinnati, Cincinnati, OH, Priv Prac, Florence,
173, 207, 234 werth, Victoria p., m.D., Prof Derm, U PA, KY, 102, 119, 123, 227
Philadelphia, PA,139, 180, 205, 234 Zalla, mark J., m.D., Volunteer Assoc Prof Derm,
wexler, patricia S., m.D., Assoc Clin Prof, Mt U Cincinnati Col Med, Cincinnati, OH, 123
U Sinai Sch Med, New York, NY, 122 Zanolli, michael D., m.D., Heritage Medical
Udey, mark C., m.D., ph.D. Chf, Derm Br, CCR, wheeland, ronald G., m.D., Prof and Chf Derm Associates, Nashville, TN, 252
NCI, NIH, Bethesda, MD, 105 Surg, Dept Derm; U MO-Columbia; Columbia, Zeichner, Joshua, m.D., 85
Uebelhoer, Nathan, D.o., 246 MO, 64 Zeikus, priya S., m.D., Dept Derm, Med Sch,
Uitto, Jouni J., m.D., ph.D., Prof and Chmn, Dept whitaker, Duane C., m.D., Clinical Prof. of Med., Brown U, Providence, RI, 251
Derm and Cut Biol, Jefferson Med Col, Univ. of Arizona, 156 Zelac, Daniel Ethan, m.D., 84
Philadelphia, PA, 105 white, Clifton robert, m.D., Prof Derm and Path, Zhang, alexandra y., m.D., 175
OHSU, Portland, OR, 235 Zic, John a., m.D., Asst Prof, Div Derm,
white, Lucile E., m.D., 102 Vanderbilt U Sch Med, Nashville, TN, 173
V white, richard Eric, m.D., 228 Zirwas, matthew, m.D., Assistant Professor of
Van Voorhees, abby S., m.D., Asst Prof, Dept wieder, Joshua m., m.D., 219 Dermatology, Columbus, OH, 74, 119
Derm, U PA, Philadelphia, PA, 203 wilkel, Caroline S., m.D., Asst Clin Prof, Derm, Zone, John Joseph, m.D., Prof and Chmn, Dept
VanBeek, marta Jane, m.D., Asst Prof, Dept of Boston U, Boston, MA, Clin Asst Prof, Brown U, Derm, U Utah, Salt Lake City, UT, 127, 253
Dermatology, University of Iowa Hospitals and Providence, RI, 235 Zug, kathryn a., m.D., Assoc Prof Derm,
Clinics, Iowa City, IA, 57, 76, 88 wilkin, Jonathan keith, m.D., Columbus, OH, 150 Dartmouth-Hitchock Med Ctr, Lebanon,
Vanderhooft, Sheryll L., m.D., 140 williams, mary L. k., m.D., San Francisco, CA, 200 NH, 90, 151
winterfield, Laura S., m.D., Instr, Dept Derm, Zwald, Fiona o’reilly, m.D., Metropolitan
Vaughan-Jones, Samantha a., m.D., 64
BWH, Boston, MA, 216 Dermatologic Surg, P.C., St Joseph’s Hospital,
Vidal, Claudia, m.D., 79 Atlanta, GA, 126, 149, 201, 222
wirtzer, allan S., m.D., Priv Pract, Sherman Oaks,
Vleugels, ruth ann, m.D., Inst., Harvard Medical
CA, 123
School, Brigham and Women’s Derm; Boston, MA, wiss, karen, m.D., Prof and Dir, Ped Derm,
74, 83, 130, 196 UMASSMED, Worcester, MA, 232

For the Latest Program Book InFormatIon PLease reFer to www.aad.org | 383
 aDVErTISING INDEX

Abbott Laboratories ....................................................................................54-55 American Academy of Dermatology

Allergan .......................................................................................................11-12
Canfield Imaging Systems. ............................................................................... 51
Centocor ................................................................................................32A-32B
Clinique.......................................................................................................... 303
Dermatology Foundation ................................................................................ 56
Divi International ........................................................................................... 305
Galderma Laboratories, L.P. ............25-26, 29, 56A-56B, 264A-264B, 295-296
Intendis .......................................................................................................13-14
Jan Marini Skin Research ............................................................................... 311
MD Solar Sciences ......................................................................................... 315
Medicis Pharmaceutical Corporation ............................. 396A-297, 352A-352B
Mentor Corporation ...................................................................................... 339
Merz Pharmaceuticals .................................................................................49-50
MMR Technologies ....................................................................................... 317
NeoStrata ..................................................................................................Cover 3
Obagi .............................................................................................................. 319
Ortho Dermatologics ....................................................................Cover 2-1, 5-6
Pacific World .................................................................................................... 31
Palomar Medical Technologies, Inc. .............................................................. 321
Phytoceuticals ................................................................................................. 323
ProPath ........................................................................................................... 344
Strata Pathology Services ................................................................................ 326
Triax Pharmaceuticals ...............................................................................Cover 4
AAD Buyer’s Guide ........................................................................................ 86
AADCareerCompass.org ..........................................................................109, 113
AAD Advantage ............................................................................................. 262
AADDermsOnline.org ..................................................................................... 129
AAD Measurement Tools .............................................................................. 183
AAD Sponsorship Recognition ........................................................................ 31
Academy Resource Center ......................................................................110-111
Advisory Board Actitivities ............................................................................. 60
Art of Aesthetic Dermatology ........................................................................ 62
Career Development Fair ............................................................................... 103
Dermatology in Action ................................................................................... 58
DermClips ...................................................................................................... 199
Derm Exam Prep Course: Refresher ................................................................ 78
Dermscopy: A Guide for the Physician ......................................................... 182
Dialogues in Dermatology ............................................................................. 153
HCNN ........................................................................................................... 201
Health Volunteers Overseas .......................................................................... 130
HIT-kit .......................................................................................................... 174
Leadership Circle for Volunteerism ............................................................... 224
Leadership Institute ....................................................................................... 184
Maintenance of Certification Manual
for Dermatology - Volume 4 (MOCmd ) ............................................... 151
TM TM

Upsher-Smith ......................................................................................................9 MedjetAssist ................................................................................................... 140

UVSunSense................................................................................................... 329
Vartitronics Inc. ................................................................................................ 50
Young Pharmaceuticals .................................................................................. 331
aDVErTISING INDEX
Named Lectureships ....................................................................................... 158
Onsite Voting ................................................................................................... 32
Practice Management Essential Series ............................................................ 123
Psoriasis Guidelines Forum ........................................................................... 106

Reception Row ................................................................................................ 63

See Spot Series ................................................................................................ 77
Staples ............................................................................................................... 88

Advertising Representatives
Elsevier Aileen Rivera
360 Park Avenue South, 9th Floor Phone: (212) 633-3721, Fax: (212) 633-3820
New York, NY 10010 E-mail: a.rivera@elsevier.com
Roxana Aldea Mike Guire, Advertising Sales Manager
Phone: (212) 633-3160, Fax: (212) 633-3820 Phone: (212) 633-3121, Fax: (212) 633-3820
E-mail: r.aldea@elsevier.com E-mail: m.guire@elsevier.com

Future Academy Meetings

AnnuAl Meetings
2012 70th Annual Meeting March 16-20 San Diego, CA
2013 71st Annual Meeting March 1-5 Miami, FL
2014 72nd Annual Meeting March 21-25 Denver, CO
2015 73rd Annual Meeting March 20-24 San Francisco, CA

suMMeR ACADeMY Meetings

2011 August 3-7 Hilton New York New York, NY
2012 August 15-19 Hynes Convention Center Boston, MA
2013 July 30-August 3 Hilton New York New York, NY

384 | amerIcan academy oF dermatoLogy • 69th annuaL meetIng

 Elite Science. Professional Results.

Introducing the
future science
of anti-aging
skincare at AAD.

There’s a new complete

anti-aging system of potent
professional products with active
benefit ingredients that work
www.neostrata.com

synergistically to address the

broadest spectrum of visible
signs of aging.
See the evidence for yourself
and receive a free sample at
NeoStrata booth #1855.
©2010 NeoStrata Company
 The efficacy
of an
Please visit us at the
69th Annual AAD
Meeting 2011
Booth 1955
Locoid Lipocream® Cream, 0.1% Rx Only
(hydrocortisone butyrate 0.1% cream)
For Topical Use Only
BRIEF SUMMARY
–––––––––––––––––––––––––––––––– INDICATIONS AND USAGE ––––––––––––––––––––––––––––––––
Locoid Lipocream is a topical corticosteroid indicated for: relief of the inflammatory and pruritic manifestations
of corticosteroid-responsive dermatoses in adults and the treatment of mild to moderate atopic dermatitis in
patients 3 months to 18 years of age.
–––––––––––––––––––––––––––––– WARNINGS AND PRECAUTIONS ––––––––––––––––––––––––––––––
Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression may occur, with the potential for
glucocorticosteroid insufficiency. Consider periodic evaluations for HPA axis suppression if Locoid Lipocream is
applied to large surface areas or used under occlusion. If HPA axis suppression is noted, reduce the application
frequency, discontinue use, or switch to a lower potency corticosteroid.
Systemic effects of topical corticosteroids may also include manifestations of Cushing’s syndrome,
hyperglycemia, and glucosuria.
Pediatric patients may be more susceptible to systemic toxicity due to their larger skin surface-to-body-mass ratios.
Initiate appropriate therapy if concomitant skin infections develop.
Discontinue use if irritation develops.
–––––––––––––––––––––––––––––––––– ADVERSE REACTIONS ––––––––––––––––––––––––––––––––––
The most common adverse reactions (>1%) are HPA axis suppression and application site reactions.
The following additional local adverse reactions have been reported infrequently with topical corticosteroids,
and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids.
These reactions included: irritation, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis,
allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria and telangiectasia.
–––––––––––––––––––––––––––––– USE IN SPECIFIC POPULATIONS ––––––––––––––––––––––––––––––
Pregnancy
Pregnancy Category C. Corticosteroids have been shown to be teratogenic in laboratory animals when
administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be
teratogenic after dermal application in laboratory animals.There are no adequate and well-controlled studies
in pregnant women. Therefore, Locoid Lipocream should be used during pregnancy only if the potential benefit
justifies the potential risk to the fetus.
Please refer to full prescribing information for detailed information regarding systemic embryofetal
development studies.
Nursing Mothers
Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with
endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical
administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in
human milk. Because many drugs are excreted in human milk, caution should be exercised when Locoid
Lipocream is administered to a nursing woman.
Pediatric Use
Safety and efficacy in pediatric patients below 3 months of age have not been established.
Because of higher skin surface-to-body-mass ratios, pediatric patients are at a greater risk than adults of HPA
axis suppression when they are treated with topical corticosteroids. They are therefore also at a greater risk of
glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing’s syndrome while on treatment.
Eighty-six (86) pediatric subjects (5 months to less than 18 years of age) with moderate to severe atopic
dermatitis affecting at least 25% of body surface area (BSA) treated with Locoid Lipocream three times daily
for up to 4 weeks were assessed for HPA axis suppression. The disease severity (moderate to severe atopic
dermatitis) and the dosing regimen (three times daily) in this HPA axis study were different from the subject
population (mild to moderate atopic dermatitis) and the dosing regimen (two times daily) for which Locoid
Lipocream is indicated.
Be sure to visit our Web site at www.locoid.com.
©2010 Triax Pharmaceuticals, LLC. All rights reserved. LC-0810-339
The elegance
of a
Five of the 82 evaluable subjects (6.1%) demonstrated laboratory evidence of suppression, where the sole
criterion for defining HPA axis suppression was a serum cortisol level of less than or equal to 18 micrograms
per deciliter after cosyntropin stimulation. Suppressed subjects ranged in age from 5 months to 16 years and,
at the time of enrollment, had 25% to 95% BSA involvement. These subjects did not develop any other signs or
symptoms of HPA axis suppression. At the first follow up visit, approximately one month after the conclusion of
treatment, cosyntropin stimulation results of all subjects had returned to normal, with the exception of one
subject. This last subject recovered adrenal function by the second post treatment visit, 65 days post-treatment.
Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have also
been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in
pediatric patients include low plasma cortisol levels to an absence of response to ACTH stimulation.
Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
Geriatric Use
Clinical studies of Locoid Lipocream did not include sufficient numbers of subjects aged 65 and over to
determine whether they respond differently from younger subjects.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No studies were conducted to determine the photococarcinogenic or dermal carcinogenic potential of Locoid
Lipocream.
Hydrocortisone butyrate revealed no evidence of mutagenic or clastogenic potential based on the results of two
in vitro genotoxicity tests (Ames test and L5178Y/TK+ mouse lymphoma assay) and one in vivo genotoxicity test
(mouse micronucleus assay).
No evidence of impairment of fertility or effect on mating performance was observed in a fertility and general
reproductive performance study conducted in male and female rats at subcutaneous doses up to and including
1.8 mg/kg/day (0.7X maximum topical human dose [MTHD]). Mild effects on maternal animals, such as reduced
food consumption and a subsequent reduction in body weight gain, were seen at doses ≥0.6 mg/kg/day
(0.2X MTHD).
–––––––––––––––––––––––––––– PATIENT COUNSELING INFORMATION ––––––––––––––––––––––––––––
Patients using Locoid Lipocream should receive the following information and instructions:
Apply a thin layer to the affected skin two or three times daily for corticosteroid-responsive dermatoses in
adults. Consult with your physician to determine if treatment is needed beyond 2 weeks. Apply a thin film to
the affected skin areas two times daily for atopic dermatitis in patients 3 months of age and older. Safety of
Locoid Lipocream in pediatric patients has not been established beyond 4 weeks of use.
Rub in gently.
Avoid contact with the eyes.
Do not bandage, otherwise cover, or wrap the affected skin area so as to be occlusive unless directed by your
physician.
Do not use Locoid Lipocream in the diaper area, as diapers or plastic pants may constitute occlusive dressings.
Do not use Locoid Lipocream on the face, underarms, or groin areas unless directed by your physician.
If no improvement is seen within 2 weeks, contact your physician.
Do not use other corticosteroid-containing products while using Locoid Lipocream without first consulting your
physician.
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].
Protect from freezing. Keep out of the reach of children.
Manufactured for: Triax Pharmaceuticals, LLC Marketed and Distributed By:
Cranford NJ 07016 Triax Pharmaceuticals, LLC
By: Ferndale Laboratories, Inc. Cranford NJ 07016
Ferndale MI 48220 www.Locoid.com
Locoid Lipocream is a registered trademark of
Astellas Pharma Europe BV licensed to
Triax Pharmaceuticals, LLC.